FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Schumm, JA O'Farrell, TJ Murphy, CM Fals-Stewart, W AF Schumm, Jeremiah A. O'Farrell, Timothy J. Murphy, Christopher M. Fals-Stewart, William TI Partner Violence Before and After Couples-Based Alcoholism Treatment for Female Alcoholic Patients SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY LA English DT Article DE female alcoholism; partner violence; couples therapy ID DOMESTIC VIOLENCE; WOMEN; CONFLICT; THERAPY; SAMPLE; SCALES AB This study examined partner violence before and in the 1st and 2nd year after behavioral couples therapy (BCT) for 103 married or cohabiting women seeking alcohol dependence treatment and their male partners; it used a demographically matched nonalcoholic comparison sample. The treatment sample received M = 16.7 BCT sessions over 5-6 months. Follow-up rates for the treatment sample at Years 1 and 2 were 88% and 83%, respectively. In the year before BCT, 68% of female alcoholic patients had been violent toward their male partner, nearly 5 times the comparison sample rate of 15%. In the year after BCT, violence prevalence decreased significantly to 31% of the treatment sample, Women were classified as remitted after treatment if they demonstrated abstinence or minimal substance use and no serious consequences related to substance use. In Year 1 following BCT, 45% were classified as remitted, and 49% were classified as remitted in Year 2. Among remitted patients in the year after BCT, violence prevalence of 22% did not differ from the comparison sample and was significantly lower than the rate among relapsed patients (38%). Results for male-perpetrated violence and for the 2nd year after BCT were similar to the 1st year. Results supported predictions that partner violence would decrease after BCT and that clinically significant violence reductions to the level of a nonalcoholic comparison sample would occur for patients whose alcoholism was remitted after BCT. These findings replicate previous research among men with alcoholism. C1 [O'Farrell, Timothy J.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Dept Psychiat,Families & Addict Program, Brockton, MA 02301 USA. [Murphy, Christopher M.] Univ Maryland Baltimore Cty, Dept Psychol, Baltimore, MD 21228 USA. [Fals-Stewart, William] Univ Rochester, Sch Nursing, Rochester, NY 14627 USA. RP O'Farrell, TJ (reprint author), Harvard Univ, Sch Med, VA Boston Healthcare Syst, Dept Psychiat,Families & Addict Program, 940 Belmont St,116B1, Brockton, MA 02301 USA. EM timothy_ofarrell@hms.harvard.edu FU NIAAA NIH HHS [R21 AA012433-01, K02 AA000234, K02 AA000234-03, K02AA0234, R01 AA008637, R01 AA010356, R01 AA014700, R01AA08637, R01AA10356, R01AA14700, R21 AA012433, R21AA12433] NR 41 TC 21 Z9 22 U1 2 U2 16 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0022-006X J9 J CONSULT CLIN PSYCH JI J. Consult. Clin. Psychol. PD DEC PY 2009 VL 77 IS 6 BP 1136 EP 1146 DI 10.1037/a0017389 PG 11 WC Psychology, Clinical SC Psychology GA 527XP UT WOS:000272404800012 PM 19968389 ER PT J AU Lee, SM Coakley, EE Dahlin, C Carleton, PF AF Lee, Susan M. Coakley, Edward E. Dahlin, Constance Carleton, Penny Ford TI An Evidence-Based Nurse Residency Program in Geropalliative Care SO JOURNAL OF CONTINUING EDUCATION IN NURSING LA English DT Article AB As U.S. baby boomers age and the older population doubles by 2030, unprecedented numbers of older adults will need and benefit from nursing care that is evidence-based and tailored to their needs and preferences. To address this need, Massachusetts General Hospital developed the RN Residency: Transitioning to Geriatrics and Palliative Care program. Guided by two national curricula, the RN Residency program was designed to expand the disease model of geriatrics to a functional, emotional, and social perspective of aging, in which palliative care is an integral component. This article describes the RN Residency program, which was designed to improve the effectiveness of nursing assessment, interventions, and outcomes for older adults and their families. J Contin Educ Nurs 2009;40(12):536-542. C1 [Lee, Susan M.] Massachusetts Gen Hosp, Yvonne L Munn Ctr Nursing Res, Boston, MA 02114 USA. [Coakley, Edward E.] Massachusetts Gen Hosp, Ctr Innovat Care Delivery, Boston, MA 02114 USA. [Dahlin, Constance] Massachusetts Gen Hosp, Palliat Care Serv, Boston, MA 02114 USA. [Carleton, Penny Ford] Harvard Univ, Sch Med, Ctr Integrat Med & Innovat Technol, Boston, MA USA. RP Lee, SM (reprint author), Massachusetts Gen Hosp, Yvonne L Munn Ctr Nursing Res, 275 Cambridge St,4th Floor, Boston, MA 02114 USA. FU Division of Nursing (DN), Bureau of Health Professions (BHPr), Health Resources and Services Administration (HRSA), Department of Health and Human Services (DHHS) [D11HP08359] FX The authors disclose that they have no significant financial interests in any product or class of products discussed directly or indirectly in this activity. This project is supported by funds from the Division of Nursing (DN), Bureau of Health Professions (BHPr), Health Resources and Services Administration (HRSA), Department of Health and Human Services (DHHS) under D11HP08359, Nurse Education, Practice, and Retention. The information or content and conclusions are those of the authors and should not be construed as the official position or policy of, nor should any official endorsement be inferred by the DN, BHPr, HRSA, DHHS, or U.S. Government. NR 14 TC 5 Z9 5 U1 0 U2 2 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0022-0124 J9 J CONTIN EDUC NURS JI J. Contin. Educ. Nursing PD DEC PY 2009 VL 40 IS 12 BP 536 EP 542 DI 10.3928/00220124-20091119-01 PG 7 WC Nursing SC Nursing GA 700HU UT WOS:000285729600004 PM 20000261 ER PT J AU Gladstone, HB Moy, RL AF Gladstone, Hayes B. Moy, Ronald L. TI Suspension suture canthopexy: a minimally invasive procedure for correcting mild to moderate ectropion SO JOURNAL OF COSMETIC DERMATOLOGY LA English DT Article DE canthopexy; ectropion; lateral canthal tendon; blepharoplasty AB Background: Ectropion of the lower eyelid can occur after blepharoplasty as well as reconstructive procedures. Even mild ectropion can cause irritation or epiphora. Patients with preexisting lid laxity are at higher risk for post procedure ectropion. Aims: To describe a method for canthopexy and discuss its indications, benefits and limitations. Methods: We describe a technique that has been used on dozens of patients by both the authors. Results: This suspension suture canthopexy corrects mild to moderate ectropion. Discussion: Suspension suture canthopexy is effective in patients with the appropriate indications. It can be performed under local anesthesia with minimal complications. Unlike other forms of lid tightening, it does not change the shape of the eye. Conclusion: Suspension suture canthopexy which is an ancillary procedure for eyelid rejuvenation is valuable procedure to master by the dermatologic surgeon. C1 [Gladstone, Hayes B.] Stanford Univ, Dept Dermatol, Sch Med, Div Dermatol Surg, Stanford, CA 94305 USA. [Moy, Ronald L.] Univ Calif Los Angeles, Div Dermatol, Los Angeles Sch Med, Los Angeles, CA 90024 USA. [Moy, Ronald L.] Los Angeles Vet Adm Med Ctr, Div Dermatol, Los Angeles, CA USA. RP Gladstone, HB (reprint author), Stanford Univ Pavill B, Dept Dermatol, Div Dermatol Surg, 4th Floor,450 Broadway St, Redwood City, CA 94063 USA. EM hbglad@stanford.edu NR 17 TC 2 Z9 2 U1 0 U2 0 PU WILEY PERIODICALS, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN STREET, MALDEN, MA 02148-529 USA SN 1473-2130 J9 J COSMET DERMATOL-US JI J. Cosmet. Dermatol. PD DEC PY 2009 VL 8 IS 4 BP 289 EP 294 DI 10.1111/j.1473-2165.2009.00463.x PG 6 WC Dermatology SC Dermatology GA V20JU UT WOS:000208137100009 PM 19958433 ER PT J AU Dang, PA Kalra, MK Blake, MA Schultz, TJ Stout, M Halpern, EF Dreyer, KJ AF Dang, Pragya A. Kalra, Mannudeep K. Blake, Michael A. Schultz, Thomas J. Stout, Markus Halpern, Elkan F. Dreyer, Keith J. TI Use of Radcube for Extraction of Finding Trends in a Large Radiology Practice SO JOURNAL OF DIGITAL IMAGING LA English DT Article DE Natural language processing; Online Analytical Processing (OLAP); data mining ID UNITED-STATES; LANGUAGE; CLASSIFICATION; BIOINFORMATICS; WAREHOUSE; DATABASE; DECADE AB The purpose of our study was to demonstrate the use of Natural Language Processing (Leximer), along with Online Analytic Processing, (NLP-OLAP), for extraction of finding trends in a large radiology practice. Prior studies have validated the Natural Language Processing (NLP) program, Leximer for classifying unstructured radiology reports based on the presence of positive radiology findings (F (POS)) and negative radiology findings (F (NEG)). The F (POS) included new relevant radiology findings and any change in status from prior imaging. Electronic radiology reports from 1995-2002 and data from analysis of these reports with NLP-Leximer were saved in a data warehouse and exported to a multidimensional structure called the Radcube. Various relational queries on the data in the Radcube were performed using OLAP technique. Thus, NLP-OLAP was applied to determine trends of F (POS) in different radiology exams for different patient and examination attributes. Pivot tables were exported from NLP-OLAP interface to Microsoft Excel for statistical analysis. Radcube allowed rapid and comprehensive analysis of F (POS) and F (NEG) trends in a large radiology report database. Trends of F (POS) were extracted for different patient attributes such as age groups, gender, clinical indications, diseases with ICD codes, patient types (inpatient, ambulatory), imaging characteristics such as imaging modalities, referring physicians, radiology subspecialties, and body regions. Data analysis showed substantial differences between F (POS) rates for different imaging modalities ranging from 23.1% (mammography, 49,163/212,906) to 85.8% (nuclear medicine, 93,852/109,374; p < 0.0001). In conclusion, NLP-OLAP can help in analysis of yield of different radiology exams from a large radiology report database. C1 [Dang, Pragya A.; Kalra, Mannudeep K.; Blake, Michael A.; Schultz, Thomas J.; Stout, Markus; Halpern, Elkan F.; Dreyer, Keith J.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Dreyer, KJ (reprint author), Massachusetts Gen Hosp, Dept Radiol, 25 New Chardon St,Ste 400E, Boston, MA 02114 USA. EM kdreyer@partners.org NR 29 TC 5 Z9 5 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0897-1889 J9 J DIGIT IMAGING JI J. Digit. Imaging PD DEC PY 2009 VL 22 IS 6 BP 629 EP 640 DI 10.1007/s10278-008-9128-x PG 12 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 524QX UT WOS:000272159000009 PM 18543033 ER PT J AU Ghigo, E Biller, BMK Colao, A Kourides, IA Rajicic, N Hutson, RK De Marinis, L Klibanski, A AF Ghigo, E. Biller, B. M. K. Colao, A. Kourides, I. A. Rajicic, N. Hutson, R. K. De Marinis, L. Klibanski, A. TI Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naive to radiation and medical therapy SO JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION LA English DT Article DE Acromegaly; octreotide long-acting release; pegvisomant ID RECEPTOR ANTAGONIST PEGVISOMANT; GROWTH-HORMONE; SOMATOSTATIN ANALOGS; TERM TREATMENT; TRANSSPHENOIDAL SURGERY; GLUCOSE-TOLERANCE; MULTICENTER; EFFICACY; SAFETY; EXPERIENCE AB Background: Normalization of IGF-I in patients with acromegaly is associated with a decrease in mortality. Pegvisomant may be more effective in lowering IGF-I than octreotide. Subjects and methods: The efficacy and safety of pegvisomant and octreotide long-acting release (LAR) were compared in 118 patients with acromegaly in this 52-week, multicenter, open-label, randomized study. The primary endpoint was IGF-I normalization at week 52. Secondary endpoints included mean changes from baseline in IGF-I, IGF binding protein 3, acromegaly signs and symptom scores, ring size, acromegaly quality of life questionnaire scores, and safety. Results: Fifty-six patients received pegvisomant and 57 received octreotide LAR. IGF-I normalized in 51% of pegvisomant patients and 34% treated with octreotide LAIR (p=0.09, ns). Patients with baseline IGF-I >= 2x upper limit of normal had a higher rate of IGF-I normalization with pegvisomant vs octreotide LAR (p=0.05). Among the patients who did not achieve a normalized IGF-I, pegvisomant-treated patients were more likely to be receiving <30 mg of study drug (71% vs 16%). Treatment-related adverse events were mild-to-moderate in both groups. Mean fasting glucose decreased in diabetic and non-diabetic patients on pegvisomant whereas octreotide LAR was associated with an increase at week 52 (p=0.005 and p=0.003 between groups, respectively). Mean change in tumor volume during treatment was similar between groups. Conclusions: Pegvisomant and octreotide LAIR were equally effective in normalizing IGF-I in the overall population, and pegvisomant was more effective in patients with higher baseline IGF-I levels. Pegvisomant had a more favorable effect on parameters of glycemic control. (J. Endocrinol. Invest. 32: 924-933, 2009) (C) 2009, Editrice Kurtis C1 [Ghigo, E.] Univ Turin, Dept Internal Med, Div Endocrinol & Metab, Molinette Hosp, I-10126 Turin, Italy. [Biller, B. M. K.; Klibanski, A.] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA. [Colao, A.] Univ Naples Federico II, Dept Endocrinol, Naples, Italy. [Kourides, I. A.] Pfizer Inc, Global Endocrine Care, New York, NY USA. [Rajicic, N.] Pfizer Inc, Global Med Res & Dev, New York, NY USA. [Hutson, R. K.] Univ Tennessee, Coll Med, Chattanooga, TN USA. [Hutson, R. K.] Erlanger Hlth Syst, Dept Radiol, Chattanooga, TN USA. [De Marinis, L.] Catholic Univ, Dept Endocrinol, Rome, Italy. RP Ghigo, E (reprint author), Univ Turin, Dept Internal Med, Div Endocrinol & Metab, Molinette Hosp, Corso Dogliotti 14, I-10126 Turin, Italy. EM ezio.ghigo@unito.it FU Pfizer Inc. [NCT00068042] FX The study was sponsored by Pfizer Inc. (NCT00068042). Editorial support was provided by Susan Sutch, PharmD at UBC-Envision Group, and was funded by Pfizer Inc. We also acknowledge the following investigators for their participation in the study: Australia: Frank Alford, Ken Ho, George Jerums, Mark McLean; Brazil: Monica Gadelha, Mauro Czepielewski, Cesar Boguszewski, Marcello Bronstein; Canada: Omar Serri, Ehud Ur; France: Philippe Chanson, Antoine Tabarin; Germany: Peter Kann, Christian Kasperk, Klaus Mann, Heinrich Schulte, Christian Strasburger, Birgit Gerbert; Greece: Marinella Tzanela, Nikolaos Thalassinos, Filippos Kaldrimidis; Italy: Francesco Minuto, Paolo Beck-Peccoz; Ireland: Christopher Thompson, Domhnall O'Halloran; Norway: Jens Bollerslev; Spain: Ricardo Astorga, Juan Ramon, Tomas Morante, Anna Sanmarti; Sweden: Eva Grenback, Britt Engstrom, Bertil Ekman; United Kingdom: Stephen Orme, Albert Atkinson, William Drake, John Monson, Paul Carroll; United States: Bahauddin Arafah, Ariel Barkan, David Clemmons, Pamela Freda, Lawrence Frohman, Murray Gordon, Shlomo Melmed, Mark Molitch, Mary Lee Vance, Steven Waguespack. NR 34 TC 19 Z9 19 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0391-4097 EI 1720-8386 J9 J ENDOCRINOL INVEST JI J. Endocrinol. Invest. PD DEC PY 2009 VL 32 IS 11 BP 924 EP 933 DI 10.3275/6723 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 557VF UT WOS:000274697500012 PM 20009494 ER PT J AU Dave, RM Patlola, R Kollmeyer, K Bunch, F Weinstock, BS Dippel, E Jaff, MR Popma, J Weissman, N AF Dave, Rajesh M. Patlola, Raghotham Kollmeyer, Kenneth Bunch, Frank Weinstock, Barry S. Dippel, Eric Jaff, Michael R. Popma, Jeffrey Weissman, Neil CA CELLO Investigators TI Excimer Laser Recanalization of Femoropopliteal Lesions and 1-Year Patency: Results of the CELLO Registry SO JOURNAL OF ENDOVASCULAR THERAPY LA English DT Article DE peripheral artery disease; superficial femoral artery; popliteal artery; atherectomy; balloon angioplasty; stenting; Walking Impairment Questionnaire ID SUPERFICIAL FEMORAL-ARTERY; ANGIOPLASTY; DISEASE; MANAGEMENT; STENTS AB Purpose: To evaluate the safety and efficacy of a modified laser catheter designed for the endovascular treatment of peripheral artery disease (PAD) affecting the superficial femoral artery (SFA) and proximal popliteal artery. Methods:The CliRpath Excimer Laser System to Enlarge Lumen Openings (CELLO) study was a single-arm, prospective registry conducted at 17 investigational sites in the United States. The primary endpoint was the reduction in index lesion percent diameter stenosis (% DS) measured by Doppler ultrasound following laser ablation prior to any adjunctive therapy. The primary safety endpoint was major adverse events at 6 months. Sixty-five patients (39 men; mean age 68.3+/-10.1 years) with intermittent claudication, stenotic lesions >70% by visual assessment, a reference vessel diameter >= 4.0 and <= 7.0 mm, and a total lesion length >= 1.0 and <= 15.0 cm underwent laser-assisted recanalization with optional balloon angioplasty (BA) or BA + stenting. Sixty-five de novo lesions (5.6+/-4.7 cm) in 13 Occluded and 52 stenotic arteries were treated. Results: Laser ablation reduced the % DS from 77%+/-15% at baseline to 34.7%+/-17.8%, which was reduced to 21%+/-14.5% after adjunctive therapy with BA (n=42, 64.6%) or BA + stenting (n=15, 23.3%). Eight (12.3%) patients did not receive post laser adjunctive therapy. Patency rates (% DS <50%) were 59% and 54% at 6 and 12 months, respectively. Target lesion revascularization was not required in 76.9% of CELLO participants within the 1-year follow-up. There were no major adverse events. The study cohort demonstrated a statistically significant improvement in the walking impairment and functional status assessments during follow-up. Conclusion: The data validate the safety and efficacy of the investigational device, with a high clinical success rate and 12-month data indicating freedom from reintervention in the majority of patients treated. J Endovasc Ther. 2009;16:665-675 C1 [Dave, Rajesh M.] Harrisburg Hosp, Pinnacle Hlth Heart & Vasc Inst, Harrisburg, PA 17101 USA. [Patlola, Raghotham] SW Med Ctr, Lafayette, LA USA. [Bunch, Frank] Thomas Hosp, Fairhope, AL USA. [Kollmeyer, Kenneth] Methodist Med Ctr, Dallas, TX USA. [Weinstock, Barry S.] Orlando Reg Med Ctr Inc, Orlando, FL USA. [Dippel, Eric] Midwest Cardiovasc Res Fdn, Davenport, IA USA. [Jaff, Michael R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Popma, Jeffrey] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Weissman, Neil] MedStar Res Inst, Washington, DC USA. RP Dave, RM (reprint author), Harrisburg Hosp, Pinnacle Hlth Heart & Vasc Inst, 111 S Front St, Harrisburg, PA 17101 USA. EM rdintervention@yahoo.com OI Dippel, Eric/0000-0003-1085-1178 FU Spectranetics Corporation FX This study was sponsored by Spectranetics Corporation. NR 15 TC 23 Z9 25 U1 0 U2 0 PU ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS PI LAWRENCE PA 810 EAST 10TH STREET, LAWRENCE, KS 66044 USA SN 1526-6028 J9 J ENDOVASC THER JI J. Endovascular Ther. PD DEC PY 2009 VL 16 IS 6 BP 665 EP 675 DI 10.1583/09-2781.1 PG 11 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 531NF UT WOS:000272673000004 PM 19995111 ER PT J AU Snyder, CW Burton, RC Brown, LE Kakade, MS Finan, KR Hawn, MT AF Snyder, Christopher W. Burton, Ryan C. Brown, Lindsay E. Kakade, Manasi S. Finan, Kelly R. Hawn, Mary T. TI Multiple Preoperative Endoscopic Interventions Are Associated with Worse Outcomes After Laparoscopic Heller Myotomy for Achalasia SO JOURNAL OF GASTROINTESTINAL SURGERY LA English DT Article; Proceedings Paper CT 50th Annual Meeting of the Society-for-Surgery-of-the-Alimentary-Tract CY MAY 30-JUN 04, 2009 CL Chicago, IL SP Soc Surg Alimentary Tract DE Achalasia; Pneumatic dilation; Botulinum toxin; Myotomy; Treatment failure; Outcomes ID BOTULINUM TOXIN INJECTION; RANDOMIZED CONTROLLED-TRIAL; ESOPHAGEAL ACHALASIA; PNEUMATIC DILATATION; DOR FUNDOPLICATION; FOLLOW-UP; OPERATION; DILATION; FAILURES; THERAPY AB The effect of preoperative pneumatic dilation or botulinum toxin injection on outcomes after laparoscopic Heller myotomy (LHM) for achalasia is unclear. We compared outcomes in patients with and without multiple preoperative endoscopic interventions. This cohort study categorized achalasia patients undergoing first-time LHM by the number of preoperative endoscopic interventions: zero or one intervention vs. two or more interventions. Outcomes of interest included surgical failure (defined as the need for re-intervention), gastrointestinal symptoms, and health-related quality of life. Logistic regression modeling was performed to determine the independent effect of multiple preoperative endoscopic interventions on the likelihood of surgical failure. One hundred thirty-four patients were included; 88 (66%) had zero to one preoperative intervention, and 46 (34%) had multiple (more than one) interventions. The incidence of surgical failure was 7% in the zero to one intervention group and 28% in the more than one intervention group (p < 0.01). Greater improvements in gastrointestinal symptoms and health-related quality of life were seen in the zero to one intervention group. On logistic regression modeling, the likelihood of surgical failure was significantly higher in the more than one intervention group (odds ratio = 5.1, 95% confidence interval 1.6-15.8, p = 0.005). Multiple endoscopic treatments are associated with poorer outcomes and should be limited to achalasia patients who fail surgical therapy. C1 [Kakade, Manasi S.; Hawn, Mary T.] Univ Alabama, Dept Surg, Sect Gastrointestinal Surg, Birmingham, AL 35294 USA. [Burton, Ryan C.; Brown, Lindsay E.] Univ Alabama, Sch Med, Birmingham, AL 35294 USA. [Finan, Kelly R.] Barnes Jewish Med Ctr, St Louis, MO USA. [Hawn, Mary T.] Birmingham Vet Affairs Med Ctr, Ctr Surg Med Acute Care Res & Transit, Birmingham, AL USA. RP Hawn, MT (reprint author), Univ Alabama, Dept Surg, Sect Gastrointestinal Surg, 1922 7th Ave S,KB 428, Birmingham, AL 35294 USA. EM mhawn@uab.edu NR 36 TC 31 Z9 32 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1091-255X J9 J GASTROINTEST SURG JI J. Gastrointest. Surg. PD DEC PY 2009 VL 13 IS 12 BP 2095 EP 2102 DI 10.1007/s11605-009-1049-6 PG 8 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 526PJ UT WOS:000272303000001 PM 19789928 ER PT J AU Bordeianou, L Hodin, R AF Bordeianou, Liliana Hodin, Richard TI Total Proctocolectomy with Ileoanal J-Pouch Reconstruction Utilizing the Hand-Assisted Laparoscopic Approach SO JOURNAL OF GASTROINTESTINAL SURGERY LA English DT Article DE Laparoscopic surgery; Total proctocolectomy; Ileoanal J-pouch; Ulcerative colitis ID ULCERATIVE-COLITIS; ILEAL POUCH; RESTORATIVE PROCTOCOLECTOMY; ANAL ANASTOMOSIS; ILEOSTOMY; SURGERY AB This manuscript describes our technique for a minimally invasive ileoanal J- pouch procedure utilizing hand-assisted laparoscopy. We detail several important maneuvers that may be helpful to the surgeon faced with the challenge of a difficult laparoscopic pouch. C1 [Bordeianou, Liliana; Hodin, Richard] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Bordeianou, L (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. EM lbordeianou@partners.org NR 17 TC 3 Z9 3 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1091-255X J9 J GASTROINTEST SURG JI J. Gastrointest. Surg. PD DEC PY 2009 VL 13 IS 12 BP 2314 EP 2320 DI 10.1007/s11605-009-0952-1 PG 7 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 526PJ UT WOS:000272303000032 PM 19847570 ER PT J AU Goetz, MB Hoang, T Henry, SR Knapp, H Anaya, HD Gifford, AL Asch, SM AF Goetz, Matthew Bidwell Hoang, Tuyen Henry, S. Randal Knapp, Herschel Anaya, Henry D. Gifford, Allen L. Asch, Steven M. CA QUERI-HIV Hepatitis Program TI Evaluation of the Sustainability of an Intervention to Increase HIV Testing SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE HIV testing; provider education; sustainability; VA hospitals ID HUMAN-IMMUNODEFICIENCY-VIRUS; IMPROVING PRIMARY-CARE; UNITED-STATES; CLINICAL REMINDERS; COST-EFFECTIVENESS; CHRONIC ILLNESS; PERSONS AWARE; QUERI SERIES; RISK; PREVENTION AB Sustainability-the routinization and institutionalization of processes that improve the quality of healthcare-is difficult to achieve and not often studied. To evaluate the sustainability of increased rates of HIV testing after implementation of a multi-component intervention in two Veterans Health Administration healthcare systems. Quasi-experimental implementation study in which the effect of transferring responsibility to conduct the provider education component of the intervention from research to operational staff was assessed. Persons receiving healthcare between 2005 and 2006 (intervention year) and 2006 and 2007 (sustainability year). Monthly HIV testing rate, stratified by frequency of clinic visits. The monthly adjusted testing rate increased from 2% at baseline to 6% at the end intervention year and then declined reaching 4% at the end of the sustainability year. However, the stratified, visit-specific testing rate for persons newly exposed to the intervention (i.e., having their first through third visits during the study period) increased throughout the intervention and sustainability years. Increases in the proportion of visits by patients who remained untested despite multiple, prior exposures to the intervention accounted for the aggregate attenuation of testing during the sustainability year. Overall, the percentage of patients who received an HIV test in the sustainability year was 11.6%, in the intervention year 11.1%, and in the pre-intervention year 5.0% Provider education combined with informatics and organizational support had a sustainable effect on HIV testing rates. The effect was most pronounced during patients' early contacts with the healthcare system. C1 [Goetz, Matthew Bidwell] VA Greater Los Angeles Healthcare Syst, Infect Dis Sect 111F, Los Angeles, CA 90073 USA. [Hoang, Tuyen; Henry, S. Randal; Knapp, Herschel; Anaya, Henry D.; Asch, Steven M.] VA Greater Los Angeles Healthcare Syst, Gen Med 111G, Los Angeles, CA 90073 USA. [Gifford, Allen L.] Edith Nourse Rogers Mem Vet Hosp, VA Bedford Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Gifford, Allen L.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Gifford, Allen L.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Goetz, Matthew Bidwell; Anaya, Henry D.; Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Goetz, MB (reprint author), VA Greater Los Angeles Healthcare Syst, Infect Dis Sect 111F, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM matthew.goetz@va.gov OI Goetz, Matthew/0000-0003-4542-992X FU Health Services Research & Development Service [SDP 06-001] FX Support: This project was supported by a research grant to Drs. Goetz and Asch by the Health Services Research & Development Service (SDP 06-001) NR 48 TC 19 Z9 20 U1 1 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2009 VL 24 IS 12 BP 1275 EP 1280 DI 10.1007/s11606-009-1120-8 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 527OC UT WOS:000272375400003 PM 19798538 ER PT J AU Hoffman, RM Walter, LC AF Hoffman, Richard M. Walter, Louise C. TI Colorectal Cancer Screening in the Elderly: The Need for Informed Decision Making SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID FECAL OCCULT-BLOOD; UNITED-STATES; VETERANS; COMORBIDITY; MORTALITY; IMPACT; DEATH C1 [Hoffman, Richard M.] Univ New Mexico, New Mexico VA Hlth Care Syst, Albuquerque, NM 87108 USA. [Walter, Louise C.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. RP Hoffman, RM (reprint author), Univ New Mexico, New Mexico VA Hlth Care Syst, 1501 San Pedro Dr SE, Albuquerque, NM 87108 USA. EM rhoffman@unm.edu NR 14 TC 7 Z9 8 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2009 VL 24 IS 12 BP 1336 EP 1337 DI 10.1007/s11606-009-1121-7 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 527OC UT WOS:000272375400014 PM 19798537 ER PT J AU Tierney, WM Gerrity, MS Byrne, C AF Tierney, William M. Gerrity, Martha S. Byrne, Cindy TI Five Years Before the Masthead: Our Journey with the Journal of General Internal Medicine SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID HOSPITAL MEDICINE; POLICY; SOCIETY; CARE C1 [Tierney, William M.] Indiana Univ, Sch Med, Indianapolis, IN USA. [Tierney, William M.; Byrne, Cindy] Regenstrief Inst Inc, Indianapolis, IN USA. [Gerrity, Martha S.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Gerrity, Martha S.] Portland VA Med Ctr, Portland, OR USA. RP Tierney, WM (reprint author), Hlth Informat & Translat Sci Bldg,410 W 10th St,S, Indianapolis, IN 46202 USA. EM wtierney@iupui.edu NR 17 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2009 VL 24 IS 12 BP 1349 EP 1355 DI 10.1007/s11606-009-1188-1 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 527OC UT WOS:000272375400016 PM 19936844 ER PT J AU Cree, RA Lynch, J Au, MG Myers, MF AF Cree, Robyn A. Lynch, John Au, Margaret G. Myers, Melanie F. TI Decisions to Seek Healthcare Based on Family Health History Among Urban Appalachian Women SO JOURNAL OF GENETIC COUNSELING LA English DT Article DE Appalachia; Family health history; Medically underserved; Grounded theory; Healthcare; Intervention ID HEART-DISEASE; CARDIOVASCULAR-DISEASE; HUMAN-GENETICS; RISK; SUSCEPTIBILITY; PERCEPTIONS; POPULATION; PREVENTION; INTERVIEW; ATTITUDES AB Family health history (FHH) is a valuable health promotion tool that can be used to assess disease risk and make lifestyle and screening recommendations. However, few FHH resources exist for medically underserved populations such as the urban Appalachian community in Cincinnati Ohio. Women of Appalachian heritage with less than a college education who did and did not participate in a prior FHH education session were interviewed by phone in a semi-structured format. Interviewees were asked to discuss their understanding of FHH and the role FHH played in seeking (or not seeking) medical care. Analysis of their discussion identified four overarching themes as well as a model identifying conditions that facilitated or impeded the choice to seek medical care based on FHH. Findings from this study may be used to develop targeted FHH educational interventions in the urban Appalachian and other communities. C1 [Cree, Robyn A.] Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA. [Lynch, John] Univ Cincinnati, Coll Arts & Sci, Dept Commun, Cincinnati, OH USA. [Au, Margaret G.] Massachusetts Gen Hosp, Reprod Endocrine Unit, Boston, MA 02114 USA. [Myers, Melanie F.] Univ Cincinnati, Coll Allied Hlth Sci, Cincinnati, OH USA. [Myers, Melanie F.] Cincinnati Childrens Hosp, Med Ctr, Div Human Genet, Cincinnati, OH USA. RP Cree, RA (reprint author), Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA. EM rac5038@psu.edu; Melanie.Myers@cchmc.org FU NIH National Human Genome Research Institute [1004897] FX We would like to thank the NIH National Human Genome Research Institute for funding part of this project ( Education and Community Involvement Branch, contract # 1004897). We would also like to thank the College of Medicine, University of Cincinnati Summer Undergraduate Research Fellowship program as well as Donna Sinclair for her help transcribing the interviews. We especially thank the community organizations and all the women who participated in the interviews who made this project possible. NR 49 TC 6 Z9 6 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1059-7700 J9 J GENET COUNS JI J. Genet. Couns. PD DEC PY 2009 VL 18 IS 6 BP 534 EP 550 DI 10.1007/s10897-009-9236-x PG 17 WC Genetics & Heredity SC Genetics & Heredity GA 517UE UT WOS:000271643000005 PM 19813081 ER PT J AU Wang, LY Leverenz, JB Larson, EB Vavrek, DA Kukull, WA McCormick, W Bowen, JD Teri, L Montine, T Tsuang, DW AF Wang, Lucy Y. Leverenz, James B. Larson, Eric B. Vavrek, Darcy A. Kukull, Walter A. McCormick, Wayne Bowen, James D. Teri, Linda Montine, Thomas Tsuang, Debby W. TI Cognitive Impairment in Older Adults Without Dementia: Clinical and Pathologic Outcomes in a Community-Based Sample SO JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY LA English DT Article DE autopsy; neuropathology; dementia; mild cognitive impairment ID ALZHEIMER-DISEASE PATHOLOGY; MEMORY COMPLAINTS; CONSORTIUM; DIAGNOSIS; ASSOCIATION; PROGRESSION; ESTABLISH; REGISTRY; HEALTH; CERAD AB This study examines clinical and neuropathologic characteristics of 37 participants in a community-based dementia series who had cognitive complaints at enrollment but did not meet dementia criteria. Participants had neuropsychological testing, were followed until death, and underwent autopsy. Twenty-four participants progressed to dementia, and their baseline characteristics were analyzed. Of the 24, 13 met criteria for neuropathologic Alzheimer disease (AD). The 13 participants who progressed to neuropathologic AD (mean intake age 78.5 +/- 7.7, mean enrollment 6.4 +/- 2.1 years) performed worse than the 11 who progressed to neuropathologic non-AD dementias (mean intake age 79.0 +/- 6.0, mean enrollment 6.0 +/- 3.2 years) on baseline Wechsler Memory Scale (WMS) delayed logical memory (3.4 +/- 2.9 vs 6.3 +/- 3.9, P = .05) and delayed visual reproduction (1.4 +/- 2.1 vs 3.1 +/- 2.7, P = .02). These observations are consistent with the view that nondemented patients with underlying AD may be more likely to present with memory than nonmemory cognitive impairment. C1 [Wang, Lucy Y.; Leverenz, James B.; Tsuang, Debby W.] VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98018 USA. [Leverenz, James B.] VA Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA 98018 USA. [Wang, Lucy Y.; Leverenz, James B.; Vavrek, Darcy A.; Tsuang, Debby W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Leverenz, James B.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Kukull, Walter A.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Larson, Eric B.; McCormick, Wayne] Univ Washington, Dept Internal Med, Seattle, WA 98195 USA. [Montine, Thomas] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Teri, Linda] Univ Washington, Dept Psychosocial & Community Hlth, Seattle, WA 98195 USA. [Kukull, Walter A.] Natl Alzheimers Coordinating Ctr, Seattle, WA USA. [Larson, Eric B.] Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA USA. [Vavrek, Darcy A.] Western States Chiropract Coll, Portland, OR USA. [Bowen, James D.] Evergreen Healthcare Syst, Kirkland, WA USA. RP Wang, LY (reprint author), VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, 1660 S Columbian Way,S-116-6E, Seattle, WA 98018 USA. EM wanglucy@u.washington.edu RI Tsuang, Debby/L-7234-2016; OI Tsuang, Debby/0000-0002-4716-1894; Kukull, Walter/0000-0001-8761-9014 FU NIH [AG006781, NS048595]; Department of Veterans Affairs Mental Illness Research, Education, and Clinical Centers Special Fellowship in Advanced Psychiatry FX This research was presented in part as a poster at the 10th International Conference on Alzheimer's Disease and Related Disorders, Madrid, Spain, July 2006. The study was supported by research grants from NIH (AG006781, NS048595) and the Department of Veterans Affairs Mental Illness Research, Education, and Clinical Centers Special Fellowship in Advanced Psychiatry. We gratefully acknowledge G. Stennis Watson, PhD, for his assistance in interpreting neuropsychological data and Andrew David for his editorial assistance. NR 36 TC 2 Z9 2 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0891-9887 J9 J GERIATR PSYCH NEUR JI J. Geriatr. Psychiatry Neurol. PD DEC PY 2009 VL 22 IS 4 BP 256 EP 265 DI 10.1177/0891988709335796 PG 10 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 520SC UT WOS:000271867200006 PM 19433862 ER PT J AU Rahman, KM Duggal, P Harris, JB Saha, SK Streatfield, PK Ryan, ET Calderwood, SB Qadri, F Yunus, M LaRocque, RC AF Rahman, Kazi Mizanur Duggal, Priya Harris, Jason B. Saha, Sajal Kumar Streatfield, Peter Kim Ryan, Edward T. Calderwood, Stephen B. Qadri, Firdausi Yunus, Mohammad LaRocque, Regina C. TI Familial Aggregation of Vibrio cholerae-associated Infection in Matlab, Bangladesh SO JOURNAL OF HEALTH POPULATION AND NUTRITION LA English DT Article DE Case-control studies; Cholera; Familial aggregation; Risk factors; Vibrio cholerae; Bangladesh ID GENETIC SUSCEPTIBILITY; BLOOD-GROUP; IMPACT; DYNAMICS; OUTBREAK; DISEASE; RISK AB Vibrio cholerae is a major cause of diarrhoeal illness in endemic regions, such as Bangladesh. Understanding the factors that determine an individual's susceptibility to infection due to V cholerae may lead to improved prevention and control strategies. Increasing evidence suggests that human genetic factors affect the severity of V. cholerae-associated infection. This study, therefore, sought to characterize the heritable component of susceptibility to infection due to V cholerae using the Matlab Health and Demographic Surveillance System database of the International Centre for Diarrhoeal Disease Research, Bangladesh. In total, 144 pedigrees that included a cholera patient and 341 pedigrees without a cholera patient were evaluated during 1 January-31 December 1992. The odds of the sibling of a patient being admitted with cholera were 7.67 times the odds of the sibling of an unaffected individual being admitted with cholera [95% confidence interval (CI) 2.40-24.5, p<0.001], after adjustment for gender, age, socioeconomic status, and hygiene practices. Although exposure to environmental reservoirs is essential in the epidemiology of cholera, household-specific factors, such as familial relatedness to an index case, may also be important determinants of risk of cholera. Further analysis of human genetic factors that contribute to susceptibility to cholera may be productive. C1 [Rahman, Kazi Mizanur] ICDDR B, Child Hlth Unit, Div Publ Hlth Sci, Dhaka 1000, Bangladesh. [Duggal, Priya] NHGRI, NIH, Baltimore, MD USA. [Harris, Jason B.; Ryan, Edward T.; Calderwood, Stephen B.; LaRocque, Regina C.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. RP Rahman, KM (reprint author), ICDDR B, Child Hlth Unit, Div Publ Hlth Sci, GPO Box 128, Dhaka 1000, Bangladesh. EM mizan@icddrb.org FU National Institutes of Health (NIH) [D43-TW05572, K01-TW07409, K01-TW07144]; National Institute of Allergy and Infectious Diseases [U01-AI58935, R03-AI063079]; Massachusetts General Hospital FX This research was funded by the Fogarty International Center of the National Institutes of Health (NIH) (Grant No. D43-TW05572 for K.M.R.), the Intramural Program of the National Human Genome Research Institute of the NIH (P.D.), the Fogarty International Center of the NIH (Grant No. K01-TW07409 for J.B.H.), the National Institute of Allergy and Infectious Diseases (Grant No. U01-AI58935 for S.B.C.), the National Institute of Allergy and Infectious Diseases (Grant No. R03-AI063079 for F.Q.), a Claflin Distinguished Scholar Award from the Massachusetts General Hospital (R.C.L.), and the Fogarty International Center of the NIH (Grant No. K01-TW07144 for R.C.L.). ICDDR,B acknowledges with gratitude the commitment of the above-mentioned institutes to the Centre's research efforts. NR 23 TC 7 Z9 7 U1 0 U2 1 PU I C D D R B-CENTRE HEALTH POPULATION RESEARCH PI DHAKA PA MOHAKHALI, 1212 DHAKA, BANGLADESH SN 1606-0997 J9 J HEALTH POPUL NUTR JI J. Heatlh Popul. Nutr. PD DEC PY 2009 VL 27 IS 6 BP 733 EP 738 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 548GN UT WOS:000273948200004 PM 20099756 ER PT J AU Xia, YM Huang, YY Lin, LD Liu, XM Jiang, S Xiong, LY AF Xia, Yumin Huang, Yingying Lin, Longde Liu, Xiaoming Jiang, Shan Xiong, Layuan TI A comparative study on the enhancement efficacy of specific and non-specific iron chelators for protoporphyrin IX production and photosensitization in HaCat cells SO JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES LA English DT Article DE aminolaevulinic acid; desferrioxamine; ethylenediaminetetraacetic acid; keratinocytes; photodynamic therapy; protoporphyrin IX ID MEDIATED PHOTODYNAMIC THERAPY; DELTA-AMINOLEVULINIC-ACID; NONMELANOMA SKIN-CANCER; 5-AMINOLEVULINIC ACID; IN-VITRO; PORPHYRIN PRODUCTION; TUMOR-CELLS; LASER; APOPTOSIS; ACCUMULATION AB The iron chelators can be utilized in target cells to improve 5-aminolaevulinic acid (ALA)-based photodynamic therapy (PDT). The purpose of this study is to compare the effect of two kinds of iron chelators, desferrioxamine (DFO) and ethylenediaminetetraacetic acid (EDTA) on the enhancement of ALA-PDT. HaCat cells were cultured in medium containing 2.0 mmol/L of ALA and 0.5 mmol/L of DFO or EDTA. After 3-h incubation in the dark, the concentration of cellular protoporphyrin IX (PpIX) was detected by high performance liquid chromatography (HPLC), and the fluorescence of PpIX was observed at 630 nm emission under confocal laser scanning microscope. For PDT, HaCat cells were irradiated using 632.8 nm laser, and the fractions of apoptotic and necrotic cells were flow cytometrically assayed. Related differences in morphology and ultrastructure of Ha-Cat cells were observed using optical microscope or transmission electron microscope. Compared to incubation with ALA alone, the addition of DFO or EDTA increased the concentration of cellular PpIX and the fluorescent density of PpIX, and also increased cell death ratio after PDT. PDT using ALA plus DFO produced the highest cellular PpIX level, greatest cell death ratio and most severe structural damage to the cells. It was concluded that both DFO and EDTA could enhance ALA-based PpIX production and PDT. Compared to the non-specific iron chelator of EDTA, the specific chelator, DFO, showed more potential for the enhancement. C1 [Xia, Yumin; Liu, Xiaoming; Jiang, Shan; Xiong, Layuan] Wuhan Univ, Dept Dermatol, Renmin Hosp, Wuhan 430060, Peoples R China. [Huang, Yingying] Guangxi Med Univ, Aesthet & Plast Ctr, Nanning 530007, Peoples R China. [Huang, Yingying] Harvard Univ, Sch Med, Wellman Ctr Photomed, Massachusetts Gen Hosp, Boston, MA 02114 USA. [Lin, Longde] Guangxi Med Univ, Sch Publ Hlth, Nanning 530027, Peoples R China. RP Xia, YM (reprint author), Wuhan Univ, Dept Dermatol, Renmin Hosp, Wuhan 430060, Peoples R China. EM ymxia@whu.edu.cn NR 25 TC 2 Z9 3 U1 0 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1672-0733 J9 J HUAZHONG U SCI-MED JI J. Huazhong Univ. Sci. Tech.-Med. PD DEC PY 2009 VL 29 IS 6 BP 765 EP 770 DI 10.1007/s11596-009-0619-x PG 6 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 537QT UT WOS:000273129100019 PM 20037824 ER PT J AU Truong, QA Toepker, M Mahabadi, AA Bamberg, F Rogers, IS Blankstein, R Brady, TJ Nagurney, JT Hoffmann, U AF Truong, Quynh A. Toepker, Michael Mahabadi, Amir A. Bamberg, Fabian Rogers, Ian S. Blankstein, Ron Brady, Thomas J. Nagurney, John T. Hoffmann, Udo TI Relation of left ventricular mass and concentric remodeling to extent of coronary artery disease by computed tomography in patients without left ventricular hypertrophy: ROMICAT study SO JOURNAL OF HYPERTENSION LA English DT Article DE computed tomography; concentric remodeling; coronary artery plaque; left ventricular mass; left ventricular mass index ID HYPERTENSIVE PATIENTS; GEOMETRIC PATTERNS; PROGNOSTIC-SIGNIFICANCE; EJECTION FRACTION; SYSTOLIC FUNCTION; RISK; HEART; ANGIOGRAPHY; MORTALITY; ADULTS AB Objective Cardiac computed tomography allows for simultaneous assessment of left ventricular mass (LVM) and coronary artery disease (CAD). We aimed to determine whether LVM, LVM index (LVMi), and the left ventricular geometric pattern of concentric remodeling are associated with the extent of CAD in patients without left ventricular hypertrophy. Methods In 348 patients from the Rule Out Myocardial Infarction Using Computer Assisted Tomography trial, 64-slice computed tomography was performed and LVM measured at end-diastole. We used three LVM indexation criteria to obtain three cohorts: LVM indexed to body surface area by echocardiography (n=337) and computed tomography criteria (n=325), and by height(2.7) (n=326). The cohorts were subdivided into concentric remodeling and normal geometry. Extent of coronary plaque was classified based on a 17-segment model, treated as a continuous variable, and stratified into three groups: zero segment, one to four segments, and more than four segments. Results Patients with more than four segments of coronary plaque had higher LVM (Delta 12.8-15.1 g) and LVMi (Delta 4.0-5.5 g/m(2) and Delta 2.2 g/m(2.7)) than those without CAD (all P <= 0.03). After multivariable adjustment, LVM and LVMi remained independent predictors of extent of coronary plaque, with 0.27-0.29 segments more plaque per 20 g increase of LVM (all P=0.02), 0.32-0.34 segments more plaque per 10 g/m(2) increase of LVMi (both P=0.02), and 0.80 segments more plaque per 10 g/m(2.7) increase of LVMi (P=0.008). Concentric remodeling patients had 1.1-1.3 segments more plaque than those with normal geometry (all P <= 0.05). Patients with more than four segments of plaque had two-fold increase in odds (all P <= 0.05) of having concentric remodeling as compared with those without CAD. Conclusion Increased LVM, LVMi, and concentric remodeling are associated with a greater degree of coronary plaque burden in patients without left ventricular hypertrophy. These findings could provide an indication to intensify medical therapy in patients with subclinical CAD and hypertension. J Hypertens 27:2472-2482 (c) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins. C1 [Truong, Quynh A.; Mahabadi, Amir A.; Bamberg, Fabian; Rogers, Ian S.; Blankstein, Ron; Brady, Thomas J.; Hoffmann, Udo] Harvard Univ, Sch Med, Cardiac MR PET CT Program, Massachusetts Gen Hosp, Boston, MA 02114 USA. [Truong, Quynh A.; Rogers, Ian S.] Harvard Univ, Sch Med, Div Cardiol, Massachusetts Gen Hosp, Boston, MA 02114 USA. [Truong, Quynh A.; Bamberg, Fabian; Brady, Thomas J.; Hoffmann, Udo] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02114 USA. [Toepker, Michael] Univ Hosp Vienna, Dept Radiol, Vienna, Austria. [Nagurney, John T.] Harvard Univ, Sch Med, Dept Emergency Med, Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Truong, QA (reprint author), Harvard Univ, Sch Med, Cardiac MR PET CT Program, Massachusetts Gen Hosp, 165 Cambridge St,Suite 400, Boston, MA 02114 USA. EM qtruong@partners.org FU NIH [R01 HL080053, T32HL076136, L30HL093896]; Siemens Medical Solutions and General Electrics Healthcare; Erwin Schroedinger; German National Academic Foundation FX We gratefully acknowledge the enthusiastic support in patient enrollment of the team of faculty, residents, nursing and administrative staff of the Emergency Department Services of the Massachusetts General Hospital.; The present work was supported by the NIH R01 HL080053 and in part supported by Siemens Medical Solutions and General Electrics Healthcare. R.B., I.S.R. and Q.A.T. received support from NIH grant T32HL076136. Q.A.T. also received support from NIH grant L30HL093896. M.T. was supported by the Erwin Schroedinger fellowship abroad. A.A.M. was supported by a grant from the German National Academic Foundation. NR 38 TC 8 Z9 10 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0263-6352 EI 1473-5598 J9 J HYPERTENS JI J. Hypertens. PD DEC PY 2009 VL 27 IS 12 BP 2472 EP 2482 DI 10.1097/HJH.0b013e328331054a PG 11 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 528DH UT WOS:000272420800024 PM 19696685 ER PT J AU Ginde, AA Clark, S Camargo, CA AF Ginde, Adit A. Clark, Sunday Camargo, Carlos A., Jr. TI Language Barriers among Patients in Boston Emergency Departments: Use of Medical Interpreters After Passage of Interpreter Legislation SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH LA English DT Article DE Interpreters; Language barriers; Emergency department; Immigrants AB Background Since 2001, Massachusetts state law dictates that emergency department (ED) patients with limited English proficiency have the right to a professional interpreter. Methods one year later, for two 24-h periods, we interviewed adult patients presenting to four Boston EDs. We assessed language barriers and compared this need with the observed use and type of interpreter during the ED visit. Results We interviewed 530 patients (70% of eligible) and estimated that an interpreter was needed for 60 (11%; 95% confidence interval, 7-12%) patients. The primary interpreter for these clinical encounters was a physician (30%), friend or family member age >= 18 years (22%), hospital interpreter services (15%), younger family member (11%), or other hospital staff (17%). Conclusions We found that 11% of ED patients had significant language barriers, but use of professional medical interpreters remained low. One year after passage of legislation mandating access, use of professional medical interpreters remained inadequate. C1 [Camargo, Carlos A., Jr.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, EMNet Coordinating Ctr,Dept Emergency Med, Boston, MA 02114 USA. [Ginde, Adit A.] Univ Colorado, Denver Sch Med, Dept Emergency Med, Aurora, CO USA. [Clark, Sunday] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. RP Camargo, CA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, EMNet Coordinating Ctr,Dept Emergency Med, 326 Cambridge St,Suite 410, Boston, MA 02114 USA. EM ccamargo@partners.org RI Siry, Bonnie/D-7189-2017 FU NIAID NIH HHS [U01 AI-67693, U01 AI067693] NR 9 TC 13 Z9 14 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1557-1912 J9 J IMMIGR MINOR HEALT JI J. Immigr. Minor. Health PD DEC PY 2009 VL 11 IS 6 BP 527 EP 530 DI 10.1007/s10903-008-9188-5 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 645ZT UT WOS:000281505400014 PM 18810638 ER PT J AU Cho, JM Sohn, IS Jang, IK AF Cho, Jin-Man Sohn, Il-Suk Jang, Ik-Kyung TI Late Sequela of Kawasaki's Disease: Optical Coherence Tomographic Finding SO JOURNAL OF INVASIVE CARDIOLOGY LA English DT Editorial Material C1 [Jang, Ik-Kyung] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. [Cho, Jin-Man; Sohn, Il-Suk] Kyung Hee Univ Hosp, Seoul, South Korea. RP Jang, IK (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, 55 Fruit St,Gray Bigelow 800, Boston, MA 02114 USA. EM ijang@partners.org NR 4 TC 1 Z9 1 U1 0 U2 0 PU H M P COMMUNICATIONS PI MALVERN PA 83 GENERAL WARREN BLVD, STE 100, MALVERN, PA 19355 USA SN 1042-3931 J9 J INVASIVE CARDIOL JI J. Invasive Cardiol. PD DEC PY 2009 VL 21 IS 12 BP 668 EP 668 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 687VW UT WOS:000284807300013 PM 19966372 ER PT J AU Maloney, JP AF Maloney, James Peter TI Genetic Factors Impacting Therapy in Acute Lung Injury/Acute Respiratory Distress Syndrome SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Article DE acute lung injury; ARDS; genetics; pre-B-cell colony-enhancing factor; mannose-binding lectin 2 ID MANNOSE-BINDING LECTIN; COLONY-ENHANCING FACTOR; TRANSCRIPTION FACTOR NRF2; UNITED-STATES; SEPSIS; LIPOPOLYSACCHARIDE; SUSCEPTIBILITY; POLYMORPHISMS; NEUTROPHIL; DISEASE AB Acute lung injury (ALI) and its most severe form the acute respiratory distress syndrome occur in patients who have a predisposing severe inflammatory insult to the lung. Most often ALI is due to sepsis from bacterial infection, but ALI can occur with any infection and with noninfectious insults such as severe trauma, acute pancreatitis, aspiration, and near-drowning. After any of these insults, the interindividual risk of progression to ALI and the risk of death remain difficult to predict. Our inability to predict an individual's susceptibility to acute lung injury has long suggested that genetic factors influence ALI risk. There is substantial evidence for heritable predispositions to severe infections and an emerging body of literature implicating genetic factors in ALI pathogenesis. A paradigm is emerging that the genetic risk for ALI can be best understood in terms of factors that control 3 overlapping stages of ALI pathogenesis: risk for the acquisition of a predisposing condition (such as a severe pneumonia), risk for progression to lung injury during systemic inflammatory states (such as severe sepsis), and risk for failure of endogenous mechanisms to resolve the lung injury. The evidence supporting this paradigm is herein reviewed, along with potential treatment strategies that could be directed by knowledge of specific genetic factors in an individual patient. C1 [Maloney, James Peter] Univ Colorado, Div Pulm & Crit Care Med, Denver, CO 80262 USA. [Maloney, James Peter] Denver VA Med Ctr, Denver, CO USA. RP Maloney, JP (reprint author), Univ Colorado, Div Pulm & Crit Care Med, 4200 E 9th Ave,C-272, Denver, CO 80262 USA. EM james.maloney@uchsc.edu RI maloney, james/K-9428-2015 OI maloney, james/0000-0001-8348-4650 FU NHLBI [HL071618] FX Supported by NHLBI grant HL071618. NR 26 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD DEC PY 2009 VL 57 IS 8 BP 865 EP 869 PG 5 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 531CW UT WOS:000272641300017 PM 18827716 ER PT J AU Lee, JY Buzney, CD Poznansky, MC Sackstein, R AF Lee, Jack Y. Buzney, Catherine D. Poznansky, Mark C. Sackstein, Robert TI Dynamic alterations in chemokine gradients induce transendothelial shuttling of human T cells under physiologic shear conditions SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Article DE chemotaxis; fugetaxis; intravasation; CXCL12; transendothelial migration; shear stress; fluid shear ID VASCULAR ENDOTHELIUM; SULFATED POLYSACCHARIDES; STEM/PROGENITOR CELLS; MULTISTEP PARADIGM; BLOOD-CIRCULATION; PROGENITOR CELLS; ACTIVE MOVEMENT; FACTOR-I; EMIGRATION; MOBILIZATION AB The active movement of cells from subendothelial compartments into the bloodstream (intravasation) has been recognized for several decades by histologic and physiologic studies, yet the molecular effectors of this process are relatively uncharacterized. For extravasation, studies based predominantly on static transwell assays support a general model, whereby transendothelial migration (TEM) occurs via chemoattraction toward increasing chemokine concentrations. However, this model of chemotaxis cannot readily reconcile how chemokines influence intravasation, as shear forces of blood flow would likely abrogate luminal chemokine gradient(s). Thus, to analyze how T cells integrate perivascular chemokine signals under physiologic flow, we developed a novel transwell-based flow chamber allowing for real-time modulation of chemokine levels above (luminal/apical compartment) and below (abluminal/subendothelial compartment) HUVEC monolayers. We routinely observed human T cell TEM across HUVEC monolayers with the combination of luminal CXCL12 and abluminal CCL5. With increasing concentrations of CXCL12 in the luminal compartment, transmigrated T cells did not undergo retro-TEM. However, when exposed to abluminal CXCL12, transmigrated T cells underwent striking retrograde transendothelial migration (retro-TEM) and re-entered the flow stream. This CXCL12 fugetactic (chemorepellant) effect was concentration-dependent, augmented by apical flow, blocked by antibodies to integrins, and reduced by AMD3100 in a dose-dependent manner. Moreover, CXCL12-induced retro-TEM was inhibited by PI3K antagonism and cAMP agonism. These findings broaden our understanding of chemokine biology and support a novel paradigm by which temporospatial modulations in subendothelial chemokine display drive cell migration from interstitial compartments into the bloodstream. J. Leukoc. Biol. 86: 1285-1294; 2009. C1 [Lee, Jack Y.; Buzney, Catherine D.; Sackstein, Robert] Brigham & Womens Hosp, Harvard Skin Dis Res Ctr, Boston, MA 02115 USA. [Lee, Jack Y.; Buzney, Catherine D.; Sackstein, Robert] Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA. [Poznansky, Mark C.] Massachusetts Gen Hosp, Dana Farber Harvard Canc Ctr, Boston, MA 02114 USA. [Sackstein, Robert] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA. [Sackstein, Robert] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Oncol, Boston, MA 02115 USA. RP Sackstein, R (reprint author), Harvard Inst Med, 77 Ave Louis Pasteur,Room 671, Boston, MA 02115 USA. EM rsackstein@rics.bwh.harvard.edu FU Public Health Service [RO1 AI49757]; Juvenile Diabetes Research Foundation [RO1 HL60528, RO1 HL73714, RO1 CA121335] FX M. C. P. was supported by Public Health Service grant RO1 AI49757 and the Juvenile Diabetes Research Foundation. R. S. was supported by RO1 HL60528, RO1 HL73714, and RO1 CA121335. We thank Ron Yip and Dr. Elda Righi for their assistance with the CXCL12 and CCL5 ELISA assays. NR 42 TC 13 Z9 13 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD DEC PY 2009 VL 86 IS 6 BP 1285 EP 1294 DI 10.1189/jlb.0309214 PG 10 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 525DF UT WOS:000272193000004 PM 19797295 ER PT J AU Jin, JF Mullen, TD Hou, Q Bielawski, J Bielawska, A Zhang, XM Obeid, LM Hannun, YA Hsu, YT AF Jin, Junfei Mullen, Thomas D. Hou, Qi Bielawski, Jacek Bielawska, Alicja Zhang, Xiaoming Obeid, Lina M. Hannun, Yusuf A. Hsu, Yi-Te TI AMPK inhibitor Compound C stimulates ceramide production and promotes Bax redistribution and apoptosis in MCF7 breast carcinoma cells SO JOURNAL OF LIPID RESEARCH LA English DT Article DE AMP-activated protein kinase signaling pathway; sphingolipid; cell death ID ACTIVATED PROTEIN-KINASE; MITOCHONDRIAL-MEMBRANE; ACID SPHINGOMYELINASE; DEPENDENT PATHWAY; SALVAGE PATHWAY; SYNTHASE; FAMILY; PROLIFERATION; SPHINGOLIPIDS; TRANSLOCATION AB Compound C is commonly used as an inhibitor of AMP-activated protein kinase (AMPK), which serves as a key energy sensor in cells. In this study, we found that Compound C treatment of MCF7 cells led to Bax redistribution from the cytoplasm to mitochondria and cell death. However, this effect does not involve AMPK. In addition, we found that treatment with this compound leads to an enhanced ceramide production. Analyses by quantitative PCR and ceramide synthase activity assay suggest that ceramide synthase 5 (LASS/CerS 5) is involved in Compound C-induced ceramide upregulation. Downregulation of LASS/CerS 5 was found to attenuate Compound C-mediated ceramide production, Bax redistribution, and cell death.-Jin, J., T. D. Mullen, Q. Hou, J. Bielawski, A. Bielawska, X. Zhang, L. M. Obeid, Y. A. Hannun, and Y-T. Hsu. AMPK inhibitor Compound C stimulates ceramide production and promotes Bax redistribution and apoptosis in MCF7 breast carcinoma cells. J. Lipid Res. 2009. 50: 2389-2397. C1 [Jin, Junfei; Hou, Qi; Bielawski, Jacek; Bielawska, Alicja; Zhang, Xiaoming; Hannun, Yusuf A.; Hsu, Yi-Te] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Jin, Junfei] Univ S China, Res Ctr Life Sci, Hengyang 421001, Hunan, Peoples R China. [Mullen, Thomas D.; Obeid, Lina M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Hou, Qi] Peking Union Med Coll, Inst Mat Med, Dept Pharmacol, Beijing 100050, Peoples R China. Chinese Acad Med Sci, Beijing 100050, Peoples R China. [Obeid, Lina M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Hsu, YT (reprint author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. EM hsuy@musc.edu OI obeid, lina/0000-0002-0734-0847 FU National Institutes of Health [NS40932, NCRR-C06RR018823] FX This research was supported in part by National Institutes of Health Grant NS40932 ( to Y-T.H.). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. Special acknowledgment is given for the National Institutes of Health Grant NCRR-C06RR018823 in providing laboratory space for lipidomics shared resource in the Children's Research Institute. NR 45 TC 53 Z9 54 U1 0 U2 6 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0022-2275 J9 J LIPID RES JI J. Lipid Res. PD DEC PY 2009 VL 50 IS 12 BP 2389 EP 2397 DI 10.1194/jlr.M900119-JLR200 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 519LV UT WOS:000271769000007 PM 19528633 ER PT J AU Sherry, AD Caravan, P Lenkinski, RE AF Sherry, A. Dean Caravan, Peter Lenkinski, Robert E. TI Primer on Gadolinium Chemistry SO JOURNAL OF MAGNETIC RESONANCE IMAGING LA English DT Article DE gadolinium MRI contrast agents; nephrogenic systemic fibrosis; thermodynamic and kinetic principles ID NEPHROGENIC SYSTEMIC FIBROSIS; IMAGING CONTRAST AGENTS; IN-VIVO; LANTHANIDE(III) COMPLEXES; KINETIC STABILITIES; WATER EXCHANGE; EQUILIBRIUM; ACID; TRANSMETALATION; DISSOCIATION AB Gadolinium is widely known by all practitioners of magnetic resonance imaging (MRI) but few appreciate the basic solution chemistry of this trivalent lanthanide ion. Given the recent linkage between gadolinium contrast agents and nephrogenic systemic fibrosis, some basic chemistry of this ion must be more widely understood. This short primer on gadolinium chemistry is intended to provide the reader the background principles necessary to understand the basics of chelation chemistry. water hydration numbers, and the differences between thermodynamic stability and kinetic stability or inertness. We illustrate the fundamental importance of kinetic dissociation rates in deter-mining gadolinium toxicity in vivo by presenting new data for a novel europium DOTA-tetraamide complex that is relatively unstable thermodynamically yet extraordinarily inert kinetically and also quite nontoxic. This, plus other literature evidence. forms the basis of the fundamental axiom that it is the kinetic stability of a gadolinium complex, not its thermodynamic stability, that deter-mines its in vivo toxicity. C1 [Sherry, A. Dean] Univ Texas SW Med Ctr Dallas, Adv Imaging Res Ctr, Dallas, TX 75390 USA. [Sherry, A. Dean] Univ Texas SW Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USA. [Sherry, A. Dean] Univ Texas Richardson, Dept Chem, Richardson, TX 75083 USA. [Lenkinski, Robert E.] Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA 02215 USA. [Caravan, Peter] Harvard Univ, Sch Med, AA Martinos Ctr Biomed Imaging, Cambridge, MA 02138 USA. [Caravan, Peter] Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA USA. RP Sherry, AD (reprint author), Univ Texas SW Med Ctr Dallas, Adv Imaging Res Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA. EM dean.sherry@utsouthwestern.edu RI Lenkinski, Robert/F-9045-2014; OI Lenkinski, Robert/0000-0001-7371-5048 FU National Institutes of Health (NIH) [CA-126608, RR-02584, EB-04582]; Robert A. Welch Foundation [AT-584] FX Contract grant sponsor: National Institutes of Health (NIH); Contract grant numbers: CA-126608, RR-02584, EB-04582; Contract grant sponsor: Robert A. Welch Foundation; Contract grant number: AT-584. NR 29 TC 95 Z9 97 U1 3 U2 60 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1053-1807 J9 J MAGN RESON IMAGING JI J. Magn. Reson. Imaging PD DEC PY 2009 VL 30 IS 6 BP 1240 EP 1248 DI 10.1002/jmri.21966 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 525HP UT WOS:000272206100004 PM 19938036 ER PT J AU Aime, S Caravan, P AF Aime, Silvio Caravan, Peter TI Biodistribution of Gadolinium-Based Contrast Agents, Including Gadolinium Deposition SO JOURNAL OF MAGNETIC RESONANCE IMAGING LA English DT Article DE gadolinium; biodistribution; MRI; nephrogenic systemic fibrosis; retention ID NEPHROGENIC SYSTEMIC FIBROSIS; STAGE RENAL-DISEASE; GADOVERSETAMIDE INJECTION OPTIMARK; IMAGING ENHANCEMENT AGENT; HUMAN BONE TISSUE; GADODIAMIDE INJECTION; GD-DTPA; DIAGNOSTIC PITFALL; HUMAN SERUM; IN-VIVO AB The biodistribution of approved gadolinium (Gd)-based contrast agents (GBCAs) is reviewed. After intravenous injection GBCAs distribute in the blood and the extracellular space and transiently through the excretory organs. Preclinical animal studies and the available clinical literature indicate that all these compounds are excreted intact. Elimination tends to be rapid and, for the most part, complete. In renally insufficient patients the plasma elimination half-life increases substantially from hours to days depending on renal function. In patients with impaired renal function and nephrogenic systemic fibrosis (NSF), the agents gadodiamide, gadoversetamide, and gadopentetate dimeglumine have been shown to result in Gd deposition in the skin and internal organs. In these cases, it is likely that the Gd is no longer present as the GBCA, but this has still not been definitively shown. In preclinical models very small amounts of Gd are retained in the bone and liver, and the amount retained correlates with the kinetic and thermodynamic stability of the GBCA with respect to Gd release in vitro. The pattern of residual Gd deposition in NSF subjects may be different than that observed in preclinical rodent models. GBCAs are designed to be used via intravenous administration. Altering the route of administration and/or the formulation of the GBCA can dramatically alter the biodistribution of the GBCA and can increase the likelihood of Gd deposition. C1 [Caravan, Peter] Massachusetts Gen Hosp, Athinoula A Martmos Ctr Biomed Imaging, Dept of Radiology, Charlestown, MA 02129 USA. [Caravan, Peter] Harvard Univ, Sch Med, Charlestown, MA USA. [Aime, Silvio] Univ Turin, Dept Chem, Turin, Italy. [Aime, Silvio] Univ Turin, IFM & Mol Imaging Ctr, Turin, Italy. RP Caravan, P (reprint author), Massachusetts Gen Hosp, Athinoula A Martmos Ctr Biomed Imaging, Dept of Radiology, 149 13th St,Suite 2301, Charlestown, MA 02129 USA. EM caravan@nmr.mgh.harvard.edu FU National Institute Of Biomedical Imaging and Bioengineering [R01EB009062] FX Contract grant sponsor: National Institute Of Biomedical Imaging and Bioengineering; Contract grant number: R01EB009062 (P.C). NR 60 TC 145 Z9 148 U1 5 U2 40 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1053-1807 J9 J MAGN RESON IMAGING JI J. Magn. Reson. Imaging PD DEC PY 2009 VL 30 IS 6 BP 1259 EP 1267 DI 10.1002/jmri.21969 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 525HP UT WOS:000272206100006 PM 19938038 ER PT J AU Abujudeh, HH Rolls, H Kaewlai, R Agarwal, S Gebreananya, ZA Saini, S Schaefer, PW Kay, J AF Abujudeh, Hani H. Rolls, Hillary Kaewlai, Rathachai Agarwal, Sheela Gebreananya, Zelalem A. Saini, Sanjay Schaefer, Pamela W. Kay, Jonathan TI Retrospective Assessment of Prevalence of Nephrogenic Systemic Fibrosis (NSF) After Implementation of a New Guideline for the Use of Gadobenate Dimeglumine as a Sole Contrast Agent for Magnetic Resonance Examination in Renally Impaired Patients SO JOURNAL OF MAGNETIC RESONANCE IMAGING LA English DT Article DE nephrogenic systemic fibrosis; gadolinium-based contrast agents; gadobenate dimeglumine ID GADOLINIUM EXPOSURE; DISEASE; DERMOPATHY; FAILURE; KIDNEY; UPDATE; RISK AB From May 2007 to January 2008, patients with Stage 3-5 chronic kidney disease (CKD) undergoing gadobenate dimeglumine (GBD)-enhanced magnetic resonance (MR) examinations were included in the retrospective investigation. The electronic medical records were reviewed to assess the prevalence of nephrogenic systemic fibrosis (NSF) in renally impaired patients underwent GBD-enhanced MR examinations. In all, 250 patients (98 men, mean age 72.6 years) were included: 97% of the patients had Stage 3 CKD (estimated GFR 30-59 mL/min/1.73 m(2)); 37% had been exclusively exposed to GBD. The remaining were exposed to GBD and other gadolinium-based contrast agents (GBCAs). The mean dose of GBD was 22 mL (standard deviation [SD], 11.2). Including exposure to other GBCAs, the mean cumulative dose of gadolinium was 61 nil, (SD, 62.3). A total of 206 patients (82%) had skin examinations following the last GBD administration (mean duration. 108 days). No evidence of suspected or diagnosed NSF was found. In conclusion, on the basis of a retrospective chart review there was no skin evidence of NSF in predominantly Stage 3 CKD patients who were exposed to GBD at an average follow-up of 108 days, either solely or in combination with other GBCAs. C1 [Abujudeh, Hani H.; Rolls, Hillary; Kaewlai, Rathachai; Agarwal, Sheela; Gebreananya, Zelalem A.; Saini, Sanjay; Schaefer, Pamela W.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Abujudeh, Hani H.; Rolls, Hillary; Kaewlai, Rathachai; Agarwal, Sheela; Gebreananya, Zelalem A.; Saini, Sanjay; Schaefer, Pamela W.; Kay, Jonathan] Harvard Univ, Sch Med, Boston, MA USA. [Kay, Jonathan] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. RP Abujudeh, HH (reprint author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St,FND 210, Boston, MA 02114 USA. EM habujudeh@partners.org OI Kaewlai, Rathachai/0000-0002-0650-9380; Kay, Jonathan/0000-0002-8970-4260 FU Bracco Diagnostics, Inc. FX Contract grant sponsor: Bracco Diagnostics, Inc. (to H.H.A.). NR 26 TC 19 Z9 19 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1053-1807 J9 J MAGN RESON IMAGING JI J. Magn. Reson. Imaging PD DEC PY 2009 VL 30 IS 6 BP 1335 EP 1340 DI 10.1002/jmri.21976 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 525HP UT WOS:000272206100015 PM 19937927 ER PT J AU Issadore, D Franke, T Brown, KA Hunt, TP Westervelt, RM AF Issadore, David Franke, Thomas Brown, Keith A. Hunt, Thomas P. Westervelt, Robert M. TI High-Voltage Dielectrophoretic and Magnetophoretic Hybrid Integrated Circuit/Microfluidic Chip SO JOURNAL OF MICROELECTROMECHANICAL SYSTEMS LA English DT Article DE Dielectrophoresis (DEP); hybrid integrated circuit (IC)/microfluidic; lab-on-a-chip; magnetophoresis (MP); vesicle ID MAGNETIC NANOPARTICLES; MANIPULATION; MEMBRANES; SYSTEM; CELLS AB A hybrid integrated circuit (IC)/microfluidic chip is presented that independently and simultaneously traps and moves microscopic objects suspended in fluid using both electric and magnetic fields. This hybrid chip controls the location of dielectric objects, such as living cells and drops of fluid, on a 60 x 61 array of pixels that are 30 x 38 mu m(2) in size, each of which can be individually addressed with a 50-V peak-to-peak dc-to-10-MHz radio-frequency voltage. These high-voltage pixels produce electric fields above the chip's surface with a magnitude vertical bar(E) over right arrow vertical bar approximate to 1 V/mu m, resulting in strong dielectrophoresis (DEP) forces vertical bar(F) over right arrow (DEP)vertical bar approximate to 1 nN. Underneath the array of DEP pixels, there is a magnetic matrix that consists of two perpendicular sets of 60 metal wires running across the chip. Each wire can be sourced with 120 mA to trap and move magnetically susceptible objects using magnetophoresis. The DEP pixel array and magnetic matrix can be used simultaneously to apply forces to microscopic objects, such as living cells or lipid vesicles, that are tagged with magnetic nanoparticles. The capabilities of the hybrid IC/microfluidic chip demonstrated in this paper provide important building blocks for a platform for biological and chemical applications. C1 [Issadore, David; Franke, Thomas; Brown, Keith A.; Westervelt, Robert M.] Harvard Univ, Sch Engn Appl Sci, Cambridge, MA 02138 USA. [Franke, Thomas] Univ Augsburg, D-86159 Augsburg, Germany. [Hunt, Thomas P.] Sunprint Inc, Richmond, CA 94802 USA. RP Issadore, D (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Boston, MA 02114 USA. EM westervelt@seas.harvard.edu RI Brown, Keith/A-9780-2010; Issadore, David/L-8451-2014 OI Brown, Keith/0000-0002-2379-2018; FU Department of Defense through the National Defense Science and Engineering Graduate Fellowship Program; Bayerische Forschungsstiftung FX This work was supported in part by the Harvard-MIT Center for Cancer Nanotechnology Excellence, in part by the Department of Defense through the National Defense Science and Engineering Graduate Fellowship Program, in part by Bayerische Forschungsstiftung, and in part by the German Excellence Initiative. Subject Editor R. Howe. NR 17 TC 15 Z9 15 U1 0 U2 7 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 1057-7157 EI 1941-0158 J9 J MICROELECTROMECH S JI J. Microelectromech. Syst. PD DEC PY 2009 VL 18 IS 6 BP 1220 EP 1225 DI 10.1109/JMEMS.2009.2030422 PG 6 WC Engineering, Electrical & Electronic; Nanoscience & Nanotechnology; Instruments & Instrumentation; Physics, Applied SC Engineering; Science & Technology - Other Topics; Instruments & Instrumentation; Physics GA 526UC UT WOS:000272318900007 PM 20625468 ER PT J AU Mikhak, Z Luster, AD AF Mikhak, Zamaneh Luster, Andrew D. TI The Emergence of Basophils as Antigen-Presenting Cells in Th2 Inflammatory Responses SO JOURNAL OF MOLECULAR CELL BIOLOGY LA English DT Editorial Material AB Basophils gain prominence in Th2 inflammatory responses with the discovery that they function as antigen-presenting cells and are sufficient to drive Th2 cell differentiation. C1 [Mikhak, Zamaneh; Luster, Andrew D.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis,Div Rheumatol Alle, Boston, MA 02482 USA. RP Luster, AD (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis,Div Rheumatol Alle, Boston, MA 02482 USA. EM aluster@mgh.harvard.edu FU NIAID NIH HHS [R37 AI040618] NR 11 TC 4 Z9 4 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1674-2788 J9 J MOL CELL BIOL JI J. Mol. Cell Biol. PD DEC PY 2009 VL 1 IS 2 BP 69 EP 71 DI 10.1093/jmcb/mjp017 PG 3 WC Cell Biology SC Cell Biology GA V15PE UT WOS:000207813100006 PM 19776083 ER PT J AU Faustman, DL Davis, M AF Faustman, Denise L. Davis, Miriam TI The primacy of CD8 T lymphocytes in type 1 diabetes and implications for therapies SO JOURNAL OF MOLECULAR MEDICINE-JMM LA English DT Review DE Autoimmunity; Immune tolerance; Type 1 diabetes; MHC class I; Proteasome; T cell ID COMPLEX CLASS-I; SELF-PEPTIDES; NOD MICE; CELLS; MELLITUS; ANTIGEN; AUTOIMMUNITY; IDENTIFICATION; POLYMORPHISMS; PROGRESSION AB Type I diabetes (TID) is an autoimmune disease in which insulin-secreting beta cells of the pancreatic islets are destroyed by T lymphocytes. Until the 1990s, the prevailing dogma was that the attack was attributable to rogue T lymphocytes bearing CD4 markers on their surface (CD4 T helper lymphocytes). Today, the prevailing view is that rogue T cells bearing CD8 markers or cytotoxic CD8 T lymphocytes are also important and perhaps the foremost contributors to beta-cell death. Recognizing CD8 T-cell subsets as the prime culprits has helped to trace the disease's pathogenesis to abnormal T-cell education. Defective education can occur when antigen-presenting cells fail to assemble and present self-antigens to na < ve T cells. The failure in that process, normally designed to prevent T cells' attack on the body's own antigens, enables self-reactive T cells to escape into the circulation. Once released, the self-reactive CD8 T cells kill specific self-antigens, which, in the case of TID, include insulin and other key proteins associated with beta cell functions. Abnormalities during T-cell education have been mapped in part to genetic defects in specific gene-encoding regions of the major histocompatibility complex class I region and to proteins that assemble self-peptides into the MHC class I structure that map within the MHC class II region. Two decades of research have led to understanding of genetic and functional defects in the immune system, placing us at the threshold of finding new therapeutic strategies aimed at eliminating autoreactive CD8 T cells, while preserving healthy immune cells. C1 [Faustman, Denise L.; Davis, Miriam] Massachusetts Gen Hosp, Immunobiol Lab, Charlestown, MA 02129 USA. [Faustman, Denise L.; Davis, Miriam] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. RP Faustman, DL (reprint author), Massachusetts Gen Hosp, Immunobiol Lab, Charlestown, MA 02129 USA. EM faustman@helix.mgh.harvard.edu NR 31 TC 17 Z9 18 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0946-2716 J9 J MOL MED-JMM JI J. Mol. Med. PD DEC PY 2009 VL 87 IS 12 BP 1173 EP 1178 DI 10.1007/s00109-009-0516-6 PG 6 WC Genetics & Heredity; Medicine, Research & Experimental SC Genetics & Heredity; Research & Experimental Medicine GA 516LI UT WOS:000271543300004 PM 19693476 ER PT J AU Eichler, AF Lamont, EB AF Eichler, April F. Lamont, Elizabeth B. TI Utility of administrative claims data for the study of brain metastases: a validation study SO JOURNAL OF NEURO-ONCOLOGY LA English DT Article DE Neoplasm Metastasis; Lung Neoplasms; Brain Metastasis; Validation Studies; ICD9 ID CANCER TRIAL PARTICIPANTS; MEDICARE CLAIMS; BREAST-CANCER; EPIDEMIOLOGY; NEOPLASMS; ACCURACY; SYSTEM; OLDER; LUNG; AGE AB In this study, we sought to determine the accuracy with which the International Classification of Diseases, 9th Edition, Clinical Modification (ICD-9-CM) diagnosis code for "secondary neoplasm of brain and spinal cord" in health insurance claims measures clinically evident central nervous system (CNS) metastases in patients with non-small cell lung cancer (NSCLC). For 241 consecutive patients with newly diagnosed NSCLC, we compared ICD-9-CM "secondary neoplasm" codes indicating tumor spread to the CNS from institutional billing records to gold-standard chart review to determine: (1) sensitivity, specificity and positive predictive value (PPV) of the site-specific secondary neoplasm code and (2) the accuracy in time of its appearance within billing records compared with the gold standard date of CNS relapse. The occurrence of at least one ICD-9-CM code for brain metastasis (Algorithm 1) had a sensitivity of 100% (95% CI: 100-100%) and PPV of 91% (95% CI: 87-94%). By requiring a parts per thousand yen 2 codes (Algorithm 2) or a parts per thousand yen 3 codes (Algorithm 3) for the diagnosis of brain metastasis in claims, specificity and PPV improved, while sensitivity did not drop substantially. The claims-based date of diagnosis was also accurate, with 92% of dates falling within 30 days of the gold standard. ICD-9-CM codes in institutional billing claims reliably documented NSCLC metastases to the CNS. These results suggest that Medicare claims data may be used to evaluate clinical and epidemiological issues related to brain metastases in elderly cancer patients. C1 [Eichler, April F.] Massachusetts Gen Hosp, Pappas Ctr Neurooncol, Boston, MA 02114 USA. [Lamont, Elizabeth B.] Harvard Univ, Dept Hlth Care Policy, Sch Med, Boston, MA 02115 USA. [Eichler, April F.; Lamont, Elizabeth B.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Lamont, Elizabeth B.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Eichler, April F.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA. RP Eichler, AF (reprint author), Massachusetts Gen Hosp, Pappas Ctr Neurooncol, 55 Fruit St,Yawkey 9E, Boston, MA 02114 USA. EM aeichler@partners.org; elamont@partners.org NR 20 TC 25 Z9 25 U1 2 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD DEC PY 2009 VL 95 IS 3 BP 427 EP 431 DI 10.1007/s11060-009-9943-z PG 5 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 515WH UT WOS:000271503100014 PM 19562256 ER PT J AU Carta, AR Kachroo, A Schintu, N Xu, K Schwarzschild, MA Wardas, J Morelli, M AF Carta, Anna R. Kachroo, Anil Schintu, Nicoletta Xu, Kui Schwarzschild, Michael A. Wardas, Jadwiga Morelli, Micaela TI Inactivation of neuronal forebrain A(2A) receptors protects dopaminergic neurons in a mouse model of Parkinson's disease SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE adenosine; astroglia; microglia; MPTP; tyrosine hydroxylase ID INDUCED STRIATAL DAMAGE; CENTRAL-NERVOUS-SYSTEM; SUBSTANTIA-NIGRA; ADENOSINE A(2A)-RECEPTORS; TRANSMITTER OUTFLOW; INDUCED APOPTOSIS; FOCAL ISCHEMIA; RAT MICROGLIA; BRAIN-DAMAGE; GLUTAMATE AB Adenosine A(2A) receptors antagonists produce neuroprotective effects in animal models of Parkinson's disease (PD). As neuroinflammation is involved in PD pathogenesis, both neuronal and glial A(2A) receptors might participate to neuroprotection. We employed complementary pharmacologic and genetic approaches to A(2A) receptor inactivation, in a multiple MPTP mouse model of PD, to investigate the cellular basis of neuroprotection by A(2A) antagonism. MPTP center dot HCl (20 mg/kg daily for 4 days) was administered in mice treated with the A(2A) antagonist SCH58261, or in conditional knockout mice lacking A(2A) receptors on forebrain neurons (fbnA(2A)KO mice). MPTP-induced partial loss of dopamine neurons in substantia nigra pars compacta (SNc) and striatum (Str), associated with increased astroglial and microglial immunoreactivity in these areas. Astroglia was similarly activated 1, 3, and 7 days after MPTP administration, whereas maximal microglial reactivity was detected on day 1, returning to baseline 7 days after MPTP administration. SCH58261 attenuated dopamine cell loss and gliosis in SNc and Str. Selective depletion of A(2A) receptors in fbnA(2A)KO mice completely prevented MPTP-induced dopamine neuron degeneration and gliosis in SNc, and partially counteracted gliosis in Str. Results provide evidence of a primary role played by neuronal A(2A) receptors in neuroprotective effects of A(2A) antagonists in a multiple MPTP injections model of PD. With the symptomatic antiparkinsonian potential of several A(2A) receptor antagonists being pursued in clinical trials, this study adds to the rationale for broader clinical benefit and use of these drugs early in the treatment of PD. C1 [Carta, Anna R.; Schintu, Nicoletta; Morelli, Micaela] Univ Cagliari, Dept Toxicol, I-09124 Cagliari, Italy. [Kachroo, Anil; Xu, Kui; Schwarzschild, Michael A.] Massachusetts Gen Hosp, Mass Gen Inst Neurodegenerat Dis, Boston, MA 02114 USA. [Wardas, Jadwiga] Polish Acad Sci, Inst Pharmacol, Dept Neuropsychopharmacol, Krakow, Poland. [Morelli, Micaela] CNR, Inst Neurosci, Cagliari, Italy. RP Carta, AR (reprint author), Univ Cagliari, Dept Toxicol, Via Osped 72, I-09124 Cagliari, Italy. EM acarta@unica.it OI morelli, micaela/0000-0003-0394-5782 FU Ministero dell'Universit e della Ricerca Scientifica e Tecnologica [RBNE03YA3L-2005]; National Institute of Health [ES010804, S54978]; U.S. Army Medical Research Acquisition Activity [W81XWH-04-1-0881] FX This study was supported by Ministero dell'Universit e della Ricerca Scientifica e Tecnologica, project FIRB [Grant number RBNE03YA3L-2005] and National Institute of Health [Grant numbers ES010804, S54978] and U.S. Army Medical Research Acquisition Activity [Grant number W81XWH-04-1-0881]. The authors thank Prof P. G. Baraldi and Dr M. A. Tabrizi, Department of Pharmaceutical Sciences, University of Ferrara, for providing SCH58261; David H. Gutmann and M. Livia Bajenaru for providing GFAP-cre mice; and Yuehang Xu for expert technical assistance. NR 55 TC 35 Z9 36 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD DEC PY 2009 VL 111 IS 6 BP 1478 EP 1489 DI 10.1111/j.1471-4159.2009.06425.x PG 12 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 524FX UT WOS:000272130300015 PM 19817968 ER PT J AU Chan, YM Broder-Fingert, S Wong, KM Seminara, SB AF Chan, Y. M. Broder-Fingert, S. Wong, K. M. Seminara, S. B. TI Kisspeptin/Gpr54-Independent Gonadotrophin-Releasing Hormone Activity in Kiss1 and Gpr54 Mutant Mice SO JOURNAL OF NEUROENDOCRINOLOGY LA English DT Article DE metastin; Kiss1r; LHRH ID HYPOGONADOTROPIC HYPOGONADISM; RECEPTOR GPR54; KISSPEPTIN; GLUTAMATE; REGULATOR; PUBERTY; SURGE; GENE; GABA AB The kisspeptin/Gpr54 signalling pathway plays a critical role in reproduction by stimulating the secretion of gonadotrophin-releasing hormone (GnRH), yet mice carrying mutations in Kiss1 (which encodes kisspeptin) or Gpr54 exhibit partial sexual maturation. For example, a proportion of female Kiss1-/- and Gpr54-/- mice exhibit vaginal oestrus, and some male Kiss1-/- and Gpr54-/- mice exhibit spermatogenesis. To characterise this partial sexual maturation, we examined the vaginal cytology of female Kiss1-/- and Gpr54-/- mice over time. Almost all mutant mice eventually enter oestrus, and then spontaneously transition from oestrus to dioestrus and back to oestrus again. These transitions are not associated with ovulation, and the frequency of these transitions increases with age. The oestrus exhibited by female Kiss1-/- and Gpr54-/- mice was disrupted by the administration of the competitive GnRH antagonist acyline, which also resulted in lower uterine weights and, in Kiss1-/- mice, lower serum follicle-stimulating hormone (FSH) and luteinising hormone (LH) concentrations. Similarly, male Kiss1-/- and Gpr54-/- mice treated with acyline had smaller testicular sizes and an absence of mature sperm. In addition to examining intact Kiss1-/- and Gpr54-/- mice, we also assessed the effects of acyline on gonadotrophin concentrations in gonadectomised mice. Gonadectomy resulted in a significant increase in serum FSH concentrations in male Gpr54-/- and Kiss1-/- mice. Acyline administration to gonadectomised Kiss1-/- and Gpr54-/- male mice lowered serum FSH and LH concentrations significantly. By contrast to males, gonadectomy did not result in significant gonadotrophin changes in female Kiss1-/- and Gpr54-/- mice, but acyline administration was followed by a decrease in LH concentrations. These results demonstrate that, although kisspeptin signalling is critical for the high levels of GnRH activity required for normal sexual maturation and for ovulation, Kiss1-/- and Gpr54-/- mice retain some degree of GnRH activity. This GnRH activity is sufficient to produce significant effects on vaginal cytology and uterine weights in female mice and on spermatogenesis and testicular weights in male mice. C1 [Chan, Y. M.; Broder-Fingert, S.; Wong, K. M.; Seminara, S. B.] Massachusetts Gen Hosp, Reprod Endocrine Unit, Boston, MA 02114 USA. [Chan, Y. M.; Broder-Fingert, S.; Wong, K. M.; Seminara, S. B.] Massachusetts Gen Hosp, Harvard Reprod Sci Ctr, Boston, MA 02114 USA. [Chan, Y. M.] Childrens Hosp, Dept Med, Div Endocrinol, Boston, MA 02115 USA. RP Chan, YM (reprint author), Massachusetts Gen Hosp, Reprod Endocrine Unit, 55 Fruit St,BHX 5, Boston, MA 02114 USA. EM ymchan@partners.org OI Broder-Fingert, Sarabeth/0000-0002-0932-4461 FU NIH [U54 HD028138, T32 HD07369, F32 HD056759, U54-HD28934]; Lawson Wilkins Pediatric Endocrine Society FX This work was supported by NIH U54 HD028138. Y.-M.C. received support from NIH T32 HD07369, F32 HD056759, and a Novo Nordisk Research Fellowship Award from the Lawson Wilkins Pediatric Endocrine Society. The University of Virginia Center for Research in Reproduction Ligand Assay and Analysis Core is supported by NIH U54-HD28934. We thank members of the Harvard Reproductive Sciences Center for valuable discussion of this work. K.M.W. is currently at the University of Amsterdam Medical School. NR 21 TC 58 Z9 59 U1 0 U2 4 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0953-8194 J9 J NEUROENDOCRINOL JI J. Neuroendocrinol. PD DEC PY 2009 VL 21 IS 12 BP 1015 EP 1023 DI 10.1111/j.1365-2826.2009.01926.x PG 9 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA 522CC UT WOS:000271974300006 PM 19840236 ER PT J AU Jha, RM Hochberg, LR Hakimelahi, R Hirsch, JA Gonzalez, RG Yoo, AJ AF Jha, R. M. Hochberg, L. R. Hakimelahi, R. Hirsch, J. A. Gonzalez, R. G. Yoo, A. J. TI Hyperacute stent placement in acute cervical internal carotid artery occlusions: the potential role of magnetic resonance imaging SO JOURNAL OF NEUROINTERVENTIONAL SURGERY LA English DT Article ID ACUTE ISCHEMIC-STROKE; PROACT II; THROMBOLYSIS; TRIAL; HEMORRHAGE; RISK AB Cervical internal carotid artery (ICA) occlusions causing acute ischemic stroke have extremely poor outcomes without rapid re-establishment of cerebral perfusion. Given the high risk for early recurrent stroke, carotid stenting at the time of intra-arterial therapy may be crucial to improving outcomes. To our knowledge, there are only two prior case series that address intra-arterial reperfusion therapy and stent placement within six hours of stroke onset (the hyperacute period). We present two cases to further support the feasibility of this intervention in the hyperacute period, and report the potential utility of MRI in identifying patients most likely to benefit from this procedure. C1 [Hirsch, J. A.; Yoo, A. J.] Massachusetts Gen Hosp, Dept Radiol, Div Intervent Neuroradiol, Boston, MA 02114 USA. [Jha, R. M.] Massachusetts Gen Hosp, Dept Internal Med, Boston, MA 02114 USA. [Hochberg, L. R.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Hakimelahi, R.; Gonzalez, R. G.] Massachusetts Gen Hosp, Dept Radiol, Div Neuroradiol, Boston, MA 02114 USA. RP Yoo, AJ (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Intervent Neuroradiol, GRB 241,55 Fruit St, Boston, MA 02114 USA. EM ajyoo@partners.org NR 14 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1759-8478 J9 J NEUROINTERV SURG JI J. NeuroInterventional Surg. PD DEC PY 2009 VL 1 IS 2 BP 171 EP 174 DI 10.1136/jnis.2009.000398 PG 4 WC Neuroimaging; Surgery SC Neurosciences & Neurology; Surgery GA 601YI UT WOS:000278103700019 PM 21994292 ER PT J AU Hirsch, JA Meyers, PM Jensen, ME AF Hirsch, Joshua A. Meyers, Phillip M. Jensen, Mary E. TI PS Augmentation SO JOURNAL OF NEUROINTERVENTIONAL SURGERY LA English DT Article ID PERCUTANEOUS VERTEBRAL AUGMENTATION; COMPRESSION FRACTURES; THERAPEUTIC-NEURORADIOLOGY; INTERVENTIONAL-RADIOLOGY; NEUROLOGICAL-SURGEONS; AMERICAN-ASSOCIATION; POSITION STATEMENT; RANDOMIZED-TRIAL; SPINE-RADIOLOGY; SINGLE-CENTER C1 [Hirsch, Joshua A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Meyers, Phillip M.] Columbia Univ, Med Ctr, Dept Neurosurg, New York, NY USA. [Meyers, Phillip M.] Columbia Univ, Med Ctr, Dept Radiol, New York, NY USA. [Jensen, Mary E.] Univ Virginia, Dept Radiol, Charlottesville, VA USA. RP Hirsch, JA (reprint author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA. EM hirsch@snisonline.org NR 15 TC 1 Z9 1 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1759-8478 J9 J NEUROINTERV SURG JI J. NeuroInterventional Surg. PD DEC PY 2009 VL 1 IS 2 BP 179 EP 180 DI 10.1136/jnis.2009.001313 PG 2 WC Neuroimaging; Surgery SC Neurosciences & Neurology; Surgery GA 601YI UT WOS:000278103700021 PM 21994294 ER PT J AU Kamalian, S Hirsch, AE Growney, ML Raskin, KA Yoo, AJ Krag, KJ Hirsch, JA AF Kamalian, S. Hirsch, A. E. Growney, M. L. Raskin, K. A. Yoo, A. J. Krag, K. J. Hirsch, J. A. TI CT guided percutaneous calcaneoplasty: a case of metastatic intra-articular calcaneus fracture SO JOURNAL OF NEUROINTERVENTIONAL SURGERY LA English DT Article ID VERTEBRAL COMPRESSION FRACTURES; FUTURE-DIRECTIONS; AUGMENTATION; CEMENT; VERTEBROPLASTY; POLYMERIZATION; KYPHOPLASTY; PALLIATION; FIXATION; DISEASE AB Symptomatic bone metastases to the calcaneus are rare. 1 Minimally invasive percutaneous augmentation is an option in the palliative management of patients with metastatic bone disease, and has been commonly used in the setting of vertebral compression fractures. 2 Calcaneal augmentation can potentially allow for earlier weight bearing and a shorter period of disability. A case report is presented of percutaneous intra-articular calcaneal fracture augmentation using polymethyl methacrylate. C1 [Kamalian, S.; Growney, M. L.; Yoo, A. J.; Hirsch, J. A.] Massachusetts Gen Hosp, Dept Radiol, Div Intervent Neuroradiol, Boston, MA 02114 USA. [Hirsch, A. E.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Hirsch, A. E.; Raskin, K. A.; Yoo, A. J.; Hirsch, J. A.] Harvard Univ, Sch Med, Boston, MA USA. [Raskin, K. A.] Massachusetts Gen Hosp, Dept Orthoped Surg, Boston, MA 02114 USA. [Krag, K. J.] N Shore Med Ctr, Dept Med Oncol, Peabody, MA USA. RP Hirsch, JA (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Intervent Neuroradiol, 55 Fruit St, Boston, MA 02114 USA. EM jahirsch@partners.org OI Kamalian, Shahmir/0000-0002-9640-8144 NR 20 TC 5 Z9 7 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1759-8478 J9 J NEUROINTERV SURG JI J. NeuroInterventional Surg. PD DEC PY 2009 VL 1 IS 2 BP 186 EP 188 DI 10.1136/jnis.2009.000414 PG 3 WC Neuroimaging; Surgery SC Neurosciences & Neurology; Surgery GA 601YI UT WOS:000278103700023 PM 21994296 ER PT J AU Kasper, EM AF Kasper, Ekkehard Matthias TI Drain associated meningitis and ventriculitis remains a pivotal problem in neurointensive care: to understand their causes we need better surveillance data SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY LA English DT Editorial Material ID INFECTION; FLUID C1 BIDMC, Dept Neurosurg, Boston, MA 02215 USA. RP Kasper, EM (reprint author), BIDMC, Dept Neurosurg, Suite 3B,110 Francis St, Boston, MA 02215 USA. EM ekasper@bidmc.harvard.edu NR 5 TC 1 Z9 1 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0022-3050 J9 J NEUROL NEUROSUR PS JI J. Neurol. Neurosurg. Psychiatry PD DEC PY 2009 VL 80 IS 12 BP 1302 EP 1302 DI 10.1136/jnnp.2009.172429 PG 1 WC Clinical Neurology; Psychiatry; Surgery SC Neurosciences & Neurology; Psychiatry; Surgery GA 520HW UT WOS:000271835300002 PM 19917813 ER PT J AU Jones, SR Pritchett, DL Sikora, MA Stufflebeam, SM Hamalainen, M Moore, CI AF Jones, Stephanie R. Pritchett, Dominique L. Sikora, Michael A. Stufflebeam, Steven M. Hamalainen, Matti Moore, Christopher I. TI Quantitative Analysis and Biophysically Realistic Neural Modeling of the MEG Mu Rhythm: Rhythmogenesis and Modulation of Sensory-Evoked Responses SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Review ID BACKWARD CORTICAL PROJECTIONS; HUMAN-BRAIN; SOMATOSENSORY CORTEX; HAND AREA; VISUOSPATIAL ATTENTION; NEURONAL OSCILLATIONS; VOLUNTARY MOVEMENT; BETA-OSCILLATIONS; PRESTIMULUS ALPHA; ACTIVE MOVEMENT AB Jones SR, Pritchett DL, Sikora MA, Stufflebeam SM, Hamalainen M, Moore CI. Quantitative analysis and biophysically realistic neural modeling of the MEG mu rhythm: rhythmogenesis and modulation of sensory-evoked responses. J Neurophysiol 102: 3554-3572, 2009. First published October 7, 2009; doi:10.1152/jn.00535.2009. Variations in cortical oscillations in the alpha (7-14 Hz) and beta (15-29 Hz) range have been correlated with attention, working memory, and stimulus detection. The mu rhythm recorded with magnetoencephalography (MEG) is a prominent oscillation generated by Rolandic cortex containing alpha and beta bands. Despite its prominence, the neural mechanisms regulating mu are unknown. We characterized the ongoing MEG mu rhythm from a localized source in the finger representation of primary somatosensory (SI) cortex. Subjects showed variation in the relative expression of mu-alpha or mu-beta, which were nonoverlapping for roughly 50% of their respective durations on single trials. To delineate the origins of this rhythm, a biophysically principled computational neural model of SI was developed, with distinct laminae, inhibitory and excitatory neurons, and feedforward (FF, representative of lemniscal thalamic drive) and feedback (FB, representative of higher-order cortical drive or input from nonlemniscal thalamic nuclei) inputs defined by the laminar location of their postsynaptic effects. The mu-alpha component was accurately modeled by rhythmic FF input at approximately 10-Hz. The mu-beta component was accurately modeled by the addition of approximately 10-Hz FB input that was nearly synchronous with the FF input. The relative dominance of these two frequencies depended on the delay between FF and FB drives, their relative input strengths, and stochastic changes in these variables. The model also reproduced key features of the impact of high prestimulus mu power on peaks in SI-evoked activity. For stimuli presented during high mu power, the model predicted enhancement in an initial evoked peak and decreased subsequent deflections. In agreement, the MEG-evoked responses showed an enhanced initial peak and a trend to smaller subsequent peaks. These data provide new information on the dynamics of the mu rhythm in humans and the model provides a novel mechanistic interpretation of this rhythm and its functional significance. C1 [Jones, Stephanie R.; Sikora, Michael A.; Stufflebeam, Steven M.; Hamalainen, Matti; Moore, Christopher I.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Pritchett, Dominique L.; Moore, Christopher I.] MIT, McGovern Inst Brain Res, Cambridge, MA 02139 USA. RP Jones, SR (reprint author), Mass Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, 149 13th St,Suite 2301, Charlestown, MA 02129 USA. EM srjones@nmr.mgh.harvard.edu RI Hamalainen, Matti/C-8507-2013; OI Pritchett, Dominique/0000-0003-1187-1162 FU National Institutes of Health [P41-RR-14075, K25-MH-072941, 1RO1-NS-045130-01, T32-GM-007484]; National Science Foundation [0316933]; Athinoula A. Martinos Center for Biomedical Imaging; McGovern Institute for Brain Research FX This work was supported by National Institutes of Health Grants P41-RR-14075, K25-MH-072941, 1RO1-NS-045130-01, and T32-GM-007484; National Science Foundation Grant 0316933; the Athinoula A. Martinos Center for Biomedical Imaging; and the McGovern Institute for Brain Research. NR 115 TC 61 Z9 62 U1 1 U2 12 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD DEC PY 2009 VL 102 IS 6 BP 3554 EP 3572 DI 10.1152/jn.00535.2009 PG 19 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 528RB UT WOS:000272463200041 PM 19812290 ER PT J AU Schrock, LE Ostrem, JL Turner, RS Shimamoto, SA Starr, PA AF Schrock, Lauren E. Ostrem, Jill L. Turner, Robert S. Shimamoto, Shoichi A. Starr, Philip A. TI The Subthalamic Nucleus in Primary Dystonia: Single-Unit Discharge Characteristics SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Review ID DEEP BRAIN-STIMULATION; GLOBUS-PALLIDUS INTERNUS; PRIMARY MOTOR CORTEX; IDIOPATHIC CERVICAL DYSTONIA; LOCAL-FIELD POTENTIALS; PARKINSONS-DISEASE; BASAL GANGLIA; NEURONAL-ACTIVITY; GENERALIZED DYSTONIA; TECHNICAL APPROACH AB Schrock LE, Ostrem JL, Turner RS, Shimamoto SA, Starr PA. The subthalamic nucleus in primary dystonia: single-unit discharge characteristics. J Neurophysiol 102: 3740-3752, 2009. First published October 21, 2009; doi:10.1152/jn.00544.2009. Most models of dystonia pathophysiology predict alterations of activity in the basal ganglia thalamocortical motor circuit. The globus pallidus interna (GPi) shows bursting and oscillatory neuronal discharge in both human dystonia and in animal models, but it is not clear which intrinsic basal ganglia pathways are implicated in this abnormal output. The subthalamic nucleus (STN) receives prominent excitatory input directly from cortical areas implicated in dystonia pathogenesis and inhibitory input from the external globus pallidus. The goal of this study was to elucidate the role of the STN in dystonia by analyzing STN neuronal discharge in patients with idiopathic dystonia. Data were collected in awake patients undergoing microelectrode recording for implantation of STN deep brain stimulation electrodes. We recorded 62 STN neurons in 9 patients with primary dystonia. As a comparison group, we recorded 143 STN neurons in 20 patients with Parkinson's disease (PD). Single-unit activity was discriminated off-line by principal component analysis and evaluated with respect to discharge rate, bursting, and oscillatory activity. The mean STN discharge rate in dystonia patients was 26.3 Hz (SD 13.6), which was lower than that in the PD patients (35.6 Hz, SD 15.2), but higher than published values for subjects without basal ganglia dysfunction. Oscillatory activity was found in both disorders, with a higher proportion of units oscillating in the beta range in PD. Bursting discharge was a prominent feature of both dystonia and PD, whereas sensory receptive fields were expanded in PD compared with dystonia. The STN firing characteristics, in conjunction with those previously published for GPi, suggest that bursting and oscillatory discharge in basal ganglia output may be transmitted via pathways involving the STN and provide a pathophysiologic rationale for STN as a surgical target in dystonia. C1 [Shimamoto, Shoichi A.; Starr, Philip A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA. [Schrock, Lauren E.; Ostrem, Jill L.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Schrock, Lauren E.; Ostrem, Jill L.; Starr, Philip A.] San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, San Francisco, CA USA. [Turner, Robert S.] Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA USA. [Turner, Robert S.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA USA. RP Starr, PA (reprint author), Univ Calif San Francisco, Dept Neurol Surg, 533 Parnassus Ave,Box 0445, San Francisco, CA 94143 USA. EM starrp@neurosurg.ucsf.edu RI Turner, Robert/A-9695-2008 OI Turner, Robert/0000-0002-6074-4365 FU NINDS NIH HHS [R01 NS044551-06, R21 NS055197, R21 NS055197-01A2, R01 NS044551] NR 102 TC 28 Z9 29 U1 1 U2 7 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD DEC PY 2009 VL 102 IS 6 BP 3740 EP 3752 DI 10.1152/jn.00544.2009 PG 13 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 528RB UT WOS:000272463200054 PM 19846625 ER PT J AU Jurjut, OF Nikolic, D Pipa, G Singer, W Metzler, D Muresan, RC AF Jurjut, Ovidiu F. Nikolic, Danko Pipa, Gordon Singer, Wolf Metzler, Dirk Muresan, Raul C. TI A Color-Based Visualization Technique for Multielectrode Spike Trains SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Article ID PRIMARY VISUAL-CORTEX; NEURONAL ENSEMBLE INTERACTIONS; COOPERATIVE FIRING ACTIVITY; NATURAL VISION; RECEPTIVE FIELDS; INFORMATION; DYNAMICS; PATTERNS; VARIABILITY; POPULATION AB Jurjut, OF, Nikolic D, Pipa G, Singer W, Metzler D, Mures, an RC. A color-based visualization technique for multielectrode spike trains. J Neurophysiol 102: 3766-3778, 2009. First published October 21, 2009; doi:10.1152/jn.00758.2009. Multi electrode recordings of neuronal activity provide an overwhelming amount of data that is often difficult to analyze and interpret. Although various methods exist for treating multielectrode datasets quantitatively, there is a particularly prominent lack of techniques that enable a quick visual exploration of such datasets. Here, by using Kohonen self-organizing maps, we propose a simple technique that allows for the representation of multiple spike trains through a sequence of color-coded population activity vectors. When multiple color sequences are grouped according to a certain criterion, e.g., by stimulation condition or recording time, one can inspect an entire dataset visually and extract quickly information about the identity, stimulus-locking and temporal distribution of multi-neuron activity patterns. Color sequences can be computed on various time scales revealing different aspects of the temporal dynamics and can emphasize high-order correlation patterns that are not detectable with pairwise techniques. Furthermore, this technique is useful for determining the stability of neuronal responses during a recording session. Due to its simplicity and reliance on perceptual grouping, the method is useful for both quick on-line visualization of incoming data and for more detailed post hoc analyses. C1 [Muresan, Raul C.] Romanian Inst Sci & Technol, Dept Expt & Theoret Neurosci, Ctr Cognit & Neural Studies Coneural, Cluj Napoca 400487, Cluj, Romania. [Jurjut, Ovidiu F.; Nikolic, Danko; Pipa, Gordon; Singer, Wolf] Frankfurt Inst Adv Studies, Frankfurt, Germany. [Jurjut, Ovidiu F.; Nikolic, Danko; Pipa, Gordon; Singer, Wolf; Muresan, Raul C.] Max Planck Inst Brain Res, D-60496 Frankfurt, Germany. [Pipa, Gordon] Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. [Metzler, Dirk] Univ Munich, Munich, Germany. RP Muresan, RC (reprint author), Romanian Inst Sci & Technol, Dept Expt & Theoret Neurosci, Ctr Cognit & Neural Studies Coneural, Str Ciresilor 29, Cluj Napoca 400487, Cluj, Romania. EM raul.muresan@gmail.com RI Muresan, Raul/A-4650-2011; Singer, Wolf/D-6874-2012; Metzler, Dirk/K-2797-2014; Pipa, Gordon/M-1813-2014 OI Muresan, Raul/0000-0001-7854-3775; Pipa, Gordon/0000-0002-3416-2652 FU MECT/UEFISCSU [RP-5/2007, 1/01.10.2007, 204/01.10.2007]; Max Planck-Coneural Partner Group; Deutsche Forschungsgemeinschaft [NI 708/2-1]; European Commission [GABA-FP6-NEST/043309]; Hertie Foundation FX This work was supported by two Romanian grants (MECT/UEFISCSU: RP-5/2007 Contract 1/01.10.2007, ID-48/2007 Contract 204/01.10.2007), a Max Planck-Coneural Partner Group grant, Deutsche Forschungsgemeinschaft Grant NI 708/2-1, European Commission Grant GABA-FP6-NEST/043309, and the Hertie Foundation. NR 57 TC 1 Z9 2 U1 0 U2 6 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 EI 1522-1598 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD DEC PY 2009 VL 102 IS 6 BP 3766 EP 3778 DI 10.1152/jn.00758.2009 PG 13 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 528RB UT WOS:000272463200056 PM 19846620 ER PT J AU Shin, JH Herrera, SR Eboli, P Aydin, S Eskandar, EH Slavin, KV AF Shin, John H. Herrera, Sebastian R. Eboli, Paula Aydin, Sabri Eskandar, Emad H. Slavin, Konstantin V. TI Entrapment of the glossopharyngeal nerve in patients with Eagle syndrome: surgical technique and outcomes in a series of 5 patients Clinical article SO JOURNAL OF NEUROSURGERY LA English DT Article DE Eagle syndrome; glossopharyngeal neuralgia; styloid process ID DIAGNOSIS AB Object. Eagle syndrome is characterized by unilateral pain in the oropharynx, face, and earlobe, and is caused by an elongated styloid process or ossification of the stylohyoid ligament with associated compression of the glossopharyngeal nerve. The pain syndrome may be successfully treated with surgical intervention that involves resection of the styloid process. Although nerve decompression is routinely considered a neurosurgical intervention, Eagle syndrome and its treatment are not sufficiently examined in the neurosurgical literature. Methods. A review was performed of cases of Eagle syndrome treated in the Department of Neurosurgery at the University of Illinois at Chicago Medical Center over the last 7 years. The clinical characteristics, radiographic imaging, operative indications, procedural details, surgical morbidity, and clinical outcomes were collected and analyzed. Results. Of the many patients with facial pain treated between 2001 and 2007, 7 were diagnosed with Eagle syndrome, and 5 of these patients underwent resection of the elongated styloid process. There were 4 women and 1 man, ranging in age from 20 to 68 years (mean 43 years). The average duration of disease was 11 years. In all patients, a preoperative workup revealed unilateral or bilateral elongation of the styloid process. All patients underwent resection of the styloid process on the symptomatic side using a lateral transcutaneous approach. There were no surgical complications. All patients experienced pain relief immediately after the operation. At the latest follow-up (average 46 months, range 7 months to 7.5 years) all but 1 patient maintained complete pain relief. In 1 patient, the pain recurred 12 months postoperatively and additional interventions were required. Conclusions. Eagle syndrome may be considered an entrapment syndrome of the glossopharyngeal nerve. It is a distinct clinical entity that should be considered when evaluating patients referred for glossopharyngeal neuralgia. The authors' experience indicates that patients with Eagle syndrome may be successfully treated using open resection of the elongated styloid process, which appears to be both safe and effective in terms of long-lasting pain relief. (DOI: 10.3171/2009.1.JNS08485) C1 [Shin, John H.; Herrera, Sebastian R.; Eboli, Paula; Aydin, Sabri; Slavin, Konstantin V.] Univ Illinois, Dept Neurosurg, Chicago, IL 60612 USA. [Eskandar, Emad H.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. RP Slavin, KV (reprint author), Univ Illinois, Dept Neurosurg, M-C 799,912 S Wood St, Chicago, IL 60612 USA. EM kslavin@uic.edu NR 13 TC 8 Z9 8 U1 0 U2 0 PU AMER ASSOC NEUROLOGICAL SURGEONS PI ROLLING MEADOWS PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA SN 0022-3085 J9 J NEUROSURG JI J. Neurosurg. PD DEC PY 2009 VL 111 IS 6 BP 1226 EP 1230 DI 10.3171/2009.1.JNS08485 PG 5 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 529CM UT WOS:000272493300022 PM 19284231 ER PT J AU Zafonte, R Friedewald, WT Lee, SM Levin, B Diaz-Arrastia, R Ansel, B Eisenberg, H Timmons, SD Temkin, N Novack, T Ricker, J Merchant, R Jallo, J AF Zafonte, Ross Friedewald, William T. Lee, Shing M. Levin, Bruce Diaz-Arrastia, Ramon Ansel, Beth Eisenberg, Howard Timmons, Shelly D. Temkin, Nancy Novack, Thomas Ricker, Joseph Merchant, Randall Jallo, Jack TI The Citicoline Brain Injury Treatment (COBRIT) Trial: Design and Methods SO JOURNAL OF NEUROTRAUMA LA English DT Article DE citicoline; clinical trial; COBRIT; therapy; traumatic brain injury ID ACUTE ISCHEMIC-STROKE; MULTIPLE END-POINTS; RANDOMIZED EFFICACY TRIAL; CDP-CHOLINE; CLINICAL-TRIALS; CEREBRAL-ISCHEMIA; HEAD-INJURY; IN-VIVO; SCALE; HIPPOCAMPAL AB Traumatic brain injury (TBI) is a major cause of death and disability. In the United States alone approximately 1.4 million sustain a TBI each year, of which 50,000 people die, and over 200,000 are hospitalized. Despite numerous prior clinical trials no standard pharmacotherapy for the treatment of TBI has been established. Citicoline, a naturally occurring endogenous compound, offers the potential of neuroprotection, neurorecovery, and neurofacilitation to enhance recovery after TBI. Citicoline has a favorable side-effect profile in humans and several meta-analyses suggest a benefit of citicoline treatment in stroke and dementia. COBRIT is a randomized, double-blind, placebo-controlled, multi-center trial of the effects of 90 days of citicoline on functional outcome in patients with complicated mild, moderate, and severe TBI. In all, 1292 patients will be recruited over an estimated 32 months from eight clinical sites with random assignment to citicoline (1000mg twice a day) or placebo (twice a day), administered enterally or orally. Functional outcomes are assessed at 30, 90, and 180 days after the day of randomization. The primary outcome consists of a set of measures that will be analyzed as a composite measure using a global test procedure at 90 days. The measures comprise the following core battery: the California Verbal Learning Test II; the Controlled Oral Word Association Test; Digit Span; Extended Glasgow Outcome Scale; the Processing Speed Index; Stroop Test part 1 and Stroop Test part 2; and Trail Making Test parts A and B. Secondary outcomes include survival, toxicity, and rate of recovery. C1 [Lee, Shing M.; Levin, Bruce] Columbia Univ, Dept Biostat, Mailman Sch Publ Hlth, New York, NY 10032 USA. [Zafonte, Ross] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Phys Med & Rehabil,Spaulding Rehabil Hosp, Boston, MA USA. [Friedewald, William T.] Columbia Univ, Dept Epidemiol, New York, NY USA. [Diaz-Arrastia, Ramon] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA. [Ansel, Beth] NICHHD, TBI & Stroke Rehabil Res Program, Natl Ctr Med Rehabil Res, Bethesda, MD 20892 USA. [Eisenberg, Howard] Univ Maryland Hosp S, Dept Neurosurg, Baltimore, MD USA. [Timmons, Shelly D.] Univ Tennessee, Ctr Hlth Sci, Dept Neurosurg, Memphis, TN 38163 USA. [Timmons, Shelly D.] Univ Tennessee, Ctr Hlth Sci, Neurotrauma Div, Semmes Murphey Clin, Memphis, TN 38163 USA. [Temkin, Nancy] Univ Washington, Dept Neurol Surg & Biostat, Seattle, WA 98195 USA. [Novack, Thomas] Univ Alabama, Dept Phys Med & Rehabil, Birmingham, AL USA. [Ricker, Joseph] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Merchant, Randall] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA USA. [Jallo, Jack] Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA. RP Friedewald, WT (reprint author), Columbia Univ, Dept Biostat, Mailman Sch Publ Hlth, Room 647,722 W 168th St, New York, NY 10032 USA. EM wtf1@columbia.edu RI Friedewald, William/C-8034-2011 FU National Institute Award [U01HD042823, U01HD042738, U01HD042687, U01HD042736, U01HD042678, U01HD042686, U01HD042653, U01HD042689, U01HD042652] FX The study is supported in part by National Institute Award numbers NICHD U01HD042823, U01HD042738, U01HD 042687, U01HD042736, U01HD042678, U01HD042686, U01H D042653, U01HD042689, and U01HD042652, to eight clinical sites and a data coordinating center. NR 57 TC 29 Z9 30 U1 2 U2 4 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 J9 J NEUROTRAUM JI J. Neurotrauma PD DEC PY 2009 VL 26 IS 12 BP 2207 EP 2216 DI 10.1089/neu.2009.1015 PG 10 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA 536AI UT WOS:000273013200008 PM 19803786 ER PT J AU Stein, PD Freeman, LM Sostman, HD Goodman, LR Woodard, PK Naidich, DP Gottschalk, A Bailey, DL Matta, F Yaekoub, AY Hales, CA Hull, RD Leeper, KV Tapson, VF Weg, JG AF Stein, Paul D. Freeman, Leonard M. Sostman, H. Dirk Goodman, Lawrence R. Woodard, Pamela K. Naidich, David P. Gottschalk, Alexander Bailey, Dale L. Matta, Fadi Yaekoub, Abdo Y. Hales, Charles A. Hull, Russell D. Leeper, Kenneth V., Jr. Tapson, Victor F. Weg, John G. TI SPECT in Acute Pulmonary Embolism SO JOURNAL OF NUCLEAR MEDICINE LA English DT Article DE pulmonary embolism; venous thromboembolic disease; pulmonary scintigraphy; SPECT; ventilation-perfusion lung scan; Technegas ID VENTILATION-PERFUSION SCINTIGRAPHY; EMISSION COMPUTED-TOMOGRAPHY; LOW PROBABILITY INTERPRETATION; PRIOR CARDIOPULMONARY DISEASE; VERY-LOW PROBABILITY; LUNG SCANS; FUSION IMAGES; CLINICAL-ASSESSMENT; V/Q SCINTIGRAPHY; PLANAR IMAGES AB The purpose of this review was to evaluate the accuracy of SPECT in acute pulmonary embolism. Sparse data are available on the accuracy of SPECT based on an objective reference test. Several investigations were reported in which the reference standard for the diagnosis of pulmonary embolism was based in part on the results of SPECT or planar ventilation-perfusion (V/Q) imaging. The sensitivity of SPECT in all but one investigation was at least 90%, and specificity also was generally at least 90%. The sensitivity of SPECT in 4 of 5 investigations was higher than that of planar V/Q imaging. The specificity of SPECT was generally higher, equal, or only somewhat lower than that of planar V/Q imaging. Most investigators reported nondiagnostic SPECT V/Q scans in no more than 3% of cases. Methods of obtaining SPECT images, methods of obtaining planar V/Q images, and the criteria for interpretation varied. The general impression is that SPECT is more advantageous than planar V/Q imaging. C1 [Stein, Paul D.; Matta, Fadi] Michigan State Univ, Coll Osteopath Med, Dept Internal Med, E Lansing, MI 48824 USA. [Stein, Paul D.; Matta, Fadi] Michigan State Univ, Coll Osteopath Med, Dept Res, E Lansing, MI 48824 USA. [Stein, Paul D.; Matta, Fadi] Michigan State Univ, Coll Osteopath Med, Adv Studies Program, E Lansing, MI 48824 USA. [Freeman, Leonard M.] Montefiore Med Ctr, Dept Nucl Med, New York, NY USA. [Freeman, Leonard M.] Montefiore Med Ctr, Dept Diagnost Radiol, New York, NY USA. [Sostman, H. Dirk] Weill Cornell Med Coll, Off Dean, Houston, TX USA. [Sostman, H. Dirk] Methodist Hosp, Houston, TX 77030 USA. [Goodman, Lawrence R.] Med Coll Wisconsin, Dept Radiol, Milwaukee, WI 53226 USA. [Woodard, Pamela K.] Washington Univ, Dept Radiol, St Louis, MO USA. [Naidich, David P.] NYU, Dept Radiol, New York, NY 10016 USA. [Gottschalk, Alexander] Michigan State Univ, Dept Radiol, E Lansing, MI 48824 USA. [Bailey, Dale L.] Univ Sydney, Dept Nucl Med, Sydney, NSW 2006, Australia. [Yaekoub, Abdo Y.] Dept Internal Med, Pontiac, MI USA. [Hales, Charles A.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Hales, Charles A.] Harvard Univ, Sch Med, Boston, MA USA. [Hull, Russell D.] Univ Calgary, Dept Med, Calgary, AB, Canada. [Leeper, Kenneth V., Jr.] Emory Univ, Dept Med, Atlanta, GA 30322 USA. [Tapson, Victor F.] Duke Univ, Dept Med, Durham, NC USA. [Weg, John G.] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA. RP Stein, PD (reprint author), Michigan State Univ, Coll Osteopath Med, St Joseph Mercy Oakland Hosp, Venous Thromboembolism Res Unit,Dept Internal Med, 44405 Woodward Ave, Pontiac, MI 48341 USA. EM steinp@trinity-health.org RI Bailey, Dale/A-3359-2012; OI naidich, david/0000-0003-3751-5836 NR 54 TC 40 Z9 40 U1 0 U2 5 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 J9 J NUCL MED JI J. Nucl. Med. PD DEC PY 2009 VL 50 IS 12 BP 1999 EP 2007 DI 10.2967/jnumed.109.063958 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 529YM UT WOS:000272555300018 PM 19949025 ER PT J AU Raphael, KG Janal, MN Ananthan, S Cook, DB Staud, R AF Raphael, Karen G. Janal, Malvin N. Ananthan, Sowmya Cook, Dane B. Staud, Roland TI Temporal Summation of Heat Pain in Temporomandibular Disorder Patients SO JOURNAL OF OROFACIAL PAIN LA English DT Article DE aftersensations; chronic pain; temporal summation; temporomandibular disorders; wind-up ID EXPERIMENTALLY EVOKED PAIN; 2ND PAIN; FIBROMYALGIA SYNDROME; MYOFASCIAL PAIN; WIND-UP; SENSITIVITY; STIMULATION; SKIN; TMD; SENSITIZATION AB Aims: To compare patients with temporomandibular disorders (TMD) to control subjects on two measures of central processing, ie, temporal summation of beat pain and decay of subsequent aftersensations, following thermal stimulation in both a trigeminal and extratrigeminal area. Methods: A "wind-up" protocol was used in which 19 female TMD patients and 17 female controls were exposed to IS beat stimuli at a rate of 0.3 Hz. Numeric pain ratings were elicited after the 1st, 5th, 10th, and 15th stimulus presentation and every 15 seconds after final presentation (aftersensations) for up to 2 minutes. In separate trials, the thermode was placed on the thenar eminence of the hand and the skin overlying the masseter muscle. Results: Groups did not differ with respect to the slope of wind-up when stimulated at either anatomic site, although asymptotic levels occurred sooner for TMD patients than for controls. In analysis of aftersensations, a significant group X site X time interaction was detected, in which TMD patients experienced more prolonged painful aftersensations than controls when stimulated on the skin overlying the masseter muscles. Conclusion: These results are consistent with the presence of enhanced central sensitivity in TMD and suggest that this sensitivity may be largely confined to the region of clinical pain. This contrasts with conditions such as fibromyalgia, where central sensitivity appears to be widespread. J OROFAC PAIN 2009;23:54-64 C1 [Raphael, Karen G.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Psychiat, Newark, NJ 07101 USA. [Raphael, Karen G.] Univ Med & Dent New Jersey, Dept Diagnost Sci, Newark, NJ USA. [Cook, Dane B.] Univ Wisconsin, William S Middleton Mem Vet Hosp, Madison, WI 53706 USA. [Cook, Dane B.] Univ Wisconsin, Dept Kinesiol, Madison, WI 53706 USA. [Staud, Roland] Univ Florida, Gainesville, FL USA. RP Raphael, KG (reprint author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Psychiat, 183 S Orange Ave,BHSB F-1555,POB 1709, Newark, NJ 07101 USA. EM raphaekg@umdnj.edu FU NIDCR NIH HHS [R01 DE018569, R01 DE018569-01] NR 46 TC 39 Z9 39 U1 1 U2 4 PU QUINTESSENCE PUBLISHING CO INC PI HANOVER PARK PA 4350 CHANDLER DRIVE, HANOVER PARK, IL 60133 USA SN 1064-6655 J9 J OROFAC PAIN JI J. Orofac. Pain PD WIN PY 2009 VL 23 IS 1 BP 54 EP 64 PG 11 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 453SU UT WOS:000266633000010 PM 19264036 ER PT J AU Blackman, AJ Blevins, JJ Sangeorzan, BJ Ledoux, WR AF Blackman, Andrew J. Blevins, Joanna J. Sangeorzan, Bruce J. Ledoux, William R. TI Cadaveric Flatfoot Model: Ligament Attenuation and Achilles Tendon Overpull SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article DE pes planus; flatfoot; Achilles tendon contracture; cadaver model ID POSTERIOR TIBIAL TENDON; ACQUIRED FLATFOOT; BIOMECHANICAL EVALUATION; FOOT; DEFORMITY; JOINT; DYSFUNCTION; KINEMATICS; INSUFFICIENCY; OPERATION AB Flatfoot deformity is characterized by loss of the medial longitudinal arch, forefoot abduction, hindfoot eversion, and often Achilles tendon contracture. Our objectives were to validate a cadaveric flatfoot model that involves selective ligament attenuation and to determine if Achilles tendon overpull is associated with increased pes planes severity. We measured the three-dimensional (3D) orientation of the bones of interest in the unloaded, loaded, and Achilles tendon overpull conditions. A flatfoot model was created by attenuating ligaments involved in the pes planes deformity followed by cyclic axial loading, and bone orientations were acquired in the three conditions. Significant differences seen between normal feet and flat feet were consistent with those seen with the pes planes deformity. The first metatarsal dorsiflexed and abducted relative to the talus. The navicular abducted relative to the talus. The calcaneus everted relative to the tibia. The talus plantar flexed and adducted. Achilles overpull resulted in first metatarsal-to-tales dorsiflexion and navicular-to-tales abduction. Thus, selective ligament attenuation followed by cyclic axial loading can create a cadaveric flatfoot model consistent with the in vivo deformity. Longitudinal arch depression, hindfoot eversion, talonavicular joint abduction, forefoot abduction, and talar plantar flexion were seen. Simulated Achilles tendon contracture increased the severity of the deformity, particularly in arch depression and forefoot abduction. (C) 2009 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 27:1547-1554, 2009 C1 [Blackman, Andrew J.; Blevins, Joanna J.; Sangeorzan, Bruce J.; Ledoux, William R.] VA Puget Sound Hlth Care Syst, RR&D Ctr Excellence Limb Loss Prevent & Prosthet, Dept Vet Affairs, Seattle, WA 98108 USA. [Sangeorzan, Bruce J.; Ledoux, William R.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA. [Ledoux, William R.] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. RP Ledoux, WR (reprint author), VA Puget Sound Hlth Care Syst, RR&D Ctr Excellence Limb Loss Prevent & Prosthet, Dept Vet Affairs, Seattle, WA 98108 USA. EM wrledoux@u.washington.edu RI Ledoux, William/K-6815-2015; OI Ledoux, William/0000-0003-4982-7714; Blackman, Andrew/0000-0003-4159-5242 FU VA Rehabilitation Research and Development Service [A2661C]; University of Washington Medical Student Research and Training Program FX Andrew J. Blackman is now at the Department of Orthopaedic Surgery, Washington University, Saint Louis, MO 63110. This study was sponsored by VA Rehabilitation Research and Development Service grant no. A2661C and the University of Washington Medical Student Research and Training Program. NR 35 TC 27 Z9 27 U1 2 U2 6 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0736-0266 J9 J ORTHOP RES JI J. Orthop. Res. PD DEC PY 2009 VL 27 IS 12 BP 1547 EP 1554 DI 10.1002/jor.20930 PG 8 WC Orthopedics SC Orthopedics GA 523UV UT WOS:000272101000002 PM 19530145 ER PT J AU Ganzini, L Goy, ER Dobscha, SK Prigerson, H AF Ganzini, Linda Goy, Elizabeth R. Dobscha, Steven K. Prigerson, Holly TI Mental Health Outcomes of Family Members of Oregonians Who Request Physician Aid in Dying SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Euthanasia; family; outcomes ID ASSISTED SUICIDE; HOSPICE PATIENTS; DEATH; EXPERIENCES; GRIEF; DEPRESSION; NURSES AB Oregon legalized physician aid in dying over 10 years ago but little is known about the effects of this choice on family members' mental health. We surveyed 95 family members of decedent Oregonians who had explicitly requested aid in dying, including 59 whose loved one received a lethal prescription and 36 whose loved one died by What ingestion. For comparison purposes, family members of Oregonians who died of cancer or amyotrophic lateral sclerosis also were surveyed. A mean of 14 months after death, 11% of family members whose loved one requested aid in dying had major depressive disorder; 2% had prolonged grief; and 38% had received mental health care. Among those whose family member requested aid in dying, whether or not the patient accessed a lethal prescription, had no influence on subsequent depression, grief, or mental health services use; however; family members of Oregonians who received a lethal prescription were more likely to believe that their loved one's choices were honored and less likely to have regrets about how the loved one died. Comparing family members of those who requested aid in dying to those who did not revealed no differences in primary mental health outcomes of depression, grief or mental health services use. Family members of Oregonians who requested aid in dying felt more prepared and accepting of the death than comparison family members. In summary, pursuit of aid in dying does not have negative effects on surviving family members and may be associated with greater preparation and acceptance of death. J Pain Symptom Manage 2009;38:807-815. (C) 2009 Us. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved. C1 [Ganzini, Linda; Goy, Elizabeth R.; Dobscha, Steven K.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, Res Serv R&D 66, Hlth Serv Res & Dev, Portland, OR 97239 USA. [Ganzini, Linda; Goy, Elizabeth R.; Dobscha, Steven K.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Prigerson, Holly] Dana Farber Canc Inst, Ctr Psychooncol & Palliat Care Res, Boston, MA 02115 USA. [Prigerson, Holly] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA. RP Ganzini, L (reprint author), Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, Res Serv R&D 66, Hlth Serv Res & Dev, POB 1034, Portland, OR 97239 USA. EM Linda.Ganzini@va.gov FU Greenwall Foundation; Department: of Veterans Affairs FX E. R. G. and S. K. D. are Department of Veterans Affairs Health Services Research and Development, Research Career Development awardees. This study was funded by the Greenwall Foundation and the Department: of Veterans Affairs. NR 29 TC 17 Z9 17 U1 2 U2 18 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD DEC PY 2009 VL 38 IS 6 BP 807 EP 815 DI 10.1016/j.jpainsymman.2009.04.026 PG 9 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 617KS UT WOS:000279280200001 PM 19783401 ER PT J AU Seow, H Snyder, CF Mularski, RA Shugarman, LR Kutner, JS Lorenz, KA Wu, AW Dy, SM AF Seow, Hsien Snyder, Claire F. Mularski, Richard A. Shugarman, Lisa R. Kutner, Jean S. Lorenz, Karl A. Wu, Albert W. Dy, Sydney M. TI A Framework for Assessing Quality Indicators for Cancer Care at the End of Life SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Cancer; quality indicators; framework; end of life; palliative care ID PALLIATIVE CARE; PERFORMANCE AB Patients with advanced cancer often do not receive high-quality pain and symptom management or support with. coordination of care, communication, and decision making. Implementing quality indicators that are reflective of the scope of care, feasible to implement, and supported by evidence might help to identify areas and settings most in need of improvement. However, recent reviews and policy initiatives identified only a few indicators that met these criteria. To help advance quality indicator development and implementation in this area, we developed a conceptual framework based on previous related initiatives, updated reviews of end-of-life cancer quality indicators and relevant data sources, and expert input. The framework describes five steps for developing and assessing a quality indicator for end-of-life care, defining the I) population of focus, 2) broad quality domains, 3) specific target areas, 4) steps of the care process, and 5) evaluation criteria for quality indicators. The defined population includes seriously or terminally ill cancer patients, who are unlikely to recover or stabilize, and their families. Domains include the structure and processes of care; the physical, psychiatric, psychosocial spiritual, and cultural aspects of care; as well as the care of the imminently dying, ethical and legal issues, and the delivery of care. Evaluation criteria include importance; scientific acceptability, including validity, evidence to improve outcomes, reliability, responsiveness, and variability; usability; and feasibility, including ready data sources. By using this conceptual framework, indicator developers, researchers, and policymakers can, refine and implement indicator sets to effectively evaluate and improve care at the end of life. J Pain Symptom Manage 2009;38:903-912. (C) 2009 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved. C1 [Seow, Hsien; Wu, Albert W.; Dy, Sydney M.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA. [Snyder, Claire F.] Johns Hopkins Sch Med, Div Gen Internal Med, Baltimore, MD USA. [Mularski, Richard A.] Oregon Hlth & Sci Univ, Ctr Hlth Res, Kaiser Permanente NW, Portland, OR 97201 USA. [Shugarman, Lisa R.] RAND Corp, Santa Monica, CA USA. [Kutner, Jean S.] Univ Colorado, Sch Med, Div Gen Internal Med, Aurora, CO USA. [Lorenz, Karl A.] VA Greater Los Angeles Healthcare Syst, Vet Integrated Palliat Program, Los Angeles, CA USA. RP Dy, SM (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, 624 N Broadway,Room 609, Baltimore, MD 21205 USA. EM sdy@jhsph.edu FU Agency for Healthcare Research and Quality [290-2005-00341]; U.S. Department of Health and Human Services FX This project was funded under Contract No. 290-2005-00341 from the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services, as part of the Developing Evidence to Inform Decisions About Effectiveness (DEcIDE) program. The authors of this report are responsible for its content. Statements in the report should not be construed as endorsement by the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services. The authors have no disclosures. NR 22 TC 23 Z9 23 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD DEC PY 2009 VL 38 IS 6 BP 903 EP 912 DI 10.1016/j.jpainsymman.2009.04.024 PG 10 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 617KS UT WOS:000279280200010 PM 19775860 ER PT J AU DeSanto-Madeya, S Nilsson, M Loggers, ET Paulk, E Stieglitz, H Kupersztoch, YM Prigerson, HG AF DeSanto-Madeya, Susan Nilsson, Matthew Loggers, Elizabeth Trice Paulk, Elizabeth Stieglitz, Heather Kupersztoch, Yankel M. Prigerson, Holly G. TI Associations between United States Acculturation and the End-of-Life Experience of Caregivers of Patients with Advanced Cancer SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID ETHNIC-DIFFERENCES; TERMINAL ILLNESS; HEALTH-CARE; RACE; PREFERENCES; ATTITUDES; POPULATION; MINORITIES; DIRECTIVES; AMERICAN AB Background: Cultural beliefs and values influence treatment preferences for and experiences with end-of-life (EOL) care among racial and ethnic groups. Within-group variations, however, may exist based on level of acculturation. Objectives: To examine the extent to which EOL treatment factors (EOL treatment preferences and physician-caregiver communication) and select psychosocial factors (mental health, complementary therapies, and internal and external social support) differ based on the level of acculturation of caregivers of patients with advanced cancer. Methods: One hundred sixty-seven primary caregivers of patients with advanced cancer were interviewed as part of the multisite, prospective Coping with Cancer Study. Results: Caregivers who were less acculturated were more positively predisposed to use of a feeding tube at EOL (odds ratio [OR] 0.99 [p = 0.05]), were more likely to perceive that they received too much information from their doctors (OR 0.95 [p = 0.05]), were less likely to use mental health services (OR 1.03 [p = 0.003] and OR 1.02 [p = 0.02]), and desire additional services (OR 1.03 [p = 0.10] to 1.05 [p = 0.009]) than their more acculturated counterparts. Additionally, caregivers who were less acculturated cared for patients who were less likely to report having a living will (OR 1.03 [p = 0.0003]) or durable power of attorney for health care (OR 1.02 [p = 0.007]) than more acculturated caregivers. Caregivers who were less acculturated felt their religious and spiritual needs were supported by both the community (beta -0.28 [p = 0.0003]) and medical system (beta -0.38 [p<0.0001]), had higher degrees of self-efficacy (beta -0.22 [p = 0.005]), and had stronger family relationships and support (beta -0.27 [p = 0.0004]). Conclusions: The level of acculturation of caregivers of patients with advanced cancer does contribute to differences in EOL preferences and EOL medical decision-making. C1 [DeSanto-Madeya, Susan] Univ Massachusetts, Coll Nursing & Hlth Sci, Boston, MA 02125 USA. [Nilsson, Matthew; Loggers, Elizabeth Trice; Prigerson, Holly G.] Dana Farber Canc Inst, Dept Psychooncol & Palliat Care, Boston, MA 02115 USA. [Loggers, Elizabeth Trice] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Paulk, Elizabeth; Stieglitz, Heather] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA. [Kupersztoch, Yankel M.] Richland Coll, Dept Biol, Sch Math Sci & Hlth Profess, Dallas, TX USA. RP DeSanto-Madeya, S (reprint author), Univ Massachusetts, Coll Nursing & Hlth Sci, 100 Morrissey Blvd, Boston, MA 02125 USA. EM susan.desantomadeya@umb.edu FU National Institutes of Health [MH63892, CA106370] FX Supported in part by the National Institutes of Health Grants No. MH63892 and CA106370. NR 36 TC 9 Z9 9 U1 2 U2 5 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD DEC PY 2009 VL 12 IS 12 BP 1143 EP 1149 DI 10.1089/jpm.2009.0063 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 529NU UT WOS:000272525200020 PM 19995291 ER PT J AU Nasrallah, SM Maytal, G Skarf, LM AF Nasrallah, Sandra M. Maytal, Guy Skarf, Lara M. TI Patient-Physician Boundaries in Palliative Care Training: A Case Study and Discussion SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Editorial Material ID ILL AB The subject of patient-physician boundaries has been most extensively explored in the psychiatric literature, but to date, little has been published about this concept within the realm of palliative care. Some palliative care physicians may be particularly susceptible to boundary crossings due to the intensity and intimacy of the bonds that form with patients at the end-of-life. We illustrate the concept of boundary crossings and violations in palliative care using the case of a palliative care trainee who experiences difficulties in maintaining boundaries with a dying patient. We discuss the nature of the patient-physician relationship using role theory and discuss how the formation of dual roles can be detrimental to the patient-physician relationship. Finally, we explore why palliative care practitioners and trainees are particularly vulnerable to crossing boundaries and how to recognize and manage these crossings when they occur. C1 [Nasrallah, Sandra M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Palliat Care Serv, Boston, MA 02114 USA. [Skarf, Lara M.] VA Boston Healthcare Syst, W Roxbury, MA USA. RP Nasrallah, SM (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Palliat Care Serv, 55 Fruit St,Founders 600, Boston, MA 02114 USA. EM snasrallah@partners.org NR 16 TC 2 Z9 2 U1 0 U2 4 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD DEC PY 2009 VL 12 IS 12 BP 1159 EP 1162 DI 10.1089/jpm.2009.0181 PG 4 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 529NU UT WOS:000272525200024 PM 19995296 ER PT J AU Millen, JC Ginde, AA Anderson, AT Fang, P Camargo, CA AF Millen, Jennifer C. Ginde, Adit A. Anderson, Angela T. Fang, Penny Camargo, Carlos A., Jr. TI Multicenter Study of Knowledge About Human Papilloma Virus and Attitudes Among Emergency Department Patients SO JOURNAL OF PEDIATRIC AND ADOLESCENT GYNECOLOGY LA English DT Article DE HPV; Vaccine; Sexually transmitted diseases; Emergency medicine; Public health ID WOMEN AB Study Objective: We sought to evaluate knowledge of human papilloma virus (HPV) and attitudes toward the HPV vaccine among emergency department (ED) patients. Design: Cross-sectional survey. Setting: Three Boston EDs. Participants: We enrolled consecutive patients during two 24-hour periods at each site. Interventions: None. Main Outcome Measures: Knowledge of HPV and attitudes toward the HPV vaccine. Results: We enrolled 387 patients (81% of eligible). Overall, 242 (63%) participants had heard of HPV and 203 (52%) supported state-mandated vaccination. In the multivariate model, characteristics associated with lower awareness of HPV were: (1) older age (compared to age 18-26-years: OR 0.45 [95%CI, 0.20-0.99] for age 27-44 years, OR 0.26 [95%CI, 0.12-0.56] for age 45-64 years, and OR 0.10 [95%CI, 0.04-0.28] for age 65 year or older), (2) black race (compared to white: OR 0.31 [95%CI, 0.15-0.64]); and (3) lower annual household income (OR 0.39 [95%CI, 0.19-0.81] for $40,000 or less). Of those people who had heard of HPV, 82% knew of its relationship to cervical cancer, but only 61% thought it was a sexually transmitted disease (STD). Support for state-mandated vaccination was higher among participants who knew that HPV was an STD (OR 2.9 [95%CI 1.7-5.0]), but was not higher among those who had heard of HPV (OR 0.64 [95%CI 0.34-1.2]) or who knew that HPV causes cervical cancer (OR 0.85 [95%CI 0.45-1.6]). Conclusions: Support for state-mandated HPV vaccination appears to be driven more by the knowledge that HPV is an STD than by its role in cervical cancer. Awareness that HPV is transmitted through sexual activity does not decrease support for vaccination and may actually enhance it. C1 [Millen, Jennifer C.; Anderson, Angela T.; Fang, Penny; Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Millen, Jennifer C.] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA. [Ginde, Adit A.] Univ Colorado Denver, Dept Emergency Med, Sch Med, Aurora, CO USA. RP Camargo, CA (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, 326 Cambridge St,Suite 410, Boston, MA 02114 USA. EM ccamargo@partners.org RI Siry, Bonnie/D-7189-2017 NR 9 TC 5 Z9 5 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-3188 J9 J PEDIATR ADOL GYNEC JI J. Pediatr Adolesc. Gynecol. PD DEC PY 2009 VL 22 IS 6 BP 356 EP 359 DI 10.1016/j.jpag.2009.03.001 PG 4 WC Obstetrics & Gynecology; Pediatrics SC Obstetrics & Gynecology; Pediatrics GA 519OH UT WOS:000271775800005 PM 19576825 ER PT J AU Martinussen, M Flanders, DW Fischl, B Busa, E Lohaugen, GC Skranes, J Vangberg, TR Brubakk, AM Haraldseth, O Dale, AM AF Martinussen, Marit Flanders, Dana W. Fischl, Bruce Busa, Evelina Lohaugen, Gro C. Skranes, Jon Vangberg, Torgil R. Brubakk, Ann-Mari Haraldseth, Olav Dale, Anders M. TI Segmental Brain Volumes and Cognitive and Perceptual Correlates in 15-Year-Old Adolescents with Low Birth Weight SO JOURNAL OF PEDIATRICS LA English DT Article AB Objective To determine whether preterm very low birth weight (VLBW) or term born small for gestational age (SGA) adolescents have reduced regional brain volumes. We also asked which perinatal factors are related to reduced brain volume in VLBW adolescents, which regional brain volumes are associated with cognitive and perceptual functioning, and if these differ between the groups. Study design Fifty adolescent preterm VLBW (<= 1500 g) births and 49 term SGA births (birth weight < 10th percentile) were compared with 57 normal-weight term births. An automated MRI segmentation technique was used. Cognitive and perceptual functions were evaluated by WISC-III and Visual Motor Integration (VMI) tests. Results The VLBW group had reduced volumes for thalamus and cerebellar white matter (P < .002). The SGA group had smaller total brains, and proportionally smaller regional brain volumes. Cerebellar white matter in the VLBW, hippocampus in the SGA, and cerebral cortical in the control group were volumes that significantly predicted cognitive and perceptual functions. Conclusions We speculate that white matter injury may explain the impaired cognitive and perceptual functioning in the prematurely born, whereas hippocampal injury may be related to cognitive dysfunction in term SGA adolescents. C1 [Martinussen, Marit; Lohaugen, Gro C.; Skranes, Jon; Brubakk, Ann-Mari] Norwegian Univ Sci & Technol, Dept Lab Med, Fac Med, Childrens & Womens Hlth, N-7034 Trondheim, Norway. [Martinussen, Marit] St Olavs Univ Hosp, Dept Gynecol & Matern Ward, N-7006 Trondheim, Norway. [Flanders, Dana W.] Norwegian Univ Sci & Technol, Dept Publ Hlth & Gen Practice, Fac Med, N-7034 Trondheim, Norway. [Fischl, Bruce; Busa, Evelina; Dale, Anders M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Nucl Magnet Resonance Ctr, Boston, MA USA. [Fischl, Bruce; Dale, Anders M.] MIT, MIT Artificial Intelligence Lab, Boston, MA USA. [Lohaugen, Gro C.; Skranes, Jon] Sorlandet Hosp, Dept Pediat, Arendal, Norway. [Skranes, Jon; Brubakk, Ann-Mari] St Olavs Univ Hosp, Dept Pediat, N-7006 Trondheim, Norway. [Vangberg, Torgil R.; Haraldseth, Olav; Dale, Anders M.] Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, Fac Med, N-7034 Trondheim, Norway. [Vangberg, Torgil R.] Univ Tromso, Radiol Med Fac, Tronso, Norway. [Haraldseth, Olav] St Olavs Univ Hosp, Dept Med Imaging, N-7006 Trondheim, Norway. [Dale, Anders M.] Univ Calif San Diego, Dept Neurosci & Radiol, San Diego, CA 92103 USA. RP Martinussen, M (reprint author), St Olavs Univ Hosp, Gynecol & Matern Ward, Olav Kyrres Gt 17, N-7006 Trondheim, Norway. EM marit.martinussen@ntnu.no RI Vangberg, Torgil/B-8075-2008 OI Vangberg, Torgil/0000-0003-4808-5464 FU CorTechs Labs, Inc. FX Funding information available at www.jpeds.com (Appendix). A.M.D. and B.F. are funded by CorTechs Labs, Inc. A.M.D. has equity in CorTechs Labs, Inc. The other authors declare no conflicts of interest. NR 32 TC 40 Z9 41 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD DEC PY 2009 VL 155 IS 6 BP 848 EP U312 DI 10.1016/j.jpeds.2009.06.015 PG 7 WC Pediatrics SC Pediatrics GA V38CQ UT WOS:000209321900018 PM 19683725 ER PT J AU Bergmann, AK Sahai, I Falcone, JF Fleming, J Bagg, A Borgna-Pignati, C Casey, R Fabris, L Hexner, E Mathews, L Ribeiro, ML Wierenga, KJ Neufeld, EJ AF Bergmann, Anke K. Sahai, Inderneel Falcone, Jill F. Fleming, Judy Bagg, Adam Borgna-Pignati, Caterina Casey, Robin Fabris, Luca Hexner, Elizabeth Mathews, Lulu Ribeiro, Maria Leticia Wierenga, Klaas J. Neufeld, Ellis J. TI Thiamine-Responsive Megaloblastic Anemia: Identification of Novel Compound Heterozygotes and Mutation Update SO JOURNAL OF PEDIATRICS LA English DT Article AB Objective To determine causative mutations and clinical status of 7 previously unreported kindreds with TRMA syndrome, ( thiamine- responsive megaloblastic anemia, online Mendelian inheritance in man, no. 249270), a recessive disorder of thiamine transporter Slc19A2. Study design Genomic DNA was purified from blood, and SLC19A2 mutations were characterized by sequencing polymerase chain reaction- amplified coding regions and intron- exon boundaries of all probands. Compound heterozygotes were further analyzed by sequencing parents, or cloning patient genomic DNA, to ascertain that mutations were in trans. Results We detected 9 novel SLC19A2 mutations. Of these, 5 were missense, 3 were nonsense, and 1 was insertion. Five patients from 4 kindreds were compound heterozygotes, a finding not reported previously for this disorder, which has mostly been found in consanguineous kindreds. Conclusion SLC19A2 mutation sites in TRMA are heterogeneous; with no regional "hot spots.'' TRMA can be caused by heterozygous compound mutations; in these cases, the disorder is found in outbred populations. To the extent that heterozygous patients were ascertained at older ages, a plausible explanation is that if one or more allele(s) is not null, partial function might be preserved. Phenotypic variability may lead to underdiagnosis or diagnostic delay, as the average time between the onset of symptoms and diagnosis was 8 years in this cohort. C1 [Bergmann, Anke K.; Falcone, Jill F.; Neufeld, Ellis J.] Childrens Hosp, Div Hematol & Oncol, Boston, MA 02115 USA. [Fleming, Judy] Childrens Hosp, Translat Res Program, Boston, MA 02115 USA. [Sahai, Inderneel] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Neufeld, Ellis J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Bagg, Adam] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA. [Hexner, Elizabeth] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Wierenga, Klaas J.] Univ Miami, Miller Sch Med, Div Genet, Dept Pediat, Miami, FL 33136 USA. [Borgna-Pignati, Caterina] Univ Ferrara, Clin Pediat, I-44100 Ferrara, Italy. [Fabris, Luca] Univ Padua, Dept Surg & Gastroenterol Sci, Padua, Italy. [Casey, Robin] Alberta Childrens Prov Gen Hosp, Dept Med Genet, Calgary, AB, Canada. [Casey, Robin] Univ Calgary, Calgary, AB, Canada. [Mathews, Lulu] Med Coll Calicut, Dept Pediat, Calicut, Kerala, India. [Ribeiro, Maria Leticia] Ctr Hosp Coimbra, Dept Hematol, Coimbra, Portugal. RP Neufeld, EJ (reprint author), Childrens Hosp, Pediat Hematol Oncol, 300 Longwood Ave,Karp 08210, Boston, MA 02115 USA. EM ellis.neufeld@childrens.harvard.edu OI Ribeiro, Maria Leticia/0000-0002-5964-5001 FU NIH [K24HL004184] FX Supported in part by NIH grant K24HL004184 to EJN. The authors declare no conflicts of interest. NR 31 TC 26 Z9 27 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD DEC PY 2009 VL 155 IS 6 BP 888 EP U356 DI 10.1016/j.jpeds.2009.06.017 PG 6 WC Pediatrics SC Pediatrics GA V38CQ UT WOS:000209321900025 PM 19643445 ER PT J AU Fontana, CR Abernethy, AD Som, S Ruggiero, K Doucette, S Marcantonio, RC Boussios, CI Kent, R Goodson, JM Tanner, ACR Soukos, NS AF Fontana, C. R. Abernethy, A. D. Som, S. Ruggiero, K. Doucette, S. Marcantonio, R. C. Boussios, C. I. Kent, R. Goodson, J. M. Tanner, A. C. R. Soukos, N. S. TI The antibacterial effect of photodynamic therapy in dental plaque-derived biofilms SO JOURNAL OF PERIODONTAL RESEARCH LA English DT Article DE dental plaque bacteria; planktonic phase; biofilms; photodynamic therapy ID TOLUIDINE-BLUE-O; IN-VITRO; LETHAL PHOTOSENSITIZATION; BACTERIAL BIOFILMS; ANTIBIOTIC-RESISTANCE; STREPTOCOCCUS-MUTANS; ORAL BACTERIA; PERIODONTAL PATHOGENS; LIGHT; SUSCEPTIBILITY AB Background and Objective: Photodynamic therapy has been advocated as an alternative to antimicrobial agents to suppress subgingival species and to treat periodontitis. Bacteria located within dense biofilms, such as those encountered in dental plaque, have been found to be relatively resistant to antimicrobial therapy. In the present study, we investigated the ability of photodynamic therapy to reduce the number of bacteria in biofilms by comparing the photodynamic effects of methylene blue on human dental plaque microorganisms in the planktonic phase and in biofilms. Material and Methods: Dental plaque samples were obtained from 10 subjects with chronic periodontitis. Suspensions of plaque microorganisms from five subjects were sensitized with methylene blue (25 mu g/mL) for 5 min then exposed to red light. Multispecies microbial biofilms developed from the same plaque samples were also exposed to methylene blue (25 mu g/mL) and the same light conditions as their planktonic counterparts. In a second set of experiments, biofilms were developed with plaque bacteria from five subjects, sensitized with 25 or 50 mu g/mL of methylene blue and then exposed to red light. After photodynamic therapy, survival fractions were calculated by counting the number of colony-forming units. Results: Photodynamic therapy killed approximately 63% of bacteria present in suspension. By contrast, in biofilms, photodynamic therapy had much less of an effect on the viability of bacteria (32% maximal killing). Conclusion: Oral bacteria in biofilms are affected less by photodynamic therapy than bacteria in the planktonic phase. The antibacterial effect of photodynamic therapy is reduced in biofilm bacteria but not to the same degree as has been reported for treatment with antibiotics under similar conditions. C1 [Fontana, C. R.; Abernethy, A. D.; Som, S.; Ruggiero, K.; Doucette, S.; Soukos, N. S.] Forsyth Inst, Appl Mol Photomed Lab, Boston, MA 02115 USA. [Fontana, C. R.; Marcantonio, R. C.] Sao Paulo State Univ, Dept Diagnost Surg, Araraquara Dent Sch, Sao Paulo, Brazil. [Boussios, C. I.] MIT, Informat & Decis Syst Lab, Boston, MA USA. [Tanner, A. C. R.] Forsyth Inst, Dept Mol Genet, Boston, MA 02115 USA. [Kent, R.] Forsyth Inst, Dept Biostat, Boston, MA 02115 USA. RP Soukos, NS (reprint author), Forsyth Inst, Appl Mol Photomed Lab, 140 Fenway, Boston, MA 02115 USA. EM nsoukos@forsyth.org RI Marcantonio, Rosemary/C-2039-2012; Fontana, Carla/C-2033-2012 OI Marcantonio, Rosemary/0000-0002-5052-7439; Fontana, Carla/0000-0002-9135-3690 FU CAPES Foundation, Brazilian government [BEX 0547/05-0]; NIDCR [RO1-DE-14360, RO1-DE-16922.] FX Dr Nikos Soukos is indebted to Dr J. Max Goodson for his many years of encouragement, support and inspiration. Carla R. Fontana was a fellow of CAPES Foundation, Brazilian government (process BEX 0547/05-0). This work was supported by NIDCR grants RO1-DE-14360 and RO1-DE-16922. NR 48 TC 75 Z9 79 U1 0 U2 26 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-3484 J9 J PERIODONTAL RES JI J. Periodont. Res. PD DEC PY 2009 VL 44 IS 6 BP 751 EP 759 DI 10.1111/j.1600-0765.2008.01187.x PG 9 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 510BG UT WOS:000271062400009 PM 19602126 ER PT J AU Larauche, M Kiank, C Tache, Y AF Larauche, M. Kiank, C. Tache, Y. TI CORTICOTROPIN RELEASING FACTOR SIGNALING IN COLON AND ILEUM: REGULATION BY STRESS AND PATHOPHYSIOLOGICAL IMPLICATIONS SO JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY LA English DT Article; Proceedings Paper CT 13th International Conference on Gastrointestinal Research/International Conference on Ulcer Research CY SEP 10-16, 2009 CL Split, CROATIA DE corticotropin releasing factor; corticotropin releasing factor receptor; urocortin; stress; colon; ileum; irritable bowel syndrome; inflammatory bowel disease ID IRRITABLE-BOWEL-SYNDROME; INTESTINAL BARRIER FUNCTION; FUNCTIONAL GASTROINTESTINAL DISORDERS; ENTERIC NERVOUS-SYSTEM; GUINEA-PIG ILEUM; CHRONIC PSYCHOLOGICAL STRESS; INDUCED VISCERAL HYPERSENSITIVITY; FOLLICLE-ASSOCIATED EPITHELIUM; NEONATAL MATERNAL SEPARATION; 5-HT3 RECEPTOR ANTAGONISTS AB It is well established that central corticotropin releasing factor (CRF) signaling mediates the gastrointestinal responses to stress. However, as shown in the brain, both CRF receptors and ligands are also widely expressed in the colon and the ileum of humans and rodents, and stress modulates their expression. Several functional studies documented that peripheral injection of CRF or urocortin stimulates colonic transit, motility, Fos expression in myenteric neurons, and defecation through activation of CRF1 receptors, whereas it decreases ileal contractility via CRF2 receptors. Additionally, intraperitoneal administration of CRF induces colonic mast cells degranulation via both CRF1 and CRF2 receptors and increases ion secretion and mucosal permeability to macromolecules, which can in turn promote intestinal inflammation and alter visceral sensitivity. Most peripheral CRF-induced alterations of colonic and Heal functions mimic effects which are observed after stress exposure, and CRF receptor antagonists given peripherally prevent stress-induced GI dysfunction. Furthermore, CRF peptides can reproduce secretomotor and mucosal alterations in vitro. Therefore, accumulated clinical and preclinical evidence supports in addition to the brain, a role for peripheral CRF signaling in mediating stress-induced effects on gastrointestinal sensorimotor, mucosal and immune functions, that may be components of underlying mechanisms involved in stress-related impact on inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). C1 VA Greater Los Angeles Hlth Care Syst, Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Dept Med, Angeles, CA USA. RP Larauche, M (reprint author), VA Greater Los Angeles Hlth Care Syst, Bldg 115,Room 3,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mlarauche@mednet.ucla.edu OI Larauche, Muriel/0000-0003-3320-3675 FU NIDDK NIH HHS [P50 DK-57238, P50 DK-64539, P50 DK064539, R01 DK-57238, R01 DK057238, R01 DK057238-10] NR 198 TC 53 Z9 53 U1 0 U2 7 PU POLISH PHYSIOLOGICAL SOC PI GRZEGORZECKA PA JAGIELLONIAN UNIV SCHOOL MED, INST PHYSIOLOGY, 31-531 KRAKOW, 16 GRZEGORZECKA, POLAND SN 0867-5910 J9 J PHYSIOL PHARMACOL JI J. Physiol. Pharmacol. PD DEC PY 2009 VL 60 SU 7 BP 33 EP 46 PG 14 WC Physiology SC Physiology GA 589RR UT WOS:000277171200005 PM 20388944 ER PT J AU Gao, BB Phipps, JA Bursell, D Clermont, AC Feener, EP AF Gao, Ben-Bo Phipps, Joanna A. Bursell, Dahlia Clermont, Allen C. Feener, Edward P. TI Angiotensin AT1 Receptor Antagonism Ameliorates Murine Retinal Proteome Changes Induced by Diabetes SO JOURNAL OF PROTEOME RESEARCH LA English DT Article DE angiotensin AT1 receptor; diabetes mellitus; diabetic retinopathy; proteome; retina ID II TYPE-1 RECEPTOR; BLOOD-PRESSURE CONTROL; NORMAL RAT RETINA; GENE-EXPRESSION; VASCULAR-PERMEABILITY; OPA1 EXPRESSION; GROWTH-FACTOR; OPTIC-NERVE; RETINOPATHY; APOPTOSIS AB Diabetic retinopathy is the most common microvascular complication caused by diabetes mellitus and is a leading cause of vision loss among working-age adults in developed countries. Understanding the effects of diabetes on the retinal proteome may provide insights into factors and mechanisms responsible for this disease. We have performed a comprehensive proteomic analysis and comparison of retina from C57BL/6 mice with 2 months of streptozotocin-induced diabetes and age-matched nondiabetic control mice. To explore the role of the angiotensin AT1 receptor in the retinal proteome in diabetes, a subgroup of mice were treated with the AT1 antagonist candesartan. We identified 1792 proteins from retinal lysates, of which 65 proteins were differentially changed more than 2-fold in diabetic mice compared with nondiabetic mice. A majority (72%) of these protein changes were normalized by candesartan treatment. Most of the significantly changed proteins were associated with metabolism, oxidative phosphorylation, and apoptotic pathways. An analysis of the proteomics data revealed metabolic and apoptotic abnormalities in the retina from diabetic mice that were ameliorated with candesartan treatment. These results provide insight into the effects of diabetes on the retina and the role of the AT1 receptor in modulating this response. C1 [Gao, Ben-Bo; Phipps, Joanna A.; Bursell, Dahlia; Clermont, Allen C.; Feener, Edward P.] Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA. RP Feener, EP (reprint author), Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA. EM edward.feener@joslin.harvard.edu FU US National Institutes of Health [EY019029, DK 36836]; Massachusetts Lions Eye Research Fund; Mary K. Iacocca Fellowship; NHMRC (Australia) CJ Martin Fellowship FX This work was supported in part by the US National Institutes of Health (grants EY019029, DK 36836), and the Massachusetts Lions Eye Research Fund. B.-B. Gao is a recipient of a Mary K. Iacocca Fellowship and J. A. Phipps is supported by an NHMRC (Australia) CJ Martin Fellowship. We thank Jane Chen for assistance with proteomic analyses, Drs. Stephen Kolwicz, Jr, and Jia Liu for their critical comments regarding this manuscript, and Astrazeneca for providing candesartan-cilexetil. NR 45 TC 15 Z9 17 U1 0 U2 1 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1535-3893 J9 J PROTEOME RES JI J. Proteome Res. PD DEC PY 2009 VL 8 IS 12 BP 5541 EP 5549 DI 10.1021/pr9006415 PG 9 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 527AV UT WOS:000272339100013 PM 19845401 ER PT J AU O'Rourke, JA Scharf, JM Yu, DM Pauls, DL AF O'Rourke, Julia A. Scharf, Jeremiah M. Yu, Dongmei Pauls, David L. TI The genetics of Tourette syndrome: A review SO JOURNAL OF PSYCHOSOMATIC RESEARCH LA English DT Review DE Tourette's Disorder; Genetics; Family study; Review ID OBSESSIVE-COMPULSIVE DISORDER; ATTENTION-DEFICIT HYPERACTIVITY; DOPAMINE TRANSPORTER GENE; AUTOSOMAL-DOMINANT TRANSMISSION; COMPLEX SEGREGATION ANALYSIS; GILLES-DELATOURETTE SYNDROME; FAMILY-BASED ASSOCIATION; GENOME-WIDE ASSOCIATION; COPY NUMBER VARIATION; D1 RECEPTOR GENE AB Objectives: This article summarizes and evaluates recent advances in the genetics of Gilles de la Tourette syndrome (GTS). Methods: This is a review of recent literature focusing on (1) the genetic etiology of GTS; (2) common genetic components of GTS, attention deficit hyperactivity disorder (ADHD), and obsessive compulsive disorder (OCD); (3) recent linkage studies of GTS; (4) chromosomal translocations in GTS; and (5) candidate gene studies. Results: Family, twin, and segregation Studies provide strong evidence for the genetic nature of GTS. GTS is a heterogeneous disorder with complex inheritance patterns and phenotypic manifestations. Family studies of GTS and OCD indicate that an early-onset form of OCD is likely to share common genetic factors with GTS. While there apparently is an etiological relationship between GTS and ADHD, it appears that the common form of ADHD does not share genetic factors with GTS. The largest genome wide linkage study to date observed evidence for linkage oil chromosome 2p23.2 (P=3.8x10(-5)). No causative candidate genes have been identified, and recent studies suggest that the newly identified candidate gene SLITRKI is not a significant risk gene for the majority of individuals with GTS. Conclusion: The genetics of GTS are complex and not well understood. The Genome Wide Association Study (GWAS) design can hopefully overcome the limitations of linkage and candidate gene studies. However, large-scale collaborations are needed to provide enough power to utilize the GWAS design for discovery of causative mutations. Knowledge of susceptibility mutations and biological pathways involved should eventually lead to new treatment paradigms for GTS. (C) 2009 Elsevier Inc. All rights reserved. C1 [O'Rourke, Julia A.; Scharf, Jeremiah M.; Yu, Dongmei; Pauls, David L.] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Ctr Human Genet Res, Boston, MA 02114 USA. [O'Rourke, Julia A.; Scharf, Jeremiah M.; Yu, Dongmei; Pauls, David L.] Harvard Univ, Sch Med, Boston, MA USA. [O'Rourke, Julia A.] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA. RP Pauls, DL (reprint author), Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Ctr Human Genet Res, 185 Cambridge St, Boston, MA 02114 USA. EM dpauls@pngu.mgh.harvard.edu FU National Institute of Neurological Disease and Stroke [NS16648, NS40024] FX Supported in part by grants from the National Institute of Neurological Disease and Stroke, NS16648 and NS40024. NR 163 TC 90 Z9 94 U1 3 U2 31 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3999 J9 J PSYCHOSOM RES JI J. Psychosomat. Res. PD DEC PY 2009 VL 67 IS 6 SI SI BP 533 EP 545 DI 10.1016/j.jpsychores.2009.06.006 PG 13 WC Psychiatry SC Psychiatry GA 523ZW UT WOS:000272114600010 PM 19913658 ER PT J AU Lopez, L Dyck, AJ AF Lopez, Lenny Dyck, Arthur J. TI EDUCATING PHYSICIANS FOR MORAL EXCELLENCE IN THE TWENTY-FIRST CENTURY SO JOURNAL OF RELIGIOUS ETHICS LA English DT Article DE empathy; physician education; moral development; virtues ID MEDICAL-STUDENTS; IDEAL PHYSICIAN; EMPATHY; SCHOOL; CARE; PERCEPTIONS; ENVIRONMENT; CURRICULUM; BEHAVIORS; RESIDENTS AB Medical professionals are a community of highly educated individuals with a commitment to a core set of ideals and principles. This community provides both technical and ethical socialization. The ideal physician is confident, empathic, forthright, respectful, and thorough. These ideals allow us to define broadly "the excellence" of being a physician. At the core of these ideals is the ability to be empathic. Empathy exhibits itself in attributes of an individual's moral character and also in actions that actualize and support communal life. Empathy, however, can be diminished or even lost and must be nurtured on an ongoing basis. The development of ethical physicians is strongly linked to experiences in the training period. Moral traits are situation-sensitive psychological and behavioral dispositions. The clinical environment of medical training programs can be so intense as to lead to conditions that may actually deprofessionalize trainees. Creating a clinical environment that is ethically nurturing and sustaining is an indispensable component of practicing medicine. C1 [Lopez, Lenny] Massachusetts Gen Hosp, Inst Hlth Policy, Boston, MA 02114 USA. [Dyck, Arthur J.] Harvard Divin Sch, Cambridge, MA 02138 USA. RP Lopez, L (reprint author), Massachusetts Gen Hosp, Inst Hlth Policy, 50 Staniford St,9th Floor, Boston, MA 02114 USA. EM llopez1@partners.org; carol_edwards@harvard.edu NR 54 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0384-9694 J9 J RELIG ETHICS JI J. Relig. Ethics PD DEC PY 2009 VL 37 IS 4 BP 651 EP 668 PG 18 WC Religion SC Religion GA 518RO UT WOS:000271711000005 ER PT J AU Mestecky, J Moldoveanu, Z Smith, PD Hel, Z Alexander, RC AF Mestecky, Jiri Moldoveanu, Zina Smith, Phillip D. Hel, Zdenek Alexander, Rashada C. TI Mucosal immunology of the genital and gastrointestinal tracts and HIV-1 infection SO JOURNAL OF REPRODUCTIVE IMMUNOLOGY LA English DT Article; Proceedings Paper CT International Congress on Bio-Immunoregulatory Mechanisms Associated with Reproductive Organs CY FEB 09-13, 2009 CL Natl Inst Immunol, New Delhi, INDIA HO Natl Inst Immunol DE HIV-1; Mucosal immunity; Macrophages; IgA ID VIRUS TYPE-1 INFECTION; T-CELL DEPLETION; NEUTRALIZING ANTIBODIES; 1-INFECTED INDIVIDUALS; VAGINAL TRANSMISSION; RHESUS MACAQUES; IGA ANTIBODIES; SECRETIONS; RESPONSES; PROTECTION AB The male and female genital tracts are protected by a local immune system that displays features distinguishing them from other mucosal sites. In contrast to the intestinal tract, where locally produced IgA is the dominant Ig, secretions of the male and female genital tract contain predominantly IgG of both local and systemic origin. Genital tract tissues also lack mucosal lymphoepithelial inductive sites analogous to intestinal Peyer's patches; consequently, local immunization or infections with sexually transmitted pathogens induce low immune responses. Human immunodeficiency virus 1 (HIV-1) infection must be primarily considered as a mucosal disease with extensive involvement of the systemic immune compartment. Although the majority of infections is acquired through the genital mucosa,a high rate of virus replication and profound CD4(+) T cell depletion occurs in the intestinal mucosa and other mucosal tissues shortly after infection. Evaluation of HIV-specific antibodies in sera and external secretions, including vaginal washes and semen, unexpectedly revealed a selective lack of IgA responses. Moreover, specific antibody-secreting cells in peripheral blood were of the IgG isotype, even in mucosally infected individuals. Whether humoral responses to previously or newly encountered antigens are compromised in HIV-1-infected persons is under current investigation. (C) 2009 Elsevier Ireland Ltd. All rights reserved. C1 [Mestecky, Jiri; Moldoveanu, Zina; Smith, Phillip D.; Hel, Zdenek; Alexander, Rashada C.] Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA. [Mestecky, Jiri; Smith, Phillip D.] Univ Alabama, Dept Med, Birmingham, AL 35294 USA. [Hel, Zdenek] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA. [Mestecky, Jiri] Charles Univ Prague, Dept Microbiol & Immunol, Prague, Czech Republic. [Smith, Phillip D.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Mestecky, J (reprint author), Univ Alabama, Dept Microbiol, Box 1,845 19th St S, Birmingham, AL 35294 USA. EM mestecky@uab.edu OI Hel, Zdenek/0000-0002-4923-4794 FU NCRR NIH HHS [RR-20136]; NIAID NIH HHS [AI-74438, AI074438, R01 AI074438, P01 AI083027, R01 AI074438-01A1, AI083027, AI-83027, P01 AI083027-01, R21 AI087178]; NIDDK NIH HHS [DK-64400, R01 DK054495-02, R01 DK047322-10, R01 DK047322, DK-54495, DK-47322, R24 DK064400, R01 DK054495] NR 41 TC 30 Z9 30 U1 0 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-0378 J9 J REPROD IMMUNOL JI J. Reprod. Immunol. PD DEC PY 2009 VL 83 IS 1-2 BP 196 EP 200 DI 10.1016/j.jri.2009.07.005 PG 5 WC Immunology; Reproductive Biology SC Immunology; Reproductive Biology GA 536ED UT WOS:000273024800036 PM 19853927 ER PT J AU Morawietz, L Martinez-Gamboa, L Scheffler, S Hausdorf, G Dankof, A Kuckelkorn, U Doerner, T Egerer, K Burmester, GR Faustman, DL Feist, E AF Morawietz, Lars Martinez-Gamboa, Lorena Scheffler, Sonja Hausdorf, Gert Dankof, Anja Kuckelkorn, Ulrike Doerner, Thomas Egerer, Karl Burmester, Gerd-R. Faustman, Denise L. Feist, Eugen TI Expression of Proteasomal Immunosubunit beta 1i Is Dysregulated in Inflammatory Infiltrates of Minor Salivary Glands in Sjogren's Syndrome SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE PROTEASOME SYSTEM; SJOGREN'S SYNDROME; beta 1i EXPRESSION; SALIVARY GLANDS ID NF-KAPPA-B; MAJOR HISTOCOMPATIBILITY COMPLEX; INTERFERON-GAMMA; 20S PROTEASOME; SUBUNIT; LMP2; CELLS; IMMUNOPROTEASOMES; TRANSCRIPTION; PROTEOLYSIS AB Objective. Minor salivary gland specimens were analyzed to investigate dysregulation of the proteasome system in patients with Sjogren's syndrome (SS) and patients with sicca syndrome. Methods. Labial biopsy specimens from 17 patients with SS and 11 patients with non-autoimmune sicca syndrome were analyzed by immunohistochemistry for expression of the inducible proteasomal subunits beta 1i, beta 2i, and beta 5i. The infiltrating subsets of lymphocytes were characterized using immunofluorescence stainings against the cell-surface markers CD20 and CD27. Two-dimensional elcctrophoresis and immunoblotting were used for detection of the proteasomal subunits beta 1 and beta 1i in peripheral blood monocyte cells. Gene expression of the constitutive subunits beta 1, beta 2, and beta 5 and the corresponding inducible subunits beta 1i, beta 2i, and beta 5i was further investigated at the mRNA level in small lip biopsies using real-time polymerase chain reaction. Results. The expression of beta 1i in infiltrating and peripheral immune cells was altered in patients with SS compared to patients with non-autoimmune sicca syndrome and healthy controls. No significant differences were found in beta 2i and beta 5i expression between the same groups in small lip biopsies. Chisholm-Mason grade and beta 1i expression were found to be inversely correlated (Spearman r = -0.46 1, p = 0.0 14). The phenotype and distribution of the lymphocytic infiltrate showed no differences between patients with primary and secondary SS regardless of beta 1i expression. Conclusion. The proteasomal beta 1i subunit is dysregulated in peripheral white blood cells and in inflammatory infiltrates of minor salivary glands in patients with SS. (First Release Oct 15 2009; J Rheumatol 2009;36:2694-703; doi: 10.3899/jrheum.081098) C1 [Martinez-Gamboa, Lorena; Scheffler, Sonja; Hausdorf, Gert; Doerner, Thomas; Egerer, Karl; Burmester, Gerd-R.; Feist, Eugen] Charite, Dept Rheumatol & Clin Immunol, D-10117 Berlin, Germany. [Morawietz, Lars; Dankof, Anja] Charite, Inst Pathol, D-10117 Berlin, Germany. [Kuckelkorn, Ulrike] Charite, Inst Biochem, D-10117 Berlin, Germany. Humboldt Univ, Berlin, Germany. Free Univ Berlin, D-1000 Berlin, Germany. [Faustman, Denise L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Immunobiol Lab, Charlestown, MA USA. RP Feist, E (reprint author), Charite, Dept Rheumatol & Clin Immunol, Charitepl 1, D-10117 Berlin, Germany. EM eugen.feist@charite.de FU Deutsche Forschungsgemeinschaft [FE 470/3-1] FX Supported by the Deutsche Forschungsgemeinschaft (FE 470/3-1). NR 39 TC 6 Z9 7 U1 0 U2 0 PU J RHEUMATOL PUBL CO PI TORONTO PA 920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADA SN 0315-162X J9 J RHEUMATOL JI J. Rheumatol. PD DEC PY 2009 VL 36 IS 12 BP 2694 EP 2703 DI 10.3899/jrheum.081098 PG 10 WC Rheumatology SC Rheumatology GA 533WN UT WOS:000272856200011 PM 19833746 ER PT J AU Walker, HC Phillips, DE Boswell, DB Guthrie, BL Guthrie, SL Nicholas, AP Montgomery, EB Watts, RL AF Walker, Harrison C. Phillips, Daniel E. Boswell, Deborah B. Guthrie, Barton L. Guthrie, Stephanie L. Nicholas, Anthony P. Montgomery, Erwin B. Watts, Ray L. TI Relief of Acquired Stuttering Associated With Parkinson's Disease by Unilateral Left Subthalamic Brain Stimulation SO JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH LA English DT Article DE stuttering; Parkinson's disease; subthalamic nucleus; deep brain stimulation; speech ID TOURETTE-SYNDROME; THALAMIC-STIMULATION; NUCLEUS STIMULATION; ALE METAANALYSIS; FOLLOW-UP; SPEECH; ALLEVIATION; HYPOTHESIS; PATIENT; SYSTEM AB Purpose: In this article, the authors report a case of acquired stuttering associated with Parkinson's disease (PD) that was responsive to unilateral subthalamic nucleus deep-brain stimulation (STN DBS) in the language-dominant hemisphere. Method: A single-subject, masked, multiple baseline design was used to evaluate the effects of unilateral left STN DBS on stuttering associated with PD. The patient underwent 3 formal speech assessments of spontaneous speech and the reading of passages with DBS off and on. Speech samples were videotaped and placed in random order, and 2 independent speech-language pathologists calculated the percentage of stuttered syllables and classified individual stuttering events. Results: Stuttering improved significantly in the DBS-on condition. In total, 10% of syllables were affected by stuttering events with DBS off, and less than 1% of syllables were affected by stuttering events with DBS on (n = 2,281 syllables, p < .00001, in a chi(2) test). The effect of unilateral STN DBS on stuttering was relatively independent of whether the patient was on or off dopaminergic medications. Conclusion: This article emphasizes the important role of the subthalamic region in the motor control of speech and language. C1 [Walker, Harrison C.; Guthrie, Barton L.; Guthrie, Stephanie L.; Nicholas, Anthony P.; Montgomery, Erwin B.; Watts, Ray L.] Univ Alabama, Birmingham, AL USA. [Phillips, Daniel E.] Auburn Univ, Auburn, AL 36849 USA. [Boswell, Deborah B.] Profess Speech Serv, Birmingham, AL USA. [Nicholas, Anthony P.; Montgomery, Erwin B.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Walker, HC (reprint author), Univ Alabama, Dept Neurol, 1720 7th Ave, Birmingham, AL 35212 USA. EM hcwalker@uab.edu NR 38 TC 11 Z9 11 U1 0 U2 4 PU AMER SPEECH-LANGUAGE-HEARING ASSOC PI ROCKVILLE PA 10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA SN 1092-4388 J9 J SPEECH LANG HEAR R JI J. Speech Lang. Hear. Res. PD DEC 1 PY 2009 VL 52 IS 6 BP 1652 EP 1657 DI 10.1044/1092-4388(2009/08-0089) PG 6 WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation GA 528YK UT WOS:000272482700017 PM 19951930 ER PT J AU Turner, TH LaRowe, S Horner, MD Herron, J Malcolm, R AF Turner, Travis H. LaRowe, Steven Horner, Michael David Herron, Janice Malcolm, Robert TI Measures of cognitive functioning as predictors of treatment outcome for cocaine dependence SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE Cocaine dependence; Treatment outcome prediction; Neuropsychology; Cognition; Substance dependence; Cognitive-Behavioral therapy; Amlodipine; Executive functioning ID NEUROCOGNITIVE DEFICITS; ALCOHOL DEPENDENCE; DECISION-MAKING; IMPAIRMENT; DRINKING; ABUSE; ACQUISITION; RELAPSE AB Amlodipine is a calcium-channel antagonist with neuropharmacological properties believed to be protective against cerebral hypoperfusion, microinfarcts, and excitoxic cell death. Based on its pharmacological properties, we hypothesized that amlodipine would be associated with improved attention, processing speed, memory, and executive functioning at treatment follow-up in 84 cocaine-dependent individuals enrolled in a 12-week, placebo-controlled, double-blind clinical trial of amlodipine. We also hypothesized that better cognitive functioning at baseline would be associated with reduced cocaine use (negative urine drug screens) and longer treatment retention (last session attended). Results indicated that amlodipine produced no measurable benefit in cognitive functioning. Percent perseverative errors on Wisconsin Card Sorting Test was negatively correlated with treatment retention (n = 84, r = -.350, p <.01). No other findings were significant. Thus, cocaine-dependent individuals who repeated mistakes and benefited less from corrective feedback on a problem-solving task discontinued treatment earlier. Notably, no other cognitive measures predicted treatment outcome. The observed relationship implicates the relevance of executive functioning to treatment outcome for cocaine dependence. (C) 2009 Elsevier Inc. All rights reserved. C1 [Turner, Travis H.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Turner, Travis H.; LaRowe, Steven; Horner, Michael David; Herron, Janice; Malcolm, Robert] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Turner, Travis H.; LaRowe, Steven; Horner, Michael David] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. RP Turner, TH (reprint author), Med Univ S Carolina, Dept Neurosci, 96 Jonathan Lucas St,Suite 307 Clin Sci Bldg,MSC, Charleston, SC 29425 USA. EM turnertr@musc.edu FU NIDA NIH HHS [R01-DA11454] NR 36 TC 43 Z9 43 U1 1 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD DEC PY 2009 VL 37 IS 4 BP 328 EP 334 DI 10.1016/j.jsat.2009.03.009 PG 7 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 518BY UT WOS:000271666300002 PM 19394790 ER PT J AU Fats-Stewart, W O'Farrell, TJ Lam, WKK AF Fats-Stewart, William O'Farrell, Timothy J. Lam, Wendy K. K. TI Behavioral couple therapy for gay and lesbian couples with alcohol use disorders SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE Gay; Lesbian; Behavioral couple therapy; Alcohol; Randomized clinical trial ID SUBSTANCE-ABUSE TREATMENT; DRUG-USE; LEARNING SOBRIETY; MEN; SEX; DRINKING; QUALITY; TRIAL; RISK AB Gay (n = 52) and lesbian (n = 48) patients with alcohol use disorder (AUD) and their non-substance-abusing same-sex relationship partners were randomly assigned to equally intensive interventions consisting of (a) behavioral couples therapy (BCT) plus individual-based treatment (IBT) or (b) IBT only. This study reports two separate trials, one with gay male participants and one with lesbian female participants. For both gay and lesbian patients with AUD, those who received BCT had a significantly lower percentage of days of heavy drinking during the year after treatment than patients who received IBT only. In addition, both gay and lesbian couples who received BCT reported higher levels of relationship adjustment at the end of treatment and in the year after treatment than those who received IBT only. Thus, the response of gay and lesbian couples with an alcoholic member to BCT was consistent with what has been observed with heterosexual couples. (C) 2009 Elsevier Inc. All rights reserved. C1 [Fats-Stewart, William; Lam, Wendy K. K.] Univ Rochester, Sch Nursing, Rochester, NY 14642 USA. [O'Farrell, Timothy J.] Harvard Univ, Sch Med, Dept Psychiat, VA Boston Healthcare Syst, Brockton, MA 02301 USA. RP Fats-Stewart, W (reprint author), Univ Rochester, Sch Nursing, 601 Elmwood Ave, Rochester, NY 14642 USA. EM william_fals-stewart@urmc.rochester.edu NR 36 TC 0 Z9 0 U1 4 U2 11 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD DEC PY 2009 VL 37 IS 4 BP 379 EP 387 DI 10.1016/j.jsat.2009.05.001 PG 9 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 518BY UT WOS:000271666300008 ER PT J AU Earle, CC Weiser, MR Ter Veer, A Skibber, JM Wilson, J Rajput, A Wong, YN Benson, AB Shibata, S Romanus, D Niland, J Schrag, D AF Earle, C. C. Weiser, M. R. Ter Veer, A. Skibber, J. M. Wilson, J. Rajput, A. Wong, Y. N. Benson, A. B., III Shibata, S. Romanus, D. Niland, J. Schrag, D. TI Effect of Lymph Node Retrieval Rates on the Utilization of Adjuvant Chemotherapy in Stage II Colon Cancer SO JOURNAL OF SURGICAL ONCOLOGY LA English DT Article; Proceedings Paper CT 44th Annual Meeting of the American-Society-of-Clinical-Oncology CY MAY 30-JUN 03, 2008 CL Chicago, IL SP Amer Soc Clin Oncol DE colon cancer; LN retrieval; chemotherapy ID RANDOMIZED CONTROLLED TRIAL; COLORECTAL-CANCER; CURATIVE RESECTION; PLUS LEVAMISOLE; RECTAL-CANCER; FOLINIC ACID; FLUOROURACIL; CARCINOMA; THERAPY; SURVIVAL AB Background: Failing to meet the benchmark of 12 lymph nodes in resection specimens is an indication for adjuvant chemotherapy in stage II colon cancer. Methods: Among consecutive eligible patients with pathologic stage II colon cancer treated at eight NCI-designated comprehensive cancer centers between September 1, 2005 and February 19, 2008, we analyzed receipt of adjuvant chemotherapy, with less than 12 versus 12+ lymph nodes removed and examined the primary explanatory variable of interest. Results: Among 258 patients, 46% received adjuvant chemotherapy. An oxaliplatin-containing regimen was used 67% of the time. Younger age (<50 years, P < 0.001), presence of lymphovascular invasion (P = 0.007), and higher T stage (P = 0.007) were independently associated with adjuvant chemotherapy use. There was significant inter-institutional variability in practice with the proportion receiving treatment ranging from 17% to 64% (P < 0.05). Notably, presence of less than 12 lymph nodes in the surgical specimen was a strong predictor of treatment (P = 0.008). Conclusions: Adjuvant chemotherapy use after resection of stage If colon cancer is common, but by no means standard practice at National Comprehensive Cancer Network (NCCN) institutions. More attention to achieving the recommended benchmark for lymph node dissection has the potential to decrease exposure to the toxicity of adjuvant treatment. J. Surg. Oncol. 2009;100:525-528. (C) 2009 Wiley-Liss, Inc. C1 [Earle, C. C.; Romanus, D.; Schrag, D.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Weiser, M. R.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Ter Veer, A.; Shibata, S.; Niland, J.] City Hope Canc Ctr, Duarte, CA USA. [Skibber, J. M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Wilson, J.] Ohio State Univ, Columbus, OH 43210 USA. [Rajput, A.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Wong, Y. N.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Benson, A. B., III] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. RP Earle, CC (reprint author), Inst Clin Evaluat Sci, 2075 Bayview Ave,G Wing Room 106, Toronto, ON M4N 3M5, Canada. EM craig.earle@ices.on.ca NR 29 TC 17 Z9 19 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0022-4790 J9 J SURG ONCOL JI J. Surg. Oncol. PD DEC 1 PY 2009 VL 100 IS 7 BP 525 EP 528 DI 10.1002/jso.21373 PG 4 WC Oncology; Surgery SC Oncology; Surgery GA 526TM UT WOS:000272317100001 PM 19697351 ER PT J AU Gopaldas, RR Huh, J Bakaeen, FG Wang, XL Coselli, JS LeMaire, SA Chu, D AF Gopaldas, Raja R. Huh, Joseph Bakaeen, Faisal G. Wang, Xing Li Coselli, Joseph S. LeMaire, Scott A. Chu, Danny TI The Impact of Resident Work-Hour Restrictions on Outcomes of Cardiac Operations SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE outcomes; residents; ACGME; work-hour; cardiac surgery ID INTERNAL-MEDICINE; CARE; NIGHT; RISK AB Background. The Accreditation Council of Graduate Medical Education mandated an 80-h/wk resident physician work-hour restriction on July 1, 2003. The objective of this study was to evaluate the impact of the resident work-hour restriction on outcomes of cardiac operations. Materials and Method. We reviewed records of 1562 patients who underwent cardiac operations at our institution between 1997 and 2007, and we compared outcomes of operations performed before July 1, 2003 (pre-reform, n = 777) and those performed after July 1, 2003 (post-reform, n = 785). Multivariate analysis with logistic regression was used to test for the independent effects of the resident work-hour reform by controlling for patient-specific confounding factors. Results. Post-reform patients had a significantly lower 30-d mortality rate (1.8% versus 3.9%; P = 0.01) and a slightly lower 6-month mortality rate (4.5% versus 6.3%; P = 0.12) than pre-reform patients. Multivariate analysis revealed that the post-reform patients had significantly lower adjusted 30-d mortality (odds ratio, 0.37; 95% CI, 0.18-0.75; P = 0.006) and 6-mo mortality (odds ratio, 0.56; 95% CI, 0.34-0.91; P = 0.02) than the pre-reform patients. Conclusions. Cardiac operations performed after the resident work-hour restriction went into effect were associated with significantly lower adjusted 30-d and 6-mo mortality rates than were operations performed before the work-hour restriction became effective. Published by Elsevier Inc. C1 [Chu, Danny] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Div Cardiothorac Surg, Houston, TX 77030 USA. [Gopaldas, Raja R.; Huh, Joseph; Wang, Xing Li; Coselli, Joseph S.; LeMaire, Scott A.] St Lukes Episcopal Hosp, Texas Heart Inst, Sect Adult Cardiac Surg, Houston, TX USA. RP Chu, D (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Div Cardiothorac Surg, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA. EM dchumd@gmail.com NR 19 TC 13 Z9 13 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 J9 J SURG RES JI J. Surg. Res. PD DEC PY 2009 VL 157 IS 2 BP 268 EP 274 DI 10.1016/j.jss.2009.03.042 PG 7 WC Surgery SC Surgery GA 583CL UT WOS:000276650200020 PM 19555974 ER PT J AU Newcorn, JH Sutton, VK Zhang, SY Wilens, T Kratochvil, C Emslie, GJ D'Souza, DN Schuh, LM Allen, AJ AF Newcorn, Jeffrey H. Sutton, Virginia K. Zhang, Shuyu Wilens, Timothy Kratochvil, Christopher Emslie, Graham J. D'Souza, Deborah N. Schuh, Leslie M. Allen, Albert J. TI Characteristics of Placebo Responders in Pediatric Clinical Trials of Attention-Deficit/Hyperactivity Disorder SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY LA English DT Article DE attention-deficit/hyperactivity disorder; placebo; response ID ONCE-DAILY ATOMOXETINE; ACTIVE-CONTROL TRIALS; DOUBLE-BLIND; OROS METHYLPHENIDATE; MAJOR DEPRESSION; EXTENDED-RELEASE; CHILDREN; ADOLESCENTS; ADHD; EFFICACY AB Objective: Understanding placebo response is a prerequisite to improving clinical trial methodology. Data from placebo-controlled trials of atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder (ADHD) were analyzed to identify demographic and clinical characteristics that might predict placebo response in future clinical trials. Method: Data were pooled across 731 placebo-treated pediatric patients who participated in 10 acute, randomized, placebo-controlled trials. Responder status was based on empirically derived thresholds of change on the total score of the ADHD Rating Scale with minimal and robust response defined as 25% or greater and 40% or greater decrease, respectively. Study design characteristics, including randomization ratio, dose, and titration strategy, and patient demographic and clinical characteristics were examined as potential predictors of placebo response. Results: Inattentive subtype, lack of previous stimulant treatment, presence of comorbid tics and nonwhite ethnicity were associated with robust placebo response. A subset analysis of patients completing 6 weeks of treatment (to eliminate the effects of early dropout) identified inattentive subtype and lack of previous stimulant experience as significant predictors of robust placebo response. Conclusions: Placebo response is less likely in subjects with combined-subtype ADHD who are not stimulant-naive. Limiting ADHD clinical trials to this more restricted subject group is likely to maximize treatment differences. However, because this is not always possible or desirable, identifying other methods of mitigating placebo response is essential. J. Am. Acad. Child Adolesc. Psychiatry, 2009;48(12):1165-1172. C1 [Newcorn, Jeffrey H.] Mt Sinai Sch Med, New York, NY 10029 USA. [Wilens, Timothy] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Emslie, Graham J.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Schuh, Leslie M.] Eli Lilly & Co, Indianapolis, IN USA. RP Newcorn, JH (reprint author), Mt Sinai Sch Med, Box 1230,1 Gustave L Levy Pl, New York, NY 10029 USA. EM Jeffrey.newcorn@mssm.edu OI Newcorn, Jeffrey /0000-0001-8993-9337 FU Eli Lilly Company FX This work was financially supported by Eli Lilly & Company. NR 30 TC 18 Z9 18 U1 3 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0890-8567 J9 J AM ACAD CHILD PSY JI J. Am. Acad. Child Adolesc. Psychiatr. PD DEC PY 2009 VL 48 IS 12 BP 1165 EP 1172 DI 10.1097/CHI.0b013e3181bc730d PG 8 WC Psychology, Developmental; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA 523DG UT WOS:000272051500005 PM 19858759 ER PT J AU Brahmbhatt, K AF Brahmbhatt, Khyati TI Adolescent Psychopathology and the Developing Brain: Integrating Brain and Prevention Science SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY LA English DT Book Review C1 [Brahmbhatt, Khyati] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Brahmbhatt, K (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. EM KBrahmbhatt@partners.org OI Brahmbhatt, Khyati/0000-0002-7834-3455 NR 1 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0890-8567 J9 J AM ACAD CHILD PSY JI J. Am. Acad. Child Adolesc. Psychiatr. PD DEC PY 2009 VL 48 IS 12 BP 1204 EP 1207 DI 10.1097/01.chi.0000360560.73284.b2 PG 4 WC Psychology, Developmental; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA 523DG UT WOS:000272051500011 ER PT J AU Cohen, ME Dimick, JB Bilimoria, KY Ko, CY Richards, K Hall, BL AF Cohen, Mark E. Dimick, Justin B. Bilimoria, Karl Y. Ko, Clifford Y. Richards, Karen Hall, Bruce Lee TI Risk Adjustment in the American College of Surgeons National Surgical Quality Improvement Program: A Comparison of Logistic Versus Hierarchical Modeling SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID PROFILING HOSPITAL PERFORMANCE; STATISTICAL METHODOLOGY; MORTALITY; OUTCOMES; CARD AB BACKGROUND: Although logistic regression has commonly been used to adjust for risk differences in patient and case mix to permit quality comparisons across hospitals, hierarchical modeling has been advocated as the preferred methodology, because it accounts for clustering of patients within hospitals. It is unclear whether hierarchical models would yield important differences in quality assessments compared with logistic models when applied to American College of Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) data. Our objective was to evaluate differences in logistic versus hierarchical modeling for identifying hospitals with outlying Outcomes in the ACS-NSQIP. STUDY DESIGN: Data from ACS-NSQIP patients who underwent colorectal operations in 2008 at hospitals that reported at least 100 operations were used to generate logistic and hierarchical prediction models for 30-day morbidity and mortality. Differences in risk-adjusted performance (ratio of observed-to-expected events) and outlier detections from the two models were compared. RESULTS: Logistic and hierarchical models identified the same 25 hospitals is morbidity outliers (14 low and 11 high outliers), but the hierarchical model identified 2 additional high outliers. Both models identified the same eight hospitals as mortality Outliers (five low and three high outliers). The values of observed-to-expected events ratios and p values from the two models were highly correlated. Results were similar when data were permitted from hospitals providing < 100 patients. CONCLUSIONS: When applied to ACS-NSQIP data, logistic and hierarchical models provided nearly identical results with respect to identification of hospitals' observed-to-expected events ratio outliers. As hierarchical models are prone to implementation problems, logistic regression will remain ail accurate and efficient method for performing risk adjustment of hospital quality comparisons. (J Am Coll Surg 2009;209:687-693. (C) 2009 by the American College of Surgeons) C1 [Cohen, Mark E.; Bilimoria, Karl Y.; Ko, Clifford Y.; Richards, Karen] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA. [Dimick, Justin B.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA. [Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Hall, Bruce Lee] Washington Univ, Sch Med, Dept Surg, John Cochran Vet Affairs Med Ctr, St Louis, MO 63110 USA. [Hall, Bruce Lee] Barnes Jewish Hosp, Ctr Hlth Policy, St Louis, MO 63110 USA. [Hall, Bruce Lee] Washington Univ, John M Olin Sch Business, St Louis, MO 63130 USA. RP Cohen, ME (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,22nd Fl, Chicago, IL 60611 USA. EM markcohen@facs.org NR 33 TC 67 Z9 67 U1 2 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD DEC PY 2009 VL 209 IS 6 BP 687 EP 693 DI 10.1016/j.jamcollsurg.2009.08.020 PG 7 WC Surgery SC Surgery GA 534EZ UT WOS:000272880400002 PM 19959035 ER PT J AU Harris, DP Chodosh, J Vassar, SD Vickrey, BG Shapiro, MF AF Harris, Dorothy P. Chodosh, Joshua Vassar, Stefanie D. Vickrey, Barbara G. Shapiro, Martin F. TI Primary Care Providers' Views of Challenges and Rewards of Dementia Care Relative to Other Conditions SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE dementia; disease management; health services research; primary care; healthcare delivery ID MANAGING ALZHEIMERS-DISEASE; RANDOMIZED CONTROLLED-TRIAL; IMPROVING PRIMARY-CARE; MANAGEMENT INTERVENTION; COGNITIVE IMPAIRMENT; INTERNAL-MEDICINE; CHRONIC ILLNESS; PHYSICIANS; GUIDELINES; COMMUNITY AB OBJECTIVES: To compare primary care providers' (PCPs') perceptions about dementia and its care within their healthcare organization with perceptions of other common chronic conditions and to explore factors associated with differences. DESIGN: Cross-sectional survey. SETTING: Three California healthcare organizations. PARTICIPANTS: One hundred sixty-four PCPs. MEASUREMENTS: PCPs' views about primary care for dementia were analyzed and compared with views about care for heart disease, diabetes mellitus, and selected other conditions. Differences in views about conditions according to PCP type (internists, family physicians) were assessed. Multivariate analysis examined relationships between provider and practice characteristics and views about dementia care. RESULTS: More PCPs strongly agreed that older patients with dementia are difficult to manage (23.8%) than for heart disease (5.0%) or diabetes mellitus (6.3%); PCPs can improve quality of life for heart disease (58.9%) and diabetes mellitus (61.6%) than for dementia (30.9%); older patients should be routinely screened for heart disease (63.8%) and diabetes mellitus (67.7%) than dementia (55.5%); and their organizations have expertise/referral resources to manage diabetes inellitus (49.4%) and heart disease (51.8%) than dementia (21.1%). More PCPs reported almost effortless organizational care coordination for heart disease (13.0%) or diabetes mellitus (13.7%) than for dementia (5.6%), and a great deal or many opportunities for improvement in their ability to manage dementia (50.6%) than incontinence, depression, or hypertension (7.4-34.0%; all P<.05). Internists' views regarding dementia care were less optimistic than those of family physicians, but PCP type was unrelated to views on diabetes mellitus or heart disease. CONCLUSION: Improving primary care management of dementia should directly address PCP concerns about expertise and referral resources, difficulty of care provision, and PCP views about prospects for patient improvement. J Am Geriatr Soc 57:2209-2216, 2009. C1 [Harris, Dorothy P.; Vassar, Stefanie D.; Vickrey, Barbara G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Chodosh, Joshua] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Dept Med, Los Angeles, CA 90095 USA. [Shapiro, Martin F.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Dept Med, Los Angeles, CA 90095 USA. [Shapiro, Martin F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Hlth Serv, Los Angeles, CA 90095 USA. [Chodosh, Joshua] Vet Affairs Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, Sepulveda, CA USA. [Chodosh, Joshua; Vickrey, Barbara G.] Vet Affairs Greater Los Angeles Healthcare Syst, Hlth Serv Res & Dev Serv Ctr Excellence, Sepulveda, CA USA. [Vassar, Stefanie D.; Vickrey, Barbara G.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Neurol, Sepulveda, CA USA. [Vassar, Stefanie D.; Vickrey, Barbara G.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Neurol, Sepulveda, CA USA. RP Harris, DP (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, 710 Westwood Plaza,RNRC C-239, Los Angeles, CA 90095 USA. EM dpharris@ucla.edu RI Max, Mad/E-5238-2010; OI Max, Mad/0000-0001-6966-6829; Chodosh, Joshua/0000-0001-7784-4306 FU California Department of Public Health [06-55314]; Alzheimer's Disease Research Center of California; American Heart Association (AHA) through funding for the AHA/Pharmaceutical Roundtable Outcomes Research Center at the University of California at Los Angeles (UCLA); National Institutes of Health; National Center on Minority Health and Health Disparities [2P20MD000182] FX This Study was supported by the California Department of Public Health (Contract 06-55314) for the Alzheimer's Disease Research Center of California and the American Heart Association (AHA) through funding for the AHA/Pharmaceutical Roundtable Outcomes Research Center at the University of California at Los Angeles (UCLA). Dr. Shapiro was supported in part by UCLA/DREW Project EXPORT, National Institutes of Health, National Center on Minority Health and Health Disparities (2P20MD000182). NR 31 TC 19 Z9 19 U1 2 U2 5 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2009 VL 57 IS 12 BP 2209 EP 2216 DI 10.1111/j.1532-5415.2009.02572.x PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 535NN UT WOS:000272976400004 PM 19943831 ER PT J AU Moore, AA Karno, MP Grella, CE Lin, JC Warda, U Liao, DH Hu, PF AF Moore, Alison A. Karno, Mitchell P. Grella, Christine E. Lin, James C. Warda, Umme Liao, Diana H. Hu, Peifeng TI Alcohol, Tobacco, and Nonmedical Drug Use in Older US Adults: Data from the 2001/02 National Epidemiologic Survey of Alcohol and Related Conditions SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE alcohol; tobacco; nonmedical drugs; epidemiology ID UNITED-STATES; COOCCURRING ALCOHOL; SUBSTANCE USE; CONSUMPTION; DISORDERS; COMORBIDITY; PREVALENCE; DEPENDENCE; DRINKING; PATTERNS AB OBJECTIVES: To exam ne the prevalence and sociodemographic and health-related correlates of substance use, including alcohol, tobacco, and nonmedical drug use, in adults aged 65 and older. DESIGN: Cross-sectional, retrospective survey of a population-based sample, the 2001/02 National Epidemiologic Survey on Alcohol and Related Conditions. SETTING: United States. PARTICIPANTS: Eight thousand two hundred five U.S. adults aged 65 and older. MEASUREMENTS: Prevalence of lifetime and previous-12-month alcohol, tobacco, and nonmedical drug use and associations between substance use and sociodemographic and health-related factors. RESULTS: Almost 80% of older adults had used any of the three substances over their lifetimes, and more than 50% reported such use over the previous 12 months. Alcohol was the most commonly used substance over the lifetime (74%) and in the previous 12 months (45%), followed by tobacco (52% lifetime; 14% previous 12 months); far fewer reported nonmedical use of drugs (5% lifetime; 14% previous 12 months). In general, being younger, male, and divorced or separated were factors consistently associated with use of any of the three substances. CONCLUSION: Most older adults had used substances over their lifetimes and in the previous 12 months. Alcohol is the substance of choice for this age group, followed by tobacco; few report nonmedical drug use. J Am Geriatr Soc 57:2275-2281, 2009. C1 [Moore, Alison A.; Warda, Umme; Liao, Diana H.; Hu, Peifeng] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr Med, Los Angeles, CA 90095 USA. [Moore, Alison A.; Karno, Mitchell P.; Grella, Christine E.] Univ Calif Los Angeles, Integrated Substance Abuse Programs, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Lin, James C.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Geriatr Med, Los Angeles, CA USA. RP Moore, AA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, 10945 Le Conte Ave,Suite 2339, Los Angeles, CA 90095 USA. EM aamoore@mednet.ucla.edu FU National Institute on Drug Abuse [R01DA020944]; National Institute on Alcoholism and Alcohol Abuse [K24AA15957]; National Institute on Aging [P30AG028748] FX National Institute on Drug Abuse (R01DA020944), National Institute on Alcoholism and Alcohol Abuse (K24AA15957), National Institute on Aging (P30AG028748), and a Veterans Affairs Special Fellowship in Advanced Geriatrics provided funding support. NR 28 TC 32 Z9 32 U1 1 U2 5 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2009 VL 57 IS 12 BP 2275 EP 2281 DI 10.1111/j.1532-5415.2009.02554.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 535NN UT WOS:000272976400014 PM 19874409 ER PT J AU Choi-Kain, LW Ackerman, J AF Choi-Kain, Lois W. Ackerman, Julie TI SELECTED POSTERS FROM THE 2009 POSTER SESSION OF THE AMERICAN PSYCHOANALYTIC ASSOCIATION ATTACHMENT AND COGNITION IN BORDERLINE PERSONALITY DISORDER SO JOURNAL OF THE AMERICAN PSYCHOANALYTIC ASSOCIATION LA English DT Article C1 [Choi-Kain, Lois W.] McLean Hosp, Belmont, MA 02478 USA. [Ackerman, Julie] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Choi-Kain, LW (reprint author), McLean Hosp, 115 Mill St, Belmont, MA 02478 USA. EM lchoikain@partners.org NR 12 TC 0 Z9 0 U1 0 U2 6 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0003-0651 J9 J AM PSYCHOANAL ASS JI J. Am. Psychoanal. Assoc. PD DEC PY 2009 VL 57 IS 6 BP 1459 EP 1464 DI 10.1177/0003065109357345 PG 6 WC Psychiatry; Psychology, Psychoanalysis SC Psychiatry; Psychology GA 543YL UT WOS:000273617200008 PM 20068247 ER PT J AU Mitchell, C Miller, FA Bierig, SM Bremer, ML Ehler, D Hanlon, T Keller, D Korcarz, CE Mangion, JR Marshall, JE McCulloch, ML Mehl, B Rigling, R Robbins, C Sanchez, L Umland, MM AF Mitchell, Carol Miller, Fletcher A., Jr. Bierig, S. Michelle Bremer, Merri L. Ehler, Donna Hanlon, Timothy Keller, Daren Korcarz, Claudia E. Mangion, Judy R. Marshall, Jane E. McCulloch, Marti L. Mehl, Brad Rigling, Rick Robbins, Cassie Sanchez, Liza Umland, Matt M. TI Advanced Cardiovascular Sonographer: A Proposal of the American Society of Echocardiography Advanced Practice Sonographer Task Force SO JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY LA English DT Article DE Advanced Cardiovascular Sonographer; Sonographer Education; Advanced Practice ID CARDIAC SONOGRAPHER AB Echocardiographic examinations require a well-trained and competent sonographer to obtain proper anatomic and physiologic data to establish an accurate diagnosis for clinical decision-making and patient management. Although the formal education and training of cardiovascular sonographers are evolving, many entry-level and staff sonographers may not have sufficient practical or clinical knowledge of the necessary components of the echocardiographic study for the individual patient's clinical presentation. In many clinical settings, echocardiograms are read after the patient has left the laboratory. Thus, there is a role for a sonographer who can practice at an advanced level in a cardiovascular ultrasound laboratory to ensure a proper echocardiographic examination is performed on every patient. In this setting, an Advanced Cardiovascular Sonographer (ACS) would be able to review the indication for and quality of the examination. If additional images were needed, the ACS would assist the sonographer in obtaining these images, which would lead to the performance of a complete and fully diagnostic examination before the patient had left the echocardiography laboratory. In clinical practice, the quality of the examinations performed would improve, advancements in echocardiographic methods could be taught and incorporated into daily practice, and patients would be better served. The present report is a proposal from the American Society of Echocardiography Advanced Practice Task Force that identifies the potential of cardiac sonographers to achieve the ACS level. (J Am Soc Echocardiogr 2009;22:1409-13.) C1 [Mitchell, Carol] Univ Wisconsin Hosp & Clin, Sch Diagnost Sonog, Madison, WI 53792 USA. [Miller, Fletcher A., Jr.; Bremer, Merri L.] Mayo Clin, Rochester, MN USA. [Bierig, S. Michelle] St Anthonys Med, St Louis, MO USA. St Charles Hosp, Bend, OR USA. Duke Univ, Med Ctr, Durham, NC USA. Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. [Mangion, Judy R.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Marshall, Jane E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [McCulloch, Marti L.] Methodist DeBakey Heart & Vasc Ctr, Houston, TX USA. [Mehl, Brad] Oklahoma Heart Hosp, Edmond, OK USA. [Rigling, Rick] Danbury Hlth Syst, Danbury, CT USA. [Robbins, Cassie] Engh Consulting Inc, Alexandria, VA USA. [Sanchez, Liza] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Umland, Matt M.] Mayo Clin, Scottsdale, AZ USA. RP Mitchell, C (reprint author), Univ Wisconsin Hosp & Clin, Sch Diagnost Med Sonog, 600 Highland Ave, Madison, WI 53792 USA. EM cc.mitchell@hosp.wisc.edu NR 9 TC 2 Z9 3 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0894-7317 J9 J AM SOC ECHOCARDIOG JI J. Am. Soc. Echocardiogr. PD DEC PY 2009 VL 22 IS 12 BP 1409 EP 1413 DI 10.1016/j.echo.2009.10.002 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 524US UT WOS:000272169800018 PM 19944959 ER PT J AU Rubin, MF Townsend, RR AF Rubin, Mario F. Townsend, Raymond R. TI Aldosterone Blockade in Diabetic Nephropathy: Relative Risks and Potential Promise SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Editorial Material ID VASCULAR ACTION; FAILURE; DISEASE C1 [Rubin, Mario F.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Townsend, Raymond R.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. RP Rubin, MF (reprint author), Massachusetts Gen Hosp, Dept Med, 165 Cambridge St,Suite 302, Boston, MA 02114 USA. EM mfrubin@partners.org NR 19 TC 2 Z9 2 U1 0 U2 1 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD DEC PY 2009 VL 20 IS 12 BP 2487 EP 2489 DI 10.1681/ASN.2009101036 PG 3 WC Urology & Nephrology SC Urology & Nephrology GA 531BJ UT WOS:000272637400005 PM 19875814 ER PT J AU Shlipak, MG Katz, R Kestenbaum, B Siscovick, D Fried, L Newman, A Rifkin, D Sarnak, MJ AF Shlipak, Michael G. Katz, Ronit Kestenbaum, Bryan Siscovick, David Fried, Linda Newman, Anne Rifkin, Dena Sarnak, Mark J. TI Rapid Decline of Kidney Function Increases Cardiovascular Risk in the Elderly SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID PERIPHERAL ARTERIAL-DISEASE; CYSTATIN-C; HEART-FAILURE; OLDER-ADULTS; RENAL-INSUFFICIENCY; MORTALITY RISK; HEALTH; PREDICTORS; CREATININE; EVENTS AB Chronic kidney disease (CKD), defined at a specific time point, is an important risk factor for cardiovascular disease. Whether the rate of kidney function decline contributes additional cardiovascular risk is unknown. In the Cardiovascular Health Study, we compared the associations of changes in kidney function during the first 7 yr with the incidence of heart failure (HF), myocardial infarction (MI), stroke, and peripheral arterial disease (PAD) during the subsequent 8 yr. We defined a rapid decline in cystatin C-based estimated GFR as >3 ml/min per 1.73 m(2)/yr, on the basis of determination at baseline, year 3, and year 7. Among eligible participants, 1083 (24%) had rapid kidney decline. The incidence of each type of cardiovascular event was significantly higher among patients with rapid decline (all P < 0.001). After multivariate adjustment for demographics, cardiovascular disease risk factors, and baseline kidney function, rapid kidney function decline was significantly associated with HF (adjusted hazard ratio [HR] 1.32; 95% confidence interval [CI] 1.13 to 1.53), MI (HR 1.48; 95% Cl 1.21 to 1.83), and PAD (HR 1.67; 95% Cl 1.02 to 2.75) but not with stroke (HR 1.19; 95% Cl 0.97 to 1.45). The association of rapid decline with each outcome did not differ by the presence or absence of CKD. In conclusion, declining kidney function associates with higher risk for HF, MI, and PAD among patients with or without CKD. C1 [Shlipak, Michael G.] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. [Katz, Ronit] Univ Washington, Sch Med, Collaborat Hlth Studies Coordinating Ctr, Seattle, WA USA. [Kestenbaum, Bryan] Univ Washington, Sch Med, Div Nephrol, Seattle, WA USA. [Siscovick, David] Univ Washington, Dept Med, Seattle, WA USA. [Siscovick, David] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Fried, Linda] VA Pittsburgh Healthcare Syst, Renal Sect, Med Serv, Pittsburgh, PA USA. [Newman, Anne] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Newman, Anne] Univ Pittsburgh, Sch Med, Div Geriatr Med, Pittsburgh, PA USA. [Rifkin, Dena; Sarnak, Mark J.] Tufts Univ New England Med Ctr, Dept Med, Div Nephrol, Boston, MA USA. RP Shlipak, MG (reprint author), 4150 Clement St,111A1, San Francisco, CA 94121 USA. EM michael.shlipak@ucsf.edu RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150 FU American Heart Association [R01 DK066488, R01 AG027002] FX This work was supported by M.S.'s American Heart Association Established Investigator Award and R01 DK066488 (principal investigator M.S.). In addition, it was supported by R01 AG027002 (principal investigator M.J.S.). NR 22 TC 128 Z9 135 U1 2 U2 4 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD DEC PY 2009 VL 20 IS 12 BP 2625 EP 2630 DI 10.1681/ASN.2009050546 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 531BJ UT WOS:000272637400020 PM 19892934 ER PT J AU Ferguson, MK Gaissert, HA Grab, JD Sheng, SB AF Ferguson, Mark K. Gaissert, Henning A. Grab, Joshua D. Sheng, Shubin TI Pulmonary complications after lung resection in the absence of chronic obstructive pulmonary disease: The predictive role of diffusing capacity SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article; Proceedings Paper CT 34th Annual Meeting of the Western-Thoracic-Surgical-Association CY JUN 25-28, 2008 CL Kona, HI SP Western Thorac Surg Assoc ID THORACIC-SURGERY; CANCER RESECTION; MORTALITY; RISK; MORBIDITY AB Objective: Diffusing capacity is not routinely used in assessing risk of lung resection, perhaps owing to uncertainty as to whether patients with normal spirometric results require additional evaluation. We determined whether diffusing capacity is predictive of pulmonary complications after lung resection in patients with normal spirometric results. Methods: We reviewed outcomes of major lung resection in The Society of Thoracic Surgeons General Thoracic Surgery Database from 2002 to 2008 to determine the relationship of diffusing capacity (expressed as percent of predicted) to postoperative pulmonary complications stratified by chronic obstructive pulmonary disease status. Results: Percent of predicted diffusing capacity was measured in 7891 (57%) patients. There were 3905 women and 3986 men with a mean age of 66.3 +/- 10.6 years who underwent lobectomy (6904; 87.5%), bilobectomy (463; 5.9%), and pneumonectomy (524; 6.6%). Chronic obstructive pulmonary disease was identified in 2711 (34.4%) patients. Pulmonary complications occurred in 13%, and the operative mortality was 1.9%. Percent of predicted diffusing capacity was strongly associated with the development of pulmonary complications (odds ratio, 1.12 per 10-point decrease; P < .0001). Decreasing percent of predicted diffusing capacity was incrementally related to an increased incidence of pulmonary complications regardless of chronic obstructive pulmonary disease status. There was no apparent interaction between percent of predicted diffusing capacity and chronic obstructive pulmonary disease status in the predictive model. Conclusions: Percent of predicted diffusing capacity predicts pulmonary complications after lung resection in patients without chronic obstructive pulmonary disease. We recommend measurement of diffusing capacity in lung resection candidates, regardless of chronic obstructive pulmonary disease, as an important element in the accurate assessment of operative risk. (J Thorac Cardiovasc Surg 2009;138:1297-302) C1 [Ferguson, Mark K.] Univ Chicago, Dept Surg, Chicago, IL 60637 USA. [Gaissert, Henning A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Grab, Joshua D.; Sheng, Shubin] Duke Clin Res Inst, Durham, NC USA. RP Ferguson, MK (reprint author), Univ Chicago, Dept Surg, 5841 S Maryland Ave,MC5035, Chicago, IL 60637 USA. EM mferguso@surgery.bsd.uchicago.edu NR 18 TC 24 Z9 25 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD DEC PY 2009 VL 138 IS 6 BP 1297 EP 1302 DI 10.1016/j.jtcvs.2009.05.045 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 522WC UT WOS:000272029800005 PM 19783010 ER PT J AU Stevens, LM Madsen, JC Isselbacher, EM Khairy, P MacGillivray, TE Hilgenberg, AD Agnihotri, AK AF Stevens, Louis-Mathieu Madsen, Joren C. Isselbacher, Eric M. Khairy, Paul MacGillivray, Thomas E. Hilgenberg, Alan D. Agnihotri, Arvind K. TI Surgical management and long-term outcomes for acute ascending aortic dissection SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article ID INTERNATIONAL-REGISTRY; A DISSECTION; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; COMPUTED-TOMOGRAPHY; RISK-FACTORS; SURGERY; MORTALITY; REPAIR; COMPLICATIONS; EXPERIENCE AB Objective: We sought to assess early and late survival and cardiovascular-specific mortality after surgical repair of acute ascending aortic dissection and the effect of differences in surgical technique, patient characteristics, and preoperative diagnostic testing. Methods: Between 1979 and 2003, 195 consecutive patients underwent repair for acute ascending aortic dissection within 2 weeks of the onset of symptoms. Mean follow-up was 7.0 +/- 5.9 years (range, 0-26 years) and was 100% complete. Results: Patients were aged 62 +/- 15 years on average and were mostly male (66%) and hypertensive (69%). Risk of death early and late after the operation decreased over the study period, with hospital mortality decreasing from 21% to 4% when comparing the first and most recent quartiles (P = .007, chi(2) test for trend). At 1, 5, 10, and 20 years postoperatively, survival was 84%, 69%, 55%, and 30%, respectively, and freedom from cardiovascular death was 86%, 80%, 71%, and 51%, respectively. Additional independent risk factors for death were older age (P < .001), renal dysfunction (P < .003), syncope (P = .007), and peripheral vascular disease (P = .006). During the study period, echocardiographic and computed tomographic diagnostic imaging replaced routine aortic angiographic analysis, and operative techniques involved more frequent use of open distal anastomoses, retrograde cerebral perfusion, earlier restoration of antegrade perfusion, and a conservative approach to aortic arch repair. Freedom from reoperation on the aorta or aortic valve was 93% and 84% at 5 and 10 years, respectively. Conclusions: Early and late survival after repair of acute ascending aortic dissection has improved progressively over 25 years in association with noticeable changes in preoperative and intraoperative management. Aortic reoperations were infrequent during follow-up. (J Thorac Cardiovasc Surg 2009;138:1349-57) C1 [Agnihotri, Arvind K.] Massachusetts Gen Hosp, Dept Cardiothorac Surg, Div Cardiac Surg, Boston, MA 02114 USA. [Isselbacher, Eric M.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Khairy, Paul] Montreal Heart Inst, Dept Med, Montreal, PQ H1T 1C8, Canada. RP Agnihotri, AK (reprint author), Massachusetts Gen Hosp, Dept Cardiothorac Surg, Div Cardiac Surg, 55 Fruit St,COX 630, Boston, MA 02114 USA. EM aagnihotri@partners.org RI Stevens, Louis-Mathieu/E-6453-2016 OI Stevens, Louis-Mathieu/0000-0003-3372-3419 FU Canadian Institutes of Health Research's Clinical Research Initiative; Rosetti Fund (Massachusetts General Hospital, Boston, Massachusetts) FX Disclosures: Salary support (to L. M. S.) was provided by a fellowship award from the Canadian Institutes of Health Research's Clinical Research Initiative and the Rosetti Fund (Massachusetts General Hospital, Boston, Massachusetts). NR 30 TC 27 Z9 29 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD DEC PY 2009 VL 138 IS 6 BP 1349 EP U14 DI 10.1016/j.jtcvs.2009.01.030 PG 10 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 522WC UT WOS:000272029800012 PM 19660400 ER PT J AU Brink, HE Bernstein, J Nicoll, SB AF Brink, Hallie E. Bernstein, Joseph Nicoll, Steven B. TI Fetal dermal fibroblasts exhibit enhanced growth and collagen production in two- and three-dimensional culture in comparison to adult fibroblasts SO JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE LA English DT Article DE fetal; dermis; tendon; proliferation; collagen; scaffold; wound healing; tissue engineering ID MESENCHYMAL STEM-CELLS; PATELLAR TENDON FIBROBLASTS; ACHILLES-TENDON; MECHANICAL STIMULATION; SUPRASPINATUS TENDON; ENGINEERED TENDON; SKIN FIBROBLASTS; ANIMAL-MODEL; WOUND REPAIR; TISSUE AB The high morbidity of tendon injuries and the poor outcomes observed following repair or replacement have stimulated interest in regenerative approaches to treatment and, in particular, the use of cell-based analogues as alternatives to autologous and allogeneic graft repair. Given the known regenerative properties of fetal tissues, the objective of this study was to assess the biological and mechanical properties of tissue-engineered three-dimensional (313) composites seeded with fetal skin cells. Dermal fibroblasts were isolated from pregnant rats and their fetuses and characterized in monolayer culture and on 3D resorbable polyester scaffolds. To determine the differences between fetal and adult fibroblasts, DNA, total protein and types I and III collagen production were measured. In addition, morphology and mechanical properties of the 3D constructs were examined. In monolayer culture, fetal fibroblasts produced significantly more types I and III collagen and displayed serum-independent growth, while adult fibroblasts elaborated less collagen and exhibited reduced cell spreading and attachment under low-serum conditions. In 3D culture, fetal constructs appeared more developed based on gross examination, with significantly more total DNA, total protein and normalized type I collagen production compared to adult specimens. Finally, after 35 days, fetal fibroblast-seeded constructs possessed superior mechanical properties compared to adult samples. Taken together, these findings indicate that fetal dermal fibroblasts may be an effective source of cells for fabricating tissue equivalents to regenerate injured tendons. Copyright (C) 2009 John Wiley & Sons, Ltd. C1 [Brink, Hallie E.; Nicoll, Steven B.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA. [Bernstein, Joseph; Nicoll, Steven B.] Univ Penn, Dept Orthopaed Surg, Philadelphia, PA 19104 USA. [Bernstein, Joseph] Philadelphia Vet Affairs Med Ctr, Dept Orthopaed Surg, Philadelphia, PA 19104 USA. RP Nicoll, SB (reprint author), Univ Penn, Dept Bioengn, 210 S 33rd St,240 Skirkanich Hall, Philadelphia, PA 19104 USA. EM nicoll@seas.upenn.edu FU National institutes of Health [R21 AR051056, P30 AR050950]; Department of Veterans Affairs [B5071R] FX The authors would like to thank Dr Louis Soslowsky and Mr David Beason for assistance with mechanical testing and Dr Kenneth Liechty for providing tissue samples. This work was supported by grants from the National institutes of Health (R21 AR051056; Pennsylvania Center for Musculoskeletal Disorders, P30 AR050950) and the Department of Veterans Affairs (B5071R). NR 62 TC 9 Z9 9 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1932-6254 J9 J TISSUE ENG REGEN M JI J. Tissue Eng. Regen. Med. PD DEC PY 2009 VL 3 IS 8 BP 623 EP 633 DI 10.1002/term.204 PG 11 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology; Engineering, Biomedical SC Cell Biology; Biotechnology & Applied Microbiology; Engineering GA 533QU UT WOS:000272840200005 PM 19685484 ER PT J AU Cohen, MJ Bir, N Rahn, P Dotson, R Brohi, K Chesebro, BB Mackersie, R Carles, M Wiener-Kronish, J Pittet, JF AF Cohen, Mitchell J. Bir, Natasha Rahn, Pamela Dotson, Rachel Brohi, Karim Chesebro, Brian B. Mackersie, Robert Carles, Michel Wiener-Kronish, Jeanine Pittet, Jean-Francois TI Protein C Depletion Early After Trauma Increases the Risk of Ventilator-Associated Pneumonia SO JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE LA English DT Article; Proceedings Paper CT 38th Annual Meeting of the Western-Trauma-Association CY FEB 24-29, 2008 CL Squaw Creek, CA DE Ventilator-associated pneumonia; Trauma; Coagulopathy; Protein C ID SEVERE SEPSIS; CONSENSUS CONFERENCE; ACUTE COAGULOPATHY; INJURY SEVERITY; PATHWAY; HYPOPERFUSION; COMPLICATIONS; PREDICTORS; ACTIVATION; MORTALITY AB Introduction: Mechanically ventilated trauma patients have a high risk for the development of ventilator-associated pneumonia (VAP). We have recently reported that reduced plasma protein C (PC) levels early after trauma/shock are associated with coagulopathy and mortality. Furthermore, trauma patients with tissue injury and shock are at higher risk for the development of VAP. Objective: We hypothesized that low PC levels early after trauma are associated with an increased susceptibility to VAP in trauma patients. Methods: Fifty-nine acutely injured, intubated trauma patients were admitted to the critical care unit. Serial blood samples were drawn and coagulation factors were measured. VAP was diagnosed by presence of bacteria bronchial alveolar lavage specimen, bilateral infiltrates on chest roentgenogram, and fever or elevated white blood cell count. Results: There were no differences in demographic or injury characteristics between patients who developed VAP and those who did not. As expected, patients who developed VAP had more ventilator days, hospital days.. e. intensive care unit days, and greater mortality (all p < 0.05). Patients in both groups had lower mean PC levels at 6 hours compared with baseline. Noninfected patients' PC subsequently returned to nearbaseline levels, whereas those patients who eventually acquired VAP had significantly lower PC levels at both 12 and 24 hours (12 hours: 79 vs. 96%, p = 0.05; 24 hours: 75 vs. 97% p = 0.02). Soluble endothelial PC receptor (sEPCR) levels were also lower at 24 hours (82 vs. 99% in the noninfected group, p = 0.04). Discussion: The activation of PC pathway early after trauma may protect the vascular endothelium by both its anticoagulant and cytoprotective effects. However, trauma patients who later developed VAP have significantly lower plasma levels of PC within 24 hours after injury, suggesting a possible consumption of this vitamin K-dependent protein and an inhibition of its activation by inflammatory mediators. EPCR is involved in the activation of PC and is also a mediator of its cytoprotective effects. Conclusion: Critically ill trauma patients have an early activation of the PC pathway, associated with a rapid decrease in the plasma levels of this protein and increase in EPCR. Plasma levels of PC return to normal levels within 24 hours in most patients. However, patients who go on to acquire VAP have persistently low plasma levels of PC in the immediate period after trauma. Whether PC could play a mechanistic role in the host response against nosocomial lung infection warrants further study. C1 [Cohen, Mitchell J.; Bir, Natasha; Mackersie, Robert; Pittet, Jean-Francois] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. [Chesebro, Brian B.; Carles, Michel; Pittet, Jean-Francois] Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA. [Dotson, Rachel] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Brohi, Karim] Royal London Hosp, London E1 1BB, England. [Wiener-Kronish, Jeanine] Harvard Univ, Sch Med, Dept Anaesthesia, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Cohen, MJ (reprint author), San Francisco Gen Hosp, Dept Surg, Ward 3A, 1001 Potrero Ave,Room 3C-38, San Francisco, CA 94110 USA. EM mcohen@sfghsurg.ucsf.edu FU NIGMS NIH HHS [R01 GM-62188, K08 GM-085689] NR 33 TC 13 Z9 14 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-5282 J9 J TRAUMA JI J. Trauma-Injury Infect. Crit. Care PD DEC PY 2009 VL 67 IS 6 BP 1176 EP 1181 DI 10.1097/TA.0b013e3181c1c1bc PG 6 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA 531IL UT WOS:000272658100009 PM 20009664 ER PT J AU Zinzow, HM Ruggiero, KJ Hanson, RF Smith, DW Saunders, BE Kilpatrick, DG AF Zinzow, Heidi M. Ruggiero, Kenneth J. Hanson, Rochelle F. Smith, Daniel W. Saunders, Benjamin E. Kilpatrick, Dean G. TI Witnessed Community and Parental Violence in Relation to Substance Use and Delinquency in a National Sample of Adolescents SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID DOMESTIC VIOLENCE; CHILD MALTREATMENT; RISK-FACTORS; ALCOHOL-USE; EXPOSURE; ABUSE; ASSOCIATION; PREVENTION; PREVALENCE; INITIATION AB This study examined whether witnessed community and parental violence represented risk factors for substance use and delinquency among adolescents, beyond the contribution of direct violence and other risk factors. We also examined the role of violence characteristics. Participants were a national sample of 3,614 adolescents. Structured telephone interviews assessed demographics, trauma history, witnessed violence, delinquency, and substance use. While accounting for trauma history and other risk factors, witnessed community and parental violence were associated with delinquency. Community violence was associated with substance use, Chronic violence, knowing the perpetrator, and violence outside of school were correlated with substance use and delinqueney among adolescents who witnessed community violence. These findings highlight the importance of targeting witnessed violence in prevention and intervention efforts. C1 [Zinzow, Heidi M.] Clemson Univ, Dept Psychol, Clemson, SC 29634 USA. [Zinzow, Heidi M.; Ruggiero, Kenneth J.; Hanson, Rochelle F.; Smith, Daniel W.; Saunders, Benjamin E.; Kilpatrick, Dean G.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Natl Crime Victims Res & Treatment Ctr, Charleston, SC 29425 USA. [Ruggiero, Kenneth J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Zinzow, HM (reprint author), Clemson Univ, Dept Psychol, 418 Brackett Hall, Clemson, SC 29634 USA. EM hzinzow@clemson.edu FU NICHD NIH HHS [R01 HD046830, R01 HD046830-01, 1R01 HD046830-01] NR 30 TC 31 Z9 32 U1 2 U2 11 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD DEC PY 2009 VL 22 IS 6 BP 525 EP 533 DI 10.1002/jts.20469 PG 9 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 538LX UT WOS:000273187100006 PM 19885872 ER PT J AU Sonis, J Lauterbach, D Palmieri, PA King, LA King, DW AF Sonis, Jeffrey Lauterbach, Dean Palmieri, Patrick A. King, Lynda A. King, Daniel W. TI Innovations in Trauma Research Methods, 2008 SO JOURNAL OF TRAUMATIC STRESS LA English DT Editorial Material C1 [Sonis, Jeffrey] Univ N Carolina, Sch Med, Dept Social Med, Chapel Hill, NC 27599 USA. [Sonis, Jeffrey] Univ N Carolina, Dept Family Med, Chapel Hill, NC 27599 USA. [Lauterbach, Dean] Eastern Michigan Univ, Dept Psychol, Ypsilanti, MI 48197 USA. [Palmieri, Patrick A.] Kent State Univ, Dept Psychol, Kent, OH 44242 USA. [Palmieri, Patrick A.] Kent State Univ, Dept Psychiat, Kent, OH 44242 USA. [King, Lynda A.; King, Daniel W.] VA Boston Healthcare Syst, Boston, MA USA. [King, Lynda A.; King, Daniel W.] Boston Univ, Dept Psychol, Boston, MA 02215 USA. [King, Lynda A.; King, Daniel W.] Boston Univ, Dept Psychiat, Boston, MA 02215 USA. RP Sonis, J (reprint author), Univ N Carolina, Sch Med, Dept Social Med, Room 345A MacNider,CB 7240, Chapel Hill, NC 27599 USA. EM jsonis@med.unc.edu FU NIMH NIH HHS [R13 MH068798, R13 MH068798-04] NR 6 TC 0 Z9 0 U1 1 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD DEC PY 2009 VL 22 IS 6 BP 593 EP 594 DI 10.1002/jts.20454 PG 2 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 538LX UT WOS:000273187100014 PM 19967771 ER PT J AU Newman, E Kaloupek, D AF Newman, Elana Kaloupek, Danny TI Overview of Research Addressing Ethical Dimensions of Participation in Traumatic Stress Studies: Autonomy and Beneficence SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID FOCUSED RESEARCH; DISASTER RESEARCH; VIOLENCE; DISORDER; WOMEN; EXPERIENCE; SURVIVORS; DISTRESS; BENEFITS; VICTIMS AB One element of the design of human research studies is ethically informed decision-making. Key issues include the safety, costs, and benefits of participation. Historically, much of this decision-making was based on opinion rather than formal evidence. Recently, however, investigators in the traumatic stress field have begun to collect data that are relevant to these decisions. In this article, the authors focus on issues emanating from the ethical concepts of autonomy and respect for persons and beneficence and nonmaleficence, and then summarize relevant evidence from studies with trauma-exposed individuals. Discussion addresses implications of this evidence for research practice and policy, and identifies some potentially informative data collections opportunities for future trauma studies. C1 [Newman, Elana] Univ Tulsa, Dept Psychol, Tulsa, OK 74103 USA. [Kaloupek, Danny] Boston Univ, Sch Med, Boston, MA 02118 USA. [Kaloupek, Danny] VA Boston Healthcare Syst, VA Natl Ctr PTSD, Boston, MA USA. RP Newman, E (reprint author), Univ Tulsa, Dept Psychol, 800 S Tucker Dr, Tulsa, OK 74103 USA. EM elana-newman@utulsa.edu OI Kaloupek, Danny/0000-0002-0795-593X NR 50 TC 23 Z9 23 U1 2 U2 11 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD DEC PY 2009 VL 22 IS 6 BP 595 EP 602 DI 10.1002/jts.20465 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 538LX UT WOS:000273187100015 PM 19885873 ER PT J AU Suvak, MK Walling, SM Iverson, KM Taft, CT Resick, PA AF Suvak, Michael K. Walling, Sherry M. Iverson, Katherine M. Taft, Casey T. Resick, Patricia A. TI Multilevel Regression Analyses to Investigate the Relationship Between Two Variables Over Time: Examining the Longitudinal Association Between Intrusion and Avoidance SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; CURVE MODELS; EVENT SCALE; TRAUMA; IMPACT AB Multilevel modeling is a powerful and flexible framework for analyzing nested data structures (e.g., repeated measures or longitudinal designs). The authors illustrate a series of multilevel regression procedures that can be used to elucidate the nature of the relationship between two variables across time. The goal is to help trauma researchers become more aware of the utility of multilevel modeling as a tool for increasing the fields understanding of posttraumatic adaptation. These procedures are demonstrated by examining the relationship between two posttraumatic symptoms, intrusion and avoidance, across five assessment points in a sample of rape and robbery survivors (n = 286). Results revealed that changes in intrusion were highly correlated with changes in avoidance over the 18-month posttrauma period. C1 [Suvak, Michael K.; Walling, Sherry M.; Iverson, Katherine M.; Taft, Casey T.; Resick, Patricia A.] VA Boston Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, Boston, MA 02130 USA. RP Suvak, MK (reprint author), VA Boston Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, 116B4,150 S Huntington Ave, Boston, MA 02130 USA. EM Michael.Suvak@VA.gov FU NIMH NIH HHS [R01-MH37296] NR 25 TC 7 Z9 7 U1 1 U2 7 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD DEC PY 2009 VL 22 IS 6 BP 622 EP 631 DI 10.1002/jts.20476 PG 10 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 538LX UT WOS:000273187100018 PM 19937725 ER PT J AU Keane, TM AF Keane, Terence M. TI Improving Models, Methods, and Measures: Contributions of CITRM to the Field of Psychological Trauma SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID VIETNAM AB In 2004, the International Society for Traumatic Stress Studies' Research Methods Special Interest Group initiated annual updates on contemporary research methods in a 2-day conference entitled, Conference on Innovations in Trauma Research Methods (CITRM). These meetings, summarized annually in the Journal of Traumatic Stress, affected the field in measurable ways. Collaborations were inspired and integration of new conceptual models, methods, and measures influenced the growing body of knowledge. After 5 years of outstanding presentations, CITRM contributions are palpable. It is clear that trauma research would benefit immeasurably by continued educational opportunities that focus upon improving models, methods, and measures. C1 [Keane, Terence M.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA. [Keane, Terence M.] Boston Univ, Sch Med, Boston, MA 02118 USA. RP Keane, TM (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD, 150 S Huntington Ave, Boston, MA 02130 USA. EM terry.keane@va.gov NR 6 TC 1 Z9 1 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD DEC PY 2009 VL 22 IS 6 BP 632 EP 633 DI 10.1002/jts.20455 PG 2 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 538LX UT WOS:000273187100019 PM 19960545 ER PT J AU Eyre, SJ Ankerst, DP Wei, JT Nair, PV Regan, MM Bueti, G Tang, J Rubin, MA Kearney, M Thompson, IM Sanda, MG AF Eyre, Stephen J. Ankerst, Donna P. Wei, John T. Nair, Prakash V. Regan, Meredith M. Bueti, Gerrardina Tang, Jeffrey Rubin, Mark A. Kearney, Michael Thompson, Ian M. Sanda, Martin G. TI Validation in a Multiple Urology Practice Cohort of the Prostate Cancer Prevention Trial Calculator for Predicting Prostate Cancer Detection SO JOURNAL OF UROLOGY LA English DT Article DE biological markers; early detection of cancer; mass screening; prostate-specific antigen; clinical trials as topic ID EXTERNAL VALIDATION; SCREENING TRIAL; ANTIGEN; BIOPSY; RISK; SERUM; FINASTERIDE; POPULATION; REGRESSION; MORTALITY AB Purpose: The Prostate Cancer Prevention Trial prostate cancer risk calculator was developed in a clinical trial cohort that does not represent men routinely referred for prostate biopsy. We assessed the generalizability of the Prostate Cancer Prevention Trial calculator in a cohort more representative of patients referred for consideration of prostate biopsy in American urology practice. Materials and Methods: Patients undergoing prostate biopsy by 12 urologists at 5 sites were enrolled in an Early Detection Research Network cohort. The Prostate Cancer Prevention Trial risk calculator was validated by examining area underneath the receiver operating characteristic curve, sensitivity, specificity and calibration comparing observed vs predicted risk of prostate cancer detection. Results: Cancer incidence was greater (43% vs 22%, p = 0.001) in the Early Detection Research Network validation cohort (645) compared to the Prostate Cancer Prevention Trial group (5,519). Early Detection Research Network participants were younger and more racially diverse, and had more abnormal digital rectal examinations and higher prostate specific antigen than Prostate Cancer Prevention Trial participants (all p < 0.001). Cancer severity was worse in the Early Detection Research Network cohort than in the Prostate Cancer Prevention Trial (Gleason 7 or higher 60% vs 21%, p < 0.001). Nevertheless, the Prostate Cancer Prevention Trial risk calculator was superior to prostate specific antigen alone for predicting cancer in the Early Detection Research Network (AUC 0.691 vs 0.655, p = 0.009) and calibration confirmed that the Prostate Cancer Prevention Trial risk score accurately predicted individual risks in the Early Detection Research Network cohort. Conclusions: Differences between the Early Detection Research Network validation cohort and the Prostate Cancer Prevention Trial cohort underscore the importance of validating calculator performance in the multicenter urology practice setting. Our findings extend the applicability of the Prostate Cancer Prevention Trial calculator for measuring the risk of prostate cancer detection on biopsy to the routine American urology practice setting. C1 [Eyre, Stephen J.; Bueti, Gerrardina; Tang, Jeffrey; Kearney, Michael; Sanda, Martin G.] Beth Israel Deaconess Med Ctr, Div Urol, Boston, MA USA. [Regan, Meredith M.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Regan, Meredith M.; Sanda, Martin G.] Harvard Univ, Sch Med, Boston, MA USA. [Ankerst, Donna P.] Tech Univ Munich, Dept Math, Munich, Germany. [Ankerst, Donna P.; Nair, Prakash V.; Thompson, Ian M.] UTHSCSA, Dept Urol, San Antonio, TX USA. [Ankerst, Donna P.; Nair, Prakash V.; Thompson, Ian M.] UTHSCSA, Dept Epidemiol & Biostat, San Antonio, TX USA. [Wei, John T.] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA. [Rubin, Mark A.] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY USA. RP Sanda, MG (reprint author), Beth Israel Deaconess Med Ctr, Div Urol, 330 Brookline Ave,Rabb 440, Boston, MA USA. EM msanda@bidmc.harvard.edu RI Sanda, Martin/A-6202-2013; Sanda, Martin/B-2023-2015; Wei, John/E-8967-2012; OI Rubin, Mark/0000-0002-8321-9950 FU Early Detection Research Network; National Cancer Institute, National Institutes of Health [U01-CA113913, U01-CA86402]; San Antonio Cancer Institute [P30-CA54174] FX Supported by the Early Detection Research Network, National Cancer Institute, National Institutes of Health Grant U01-CA113913 and U01-CA86402, and the San Antonio Cancer Institute (P30-CA54174). NR 23 TC 38 Z9 38 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD DEC PY 2009 VL 182 IS 6 BP 2653 EP 2658 DI 10.1016/j.juro.2009.08.056 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 518CU UT WOS:000271668600043 PM 19836788 ER PT J AU Smith, MR Saad, F Egerdie, B Szwedowski, M Tammela, TLJ Ke, CL Leder, BZ Goessl, C AF Smith, Matthew R. Saad, Fred Egerdie, Blair Szwedowski, Maciej Tammela, Teuvo L. J. Ke, Chunlei Leder, Benjamin Z. Goessl, Carsten TI Effects of Denosumab on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer SO JOURNAL OF UROLOGY LA English DT Article DE RANK ligand; denosumab; clinical trial; bone resorption; prostatic neoplasms ID RANDOMIZED-TRIAL; FRACTURE RISK; ALENDRONATE; CARCINOMA AB Purpose: In a recently completed 3-year, randomized, double-blind study, denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor kappa B ligand, significantly increased bone mineral density and decreased new vertebral fractures in men receiving androgen deprivation therapy for prostate cancer. We conducted subgroup analyses to evaluate the relationships between subject characteristics and the effects of denosumab on bone mineral density at multiple skeletal sites. Materials and Methods: A total of 1,468 subjects were randomized 1:1 to receive 60 mg subcutaneous denosumab every 6 months or placebo for 36 months. In these analyses we evaluated the effects of denosumab on bone mineral density at the lumbar spine, total hip and distal 1/3 radius (substudy of 309 subjects) during 36 months in specific subgroups according to age, duration and type of prior androgen deprivation therapy, bone mineral density T score, weight, body mass index, bone turnover marker levels and prevalent vertebral fractures. Results: After 36 months denosumab significantly increased bone mineral density of the lumbar spine, total hip and distal 1/3 radius by 7.9%, 5.7% and 6.9%, respectively, compared with placebo (p < 0.0001 for each comparison). Denosumab significantly increased bone mineral density to a degree similar to that observed in the overall analysis for every subgroup including older men as well as those with prevalent fractures, lower baseline bone mineral density, and higher serum C-telopeptide and tartrate-resistant alkaline phosphatase 5b. Mean increases in bone mineral density at each skeletal site were greatest for men with the highest levels of serum C-telopeptide and tartrate-resistant alkaline phosphatase 5b. Conclusions: Denosumab significantly and consistently increased bone mineral density at all skeletal sites and in every subgroup, including men at greatest risk for bone loss and fractures. C1 [Smith, Matthew R.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Leder, Benjamin Z.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. [Saad, Fred] Ctr Hosp Univ Montreal, Montreal, PQ, Canada. [Egerdie, Blair] Urol Associates Urol Med Res, Kitchener, ON, Canada. [Szwedowski, Maciej] Wojewodzkie Centrum Med, Opole, Poland. [Ke, Chunlei; Goessl, Carsten] Amgen Inc, Thousand Oaks, CA 91320 USA. [Tammela, Teuvo L. J.] Tampere Univ Hosp, Tampere, Finland. RP Smith, MR (reprint author), Massachusetts Gen Hosp, Ctr Canc, Yawkey 7038,55 Fruit St, Boston, MA 02114 USA. EM smith.matthew@mgh.harvard.edu FU National Institutes of Health [5K24CA121990-02]; Prostate Cancer Foundation FX Supported by a National Institutes of Health K24 Midcareer Investigator Award (5K24CA121990-02) and grants from the Prostate Cancer Foundation. NR 20 TC 55 Z9 55 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD DEC PY 2009 VL 182 IS 6 BP 2670 EP 2675 DI 10.1016/j.juro.2009.08.048 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 518CU UT WOS:000271668600046 PM 19836774 ER PT J AU Mach, KE Du, CB Phull, H Haake, DA Shih, MC Baron, EJ Liao, JC AF Mach, Kathleen E. Du, Christine B. Phull, Hardeep Haake, David A. Shih, Mei-Chiung Baron, Ellen Jo Liao, Joseph C. TI Multiplex Pathogen Identification for Polymicrobial Urinary Tract Infections Using Biosensor Technology: A Prospective Clinical Study SO JOURNAL OF UROLOGY LA English DT Article DE urinary bladder; neurogenic; spinal cord injuries; urinary tract infections; biosensing techniques; RNA, ribosomal, 16S ID SPINAL-CORD-INJURY; BBL CHROMAGAR ORIENTATION; UROLOGIC DISEASES; AMERICA PROJECT; RESOURCE USE; TRENDS AB Purpose: Rapid diagnosis of urinary tract infection would have a significant beneficial impact on clinical management, particularly in patients with structural or functional urinary tract abnormalities who are highly susceptible to recurrent polymicrobial infections. We examined the analytical validity of an electrochemical biosensor array for rapid molecular diagnosis of urinary tract infection in a prospective clinical study in patients with neurogenic bladder. Materials and Methods: The electrochemical biosensor array was functionalized with DNA probes against 16S rRNA of the most common uropathogens. Spinal cord injured patients at a Veterans Affairs hospital were recruited into the study. Urine samples were generally tested on the biosensor within 1 to 2 hours of collection. Biosensor results were compared with those obtained using standard clinical microbiology laboratory methods. Results: We successfully developed a 1-hour biosensor assay for multiplex identification of pathogens. From July 2007 to December 2008 we recruited 116 patients, yielding a total of 109 urine samples suitable for analysis and comparison between biosensor assay and standard urine culture. Of the samples 74% were positive, of which 42% were polymicrobial. We identified 20 organisms, of which Escherichia coli, Pseudomonas aeruginosa and Enterococcus species were the most common. Biosensor assay specificity and positive predictive value were 100%. Pathogen detection sensitivity was 89%, yielding a 76% negative predictive value. Conclusions: To our knowledge we report the first prospective clinical study to successfully identify pathogens within a point of care time frame using an electrochemical biosensor platform. Additional efforts to improve the limit of detection and probe design are needed to further enhance assay sensitivity. C1 [Liao, Joseph C.] Stanford Univ, Dept Urol, Sch Med, Stanford, CA 94305 USA. Stanford Univ, Dept Hlth Res & Policy, Sch Med, Stanford, CA 94305 USA. Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA. Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Liao, JC (reprint author), Stanford Univ, Dept Urol, Sch Med, 300 Pasteur Dr,S-287, Stanford, CA 94305 USA. EM jliao@stanford.edu RI Liao, Joseph/J-5874-2015 FU NIAID NIH HHS [AI075565, U01 AI075565, U01 AI082457-02, U01 AI082457-01, U01 AI082457] NR 14 TC 24 Z9 24 U1 0 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD DEC PY 2009 VL 182 IS 6 BP 2735 EP 2741 DI 10.1016/j.juro.2009.08.028 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 518CU UT WOS:000271668600072 PM 19837423 ER PT J AU Chen, SL Jackson, SL Boyko, EJ AF Chen, Swaine L. Jackson, Sara L. Boyko, Edward J. TI Diabetes Mellitus and Urinary Tract Infection: Epidemiology, Pathogenesis and Proposed Studies in Animal Models SO JOURNAL OF UROLOGY LA English DT Article; Proceedings Paper CT Symposium on Urologic Complications of Obesity and Diabetes CY MAR 10-11, 2009 CL Baltimore, MD SP Natl Inst Diabet & Digest & Kidney Dis, NIH, Div Kidney, Urol & Hematol Dis DE urinary tract infections; diabetes complications; diabetes mellitus, experimental; adhesins, Escherichia coli; genomic islands ID UROPATHOGENIC ESCHERICHIA-COLI; INTRACELLULAR BACTERIAL COMMUNITIES; BLADDER EPITHELIAL-CELLS; ASYMPTOMATIC BACTERIURIA; POSTMENOPAUSAL WOMEN; FIMH ADHESIN; RISK-FACTORS; TYPE-1; COLONIZATION; PERSISTENCE AB Purpose: We reviewed the current state of knowledge about urinary tract infection in patients with diabetes from the clinical and basic science perspectives. We identified key knowledge gaps and areas for further research. Materials and Methods: We performed a focused literature search on certain topics, including clinical studies related to etiology and pathophysiology of urinary tract infection in patients with diabetes, urinary tract infection studies in animal models of diabetes and basic science studies of the molecular mechanisms of urinary tract infection. Results: Individuals with diabetes are at higher risk for urinary tract infection Increased susceptibility in patients with diabetes is positively associated with increased duration and severity of diabetes. Clinical epidemiological data identifying mechanisms of increased urinary tract infection susceptibility in patients with diabetes are generally lacking and indicate only that urinary tract infections in women with and without diabetes are qualitatively similar in bacterial etiology and morbid sequelae. Existing animal models for diabetes have not been well characterized for urinary tract infection research. The increased incidence, prevalence and severity of urinary tract infection in patients with diabetes argue for aggressive antibacterial chemotherapy but novel therapies resulting from urinary tract infection research in nondiabetic animal models are still not available. Conclusions: Future clinical investigations of urinary tract infection in patients with diabetes should focus on how the disease differs from that in patients without diabetes, notably on the role of glycosuria and urinary tract infection risk. Basic science research priorities for urinary tract infection in patients with diabetes should emphasize further development of diabetic animal models for urinary tract infection research and clinical translation of known important virulence determinants into new therapies. C1 [Boyko, Edward J.] Univ Washington, Dept Med, Seattle, WA 98101 USA. [Jackson, Sara L.; Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA. RP Boyko, EJ (reprint author), Univ Washington, Dept Med, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM eboyko@u.washington.edu OI Chen, Swaine/0000-0002-0107-2861 FU NIDDK NIH HHS [DK081620, DK43134, DK51406, DK64540, P30-DK17047] NR 49 TC 31 Z9 33 U1 1 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD DEC PY 2009 VL 182 IS 6 BP S51 EP S56 DI 10.1016/j.juro.2009.07.090 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 518CW UT WOS:000271668800010 PM 19846134 ER PT J AU Callstrom, MR York, JD Gaba, RC Gemmete, JJ Gervais, DA Millward, SF Brown, DB Dupuy, D Goldberg, SN Kundu, S Rose, SC Thomas, JJT Cardella, JF AF Callstrom, Matthew R. York, John D. Gaba, Ron C. Gemmete, Joseph J. Gervais, Debra A. Millward, Steven F. Brown, Daniel B. Dupuy, Damian Goldberg, S. Nahum Kundu, Sanjoy Rose, Steven C. Thomas, John J. T. Cardella, John F. CA Soc Interventional Radiology TI Research Reporting Standards for Image-guided Ablation of Bone and Soft Tissue Tumors SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Article ID PERCUTANEOUS RADIOFREQUENCY ABLATION; METASTASES INVOLVING BONE; OSTEOID-OSTEOMA; CT GUIDANCE; RANDOMIZED-TRIAL; LASER PHOTOCOAGULATION; FOLLOW-UP; PAIN; MANAGEMENT; EXCISION C1 [Callstrom, Matthew R.] Mayo Clin, Dept Radiol, Rochester, MN 55905 USA. [Gaba, Ron C.] Univ Illinois, Med Ctr Chicago, Dept Radiol, Chicago, IL USA. [Gemmete, Joseph J.] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA. [York, John D.] USN, Med Ctr Portsmouth, Charette Hlth Care Ctr, Portsmouth, VA USA. [Gervais, Debra A.] Massachusetts Gen Hosp, Dept Radiol, Gastrointestinal Genitourinary Div, Boston, MA 02114 USA. [Goldberg, S. Nahum] Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA 02215 USA. [Millward, Steven F.] Univ Western Ontario, Dept Radiol, London, ON, Canada. [Millward, Steven F.] Peterborough Reg Hlth Ctr, Dept Radiol, Peterborough, ON, Canada. [Kundu, Sanjoy] Scarborough Gen Hosp, Dept Radiol, Toronto, ON, Canada. [Brown, Daniel B.] Thomas Jefferson Univ, Dept Intervent Radiol, Philadelphia, PA 19107 USA. [Cardella, John F.] Geisinger Hlth Syst, Syst Radiol, Danville, PA USA. [Dupuy, Damian] Brown Univ, Rhode Isl Hosp, Dept Diagnost Imaging, Providence, RI 02903 USA. [Rose, Steven C.] Univ Calif San Diego, Med Ctr, Dept Radiol, San Diego, CA 92103 USA. [Thomas, John J. T.] S Texas Radiol Grp, San Antonio, TX USA. RP Callstrom, MR (reprint author), Mayo Clin, Dept Radiol, 200 1st St SW, Rochester, MN 55905 USA. EM callstrom.matthew@mayo.edu OI Dupuy, Damian/0000-0003-0524-5982 NR 69 TC 15 Z9 17 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1051-0443 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD DEC PY 2009 VL 20 IS 12 BP 1527 EP 1540 DI 10.1016/j.jvir.2009.08.009 PG 14 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA 531AX UT WOS:000272636200003 PM 19864161 ER PT J AU Cambria, RP Crawford, RS Cho, JS Bavaria, J Farber, M Lee, WA Ramaiah, V Kwolek, CJ AF Cambria, Richard P. Crawford, Robert S. Cho, Jae-Sung Bavaria, Joseph Farber, Mark Lee, W. Anthony Ramaiah, Venkatesh Kwolek, Christopher J. CA GORE TAG Investigators TI A multicenter clinical trial of endovascular stent graft repair of acute catastrophes of the descending thoracic aorta SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID SINGLE-CENTER EXPERIENCE; OF-TRAUMA MULTICENTER; OPEN SURGICAL REPAIR; ANEURYSM REPAIR; INTERNATIONAL REGISTRY; OPERATIVE REPAIR; DISSECTION IRAD; COMPLICATIONS; METAANALYSIS; RUPTURE AB Objective: Thoracic endovascular aortic repair (TEVAR) is applicable to a spectrum of thoracic aortic pathology with half of the procedures performed world-wide for indications other than degenerative aneurysm of the descending thoracic aorta (DTA). This multicenter, prospective study queried perioperative and one-year results of TEVAR using the commercially available GORE TAG device, in the treatment of acute complicated Type B dissection (cTBD), traumatic aortic tear (TT), and ruptured degenerative aneurysm (RDA) of the DTA. Methods: This prospective, non-randomized, literature controlled study included 59 patients; cTBD, n = 19; RDA, n 20; TT, n = 20. The primary end-point was the composite of death and total paraplegia in subjects at <= 30 days post-treatment compared with a cohort from current literature. Secondary end-points included adverse events related to device, procedural and systemic complications, and one-year survival. Results: All 59 patients had successful endoprosthesis deployment. Fifteen of 19 (79%) patients in the cTBD group had either rupture or malperfusion syndromes at presentation. Combined 30-day mortality/paraplegia rate was 13.6% (8/59), with seven (11.9%) deaths (cTBD [3], RDA [3] and TT [1]) and I (TT, 1.7%) case of paraplegia. The primary end-point for the TEVAR cohort was significantly lower (P = .008) when compared with a composite literature control of 800 patients (combined 30-day mortality/paraplegia of 29.6%). Thirty-day complications of any nature occurred in 48 (81%) patients; 11 (18.6%) were device related, and 43 (73%) experienced one or more systemic adverse events. Six (10%) patients required additional TEVAR implantations and 3 (5%) patients (one in each pathology group) required conversion to open surgery. Seventeen (29%) patients had endoleaks of any kind or degree through 30 days; cTBD (7), TT (2), RDA (8). Nine patients (15.3%) had perioperative strokes with two resultant deaths. During mean follow-up time of 409 309 days, an additional 12 patients died, one patient required open conversion (cTBD), and two patients had major device related events. Actuarial survival at one year was 66% (range, 52%-77%) for the entire cohort; (cTBD) 79% (range, 53%-92%), (TT) 79% (range, 53%-92%) and (RDA) 37% (range, 16%-59%). On regression analysis, age at treatment (1.05 [range, 1.01-1.09]; P = .008) and chronic obstructive pulmonary disease (COPD) (4.3 [range, 1.3-14.4]; P = .02) were predictive of death at one year. Conclusion: This study confirmed treatment advantages for TEVAR for thoracic aortic catastrophes when compared with literature-based results of open repair. One-year treatment results indicate a low incidence of graft-related complications. TEVAR is the preferred initial treatment for the DTA catastrophes studied herein. (J Vasc Surg 2009;50:1255-64.) C1 [Cambria, Richard P.; Crawford, Robert S.; Kwolek, Christopher J.] Massachusetts Gen Hosp, Div Vasc & Endovasc Surg, Boston, MA 02114 USA. [Cambria, Richard P.; Crawford, Robert S.; Kwolek, Christopher J.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Cho, Jae-Sung] Univ Pittsburgh, Med Ctr, Div Vasc Surg, Pittsburgh, PA 15260 USA. [Bavaria, Joseph] Univ Penn, Sch Med, Dept Surg, Div Cardiovasc Surg, Philadelphia, PA 19104 USA. [Farber, Mark] Univ N Carolina, Dept Surg, Div Vasc Surg, Chapel Hill, NC 27515 USA. [Lee, W. Anthony] Univ Florida, Coll Med, Div Vasc Surg & Endovasc Therapy, Gainesville, FL 32611 USA. [Ramaiah, Venkatesh] Arizona Heart Inst, Tucson, AZ USA. RP Cambria, RP (reprint author), Massachusetts Gen Hosp, Div Vasc & Endovasc Surg, 15 Parkman St,WAC 440, Boston, MA 02114 USA. EM rcambria@partners.org NR 55 TC 78 Z9 80 U1 0 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD DEC PY 2009 VL 50 IS 6 BP 1255 EP 1264 DI 10.1016/j.jvs.2009.07.104 PG 10 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 533YA UT WOS:000272860900002 PM 19958982 ER PT J AU Abularrage, CJ Crawford, RS Durand, ML LaMuraglia, GM AF Abularrage, Christopher J. Crawford, Robert S. Durand, Marlene L. LaMuraglia, Glenn M. TI Extracranial infected carotid artery aneurysm SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID MYCOTIC-ANEURYSM; COMPLICATION; MANAGEMENT AB Infected aneurysms of the extracranial carotid arteries are rare. This is a case report of a 63-year-old female who developed an infected internal carotid artery aneurysm due to group B Streptococcus ten days after a dental procedure. She was successfully treated with excision of the aneurysm and common to internal carotid artery bypass with greater saphenous vein. (J Vase Surg 2009;50:1484-6.) C1 [Abularrage, Christopher J.; Crawford, Robert S.; LaMuraglia, Glenn M.] Massachusetts Gen Hosp, Div Vasc, Boston, MA 02114 USA. [Abularrage, Christopher J.; Crawford, Robert S.; LaMuraglia, Glenn M.] Massachusetts Gen Hosp, Div Endovasc Surg, Gen Surg Serv, Boston, MA 02114 USA. [Durand, Marlene L.] Massachusetts Gen Hosp, Infect Dis Unit, Gen Med Serv, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Abularrage, CJ (reprint author), Massachusetts Gen Hosp, Div Vasc, 15 Parkmann St,WAC 440, Boston, MA 02114 USA. EM chrisabularrage@yahoo.com NR 16 TC 1 Z9 1 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD DEC PY 2009 VL 50 IS 6 BP 1484 EP 1486 DI 10.1016/j.jvs.2009.07.014 PG 3 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 533YA UT WOS:000272860900032 PM 19703747 ER PT J AU Bharel, M Casey, C Wittenberg, E AF Bharel, Monica Casey, Carolyn Wittenberg, Eve TI Disparities in Cancer Screening: Acceptance of Pap Smears among Homeless Women SO JOURNAL OF WOMENS HEALTH LA English DT Article ID INCOME HOUSED MOTHERS; CERVICAL-CANCER; UNITED-STATES; POPULATION; MORTALITY; PREVALENCE; BEHAVIORS; SERVICES AB Aims: Cervical cancer is a preventable disease through screening and early treatment. Rates of cervical cancer are higher in impoverished women, including homeless women. This study assessed the acceptance of free and accessible Pap smears offered to homeless women in a respite care setting. Methods: A convenience sample of 205 adult women receiving respite care at a facility for homeless people in Boston, Massachusetts, between 2004 and 2007 were offered screening for cervical cancer during routine encounters with the medical staff during their stay. Rates of acceptance of screening as well as medical and sociodemographic information were collected on the women. Results: Of 205 women enrolled in the study, 129 (63%) were in need of screening and offered a Pap smear; 80 (62%) accepted and 49 (38%) declined. Of those who agreed to be tested, 56 (70%) had a Pap smear performed, resulting in 10 (18%) atypical results (atypical squamous cells of undetermined significance [ASCUS] or low-grade squamous intraepithelial lesion [LGSIL]) and 15 (27%) benign findings needing follow-up (e.g., vaginitis without evidence of malignancy). Conclusions: A large proportion of homeless women receiving respite care decline a free Pap smear despite being in medical need of cervical cancer screening. Access and cost may not be the only barriers to screening among homeless women, and new and innovative approaches to screening in vulnerable populations need to be investigated in order to close the disparity gap. C1 [Bharel, Monica] Boston Hlth Care Homeless, Dept Med, Boston Med Ctr, Boston, MA 02118 USA. [Bharel, Monica] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Casey, Carolyn] Univ Calif San Francisco, Dept Obstet & Gynecol, San Francisco, CA 94143 USA. [Wittenberg, Eve] Brandeis Univ, Schneider Inst Hlth Policy, Heller Sch Social Policy & Management, Waltham, MA USA. RP Bharel, M (reprint author), Boston Hlth Care Homeless, Dept Med, Boston Med Ctr, 780 Albany St, Boston, MA 02118 USA. EM mbharel@bhchp.org FU AHRQ [K02 HS014010]; BHCHP FX M. B. had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. NR 26 TC 8 Z9 8 U1 0 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD DEC PY 2009 VL 18 IS 12 BP 2011 EP 2016 DI 10.1089/jwh.2008.1111 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 538TI UT WOS:000273206500014 PM 20044864 ER PT J AU Zhang, YQ Ikeno, Y Qi, WB Chaudhuri, A Li, Y Bokov, A Thorpe, SR Baynes, JW Epstein, C Richardson, A Van Remmen, H AF Zhang, Yiqiang Ikeno, Yuji Qi, Wenbo Chaudhuri, Asish Li, Yan Bokov, Alex Thorpe, Suzanne R. Baynes, John W. Epstein, Charles Richardson, Arlan Van Remmen, Holly TI Mice Deficient in Both Mn Superoxide Dismutase and Glutathione Peroxidase-1 Have Increased Oxidative Damage and a Greater Incidence of Pathology but No Reduction in Longevity SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Oxidative stress; Longevity ID LIFE-SPAN; KNOCKOUT MICE; CALORIC RESTRICTION; MUTANT MICE; CAENORHABDITIS-ELEGANS; MITOCHONDRIAL-FUNCTION; INCREASED SENSITIVITY; STRESS; GENE; OVEREXPRESSION AB To test the impact of increased mitochondrial oxidative stress as a mechanism underlying aging and age-related pathologies, we generated mice with a combined deficiency in two mitochondrial-localized antioxidant enzymes, Mn superoxide dismutase (MnSOD) and glutathione peroxidase-1 (Gpx-1). We compared life span, pathology, and oxidative damage in Gpx1(-/)-, Sod2(+/)-Gpx1(+/)-, Sod2(+/)-Gpx1(-/)-, and wild-type control mice. Oxidative damage was elevated in Sod2(+/)-Gpx1(-/)-mice, as shown by increased DNA oxidation in liver and skeletal muscle and increased protein oxidation in brain. Surprisingly, Sod2(+/)-Gpx1(-/)- mice showed no reduction in life span, despite increased levels of oxidative damage. Consistent with the important role for oxidative stress in tumorigenesis during aging, the incidence of neoplasms was significantly increased in the older Sod2(+/)-Gpx1(-/)-mice (28-30 months). Thus, these data do not support a significant role for increased oxidative stress as a result of compromised mitochondrial antioxidant defenses in modulating life span in mice and do not support the oxidative stress theory of aging. C1 [Zhang, Yiqiang; Ikeno, Yuji; Qi, Wenbo; Chaudhuri, Asish; Li, Yan; Bokov, Alex; Richardson, Arlan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. [Zhang, Yiqiang; Richardson, Arlan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78245 USA. [Ikeno, Yuji; Chaudhuri, Asish; Richardson, Arlan; Van Remmen, Holly] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Ikeno, Yuji] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78245 USA. [Ikeno, Yuji; Bokov, Alex; Richardson, Arlan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78245 USA. [Chaudhuri, Asish] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78245 USA. [Thorpe, Suzanne R.; Baynes, John W.] Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA. [Baynes, John W.] Univ S Carolina, Dept Exercise Sci, Columbia, SC 29208 USA. [Epstein, Charles] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA. [Epstein, Charles] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA. RP Van Remmen, H (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, 15355 Lambda Dr, San Antonio, TX 78245 USA. EM vanremmen@uthscsa.edu FU The Department of Veterans Affair Merit; Glenn Foundation; The National Institute of Health [DK19971] FX The Department of Veterans Affair Merit Grants (H. R. R., A. C., Y.I., and A. R.); Glenn Foundation (Y.I.); The National Institute of Health grant (DK19971 to J.W.B.) NR 57 TC 87 Z9 88 U1 1 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD DEC PY 2009 VL 64 IS 12 BP 1212 EP 1220 DI 10.1093/gerona/glp132 PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 516WI UT WOS:000271573600002 PM 19776219 ER PT J AU Dickson, DW Braak, H Duda, JE Duyckaerts, C Gasser, T Halliday, GM Hardy, J Leverenz, JB Del Tredici, K Wszolek, ZK Litvan, I AF Dickson, Dennis W. Braak, Heiko Duda, John E. Duyckaerts, Charles Gasser, Thomas Halliday, Glenda M. Hardy, John Leverenz, James B. Del Tredici, Kelly Wszolek, Zbigniew K. Litvan, Irene TI Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria SO LANCET NEUROLOGY LA English DT Review ID LEWY-BODY DISEASE; ALPHA-SYNUCLEIN PATHOLOGY; MULTIPLE-SYSTEM ATROPHY; BRAINNET EUROPE CONSORTIUM; AUTONOMIC NERVOUS-SYSTEM; SUBSTANTIA-NIGRA; ALZHEIMER-DISEASE; AXONAL-TRANSPORT; STRIATAL PATHOLOGY; TAU-SYNUCLEIN AB To date, there have been few systematic attempts to provide a standard operating procedure for the neuropathological diagnosis of Parkinson's disease (PD). Pathological examination cannot classify the clinical syndrome with certainty; therefore, the neuropathological diagnosis is, at best, a probability statement. The neuropathological diagnosis of parkinsonism has become increasingly based on fundamental molecular underpinnings, with recognition that the genetics of parkinsonism is heterogeneous and includes disorders that are associated with and without Lewy bodies. The advent of a-synuclein immunchistochemistry has substantially improved the ability to identify Lewy pathology, particularly cortical Lewy bodies and smaller aggregates within processes and the neuropil. In this Review we discuss the diagnostic criteria for the neuropathological assessment of PD. These criteria are provisional and need to be validated through an iterative process that could help with their refinement. Additionally, we suggest future directions for neuropathology research on PD. C1 [Litvan, Irene] Univ Louisville, Dept Neurol, Louisville, KY 40202 USA. [Dickson, Dennis W.; Wszolek, Zbigniew K.] Mayo Clin, Jacksonville, FL 32224 USA. [Braak, Heiko; Del Tredici, Kelly] Univ Ulm, Ulm, Germany. [Duda, John E.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Duyckaerts, Charles] Hop La Pitie Salpetriere, Paris, France. [Gasser, Thomas] Univ Tubingen, Tubingen, Germany. [Halliday, Glenda M.] Prince Wales Med Res Inst, Randwick, NSW, Australia. [Hardy, John] UCL, London, England. [Leverenz, James B.] Univ Washington, Seattle, DC USA. RP Litvan, I (reprint author), Univ Louisville, Dept Neurol, 220 Abraham Flexner Way,Suite 1503, Louisville, KY 40202 USA. EM i.litvan@louisville.edu RI Hardy, John/C-2451-2009; Halliday, Glenda/E-8555-2011; OI Halliday, Glenda/0000-0003-0422-8398; Dickson, Dennis W/0000-0001-7189-7917; Litvan, Irene/0000-0002-3485-3445 FU Medical Research Council [G0701075, G0901254]; NIA NIH HHS [R01 AG024040]; Parkinson's UK [G-0907] NR 93 TC 235 Z9 236 U1 2 U2 21 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1474-4422 J9 LANCET NEUROL JI Lancet Neurol. PD DEC PY 2009 VL 8 IS 12 BP 1150 EP 1157 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 523WS UT WOS:000272106100019 PM 19909913 ER PT J AU Sharma, N Cunningham, K Porter, RG Marzo, SJ Jones, KJ Foecking, EM AF Sharma, Nijee Cunningham, Kelly Porter, Ryan G. Marzo, Sam J. Jones, Kathryn J. Foecking, Eileen M. TI Comparison of Extratemporal and Intratemporal Facial Nerve Injury Models SO LARYNGOSCOPE LA English DT Article; Proceedings Paper CT 112th Annual Meeting of the Triological-Society/Combined Otolaryngology Spring Meeting CY MAY 28-31, 2009 CL Phoenix, AZ SP Triol Soc DE Facial nerve injury; facial paralysis; nerve regeneration; peripheral nerve injury ID ELECTRICAL-STIMULATION; GONADAL-STEROIDS; CRUSH INJURY; BELLS-PALSY; RAT; RECOVERY; MOTONEURONS AB Objectives/Hypothesis: The purpose of this study was to compare functional recovery and motor nerve conduction following a distal extratemporal crush injury of the facial nerve to a more proximal intratemporal crush injury. Study Design: Prospective, controlled animal study. Methods: Adult male Sprague-Dawley rats were divided into four experimental groups: 1) extratemporal crush, 2) extratemporal sham-operated, 3) intratemporal crush, and 4) intratemporal sham-operated. Each group had an n of 4-9. The facial nerve was crushed near its exit from the stylomastoid foramen for extratemporal facial nerve injuries and within the facial canal in the temporal bone for intratemporal facial nerve injuries. Recovery times for the return of facial nerve functional parameters were compared between the two injury models. Motor nerve conduction studies were also done weekly to quantify the changes in peak amplitude and latency of evoked response. Results: Rats receiving the extratemporal facial nerve injury recovered full facial function by similar to 2 weeks postoperative (wpo) and displayed normal peak amplitude and latency recordings by 4 wpo. In comparison, rats receiving the intratemporal facial nerve injury failed to reach complete functional recovery at the end of 8 wpo. Although latency of evoked response returned to normal by 2 weeks following the intratemporal injury, peak amplitude remained similar to 70% below normal at the end of 8 wpo. Conclusions: An intratemporal crush of the facial nerve leads to significantly delayed functional recovery and decreased motor nerve conduction as compared to an extratemporal crush, indicating that the location of injury strongly influences the recovery outcome. C1 [Sharma, Nijee] Loyola Univ Chicago, Stritch Sch Med, Neurosci Program, Maywood, IL USA. [Cunningham, Kelly; Porter, Ryan G.; Marzo, Sam J.; Jones, Kathryn J.; Foecking, Eileen M.] Loyola Univ, Med Ctr, Dept Otolaryngol Head & Neck Surg, Maywood, IL 60153 USA. [Jones, Kathryn J.] Loyola Univ Chicago, Stritch Sch Med, Dept Cell Biol Neurobiol & Anat, Maywood, IL USA. [Jones, Kathryn J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, R & D Serv, Hines, IL 60141 USA. RP Sharma, N (reprint author), Edward Hines Jr VA Hosp, 5000 S 5th Ave,Bldg 1,Room A241A, Hines, IL 60141 USA. EM nijeesharma@gmail.com NR 14 TC 8 Z9 10 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD DEC PY 2009 VL 119 IS 12 BP 2324 EP 2330 DI 10.1002/lary.20627 PG 7 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 527ZA UT WOS:000272408600008 PM 19718755 ER PT J AU Kieff, DA Busaba, NY AF Kieff, David A. Busaba, Nicolas Y. TI Reformation of Concha Bullosa Following Treatment by Crushing Surgical Technique: Implication for Balloon Sinuplasty SO LARYNGOSCOPE LA English DT Article; Proceedings Paper CT Eastern Section Meeting of the Triological-Society CY JAN 24-25, 2009 CL Boston, MA SP Triol Soc DE Concha bullosa; sinuplasty; balloon; rhinosinusitis AB Objectives/Hypothesis: There are various surgical techniques designed to treat conchae bullosae (CB). These include partial or total resection and crushing. Frontal sinus balloon sinuplasty is thought to work by the crushing/remodeling of the agger nasi and frontal recess air cells. The long-term outcome of sinuplasty in the frontal/ethmoid air cell region is unknown. To date, no study has been done on the reformation of CB after crushing. We report on the long-term outcome of a series of patients who underwent crushing of their CB and suggest implications for frontal sinus balloon sinuplasty. Study Design: Retrospective case series. Methods: Retrospective review of 10 patients who re-presented with CB as a component of their nasal obstructive symptoms despite previously undergoing crushing of their CB. Data analyzed included paranasal sinus computed tomography (CT) scans and operative reports. Results: These 10 patients re-presented with recurrent rhinosinusitis and nasal obstructive symptoms. The patients had previously undergone septoplasty surgery with crushing of the CB and were noted to have reformed the CB on their most recent sinus CT. The previous surgeries were preformed from 2 to 15 years prior to their representation. Conclusions: CB can reform following crushing technique. One may extrapolate that agger nasi and frontal recess air cells may reform following balloon sinuplasty leading to recurrent obstruction of the frontal sinus outflow tract. C1 [Kieff, David A.; Busaba, Nicolas Y.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, Boston, MA 02114 USA. [Kieff, David A.] Harvard Vanguard Med Associates, Boston, MA USA. [Kieff, David A.; Busaba, Nicolas Y.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. [Busaba, Nicolas Y.] VA Boston HealthCare Syst, Div Otolaryngol, Boston, MA USA. RP Busaba, NY (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. EM nicolas_busaba@meei.harvard.edu NR 7 TC 13 Z9 13 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD DEC PY 2009 VL 119 IS 12 BP 2454 EP 2456 DI 10.1002/lary.20640 PG 3 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 527ZA UT WOS:000272408600030 PM 19780034 ER PT J AU Avram, M AF Avram, Mathew TI Introduction SO LASERS IN SURGERY AND MEDICINE LA English DT Editorial Material C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. RP Avram, M (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD DEC PY 2009 VL 41 IS 10 BP 701 EP 702 DI 10.1002/lsm.20878 PG 2 WC Dermatology; Surgery SC Dermatology; Surgery GA 542ES UT WOS:000273475800001 PM 20014263 ER PT J AU Avram, MM Harry, RS AF Avram, Mathew M. Harry, Rosemary S. TI Cryolipolysis (TM) for Subcutaneous Fat Layer Reduction SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE cryolipolysis; fat reduction; non-invasive cooling; body contouring ID COLD PANNICULITIS AB Background and Objective: Cryolipolysis is a unique non-invasive method for the selective reduction of fat cells with controlled, localized cooling. It is important, therefore, to understand the potential efficacy and safety of this new procedure for rat layer reduction. Materials and Methods: A review of the literature associated with cryolipolysis was performed to evaluate the findings from pre-clinical and clinical studies with respect to the mechanism of action, efficacy, and safety. Results: Cryolipolysis has demonstrated efficacy in both human and animal studies. Histology findings also confirm the selective reduction of fat in both humans and animals, with evidence of a gradual thinning of the fat layer over a period of two to four months. Importantly, cryolipolysis has not produced any significant adverse side effects in studies to date and any noted effects have been minor and temporary. Conclusion: Although the mechanism of action for cryolipolysis is not yet completely understood, the efficacy and safety of this non-invasive procedure for fat layer reduction has been demonstrated in the studies available to data. Further studies will assist in identifying the mechanism and elucidate the full potential of this technology to perform safe, non-invasive fat reduction for areas of local fat accumulation. Lasers Surg. Med. 41:703-708, 2009. (C) 2009 Wiley-Liss, Inc. C1 [Avram, Mathew M.] Massachusetts Gen Hosp, Dermatol Laser & Cosmet Ctr, Boston, MA 02114 USA. [Harry, Rosemary S.] RHarry Consulting, Killingworth, CT 06419 USA. RP Avram, MM (reprint author), Massachusetts Gen Hosp, Dermatol Laser & Cosmet Ctr, 50 Staniford St,Suite 250, Boston, MA 02114 USA. EM mavram@partners.org NR 9 TC 50 Z9 50 U1 1 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0196-8092 EI 1096-9101 J9 LASER SURG MED JI Lasers Surg. Med. PD DEC PY 2009 VL 41 IS 10 SI SI BP 703 EP 708 DI 10.1002/lsm.20864 PG 6 WC Dermatology; Surgery SC Dermatology; Surgery GA 542ES UT WOS:000273475800002 PM 20014262 ER PT J AU Medina, MA Nguyen, JT McCormack, MM Randolph, MA Austen, WG AF Medina, Miguel A., III Nguyen, John T. McCormack, Michael M. Randolph, Mark A. Austen, William G., Jr. TI A High-Throughput Model for Fat Graft Assessment SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE fat grafting; apoptosis; liposuction; adipose viability ID IN-VIVO; INJECTION; VIABILITY; COMPLICATIONS; LIPOSUCTION; SURVIVAL; INJURY; BREAST; MICE AB Background and Objectives: Current fat-graft animal models require weeks, to months, for results. The purpose of this study was to develop a model for the rapid identification of adipocyte protectants, using apoptosis-specific fluorescence. The goal of our model was to predict long-term fat graft survival within a 10-day period. Study Design/Materials and Methods: Human fat was obtained from liposuction. aspirates, washed with saline, and centrifuged at 200g. The fat was then treated with one of four agents: P188, polyethylene glycol (PEG 8000), lipoic acid (LA), or saline control. Fat lobules were explanted over a 10-day period, and then at six weeks. The explanted fat was measured for apoptosis. Samples were weighed, sent for histology, measured for DNA content, and examined using confocal microscopy. Results: Fat-grafts demonstrated variable apoptosis over the 10-day period. P188 and LA treated samples demonstrated 11-28% less apoptosis during early engraftment than saline treated controls. This early reduction in apoptosis correlated to a similar to 20% reduction in reabsorption by weight six weeks later. P188 and LA samples demonstrated three-times higher DNA content by PICO green analysis when compared to saline controls. PEG 8000 treated samples demonstrated 11% more apoptosis than saline. PEG 8000 treated samples demonstrated an approximately 10% higher level of reabsorption by weight, and two-times higher levels of DNA. Histology of treated samples at six weeks showed architecturally normal fat in P188 and LA treated fat; whereas PEG 8000 had high levels of inflammatory infiltrates, and saline had large amounts of fibrosis. Conclusions: This model of fat-grafting and early apoptosis can be used to screen agents and grafting methods and predict long-term graft survival. We show that levels of apoptosis within ten days correlate with weight, DNA, and histology, at six weeks. Using this model, long-term adipocyte survival and graft take can be predicted during the first 10 days post-implantation. Lasers Surg. Med. 41:738-744, 2009. (C) 2009 Wiley-Liss, Inc. C1 [Medina, Miguel A., III; Nguyen, John T.; McCormack, Michael M.; Randolph, Mark A.; Austen, William G., Jr.] Massachusetts Gen Hosp, Div Plast & Reconstruct Surg, Boston, MA 02114 USA. RP Medina, MA (reprint author), Massachusetts Gen Hosp, Div Plast & Reconstruct Surg, Fruit St,Wang 435, Boston, MA 02114 USA. EM mamedina@partners.org NR 22 TC 3 Z9 3 U1 0 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD DEC PY 2009 VL 41 IS 10 BP 738 EP 744 DI 10.1002/lsm.20874 PG 7 WC Dermatology; Surgery SC Dermatology; Surgery GA 542ES UT WOS:000273475800007 PM 20014260 ER PT J AU Shek, S Yu, C Yeung, CK Kono, T Chan, HH AF Shek, Sam Yu, Carol Yeung, C. K. Kono, Taro Chan, Henry H. TI The Use of Focused Ultrasound for Non-Invasive Body Contouring in Asians SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE focused ultrasound; body contouring; fat ID CELLULITE AB Introduction: Previous studies demonstrated that multiple treatments using focused ultrasound can be effective as an non-invasive method for reducing unwanted localized fat deposits. The objective of the study is to investigate the safety and efficacy of this focused ultrasound device in body contouring in Asians. Method: Fifty-three (51 females and 2 males) patients were enrolled into the study. Subjects had up to three treatment sessions with approximately 1-month interval in between treatment. Efficacy was assessed by changes in abdominal circumference, ultrasound fat thickness, and caliper fat thickness. Weight change was monitored to distinguish weight loss induced changes in these measurements. Patient questionnaire was completed after each treatment. The level of pain or discomfort, improvement in body contour and overall satisfaction were graded with a score of 1-5 (1 being the least). Any adverse effects such as erythema, pain during treatment or blistering were recorded. Result: The overall satisfaction amongst subjects was poor. Objective measurements by ultrasound, abdominal circumference, and caliper did not show significant difference after treatment. There is a negative correlation between the abdominal fat thickness and number of shots per treatment session. Conclusion: Focused ultrasound is not effective for non-invasive body contouring among Southern Asians as compared with Caucasian. Such observation is likely due to smaller body figures. Design modifications can overcome this problem and in doing so, improve clinical outcome. Lasers Surg. Med. 41:751-759, 2009. (C) 2009 Wiley-Liss, Inc. C1 [Shek, Sam; Yu, Carol; Yeung, C. K.; Chan, Henry H.] Univ Hong Kong, Dept Med, Div Dermatol, Hong Kong, Hong Kong, Peoples R China. [Kono, Taro] Tokyo Womens Med Sch, Dept Plast & Reconstruct Surg, Tokyo, Japan. [Chan, Henry H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. RP Chan, HH (reprint author), Hong Kong Dermatol & Laser Ctr, 13th Floor,16 Ice House St, Hong Kong, Hong Kong, Peoples R China. EM hhlchan@hku.hk RI Yeung, Chi Keung/L-4795-2013; Chan, Henry Hin Lee/L-2267-2013 NR 11 TC 16 Z9 16 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0196-8092 EI 1096-9101 J9 LASER SURG MED JI Lasers Surg. Med. PD DEC PY 2009 VL 41 IS 10 SI SI BP 751 EP 759 DI 10.1002/lsm.20875 PG 9 WC Dermatology; Surgery SC Dermatology; Surgery GA 542ES UT WOS:000273475800009 PM 20014261 ER PT J AU Bernardi, RE Ryabinin, AE Berger, SP Lattal, KM AF Bernardi, Rick E. Ryabinin, Andrey E. Berger, S. Paul Lattal, K. Matthew TI Post-retrieval disruption of a cocaine conditioned place preference by systemic and intrabasolateral amygdala beta(2)- and alpha(1)-adrenergic antagonists SO LEARNING & MEMORY LA English DT Article ID BASOLATERAL AMYGDALA; PROTEIN-SYNTHESIS; MEMORY RECONSOLIDATION; NUCLEUS-ACCUMBENS; NORADRENERGIC RECEPTORS; ADRENERGIC-RECEPTORS; SEEKING BEHAVIOR; D-CYCLOSERINE; FEAR MEMORY; EXTINCTION AB Previous work has demonstrated post-retrieval impairment in associative learning paradigms, including those mediated by drugs of abuse, using nonspecific beta-adrenergic receptor (beta-AR) antagonists. Remarkably little is known about the role of the specific beta-AR subtypes, or other adrenergic receptors, in these effects. The current study examined the effects of beta(1) and beta(2), as well as alpha(1)-adrenergic receptor antagonism following retrieval of a cocaine conditioned place preference (CPP). We found that rats administered the beta(2) antagonist ICI 118,551 (8 mg/kg intraperitoneal [IP]) or the alpha(1) antagonist prazosin (1 mg/kg IP) following a drug-free test for CPP showed attenuated preference during a subsequent test, while the beta(1) antagonist betaxolol (5 or 10 mg/kg IP) and a lower dose of prazosin (0.3 mg/kg IP) had no effect. Furthermore, post-test microinfusion of ICI 118,551 (6 nmol/side) or prazosin (0.5 nmol/side) into the basolateral amygdala (BLA) also impaired a subsequent preference. Systemic or intra-BLA ICI 118,551 or prazosin administered to rats in their home cages, in the absence of a preference test, had no effect on CPP 24 h later. ICI 118,551 also attenuated the FOS response in the BLA induced by the CPP test. These results are the first to demonstrate a role for alpha(1)- and beta(2)-specific adrenergic mechanisms in post-retrieval memory processes. These systemic and site-specific injections, as well as the FOS immunohistochemical analyses, implicate the importance of specific noradrenergic signaling mechanisms within the BLA in post-retrieval plasticity. C1 [Bernardi, Rick E.; Ryabinin, Andrey E.; Berger, S. Paul; Lattal, K. Matthew] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. [Berger, S. Paul] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA. [Berger, S. Paul] Portland VA Med Ctr, Dept Psychiat, Portland, OR 97239 USA. RP Bernardi, RE (reprint author), Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. EM rick.bernardi@zi-mannheim.de FU Department of Veterans Affairs Merit Review program [07-1003]; National Institute of Mental Health [R01 MH077111]; National Institute on Drug Abuse [R01 DA025922, R03 DA025854, F31 DA022844] FX We thank Erika Spangler for help with the FOS studies and Chris Cunningham, Greg Mark, and Laura Kozell for helpful discussions. This research was supported by a grant from the Department of Veterans Affairs Merit Review program (07-1003) to S. P. B., a grant from the National Institute of Mental Health (R01 MH077111) to K. M. L., and grants from the National Institute on Drug Abuse to K. M. L. (R01 DA025922), A. E. R. (R03 DA025854), and R. E. B. (F31 DA022844). NR 64 TC 47 Z9 49 U1 0 U2 5 PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT PI COLD SPRING HARBOR PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA SN 1072-0502 EI 1549-5485 J9 LEARN MEMORY JI Learn. Mem. PD DEC PY 2009 VL 16 IS 12 BP 777 EP 789 DI 10.1101/lm.1648509 PG 13 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 525BK UT WOS:000272187900007 PM 19940038 ER PT J AU Fonseca, R Bergsagel, PL Drach, J Shaughnessy, J Gutierrez, N Stewart, AK Morgan, G Van Ness, B Chesi, M Minvielle, S Neri, A Barlogie, B Kuehl, WM Liebisch, P Davies, F Chen-Kiang, S Durie, BGM Carrasco, R Sezer, O Reiman, T Pilarski, L Avet-Loiseau, H AF Fonseca, R. Bergsagel, P. L. Drach, J. Shaughnessy, J. Gutierrez, N. Stewart, A. K. Morgan, G. Van Ness, B. Chesi, M. Minvielle, S. Neri, A. Barlogie, B. Kuehl, W. M. Liebisch, P. Davies, F. Chen-Kiang, S. Durie, B. G. M. Carrasco, R. Sezer, Orhan Reiman, Tony Pilarski, Linda Avet-Loiseau, H. TI International Myeloma Working Group molecular classification of multiple myeloma: spotlight review SO LEUKEMIA LA English DT Review DE multiple myeloma; genetics; cytogenetics; molecular; prognosis; gene expression profiling ID IN-SITU HYBRIDIZATION; STEM-CELL TRANSPLANTATION; ADVERSE PROGNOSTIC-FACTOR; COOPERATIVE-ONCOLOGY-GROUP; BORTEZOMIB PLUS MELPHALAN; GROWTH-FACTOR RECEPTOR-3; P53 GENE DELETION; HIGH-DOSE THERAPY; UNDETERMINED SIGNIFICANCE; MONOCLONAL GAMMOPATHY AB Myeloma is a malignant proliferation of monoclonal plasma cells. Although morphologically similar, several subtypes of the disease have been identified at the genetic and molecular level. These genetic subtypes are associated with unique clinicopathological features and dissimilar outcome. At the top hierarchical level, myeloma can be divided into hyperdiploid and non-hyperdiploid subtypes. The latter is mainly composed of cases harboring IgH translocations, generally associated with more aggressive clinical features and shorter survival. The three main IgH translocations in myeloma are the t(11;14)(q13;q32), t(4;14)(p16;q32) and t(14;16)(q32;q23). Trisomies and a more indolent form of the disease characterize hyperdiploid myeloma. A number of genetic progression factors have been identified including deletions of chromosomes 13 and 17 and abnormalities of chromosome 1 (1p deletion and 1q amplification). Other key drivers of cell survival and proliferation have also been identified such as nuclear factor-B-activating mutations and other deregulation factors for the cyclin-dependent pathways regulators. Further understanding of the biological subtypes of the disease has come from the application of novel techniques such as gene expression profiling and array-based comparative genomic hybridization. The combination of data arising from these studies and that previously elucidated through other mechanisms allows for most myeloma cases to be classified under one of several genetic subtypes. This paper proposes a framework for the classification of myeloma subtypes and provides recommendations for genetic testing. This group proposes that genetic testing needs to be incorporated into daily clinical practice and also as an essential component of all ongoing and future clinical trials. Leukemia (2009) 23, 2210-2221; doi:10.1038/leu.2009.174; published online 1 October 2009 C1 [Fonseca, R.; Bergsagel, P. L.; Stewart, A. K.; Chesi, M.] Mayo Clin, Dept Hematol Oncol, Scottsdale, AZ USA. [Drach, J.] Univ Hosp Vienna, Dept Med, Div Clin Oncol, Vienna, Austria. [Shaughnessy, J.; Barlogie, B.] Univ Arkansas Med Sci, MIRT, Dept MIRT, Little Rock, AR 72205 USA. [Gutierrez, N.] Hosp Univ Salamanca, CIC, Dept Hematol, Salamanca, Spain. [Morgan, G.; Davies, F.] Royal Marsden Hosp, Inst Canc Res, Sutton, Surrey, England. [Van Ness, B.] Univ Minnesota, Inst Human Genet, Dept Genet, Minneapolis, MN 55455 USA. [Minvielle, S.; Avet-Loiseau, H.] Univ Nantes, Nantes, France. [Minvielle, S.; Avet-Loiseau, H.] Inst Biol, Hematol Lab, Nantes, France. [Neri, A.] Univ Milan, Ist Sci Med, Osped Maggiore, Serv Ematol,IRCCS, I-20122 Milan, Italy. [Kuehl, W. M.] NCI, Genet Branch, Bethesda, MD 20892 USA. [Liebisch, P.] Univ Ulm, Dept Internal Med 3, D-7900 Ulm, Germany. [Chen-Kiang, S.] Columbia Univ, Dept Pathol, Weill Cornell Med Coll, New York, NY USA. [Durie, B. G. M.] Samuel Oschin Comprehens Canc Inst, Cedars Sinai Outpatient Canc Ctr, Los Angeles, CA USA. [Carrasco, R.] Harvard Univ, Dana Farber Canc Inst, Dept Med Oncol Hematol Neoplasia, Boston, MA 02115 USA. [Sezer, Orhan] Univ Klinikum Charite, Dept Hem Onc, Berlin, Germany. [Reiman, Tony] Dalhousie Univ, Dept Oncol, John Reg Hosp, Halifax, NS, Canada. [Pilarski, Linda] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada. RP Fonseca, R (reprint author), Mayo Clin Arizona, Dept Haematol Oncol, Collaborative Res Bldg 3-006,13400 E Shea Blvd, Scottsdale, AZ 85259 USA. EM fonseca.rafael@mayo.edu RI 2009, Secribsal/A-1266-2012; Bergsagel, Peter/A-7842-2011; Minvielle, Stephane/K-8251-2015; OI Bergsagel, Peter/0000-0003-1523-7388; neri, antonino/0000-0001-9047-5912; Fonseca, Rafael/0000-0002-5938-3769; Gutierrez, Norma/0000-0001-5834-9510 FU Cylene and Proteolix; Merck. B Van Ness serves on the IMF Scientific Advisory Board; NCI, Millennium, Celgene; Novartis FX R Fonseca is a consultant for Genzyme, Celgene, BMS, Otsuka, Halozyme and Medtronic. His research was funded by Cylene and Proteolix. PL Bergsagel is on the advisory board of Amgen, Genentech, Celgene. Hid research was funded by Merck. B Van Ness serves on the IMF Scientific Advisory Board. The rest of the authors declare no conflict of interest. Shaughnessy's work was patented by Myelogix, Genzyme and Novartis. He is a scientific advisor to Myelogix, Genzyme, Novartis and Celgene. He receives royalties from Myelogix, Genzyme, Novartis and Celgene, and is the owner of Myelogix. Bart Barlogie's research was funded by NCI, Millennium, Celgene and Novartis. He has received honoraria from Millennium, Celgene and IMF. He is on the speakers Bureau of Millennium, Celgene and SWOG, and is a consultant for Celegene and Genzyme. He also has membership on an entity's Board of Directors or advisory committees of IMF, MMRF and SWOG. NR 88 TC 365 Z9 381 U1 6 U2 32 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 J9 LEUKEMIA JI Leukemia PD DEC PY 2009 VL 23 IS 12 BP 2210 EP 2221 DI 10.1038/leu.2009.174 PG 12 WC Oncology; Hematology SC Oncology; Hematology GA 533HO UT WOS:000272814600003 PM 19798094 ER PT J AU Laubach, JP Mahindra, A Mitsiades, CS Schlossman, RL Munshi, NC Ghobrial, IM Carreau, N Hideshima, T Anderson, KC Richardson, PG AF Laubach, J. P. Mahindra, A. Mitsiades, C. S. Schlossman, R. L. Munshi, N. C. Ghobrial, I. M. Carreau, N. Hideshima, T. Anderson, K. C. Richardson, P. G. TI The use of novel agents in the treatment of relapsed and refractory multiple myeloma SO LEUKEMIA LA English DT Review DE multiple myeloma; chemotherapy; lenalidomide; thalidomide; bortezomib ID PEGYLATED LIPOSOMAL DOXORUBICIN; PROTEASOME INHIBITOR PS-341; LOW-DOSE THALIDOMIDE; LENALIDOMIDE PLUS DEXAMETHASONE; HISTONE DEACETYLASE INHIBITION; BONE-MARROW-TRANSPLANTATION; PREVIOUSLY TREATED PATIENTS; OVERCOMES DRUG-RESISTANCE; EXTENDED FOLLOW-UP; PHASE-II AB Although outcomes for patients with multiple myeloma (MM) have improved over the past decade, the disease remains incurable and even patients who respond well to induction therapy ultimately relapse and require additional treatment. Conventional chemotherapy and high-dose therapy with stem cell transplantation (SCT) have historically been utilized in the management of relapsed MM, but in recent years the immunomodulatory drugs (IMiDs) thalidomide and lenalidomide, as well as the proteasome inhibitor bortezomib, have assumed a primary role in this setting. This review focuses on the role of thalidomide, lenalidomide and bortezomib in relapsed and refractory MM, with additional discussion dedicated to emerging drugs in relapsed MM that may prove beneficial to patients with this disease. Leukemia (2009) 23, 2222-2232; doi:10.1038/leu.2009.179; published online 10 September 2009 C1 [Laubach, J. P.; Mitsiades, C. S.; Schlossman, R. L.; Munshi, N. C.; Ghobrial, I. M.; Carreau, N.; Hideshima, T.; Anderson, K. C.; Richardson, P. G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Mahindra, A.] Cleveland Clin, Taussig Canc Ctr, Dept Med Oncol, Cleveland, OH 44106 USA. RP Laubach, JP (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA. EM jacobp_laubach@dfci.harvard.edu FU Celegene Corporation; Millennium Pharmaceuticals FX JP Laubach: Advisory Board Novartis Pharmaceuticals. CS Mitsiades: Consultant Millennium Pharmaceuticals, Novartis Pharmaceuticals, and Kosan Pharmaceuticals. RL Schlossman: Speakers Bureau Celgene Corporation and Millennium Pharmaceuticals. IM Ghobrail: Speakers Bureau Celgene Corporation, Millennium Pharmaceuticals, and Novartis Pharmaceuticals. KC Anderson: Advisory Board Celgene Corporation, Millennium Pharmaceuticals; Consultant Celgene Corporation and Millennium Pharmaceuticals. PG Richardson: Advisory Board Celgene Corporation, Millennium Pharmaceuticals; Speakers Bureau Celgene Corporation, Millennium Pharmaceuticals. Research support was provided by Celegene Corporation, Millennium Pharmaceuticals. NR 125 TC 53 Z9 54 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 J9 LEUKEMIA JI Leukemia PD DEC PY 2009 VL 23 IS 12 BP 2222 EP 2232 DI 10.1038/leu.2009.179 PG 11 WC Oncology; Hematology SC Oncology; Hematology GA 533HO UT WOS:000272814600004 PM 19741729 ER PT J AU Ayala, F Dewar, R Kieran, M Kalluri, R AF Ayala, F. Dewar, R. Kieran, M. Kalluri, R. TI Contribution of bone microenvironment to leukemogenesis and leukemia progression SO LEUKEMIA LA English DT Review DE acute leukemia; microenvironment; angiogenesis; bone marrow; endosteal niche; endovascular niche ID ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; ENDOTHELIAL GROWTH-FACTOR; ACUTE MYELOGENOUS LEUKEMIA; MARROW STROMAL CELLS; MINIMAL RESIDUAL DISEASE; HEMATOPOIETIC STEM-CELLS; NF-KAPPA-B; MYELODYSPLASTIC SYNDROMES; FACTOR VEGF AB Tumor microenvironment has a major role in cancer progression and resistance to treatment. The bone marrow (BM) is a dynamic network of growth factors, cytokines and stromal cells, providing a permissive environment for leukemogenesis and progression. Both BM stroma and leukemic blasts promote angiogenesis, which is increased in acute lymphoblastic leukemia and acute myeloid leukemia. Growth factors like vascular endothelial growth factor (VEGF), basic fibroblast growth factor and angiopoietins are the main proangiogenic mediators in acute leukemia. Autocrine proleukemic loops have been described for VEGF and angiopoietin in hematopoietic cells. Interactions of stromal cells and extracellular matrix with leukemic blasts can also generate antiapoptotic signals that contribute to neoplastic progression and persistence of treatment-resistant minimal residual disease. High expression of CXC chemokine ligand 4 (CXCR4) by leukemic blasts and activation of the CXCR4-CXCL12 axis is involved in leukemia progression and disruption of normal hematopoiesis. Leukemia-associated bone microenvironment markers could be used as prognostic or predictive indicators of disease progression and/or treatment outcome. Studies related to bone microenvironment would likely provide a better understanding of the treatment resistance associated with leukemia therapy and design of new treatments. Leukemia (2009) 23, 2233-2241; doi:10.1038/leu.2009.175; published online 3 September 2009 C1 [Ayala, F.; Dewar, R.; Kalluri, R.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Matrix Biol, Boston, MA 02215 USA. [Dewar, R.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA. [Kieran, M.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Kalluri, R.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02215 USA. [Kalluri, R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. RP Kalluri, R (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Matrix Biol, CLS 11086,3 Blackfan Circle, Boston, MA 02215 USA. EM rkalluri@bidmc.harvard.edu RI Ayala, Francisco/C-5280-2011; Kalluri, Raghu/E-2677-2015; OI Ayala, Francisco/0000-0001-6311-920X; Kalluri, Raghu/0000-0002-2190-547X; Kieran, Mark/0000-0003-2184-7692 FU National Institutes of Health [DK62987, DK55001, AA13913, DK61688, CA125550]; Champalimaud Foundation; Department of Medicine for the Division of Matrix Biology at Beth Israel Deaconess Medical Center; Health Research Fund, Ministry of Health, Spain [BAE-90058]; Health Service from Comunidad Autonoma of Murcia, Spain FX This work was primarily supported by National Institutes of Health Grants DK62987, DK55001, AA13913, DK61688 and CA125550; Champalimaud Foundation, Stop and Shop Pediatric Brain Cancer Fund and funds from the Department of Medicine for the Division of Matrix Biology at Beth Israel Deaconess Medical Center. FA was supported by Grant BAE-90058 from the Health Research Fund, Ministry of Health, Spain; and by Health Service from Comunidad Autonoma of Murcia, Spain. NR 98 TC 119 Z9 122 U1 3 U2 18 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 J9 LEUKEMIA JI Leukemia PD DEC PY 2009 VL 23 IS 12 BP 2233 EP 2241 DI 10.1038/leu.2009.175 PG 9 WC Oncology; Hematology SC Oncology; Hematology GA 533HO UT WOS:000272814600005 PM 19727127 ER PT J AU Hijiya, N Gaynon, P Barry, E Silverman, L Thomson, B Chu, R Cooper, T Kadota, R Rytting, M Steinherz, P Shen, V Jeha, S Abichandani, R Carroll, WL AF Hijiya, N. Gaynon, P. Barry, E. Silverman, L. Thomson, B. Chu, R. Cooper, T. Kadota, R. Rytting, M. Steinherz, P. Shen, V. Jeha, S. Abichandani, R. Carroll, W. L. TI A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia SO LEUKEMIA LA English DT Article DE clofarabine; ALL; AML; relapse; children ID ACUTE LYMPHOBLASTIC-LEUKEMIA; RIBONUCLEOTIDE REDUCTASE; 2-CHLORO-9-(2-DEOXY-2-FLUORO-BETA-D-ARABINOFURANOSYL)ADENINE; FLUDARABINE; CELLS; NEUROTOXICITY; INHIBITION; METABOLISM; CHILDREN AB This Phase I study of clofarabine with etoposide and cyclophosphamide for children with relapsed/refractory acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML) was conducted to determine the maximum tolerated dose (MTD), dose-limiting toxicities and the recommended phase 2 doses (RP2Ds). All three drugs were administered for five consecutive days in induction and four consecutive days in consolidation, for a maximum of eight cycles. A total of 25 patients (20 ALL and 5 AML) were enrolled in five cohorts. An MTD was not reached. The RP2Ds of clofarabine, cyclophosphamide and etoposide were 40, 440 and 100 mg/m(2)/day, respectively. Complete remission (CR) was achieved in 10 patients (ALL: nine; AML: one), and CR without platelet recovery in six patients (ALL: two; AML: four) for an overall response rate of 64% (ALL: 55%; AML: 100%). Of the 16 responders, 9 patients proceeded to hematopoietic stem cell transplantation. In conclusion, the combination of clofarabine, etoposide and cyclophosphamide was well tolerated and effective in pediatric patients with relapsed/refractory leukemia. Of note, the phase II portion of the trial was amended after the occurrence of unexpected hepatotoxicity. The ongoing phase II study will evaluate the efficacy and safety of this regimen in ALL patients. Leukemia (2009) 23, 2259-2264; doi:10.1038/leu.2009.185; published online 10 September 2009 C1 [Hijiya, N.] Northwestern Univ, Childrens Mem Hosp, Feinberg Sch Med, Dept Pediat Hematol Oncol, Chicago, IL 60614 USA. [Gaynon, P.] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. [Barry, E.; Abichandani, R.] Genzyme Corp, Cambridge, MA USA. [Silverman, L.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Thomson, B.] Seattle Childrens Hosp, Reg Med Ctr, Seattle, WA USA. [Chu, R.] Childrens Hosp Michigan, Detroit, MI 48201 USA. [Cooper, T.] Childrens Healthcare Atlanta, Atlanta, GA USA. [Kadota, R.] Rady Childrens Hosp, San Diego, CA USA. [Rytting, M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Steinherz, P.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Shen, V.] Childrens Hosp Orange Cty, Orange, CA 92668 USA. [Jeha, S.] St Jude Childrens Hosp, Memphis, TN 38105 USA. [Carroll, W. L.] NYU, Inst Canc, New York, NY USA. RP Hijiya, N (reprint author), Northwestern Univ, Childrens Mem Hosp, Feinberg Sch Med, Dept Pediat Hematol Oncol, Box 30,2300 Childrens Plaza, Chicago, IL 60614 USA. EM nhijiya@childrensmemorial.org OI Silverman, Lauren/0000-0002-0023-4208 NR 20 TC 45 Z9 46 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 J9 LEUKEMIA JI Leukemia PD DEC PY 2009 VL 23 IS 12 BP 2259 EP 2264 DI 10.1038/leu.2009.185 PG 6 WC Oncology; Hematology SC Oncology; Hematology GA 533HO UT WOS:000272814600008 PM 19741725 ER PT J AU Steensma, DP AF Steensma, David P. TI Decitabine treatment of patients with higher-risk myelodysplastic syndromes SO LEUKEMIA RESEARCH LA English DT Article DE Myelodysplastic syndromes; Clinical trials; DNA methylation; Decitabine; 5-Aza-2 '-deoxycytidine; Azacitidine ID CHRONIC-MYELOMONOCYTIC-LEUKEMIA; INTERNATIONAL WORKING GROUP; RESPONSE CRITERIA; CLINICAL-RESPONSE; PHASE-III; AZACITIDINE; MONOSOMY-7; EFFICACY; CANCER; TRIAL AB Since receiving US regulatory approval in 2006 for the treatment of patients with myelodysplastic syndromes, decitabine has also gained marketing approval in several other countries. Rates of complete remission (CR) reported for decitabine range from 9% in the US registration trial to 34% in a study of novel treatment schedules, while reported overall improvement rates range from 30% to 73%. Further studies are needed to determine the relative merits of decitabine compared with azacitidine, the optimal decitabine dose and schedule, how best to proceed following CR, molecular predictors of treatment response, and the possible role of this agent in combination regimens. (C) 2009 Elsevier Ltd. All rights reserved. C1 Dana Farber Canc Inst, Dept Hematol Malignancies, Boston, MA 02115 USA. RP Steensma, DP (reprint author), Dana Farber Canc Inst, Dept Hematol Malignancies, Suite D1B30,44 Binney St, Boston, MA 02115 USA. EM David_Steensma@dfci.harvard.edu FU Celgene Corporation FX The author received editorial support in the preparation of this manuscript from Excerpta Medica, funded by Celgene Corporation. The author carefully revised the manuscript, and is fully responsible for content and editorial decisions for this manuscript. NR 22 TC 9 Z9 11 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0145-2126 J9 LEUKEMIA RES JI Leuk. Res. PD DEC PY 2009 VL 33 SU 2 BP S12 EP S17 PG 6 WC Oncology; Hematology SC Oncology; Hematology GA 562AC UT WOS:000275020200004 PM 20004791 ER PT J AU Spungen, AM Bauman, WA Lesser, M McCool, FD AF Spungen, Ann M. Bauman, William A. Lesser, Marvin McCool, F. Dennis TI Breathing Pattern and Ventilatory Control in Chronic Tetraplegia SO LUNG LA English DT Article DE Resting breathing; Spinal cord injury; Tidal volume; Minute ventilation; Sigh frequency ID SPINAL-CORD INJURY; OCCLUSION PRESSURE; RESPIRATORY APPARATUS; QUADRIPLEGIA; RESPONSES; HYPERCAPNIA AB Blunted ventilatory responses to carbon dioxide indicate that respiratory control is impaired when ventilation is stimulated in individuals with tetraplegia; however, respiratory control during resting breathing has not been extensively studied in this population. Our objective was to evaluate respiratory control and sigh frequency during resting breathing in persons with tetraplegia. A prospective, two-group comparative study was performed. Breathing pattern was assessed in ten outpatients with chronic tetraplegia and eight age- and gender-matched able-bodied controls. Subjects were noninvasively monitored for 1 h, while seated and at rest. Tidal volume (V(T)) was calculated from the sum of the anteroposterior displacements of the rib cage and abdomen and the axial displacement of the chest wall. Inspiratory time (T(I)), V(T), and the ratio of V(T) to inspiratory time (V(T)/T(I)) were calculated breath by breath. A sigh was defined as any breath greater than two or more times an individual's mean V(T). Minute ventilation, V(T)/T(I), and sigh frequency were reduced in tetraplegia compared with controls (5.24 +/- A 1.15 vs. 7.16 +/- A 1.29 L/min, P < 0.005; 208 +/- A 45 vs. 284 +/- A 47 ml/s, P < 0.005; and 11 +/- A 7 vs. 42 +/- A 19 sighs/h, P < 0.0005, respectively). V(T)/T(I) was associated with sigh frequency in both groups (tetraplegia: R = 0.88; P = 0.001 and control: R = 0.70; P < 0.05). We concluded that reductions in minute ventilation, V(T)/T(I), and sigh frequency suggest that respiratory drive is diminished during resting breathing in subjects with tetraplegia. These findings extend prior observations of disordered respiratory control during breathing stimulated by CO(2) in tetraplegia to resting breathing. C1 [Spungen, Ann M.; Bauman, William A.; Lesser, Marvin; McCool, F. Dennis] James J Peters VA Med Ctr, VA RR&D Ctr Excellence Med Consequences SCI, Bronx, NY 10468 USA. [Spungen, Ann M.; Bauman, William A.] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. [Spungen, Ann M.; Bauman, William A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA. [McCool, F. Dennis] Brown Univ, Alpert Med Sch, Providence, RI 02860 USA. [McCool, F. Dennis] Brown Univ, Mem Hosp Rhode Isl, Dept Med, Providence, RI 02860 USA. RP Spungen, AM (reprint author), James J Peters VA Med Ctr, VA RR&D Ctr Excellence Med Consequences SCI, Room 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM ann.spungen@va.gov FU Department of Veterans Affairs Rehabilitation; Research and Development Service; Center of Excellence for the Medical Consequences of Spinal Cord Injury [B4162C]; United Spinal Association (formerly Eastern Paralyzed Veterans Association) FX This work was funded by the Department of Veterans Affairs Rehabilitation, Research and Development Service, Center of Excellence for the Medical Consequences of Spinal Cord Injury # B4162C and the United Spinal Association (formerly Eastern Paralyzed Veterans Association). NR 23 TC 3 Z9 3 U1 1 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0341-2040 J9 LUNG JI Lung PD DEC PY 2009 VL 187 IS 6 BP 375 EP 381 DI 10.1007/s00408-009-9186-y PG 7 WC Respiratory System SC Respiratory System GA 516LU UT WOS:000271544500003 PM 19820994 ER PT J AU Caramia, F Francia, A Mainero, C Tinelli, E Palmieri, MG Colonnese, C Bozzao, L Caramia, MD AF Caramia, Francesca Francia, Ada Mainero, Caterina Tinelli, Emanuele Palmieri, Maria Giuseppina Colonnese, Claudio Bozzao, Luigi Caramia, Maria Donatella TI Neurophysiological and functional MRI evidence of reorganization of cortical motor areas in cerebral arteriovenous malformation SO MAGNETIC RESONANCE IMAGING LA English DT Article DE Cortical evoked potential; fMRI; Arteriovenous malformation ID MAGNETIC STIMULATION; MULTIPLE-SCLEROSIS; VASCULAR MALFORMATIONS; SENSORIMOTOR CORTEX; EVOKED-POTENTIALS; BRAIN; ACTIVATION; LESIONS; STROKE; PET AB Functional magnetic resonance imaging (fMRI) research has shown that brain arteriovenous malformations (AVMs) lead to reorganization of cortical motor areas. Since it is known that blood oxygenation level-dependent signal in fMRI may be influenced by the hemodynamic Perturbation associated with the presence of the AVM, in the present Study, a combined exploration with fMRI and transcranial magnetic Stimulation was performed in a patient with a right rolandic ANN in order to explore the relationship between neuronal and hemodynamic activity, The combined protocol of investigation adopted in this Study was able to provide significant information regarding neuronal activity of the different cortical areas that partake to post-lesional reorganization. (C) 2009 Elsevier Inc. All rights reserved. C1 [Caramia, Francesca; Francia, Ada; Tinelli, Emanuele; Colonnese, Claudio; Bozzao, Luigi] Univ Roma La Sapienza, Dept Neurol Sci, I-00185 Rome, Italy. [Mainero, Caterina] Harvard Univ, Athinoula A Martinos Ctr Biomed Imaging, Massachusetts Gen Hosp, Sch Med, Charlestown, MA 02129 USA. [Palmieri, Maria Giuseppina; Caramia, Maria Donatella] Univ Roma Tor Vergata, Dept Publ Hlth, I-00133 Rome, Italy. RP Caramia, F (reprint author), Univ Roma La Sapienza, Dept Neurol Sci, I-00185 Rome, Italy. EM francesca.caramia@uniroma1.it NR 36 TC 8 Z9 8 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0730-725X J9 MAGN RESON IMAGING JI Magn. Reson. Imaging PD DEC PY 2009 VL 27 IS 10 BP 1360 EP 1369 DI 10.1016/j.mri.2009.05.029 PG 10 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 524BS UT WOS:000272119400006 PM 19608370 ER PT J AU Seker, E Reed, ML Begley, MR AF Seker, Erkin Reed, Michael L. Begley, Matthew R. TI Nanoporous Gold: Fabrication, Characterization, and Applications SO MATERIALS LA English DT Review DE nanoporous; gold; microfabrication; characterization; surface area; morphology; MEMS; catalyst; sensor, gold-silver alloy AB Nanoporous gold (np-Au) has intriguing material properties that offer potential benefits for many applications due to its high specific surface area, well-characterized thiol-gold surface chemistry, high electrical conductivity, and reduced stiffness. The research on np-Au has taken place on various fronts, including advanced microfabrication and characterization techniques to probe unusual nanoscale properties and applications spanning from fuel cells to electrochemical sensors. Here, we provide a review of the recent advances in np-Au research, with special emphasis on microfabrication and characterization techniques. We conclude the paper with a brief outline of challenges to overcome in the study of nanoporous metals. C1 [Seker, Erkin] Harvard Univ, Massachusetts Gen Hosp, Sch Med,Shriners Hosp Children, Ctr Engn Med,Dept Surg, Boston, MA 02114 USA. [Reed, Michael L.; Begley, Matthew R.] Univ Virginia, Dept Elect & Comp Engn, Charlottesville, VA 22904 USA. [Begley, Matthew R.] Univ Virginia, Dept Mech & Aerosp Engn, Charlottesville, VA 22904 USA. [Begley, Matthew R.] Univ Virginia, Dept Mat Sci & Engn, Charlottesville, VA 22904 USA. RP Seker, E (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med,Shriners Hosp Children, Ctr Engn Med,Dept Surg, Boston, MA 02114 USA. EM eseker@partners.org; reed@virginia.edu; begley@virginia.edu OI Seker, Erkin/0000-0003-2401-3562 FU NSF [DMI-0507023, CMS-0800790] FX The authors gratefully acknowledge the grant NSF Grant DMI-0507023. MRB gratefully acknowledges additional partial support through NSF Grant CMS-0800790. NR 89 TC 85 Z9 86 U1 13 U2 105 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 1996-1944 J9 MATERIALS JI Materials PD DEC PY 2009 VL 2 IS 4 BP 2188 EP 2215 DI 10.3390/ma2042188 PG 28 WC Materials Science, Multidisciplinary SC Materials Science GA V20KZ UT WOS:000208140200027 ER PT J AU Silber, JH Rosenbaum, PR Rosen, AK Romano, PS Itani, KMF Cen, LY Mi, LY Halenar, MJ Even-Shoshan, O Volpp, KG AF Silber, Jeffrey H. Rosenbaum, Paul R. Rosen, Amy K. Romano, Patrick S. Itani, Kamal M. F. Cen, Liyi Mi, Lanyu Halenar, Michael J. Even-Shoshan, Orit Volpp, Kevin G. TI Prolonged Hospital Stay and the Resident Duty Hour Rules of 2003 SO MEDICAL CARE LA English DT Article DE prolonged length of stay; teaching hospitals; difference-in-differences ID QUALITY-OF-CARE; PATIENT SAFETY; MEDICARE BENEFICIARIES; ADMINISTRATIVE DATA; WORK HOURS; MORTALITY; REGULATIONS; REFORM; PHYSICIAN AB Background: Resident duty hour reforms of 2003 had the potential to create a major impact on the delivery of inpatient care. Objective: We examine whether the reforms influenced the probability of a patient experiencing a prolonged hospital length of stay (PLOS), a measure reflecting either inefficiency of care or the development of complications that may slow the rate of discharge. Research Design: Conditional logistic models to compare PLOS in more versus less teaching-intensive hospitals before and after the reform, adjusting for patient comorbidities, common time trends, and hospital site. Subjects: Medicare (N = 6,059,015) and Veterans Affairs (VA) (N = 210,276) patients admitted for medical conditions (acute myocardial infarction, heart failure, stroke, or gastrointestinal bleeding) or surgical procedures (general, orthopedic, and vascular) from July 2000 to June 2005. Measures: Prolonged length of stay. Results: Modeling all medical conditions together, the odds of prolonged stay in the first year post reform at more versus less teaching intensive hospitals was 1.01 (95% CI: 0.97-1.05) for Medicare and 1.07 (0.94-1.20) for the VA. Results were similarly negative in the second year post reform. For "combined surgery" the post year 1 odds ratios were 1.04 (0.98-1.09) and 0.94 (0.78-1.14) for Medicare and the VA respectively, and similarly unchanged in post year 2. Isolated increases in the probability of prolonged stay did occur for some vascular surgery procedures. Conclusions: Hospitals generally found ways to cope with duty hour reform without increasing the prevalence of prolonged hospital stays, a marker of either inefficient care or complications. C1 [Silber, Jeffrey H.; Mi, Lanyu; Even-Shoshan, Orit] Childrens Hosp Philadelphia, Ctr Outcomes Res, Philadelphia, PA 19104 USA. [Silber, Jeffrey H.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. [Silber, Jeffrey H.] Univ Penn, Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA. [Silber, Jeffrey H.; Volpp, Kevin G.] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent, Philadelphia, PA 19104 USA. [Rosenbaum, Paul R.] Univ Penn, Wharton Sch, Dept Stat, Philadelphia, PA 19104 USA. [Rosen, Amy K.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. [Rosen, Amy K.] Vet Adm Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Romano, Patrick S.] Univ Calif Davis, Sch Med, Div Gen Med, Sacramento, CA 95817 USA. [Romano, Patrick S.] Univ Calif Davis, Sch Med, Ctr Healthcare Policy & Res, Sacramento, CA 95817 USA. [Itani, Kamal M. F.] Boston Univ, VA Boston Hlth Care Management, W Roxbury, MA USA. [Cen, Liyi; Halenar, Michael J.; Volpp, Kevin G.] Vet Adm Hosp, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Halenar, Michael J.; Volpp, Kevin G.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. RP Silber, JH (reprint author), Childrens Hosp Philadelphia, Ctr Outcomes Res, 3535 Market St,Suite 1029, Philadelphia, PA 19104 USA. EM silberj@wharton.upenn.edu RI Rosenbaum, Paul/H-8687-2012; Romano, Patrick/N-4225-2014 OI Romano, Patrick/0000-0001-6749-3979 FU National Heart, Lung, and Blood Institute [R01 HL082637]; Department of Veterans Affairs [IIR 04-202]; National Science Foundation [SES 0646002] FX Supported by the National Heart, Lung, and Blood Institute grant (R01 HL082637), The Department of Veterans Affairs grant (IIR 04-202), and The National Science Foundation grant (SES 0646002). NR 29 TC 22 Z9 23 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD DEC PY 2009 VL 47 IS 12 BP 1191 EP 1200 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 529AM UT WOS:000272488100002 PM 19786912 ER PT J AU Harris, AHS Kivlahan, DR Bowe, T Finney, JW Humphreys, K AF Harris, Alex H. S. Kivlahan, Daniel R. Bowe, Thomas Finney, John W. Humphreys, Keith TI Developing and Validating Process Measures of Health Care Quality An Application to Alcohol Use Disorder Treatment SO MEDICAL CARE LA English DT Article; Proceedings Paper CT AcademyHealth Annual Research Meeting CY JUN 08-10, 2008 CL Washington, DC SP AcademyHealth DE alcoholism and addictive behavior; quality of care; quality assessment; quality measurement; substance abuse ID PERFORMANCE-MEASURES; CLINICAL-OUTCOMES; CONTINUING CARE; MISSING DATA; SYSTEM; NHS AB Background: Health care process quality measures usually are designed by expert panels attempting to synthesize nuanced clinical evidence and subsequently operationalized using administrative data. Many quality measures are then adopted without directly validating their presumed links with outcomes. Later efforts to validate process measures often yield negative results, leaving policy makers without a defensible means of measuring quality. This article presents an alternative strategy for developing and validating process quality measures. The development of an alcohol use disorder (AUD) treatment quality measure is used as an example. Methods: An expert panel generated a range of candidate process quality measures of AUD treatment derivable from administrative data that were then tested to determine which had the strongest associations with facility- and patient-level outcomes. Outcome and process data were from 2701 US Veterans Health Administration patients starting a new episode of care at 54 VA facilities. Results: Several of the candidate process-of-care quality measures predicted facility- and patient-level outcomes. Having at least 3 visits during the first month of specialty AUD treatment was correlated with improvement on the Addiction Severity Index Alcohol composite at the facility level, r = 0.41 (95% Confidence Interval 0.16-0.61), and at the patient level, r = 0.07 (CI: 0.03-0.11). Conclusions: These "prevalidated" quality measures can now be judged for the extent they map onto the extant clinical literature and other design requirements. The development and validation strategy we describe should aid in efficiently producing quality measures in other areas of health care. C1 [Harris, Alex H. S.; Bowe, Thomas; Finney, John W.; Humphreys, Keith] Stanford Univ, Sch Med, VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA 94025 USA. [Kivlahan, Daniel R.] Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Harris, AHS (reprint author), Stanford Univ, Sch Med, VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, 795 Willow Rd 152-MPD, Menlo Pk, CA 94025 USA. EM alexander.harris2@va.gov NR 39 TC 13 Z9 14 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD DEC PY 2009 VL 47 IS 12 BP 1244 EP 1250 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 529AM UT WOS:000272488100008 PM 19786908 ER PT J AU Wang, HW Salatin, B Grindle, GG Ding, D Cooper, RA AF Wang, Hongwu Salatin, Benjamin Grindle, Garrett G. Ding, Dan Cooper, Rory A. TI Real-time model based electrical powered wheelchair control SO MEDICAL ENGINEERING & PHYSICS LA English DT Article DE Electric-powered wheelchair; 3D dynamic model; Model based control; PID; Medical rehabilitation AB The purpose of this study was to evaluate the effects of three different control methods on driving speed variation and wheel slip of an electric-powered wheelchair (EPW). A kinematic model as well as 3D dynamic model was developed to control the velocity and traction of the wheelchair. A smart wheelchair platform was designed and built with a computerized controller and encoders to record wheel speeds and to detect the slip. A model based, a proportional-integral-derivative (PID) and an open-loop controller were applied with the EPW driving on four different surfaces at three specified speeds. The speed errors, variation, rise time, settling time and slip coefficient were calculated and compared for a speed step-response input. Experimental results showed that model based control performed best on all surfaces across the speeds. Published by Elsevier Ltd on behalf of IPEM. C1 [Wang, Hongwu; Salatin, Benjamin; Grindle, Garrett G.; Ding, Dan; Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. [Wang, Hongwu; Salatin, Benjamin; Grindle, Garrett G.; Ding, Dan; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15261 USA. [Ding, Dan; Cooper, Rory A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15261 USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs 151R 1, 7180 Highland Dr,Bldg 4,Room 243E 151R-1, Pittsburgh, PA 15206 USA. EM rcooper+@pitt.edu RI Wang, Hongwu/J-6133-2013 OI Wang, Hongwu/0000-0002-6567-9144 FU Quality of Life Technology Engineering Research Center; National Science Foundation [EEC-0540865]; National Institutes of Health [1R03HD048465-01A1]; VA Rehabilitation Research and Development Service [B3142C] FX This work was supported in part by Quality of Life Technology Engineering Research Center, National Science Foundation (EEC-0540865), the National Institutes of Health (1R03HD048465-01A1), and the VA Rehabilitation Research and Development Service (B3142C). NR 23 TC 16 Z9 16 U1 2 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1350-4533 J9 MED ENG PHYS JI Med. Eng. Phys. PD DEC PY 2009 VL 31 IS 10 BP 1244 EP 1254 DI 10.1016/j.medengphy.2009.08.002 PG 11 WC Engineering, Biomedical SC Engineering GA 534UG UT WOS:000272922200006 PM 19733494 ER PT J AU Dowdell, S Clasie, B Wroe, A Guatelli, S Metcalfe, P Schulte, R Rosenfeld, A AF Dowdell, Stephen Clasie, Ben Wroe, Andrew Guatelli, Susanna Metcalfe, Peter Schulte, Reinhard Rosenfeld, Anatoly TI Tissue equivalency of phantom materials for neutron dosimetry in proton therapy SO MEDICAL PHYSICS LA English DT Article DE proton therapy; secondary neutrons; Monte Carlo ID DOSE EQUIVALENTS; PROSTATE-CANCER; 2ND CANCERS; RADIATION; BEAMS; FIELD; RADIOTHERAPY; PHOTON; TUMORS; MEDULLOBLASTOMA AB Purpose: Previous Monte Carlo and experimental studies involving secondary neutrons in proton therapy have employed a number of phantom materials that are designed to represent human tissue. In this study, the authors determined the suitability of common phantom materials for dosimetry of secondary neutrons, specifically for pediatric and intracranial proton therapy treatments. Methods: This was achieved through comparison of the absorbed dose and dose equivalent from neutrons generated within the phantom materials and various ICRP tissues. The phantom materials chosen for comparison were Lucite, liquid water, solid water, and A150 tissue equivalent plastic. These phantom materials were compared to brain, muscle, and adipose tissues. Results: The magnitude of the doses observed were smaller than those reported in previous experimental and Monte Carlo studies, which incorporated neutrons generated in the treatment head. The results show that for both neutron absorbed dose and dose equivalent, no single phantom material gives agreement with tissue within 5% at all the points considered. Solid water gave the smallest mean variation with the tissues out of field where neutrons are the primary contributor to the total dose. Conclusions: Of the phantom materials considered, solid water shows best agreement with tissues out of field. (C) 2009 American Association of Physicists in Medicine. [DOI: 10.1118/1.3250857] C1 [Dowdell, Stephen; Wroe, Andrew; Guatelli, Susanna; Metcalfe, Peter; Rosenfeld, Anatoly] Univ Wollongong, Ctr Med Radiat Phys, Wollongong, NSW 2522, Australia. [Clasie, Ben] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Clasie, Ben] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Wroe, Andrew; Schulte, Reinhard] Loma Linda Univ, Med Ctr, Dept Radiat Med, Loma Linda, CA 92354 USA. [Guatelli, Susanna] Australian Nucl Sci & Technol Org, Lucas Heights, NSW 2234, Australia. RP Dowdell, S (reprint author), Univ Wollongong, Ctr Med Radiat Phys, Wollongong, NSW 2522, Australia. EM sjd431@uow.edu.au RI Guatelli, Susanna/C-2896-2014; Rosenfeld, Anatoly/D-1989-2014; Metcalfe, Peter/D-4040-2014 OI Metcalfe, Peter/0000-0002-6820-0055 FU Australian Rotary Health; Rotary Clubs of Riverside; Cancer Institute of NSW Clinical Leaders Program FX One of the authors (S.D.) acknowledges financial support from Australian Rotary Health and the Rotary Clubs of Riverside. The authors (P.M. and A.R.) acknowledge support from the Cancer Institute of NSW Clinical Leaders Program. NR 32 TC 10 Z9 10 U1 0 U2 1 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD DEC PY 2009 VL 36 IS 12 BP 5412 EP 5419 DI 10.1118/1.3250857 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 524QJ UT WOS:000272157500005 PM 20095253 ER PT J AU Song, QH An, XJ Li, DM Sodha, NR Boodhwani, M Tian, Y Sellke, FW Li, J AF Song, Qinhui An, Xiaojin Li, Dongmei Sodha, Neel R. Boodhwani, Munir Tian, Ye Sellke, Frank W. Li, Jian TI Hyperglycemia attenuates angiogenic capability of survivin in endothelial cells SO MICROVASCULAR RESEARCH LA English DT Article DE Survivin; Angiogenesis; Apoptosis; Hyperglycemia ID MYOCARDIAL-INFARCTION; INDUCED APOPTOSIS; UP-REGULATION; EXPRESSION; INHIBITION; BRAIN; SUPPRESSION; INDUCTION; GROWTH AB Survivin, an anti-apoptotic protein, can be induced by hypoxia and contributes to angiogenic activity in endothelial cells. To determine the potential mechanism of survivin in endothelial dysfunction caused by hyperglycemia in diabetes, we evaluated the role of survivin in hyperglycemia and its effect on endothelial homeostasis. We demonstrated that an increase Of D-glucose was sufficient to down-regulate survivin expression, impacting survivin's angiogenic role in endothelial cells. We additionally showed that survivin expression was increased in response to hypoxia yet this reaction was mitigated when the endothelial cells were in hyperglycemic conditions prior to hypoxia. Hyperglycemia also affected survivin-related proliferation and migration of endothelial cells and increased the number of apoptotic cells. In the ischemic porcine myocardium, the expression of survivin was induced. Moreover, survivin expression in the aorta, myocardium, and isolated endothelial cells was attenuated in a porcine model of diabetes in comparison to non-diabetes, which correlated negatively with the levels of fasting blood sugars and positively with territory perfusion. These results demonstrate that hyperglycemia critically alters survivin expression in vitro and in vivo, which leads to attenuation of angiogenic activity and impacts endothelial metabolism. (C) 2009 Elsevier Inc. All rights reserved. C1 [Song, Qinhui; An, Xiaojin; Li, Dongmei; Li, Jian] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiovasc Med, Boston, MA 02115 USA. [Sodha, Neel R.; Boodhwani, Munir; Sellke, Frank W.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiothorac Surg, Boston, MA 02215 USA. [An, Xiaojin] Peking Univ, Inst Mol Med, Beijing 100871, Peoples R China. [Li, Dongmei; Tian, Ye] Harbin Med Coll, Affiliated Hosp 2, Dept Anesthesiol, Harbin, Peoples R China. RP Li, J (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiovasc Med, Ctr Life Sci Bldg,3 Blackfan Circle, Boston, MA 02115 USA. EM jli@bidmc.harvard.edu FU NIH [R21 HL088219, R01 HL69024, HL07374-22] FX We thank Dr. Dario Altieri (University of Massachusetts Medical School, MA) for providing the adenoviral constructs of survivin and Ms Brittany L. Cully for editing the manuscript. This study was supported by NIH R21 HL088219 (J.L.), NIH R01 HL69024 (F.W.S.), and by NIH Training Grant HL07374-22 (Q.S.). NR 22 TC 9 Z9 13 U1 1 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0026-2862 J9 MICROVASC RES JI Microvasc. Res. PD DEC PY 2009 VL 78 IS 3 BP 257 EP 264 DI 10.1016/j.mvr.2009.08.006 PG 8 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 528HI UT WOS:000272433300001 PM 19716375 ER PT J AU Grubaugh, AL Elhai, JD Ruggiero, KJ Egede, LE Naifeh, JA Frueh, C AF Grubaugh, Anouk L. Elhai, Jon D. Ruggiero, Kenneth J. Egede, Leonard E. Naifeh, James A. Frueh, Christopher TI Equity in Veterans Affairs Disability Claims Adjudication in a National Sample of Veterans SO MILITARY MEDICINE LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH-SERVICES; VIETNAM VETERANS; MILITARY SERVICE; CARE SERVICES; HELP-SEEKING; IRAQ; AFGHANISTAN; CONNECTION; PREDICTORS AB Objectives: To address potential equity concerns about the U.S. Department of Veterans Affairs' (VA) process for adjudicating military service-related disability claims. Methods: Participants were a nationally representative sample of 20,048 veterans completing the 2001 National Survey of Veterans. Sociodemographic, access, and illness correlates of both the award and rate of general disability benefits awarded by the VA were examined using an established theoretical framework. Results: Sociodemographic, access, and illness variables were associated with both the award ("yes/no") and rate of benefits (0-100%) awarded, with combat exposure, unemployment, and physical impairment accounting for the strongest model effects. Conclusions: Veterans' needs were not overshadowed by factors related to demographic background or access (e.g., race, gender, insurance), reducing concerns about disparities in general VA disability disbursements. These data are timely as disability claims/payments will likely increase dramatically in the near future because of current conflicts in the Middle East. C1 [Grubaugh, Anouk L.; Ruggiero, Kenneth J.; Egede, Leonard E.] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. [Grubaugh, Anouk L.; Ruggiero, Kenneth J.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Elhai, Jon D.] Univ Toledo, Dept Psychol, Toledo, OH 43606 USA. [Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Naifeh, James A.] Univ Mississippi, Med Ctr, Dept Psychiat & Human Behav, Jackson, MS 39216 USA. [Frueh, Christopher] Univ Hawaii, Hilo, HI 96720 USA. RP Grubaugh, AL (reprint author), Med Univ S Carolina, Ralph H Johnson VAMC, POB 250861, Charleston, SC 29425 USA. FU Veterans Affairs Health Service Research [CD-207015]; National Institute of Mental Health [MH074468] FX This work was partially supported by Grant CD-207015 from Veterans Affairs Health Service Research and Development and Grant MH074468 from the National Institute of Mental Health. NR 28 TC 3 Z9 3 U1 0 U2 2 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 J9 MIL MED JI Milit. Med. PD DEC PY 2009 VL 174 IS 12 BP 1241 EP 1246 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 601LM UT WOS:000278061000018 PM 20055063 ER PT J AU Hasserjian, RP Chen, S Perkins, SL de Leval, L Kinney, MC Barry, TS Said, J Lim, MS Finn, WG Medeiros, LJ Harris, NL O'Malley, DP AF Hasserjian, Robert P. Chen, Steve Perkins, Sherrie L. de Leval, Laurence Kinney, Marsha C. Barry, Todd S. Said, Jonathan Lim, Megan S. Finn, William G. Medeiros, L. Jeffrey Harris, Nancy L. O'Malley, Dennis P. TI Immunomodulator agent-related lymphoproliferative disorders SO MODERN PATHOLOGY LA English DT Article DE immunotherapy; lymphoma; monoclonal antibody ID TUMOR-NECROSIS-FACTOR; B-CELL LYMPHOMA; RHEUMATOID-ARTHRITIS; METHOTREXATE THERAPY; HODGKINS-DISEASE; CROHNS-DISEASE; FACTOR-ALPHA; RISK; INTERLEUKIN-1; ANTAGONIST AB The recent development of inhibitors of key immune response proteins has revolutionized the therapy of autoimmune diseases; these immunomodulator agents include monoclonal antibodies and receptor antagonists. However, as with all therapies, these new agents are not without side effects and complications. In particular, anti-tumor necrosis factor alpha (TNF alpha) agents have been reported to be associated with an increased incidence of lymphoproliferative disorders, infections, and vasculitis. We evaluated the clinicopathological features of 18 cases of immunomodulator agent-related lymphoproliferative disorders (IAR-LPD) from several institutions. These included 6 cases of B-cell lymphoma, 2 cases of T-cell lymphoma, 3 cases of classical Hodgkin lymphoma, and 7 atypical lymphoid proliferations that did not fulfill diagnostic criteria for lymphoma; two of the latter regressed after discontinuation of the immunomodulator agent therapy. All eight lymphoma patients with available information had also received prior chemotherapy (methotrexate or 6-mercaptopurine). EBV was strongly associated with the B-cell and classical Hodgkin lymphomas. This case series illustrates that a broad range of lymphoid proliferations can occur after immunomodulator agent therapy and that these immunomodulator agent-related lymphoproliferative disorders have considerable overlap with other well-defined lymphoproliferative diseases associated with iatrogenic immunosuppression. Further study is warranted to evaluate how these therapies interact with other immunosuppressive agents and the underlying abnormal immune system to enhance the development of lymphomas and atypical lymphoid proliferations. Modern Pathology (2009) 22, 1532-1540; doi:10.1038/modpathol.2009.131; published online 18 September 2009 C1 [Hasserjian, Robert P.; Harris, Nancy L.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Chen, Steve; Barry, Todd S.; O'Malley, Dennis P.] Clarient Inc, Aliso Viejo, CA USA. [Perkins, Sherrie L.] Univ Utah, Dept Pathol, Salt Lake City, UT USA. [Perkins, Sherrie L.] Univ Utah, ARUP Labs, Salt Lake City, UT USA. [de Leval, Laurence] CHU Sart Tilman, Dept Pathol, B-4000 Liege, Belgium. [Kinney, Marsha C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Said, Jonathan] Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90024 USA. [Lim, Megan S.; Finn, William G.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA. [Medeiros, L. Jeffrey] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA. RP Hasserjian, RP (reprint author), Massachusetts Gen Hosp, Dept Pathol, WRN 244,55 Fruit St, Boston, MA 02114 USA. EM rhasserjian@partners.org NR 26 TC 22 Z9 22 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD DEC PY 2009 VL 22 IS 12 BP 1532 EP 1540 DI 10.1038/modpathol.2009.131 PG 9 WC Pathology SC Pathology GA 525HZ UT WOS:000272207200002 PM 19767727 ER PT J AU DelBove, J Kuwahara, Y Mora-Blanco, EL Godfrey, V Funkhouser, WK Fletcher, CDM Van Dyke, T Roberts, CWM Weissman, BE AF DelBove, Jessica Kuwahara, Yasumichi Mora-Blanco, E. Lorena Godfrey, Virginia Funkhouser, William K. Fletcher, Christopher D. M. Van Dyke, Terry Roberts, Charles W. M. Weissman, Bernard E. TI Inactivation of SNF5 Cooperates With p53 Loss to Accelerate Tumor Formation in Snf5(+/-);p53(+/-) Mice SO MOLECULAR CARCINOGENESIS LA English DT Article DE SNF5; p53; malignant rhabdoid tumor; SWI/SNF ID MALIGNANT RHABDOID TUMOR; CELL LINES; CHROMOSOMAL INSTABILITY; SOFT-TISSUE; TUMORIGENESIS; MUTATIONS; KIDNEY; CANCER; GENE; SCHWANNOMATOSIS AB Malignant rhabdoid tumors (MRTs) are poorly differentiated pediatric cancers that arise in various anatomical locations and have a very poor outcome. The large majority of these malignancies are caused by loss of function of the SNF5/INI1 component of the SWI/SNF chromatin remodeling complex. However, the mechanism of tumor development associated with SNF5 loss remains unclear. Multiple studies have demonstrated a role for SNF5 in the regulation of cyclin D1, p16(INK4A), and pRb(f) activities suggesting it functions through the SWI/SNF complex to affect transcription of genes involved in cell cycle control. Previous studies in genetically engineered mouse models (GEMM) have shown that loss of SNF5 on a p53-null background significantly accelerates tumor development. Here, we use established GEMM to further define the relationship between the SNF5 and p53 tumor suppressor pathways. Combined haploinsufficiency of p53 and Snf5 leads to decreased latency for MRTs arising in alternate anatomical locations but not for the standard facial MRTs. We also observed acceleration in the appearance of T-cell lymphomas in the p53(+/-);Snf5(+/-) mice. Our studies suggest that loss of SNF5 activity does not bestow a selective advantage on the p53 spectrum of tumors in the p53(+/-);Snf5(+/-) mice. However, reduced p53 expression specifically accelerated the growth of a subset of MRTs in these mice. (C) 2009 Wiley-Liss, Inc. C1 [Weissman, Bernard E.] Univ N Carolina, Dept Pathol & Lab Med, LCCC, Chapel Hill, NC 27599 USA. [Mora-Blanco, E. Lorena; Roberts, Charles W. M.] Childrens Hosp, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Mora-Blanco, E. Lorena; Roberts, Charles W. M.] Harvard Univ, Boston, MA 02115 USA. [Funkhouser, William K.] UNC Hosp, Multidisiplinary Thorac Oncol Program, Chapel Hill, NC USA. [Fletcher, Christopher D. M.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Van Dyke, Terry] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA. RP Weissman, BE (reprint author), Univ N Carolina, Dept Pathol & Lab Med, LCCC, Room 32-048,450 West Dr, Chapel Hill, NC 27599 USA. FU National Institutes of Health [R01CA91048, R01CA113794, R01 CA046283, T32ES007017]; Garrett B. Smith Foundation; Claudia Adams Barr Foundation FX We thank Dr. Gary Rosson and Dr. Karen Knudsen for helpful discussions. The work was supported by grants from the National Institutes of Health R01CA91048 (BEW), R01CA113794 (CWMR), and R01 CA046283(TVD). Dr. Delbove was supported, in part, by a training grant from the National Institutes of Health T32ES007017. Dr. Roberts gratefully acknowledges support from the Garrett B. Smith Foundation and the Claudia Adams Barr Foundation. NR 42 TC 9 Z9 10 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0899-1987 J9 MOL CARCINOGEN JI Mol. Carcinog. PD DEC PY 2009 VL 48 IS 12 BP 1139 EP 1148 DI 10.1002/mc.20568 PG 10 WC Biochemistry & Molecular Biology; Oncology SC Biochemistry & Molecular Biology; Oncology GA 529PB UT WOS:000272528600008 PM 19676100 ER PT J AU Shin, JM Sachs, G Cho, YM Garst, M AF Shin, Jai Moo Sachs, George Cho, Young-moon Garst, Michael TI 1-Arylsulfonyl-2-(Pyridylmethylsulfinyl) Benzimidazoles as New Proton Pump Inhibitor Prodrugs SO MOLECULES LA English DT Article DE proton pump inhibitor; prodrug; gastric acid secretion ID GASTRIC-ACID-SECRETION; OMEPRAZOLE; SUPPRESSION; DERIVATIVES; EFFICACY AB New arylsulfonyl proton pump inhibitor (PPI) prodrug forms were synthesized. These prodrugs provided longer residence time of an effective PPI plasma concentration, resulting in better gastric acid inhibition. C1 [Shin, Jai Moo; Sachs, George; Cho, Young-moon] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90073 USA. [Shin, Jai Moo; Sachs, George; Cho, Young-moon] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Garst, Michael] Allergan Pharmaceut Inc, Irvine, CA 92660 USA. RP Shin, JM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90073 USA. EM jaishin@ucla.edu; gsachs@ucla.edu; ymkscho@yahoo.com; garst_michael@allergan.com FU US VA Merit Grant; NIH/NIDDK [DK053642, DK58333]; Winston Pharmaceuticals; LLC.; Allergan, Inc FX This work was supported by US VA Merit Grant, NIH/NIDDK grant number's DK053642 and DK58333, and Winston Pharmaceuticals, LLC., and Allergan, Inc. NR 23 TC 3 Z9 3 U1 0 U2 1 PU MOLECULAR DIVERSITY PRESERVATION INTERNATIONAL-MDPI PI BASEL PA KANDERERSTRASSE 25, CH-4057 BASEL, SWITZERLAND SN 1420-3049 J9 MOLECULES JI Molecules PD DEC PY 2009 VL 14 IS 12 BP 5247 EP 5280 DI 10.3390/molecules14125247 PG 34 WC Chemistry, Organic SC Chemistry GA 536KL UT WOS:000273043200031 PM 20032890 ER PT J AU Amato, AA Parrish, J AF Amato, Anthony A. Parrish, Jane TI LISA S. KRIVACKAS OBITUARY SO MUSCLE & NERVE LA English DT Biographical-Item C1 [Amato, Anthony A.] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA. [Parrish, Jane] Massachusetts Gen Hosp, Dept Phys Med & Rehabil, Boston, MA 02114 USA. RP Amato, AA (reprint author), Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0148-639X J9 MUSCLE NERVE JI Muscle Nerve PD DEC PY 2009 VL 40 IS 6 BP 915 EP 916 DI 10.1002/mus.21582 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 523JM UT WOS:000272069400001 PM 19902538 ER PT J AU Salameh, J Baran, JL Chong, PST AF Salameh, Johnny Baran, Johanna L. Chong, Peter Siao Tick TI PATIENT WITH AMYLOIDOMA OF THE ULNAR NERVE AND SALIVARY GLANDS SO MUSCLE & NERVE LA English DT Article DE localized amyloidoma; ulnar nerve; salivary gland; amyloidosis ID TUMOR AB Amyloidomas of the peripheral nervous system have been reported rarely. We describe a patient with a history of localized amyloidosis of the salivary glands who presented a few years later with paresthesias of her left medial arm, forearm, and fifth digit. A mass affecting the left ulnar nerve was confirmed by MRI studies. It was excised and proven on pathological examination to be an amyloidoma. The benign course of this patient's illness is consistent with localized amyloidosis affecting two different organs. Muscle Nerve 40: 1054-1058, 2009 C1 [Salameh, Johnny; Chong, Peter Siao Tick] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Baran, Johanna L.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Salameh, J (reprint author), Massachusetts Gen Hosp, Dept Neurol, 165 Cambridge St,Suite 820, Boston, MA 02114 USA. EM johnnysalameh@hotmail.com NR 9 TC 3 Z9 3 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0148-639X J9 MUSCLE NERVE JI Muscle Nerve PD DEC PY 2009 VL 40 IS 6 BP 1054 EP 1058 DI 10.1002/mus.21400 PG 5 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 523JM UT WOS:000272069400020 PM 19645062 ER PT J AU Zhang, Y Zhou, JQ Baldwin, J Held, KD Prise, KM Redmond, RW Liber, HL AF Zhang, Ying Zhou, Junqing Baldwin, Joseph Held, Kathryn D. Prise, Kevin M. Redmond, Robert W. Liber, Howard L. TI Ionizing radiation-induced bystander mutagenesis and adaptation: Quantitative and temporal aspects SO MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS LA English DT Article DE Bystander effect; Adaptive response; Ionizing radiation mutagenesis ID C3H 10T(1)/(2) CELLS; INDUCED GENOMIC INSTABILITY; SISTER-CHROMATID EXCHANGES; HUMAN LYMPHOBLASTOID-CELLS; DNA-DAMAGE RESPONSE; ADAPTIVE RESPONSE; RADIOADAPTIVE RESPONSE; MAMMALIAN-CELLS; ALPHA-PARTICLES; INTERCELLULAR COMMUNICATION AB This work explores several quantitative aspects of radiation-induced bystander mutagenesis in WTK1 human lymphoblast cells. Gamma-irradiation of cells was used to generate conditioned medium containing bystander signals, and that medium was transferred onto naive recipient cells. Kinetic studies revealed that it required up to 1 h to generate sufficient signal to induce the maximal level of mutations at the thymidine kinase locus in the bystander cells receiving the conditioned medium. Furthermore, it required at least I h of exposure to the signal in the bystander cells to induce mutations. Bystander signal was fairly stable in the medium, requiring 12-24 h to diminish. Medium that contained bystander signal was rendered ineffective by a 4-fold dilution; in contrast a greater than 20-fold decrease in the cell number irradiated to generate a bystander signal was needed to eliminate bystander-induced mutagenesis. This suggested some sort of feedback inhibition by bystander signal that prevented the signaling cells from releasing more signal. Finally, an ionizing radiation-induced adaptive response was shown to be effective in reducing bystander mutagenesis; in addition, low levels of exposure to bystander signal in the transferred medium induced adaptation that was effective in reducing mutations induced by subsequent gamma-ray exposures.(C) 2009 Elsevier B.V. All rights reserved. C1 [Zhang, Ying; Zhou, Junqing; Baldwin, Joseph; Liber, Howard L.] Colorado State Univ, Dept Environm & Radiol Hlth Sci, Ft Collins, CO 80523 USA. [Held, Kathryn D.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Prise, Kevin M.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland. [Redmond, Robert W.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Liber, Howard L.] Univ Colorado, Denver, CO 80202 USA. RP Liber, HL (reprint author), Colorado State Univ, Dept Environm & Radiol Hlth Sci, 1618 Campus Delivery, Ft Collins, CO 80523 USA. EM howard.liber@colostate.edu RI Prise, Kevin/N-7872-2015 OI Prise, Kevin/0000-0001-6134-7946 FU NIH [P01CA095227]; National Science Foundation [DBI-0552425]; Cancer Research UK JCUKJ [C1513/A7047]; European Union NOTE project [FI6R 036465] FX This work was supported by NIH Grant P01CA095227 (K.D. Held).; J. Baldwin was supported by a summer fellowship from the National Science Foundation (DBI-0552425). K. Prise was partially supported by grants from Cancer Research UK JCUKJ (C1513/A7047) and European Union NOTE project (FI6R 036465). NR 59 TC 23 Z9 25 U1 1 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0027-5107 EI 1873-135X J9 MUTAT RES-FUND MOL M JI Mutat. Res.-Fundam. Mol. Mech. Mutagen. PD DEC 1 PY 2009 VL 671 IS 1-2 BP 20 EP 25 DI 10.1016/j.mrfmmm.2009.08.006 PG 6 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology SC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology GA 528HE UT WOS:000272432800004 PM 19695271 ER PT J AU Zhang, JM Ji, JY Yu, M Overholtzer, M Smolen, GA Wang, R Brugge, JS Dyson, NJ Haber, DA AF Zhang, Jianmin Ji, Jun-Yuan Yu, Min Overholtzer, Michael Smolen, Gromoslaw A. Wang, Rebecca Brugge, Joan S. Dyson, Nicholas J. Haber, Daniel A. TI YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway SO NATURE CELL BIOLOGY LA English DT Article ID BREAST-CANCER; ORGAN SIZE; GROWTH-CONTROL; DROSOPHILA; PROLIFERATION; APOPTOSIS; SALVADOR; FAT; ACTIVATION; ONCOGENE AB The Hippo signalling pathway regulates cellular proliferation and survival, thus has profound effects on normal cell fate and tumorigenesis(1-3). The pivotal effector of this pathway is YAP (yes-associated protein), a transcriptional co-activator amplified in mouse and human cancers, where it promotes epithelial to mesenchymal transition (EMT) and malignant transformation(4-10). So far, studies of YAP target genes have focused on cell-autonomous mediators; here we show that YAP-expressing MCF10A breast epithelial cells enhance the proliferation of neighbouring untransfected cells, implicating a non-cell-autonomous mechanism. We identify the gene for the epidermal growth factor receptor ( EGFR) ligand amphiregulin (AREG) as a transcriptional target of YAP, whose induction contributes to YAP-mediated cell proliferation and migration, but not EMT. Knockdown of AREG or addition of an EGFR kinase inhibitor abrogates the proliferative effects of YAP expression. Suppression of the negative YAP regulators LATS1 and 2 ( large tumour suppressor 1 and 2) is sufficient to induce AREG expression, consistent with physiological regulation of AREG by the Hippo pathway. Genetic interaction between the Drosophila YAP orthologue Yorkie and Egfr signalling components supports the link between these two highly conserved signalling pathways. Thus, YAP-dependent secretion of AREG indicates that activation of EGFR signalling is an important non-cell-autonomous effector of the Hippo pathway, which has implications for the regulation of both physiological and malignant cell proliferation. C1 [Zhang, Jianmin; Ji, Jun-Yuan; Yu, Min; Smolen, Gromoslaw A.; Wang, Rebecca; Dyson, Nicholas J.; Haber, Daniel A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA. [Yu, Min; Haber, Daniel A.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA. [Overholtzer, Michael; Brugge, Joan S.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA. RP Haber, DA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA. EM haber@helix.mgh.harvard.edu FU National Institutes of Health (NIH) [R01 95281]; Doris Duke Foundation Distinguished Clinical Investigator Award; National Foundation for Cancer Research; Howard Hughes Medical Institute; NIH [CA080111, CA089393, CA09361-27, CA09361, F32 CA117737, GM81607, GM053203]; Breast Cancer Research Foundation; Saltonstall Foundation; Tosteson postdoctoral Fellowship FX We thank D. Pan, M. Frolov, G. Halder and Z. Lai for providing Drosophila stocks. We appreciate discussions with J. Wells, F. Yang and T. Zhang and thank B. Fowle for assistance with electron microscopy. This work was supported by the National Institutes of Health (NIH) grant R01 95281, the Doris Duke Foundation Distinguished Clinical Investigator Award, the National Foundation for Cancer Research grant and the Howard Hughes Medical Institute ( to D. A. H.); NIH grants CA080111 and CA089393 and the Breast Cancer Research Foundation ( to J. S. B.); NIH T32 training grants CA09361-27 ( to J. Z.) and CA09361 ( to M. O.); NIH grants F32 CA117737 ( to G. A. S.); NIH grants GM81607 and GM053203 and the Saltonstall Foundation ( to N. J. D.); and the Tosteson postdoctoral Fellowship ( to J. Y. J.). NR 31 TC 184 Z9 190 U1 4 U2 33 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1465-7392 J9 NAT CELL BIOL JI Nat. Cell Biol. PD DEC PY 2009 VL 11 IS 12 BP 1444 EP U134 DI 10.1038/ncb1993 PG 13 WC Cell Biology SC Cell Biology GA 525XO UT WOS:000272251300011 PM 19935651 ER PT J AU Raychaudhuri, S Thomson, BP Remmers, EF Eyre, S Hinks, A Guiducci, C Catanese, JJ Xie, G Stahl, EA Chen, R Alfredsson, L Amos, CI Ardlie, KG Barton, A Bowes, J Burtt, NP Chang, M Coblyn, J Costenbader, KH Criswell, LA Crusius, JBA Cui, J De Jager, PL Ding, B Emery, P Flynn, E Harrison, P Hocking, LJ Huizinga, TWJ Kastner, DL Ke, XY Kurreeman, FAS Lee, AT Liu, XD Li, YH Martin, P Morgan, AW Padyukov, L Reid, DM Seielstad, M Seldin, MF Shadick, NA Steer, S Tak, PP Thomson, W van der Helm-van Mil, AHM van der Horst-Bruinsma, IE Weinblatt, ME Wilson, AG Wolbink, GJ Wordsworth, P Altshuler, D Karlson, EW Toes, REM de Vries, N Begovich, AB Siminovitch, KA Worthington, J Klareskog, L Gregersen, PK Daly, MJ Plenge, RM AF Raychaudhuri, Soumya Thomson, Brian P. Remmers, Elaine F. Eyre, Stephen Hinks, Anne Guiducci, Candace Catanese, Joseph J. Xie, Gang Stahl, Eli A. Chen, Robert Alfredsson, Lars Amos, Christopher I. Ardlie, Kristin G. Barton, Anne Bowes, John Burtt, Noel P. Chang, Monica Coblyn, Jonathan Costenbader, Karen H. Criswell, Lindsey A. Crusius, J. Bart A. Cui, Jing De Jager, Phillip L. Ding, Bo Emery, Paul Flynn, Edward Harrison, Pille Hocking, Lynne J. Huizinga, Tom W. J. Kastner, Daniel L. Ke, Xiayi Kurreeman, Fina A. S. Lee, Annette T. Liu, Xiangdong Li, Yonghong Martin, Paul Morgan, Ann W. Padyukov, Leonid Reid, David M. Seielstad, Mark Seldin, Michael F. Shadick, Nancy A. Steer, Sophia Tak, Paul P. Thomson, Wendy van der Helm-van Mil, Annette H. M. van der Horst-Bruinsma, Irene E. Weinblatt, Michael E. Wilson, Anthony G. Wolbink, Gert Jan Wordsworth, Paul Altshuler, David Karlson, Elizabeth W. Toes, Rene E. M. de Vries, Niek Begovich, Ann B. Siminovitch, Katherine A. Worthington, Jane Klareskog, Lars Gregersen, Peter K. Daly, Mark J. Plenge, Robert M. CA BIRAC Consortium Consortium, Y TI Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk SO NATURE GENETICS LA English DT Article ID GENOME-WIDE ASSOCIATION; SINGLE-NUCLEOTIDE POLYMORPHISM; MULTIPLE-SCLEROSIS; SUSCEPTIBILITY LOCI; CELIAC-DISEASE; PTPN22; REPLICATION; PTPRC; CD45; MUTATION AB To discover new rheumatoid arthritis (RA) risk loci, we systematically examined 370 SNPs from 179 independent loci with P < 0.001 in a published meta-analysis of RA genome-wide association studies (GWAS) of 3,393 cases and 12,462 controls(1). We used Gene Relationships Across Implicated Loci (GRAIL)(2), a computational method that applies statistical text mining to PubMed abstracts, to score these 179 loci for functional relationships to genes in 16 established RA disease loci(1,3-11). We identified 22 loci with a significant degree of functional connectivity. We genotyped 22 representative SNPs in an independent set of 7,957 cases and 11,958 matched controls. Three were convincingly validated: CD2-CD58 (rs11586238, P = 1 x 10(-6) replication, P = 1 x 10(-9) overall), CD28 (rs1980422, P = 5 x 10(-6) replication, P = 1 x 10(-9) overall) and PRDM1 (rs548234, P = 1 x 10(-5) replication, P = 2 x 10(-8) overall). An additional four were replicated (P < 0.0023): TAGAP (rs394581, P = 0.0002 replication, P = 4 x 10(-7) overall), PTPRC (rs10919563, P = 0.0003 replication, P = 7 x 10(-7) overall), TRAF6-RAG1 (rs540386, P = 0.0008 replication, P = 4 x 10(-6) overall) and FCGR2A (rs12746613, P = 0.0022 replication, P = 2 x 10(-5) overall). Many of these loci are also associated to other immunologic diseases. C1 [Raychaudhuri, Soumya; Stahl, Eli A.; Chen, Robert; Coblyn, Jonathan; Costenbader, Karen H.; Cui, Jing; Kurreeman, Fina A. S.; Shadick, Nancy A.; Weinblatt, Michael E.; Karlson, Elizabeth W.; Plenge, Robert M.] Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA. [Raychaudhuri, Soumya; Thomson, Brian P.; Guiducci, Candace; Ardlie, Kristin G.; Burtt, Noel P.; De Jager, Phillip L.; Altshuler, David; Daly, Mark J.; Plenge, Robert M.] Broad Inst, Cambridge, MA USA. [Raychaudhuri, Soumya; Altshuler, David; Daly, Mark J.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Remmers, Elaine F.; Kastner, Daniel L.] NIAMSD, Genet & Genom Branch, US Natl Inst Hlth, Bethesda, MD 20892 USA. [Eyre, Stephen; Hinks, Anne; Barton, Anne; Bowes, John; Flynn, Edward; Ke, Xiayi; Martin, Paul; Thomson, Wendy; Worthington, Jane] Univ Manchester, Arthrit Res Campaign Epidemiol Unit, Manchester, Lancs, England. [Catanese, Joseph J.; Chang, Monica; Li, Yonghong; Begovich, Ann B.] Celera, Alameda, CA USA. [Xie, Gang; Liu, Xiangdong; Siminovitch, Katherine A.] Univ Toronto, Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada. [Xie, Gang; Liu, Xiangdong; Siminovitch, Katherine A.] Univ Hlth Network, Toronto, ON, Canada. [Alfredsson, Lars; Ding, Bo] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden. [Amos, Christopher I.] Univ Texas MD Anderson Canc Ctr, Houston, TX USA. [Criswell, Lindsey A.] Univ Calif San Francisco, Dept Med, Rosalind Russell Med Res Ctr Arthrit, San Francisco, CA USA. [Crusius, J. Bart A.] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, Immunogenet Lab, Amsterdam, Netherlands. [De Jager, Phillip L.] Brigham & Womens Hosp, Dept Neurol, Ctr Neurol Dis, Boston, MA 02115 USA. [Emery, Paul; Morgan, Ann W.] Univ Leeds, Leeds Inst Mol Med, Natl Inst Hlth Res, Leeds Musculoskeletal Biomed Res Unit, Leeds LS2 9JT, W Yorkshire, England. [Harrison, Pille; Wordsworth, Paul] Univ Oxford, Inst Musculoskeletal Sci, Botnar Res Ctr, Oxford, England. [Hocking, Lynne J.; Reid, David M.] Univ Aberdeen, Div Appl Med, Musculoskeletal & Genet Sect, Aberdeen AB9 1FX, Scotland. [Huizinga, Tom W. J.; Kurreeman, Fina A. S.; van der Helm-van Mil, Annette H. M.; Toes, Rene E. M.] Leiden Univ, Med Ctr, Dept Rheumatol, Leiden, Netherlands. [Lee, Annette T.; Gregersen, Peter K.] N Shore Long Isl Jewish Hlth Syst, Feinstein Inst Med Res, Manhasset, NY USA. [Padyukov, Leonid; Klareskog, Lars] Karolinska Univ Hosp Solna, Karolinska Inst, Dept Med, Rheumatol Unit, Stockholm, Sweden. [Seielstad, Mark] Genome Inst Singapore, Singapore, Singapore. [Seldin, Michael F.] Univ Calif Davis, Rowe Program Genet, Davis, CA 95616 USA. [Steer, Sophia] Kings Coll Hosp London, Natl Hlth Serv Fdn Trust, London, England. [Tak, Paul P.; de Vries, Niek] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands. [van der Horst-Bruinsma, Irene E.] Vrije Univ Amsterdam, Med Ctr, Dept Rheumatol, Amsterdam, Netherlands. [Wilson, Anthony G.] Univ Sheffield, Sch Med & Biomed Sci, Sheffield, S Yorkshire, England. [Wolbink, Gert Jan] Jan van Breemen Inst, Amsterdam, Netherlands. [Wolbink, Gert Jan] Univ Amsterdam, Acad Med Ctr, Sanquin Res Landsteiner Lab, NL-1105 AZ Amsterdam, Netherlands. [Begovich, Ann B.] Roche Diagnost, Pleasanton, CA USA. RP Raychaudhuri, S (reprint author), Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, 75 Francis St, Boston, MA 02115 USA. EM soumya@broad.mit.edu; rplenge@partners.org RI Altshuler, David/A-4476-2009; de Vries, Niek/J-9348-2013; Siminovitch, Katherine/K-1475-2013; Worthington, Jane/M-9770-2014; Barton, Anne/N-2053-2014; Bowes, John/B-3472-2015; Hinks, Anne/E-1853-2015; OI Altshuler, David/0000-0002-7250-4107; de Vries, Niek/0000-0002-6257-8604; Worthington, Jane/0000-0003-0544-042X; Barton, Anne/0000-0003-3316-2527; Bowes, John/0000-0003-4659-031X; Hinks, Anne/0000-0001-8843-3967; McInnes, Iain/0000-0002-6462-4280; Hocking, Lynne J/0000-0002-2414-2826; Alfredsson, Lars/0000-0003-1688-6697; Seielstad, Mark/0000-0001-5783-1401; Martin, Paul/0000-0002-1016-6851; Klareskog, Lars/0000-0001-9601-6186; Thomson, Wendy/0000-0002-9022-5179; Eyre, Stephen/0000-0002-1251-6974; Padyukov, Leonid/0000-0003-2950-5670; Young-Min, Steven/0000-0001-8270-6207 FU US National Institutes of Health (NIH) Career Development Award [1K08AR055688-01A1]; American College of Rheumatology Bridge Grant; NIH [AI55314-3, U01 HG004171, DK62432, R01 DK083756-1, DK64869, NO1-AR-2-2263, RO1 AR44422]; Fox Trot Fund; William Randolph Hearst Fund of Harvard University; Burroughs Wellcome Fund; National Center for Research Resources [U54 RR020278]; Millennium Pharmaceuticals; Intramural Research Program of the National Institute of Arthritis; Musculoskeletal and Skin Diseases of the NIH; Canadian Institutes for Health Research [MOP79321, IIN-84042]; Ontario Research Fund [RE01061]; Canada Research Chair; Biogen-Idec; National Heart, Lung, and Blood Institute's (STAMPEED); [R01HL087676] FX S. R. is supported by a US National Institutes of Health (NIH) Career Development Award (1K08AR055688-01A1) and an American College of Rheumatology Bridge Grant. R. M. P. is supported by a K08 grant from the NIH (AI55314-3), a private donation from the Fox Trot Fund, the William Randolph Hearst Fund of Harvard University, the American College of Rheumatology 'Within Our Reach' campaign and holds a Career Award for Medical Scientists from the Burroughs Wellcome Fund. M. J. D. is supported by NIH grants through the U01 (HG004171, DK62432) and R01 (DK083756-1, DK64869) mechanisms. The Broad Institute Center for Genotyping and Analysis is supported by grant U54 RR020278 from the National Center for Research Resources. The Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study (BRASS) Registry is supported by a grant from Millennium Pharmaceuticals and Biogen-Idec. The North American Rheumatoid Arthritis Consortium (NARAC) is supported by the NIH (NO1-AR-2-2263 and RO1 AR44422). This research was also supported in part by the Intramural Research Program of the National Institute of Arthritis, Musculoskeletal and Skin Diseases of the NIH. This research was also supported in part by grants to KAS from the Canadian Institutes for Health Research (MOP79321 and IIN-84042) and the Ontario Research Fund (RE01061) and by a Canada Research Chair. We acknowledge the help of C. E. van der Schoot for healthy control samples for the Genetics Network Rheumatology Amsterdam (GENRA) and the help of B. A. C. Dijkmans, D. van Schaardenburg, A. S. Pe a, P. L. Klarenbeek, Z. Zhang, M. T. Nurmohammed, W. F. Lems, R. R. J. van de Stadt, W. H. Bos, J. Ursum, M. G. M. Bartelds, D. M. Gerlag, M. G. H. van der Sande, C. A. Wijbrandts and M. M. J. Herenius in gathering GENRA patient samples and data. We thank the Myocardial Infarction Genetics Consortium (MIGen) study for the use of genotype data from their healthy controls in our study. The MIGen study was funded by the US NIH and National Heart, Lung, and Blood Institute's SNP Typing for Association with Multiple Phenotypes from Existing Epidemiologic Data (STAMPEED) genomics research program R01HL087676 and a grant from the National Center for Research Resources. We thank the Johanna Seddon Progression of AMD Study, AMD Registry Study, Family Study of AMD, The US Twin Study of AMD and the Age-Related Eye Disease Study (AREDS) for use of genotype data from their healthy controls in our study. We thank D. Hafler and the Multiple Sclerosis collaborative for use of genotype data from their healthy controls recruited at Brigham and Women's Hospital. NR 43 TC 181 Z9 184 U1 4 U2 20 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1061-4036 J9 NAT GENET JI Nature Genet. PD DEC PY 2009 VL 41 IS 12 BP 1313 EP U76 DI 10.1038/ng.479 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA 524LN UT WOS:000272144900013 PM 19898481 ER PT J AU Imielinski, M Baldassano, RN Griffiths, A Russell, RK Annese, V Dubinsky, M Kugathasan, S Bradfield, JP Walters, TD Sleiman, P Kim, CE Muise, A Wang, K Glessner, JT Saeed, S Zhang, HT Frackelton, EC Hou, CP Flory, JH Otieno, G Chiavacci, RM Grundmeier, R Castro, M Latiano, A Dallapiccola, B Stempak, J Abrams, DJ Taylor, K McGovern, D Heyman, MB Ferry, GD Kirschner, B Lee, J Essers, J Grand, R Stephens, M Levine, A Piccoli, D Van Limbergen, J Cucchiara, S Monos, DS Guthery, SL Denson, L Wilson, DC Grant, SFA Daly, M Silverberg, MS Satsangi, J Hakonarson, H AF Imielinski, Marcin Baldassano, Robert N. Griffiths, Anne Russell, Richard K. Annese, Vito Dubinsky, Marla Kugathasan, Subra Bradfield, Jonathan P. Walters, Thomas D. Sleiman, Patrick Kim, Cecilia E. Muise, Aleixo Wang, Kai Glessner, Joseph T. Saeed, Shehzad Zhang, Haitao Frackelton, Edward C. Hou, Cuiping Flory, James H. Otieno, George Chiavacci, Rosetta M. Grundmeier, Robert Castro, Massimo Latiano, Anna Dallapiccola, Bruno Stempak, Joanne Abrams, Debra J. Taylor, Kent McGovern, Dermot Heyman, Melvin B. Ferry, George D. Kirschner, Barbara Lee, Jessica Essers, Jonah Grand, Richard Stephens, Michael Levine, Arie Piccoli, David Van Limbergen, Johan Cucchiara, Salvatore Monos, Dimitri S. Guthery, Stephen L. Denson, Lee Wilson, David C. Grant, Struan F. A. Daly, Mark Silverberg, Mark S. Satsangi, Jack Hakonarson, Hakon CA Western Reg Res Alliance Pediat IB Int IBD Genetics Consortium TI Common variants at five new loci associated with early-onset inflammatory bowel disease SO NATURE GENETICS LA English DT Article ID GENOME-WIDE ASSOCIATION; CROHNS-DISEASE; SUSCEPTIBILITY LOCI; SEQUENCE VARIANTS; GENE; EXPRESSION; CONTRIBUTE; AUTOPHAGY; MULTIPLE; HISTORY AB The inflammatory bowel diseases (IBD) Crohn's disease and ulcerative colitis are common causes of morbidity in children and young adults in the western world. Here we report the results of a genome-wide association study in early-onset IBD involving 3,426 affected individuals and 11,963 genetically matched controls recruited through international collaborations in Europe and North America, thereby extending the results from a previous study of 1,011 individuals with early-onset IBD(1). We have identified five new regions associated with early-onset IBD susceptibility, including 16p11 near the cytokine gene IL27 (rs8049439, P = 2.41 x 10(-9)), 22q12 (rs2412973, P = 1.55 x 10(-9)), 10q22 (rs1250550, P = 5.63 x 10(-9)), 2q37 (rs4676410, P = 3.64 x 10(-8)) and 19q13.11 (rs10500264, P = 4.26 x 10(-10)). Our scan also detected associations at 23 of 32 loci previously implicated in adult-onset Crohn's disease and at 8 of 17 loci implicated in adult-onset ulcerative colitis, highlighting the close pathogenetic relationship between early- and adult-onset IBD. C1 [Imielinski, Marcin; Bradfield, Jonathan P.; Sleiman, Patrick; Kim, Cecilia E.; Wang, Kai; Glessner, Joseph T.; Zhang, Haitao; Frackelton, Edward C.; Hou, Cuiping; Flory, James H.; Otieno, George; Chiavacci, Rosetta M.; Grant, Struan F. A.; Hakonarson, Hakon] Childrens Hosp Philadelphia, Ctr Appl Genom, Philadelphia, PA 19104 USA. [Baldassano, Robert N.; Grundmeier, Robert; Piccoli, David; Grant, Struan F. A.; Hakonarson, Hakon] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. [Baldassano, Robert N.; Abrams, Debra J.; Piccoli, David] Childrens Hosp Philadelphia, Div Gastroenterol, Philadelphia, PA 19104 USA. [Griffiths, Anne; Walters, Thomas D.; Muise, Aleixo] Univ Toronto, Hosp Sick Children, Toronto, ON M5G 1X8, Canada. [Russell, Richard K.] Royal Hosp Sick Children, Glasgow G3 8SJ, Lanark, Scotland. [Annese, Vito] CSS, IRCCS, Dept Med Sci, Gastroenterol Unit, San Giovanni Rotondo, Italy. [Dubinsky, Marla] Cedars Sinai Med Ctr, Dept Pediat, Los Angeles, CA 90048 USA. [Dubinsky, Marla; Taylor, Kent; McGovern, Dermot] Cedars Sinai Med Ctr, Dept Common Dis Genet, Los Angeles, CA 90048 USA. [Kugathasan, Subra] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA. [Kugathasan, Subra] Childrens Hlth Care Atlanta, Atlanta, GA USA. [Saeed, Shehzad] Univ Alabama, Dept Pediat, Birmingham, AL USA. [Grundmeier, Robert] Childrens Hosp Philadelphia, Ctr Biomed Informat, Philadelphia, PA 19104 USA. [Castro, Massimo; Latiano, Anna] Bambino Gesu Pediat Hosp, Gastroenterol Unit, Rome, Italy. [Dallapiccola, Bruno] Univ Roma La Sapienza, Mendel Inst, IRCCS, CSS Hosp, San Giovanni Rotondo, Italy. [Stempak, Joanne; Silverberg, Mark S.] Univ Toronto, Mt Sinai Hosp, Ctr Inflammatory Bowel Dis, Toronto, ON M5G 1X5, Canada. [Heyman, Melvin B.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA. [Ferry, George D.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. [Kirschner, Barbara] Univ Chicago, Comer Childrens Hosp, Chicago, IL 60637 USA. [Lee, Jessica; Essers, Jonah; Grand, Richard] Childrens Hosp, Div Gastroenterol, Boston, MA 02115 USA. [Stephens, Michael] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA. [Levine, Arie] Tel Aviv Univ, Wolfson Med Ctr, Pediat Gastroenterol Unit, IL-69978 Tel Aviv, Israel. [Van Limbergen, Johan; Satsangi, Jack] Univ Edinburgh, Western Gen Hosp, Sch Mol & Clin Med, Div Med Sci,Gastrointestinal Unit, Edinburgh, Midlothian, Scotland. [Cucchiara, Salvatore] Univ Roma La Sapienza, Pediat Gastroenterol & Liver Unit, Rome, Italy. [Monos, Dimitri S.] Childrens Hosp Philadelphia, Dept Pathol, Philadelphia, PA 19104 USA. [Guthery, Stephen L.] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT USA. [Guthery, Stephen L.] Primary Childrens Med Ctr, Salt Lake City, UT 84103 USA. [Denson, Lee] Cincinnati Childrens Hosp, Med Ctr, Div Gastroenterol, Ctr Inflammatory Bowel Dis, Cincinnati, OH USA. [Wilson, David C.] Royal Hosp Sick Children, Edinburgh EH9 1LF, Midlothian, Scotland. [Grant, Struan F. A.; Hakonarson, Hakon] Childrens Hosp Philadelphia, Div Human Genet, Philadelphia, PA 19104 USA. [Daly, Mark] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. RP Hakonarson, H (reprint author), Childrens Hosp Philadelphia, Ctr Appl Genom, Philadelphia, PA 19104 USA. EM hakonarson@chop.edu RI Silverberg, Mark/B-4183-2008; Rioux, John/A-9599-2015; Latiano, Anna/R-1965-2016; Dallapiccola, Bruno/K-8692-2016; OI Rioux, John/0000-0001-7560-8326; Latiano, Anna/0000-0003-3719-2061; Laukens, Debby/0000-0002-1984-5850; Dallapiccola, Bruno/0000-0002-5031-1013; Cucchiara, Salvatore/0000-0002-2939-9698 FU Children's Hospital of Philadelphia; Primary Children's Medical Center Foundation; National Center for Research Resources [DK069513, M01-RR00064, M01 RR002172-26, C06-RR11234]; NIH/NIDDK [DK062423]; Gale and Graham Wright Research Chair in Digestive Diseases; Canadian Association of Gastroenterology (CAG); Crohn's Colitis Foundation of Canada (CCFC); Canadian Institutes of Health Research (CIHR); Astra-Zeneca; CCFC/CAG/CIHR Transition Award; Canadian Child Health Clinician Scientist Program (CCHCSP); Children's Hospital Boston; NIDDK [DK069513, T32 DK007477]; NCRR [M01-RR00064, C06-RR11234]; Action Medical Research; Gay-Ramsay-SteelMaitland or Stafford Trust; Hazel M Wood Charitable Trust; Medical Research Council Patient Cohorts Research Initiative award [G0800675]; Wellcome Trust Programme Grant [072789/Z/03/Z]; Chief Scientist Office of the Scottish Government Health Department; University of Edinburgh Medical Faculty Fellowship; GI/Nutrition Research Fund; Child Life and Health; University of Edinburgh FX We thank all participating subjects and families. We thank the medical assistants, nursing staff and clinicians at CHOP who assisted with the recruitment of control subjects, which made this work possible; and members of the International HapMap and Wellcome Trust Case Control Consortiums for publicly providing data that were critically important for part of our analyses. The following physicians of the SIGENP (Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition) contributed by providing DNA samples and clinical information from their patients: A. Andriulli, M. R. Valvano, O. Palmieri, F. Bossa, E. Colombo, M. Pastore, M. D'Altilia, O. Borrelli, C. Bascietto, A. Ferraris, B. Papadatou, A. Diamanti, P. Lionetti, E. Pozzi, A. Barabino, A. Calvi, G. L. de' Angelis, G. Guariso, V. Lodde, G. Vieni, C. Sferlazzas, S. Accomando, G. Iacono, E. Berni Canani, A. M. Staiano, V. Rutigliano, D. De Venuto, C. Romano, G. Lombardi, S. Nobile, C. Catassi and A. Campanozzi. The following physicians of SPGHANG (Scottish Pediatric Gastroenterology, Hepatology and Nutrition Group) contributed by providing DNA samples and clinical information from their patients: W. M. Bisset, P. M. Gillett, G. Mahdi and P. McGrogan. This research was supported by the Children's Hospital of Philadelphia, the Primary Children's Medical Center Foundation and grants DK069513, M01-RR00064, M01 RR002172-26 and C06-RR11234 from the National Center for Research Resources. All genomewide genotyping was funded by an Institute Development Award from the Children's Hospital of Philadelphia. M. S. is funded by NIH/NIDDK grant DK062423 and the Gale and Graham Wright Research Chair in Digestive Diseases. T. W. received fellowship funding support jointly from the Canadian Association of Gastroenterology (CAG), Crohn's Colitis Foundation of Canada (CCFC), Canadian Institutes of Health Research (CIHR) and Astra-Zeneca. A. M. received a CCFC/CAG/CIHR Transition Award and Canadian Child Health Clinician Scientist Program (CCHCSP) Award for training. J. L. received Junior Faculty Development Award from Children's Hospital Boston. J. E. is supported by a Training grant (T32 DK007477) from NIDDK. S. L. G. received support from the Primary Children's Medical Center Foundation, NIDDK (DK069513) and NCRR (M01-RR00064 and C06-RR11234). J. V. L. was funded by a Research Training Fellowship from Action Medical Research, the Gay-Ramsay-SteelMaitland or Stafford Trust and the Hazel M Wood Charitable Trust. D. C. W. is the holder of a Medical Research Council Patient Cohorts Research Initiative award (G0800675). Financial assistance was also provided by a Wellcome Trust Programme Grant (072789/Z/03/Z), the Chief Scientist Office of the Scottish Government Health Department, a University of Edinburgh Medical Faculty Fellowship and the GI/Nutrition Research Fund, Child Life and Health, University of Edinburgh. NR 24 TC 261 Z9 262 U1 1 U2 23 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1061-4036 J9 NAT GENET JI Nature Genet. PD DEC PY 2009 VL 41 IS 12 BP 1335 EP U107 DI 10.1038/ng.489 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA 524LN UT WOS:000272144900017 PM 19915574 ER PT J AU McCarroll, SA Bradner, JE Turpeinen, H Volin, L Martin, PJ Chilewski, SD Antin, JH Lee, SJ Ruutu, T Storer, B Warren, EH Zhang, B Zhao, LP Ginsburg, D Soiffer, RJ Partanen, J Hansen, JA Ritz, J Palotie, A Altshuler, D AF McCarroll, Steven A. Bradner, James E. Turpeinen, Hannu Volin, Liisa Martin, Paul J. Chilewski, Shannon D. Antin, Joseph H. Lee, Stephanie J. Ruutu, Tapani Storer, Barry Warren, Edus H. Zhang, Bo Zhao, Lue Ping Ginsburg, David Soiffer, Robert J. Partanen, Jukka Hansen, John A. Ritz, Jerome Palotie, Aarno Altshuler, David TI Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease SO NATURE GENETICS LA English DT Article ID MINOR HISTOCOMPATIBILITY ANTIGEN; COPY-NUMBER-VARIATION; BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; H-Y-ANTIGEN; HUMAN GENOME; FEMALE DONORS; RISK-FACTOR; LEUKEMIA; UGT2B17 AB Transplantation and pregnancy, in which two diploid genomes reside in one body, can each lead to diseases in which immune cells from one individual target antigens encoded in the other's genome. One such disease, graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation (HSCT, or bone marrow transplant), is common even after transplants between HLA-identical siblings, indicating that cryptic histocompatibility loci exist outside the HLA locus. The immune system of an individual whose genome is homozygous for a gene deletion could recognize epitopes encoded by that gene as alloantigens. Analyzing common gene deletions in three HSCT cohorts (1,345 HLA-identical sibling donor-recipient pairs), we found that risk of acute GVHD was greater (odds ratio (OR) = 2.5; 95% confidence interval (CI) 1.4-4.6) when donor and recipient were mismatched for homozygous deletion of UGT2B17, a gene expressed in GVHD-affected tissues and giving rise to multiple histocompatibility antigens. Human genome structural variation merits investigation as a potential mechanism in diseases of alloimmunity. C1 [McCarroll, Steven A.; Altshuler, David] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. [McCarroll, Steven A.; Altshuler, David] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA. [McCarroll, Steven A.; Bradner, James E.; Chilewski, Shannon D.; Palotie, Aarno; Altshuler, David] Harvard & MIT, Broad Inst, Cambridge, MA USA. [Bradner, James E.; Antin, Joseph H.; Lee, Stephanie J.; Soiffer, Robert J.; Ritz, Jerome] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Bradner, James E.; Antin, Joseph H.; Lee, Stephanie J.; Soiffer, Robert J.; Ritz, Jerome] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Turpeinen, Hannu; Partanen, Jukka] Finnish Red Cross Blood Serv, Dept Res & Dev, Helsinki, Finland. [Volin, Liisa; Ruutu, Tapani] Univ Helsinki, Cent Hosp, Dept Med, Helsinki, Finland. [Martin, Paul J.; Lee, Stephanie J.; Storer, Barry; Warren, Edus H.; Zhang, Bo; Zhao, Lue Ping; Hansen, John A.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Martin, Paul J.; Warren, Edus H.; Hansen, John A.] Univ Washington, Dept Med, Seattle, WA USA. [Ginsburg, David] Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA. [Ginsburg, David] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Palotie, Aarno] Univ Helsinki, Finnish Inst Mol Med, Helsinki, Finland. [Palotie, Aarno] Wellcome Trust Sanger Inst, Cambridge, England. RP McCarroll, SA (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. EM mccarroll@genetics.med.harvard.edu RI Altshuler, David/A-4476-2009; Partanen, Jukka/B-7207-2014; OI Altshuler, David/0000-0002-7250-4107; Partanen, Jukka/0000-0001-6681-4734; Warren, Edus/0000-0002-9570-2755; McCarroll, Steven/0000-0002-6954-8184 FU Broad Institute of MIT and Harvard; Academy of Finland; Helsinki University Central Hospital Research Fund; Fred Hutchinson Cancer Research Center; Lilly Life Sciences Research fellowship; S. Juselius Foundation; Center of Excellence Program of the Finnish Academy; National Institutes of Health [HA070149, AI29530, AI33484, CA18029, HL087690] FX We wish to thank the patients, donors and clinical care teams at Helsinki University Central Hospital, the Dana-Farber Cancer Institute and the Fred Hutchinson Cancer Research Center. We also wish to thank D. Sese and colleagues at the Brigham and Women's Hospital Tissue Typing Laboratory; the Ted and Eileen Pasquarello Tissue Bank; Q. Yang and colleagues at the Quality Assurance Office for Clinical Trials at Dana-Farber Cancer Institute; E. Lander, Y. Ofran, J. Chien and M. Daly for helpful conversations on the project and data; and B. Blazar, C. KeeverTaylor and D. Senitzer for providing patient samples for the Nichols et al. cohort further studied here. This work was supported by the Broad Institute of MIT and Harvard (D. A., S. A. M.), the Academy of Finland (L. V., H. T., J. P.), the Helsinki University Central Hospital Research Fund (L. V.), the Fred Hutchinson Cancer Research Center, a Lilly Life Sciences Research fellowship (S. A. M.), the S. Juselius Foundation (J. P.), the Center of Excellence Program of the Finnish Academy (A. P.) and the National Institutes of Health (HA070149 to J. H. A.; AI29530 to J. R.; AI33484, CA18029 and HL087690 to J. A. H.). NR 32 TC 53 Z9 55 U1 1 U2 7 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1061-4036 J9 NAT GENET JI Nature Genet. PD DEC PY 2009 VL 41 IS 12 BP 1341 EP U112 DI 10.1038/ng.490 PG 5 WC Genetics & Heredity SC Genetics & Heredity GA 524LN UT WOS:000272144900018 PM 19935662 ER PT J AU Guo, ZV Hart, AC Ramanathan, S AF Guo, Zengcai V. Hart, Anne C. Ramanathan, Sharad TI Optical interrogation of neural circuits in Caenorhabditis elegans SO NATURE METHODS LA English DT Article ID C-ELEGANS; NERVOUS-SYSTEM; NEURONS; CHANNEL; CELLS; CHANNELRHODOPSIN-2; SENSITIVITY; EXPRESSION; INDICATORS; PROTEINS AB The nematode Caenorhabditis elegans has a compact nervous system with only 302 neurons. Whereas most of the synaptic connections between these neurons have been identified by electron microscopy serial reconstructions, functional connections have been inferred between only a few neurons through combinations of electrophysiology, cell ablation, in vivo calcium imaging and genetic analysis. To map functional connections between neurons, we combined in vivo optical stimulation with simultaneous calcium imaging. We analyzed the connections from the ASH sensory neurons and RIM interneurons to the command interneurons AVA and AVD. Stimulation of ASH or RIM neurons using channelrhodopsin-2 (ChR2) resulted in activation of AVA neurons, evoking an avoidance behavior. Our results demonstrate that we can excite specific neurons expressing ChR2 while simultaneously monitoring G-CaMP fluorescence in several other neurons, making it possible to rapidly decipher functional connections in C. elegans neural circuits. C1 [Guo, Zengcai V.; Ramanathan, Sharad] Harvard Univ, Fac Arts & Sci, Ctr Syst Biol, Cambridge, MA 02138 USA. [Guo, Zengcai V.; Ramanathan, Sharad] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA. [Guo, Zengcai V.; Ramanathan, Sharad] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA. [Hart, Anne C.] Harvard Univ, Ctr Canc Res, Massachusetts Gen Hosp, Sch Med, Charlestown, MA USA. [Hart, Anne C.] Harvard Univ, Dept Pathol, Sch Med, Charlestown, MA USA. RP Ramanathan, S (reprint author), Harvard Univ, Fac Arts & Sci, Ctr Syst Biol, Cambridge, MA 02138 USA. EM sharad@post.harvard.edu FU US National Institute of General Medical Sciences FX We thank P. Swain and S. H. Simon for discussions, members of the Caenorhabditis Genetic Center (CGC) for strains, J. Naki (RIKEN Brain Science Institute) for G-CaMP plasmid, A. Gottschalk (Goethe University Frankfurt) for chop-2(H134R) cDNA and A. Fire (Stanford University) for plasmid vectors. Z. V. G. thanks A. Ahmed, M. Debono and A. Desai for 2007 C. elegans course. A. C. H. was supported by the US National Institute of General Medical Sciences. NR 33 TC 94 Z9 94 U1 3 U2 22 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1548-7091 EI 1548-7105 J9 NAT METHODS JI Nat. Methods PD DEC PY 2009 VL 6 IS 12 BP 891 EP U47 DI 10.1038/nmeth.1397 PG 8 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 525BD UT WOS:000272187200018 PM 19898486 ER PT J AU Kufe, DW AF Kufe, Donald W. TI Mucins in cancer: function, prognosis and therapy SO NATURE REVIEWS CANCER LA English DT Review ID CARCINOMA-ASSOCIATED ANTIGEN; CELL-SURFACE MUCIN; INFLAMMATORY-BOWEL-DISEASE; EPITHELIAL-MESENCHYMAL TRANSITIONS; GROWTH-FACTOR RECEPTOR; GEL-FORMING MUCINS; NF-KAPPA-B; OVARIAN-CANCER; MONOCLONAL-ANTIBODY; SIALOMUCIN COMPLEX AB Epithelia are protected from adverse conditions by a mucous barrier. The secreted and transmembrane mucins that constitute the mucous barrier are largely unrecognized as effectors of carcinogenesis. However, both types of mucins are intimately involved in inflammation and cancer. Moreover, diverse human malignancies overexpress transmembrane mucins to exploit their role in signalling cell growth and survival. Mucins have thus been identified as markers of adverse prognosis and as attractive therapeutic targets. Notably, the findings that certain transmembrane mucins induce transformation and promote tumour progression have provided the experimental basis for demonstrating that inhibitors of their function are effective as anti-tumour agents in preclinical models. C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Kufe, DW (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM Donald_Kufe@dfci.harvard.edu FU NCI NIH HHS [CA100707, CA42802, CA97098, P50 CA100707, P50 CA100707-010003, R01 CA042802, R01 CA042802-13, R01 CA097098, R01 CA097098-01] NR 153 TC 408 Z9 417 U1 12 U2 72 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1474-175X J9 NAT REV CANCER JI Nat. Rev. Cancer PD DEC PY 2009 VL 9 IS 12 BP 874 EP 885 DI 10.1038/nrc2761 PG 12 WC Oncology SC Oncology GA 524LI UT WOS:000272144400007 PM 19935676 ER PT J AU Choueiri, TK Atkins, MB AF Choueiri, Toni K. Atkins, Michael B. TI TARGETED THERAPIES Sunitinib in RCC-expanded access equals expanded benefit? SO NATURE REVIEWS CLINICAL ONCOLOGY LA English DT Editorial Material ID RENAL-CELL CARCINOMA; INTERFERON-ALPHA; TRIAL C1 [Atkins, Michael B.] Beth Israel Deaconess Med Ctr, Div Hematol & Oncol, Boston, MA 02115 USA. [Choueiri, Toni K.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Atkins, MB (reprint author), Beth Israel Deaconess Med Ctr, Div Hematol Oncol, MASCO Bldg,Room 412,375 Longwood Ave, Boston, MA 02115 USA. EM matkins@bidmc.harvard.edu NR 8 TC 3 Z9 4 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-4774 J9 NAT REV CLIN ONCOL JI Nat. Rev. Clin. Oncol. PD DEC PY 2009 VL 6 IS 12 BP 679 EP 680 DI 10.1038/nrclinonc.2009.170 PG 2 WC Oncology SC Oncology GA 523NC UT WOS:000272079800001 PM 19942921 ER PT J AU Belmonte, JCI Ellis, J Hochedlinger, K Yamanaka, S AF Belmonte, Juan Carlos Izpisua Ellis, James Hochedlinger, Konrad Yamanaka, Shinya TI VIEWPOINT Induced pluripotent stem cells and reprogramming: seeing the science through the hype SO NATURE REVIEWS GENETICS LA English DT Editorial Material ID IPS CELLS; MOTOR-NEURONS; GENERATION; VECTORS; PATIENT; PATHWAY AB No-one can have failed to notice the splash that induced pluripotent stem (iPS) cells have made in the few years since somatic cells were first reprogrammed to pluripotency. But what is their real promise, where should research efforts be focused, and are we at a stage where we can replace embryonic stem cells? Four pioneering iPS cell researchers offer their personal insights into these and other questions of current debate. As well expressing hope for the improved understanding and treatment of human disease, they urge caution over safety and propose the establishment of iPS cell banks. C1 [Belmonte, Juan Carlos Izpisua] Ctr Regenerat Med Barcelona, Barcelona 08003, Spain. [Belmonte, Juan Carlos Izpisua] Salk Inst Biol Studies, La Jolla, CA 93027 USA. [Ellis, James] Hosp Sick Children, Toronto, ON M5G 1L7, Canada. [Ellis, James] MaRS Ctr, Ontario Human iPS Cell Facil, Toronto, ON M5G 1L7, Canada. [Hochedlinger, Konrad] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA. [Hochedlinger, Konrad] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Hochedlinger, Konrad] Harvard Stem Cell Inst, Ctr Regenerat Med, Boston, MA 02114 USA. [Yamanaka, Shinya] Inst Frontier Med Sci, Dept Stem Cell Biol, Inst Integrated Cell Mat Sci iCeMS, Ctr iPS Cell Res & Applicat CiRA,Shogoin Sakyo Ku, Kyoto 6068507, Japan. RP Belmonte, JCI (reprint author), Ctr Regenerat Med Barcelona, Dr Aiguader 88, Barcelona 08003, Spain. EM belmonte@salk.edu; jellis@sickkids.ca; khochedlinger@helix.mgh.harvard.edu; yamanaka@frontier.kyoto-u.ac.jp RI Ellis, James/F-4789-2011 NR 21 TC 60 Z9 62 U1 1 U2 12 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1471-0056 J9 NAT REV GENET JI Nat. Rev. Genet. PD DEC PY 2009 VL 10 IS 12 BP 878 EP U80 DI 10.1038/nrg2700 PG 6 WC Genetics & Heredity SC Genetics & Heredity GA 521KC UT WOS:000271919200014 ER PT J AU Wang, BB Li, SQ Qi, HH Chowdhury, D Shi, Y Novina, CD AF Wang, Bingbing Li, Shuqiang Qi, Hank H. Chowdhury, Dipanjan Shi, Yang Novina, Carl D. TI Distinct passenger strand and mRNA cleavage activities of human Argonaute proteins SO NATURE STRUCTURAL & MOLECULAR BIOLOGY LA English DT Article ID MICRORNA TARGETS; HUMAN-CELLS; IN-VITRO; SILENCING COMPLEX; CRYSTAL-STRUCTURE; ENZYME COMPLEX; GUIDE-STRAND; HUMAN RISC; SIRNA; IDENTIFICATION AB Argonaute (AGO) proteins bind to small RNAs and mediate small RNA-induced silencing in eukaryotes. Using a minimal in vitro system, we show that bacterially expressed human AGO1 and AGO2 but not AGO3 and AGO4 possess strand-dissociating activity of microRNA (miRNA) duplexes. Both AGO1 and AGO2 function as RNA chaperones, capable of performing multiple rounds of strand dissociation. Unexpectedly, both AGO1 and AGO2 demonstrate passenger strand cleavage activity of a small interfering RNA (siRNA) duplex, but only AGO2 has target RNA cleavage activity. These observations indicate that passenger strand and mRNA endonuclease activities are mechanistically distinct. We further validate these observations in mammalian extracts and cultured mammalian cells, in which we demonstrate that AGO1 uses only miRNA duplexes when assembling translational repression-competent complexes, whereas AGO2 can use both miRNA and siRNA duplexes. We show that passenger strand cleavage and RNA chaperone activities that are intrinsic to both AGO1 and AGO2 are sufficient for RNA-induced silencing complex (RISC) loading. C1 [Wang, Bingbing; Li, Shuqiang; Novina, Carl D.] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. [Wang, Bingbing; Li, Shuqiang; Qi, Hank H.; Shi, Yang; Novina, Carl D.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Chowdhury, Dipanjan] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Chowdhury, Dipanjan] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Novina, Carl D.] Broad Inst Harvard & MIT, Cambridge, MA USA. RP Novina, CD (reprint author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. EM carl_novina@dfci.harvard.edu FU W. M. Keck Foundation FX We thank M. Janas and J. Doench for insightful recommendations and critical reading of the manuscript. We also thank Y. Pan for assistance with the AGO pull-down assays. We thank E. Gagnon for creating Figure 6. This work was supported by a Distinguished Young Scholars Award from the W. M. Keck Foundation to C. D. N. NR 47 TC 75 Z9 76 U1 0 U2 13 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1545-9985 J9 NAT STRUCT MOL BIOL JI Nat. Struct. Mol. Biol. PD DEC PY 2009 VL 16 IS 12 BP 1259 EP U76 DI 10.1038/nsmb.1712 PG 9 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA 530RE UT WOS:000272609200013 PM 19946268 ER PT J AU Wen, PY Yung, WKA Lamborn, KR Norden, AD Cloughesy, TF Abrey, LE Fine, HA Chang, SM Robins, HI Fink, K DeAngelis, LM Mehta, M Di Tomaso, E Drappatz, J Kesari, S Ligon, KL Aldape, K Jain, RK Stiles, CD Egorin, MJ Prados, MD AF Wen, Patrick Y. Yung, W. K. Alfred Lamborn, Kathleen R. Norden, Andrew D. Cloughesy, Timothy F. Abrey, Lauren E. Fine, Howard A. Chang, Susan M. Robins, H. Ian Fink, Karen DeAngelis, Lisa M. Mehta, Minesh Di Tomaso, Emmanuelle Drappatz, Jan Kesari, Santosh Ligon, Keith L. Aldape, Ken Jain, Rakesh K. Stiles, Charles D. Egorin, Merrill J. Prados, Michael D. TI Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08) SO NEURO-ONCOLOGY LA English DT Article DE imatinib; meningioma; pharmacokinetics; toxicities ID CHRONIC MYELOID-LEUKEMIA; GROWTH-FACTOR RECEPTORS; MALIGNANT GLIOMAS; TYROSINE KINASE; FACTOR PDGF; EXPRESSION; HYDROXYUREA; PHARMACOKINETICS; AUTOCRINE; CELLS AB Platelet-derived growth factor (PDGF) and its receptors (PDGFR) are frequently coexpressed in meningiomas, potentially contributing to their pathogenesis. The North American Brain Tumor Consortium conducted a phase II study to evaluate the therapeutic potential of imatinib mesylate (Gleevec), a PDGFR inhibitor, in patients with recurrent meningiomas. Patients were stratified into benign (WHO grade I) meningiomas or atypical (WHO grade II) and malignant (WHO grade III) meningiomas. The primary end point was 6-month progression-free survival (6M-PFS). Patients requiring enzyme-inducing antiepileptic drugs were ineligible. Patients received imatinib at a dose of 600 mg/day for the first 4-week cycle and then gradually increased to 800 mg/day for subsequent cycles, if there were no unacceptable toxicities. Plasma concentrations of imatinib and its active metabolite, CGP74588, were assessed. Twenty-three heavily pre-treated patients were enrolled into the study (13 benign, 5 atypical, and 5 malignant meningiomas), of whom 22 were eligible. The study was closed prematurely due to slow accrual. Tissue was available only from a minority of patients, but in these specimens there was uniform distribution of PDGFR, the drug target. Imatinib was generally well tolerated. Of 19 patients evaluable for response, 10 progressed at the first scan, and 9 were stable. There were no complete or partial responses. Overall median PFS was 2 months (range, 0.7-34 months); 6M-PFS was 29.4%. For benign meningiomas, median PFS was 3 months (range, 1.1-34 months); 6M-PFS was 45%. For atypical and malignant meningiomas, median PFS was 2 months (range, 0.7-3.7 months); 6M-PFS was 0%. Cycle I trough concentrations of imatinib and CGP74588 were 2,129 +/- 1,600 ng/ml and 517 +/- 326 ng/ml, respectively. Single-agent imatinib was well tolerated but had no significant activity in recurrent meningiomas. Trough Plasma concentrations of imatinib exceeded those associated with imatinib activity in chronic myelogenous leukemia. Neuro-Oncology 11, 853-860, 2009 (Posted to Neuro-Oncology [serial online], Doc. D08-00173, March 17, 2009. URL http://neuro-oncology.dukejournals.org; DOI: 10.1215/15228517-2009-010) C1 [Wen, Patrick Y.] Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA 02115 USA. [Yung, W. K. Alfred; Aldape, Ken] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Lamborn, Kathleen R.; Chang, Susan M.; Prados, Michael D.] Univ Calif San Francisco, San Francisco Med Ctr, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA. [Cloughesy, Timothy F.] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA. [Abrey, Lauren E.; DeAngelis, Lisa M.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Fine, Howard A.] NIH, Neurooncol Branch, Bethesda, MD 20892 USA. [Robins, H. Ian; Mehta, Minesh] Univ Wisconsin, Madison, WI USA. [Fink, Karen] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Di Tomaso, Emmanuelle; Jain, Rakesh K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Egorin, Merrill J.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA. RP Wen, PY (reprint author), Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, SW430D,44 Binney St, Boston, MA 02115 USA. EM pwen@partners.org RI Kesari, Santosh/E-8461-2013; OI mehta, minesh/0000-0002-4812-5713 FU National Institutes of Health to the North American Brain Tumor Consortium (NABTC) [CA 62399] FX Support for this article, which is designated the NABTC Study 01-08, was received through prime award CA 62399 from the National Institutes of Health to the North American Brain Tumor Consortium (NABTC) investigators who coauthored this article and through the individual NABTC and General Clinical Research Center (GCRC) grants listed below. NR 49 TC 59 Z9 60 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD DEC PY 2009 VL 11 IS 6 BP 853 EP 860 DI 10.1215/15228517-2009-010 PG 8 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 535MU UT WOS:000272974100015 PM 19293394 ER PT J AU Quant, EC Silver, M Yip, S Ryg, P McCormack, K Provencher, K Louis, DN Betensky, R Nutt, C Batchelor, TT AF Quant, Eudocia C. Silver, Michael Yip, Stephen Ryg, Peter McCormack, Kaitlyn Provencher, Katelyn Louis, David N. Betensky, Rebecca Nutt, Catherine Batchelor, Tracy T. TI CASE-CONTROL STUDY OF LONG-TERM SURVIVORS OF PRIMARY GLIOBLASTOMA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 3rd Quadrennial Meeting of the World-Federation-of-Neuro-Oncoloyg/6th Meeting of the Asian-Society-for-Neuro-Oncology CY MAY 11-14, 2009 CL Yokohama, JAPAN SP World Federat Neuro Oncol, Asian Soc Neuro Oncol C1 [Quant, Eudocia C.; Ryg, Peter; Batchelor, Tracy T.] Harvard Univ, Sch Publ Hlth, Dept Neurol, Boston, MA 02115 USA. [Silver, Michael; Betensky, Rebecca] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Yip, Stephen; McCormack, Kaitlyn; Provencher, Katelyn; Louis, David N.; Nutt, Catherine] Harvard Univ, Sch Publ Hlth, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD DEC PY 2009 VL 11 IS 6 BP 898 EP 899 PG 2 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 535MU UT WOS:000272974100119 ER PT J AU Batchelor, TT de Bono, JS Wen, PY Drappatz, J Plotkin, SR Hochberg, FH Chi, AS Harris, D Barriuso, J Frentzas, S Robertson, J Xu, Q Liu, Q AF Batchelor, T. T. de Bono, J. S. Wen, P. Y. Drappatz, J. Plotkin, S. R. Hochberg, F. H. Chi, A. S. Harris, D. Barriuso, J. Frentzas, S. Robertson, J. Xu, Q. Liu, Q. TI A PHASE I, OPEN LABEL, MULTICENTER STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF CEDIRANIB (RECENTINTM) IN COMBINATION WITH LOMUSTINE CHEMOTHERAPY FOR PATIENTS WITH RECURRENT GLIOBLASTOMA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 3rd Quadrennial Meeting of the World-Federation-of-Neuro-Oncoloyg/6th Meeting of the Asian-Society-for-Neuro-Oncology CY MAY 11-14, 2009 CL Yokohama, JAPAN SP World Federat Neuro Oncol, Asian Soc Neuro Oncol C1 [Batchelor, T. T.; de Bono, J. S.; Plotkin, S. R.; Hochberg, F. H.; Chi, A. S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Neurooncol,Dept Neurol, Boston, MA USA. [de Bono, J. S.; Harris, D.; Barriuso, J.; Frentzas, S.] Royal Marsden Hosp, Inst Canc Res, London SW3 6JJ, England. [Wen, P. Y.; Drappatz, J.] Harvard Univ, Sch Med, Ctr Neurooncol, Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Robertson, J.; Xu, Q.; Liu, Q.] AstraZeneca, London, England. NR 0 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD DEC PY 2009 VL 11 IS 6 BP 905 EP 905 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 535MU UT WOS:000272974100145 ER PT J AU Gilbert, MR Wen, PY Kuhn, J Prados, M Cloughesy, T AF Gilbert, Mark R. Wen, Patrick Y. Kuhn, John Prados, Michael Cloughesy, Timothy TI MULTIARM COMBINATORIAL STUDY OF SIGNAL TRANSDUCTION MODULATORS USING A SEQUENTIAL ACCRUAL DESIGN: A REPORT OF THE NORTH AMERICAN BRAIN TUMOR CONSORTIUM (NABTC) 0502 SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 3rd Quadrennial Meeting of the World-Federation-of-Neuro-Oncoloyg/6th Meeting of the Asian-Society-for-Neuro-Oncology CY MAY 11-14, 2009 CL Yokohama, JAPAN SP World Federat Neuro Oncol, Asian Soc Neuro Oncol C1 [Gilbert, Mark R.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA. [Wen, Patrick Y.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kuhn, John] Univ Texas San Antonio, San Antonio, TX USA. [Prados, Michael] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Cloughesy, Timothy] Univ Calif Los Angeles, Los Angeles, CA USA. RI Gilbert, Mark/J-7494-2016 OI Gilbert, Mark/0000-0003-2556-9722 NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD DEC PY 2009 VL 11 IS 6 BP 905 EP 905 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 535MU UT WOS:000272974100146 ER PT J AU Macdonald, DR Chang, SM van den Bent, MJ Vogelbaum, MA Wen, PY AF Macdonald, David R. Chang, Susan M. van den Bent, Martin. J. Vogelbaum, Michael A. Wen, Patrick Y. TI RESPONSE ASSESSMENT IN NEURO-ONCOLOGY SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 3rd Quadrennial Meeting of the World-Federation-of-Neuro-Oncoloyg/6th Meeting of the Asian-Society-for-Neuro-Oncology CY MAY 11-14, 2009 CL Yokohama, JAPAN SP World Federat Neuro Oncol, Asian Soc Neuro Oncol C1 [Macdonald, David R.] London Reg Canc Program, Dept Oncol, London, ON, Canada. [Chang, Susan M.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA. [van den Bent, Martin. J.] Rotterdam Canc Ctr, Dept Neurooncol, Rotterdam, Netherlands. [Vogelbaum, Michael A.] Cleveland Clin Fdn, Dept Neurosurg, Cleveland, OH 44195 USA. [Wen, Patrick Y.] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD DEC PY 2009 VL 11 IS 6 BP 906 EP 906 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 535MU UT WOS:000272974100151 ER PT J AU Chi, SN AF Chi, Susan N. TI MEDULLOBLASTOMA IN INFANTS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 3rd Quadrennial Meeting of the World-Federation-of-Neuro-Oncoloyg/6th Meeting of the Asian-Society-for-Neuro-Oncology CY MAY 11-14, 2009 CL Yokohama, JAPAN SP World Federat Neuro Oncol, Asian Soc Neuro Oncol C1 [Chi, Susan N.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD DEC PY 2009 VL 11 IS 6 BP 910 EP 910 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 535MU UT WOS:000272974100167 ER PT J AU Chi, AS Gerstner, ER Eichler, AF Chea, HK Shearer, N Drappatz, J Wen, PY Ivy, SP Loeffler, JS Sorensen, AG Jain, RK Batchelor, TT AF Chi, Andrew S. Gerstner, Elisabeth R. Eichler, April F. Chea, Houng K. Shearer, Nancy Drappatz, Jan Wen, Patrick Y. Ivy, S. Percy Loeffler, Jay S. Sorensen, A. Gregory Jain, Rakesh K. Batchelor, Tracy T. TI A PHASE IB TRIAL OF CEDIRANIB IN ADDITION TO STANDARD TEMOZOLOMIDE AND RADIATION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 3rd Quadrennial Meeting of the World-Federation-of-Neuro-Oncoloyg/6th Meeting of the Asian-Society-for-Neuro-Oncology CY MAY 11-14, 2009 CL Yokohama, JAPAN SP World Federat Neuro Oncol, Asian Soc Neuro Oncol C1 [Chi, Andrew S.; Gerstner, Elisabeth R.; Eichler, April F.; Chea, Houng K.; Shearer, Nancy; Batchelor, Tracy T.] Massachusetts Gen Hosp, Dept Neurol, Div Neurooncol, Boston, MA 02114 USA. [Drappatz, Jan; Wen, Patrick Y.] Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA USA. [Ivy, S. Percy] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA. [Loeffler, Jay S.; Jain, Rakesh K.] Harvard Univ, Sch Med, Dept Radiat Oncol, Massachusetts Gen Hosp, Boston, MA USA. [Sorensen, A. Gregory] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD DEC PY 2009 VL 11 IS 6 BP 946 EP 947 PG 2 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 535MU UT WOS:000272974100333 ER PT J AU Hakimi, K Kinney, G Kraft, G Micklesen, P Robinson, L AF Hakimi, Kevin Kinney, Greg Kraft, George Micklesen, Paula Robinson, Lawrence TI Reliability in Interpretation of Median Somatosensory Evoked Potentials in the Setting of Coma: Factors and Implications SO NEUROCRITICAL CARE LA English DT Article DE Cerebral anoxia; Coma; Somatosensory evoked potentials; Interobserver variation; Hypoxic ischemic encephalopathy; Median nerve ID ANOXIC-ISCHEMIC COMA AB Median nerve short-latency somatosensory evoked potentials (SSEPs) are useful in determining prognosis for awakening after coma following hypoxic ischemic encephalopathy, but reliability of interpretation is unclear. To measure inter- and intra-observer reliability of determining presence or absence of SSEPs in comatose patients following hypoxic ischemic encephalopathy and to identify factors that enhance reliability. Retrospective review by four readers (experience ranging from 2-27 years) of SSEP recordings in 95 comatose patients. Twenty waveforms were presented twice and five waveforms were presented pre- and post-neuromuscular junction (NMJ) blockade. Academic teaching hospital and level 1 trauma center. Inpatients in coma due to hypoxic ischemic encephalopathy. Kappa values among the four readers, reflecting inter-observer reliability, ranged from 0.39 to 0.79 (mean 0.60, SD 0.16), a level of agreement interpreted as "moderate." Better inter-observer reliability was seen when: cortical amplitudes were a parts per thousand yen0.7 mu V, baseline noise was smaller, and when experience level between reviewers was most similar. In cases examined both pre- and post-NMJ blockade, average kappa values of inter-observer reliability increased significantly from 0.03 pre-NMJ blockade to 0.41 post-NMJ blockade. Intra-observer reliability was higher than that for inter-observer, with a "substantial" average kappa of 0.84 (range 0.79-0.89, SD .06). Inter- and intra-observer reliability of SSEP interpretation in comatose patients varies from moderate to substantial, respectively. In order to reliably interpret the presence of small cortical responses, NMJ blockade should be used when baseline noise is excessive. C1 [Hakimi, Kevin] VA Puget Sound Hlth Care Syst, Rehabil Care Serv 117, Seattle, WA 98108 USA. [Hakimi, Kevin; Kinney, Greg; Kraft, George; Micklesen, Paula; Robinson, Lawrence] Univ Washington, Sch Med, Harborview Med Ctr, Dept Rehabil Med, Seattle, WA 98195 USA. RP Hakimi, K (reprint author), VA Puget Sound Hlth Care Syst, Rehabil Care Serv 117, 1660 S Columbian Way, Seattle, WA 98108 USA. EM khakimi@u.washington.edu; lorenzo@u.washington.edu FU Harborview Medical Center; University of Washington FX This work was supported by the Department of Rehabilitation Medicine, Harborview Medical Center, University of Washington School of Medicine. NR 8 TC 4 Z9 4 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1541-6933 J9 NEUROCRIT CARE JI Neurocrit. Care PD DEC PY 2009 VL 11 IS 3 BP 353 EP 361 DI 10.1007/s12028-009-9251-7 PG 9 WC Critical Care Medicine; Clinical Neurology SC General & Internal Medicine; Neurosciences & Neurology GA 521SH UT WOS:000271943800009 PM 19649750 ER PT J AU Zhang, L Xiao, C Wang, JK Zhang, LC Zeng, YM AF Zhang, Lin Xiao, Chun Wang, Jun-Ke Zhang, Li-Cai Zeng, Yin-Ming TI Activation of extracellular signal-regulated protein kinases 5 in the spinal cord contributes to the neuropathic pain behaviors induced by CCI in rats SO NEUROLOGICAL RESEARCH LA English DT Article DE Extracellular signal-regulated protein kinase 5; spinal cord; neuropathic pain; CCI; mitogen-activated protein kinase; cAMP response-element binding protein ID SYNAPTIC PLASTICITY; INFLAMMATORY PAIN; HYPERALGESIA; NEURONS; PATHWAY; EXPRESSION; ERK5 AB Objective: To investigate whether activation and translocation of extracellular signal-regulated kinase 5 (ERK5) is involved in the induction and maintenance of neuropathic pain and observe the effects of activation and translocation of ERK5 on the expression of phosphorylated cAMP response element binding (pCREB) in the chronic neuropathic pain. Methods: Lumbar intrathecal catheters were chronically implanted in male Sprague-Dawley rats. The left sciatic nerve was loosely ligated proximal to the sciatica's trifurcation at similar to 1.0 mm intervals with 4-0 silk sutures. The phosphorothioate-modified antisense oligonucleotides (AS-ODNs) were intrathecally administered every 12 hours, 1 day pre-chronic constriction injury (CCI) and 3 day post-CCI. Thermal and mechanical nociceptive thresholds were assessed with the paw withdrawal latency to a radiant heat and von Frey filaments. Expressions of phosphorylated ERK5 (pERK5), pCREB, were assessed by both Western blotting and immunohistochemical analysis. Results: Intrathecal injection of ERK5 AS-ODN significantly attenuated CCI-induced mechanical allodynia and thermal hyperalgesia. CCI significantly increased the expression of pERK5 neurons in the ipsilateral spinal dorsal horn to injury, not in the contralateral spinal dorsal horn. The time courses of pERK5 expression showed that the levels of both cytosol and nuclear pERK5 were increased at all points after CCI and reached a peak level on post-operative day 5. CCI significantly increased the expression of pERK5 neurons in the laminae I and II of ipsilateral spinal dorsal horn to injury, not in the contralateral spinal dorsal horn. Phospho-CREB-positive neurons were distributed in all laminae of the bilateral spinal cord. Intrathecal injection AS-ODN markedly suppressed the increase of CCI-induced pERK5, pCREB expression in the spinal cord. Conclusion: The activation of ERK5 pathways contributes to neuropathic pain in CCI rats, and the function of pERK5 may partly be accomplished via the CREB protein-dependent gene expression. [Neurol Res 2009; 31: 1037-1043] C1 [Zhang, Lin; Xiao, Chun; Zhang, Li-Cai; Zeng, Yin-Ming] Jiangsu Inst Anesthesiol, Jiangsu Key Lab Anesthesiol, Xuzhou 221002, Peoples R China. [Zhang, Lin] Qingdao Univ, Dept Anesthesia, Affiliated Hosp 1, Coll Med, Qingdao, Peoples R China. [Zhang, Lin] Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. [Zhang, Lin] Harvard Univ, Sch Med, Boston, MA USA. [Wang, Jun-Ke] China Med Univ, Dept Anesthesia, Affiliated Hosp 1, Shenyang, Peoples R China. RP Zhang, L (reprint author), Jiangsu Inst Anesthesiol, Jiangsu Key Lab Anesthesiol, 99 Huaihai W Rd, Xuzhou 221002, Peoples R China. EM licaizhang001@163.com FU National Natural Science Foundation of China [30871307]; Jiangsu Key Laboratory of Anesthesiology Open Foundation [KJS050001] FX This work was supported in part by a grant from the National Natural Science Foundation of China (no. 30871307) and the Open Research Center grant, Jiangsu Key Laboratory of Anesthesiology Open Foundation (no. KJS050001). NR 22 TC 2 Z9 3 U1 0 U2 2 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 0161-6412 J9 NEUROL RES JI Neurol. Res. PD DEC PY 2009 VL 31 IS 10 BP 1037 EP 1043 DI 10.1179/174313209X405128 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 530XR UT WOS:000272626800006 PM 19426589 ER PT J AU Balcioglu, A Ren, JQ McCarthy, D Spencer, TJ Biederman, J Bhide, PG AF Balcioglu, Aygul Ren, Jia-Qian McCarthy, Deirdre Spencer, Thomas J. Biederman, Joseph Bhide, Pradeep G. TI Plasma and brain concentrations of oral therapeutic doses of methylphenidate and their impact on brain monoamine content in mice SO NEUROPHARMACOLOGY LA English DT Article DE Methylphenidate; Ritalinic acid; Dopamine; Striatum; Frontal cortex ID DEFICIT HYPERACTIVITY DISORDER; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; THREO-METHYLPHENIDATE; TISSUE DISTRIBUTION; EARLY EXPOSURE; DOPAMINE; RATS; ENANTIOMERS; PHARMACOKINETICS; CHILDREN AB Methylphenidate is a frequently prescribed stimulant for the treatment of attention deficit hyperactivity disorder (ADHD). An important assumption in the animal models that have been employed to study methylphenidate's effects on the brain and behavior is that bioavailability of methylphenidate in the animal models reflects that in human subjects. From this perspective, the dose and route of administration of methylphenidate assume critical importance because both these factors likely influence rate of uptake, plasma and brain concentrations of the drug. In the present study, plasma and brain concentrations of D- and L-methylphenidate and D- and L-ritalinic acid were measured in 2-month old mice (equivalent to young adulthood in humans) following a single oral administration of a racemic mixture. Our data show that oral administration of 0.75 mg/kg dose produced within 15 min, plasma levels of D-methylphenidate that correspond to the clinically effective plasma levels in human subjects (estimated to be 6-10 ng/ml). Brain concentrations of D- and L-methylpheniclate tended to exceed their plasma concentrations, while the plasma concentrations Of D- and L-ritalinic acid exceeded their brain concentrations. A single oral administration at 0.75 mg/kg dose increased dopamine content of the frontal cortex within I h, without producing statistically significant changes in serotonin or noradrenaline contents. Striatal monoamine levels remained unaltered. These data highlight disparities between plasma and brain concentrations of methylphenidate and its metabolites following oral administration and illustrate brain region- and moncamine-specific changes produced by the low oral dose of methylphenidate. (C) 2009 Elsevier Ltd. All rights reserved. C1 [Balcioglu, Aygul; Ren, Jia-Qian; McCarthy, Deirdre; Spencer, Thomas J.; Biederman, Joseph; Bhide, Pradeep G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Balcioglu, Aygul; Ren, Jia-Qian; McCarthy, Deirdre; Spencer, Thomas J.; Biederman, Joseph; Bhide, Pradeep G.] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Bhide, PG (reprint author), Massachusetts Gen Hosp, 149 13th St, Charlestown, MA 02129 USA. EM Bhide@helix.mgh.harvard.edu OI Bhide, Pradeep/0000-0003-4236-9415 FU PHS [R01 DA020796]; Pediatric Psycho pharmacology Philanthropic Fund; Massachusetts General Hospital, Boston, MA FX Analysis of plasma and brain methylphenidate concentrations were performed by Drs. Rodger Foltz and Shen-Nan Lin of the Human Toxicology Research Center at the University of Utah, Salt Lake City, UT under an NIH-NIDA sponsored program. We thank Dr. Michael Schwarzschild, Massachusetts General Hospital, Boston, MA for giving us access to the HPLC facility in his laboratory. This study was supported by PHS grant R01 DA020796. Additional partial support was received from The Pediatric Psycho pharmacology Philanthropic Fund, Massachusetts General Hospital, Boston, MA. NR 45 TC 25 Z9 26 U1 1 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3908 J9 NEUROPHARMACOLOGY JI Neuropharmacology PD DEC PY 2009 VL 57 IS 7-8 BP 687 EP 693 DI 10.1016/j.neuropharm.2009.07.025 PG 7 WC Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA 521ZE UT WOS:000271964500014 PM 19631228 ER PT J AU Thase, ME AF Thase, Michael E. TI Atypical Depression: Useful Concept, but it's Time to Revise the DSM-IV Criteria SO NEUROPSYCHOPHARMACOLOGY LA English DT Article DE DSM-IV; atypical depression; MAOIs; mood reactivity; reverse neurovegetative features ID ANERGIC BIPOLAR DEPRESSION; DOUBLE-BLIND CROSSOVER; STAR-ASTERISK-D; AGE-OF-ONSET; MAJOR DEPRESSION; NEUROVEGETATIVE SYMPTOMS; RECURRENT DEPRESSION; HYSTEROID DYSPHORIA; OXIDASE-INHIBITORS; FEATURES AB Stewart et al (2009) have outlined the evidence in support of the validity of the DSM-IV definition of the 'With Atypical Features' episode specifier. Although recognizing the historical significance and clinical utility of the concept of atypical depression, this article takes issue with the DSM-IV criteria. It is concluded that mood reactivity, the A or obligative criterion, is neither significantly associated with the other symptomatic criteria nor useful to diagnose atypical depression, and thus should be eliminated. Problems with operationalization, specification, and reliability of ratings of the diagnostic criteria further limit validity. Despite these limitations in classification, many of the features associated with atypical depression are linked to an early onset of affective illness, including trait-like interpersonal sensitivity, comorbid social anxiety and agoraphobia, a history of childhood physical or sexual trauma, and indicators of the 'soft' side of the bipolar spectrum. Neurophysiologic studies also suggest that chronic, early-onset atypical depressions differ from both melancholia and normality. Re-analyses of the Columbia group's seminal studies suggest that preferential response to phenelzine vs imipramine-arguably the strongest validator of atypical depression-similarly appears to be limited to patients with chronic, early-onset syndromes. The criteria for atypical depression need to be revised in DSM-V, including sharpening the operational definitions for the specific symptoms. The importance of age of onset and comorbid anxiety warrant further study. Research examining the validity of a subform of atypical depression characterized by trait-like interpersonal sensitivity and a chronic, early-onset course may further enhance the clinical utility of the DSM-V classification. Neuropsychopharmacology (2009) 34, 2633-2641; doi:10.1038/npp.2009.100; published online 9 September 2009 C1 [Thase, Michael E.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 15213 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 15213 USA. RP Thase, ME (reprint author), Univ Penn, Sch Med, Dept Psychiat, 3535 Market St,Suite 670, Philadelphia, PA 15213 USA. EM thase@mail.med.upenn.edu NR 65 TC 29 Z9 30 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD DEC PY 2009 VL 34 IS 13 BP 2633 EP 2641 DI 10.1038/npp.2009.100 PG 9 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 517TC UT WOS:000271639700005 PM 19741592 ER PT J AU Jacobs, JV Lou, JS Kraakevik, JA Horak, FB AF Jacobs, J. V. Lou, J. S. Kraakevik, J. A. Horak, F. B. TI THE SUPPLEMENTARY MOTOR AREA CONTRIBUTES TO THE TIMING OF THE ANTICIPATORY POSTURAL ADJUSTMENT DURING STEP INITIATION IN PARTICIPANTS WITH AND WITHOUT PARKINSON'S DISEASE SO NEUROSCIENCE LA English DT Article DE gait; balance; posture; cerebral cortex; transcranial magnetic stimulation ID TRANSCRANIAL MAGNETIC STIMULATION; STRIDE LENGTH REGULATION; LATERAL PREMOTOR CORTEX; LOW-FREQUENCY RTMS; GAIT APRAXIA; SURFACE EMG; LEG AREA; EXCITABILITY; RESPONSES; MOVEMENT AB The supplementary motor area (SMA) is thought to contribute to the generation of anticipatory postural adjustments (APAs, which act to stabilize supporting body segments prior to movement), but its precise role remains unclear. In addition, participants with Parkinson's disease (PD) exhibit impaired function of the SMA as well as decreased amplitudes and altered timing of the APA during step initiation, but the contribution of the SMA to these impairments also remains unclear. To determine how the SMA contributes to generating the APA and to the impaired APAs of participants with PD, we examined the voluntary steps of eight participants with PD and eight participants without PD, before and after disrupting the SMA and dorsolateral premotor cortex (dIPMC), in separate sessions, with 1-Hz repetitive transcranial magnetic stimulation (rTMS). Both groups exhibited decreased durations of their APAs after rTMS over the SMA but not over the dIPMC. Peak amplitudes of the APAs were unaffected by rTMS to either site. The symptom severity of the participants with PD positively correlated with the extent that rTMS over the SMA affected the durations of their APAs. The results suggest that the SMA contributes to the timing of the APA and that participants with PD exhibit impaired timing of their APAs, in part, due to progressive dysfunction of circuits associated with the SMA. (C) 2009 IBRO. Published by Elsevier Ltd. All rights reserved. C1 [Jacobs, J. V.] Univ Vermont, Dept Rehabil & Movement Sci, Burlington, VT 05405 USA. [Lou, J. S.; Kraakevik, J. A.; Horak, F. B.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Kraakevik, J. A.] Portland VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Portland, OR USA. RP Jacobs, JV (reprint author), Univ Vermont, Dept Rehabil & Movement Sci, Burlington, VT 05405 USA. EM JJacobs@uvm.edu FU National Institute of Neurological Disorders and Stroke [F31NS048800]; National Institute of Aging [AG-06457] FX Acknowledgments-We thank our research participants for their participation, Andrew Owings and Ryan Eaton for hardware assistance, George Knafl for statistical consultation, as well as Dr. John Nutt and the staff of the Parkinson's Center of Oregon for their help with participant recruitment. We also thank Triana Nagel-Nelson and the other members of the Balance Disorders Laboratory for assisting the participants during data collection. This research was supported by the National Institutes of Health grants F31NS048800 (Jacobs) from the National Institute of Neurological Disorders and Stroke and AG-06457 (Horak) from the National Institute of Aging. NR 60 TC 61 Z9 62 U1 3 U2 18 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 J9 NEUROSCIENCE JI Neuroscience PD DEC 1 PY 2009 VL 164 IS 2 BP 877 EP 885 DI 10.1016/j.neuroscience.2009.08.002 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 518YI UT WOS:000271731700052 PM 19665521 ER PT J AU LaSala, CA AF LaSala, Cynthia Ann TI Moral Accountability and Integrity in Nursing Practice SO NURSING CLINICS OF NORTH AMERICA LA English DT Article DE Ethics; Nursing; Moral accountability; Integrity; Moral agency ID WORK-ENVIRONMENT AB The therapeutic nature of the nurse-patient relationship is grounded in an ethic of caring. Florence Nightingale envisioned nursing as an art and a science...a blending of humanistic, caring presence with evidence-based knowledge and exquisite skill. In this article, the author explores the caring practice of nursing as a framework for understanding moral accountability and integrity in practice. Being morally accountable and responsible for one's judgment and actions is central to the nurse's role as a moral agent. Nurses who practice with moral integrity possess a strong sense of themselves and act in ways consistent with what they understand is the right thing to do. A review of the literature related to caring theory, the concepts of moral accountability and integrity, and the documents that speak of these values and concepts in professional practice (eg, Code of Ethics for Nurses with Interpretive Statements, Nursing's Social Policy Statement) are presented in this article. C1 [LaSala, Cynthia Ann] Massachusetts Gen Hosp, Dept Nursing, Boston, MA 02114 USA. [LaSala, Cynthia Ann] Amer Nurses Assoc, Ctr Eth & Human Rights, Silver Spring, MD 20910 USA. RP LaSala, CA (reprint author), Massachusetts Gen Hosp, Dept Nursing, 55 Fruit St, Boston, MA 02114 USA. EM clasala@partners.org NR 32 TC 2 Z9 4 U1 1 U2 12 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0029-6465 J9 NURS CLIN N AM JI Nurs. Clin. North Am. PD DEC PY 2009 VL 44 IS 4 BP 423 EP + DI 10.1016/j.cnur.2009.07.006 PG 13 WC Nursing SC Nursing GA 529MT UT WOS:000272522200005 PM 19850179 ER PT J AU Horton, ES AF Horton, Edward S. TI Effects of Lifestyle Changes to Reduce Risks of Diabetes and Associated Cardiovascular Risks: Results from Large Scale Efficacy Trials SO OBESITY LA English DT Article ID IMPAIRED GLUCOSE-TOLERANCE; PHYSICAL-ACTIVITY; PREVENTION PROGRAM; METABOLIC SYNDROME; WEIGHT-GAIN; CARDIORESPIRATORY FITNESS; INSULIN-RESISTANCE; FASTING GLUCOSE; MELLITUS; DISEASE AB The increasing prevalence of type 2 diabetes throughout the world is now recognized as a major health problem. A growing segment of the population has impaired glucose tolerance (IGT), which is a strong predictor of progression to type 2 diabetes. Further, 24% of Americans now meet the criteria for the metabolic syndrome, a risk factor for both type 2 diabetes and cardiovascular disease (CVD). The diabetes epidemic is associated with changes in lifestyle-most notably increased energy intake, changes in diet composition and decreased levels of physical activity-and the development of overweight and obesity. This review examines the effects of several intensive lifestyle intervention trials on the risk of diabetes and CVD among high-risk populations. Common features of these lifestyle interventions are dietary modification, weight loss and increased physical activity. These trials indicate that lifestyle modification is effective in decreasing the progression from IGT to type 2 diabetes and reducing CVD risk factors. However, the effectiveness of lifestyle interventions for reductions in CVD events has yet to be determined. C1 Joslin Diabet Ctr, Sect Clin Res, Boston, MA 02215 USA. RP Horton, ES (reprint author), Joslin Diabet Ctr, Sect Clin Res, Boston, MA 02215 USA. EM edward.horton@joslin.harvard.edu NR 43 TC 49 Z9 49 U1 0 U2 5 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1930-7381 J9 OBESITY JI Obesity PD DEC PY 2009 VL 17 BP S43 EP S48 DI 10.1038/oby.2009.388 PG 6 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 523RB UT WOS:000272091000008 PM 19927146 ER PT J AU Chan, AT Ogino, S Fuchs, CS AF Chan, Andrew T. Ogino, Shuji Fuchs, Charles S. TI Aspirin Use and Survival After Diagnosis of Colorectal Cancer EDITORIAL COMMENT SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Editorial Material C1 [Chan, Andrew T.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. Harvard Univ, Dept Epidemiol, Sch Publ Hlth, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA. RP Chan, AT (reprint author), Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7828 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD DEC PY 2009 VL 64 IS 12 BP 803 EP 805 PG 3 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 529SM UT WOS:000272537500018 ER PT J AU Mischoulon, D AF Mischoulon, David TI Update and Critique of Natural Remedies as Antidepressant Treatments SO OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA LA English DT Article DE Omega-3; St John's wort; Hypericum; S-Adenosyl methionine; SAMe; Eicosapentaenoic; Docosahexaenoic; Depression ID ST-JOHNS-WORT; MAJOR DEPRESSIVE DISORDER; PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED-TRIAL; ETHYL-EICOSAPENTAENOIC ACID; ADENOSYL-L-METHIONINE; DOUBLE-BLIND TRIAL; POLYUNSATURATED FATTY-ACIDS; TO-MODERATE DEPRESSION; HYPERICUM-PERFORATUM AB The popularity of natural or "alternative" remedies to treat medical and psychiatric disorders has accelerated dramatically over the past decade, in the United States and worldwide. This article reviews the evidence for clinical efficacy, active ingredients, mechanisms of action, recommended dosages, and toxicities of the 3 best-studied putative natural antidepressants, St. John's wort (hypericum), S-adenosyl methionine, and the Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid. Despite growing evidence for efficacy and safety, more comprehensive studies are required before these remedies can be recommended as safe and effective alternatives or adjuncts to conventional psychotropic agents. There are limited data regarding safety in pregnancy and during lactation, and caution is therefore recommended in women who are pregnant or breastfeeding. C1 [Mischoulon, David] Massachusetts Gen Hosp, Dept Psychiat, Depress Clin & Res Program, Boston, MA 02114 USA. [Mischoulon, David] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Mischoulon, D (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Depress Clin & Res Program, 50 Staniford St,Suite 401, Boston, MA 02114 USA. EM dmischoulon@partners.org FU Schwabe; NordicNaturals; Amarin (Laxdale Ltd); Lichtwer; Cederroth; SwissMedica; Ganeden; Bristol-Meyers-Squibb (BMS); National Center for Complementary and Alternative Medicine [5K23AT001129-05] FX The author has received research support from the following companies: Schwabe, NordicNaturals, Amarin (Laxdale Ltd), Lichtwer, Cederroth, SwissMedica, Ganeden, and Bristol-Meyers-Squibb (BMS). He has received honoraria from BMS, Pfizer, Pamlab, Virbac, Nordic Naturals, and Reed Medical Education/MGH Psychiatry Academy (commercial entities supporting the MGH Psychiatry Academy are listed on the Academy's Web site http://www.mghcme.org). He has received royalty income from Back Bay Scientific. This publication was made possible in part by grant number 5K23AT001129-05 from the National Center for Complementary and Alternative Medicine. Its contents are solely the responsibility of the author and do not necessarily represent the official views of the National Center for Complementary and Alternative Medicine, National Institutes of Health. NR 116 TC 11 Z9 11 U1 3 U2 13 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8545 J9 OBSTET GYN CLIN N AM JI Obstet. Gynecol. Clin. N. Am. PD DEC PY 2009 VL 36 IS 4 BP 789 EP + DI 10.1016/j.ogc.2009.10.005 PG 20 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 575BD UT WOS:000276037200006 PM 19944301 ER PT J AU Barnes, JA Abramson, JS AF Barnes, Jeffrey A. Abramson, Jeremy S. TI Adult T-cell Leukemia/Lymphoma: Complexities in Diagnosis and Novel Treatment Strategies The Tobinai Article Reviewed SO ONCOLOGY-NEW YORK LA English DT Editorial Material C1 [Barnes, Jeffrey A.] Massachusetts Gen Hosp, Ctr Canc, Lymphoma Program Instructor Med, Ctr Lymphoma, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Barnes, JA (reprint author), Massachusetts Gen Hosp, Ctr Canc, Lymphoma Program Instructor Med, Ctr Lymphoma, Boston, MA 02114 USA. NR 15 TC 1 Z9 1 U1 0 U2 0 PU UBM MEDICA PI NORWALK PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA SN 0890-9091 J9 ONCOLOGY-NY JI Oncology-NY PD DEC PY 2009 VL 23 IS 14 BP 1267 EP 1270 PG 2 WC Oncology SC Oncology GA V18PX UT WOS:000208017800006 PM 20120839 ER PT J AU Salomatina-Motts, E Neel, VA Yaroslavskaya, AN AF Salomatina-Motts, E. Neel, V. A. Yaroslavskaya, A. N. TI Multimodal polarization system for imaging skin cancer SO OPTICS AND SPECTROSCOPY LA English DT Article ID OPTICAL COHERENCE TOMOGRAPHY; BASAL-CELL CARCINOMA; IN-VIVO; FLUORESCENCE SPECTROSCOPY; TUMOR SIZE; SURGERY; LIGHT; HISTOPATHOLOGY; MICROSCOPY; EXCISIONS AB An optical system is created that is capable of detecting tumor formations in vivo in real time by means of the spectrally resolved polarization imaging of light elastically scattered by tissue and imaging of fluorescence polarization of exogenous fluorophores. The performance characteristics of the system, such as the resolution, field of view, and power density and stability of the radiation, as well as the calibration G factor, are determined. The functionality of the system is tested under clinical conditions. Spectrally resolved signals of elastic scattering and fluorescence polarization images are detected both from the wound surface in vivo and from the bioptic material. The reliability of the method is proven by comparing the results with the data of histological studies. C1 [Salomatina-Motts, E.; Neel, V. A.; Yaroslavskaya, A. N.] Wellman Ctr Photomed, Boston, MA 02114 USA. [Salomatina-Motts, E.; Neel, V. A.; Yaroslavskaya, A. N.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Yaroslavskaya, A. N.] Harvard Univ, Dept Dermatol, Boston, MA 02114 USA. RP Salomatina-Motts, E (reprint author), Wellman Ctr Photomed, Boston, MA 02114 USA. EM Yaroslav@helix.mgh.harvard.edu NR 33 TC 14 Z9 14 U1 0 U2 4 PU MAIK NAUKA/INTERPERIODICA/SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA SN 0030-400X J9 OPT SPECTROSC+ JI Opt. Spectrosc. PD DEC PY 2009 VL 107 IS 6 BP 884 EP 890 DI 10.1134/S0030400X0912008X PG 7 WC Optics; Spectroscopy SC Optics; Spectroscopy GA 537DT UT WOS:000273093900008 ER PT J AU Sonis, ST AF Sonis, Stephen T. TI Mucositis: The impact, biology and therapeutic opportunities of oral mucositis SO ORAL ONCOLOGY LA English DT Review DE Mucositis; Review; Toxicity; Radiation; Chemotherapy ID STEM-CELL TRANSPLANTATION; HERPES-SIMPLEX-VIRUS; CHEMOTHERAPY-INDUCED MUCOSITIS; NF-KAPPA-B; CANCER-PATIENTS; CONTROLLED-TRIAL; NECK-CANCER; HEMATOLOGIC CANCERS; INTENSIVE THERAPY; GROWTH-FACTOR AB The history of mucositis is as old as radiation- and chemotherapy. Despite being regularly reported and documented as one of the worst side effects of cancer therapy, relatively little was appreciated about the complexities of mucositis' pathogenesis until relatively recently. More frustrating for patients and clinicians, no effective treatment existed. Fortunately, the situation is changing; ongoing research is leading to a comprehensive understanding of the biology of mucositis, which has resulted in the development of novel interventions. While the FDA's approval of palifermin in 2004 was limited to only a small percentage of the at-risk population, the fact that the first registered anti-OM agent derived its efficacy from its pleotropic activities was conceptually demonstrative of the therapeutic potential of drugs that selectively interfere with mucositis' pathogenesis. A number of eclectic molecules, all designed to interfere with pathways that lead to injury are in pre-clinical and clinical development. (C) 2009 Elsevier Ltd. All rights reserved. C1 Brigham & Womens Hosp, Harvard Farber Canc Ctr, Boston, MA 02115 USA. RP Sonis, ST (reprint author), Brigham & Womens Hosp, Harvard Farber Canc Ctr, 75 Francis St, Boston, MA 02115 USA. EM ssonis@partners.org FU Amgen, Inc.; Biomodels, LLC FX Dr. Sonis received a research grant from Amgen, Inc. and is a partner in Biomodels, LLC. NR 46 TC 122 Z9 128 U1 4 U2 15 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1368-8375 J9 ORAL ONCOL JI Oral Oncol. PD DEC PY 2009 VL 45 IS 12 BP 1015 EP 1020 DI 10.1016/j.oraloncology.2009.08.006 PG 6 WC Oncology; Dentistry, Oral Surgery & Medicine SC Oncology; Dentistry, Oral Surgery & Medicine GA 521QK UT WOS:000271937000004 PM 19828360 ER PT J AU Kim, JH Studer, RK Vo, NV Sowa, GA Kang, JD AF Kim, J. H. Studer, R. K. Vo, N. V. Sowa, G. A. Kang, J. D. TI p38 MAPK inhibition selectively mitigates inflammatory mediators and VEGF production in AF cells co-cultured with activated macrophage-like THP-1 cells SO OSTEOARTHRITIS AND CARTILAGE LA English DT Article DE Low back pain; Macrophages; Annulus fibrosus; p38 MAPK; SB202190 ID ENDOTHELIAL GROWTH-FACTOR; INTERVERTEBRAL DISC DEGENERATION; NUCLEUS PULPOSUS CELLS; NECROSIS-FACTOR-ALPHA; NEUROPATHIC PAIN; GENE-EXPRESSION; KAPPA-B; ANGIOGENESIS; INTERLEUKIN-6; CHONDROCYTES AB Objectives: Recent data have suggested that macrophages are involved in the pathogenesis of discogenic back pain and enhance the secretion of inflammatory mediators in co-cultured annulus fibrosus (AF) cells. The purpose of these studies is to determine the role of p38 mitogen-activated protein kinase (p38 MAPK) signaling in the interactions between macrophage and AF cells. Methods: Human AF cells were co-cultured with phorbol myristate acetate-stimulated macrophage-like THP-1 cells with and without p38 MAPK inhibition. Conditioned media from co-cultured cells were assayed for interleukin (IL)-6, IL-8, prostaglandin E2 (PGE2), PGF2 alpha, and vascular endothelial growth factor (VEGF). Naive and macrophage-exposed AF cell responses to 10 ng/ml tumor necrosis factor-alpha. (TNF-alpha) were compared using the same outcome measures. Results: IL-6, IL-8, PGE2, PGF2 alpha, and VEGF were secreted in greater quantities by cells maintained in co-culture compared to macrophages or AF cells cultured alone. SB202190 blunted IL-6, PGE2, and PGF2 alpha production in a dose-dependent manner in co-culture. However, it did not suppress IL-8 and VEGF production. TNF-alpha-stimulated AF cell inflammatory mediators were up-regulated by macrophage exposure. SB202190 successfully suppressed IL-6, IL-8, PGE2, and PGF2 alpha secretion in macrophage-exposed AF cells in response to TNF-alpha. Conclusions: Annular injury can result in macrophage infiltration, and this can cause enhanced inflammatory mediator and VEGF production by AF cells. The p38 MAPK pathway signals are responsible for much of IL-6 and PG secretion from AF cells with macrophage-like cells, suggesting that blockade of this signal may serve as a therapeutic approach to discogenic pain. (C) 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved. C1 [Kim, J. H.; Vo, N. V.; Kang, J. D.] Univ Pittsburgh, Ferguson Lab Orthopaed Res, Dept Orthopaed Surg, Sch Med, Pittsburgh, PA 15261 USA. [Kim, J. H.] Korea Univ, Coll Med, Dept Neurosurg, Seoul 136705, South Korea. [Studer, R. K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Sowa, G. A.] Univ Pittsburgh, Dept Phys Med & Rehabil, Sch Med, Pittsburgh, PA 15261 USA. RP Kang, JD (reprint author), Univ Pittsburgh, Ferguson Lab Orthopaed Res, Dept Orthopaed Surg, Sch Med, 200 Lothrop St,E1641 BST, Pittsburgh, PA 15261 USA. EM kangjd@upmc.edu FU Pittsburgh Foundation at Department of Orthopaedic Surgery, University of Pittsburgh FX Source of support: This work was supported by the Pittsburgh Foundation at Department of Orthopaedic Surgery, University of Pittsburgh. NR 43 TC 19 Z9 20 U1 1 U2 7 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 1063-4584 J9 OSTEOARTHR CARTILAGE JI Osteoarthritis Cartilage PD DEC PY 2009 VL 17 IS 12 BP 1662 EP 1669 DI 10.1016/j.joca.2009.06.004 PG 8 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA 535KI UT WOS:000272966700020 PM 19583958 ER PT J AU Fayad, JN Semaan, MT Meier, JC House, JW AF Fayad, Jose N. Semaan, Maroun T. Meier, Josh C. House, John W. TI Hearing Results Using the SMart Piston Prosthesis SO OTOLOGY & NEUROTOLOGY LA English DT Article; Proceedings Paper CT 2nd International Symposium of the Politzer-Society-on-Otosclerosis-and-Stapes-Surgery CY MAY 08-10, 2008 CL Biarritz, FRANCE SP Politzer Soc Otosclerosis & Stapes Surg DE Nitinol; Otosclerosis; Stapedectomy; Stapedotomy; SMart ID NITINOL STAPES PROSTHESIS; OTOSCLEROSIS SURGERY; STAPEDOTOMY; STAPEDECTOMY AB Objective: SMart, a newly introduced piston prosthesis for stapedotomy, is a nitinol-based, heat-activated, self-crimping prosthesis. We review our hearing results and postoperative complications using this self-crimped piston prosthesis and compare them with those obtained using stainless steel or platinum piston prostheses. Hypothesis: Audiometric results using the SMart piston are identical to those obtained using a conventional piston prosthesis. Study Design: Retrospective chart review. Setting: Private neurotologic tertiary referral center. Patients: The 416 ears reviewed included 306 with a SMart prosthesis and 110 conventional prostheses. 61% were women. Mean follow-up time was 5.6 ( standard deviation [SD], 6.3 mo) and 6.9 months (SD, 7.0 mo) for the 2 groups, respectively. Intervention: Stapedotomy using the SMart or a conventional (non-SMart) prosthesis. Main Outcome Measures: Audiometric hearing results, including pure-tone average ( PTA) and air-bone gap (ABG), and prevalence of postoperative complications. Results: Mean postoperative PTA was 32.6 (SD, 16.8) dB for the SMart group and 29.4 (SD, 13.5) dB for the non-SMart group, with ABGs of 7.6 (SD, 8.9) and 6.0 (SD, 5.2) dB, respectively. Mean change ( decrease) in ABG was 18.7 ( SD, 13.1) dB for the SMart group and 19.9 (SD, 10.3) dB for the non-SMart group. High-frequency bone PTAs showed overclosure of 2.0 (SD, 7.9) dB for the SMart group and 3.6 (SD, 8.6) dB for the non-SMart group. Postoperative vertigo and tinnitus were infrequent. No significant differences in these audiometric outcomes or complication rates were noted between groups. There was no significant difference in rate of gap closure to within10 dB (78.3 versus 84.2%, SMart and non-SMart, respectively) or 20 dB (94.2 and 98.0%). Conclusion: Compared with conventional stapes prostheses, the nitinol-based SMart is a safe and reliable stapes prosthesis that eliminates manual crimping without significantly altering the audiometric outcome. Complications are rare, but longer follow-up is needed before establishing long-term stability. C1 [Fayad, Jose N.; Semaan, Maroun T.; House, John W.] House Ear Clin, Los Angeles, CA 90057 USA. [Fayad, Jose N.; Semaan, Maroun T.; House, John W.] House Ear Res Inst, Los Angeles, CA USA. [Meier, Josh C.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. RP Fayad, JN (reprint author), House Ear Clin, 2100 West 3rd St,Suite 111, Los Angeles, CA 90057 USA. EM jfayad@hei.org NR 12 TC 14 Z9 14 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1531-7129 J9 OTOL NEUROTOL JI Otol. Neurotol. PD DEC PY 2009 VL 30 IS 8 BP 1122 EP 1127 DI 10.1097/MAO.0b013e3181be645d PG 6 WC Clinical Neurology; Otorhinolaryngology SC Neurosciences & Neurology; Otorhinolaryngology GA 586QU UT WOS:000276927300017 PM 19816231 ER PT J AU Keane, D Hynes, B Lamkin, R Houghtaling, C Zhou, L Aretz, T Ruskin, J AF Keane, David Hynes, Brian Lamkin, Robert Houghtaling, Christopher Zhou, Li Aretz, Thomas Ruskin, Jeremy TI Linear Radiofrequency Microcatheter Ablation Guided by Phased Array Intracardiac Echocardiography Combined with Temperature Decay SO PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY LA English DT Article DE catheter ablation; intracardiac echocardiography; temperature control; atrial fibrillation; temperature ID PARKINSON-WHITE SYNDROME; ATRIAL-FIBRILLATION; CATHETER ABLATION; SUBSTRATE MODIFICATION; TACHYCARDIA; LESIONS; GUIDANCE; ISTHMUS; CURE; TIP AB Methods: Sixty endocardial lesions were created in the atria and ventricles of six goats by simultaneous delivery of the radiofrequency current through two linear electrodes of a microcatheter with a central interelectrode thermocouple. Catheter placement was guided by fluoroscopy. A 7.5-MHz ICE transducer in the right atrium or ventricle assessed electrode contact. T90 and previously reported parameters of electrode contact and lesion formation were recorded. Histomorphometry was performed on the lesions. Results: T90 was 4.27 +/- 4.98 seconds. Lesion depth significantly correlated with ICE assessment of electrode contact (r = 0.56, P = 0.001); T90 upon radiofrequency current offset (r = 0.48, P = 0.008), impedance fall upon radiofrequency current onset (r = 0.37, P = 0.008), bipolar pacing threshold preablation (r = -0.56, P = 0.001), bipolar electrogram amplitude preablation (r = 0.43, P = 0.02), but not with fluoroscopic assessment of the electrode contact (r = 0.18, n.s.). For the prediction of achieving a lesion depth of > 2 mm, a T90 of > 4.0 seconds yielded a specificity of 86% and a sensitivity of 52%, ICE yielded a specificity and sensitivity of 58% and 68%, respectively, while the specificity and sensitivity of fluoroscopy were 26% and 68%, respectively. Both ICE and T90 provide additional clinical relevance during guidance of cardiac microcatheter ablation. (PACE 2009; 32:1543-1552). C1 [Keane, David; Hynes, Brian] St Vincents Univ Hosp, Cardiac Arrhythmia Serv, Dublin 4, Ireland. [Lamkin, Robert; Houghtaling, Christopher; Zhou, Li; Ruskin, Jeremy] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA 02114 USA. [Aretz, Thomas] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Hynes, B (reprint author), St Vincents Univ Hosp, Cardiac Arrhythmia Serv, Elm Pk, Dublin 4, Ireland. EM bghynes@hotmail.com FU Center for Innovative Minimally Invasive Therapy (CIMIT) at the Massachusetts General Hospital; Blum Family, Newton, MA; Cardima, Fremont CA FX This work is supported in part by research grants from the Center for Innovative Minimally Invasive Therapy (CIMIT) at the Massachusetts General Hospital; The Blum Family, Newton, MA; and Cardima, Fremont CA. NR 29 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0147-8389 J9 PACE JI PACE-Pacing Clin. Electrophysiol. PD DEC PY 2009 VL 32 IS 12 BP 1543 EP 1552 DI 10.1111/j.1540-8159.2009.02512.x PG 10 WC Cardiac & Cardiovascular Systems; Engineering, Biomedical SC Cardiovascular System & Cardiology; Engineering GA 521FP UT WOS:000271906100010 PM 19732360 ER PT J AU Haidet, P Fecile, ML West, HF Teal, CR AF Haidet, Paul Fecile, Mary Lynn West, Heather F. Teal, Cayla R. TI Reconsidering the team concept: Educational implications for patient-centered cancer care SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE Physician-patient relations; Patient-centered care; Medical oncology; Radiation oncology; Oncology service ID SKILLS TRAINING-PROGRAM; COMMUNICATION-SKILLS; PALLIATIVE CARE; FAMILY-MEMBERS; PHYSICIANS; ONCOLOGISTS; EFFICACY; INTERDISCIPLINARY; CURRICULUM AB Patient-centered cancer care has become a priority in the oncology field. Increasing efforts to train oncologists in communication skills have led to a growing literature on patient-centered cancer education. In addition, systems approaches have led to an increased emphasis on the concept of teams as an Organizing framework for cancer care. In this essay, we examine issues involved in educating teams to provide patient-centered cancer care. in the process, we question the applicability of a tightly coordinated 'team' concept, and suggest the concept of a 'care community' as a more achievable ideal for the way that cancer care is commonly delivered. We discuss the implications that this has for cancer communication education, and Propose three principles to guide the development of educational interventions aimed at increasing patient-centeredness in cancer care delivery systems. (C) 2009 Elsevier Ireland Ltd. All rights reserved. C1 [Haidet, Paul] Penn State Univ, Coll Med, Off Med Educ, Hershey, PA 17033 USA. [Haidet, Paul] Penn State Univ, Coll Med, Dept Med, Hershey, PA 17033 USA. [Fecile, Mary Lynn] Penn State Univ, Coll Med, Div Pediat Hematol Oncol, Hershey, PA 17033 USA. [West, Heather F.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA. [West, Heather F.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Teal, Cayla R.] Baylor Coll Med, DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. [Teal, Cayla R.] Baylor Coll Med, Sect Hlth Serv Res, Houston, TX 77030 USA. RP Haidet, P (reprint author), Penn State Univ, Coll Med, Off Med Educ, 500 Univ Dr HU15, Hershey, PA 17033 USA. EM phaidet@hmc.psu.edu FU Office of Research and Development, U.S. Department of Veterans Affairs [HFP 90-020]; National Heart, Lung, and Blood Institute [K07-HL85622] FX The opinions contained herein are those of the authors and do not necessarily represent the views of the US Department of Veterans Affairs, the National Heart, Lung, and Blood Institute, The Pennsylvania State University, or Baylor College of Medicine. NR 45 TC 24 Z9 24 U1 2 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD DEC PY 2009 VL 77 IS 3 BP 450 EP 455 DI 10.1016/j.pec.2009.09.020 PG 6 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA 538BI UT WOS:000273158600019 PM 19850437 ER PT J AU Sotir, MJ Ewald, G Kimura, AC Higa, JI Sheth, A Troppy, S Meyer, S Hoekstra, M Austin, J Archer, J Spayne, M Daly, ER Griffin, PM AF Sotir, Mark J. Ewald, Gwen Kimura, Akiko C. Higa, Jeffrey I. Sheth, Anandi Troppy, Scott Meyer, Stephanie Hoekstra, Michael Austin, Jana Archer, John Spayne, Mary Daly, Elizabeth R. Griffin, Patricia M. CA Salmonella Wandsworth Outbreak Inv TI Outbreak of Salmonella Wandsworth and Typhimurium Infections in Infants and Toddlers Traced to a Commercial Vegetable-Coated Snack Food SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article; Proceedings Paper CT 45th Annual Meeting of the Infectious-Diseases-Society-of-America CY OCT, 2007 CL San Diego, CA SP Infect Dis Soc Amer DE Salmonella; toddlers; children; food intake; infection ID EAT SAVOURY SNACK; MULTISTATE OUTBREAK; AGONA INFECTION; UNITED-STATES; ORANIENBURG; PULSENET; CHILDREN AB Objective: Human outbreaks of salmonella infection have been attributed to a variety of food vehicles. Processed snack foods are increasingly consumed by children. In May 2007, state and local health departments and the Centers for Disease Control and Prevention investigated human infections from Salmonella Wandsworth, an extremely rare serotype. Materials and Methods: Serotyping and pulsed-field gel electrophoresis were used to identify outbreak-associated illnesses. Food history questionnaires and open-ended interviews were used to generate exposure hypotheses. A nationwide case-control study was conducted to epidemiologically implicate a source. Public health laboratories cultured implicated product from patient homes and retail stores. Results: Sixty-nine patients from 23 states were identified; 93% were aged 10 months to 3 years. Eighty-one percent of child patients had bloody diarrhea; 6 were hospitalized. No deaths were reported. The case-control study strongly associated illness with a commercial puffed vegetable-coated ready-to-eat snack food (mOR = 23.3, P = 0.0001), leading to a nationwide recall. Parents of 92% of interviewed case-children reported that children consumed the food during the week before their illness began; 43% reported daily consumption. Salmonella Wandsworth, 3 additional Salmonella serotypes and Chronobacter (formerly Enterobacter) sakazaki were all cultured from this product, leading to the identification of 18 human outbreak-related Salmonella Typhimurium illnesses. Conclusions: This report documents a nationwide outbreak associated with a commercial processed ready-to-eat snack food. Cases occurred primarily in infants and toddlers, many of whom frequently consumed the food. Measures are needed to ensure that ingredients added to ready-to-cat foods after the final lethal processing step are free of pathogens. C1 [Sotir, Mark J.] Ctr Dis Control & Prevent, Div Foodborne Bacterial & Mycot Dis, Enter Dis Epidemiol Branch, Atlanta, GA 30306 USA. [Ewald, Gwen] US Dept Vet Affairs, Atlanta Res & Educ Fdn, Atlanta, GA USA. [Kimura, Akiko C.; Higa, Jeffrey I.] Calif Dept Publ Hlth, Gardena, CA USA. [Troppy, Scott] Massachusetts Dept Hlth, Jamaica Plain, MA USA. [Meyer, Stephanie] Minnesota Dept Hlth, St Paul, MN USA. [Archer, John] Wisconsin Dept Hlth & Family Serv, Madison, WI USA. [Spayne, Mary] Vermont Dept Hlth, Burlington, VT 05402 USA. [Daly, Elizabeth R.] New Hampshire Dept Hlth & Human Serv, Concord, NH 03301 USA. RP Sotir, MJ (reprint author), Ctr Dis Control & Prevent, Div Foodborne Bacterial & Mycot Dis, Enter Dis Epidemiol Branch, 1600 Clifton Rd NE,MS A-38, Atlanta, GA 30306 USA. EM msotir@cdc.gov NR 27 TC 11 Z9 14 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD DEC PY 2009 VL 28 IS 12 BP 1041 EP 1046 DI 10.1097/INF.0b013e3181af6218 PG 6 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 525OH UT WOS:000272225200001 PM 19779390 ER PT J AU Yaremchuk, MJ Kahn, DM AF Yaremchuk, Michael J. Kahn, David M. TI Periorbital Skeletal Augmentation to Improve Blepharoplasty and Midfacial Results SO PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Article ID SOFT-TISSUE CHANGES; FORM; AGE; REJUVENATION; CANTHOPEXY; MORPHOLOGY; EYE AB Background: Narrow palpebral fissures, short lower lids, and full cheeks are hallmarks of youthful periorbita. The presence of these features is predicated on a convex upper midface skeleton. Faces whose midface skeletons are flat or concave do not manifest these youthful attributes, tend to age prematurely, and are prone to lower lid malposition after blepharoplasty. Methods: Augmentation of the infraorbital rim with alloplastic implants can provide convexity to the deficient upper midface skeleton. Suspension of the cheek soft tissues (subperiosteal midface lift) on this now supportive framework narrows the palpebral fissure, shortens the lower lid, and gives fullness to the cheek. The addition of lateral canthopexy to skeletal augmentation and subperiosteal midface lift can restore lower lid position when previous blepharoplasty has resulted in lower lid malposition in patients with deficient midface skeletons. Results: This concept has been utilized in 87 patients (65 female, 22 male) over the last 7 years. Of these 87 patients, four patients (5 percent) required revision surgery to correct implant malposition or prominence. Three patients (3 percent) required implant removal to treat infection. Implants were later replaced in two of these three patients. Conclusions: Augmentation of the infraorbital rim with alloplastic implants provides convexity to the upper midface skeleton. Together with lower lid and midface soft-tissue suspension, it creates or restores youthful periorbital aesthetics. (Plast. Reconstr. Surg. 124: 2151, 2009.) C1 [Yaremchuk, Michael J.] Harvard Univ, Massachusetts Gen Hosp, Div Plast Surg, Sch Med,Dept Gen Surg, Boston, MA 02114 USA. Stanford Sch Med, Div Plast Surg, Dept Surg, Palo Alto, CA USA. RP Yaremchuk, MJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Div Plast Surg, Sch Med,Dept Gen Surg, 15 Parkman St, Boston, MA 02114 USA. EM myaremchuk@partners.org NR 34 TC 17 Z9 18 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0032-1052 J9 PLAST RECONSTR SURG JI Plast. Reconstr. Surg. PD DEC PY 2009 VL 124 IS 6 BP 2151 EP 2160 DI 10.1097/PRS.0b013e3181bcf5bc PG 10 WC Surgery SC Surgery GA 530TQ UT WOS:000272615600048 PM 19952674 ER PT J AU Mar, JC Quackenbush, J AF Mar, Jessica C. Quackenbush, John TI Decomposition of Gene Expression State Space Trajectories SO PLOS COMPUTATIONAL BIOLOGY LA English DT Article ID RETINOIC ACID RECEPTOR; MYELOID-LEUKEMIA CELLS; BINDING PROTEIN; HL-60 CELLS; HL60 CELLS; DIFFERENTIATION; INDUCTION; DIMETHYLSULFOXIDE; ACTIVATION; DYNAMICS AB Representing and analyzing complex networks remains a roadblock to creating dynamic network models of biological processes and pathways. The study of cell fate transitions can reveal much about the transcriptional regulatory programs that underlie these phenotypic changes and give rise to the coordinated patterns in expression changes that we observe. The application of gene expression state space trajectories to capture cell fate transitions at the genome-wide level is one approach currently used in the literature. In this paper, we analyze the gene expression dataset of Huang et al. (2005) which follows the differentiation of promyelocytes into neutrophil-like cells in the presence of inducers dimethyl sulfoxide and all-trans retinoic acid. Huang et al. (2005) build on the work of Kauffman (2004) who raised the attractor hypothesis, stating that cells exist in an expression landscape and their expression trajectories converge towards attractive sites in this landscape. We propose an alternative interpretation that explains this convergent behavior by recognizing that there are two types of processes participating in these cell fate transitions-core processes that include the specific differentiation pathways of promyelocytes to neutrophils, and transient processes that capture those pathways and responses specific to the inducer. Using functional enrichment analyses, specific biological examples and an analysis of the trajectories and their core and transient components we provide a validation of our hypothesis using the Huang et al. (2005) dataset. C1 [Mar, Jessica C.; Quackenbush, John] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Quackenbush, John] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Quackenbush, John] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. RP Mar, JC (reprint author), Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. EM johnq@jimmy.harvard.edu FU US National Institutes of Health [P50HG004233] FX This work was supported by a grant (P50HG004233) from the National Human Genome Institute of the US National Institutes of Health (http://www.genome.gov). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 26 TC 17 Z9 17 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-734X J9 PLOS COMPUT BIOL JI PLoS Comput. Biol. PD DEC PY 2009 VL 5 IS 12 AR e1000626 DI 10.1371/journal.pcbi.1000626 PG 10 WC Biochemical Research Methods; Mathematical & Computational Biology SC Biochemistry & Molecular Biology; Mathematical & Computational Biology GA 551SE UT WOS:000274229000043 PM 20041215 ER PT J AU Fellay, J Ge, DL Shianna, KV Colombo, S Ledergerber, B Cirulli, ET Urban, TJ Zhang, KL Gumbs, CE Smith, JP Castagna, A Cozzi-Lepri, A De Luca, A Easterbrook, P Gunthard, HF Mallal, S Mussini, C Dalmau, J Martinez-Picado, J Miro, JM Obel, N Wolinsky, SM Martinson, JJ Detels, R Margolick, JB Jacobson, LP Descombes, P Antonarakis, SE Beckmann, JS O'Brien, SJ Letvin, NL McMichael, AJ Haynes, BF Carrington, M Feng, S Telenti, A Goldstein, DB AF Fellay, Jacques Ge, Dongliang Shianna, Kevin V. Colombo, Sara Ledergerber, Bruno Cirulli, Elizabeth T. Urban, Thomas J. Zhang, Kunlin Gumbs, Curtis E. Smith, Jason P. Castagna, Antonella Cozzi-Lepri, Alessandro De Luca, Andrea Easterbrook, Philippa Guenthard, Huldrych F. Mallal, Simon Mussini, Cristina Dalmau, Judith Martinez-Picado, Javier Miro, Jose M. Obel, Niels Wolinsky, Steven M. Martinson, Jeremy J. Detels, Roger Margolick, Joseph B. Jacobson, Lisa P. Descombes, Patrick Antonarakis, Stylianos E. Beckmann, Jacques S. O'Brien, Stephen J. Letvin, Norman L. McMichael, Andrew J. Haynes, Barton F. Carrington, Mary Feng, Sheng Telenti, Amalio Goldstein, David B. CA NIAID Ctr HIV AIDS Vaccine Immunol TI Common Genetic Variation and the Control of HIV-1 in Humans SO PLOS GENETICS LA English DT Article ID GENOME-WIDE ASSOCIATION; HLA-C; HOST GENETICS; INFECTION; AIDS; PROGRESSION; DISEASE; POLYMORPHISM; RESISTANCE; HCP5 AB To extend the understanding of host genetic determinants of HIV-1 control, we performed a genome-wide association study in a cohort of 2,554 infected Caucasian subjects. The study was powered to detect common genetic variants explaining down to 1.3% of the variability in viral load at set point. We provide overwhelming confirmation of three associations previously reported in a genome-wide study and show further independent effects of both common and rare variants in the Major Histocompatibility Complex region (MHC). We also examined the polymorphisms reported in previous candidate gene studies and fail to support a role for any variant outside of the MHC or the chemokine receptor cluster on chromosome 3. In addition, we evaluated functional variants, copy-number polymorphisms, epistatic interactions, and biological pathways. This study thus represents a comprehensive assessment of common human genetic variation in HIV-1 control in Caucasians. C1 [Fellay, Jacques; Ge, Dongliang; Shianna, Kevin V.; Cirulli, Elizabeth T.; Urban, Thomas J.; Gumbs, Curtis E.; Feng, Sheng; Goldstein, David B.] Duke Univ, Ctr Human Genome Variat, Duke Inst Genome Sci & Policy, Durham, NC 27706 USA. [Shianna, Kevin V.; Smith, Jason P.] Duke Univ, Genom Anal Facil, Duke Inst Genome Sci & Policy, Durham, NC USA. [Colombo, Sara; Zhang, Kunlin; Telenti, Amalio] Univ Lausanne, Inst Microbiol, Lausanne, Switzerland. [Ledergerber, Bruno; Guenthard, Huldrych F.] Univ Zurich, Univ Hosp, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland. [Zhang, Kunlin] Chinese Acad Sci, Inst Psychol, Behav Genet Ctr, Beijing 100101, Peoples R China. [Castagna, Antonella] Vita Salute San Raffaele Univ & Diagnost & Ric Sa, Clin Infect Dis, Milan, Italy. [Cozzi-Lepri, Alessandro] UCL, Res Dept Infect & Populat Hlth, London, England. [De Luca, Andrea] Univ Cattolica Sacro Cuore, Inst Clin Infect Dis, I-00168 Rome, Italy. [Easterbrook, Philippa] Kings Coll London, Acad Dept HIV GUM, Weston Educ Ctr, Guys Hosp, London WC2R 2LS, England. [Easterbrook, Philippa] Kings Coll London, Acad Dept HIV GUM, Weston Educ Ctr, Kings Hosp, London WC2R 2LS, England. [Easterbrook, Philippa] Kings Coll London, Acad Dept HIV GUM, St Thomas Hosp, Weston Educ Ctr, London, England. [Mallal, Simon] Royal Perth Hosp, Ctr Clin Immunol & Biomed Stat, Inst Immunol & Infect Dis, Perth, WA, Australia. [Mallal, Simon] Murdoch Univ, Perth, WA, Australia. [Mussini, Cristina] Azienda Osped Univ, Infect Dis Clin, Modena, Italy. [Dalmau, Judith; Martinez-Picado, Javier] IrsiCaixa Fdn, Badalona, Spain. [Dalmau, Judith; Martinez-Picado, Javier] Hosp Badalona Germans Trias & Pujol, Badalona, Spain. [Martinez-Picado, Javier] ICREA, Barcelona, Spain. [Miro, Jose M.] Univ Barcelona, Hosp Clin, IDIBAPS, Barcelona, Spain. [Obel, Niels] Univ Copenhagen Hosp, Rigshosp, Dept Infect Dis, DK-2100 Copenhagen, Denmark. [Wolinsky, Steven M.] Northwestern Univ, Feinberg Sch Med, Div Infect Dis, Chicago, IL 60611 USA. [Martinson, Jeremy J.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. [Detels, Roger] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Margolick, Joseph B.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD USA. [Jacobson, Lisa P.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Descombes, Patrick] Univ Geneva, Natl Ctr Competence Res Frontiers Genet, Geneva, Switzerland. [Antonarakis, Stylianos E.] Univ Geneva, Sch Med, Dept Genet Med & Dev, CH-1211 Geneva, Switzerland. [Beckmann, Jacques S.] Univ Lausanne, Dept Med Genet, Lausanne, Switzerland. [Beckmann, Jacques S.] CHU Vaudois, Serv Med Genet, CH-1011 Lausanne, Switzerland. [O'Brien, Stephen J.] NCI, Lab Genom Divers, Frederick, MD 21701 USA. [Letvin, Norman L.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Viral Pathogenesis, Boston, MA 02215 USA. [McMichael, Andrew J.] John Radcliffe Hosp, MRC, Human Immunol Unit, Weatherall Inst Mol Med, Oxford OX3 9DU, England. [Haynes, Barton F.] Duke Univ, Duke Human Vaccine Inst, Durham, NC USA. [Carrington, Mary] NCI, Canc & Inflammat Program, Expt Immunol Lab, SAIC Frederick Inc, Frederick, MD 21701 USA. [Carrington, Mary] Massachusetts Gen Hosp, Ragon Inst, MIT& Harvard, Boston, MA 02114 USA. RP Fellay, J (reprint author), Duke Univ, Ctr Human Genome Variat, Duke Inst Genome Sci & Policy, Durham, NC 27706 USA. EM amalio.telenti@chuv.ch; d.goldstein@duke.edu RI Ledergerber, Bruno/B-5656-2009; Beckmann, Jacques S /A-9772-2008; De Luca, Andrea/G-8810-2011; Wolinsky, Steven/B-2893-2012; gunthard, huldrych/F-1724-2011; Martinez-Picado, Javier/G-5507-2012; Infektiologie, USZ/A-6921-2011; SHCS, all/G-4072-2011; SHCS, int. coll. A/G-4083-2011; Fellay, Jacques/A-6681-2009; Antonarakis, Stylianos/N-8866-2014; OI Ledergerber, Bruno/0000-0002-6881-4401; Martinson, Jeremy/0000-0003-4673-7238; Wolinsky, Steven/0000-0002-9625-6697; Beckmann, Jacques S /0000-0002-9741-1900; gunthard, huldrych/0000-0002-1142-6723; Martinez-Picado, Javier/0000-0002-4916-2129; Fellay, Jacques/0000-0002-8240-939X; Antonarakis, Stylianos/0000-0001-8907-5823; Cirulli Rogers, Liz/0000-0001-7808-2809 FU NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI) [AI067854]; National Cancer Institute, National Institutes of Health [HHSN261200800001E]; Swiss National Science Foundation; Infectigen Foundation FX Funding: Funding was provided by the NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI) grant AI067854. This project has also been funded in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E, and by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U. S. Government. AT and SEA are supported by the Swiss National Science Foundation and by the Infectigen Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 40 TC 206 Z9 210 U1 2 U2 13 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7390 J9 PLOS GENET JI PLoS Genet. PD DEC PY 2009 VL 5 IS 12 AR e1000791 DI 10.1371/journal.pgen.1000791 PG 12 WC Genetics & Heredity SC Genetics & Heredity GA 542CT UT WOS:000273469700041 PM 20041166 ER PT J AU Goula, AV Berquist, BR Wilson, DM Wheeler, VC Trottier, Y Merienne, K AF Goula, Agathi-Vassiliki Berquist, Brian R. Wilson, David M., III Wheeler, Vanessa C. Trottier, Yvon Merienne, Karine TI Stoichiometry of Base Excision Repair Proteins Correlates with Increased Somatic CAG Instability in Striatum over Cerebellum in Huntington's Disease Transgenic Mice SO PLOS GENETICS LA English DT Article ID DNA-POLYMERASE-BETA; TRINUCLEOTIDE REPEAT INSTABILITY; ABASIC ENDONUCLEASE ACTIVITY; KNOCK-IN MOUSE; MYOTONIC-DYSTROPHY; DEPENDENT MANNER; LIGASE-I; BRAIN; EXPANSION; GENE AB Huntington's disease (HD) is a progressive neurodegenerative disorder caused by expansion of an unstable CAG repeat in the coding sequence of the Huntingtin (HTT) gene. Instability affects both germline and somatic cells. Somatic instability increases with age and is tissue-specific. In particular, the CAG repeat sequence in the striatum, the brain region that preferentially degenerates in HD, is highly unstable, whereas it is rather stable in the disease-spared cerebellum. The mechanisms underlying the age-dependence and tissue-specificity of somatic CAG instability remain obscure. Recent studies have suggested that DNA oxidation and OGG1, a glycosylase involved in the repair of 8-oxoguanine lesions, contribute to this process. We show that in HD mice oxidative DNA damage abnormally accumulates at CAG repeats in a length-dependent, but age-and tissue-independent manner, indicating that oxidative DNA damage alone is not sufficient to trigger somatic instability. Protein levels and activities of major base excision repair (BER) enzymes were compared between striatum and cerebellum of HD mice. Strikingly, 59-flap endonuclease activity was much lower in the striatum than in the cerebellum of HD mice. Accordingly, Flap Endonuclease-1 (FEN1), the main enzyme responsible for 59-flap endonuclease activity, and the BER cofactor HMGB1, both of which participate in long-patch BER (LP-BER), were also significantly lower in the striatum compared to the cerebellum. Finally, chromatin immunoprecipitation experiments revealed that POL beta was specifically enriched at CAG expansions in the striatum, but not in the cerebellum of HD mice. These in vivo data fit a model in which POL beta strand displacement activity during LP-BER promotes the formation of stable 59-flap structures at CAG repeats representing pre-expanded intermediate structures, which are not efficiently removed when FEN1 activity is constitutively low. We propose that the stoichiometry of BER enzymes is one critical factor underlying the tissue selectivity of somatic CAG expansion. C1 [Goula, Agathi-Vassiliki; Trottier, Yvon; Merienne, Karine] UdS, INSERM, CNRS,UMR 7104, Dept Neurobiol & Genet,Inst Genet & Mol & Cellula, Illkirch Graffenstaden, France. [Berquist, Brian R.; Wilson, David M., III] NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA. [Wilson, David M., III] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. RP Goula, AV (reprint author), UdS, INSERM, CNRS,UMR 7104, Dept Neurobiol & Genet,Inst Genet & Mol & Cellula, Illkirch Graffenstaden, France. EM yvon@igbmc.fr; merienne@igbmc.fr RI Trottier, Yvon/H-8852-2016 FU CNRS; INSERM; Hereditary Disease Foundation (USA); NIH (National Institute of Neurological Disease and Stroke) [NS049206]; Intramural Research Program of the NIH, National Institute on Aging FX Funding: This work was supported by funds from CNRS and INSERM, by the Hereditary Disease Foundation (USA), by the NIH (National Institute of Neurological Disease and Stroke) grant NS049206, and by the Intramural Research Program of the NIH, National Institute on Aging. The funders have not been implicated in the design, realization, and analysis of the study. They were not involved in manuscript preparation or the decision to submit. NR 55 TC 69 Z9 69 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7390 J9 PLOS GENET JI PLoS Genet. PD DEC PY 2009 VL 5 IS 12 AR e1000749 DI 10.1371/journal.pgen.1000749 PG 15 WC Genetics & Heredity SC Genetics & Heredity GA 542CT UT WOS:000273469700001 PM 19997493 ER PT J AU Hagg, S Skogsberg, J Lundstrom, J Noori, P Nilsson, R Zhong, H Maleki, S Shang, MM Brinne, B Bradshaw, M Bajic, VB Samnegard, A Silveira, A Kaplan, LM Gigante, B Leander, K de Faire, U Rosfors, S Lockowandt, U Liska, J Konrad, P Takolander, R Franco-Cereceda, A Schadt, EE Ivert, T Hamsten, A Tegner, J Bjorkegren, J AF Hagg, Sara Skogsberg, Josefin Lundstrom, Jesper Noori, Peri Nilsson, Roland Zhong, Hua Maleki, Shohreh Shang, Ming-Mei Brinne, Bjorn Bradshaw, Maria Bajic, Vladimir B. Samnegard, Ann Silveira, Angela Kaplan, Lee M. Gigante, Bruna Leander, Karin de Faire, Ulf Rosfors, Stefan Lockowandt, Ulf Liska, Jan Konrad, Peter Takolander, Rabbe Franco-Cereceda, Anders Schadt, Eric E. Ivert, Torbjorn Hamsten, Anders Tegner, Jesper Bjorkegren, Johan TI Multi-Organ Expression Profiling Uncovers a Gene Module in Coronary Artery Disease Involving Transendothelial Migration of Leukocytes and LIM Domain Binding 2: The Stockholm Atherosclerosis Gene Expression (STAGE) Study SO PLOS GENETICS LA English DT Article ID SMOOTH-MUSCLE-CELLS; INTIMA-MEDIA THICKNESS; ADIPOSE-TISSUE; PROTEIN; MICE; INFLAMMATION; VACCINATION; MECHANISMS; LEUKEMIA; NETWORKS AB Environmental exposures filtered through the genetic make-up of each individual alter the transcriptional repertoire in organs central to metabolic homeostasis, thereby affecting arterial lipid accumulation, inflammation, and the development of coronary artery disease (CAD). The primary aim of the Stockholm Atherosclerosis Gene Expression (STAGE) study was to determine whether there are functionally associated genes (rather than individual genes) important for CAD development. To this end, two-way clustering was used on 278 transcriptional profiles of liver, skeletal muscle, and visceral fat (n = 66/tissue) and atherosclerotic and unaffected arterial wall ( n = 40/tissue) isolated from CAD patients during coronary artery bypass surgery. The first step, across all mRNA signals (n = 15,042/12,621 RefSeqs/genes) in each tissue, resulted in a total of 60 tissue clusters (n=3958 genes). In the second step (performed within tissue clusters), one atherosclerotic lesion (n = 49/48) and one visceral fat ( n = 59) cluster segregated the patients into two groups that differed in the extent of coronary stenosis (P=0.008 and P=0.00015). The associations of these clusters with coronary atherosclerosis were validated by analyzing carotid atherosclerosis expression profiles. Remarkably, in one cluster (n = 55/54) relating to carotid stenosis (P=0.04), 27 genes in the two clusters relating to coronary stenosis were confirmed (n=16/17, P<10(-27and-30)). Genes in the transendothelial migration of leukocytes (TEML) pathway were overrepresented in all three clusters, referred to as the atherosclerosis module (A-module). In a second validation step, using three independent cohorts, the A-module was found to be genetically enriched with CAD risk by 1.8-fold (P<0.004). The transcription co-factor LIM domain binding 2 (LDB2) was identified as a potential high-hierarchy regulator of the A-module, a notion supported by subnetwork analysis, by cellular and lesion expression of LDB2, and by the expression of 13 TEML genes in Ldb2-deficient arterial wall. Thus, the A-module appears to be important for atherosclerosis development and, together with LDB2, merits further attention in CAD research. C1 [Hagg, Sara; Skogsberg, Josefin; Lundstrom, Jesper; Noori, Peri; Maleki, Shohreh; Shang, Ming-Mei; Bradshaw, Maria; Tegner, Jesper; Bjorkegren, Johan] Karolinska Inst, Dept Med, Atherosclerosis Res Unit, Computat Med Grp, Stockholm, Sweden. [Hagg, Sara; Lundstrom, Jesper; Nilsson, Roland; Brinne, Bjorn; Bradshaw, Maria; Tegner, Jesper; Bjorkegren, Johan] Linkoping Univ, Linkoping Inst Technol, Dept Computat Biol, Linkoping, Sweden. [Hagg, Sara; Skogsberg, Josefin; Lundstrom, Jesper; Noori, Peri; Nilsson, Roland; Shang, Ming-Mei; Bradshaw, Maria; Tegner, Jesper; Bjorkegren, Johan] Clin Gene Networks AB, Stockholm, Sweden. [Zhong, Hua; Schadt, Eric E.] Merck, Rosetta Inpharmat, Seattle, WA USA. [Bajic, Vladimir B.] Univ Western Cape, SANBI, Cape Town, South Africa. [Bajic, Vladimir B.] KAUST, CBRC, Thuwal, Saudi Arabia. [Samnegard, Ann] Danderyd Hosp, Karolinska Inst, Dept Clin Sci, Stockholm, Sweden. [Silveira, Angela; Hamsten, Anders] Karolinska Inst, Dept Med, Atherosclerosis Res Unit, Cardiovasc Genet Grp, Stockholm, Sweden. [Kaplan, Lee M.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Kaplan, Lee M.] Massachusetts Gen Hosp, Weight Ctr, Boston, MA 02114 USA. [Gigante, Bruna; Leander, Karin; de Faire, Ulf] Karolinska Inst, Dept Environm Med, Stockholm, Sweden. [Rosfors, Stefan] Stockholm Soder Hosp, Karolinska Inst, Dept Clin Physiol, Stockholm, Sweden. [Lockowandt, Ulf; Liska, Jan; Franco-Cereceda, Anders; Ivert, Torbjorn] Karolinska Univ Hosp, Dept Thorac Surg & Anesthesiol, Stockholm, Sweden. [Lockowandt, Ulf; Liska, Jan; Franco-Cereceda, Anders; Ivert, Torbjorn] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden. [Konrad, Peter; Takolander, Rabbe] Stockholm Soder Hosp, Dept Surg, Karolinska Inst, Stockholm, Sweden. RP Hagg, S (reprint author), Karolinska Inst, Dept Med, Atherosclerosis Res Unit, Computat Med Grp, Stockholm, Sweden. EM johan.bjorkegren@ki.se RI Gigante, Bruna/I-9252-2012; Leander, Karin/C-7261-2017; Bajic, Vladimir/D-2810-2009 OI Leander, Karin/0000-0002-1404-9222; Bajic, Vladimir/0000-0001-5435-4750 FU Swedish Research Council; Karolinska Institute; Stockholm County Council; Swedish Foundation for Strategic Research; Swedish Heart-Lung Foundation; King Gustaf V and Queen Victoria Foundation; Swedish Society of Medicine; Hans and Loo Osterman Foundation for Geriatric Research; Professor Nanna Swartz Fund; Foundation for Old Servants; Magnus Bergvalls Foundation; Ake Wiberg Stiftelse; Wennergren Foundation; Vinnova SAMPOST; PhD Programme in Medical Bioinformatics; Linkoping University and Stockholm Bioinformatics Center; Carl Tryggers Foundation; Swedish Match; AstraZeneca; Clinical Gene Networks FX Funding: This work was supported by grants from the Swedish Research Council (JB, JT, JS), the Karolinska Institute (JB, AH), the Stockholm County Council (JB, AH), the Swedish Foundation for Strategic Research (JB, JT), the Swedish Heart-Lung Foundation (JB), the King Gustaf V and Queen Victoria Foundation (JB), the Swedish Society of Medicine (JB, JT), the Hans and Loo Osterman Foundation for Geriatric Research (JB, JS), the Professor Nanna Swartz Fund (JB), the Foundation for Old Servants (JB, JS), the Magnus Bergvalls Foundation (JB), Ake Wiberg Stiftelse (JB, JT), Wennergren Foundation (JT), Vinnova Sweden- Japan (JB, JT), Vinnova research grant (SM, JT, JB), Vinnova SAMPOST grant (M-MS, JB), the PhD Programme in Medical Bioinformatics (JB, JT), Linkoping University and Stockholm Bioinformatics Center (JT) and Carl Tryggers Foundation (JT), Swedish Match (unconditional research grant to JT), AstraZeneca (unconditional research grants to JB, AH), and Clinical Gene Networks (JB, JT). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 59 TC 50 Z9 50 U1 0 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7390 J9 PLOS GENET JI PLoS Genet. PD DEC PY 2009 VL 5 IS 12 AR e1000754 DI 10.1371/journal.pgen.1000754 PG 15 WC Genetics & Heredity SC Genetics & Heredity GA 542CT UT WOS:000273469700006 PM 19997623 ER PT J AU Lavigne, M Eskeland, R Azebi, S Saint-Andre, V Jang, SM Batsche, E Fan, HY Kingston, RE Imhof, A Muchardt, C AF Lavigne, Marc Eskeland, Ragnhild Azebi, Saliha Saint-Andre, Violaine Jang, Suk Min Batsche, Eric Fan, Hua-Ying Kingston, Robert E. Imhof, Axel Muchardt, Christian TI Interaction of HP1 and Brg1/Brm with the Globular Domain of Histone H3 Is Required for HP1-Mediated Repression SO PLOS GENETICS LA English DT Article ID CHROMATIN-REMODELING COMPLEX; TARGET GENES REQUIRES; HETEROCHROMATIN PROTEIN-1; MAMMALIAN-CELLS; HIGH-MOBILITY; BAF COMPLEX; LYSINE 9; BINDING; SWI/SNF; METHYLATION AB The heterochromatin-enriched HP1 proteins play a critical role in regulation of transcription. These proteins contain two related domains known as the chromo- and the chromoshadow-domain. The chromo- domain binds histone H3 tails methylated on lysine 9. However, in vivo and in vitro experiments have shown that the affinity of HP1 proteins to native methylated chromatin is relatively poor and that the opening of chromatin occurring during DNA replication facilitates their binding to nucleosomes. These observations prompted us to investigate whether HP1 proteins have additional histone binding activities, envisioning also affinity for regions potentially occluded by the nucleosome structure. We find that the chromoshadow-domain interacts with histone H3 in a region located partially inside the nucleosomal barrel at the entry/exit point of the nucleosome. Interestingly, this region is also contacted by the catalytic subunits of the human SWI/SNF complex. In vitro, efficient SWI/SNF remodeling requires this contact and is inhibited in the presence of HP1 proteins. The antagonism between SWI/SNF and HP1 proteins is also observed in vivo on a series of interferon-regulated genes. Finally, we show that SWI/SNF activity favors loading of HP1 proteins to chromatin both in vivo and in vitro. Altogether, our data suggest that HP1 chromoshadow-domains can benefit from the opening of nucleosomal structures to bind chromatin and that HP1 proteins use this property to detect and arrest unwanted chromatin remodeling. C1 [Lavigne, Marc; Azebi, Saliha; Saint-Andre, Violaine; Jang, Suk Min; Batsche, Eric; Muchardt, Christian] Inst Pasteur, INSERM, CNRS,Unite Regulat Epigenet,Equipe AVENIR, Dept Biol & Dev,Unite Rech Associee URA2578, F-75724 Paris, France. [Eskeland, Ragnhild; Imhof, Axel] Univ Munich, Histone Modificat Grp, Adolf Butenandt Inst, Munich Ctr Integrated Prot Sci CIPSM, Munich, Germany. [Fan, Hua-Ying; Kingston, Robert E.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. RP Lavigne, M (reprint author), Inst Pasteur, CNRS, Unite Virol Struct, URA3015, Paris, France. EM muchardt@pasteur.fr RI Eskeland, Ragnhild/K-7018-2014 OI Eskeland, Ragnhild/0000-0003-2789-3171 FU "Agence National de la Recherche''; "L'Association pour la Recherche sur le Cancer''; NIH; "Canceropole Ile-de-France''; EMBO FX The work was supported by grants from the "Agence National de la Recherche'' and "L'Association pour la Recherche sur le Cancer'' to CM and by grants from the NIH to REK and HF. VSA received fellowships from "Canceropole Ile-de-France'' and "L'Association pour la Recherche sur le Cancer.'' ML was supported by a long term EMBO fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 56 TC 38 Z9 38 U1 1 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7390 J9 PLOS GENET JI PLoS Genet. PD DEC PY 2009 VL 5 IS 12 AR e1000769 DI 10.1371/journal.pgen.1000769 PG 11 WC Genetics & Heredity SC Genetics & Heredity GA 542CT UT WOS:000273469700020 PM 20011120 ER PT J AU Richards, JB Waterworth, D O'Rahilly, S Hivert, MF Loos, RJF Perry, JRB Tanaka, T Timpson, NJ Semple, RK Soranzo, N Song, K Rocha, N Grundberg, E Dupuis, J Florez, JC Langenberg, C Prokopenko, I Saxena, R Sladek, R Aulchenko, Y Evans, D Waeber, G Erdmann, J Burnett, MS Sattar, N Devaney, J Willenborg, C Hingorani, A Witteman, JCM Vollenweider, P Glaser, B Hengstenberg, C Ferrucci, L Melzer, D Stark, K Deanfield, J Winogradow, J Grassl, M Hall, AS Egan, JM Thompson, JR Ricketts, SL Konig, IR Reinhard, W Grundy, S Wichmann, HE Barter, P Mahley, R Kesaniemi, YA Rader, DJ Reilly, MP Epstein, SE Stewart, AFR Van Duijn, CM Schunkert, H Burling, K Deloukas, P Pastinen, T Samani, NJ McPherson, R Smith, GD Frayling, TM Wareham, NJ Meigs, JB Mooser, V Spector, TD AF Richards, J. Brent Waterworth, Dawn O'Rahilly, Stephen Hivert, Marie-France Loos, Ruth J. F. Perry, John R. B. Tanaka, Toshiko Timpson, Nicholas John Semple, Robert K. Soranzo, Nicole Song, Kijoung Rocha, Nuno Grundberg, Elin Dupuis, Josee Florez, Jose C. Langenberg, Claudia Prokopenko, Inga Saxena, Richa Sladek, Robert Aulchenko, Yurii Evans, David Waeber, Gerard Erdmann, Jeanette Burnett, Mary-Susan Sattar, Naveed Devaney, Joseph Willenborg, Christina Hingorani, Aroon Witteman, Jaquelin C. M. Vollenweider, Peter Glaser, Beate Hengstenberg, Christian Ferrucci, Luigi Melzer, David Stark, Klaus Deanfield, John Winogradow, Janina Grassl, Martina Hall, Alistair S. Egan, Josephine M. Thompson, John R. Ricketts, Sally L. Koenig, Inke R. Reinhard, Wibke Grundy, Scott Wichmann, H-Erich Barter, Phil Mahley, Robert Kesaniemi, Y. Antero Rader, Daniel J. Reilly, Muredach P. Epstein, Stephen E. Stewart, Alexandre F. R. Van Duijn, Cornelia M. Schunkert, Heribert Burling, Keith Deloukas, Panos Pastinen, Tomi Samani, Nilesh J. McPherson, Ruth Smith, George Davey Frayling, Timothy M. Wareham, Nicholas J. Meigs, James B. Mooser, Vincent Spector, Tim D. CA GIANT Consortium TI A Genome-Wide Association Study Reveals Variants in ARL15 that Influence Adiponectin Levels SO PLOS GENETICS LA English DT Article ID MOLECULAR-WEIGHT ADIPONECTIN; BONE-MINERAL DENSITY; SMALL G-PROTEINS; INSULIN-RESISTANCE; PLASMA ADIPONECTIN; METABOLIC SYNDROME; CIRCULATING ADIPONECTIN; MYOCARDIAL-INFARCTION; SERUM CONCENTRATION; APM1 GENE AB The adipocyte-derived protein adiponectin is highly heritable and inversely associated with risk of type 2 diabetes mellitus (T2D) and coronary heart disease (CHD). We meta-analyzed 3 genome-wide association studies for circulating adiponectin levels (n = 8,531) and sought validation of the lead single nucleotide polymorphisms ( SNPs) in 5 additional cohorts (n = 6,202). Five SNPs were genome-wide significant in their relationship with adiponectin (P <= 5x10(-8)). We then tested whether these 5 SNPs were associated with risk of T2D and CHD using a Bonferroni-corrected threshold of P <= 0.011 to declare statistical significance for these disease associations. SNPs at the adiponectin-encoding ADIPOQ locus demonstrated the strongest associations with adiponectin levels (P-combined = 9.2x10(-19) for lead SNP, rs266717, n = 14,733). A novel variant in the ARL15 (ADP-ribosylation factor-like 15) gene was associated with lower circulating levels of adiponectin (rs4311394-G, P-combined = 2.9x10(-8), n = 14,733). This same risk allele at ARL15 was also associated with a higher risk of CHD (odds ratio [OR] = 1.12, P = 8.5610 26, n = 22,421) more nominally, an increased risk of T2D (OR = 1.11, P = 3.2x10(-3), n = 10,128), and several metabolic traits. Expression studies in humans indicated that ARL15 is well-expressed in skeletal muscle. These findings identify a novel protein, ARL15, which influences circulating adiponectin levels and may impact upon CHD risk. C1 [Richards, J. Brent; Grundberg, Elin; Sladek, Robert] McGill Univ, Jewish Gen Hosp, Dept Med, Montreal, PQ H3T 1E2, Canada. [Richards, J. Brent; Grundberg, Elin; Sladek, Robert] McGill Univ, Jewish Gen Hosp, Dept Human Genet, Montreal, PQ H3T 1E2, Canada. [Richards, J. Brent; Grundberg, Elin; Sladek, Robert] McGill Univ, Jewish Gen Hosp, Dept Epidemiol & Biostat, Montreal, PQ H3T 1E2, Canada. [Richards, J. Brent; Soranzo, Nicole; Spector, Tim D.] Kings Coll London, London WC2R 2LS, England. [Waterworth, Dawn; Song, Kijoung; Mooser, Vincent] GlaxoSmithKline Inc, Div Genet, King Of Prussia, PA USA. [O'Rahilly, Stephen; Semple, Robert K.; Rocha, Nuno; Burling, Keith] Univ Cambridge, Addenbrookes Hosp, Inst Metab Sci, Metab Res Labs, Cambridge CB2 2QQ, England. [Hivert, Marie-France; Meigs, James B.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA. [Hivert, Marie-France; Florez, Jose C.; Meigs, James B.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Loos, Ruth J. F.; Wareham, Nicholas J.] Addenbrookes Hosp, Inst Metab Sci, Epidemiol Unit, MRC, Cambridge, England. [Perry, John R. B.; Melzer, David; Frayling, Timothy M.] Peninsula Med Sch, Inst Biomed & Clin Sci, Exeter, Devon, England. [Tanaka, Toshiko; Ferrucci, Luigi] NIA, Clin Res Branch, Baltimore, MD 21224 USA. [Tanaka, Toshiko] Medstar Res Inst, Baltimore, MD USA. [Timpson, Nicholas John; Evans, David; Glaser, Beate; Smith, George Davey] Ctr Causal Anal Translat Epidemiol, MRC, Dept Social Med, Bristol, Avon, England. [Soranzo, Nicole; Deloukas, Panos] Wellcome Trust Sanger Inst, Hinxton, England. [Grundberg, Elin; Pastinen, Tomi] McGill Univ, Montreal, PQ, Canada. [Grundberg, Elin; Pastinen, Tomi] Genome Quebec Innovat Ctr, Montreal, PQ, Canada. [Dupuis, Josee] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Florez, Jose C.; Saxena, Richa] Massachusetts Gen Hosp, Dept Med, Ctr Human, Genet Res & Diabet Ctr,Diabet Unit, Boston, MA 02114 USA. [Florez, Jose C.; Saxena, Richa] Broad Inst Harvard, Program Med & Populat Genet, Cambridge, MA USA. [Florez, Jose C.; Saxena, Richa] MIT, Cambridge, MA 02139 USA. [Prokopenko, Inga] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England. [Prokopenko, Inga] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England. [Aulchenko, Yurii; Witteman, Jaquelin C. M.; Van Duijn, Cornelia M.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands. [Waeber, Gerard; Vollenweider, Peter] Univ Lausanne Hosp, CHU Vaudois, Dept Internal Med, Lausanne, Switzerland. [Erdmann, Jeanette; Willenborg, Christina; Schunkert, Heribert] Med Univ Lubeck, Med Klin 2, D-23538 Lubeck, Germany. [Burnett, Mary-Susan; Devaney, Joseph; Epstein, Stephen E.] Washington Hosp Ctr, Cardiovasc Res Inst, Washington, DC 20010 USA. [Sattar, Naveed] Univ Glasgow, British Heart Fdn, Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland. [Willenborg, Christina; Koenig, Inke R.] Med Univ Lubeck, Inst Med Biometrie & Stat, D-23538 Lubeck, Germany. [Hingorani, Aroon] UCL, Ctr Clin Pharmacol, London, England. [Hengstenberg, Christian; Stark, Klaus; Winogradow, Janina; Grassl, Martina; Reinhard, Wibke] Univ Regensburg, Klin & Poliklin Innere Med 2, Regensburg, Germany. [Deanfield, John] Great Ormond St Hosp Sick Children, Cardiothorac Unit, Natl Hlth Serv Trust, London WC1N 3JH, England. [Hall, Alistair S.] Univ Leeds, Fac Med & Hlth, Leeds Inst Mol Med, Leeds, W Yorkshire, England. [Hall, Alistair S.] Univ Leeds, Fac Med & Hlth, Leeds Inst Genet Hlth & Therapeut, Leeds, W Yorkshire, England. [Egan, Josephine M.] NIA, Clin Invest Lab, Baltimore, MD 21224 USA. [Thompson, John R.] Univ Leicester, Dept Hlth Sci, Leicester, Leics, England. [Ricketts, Sally L.] Univ Cambridge, Dept Publ Hlth & Primary Care, Strangeways Res Lab, Cambridge, England. [Grundy, Scott] Univ Texas SW Med Ctr Dallas, Dept Clin Nutr, Ctr Human Nutr, Dallas, TX 75390 USA. [Wichmann, H-Erich] German Res Ctr Environm Hlth, Inst Epidemiol, Helmholtz Zentrum Munchen, Neuherberg, Germany. [Wichmann, H-Erich] Univ Munich, Inst Med Informat Sci Biometry & Epidemiol, Munich, Germany. [Barter, Phil] Heart Res Inst, Sydney, NSW, Australia. [Mahley, Robert] Gladstone Inst Neurol Dis, San Francisco, CA USA. [Mahley, Robert] Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, Cardiovasc Res Inst, San Francisco, CA 94141 USA. [Kesaniemi, Y. Antero] Univ Oulu, Dept Internal Med, SF-90220 Oulu, Finland. [Kesaniemi, Y. Antero] Univ Oulu, Bioctr Oulu, Oulu, Finland. [Rader, Daniel J.; Reilly, Muredach P.] Univ Penn, Sch Med, Cardiovasc Inst, Philadelphia, PA 19104 USA. [Rader, Daniel J.; Reilly, Muredach P.] Univ Penn, Sch Med, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA. [Stewart, Alexandre F. R.; McPherson, Ruth] Univ Ottawa, Inst Heart, Div Cardiol, Ottawa, ON, Canada. [Samani, Nilesh J.] Univ Leicester, Glenfield Hosp, Dept Cardiovasc Sci, Leicester, Leics, England. RP Richards, JB (reprint author), McGill Univ, Jewish Gen Hosp, Dept Med, Montreal, PQ H3T 1E2, Canada. EM brent.richards@mcgill.ca RI Erdmann, Jeanette/P-7513-2014; Stark, Klaus/D-3813-2009; Stewart, Alexandre/A-5677-2011; Willenborg, Christina/D-2668-2012; Deloukas, Panos/B-2922-2013; Colaus, PsyColaus/K-6607-2013; Aulchenko, Yurii/M-8270-2013; Prokopenko, Inga/H-3241-2014; Fox, Laura /C-6249-2016; Konig, Inke/A-4544-2009; Erdmann, Jeanette/A-4417-2009; Davey Smith, George/A-7407-2013; OI Stewart, Alexandre/0000-0003-2673-9164; Erdmann, Jeanette/0000-0002-4486-6231; Dupuis, Josee/0000-0003-2871-3603; Soranzo, Nicole/0000-0003-1095-3852; Semple, Robert/0000-0001-6539-3069; St Pourcain, Beate/0000-0002-4680-3517; Melzer, David/0000-0002-0170-3838; Sladek, Robert/0000-0002-2730-1204; Evans, David/0000-0003-0663-4621; Timpson, Nicholas/0000-0002-7141-9189; Stark, Klaus/0000-0002-7832-1942; Willenborg, Christina/0000-0001-5217-6882; Deloukas, Panos/0000-0001-9251-070X; Aulchenko, Yurii/0000-0002-7899-1575; Prokopenko, Inga/0000-0003-1624-7457; Davey Smith, George/0000-0002-1407-8314; Monsalve, Beatriz Elena/0000-0002-5994-866X FU Wellcome Trust [080952/Z/06/Z, 078986/Z/06/Z]; United Kingdom Medical Research Council Centre for Obesity and Related Metabolic Diseases; Canadian Institutes of Health Research (CIHR); the Cardiovascular Institute of the University of Pennsylvania; GlaxoSmithKline; Deutsche Forschungsgemeinschaft; German Federal Ministry of Education and Research ( BMBF) in the context of the German National Genome Research Network [NGFN-2, NGFN-plus]; EU [LSHM-CT-2006-037593]; German Federal Ministry of Education and Research; State of Bavaria; Cancer Research United Kingdom; Medical Research Council; BHF; UK Medical Research Council; University of Bristol; British Heart Foundation [MRC PG/07/002]; National Heart, Lung, and Blood Institute's Framingham Heart Study [N01-HC-25195, N02-HL-6-4278]; Framingham Heart Study SNP Health Association Resource (SHARe) project; National Institutes of Health; National Center for Research Resources, General Clinical Research Centers Program [M01-RR-01066]; American Diabetes Association Career Development Award; sanofi-aventis; NIH NCRR Shared Instrumentation [1S10RR163736-01A1]; Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center; National Institute for Diabetes and Digestive and Kidney Diseases ( NIDDK) [R01 DK078616, K24 DK080140, K23 DK65978]; Massachusetts General Hospital Physician Scientist Development Award; Doris Duke Charitable Foundation Clinical Scientist Development Award; Centre de Recherche Medicale de l'Universite de Sherbrooke (CRMUS); CIHR; European Community [FP7/2007-2013, HEALTH-F2-2008-201865-GEFOS, HEALTH-F4-2007-201413]; FP-5 GenomEUtwin Project [QLG2-CT-2002-01254]; Department of Health via the National Institute for Health Research ( NIHR); St Thomas' NHS Foundation Trust in partnership with King's College London; Biotechnology and Biological Sciences Research Council (BBSRC) [Biotechnology and Biological Sciences Research Council ( BBSRC) project grant (G20234]; National Eye Institute via an NIH/CIDR genotyping project FX N01-HC-25195), National Institute for Diabetes and Digestive and Kidney Diseases ( NIDDK) R01 DK078616 to JBM, JD, and JCF, NIDDK K24 DK080140 to JBM, NIDDK Research Career Award K23 DK65978, a Massachusetts General Hospital Physician Scientist Devlopment Award and a Doris Duke Charitable Foundation Clinical Scientist Development Award to JCF, and the Boston University Linux Cluster for Genetic Analysis ( LinGA) funded by the NIH NCRR Shared Instrumentation grant (1S10RR163736-01A1). MFH was supported by the Centre de Recherche Medicale de l'Universite de Sherbrooke (CRMUS) and the CIHR. TwinsUK: The study was funded by the Wellcome Trust, European Community's Seventh Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F2-2008-201865-GEFOS and (FP7/2007-2013), ENGAGE project grant agreement HEALTH-F4-2007-201413, and the FP-5 GenomEUtwin Project (QLG2-CT-2002-01254). The study also receives support from the Department of Health via the National Institute for Health Research ( NIHR) comprehensive Biomedical Research Centre award to Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London. TDS is an NIHR senior Investigator. The project also received support from a Biotechnology and Biological Sciences Research Council ( BBSRC) project grant (G20234). The authors acknowledge the funding and support of the National Eye Institute via an NIH/CIDR genotyping project ( PI: Terri Young). We thank the staff from the Genotyping Facilities at the Wellcome Trust Sanger Institute for sample preparation, quality control, and genotyping led by Leena Peltonen and Panos Deloukas; Le Centre National de Genotypage, France, led by Mark Lathrop, for genotyping; Duke University, North Carolina, USA, led by David Goldstein, for genotyping; and the Finnish Institute of Molecular Medicine, Finnish Genome Center, University of Helsinki, led by Aarno Palotie. Genotyping was also performed by CIDR as part of an NEI/NIH project grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 59 TC 78 Z9 80 U1 0 U2 21 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7390 J9 PLOS GENET JI PLoS Genet. PD DEC PY 2009 VL 5 IS 12 AR e1000768 DI 10.1371/journal.pgen.1000768 PG 10 WC Genetics & Heredity SC Genetics & Heredity GA 542CT UT WOS:000273469700019 PM 20011104 ER PT J AU Koh, KP Sundrud, MS Rao, A AF Koh, Kian Peng Sundrud, Mark S. Rao, Anjana TI Domain Requirements and Sequence Specificity of DNA Binding for the Forkhead Transcription Factor FOXP3 SO PLOS ONE LA English DT Article ID REGULATORY T-CELLS; NF-KAPPA-B; IMMUNE DYSREGULATION; NUCLEAR FACTOR; HELIX PROTEIN; TARGET GENES; MUTATIONS; FAMILY; MOUSE; MICE AB The forkhead, winged-helix transcription factor FOXP3 is preferentially expressed in T regulatory (Treg) cells and is critical for their immunosuppressive function. Mutations that abolish FOXP3 function lead to systemic autoimmunity in mice and humans. However, the manner by which FOXP3 recognizes cognate DNA elements is unclear. Here we identify an in vitro optimized DNA sequence to assess FOXP3 DNA binding by electrophoretic mobility shift assay (EMSA). The optimized sequence contains two tandem copies of a core DNA element resembling, but not identical to, the canonical forkhead (FKH) binding element. The tandem nature of this optimized FOXP3-binding oligonucleotide suggests a requirement for multimerization, and EMSA experiments confirm that both the DNA-binding FKH domain and an intact leucine-zipper domain, which mediates homo-multimerization of FOXP3, are required for DNA binding. These results establish a practical framework for understanding the molecular basis by which FOXP3 regulates gene transcription and programs Treg suppressive function. C1 [Koh, Kian Peng] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. Immune Dis Inst, Boston, MA USA. RP Koh, KP (reprint author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. EM arao@idi.harvard.edu FU NIH [ROI AI48213, R37 CA42471]; Cancer Research Institute FX This work was funded by NIH grants to A. R. (ROI AI48213 and R37 CA42471). M. S. S was supported by the Irvington Institute fellowship program of the Cancer Research Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 40 TC 24 Z9 24 U1 1 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 1 PY 2009 VL 4 IS 12 AR e8109 DI 10.1371/journal.pone.0008109 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 533MT UT WOS:000272828700020 PM 19956618 ER PT J AU Paganetti, H AF Paganetti, Harald TI The Use of Computational Patient Models to Assess the Risk of Developing Radiation-Induced Cancers From Radiation Therapy of the Primary Cancer SO PROCEEDINGS OF THE IEEE LA English DT Article DE Cancer; Monte Carlo methods; radiation effects ID DOSE CONVERSION COEFFICIENTS; MAN ANATOMICAL MODEL; MONTE-CARLO CALCULATIONS; INDUCED 2ND CANCERS; VIP-MAN; PROTON THERAPY; PEDIATRIC-PATIENTS; MONOENERGETIC NEUTRONS; SECONDARY NEUTRONS; ABSORBED FRACTIONS AB Even with highly conformal treatment delivery techniques for radiation therapy, one cannot avoid the irradiation of healthy tissues surrounding the tumor. In treatment planning, absorbed dose constraints are defined for organs at risk visible in the patient's computed tomography scan in order to minimize side effects. However, scattered or secondary absorbed dose is also deposited in areas outside of the imaged volume. Although these doses are typically quite low (well below 1% of the therapeutic dose), there is the potential risk for patients to develop a radiation-induced second malignancy later in life. For a systematic analysis of scattered or secondary doses and their carcinogenic effects, accurate patient-specific organ dosimetry is necessary. Computational patient models are needed because low absorbed doses to organs away from the primarily irradiated target area cannot be measured easily. Monte Carlo simulations can incorporate the geometry and tissue properties of computational phantoms to simulate dose deposition events weighted with radiation weighting factors. Epidemiological models can then be applied to relate organ equivalent absorbed doses to cancer risks. This paper describes the use of computational phantoms in conjunction with Monte Carlo dose calculations and epidemiological risk models. We demonstrate how these simulations are applied with the purpose of estimating second cancer risks in radiation therapy and of improving existing epidemiological risk models. C1 [Paganetti, Harald] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Paganetti, Harald] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Paganetti, H (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. EM hpaganetti@partners.org FU National Cancer Institute [CO6 CA059267] FX This work was supported in part by the National Cancer Institute under Grant CO6 CA059267. NR 71 TC 1 Z9 1 U1 1 U2 1 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855 USA SN 0018-9219 J9 P IEEE JI Proc. IEEE PD DEC PY 2009 VL 97 IS 12 BP 1977 EP 1987 DI 10.1109/JPROC.2009.2023809 PG 11 WC Engineering, Electrical & Electronic SC Engineering GA 521VF UT WOS:000271952100006 ER PT J AU Emery, CM Vijayendran, KG Zipser, MC Sawyer, AM Niu, LL Kim, JJ Hatton, C Chopra, R Oberholzer, PA Karpova, MB MacConaill, LE Zhang, JM Gray, NS Sellers, WR Dummer, R Garraway, LA AF Emery, Caroline M. Vijayendran, Krishna G. Zipser, Marie C. Sawyer, Allison M. Niu, Lili Kim, Jessica J. Hatton, Charles Chopra, Rajiv Oberholzer, Patrick A. Karpova, Maria B. MacConaill, Laura E. Zhang, Jianming Gray, Nathanael S. Sellers, William R. Dummer, Reinhard Garraway, Levi A. TI MEK1 mutations confer resistance to MEK and B-RAF inhibition SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE BRAF; drug resistance; MAP kinase; melanoma ID FACIO-CUTANEOUS SYNDROME; SMALL-CELL LUNG; HUMAN CANCER; PHASE-II; BCR-ABL; KINASE; TUMOR; GENE; BRAF; IDENTIFICATION AB Genetic alterations that activate the mitogen-activated protein kinase (MAP kinase) pathway occur commonly in cancer. For example, the majority of melanomas harbor mutations in the BRAF oncogene, which are predicted to confer enhanced sensitivity to pharmacologic MAP kinase inhibition (e. g., RAF or MEK inhibitors). We investigated the clinical relevance of MEK dependency in melanoma by massively parallel sequencing of resistant clones generated from a MEK1 random mutagenesis screen in vitro, as well as tumors obtained from relapsed patients following treatment with AZD6244, an allosteric MEK inhibitor. Most mutations conferring resistance to MEK inhibition in vitro populated the allosteric drug binding pocket or alpha-helix C and showed robust (approximate to 100-fold) resistance to allosteric MEK inhibition. Other mutations affected MEK1 codons located within or abutting the N-terminal negative regulatory helix (helix A), which also undergo gain-of-function germline mutations in cardio-facio-cutaneous (CFC) syndrome. One such mutation, MEK1(P124L), was identified in a resistant metastatic focus that emerged in a melanoma patient treated with AZD6244. Both MEK1(P124L) and MEK1(Q56P), which disrupts helix A, conferred cross-resistance to PLX4720, a selective B-RAF inhibitor. However, exposing BRAF-mutant melanoma cells to AZD6244 and PLX4720 in combination prevented emergence of resistant clones. These results affirm the importance of MEK dependency in BRAF-mutant melanoma and suggest novel mechanisms of resistance to MEK and B-RAF inhibitors that may have important clinical implications. C1 [Emery, Caroline M.; Vijayendran, Krishna G.; Sawyer, Allison M.; Niu, Lili; Kim, Jessica J.; Hatton, Charles; Oberholzer, Patrick A.; MacConaill, Laura E.; Garraway, Levi A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Emery, Caroline M.; Vijayendran, Krishna G.; Sawyer, Allison M.; Niu, Lili; Kim, Jessica J.; Hatton, Charles; Oberholzer, Patrick A.; MacConaill, Laura E.; Garraway, Levi A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA. [Zipser, Marie C.; Oberholzer, Patrick A.; Karpova, Maria B.; Dummer, Reinhard] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland. [Chopra, Rajiv; Sellers, William R.] Novartis Inst BioMed Res, Cambridge, MA 02139 USA. [Oberholzer, Patrick A.; Garraway, Levi A.] Broad Inst, Cambridge, MA 02142 USA. [Zhang, Jianming; Gray, Nathanael S.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. RP Garraway, LA (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA. EM levi_garraway@dfci.harvard.edu FU Swiss National Foundation [310040-103671]; Gottfried and Julia Bangerter Rhyner Stiftung; Burroughs-Wellcome Fund; Robert Wood Johnson Foundation; Melanoma Research Alliance; Starr Cancer Consortium; Novartis Institute for Biomedical Research [K08CA115927, P50CA093683, DP2OD002750] FX This work was supported by grants from the Swiss National Foundation (grant 310040-103671), the Gottfried and Julia Bangerter Rhyner Stiftung, the Burroughs-Wellcome Fund, the Robert Wood Johnson Foundation, the Melanoma Research Alliance, The Starr Cancer Consortium, and the Novartis Institute for Biomedical Research, grants K08CA115927, P50CA093683, and DP2OD002750. NR 31 TC 296 Z9 298 U1 1 U2 21 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD DEC 1 PY 2009 VL 106 IS 48 BP 20411 EP 20416 DI 10.1073/pnas.0905833106 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 525YQ UT WOS:000272254400051 PM 19915144 ER PT J AU Liu, HS Stufflebeam, SM Sepulcre, J Hedden, T Buckner, RL AF Liu, Hesheng Stufflebeam, Steven M. Sepulcre, Jorge Hedden, Trey Buckner, Randy L. TI Evidence from intrinsic activity that asymmetry of the human brain is controlled by multiple factors SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE fMRI; functional connectivity; laterality ID RESTING HUMAN BRAIN; LANGUAGE LATERALIZATION; FUNCTIONAL CONNECTIVITY; CEREBRAL LATERALIZATION; BIOLOGICAL MECHANISMS; SEX-DIFFERENCES; HANDEDNESS; CORTEX; DISEASE; AUTISM AB Cerebral lateralization is a fundamental property of the human brain and a marker of successful development. Here we provide evidence that multiple mechanisms control asymmetry for distinct brain systems. Using intrinsic activity to measure asymmetry in 300 adults, we mapped the most strongly lateralized brain regions. Both men and women showed strong asymmetries with a significant, but small, group difference. Factor analysis on the asymmetric regions revealed 4 separate factors that each accounted for significant variation across subjects. The factors were associated with brain systems involved in vision, internal thought (the default network), attention, and language. An independent sample of right-and left-handed individuals showed that hand dominance affects brain asymmetry but differentially across the 4 factors supporting their independence. These findings show the feasibility of measuring brain asymmetry using intrinsic activity fluctuations and suggest that multiple genetic or environmental mechanisms control cerebral lateralization. C1 [Sepulcre, Jorge; Hedden, Trey; Buckner, Randy L.] Harvard Univ, Dept Psychol, Ctr Brain Sci, Cambridge, MA 02138 USA. [Liu, Hesheng; Stufflebeam, Steven M.; Sepulcre, Jorge; Hedden, Trey; Buckner, Randy L.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA 02129 USA. [Stufflebeam, Steven M.] Harvard MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Buckner, Randy L.] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA. [Sepulcre, Jorge; Buckner, Randy L.] Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA. RP Buckner, RL (reprint author), Harvard Univ, Dept Psychol, Ctr Brain Sci, 52 Oxford St,Room 280, Cambridge, MA 02138 USA. EM rbuckner@wjh.harvard.edu OI Liu, Hesheng/0000-0002-7233-1509 FU National Institutes of Health [R01AG021910, R01AG034556, P41RR14074, K08MH067966]; Simons Foundation; Howard Hughes Medical Institute FX We thank Abraham Snyder, Jessica Andrews-Hanna, Itamar Kahn, Ting Ren, and Tanveer Talukdar for assistance with functional connectivity; Marisa Hollinshead and Betsy Hemphill for data collection; Timothy O'Keefe and Gabriele Fariello for neuroinformatics; and the Harvard Center for Brain Science and the Athinoula A. Martinos Center for Biomedical Imaging for imaging support. This work was supported by National Institutes of Health Grants R01AG021910, R01AG034556, P41RR14074, and K08MH067966; the Simons Foundation; and the Howard Hughes Medical Institute. NR 39 TC 116 Z9 118 U1 4 U2 21 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD DEC 1 PY 2009 VL 106 IS 48 BP 20499 EP 20503 DI 10.1073/pnas.0908073106 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 525YQ UT WOS:000272254400066 PM 19918055 ER PT J AU Gutierrez, PM Brenner, LA Olson-Madden, JH Breshears, RE Homaifar, BY Betthauser, LM Staves, P Adler, LE AF Gutierrez, Peter M. Brenner, Lisa A. Olson-Madden, Jennifer H. Breshears, Ryan E. Homaifar, Beeta Y. Betthauser, Lisa M. Staves, Pamela Adler, Lawrence E. TI Consultation as a Means of Veteran Suicide Prevention SO PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE LA English DT Article DE suicide; veterans; consultation; assessment; collaboration ID SELF-HARM; COUNTERTRANSFERENCE; BEHAVIOR; REASONS; RISK; IMPULSIVITY; VALIDATION; ATTEMPTERS; INVENTORY; WORKING AB The development and implementation of a suicide consultation service being run by an interdisciplinary team in a metropolitan Veteran's Administration (VA) medical center is described. This service is grounded in a collaborative theoretical framework. An overview of the consultation process and theoretical and empirical literature to support the framework used by the service are provided. Some of the interventions commonly recommended to referring clinicians to reduce client suicide risk are reviewed. Although there are many challenges to running a service such as this, the authors conclude that the model presented is flexible enough to be applied in a variety of settings. C1 [Gutierrez, Peter M.] Denver VA Med Ctr, MIRECC, Denver, CO 80220 USA. [Gutierrez, Peter M.] Univ Colorado Denver, Sch Med, Dept Psychiat, Denver, CO USA. RP Gutierrez, PM (reprint author), Denver VA Med Ctr, MIRECC, 1055 Clermont St, Denver, CO 80220 USA. EM peter.gutierrez@va.gov NR 68 TC 2 Z9 2 U1 0 U2 2 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0735-7028 J9 PROF PSYCHOL-RES PR JI Prof. Psychol.-Res. Pract. PD DEC PY 2009 VL 40 IS 6 BP 586 EP 592 DI 10.1037/a0016497 PG 7 WC Psychology, Multidisciplinary SC Psychology GA 532RK UT WOS:000272767000007 ER PT J AU Dellon, EP Shores, MD Nelson, KI Wolfe, J Noah, TL Hanson, LC AF Dellon, Elisabeth P. Shores, Mitchell D. Nelson, Katherine I. Wolfe, Joanne Noah, Terry L. Hanson, Laura C. TI Caregivers' perspectives on decision making about lung transplantation in cystic fibrosis SO PROGRESS IN TRANSPLANTATION LA English DT Article ID ALLOCATION; SURVIVAL; TIME; LIFE AB Context-Lung transplantation extends survival for some patients with advanced cystic fibrosis, but it is complicated, has many potential risks, and its outcomes are difficult to predict. No standards exist for informed decision making about transplantation. Objective-To assess decision making from the perspective of caregivers; of patients who faced the transplant decision before dying of cystic fibrosis or transplant complications. Design-Semistructured interviews with descriptive and qualitative content analysis. Participants-Twenty-eight caregivers of patients with cystic fibrosis who received care at our center and died between 1996 and 2006. Results-Of 28 patients who considered lung transplantation, 19 (68%) received transplants, 6 (21%) died while waiting for transplant, and 3 (11%) declined transplant. Three caregivers (11%) thought that the patient did not fully understand the reason for transplant referral. Five (18%) thought that the patient did not fully understand potential risks. Ten (36%) thought that alternatives were not fully understood. The only alternatives to transplant identified, progressive illness and the possibility of earlier death without transplant, were unacceptable to most. Thirteen caregivers (46%) reported that the patient thought that declining transplant was not an option. Caregivers described the decision as "easy" for 19 (68%), often expressing a sentiment of "do or die." Those who described the decision as "easy" recalled fewer elements of informed decision making. Conclusions-From caregivers' reports, patients with cystic fibrosis may not fully understand risks of and alternatives to lung transplantation. Because a strong desire to prolong life necessitates honest communication about potential outcomes interventions are needed to facilitate high-quality decision making. (Progress in Transplantation. 2009;19:318-325) C1 [Dellon, Elisabeth P.] Univ N Carolina, Sch Med, Dept Pediat, Div Pulmonol, Chapel Hill, NC 27599 USA. [Wolfe, Joanne] Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Dellon, EP (reprint author), Univ N Carolina, Sch Med, Dept Pediat, Div Pulmonol, CB 7217,5119-B Bioinformat Bldg,130 Mason Farm Rd, Chapel Hill, NC 27599 USA. EM elisabeth_dellon@med.unc.edu FU Cystic Fibrosis Foundation [DELLON07DO, DELLO08A0]; Agency for Healthcare Research and Quality [U18HS10397-06] FX This work was supported by grants from the Cystic Fibrosis Foundation (DELLON07DO and DELLO08A0) and the Agency for Healthcare Research and Quality (U18HS10397-06, PI Alan Stiles). NR 20 TC 9 Z9 9 U1 1 U2 3 PU INNOVISION COMMUNICATIONS PI ALISO VIEJO PA 101 COLUMBIA, ALISO VIEJO, CA 92656 USA SN 1526-9248 J9 PROG TRANSPLANT JI Prog. Transplant. PD DEC PY 2009 VL 19 IS 4 BP 318 EP 325 PG 8 WC Surgery; Transplantation SC Surgery; Transplantation GA 531GY UT WOS:000272653600005 PM 20050454 ER PT J AU Lybrand, J Caroff, S AF Lybrand, Janice Caroff, Stanley TI Management of Schizophrenia with Substance Use Disorders SO PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Article DE Schizophrenia; Substance use disorders; Alcohol; Cannabis; Nicotine; Cocaine ID SEVERE MENTAL-ILLNESS; SELF-MEDICATION HYPOTHESIS; DRUG-USE DISORDERS; DUAL DIAGNOSIS; COCAINE DEPENDENCE; ALCOHOL-USE; TARDIVE-DYSKINESIA; SMOKING-CESSATION; CIGARETTE-SMOKING; EXCESS MORTALITY AB Around 50% of patients with schizophrenia develop a co-occurring substance use disorder involving alcohol or illicit substances at some time during their lives. The comorbid substance abuse will markedly affect the course of illness of schizophrenia. In this article, the authors review the epidemiology, theories of causation, effect on the course of illness, and treatment of co-occurring schizophrenia and substance use disorder. C1 [Lybrand, Janice; Caroff, Stanley] Philadelphia VA Med Ctr, Dept Psychiat, Philadelphia, PA 19104 USA. [Caroff, Stanley] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. RP Lybrand, J (reprint author), Philadelphia VA Med Ctr, Dept Psychiat, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM janice.lybrand@va.gov NR 75 TC 10 Z9 10 U1 2 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0193-953X EI 1558-3147 J9 PSYCHIAT CLIN N AM JI Psychiatr. Clin. North Amer. PD DEC PY 2009 VL 32 IS 4 BP 821 EP + DI 10.1016/j.psc.2009.09.002 PG 14 WC Psychiatry SC Psychiatry GA 601KO UT WOS:000278058200007 PM 19944886 ER PT J AU Goldstein, G Luther, JF Haas, GL Gordon, AJ Appelt, C AF Goldstein, Gerald Luther, James F. Haas, Gretchen L. Gordon, Adam J. Appelt, Cathleen TI Comorbidity Between Psychiatric and General Medical Disorders in Homeless Veterans SO PSYCHIATRIC QUARTERLY LA English DT Article DE Homelessness; Comorbidity; Health Status ID MENTALLY-ILL VETERANS; EXPERIENCING HOMELESSNESS; SUBSTANCE-ABUSE; URBAN HOMELESS; HEALTH; PEOPLE; SERVICES; ILLNESS; PROGRAM; DISEASE AB Homeless veterans have numerous co-occurring medical and behavioral health problems. Identification of common patterns of comorbid conditions may help providers to determine severity of medical conditions and triage health care more effectively. In this study we identify such patterns of comorbid medical and psychiatric disorders using cluster analysis and we evaluate relationships between these patterns and sociodemographic factors. We used data from a survey of 3,595 veterans in a regional VA network who were presently or recently homeless assessing nine major medical disorder and six psychiatric disorder categories. Diagnostic ratings of presence or absence of these disorders were placed into the same cluster analysis to determine whether separable clusters emerged reflecting differing diagnostic profiles. There are recognizable patterns of comorbidity involving several psychiatric and general medical disorders, as well as disorders of both types that exist independently. Cluster membership was associated with various sociodemographic indices. Mental and general medical health problems in homeless veterans often occur in association with each other and form identifiable patterns that vary on sociodemographic factors. C1 [Goldstein, Gerald; Luther, James F.; Haas, Gretchen L.; Gordon, Adam J.; Appelt, Cathleen] VA Pittsburgh Healthcare Syst, MIRECC, VISN MIRECC 4, Pittsburgh, PA 15206 USA. [Goldstein, Gerald; Luther, James F.; Haas, Gretchen L.; Gordon, Adam J.; Appelt, Cathleen] Univ Pittsburgh, Pittsburgh, PA USA. RP Goldstein, G (reprint author), VA Pittsburgh Healthcare Syst, MIRECC, VISN MIRECC 4, 7180 Highland Dr 151R, Pittsburgh, PA 15206 USA. EM ggold@nb.net FU NIMH NIH HHS [T32 MH015169, T32 MH015169-31] NR 22 TC 7 Z9 7 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0033-2720 J9 PSYCHIAT QUART JI Psychiatr. Q. PD DEC PY 2009 VL 80 IS 4 BP 199 EP 212 DI 10.1007/s11126-009-9106-6 PG 14 WC Psychiatry SC Psychiatry GA 523BP UT WOS:000272046500001 PM 19597992 ER PT J AU Chan, D Cheadle, AD Reiber, G Unutzer, J Chaney, EF AF Chan, Domin Cheadle, Allen D. Reiber, Gayle Unutzer, Jurgen Chaney, Edmund F. TI Health Care Utilization and Its Costs for Depressed Veterans With and Without Comorbid PTSD Symptoms SO PSYCHIATRIC SERVICES LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; COLLABORATIVE CARE; ANXIETY DISORDERS; VIETNAM VETERANS; MAJOR DEPRESSION; IMPACT; AFGHANISTAN; DIAGNOSES; SERVICES; TRAUMA AB Objective: This study examined health care utilization and costs of care among Veterans Affairs (VA) patients with depression and with or without symptoms of comorbid posttraumatic stress disorder (PTSD). Methods: Cross-sectional comparisons of health care utilization and costs were conducted with VA administrative data for a sample of veterans from a randomized trial of collaborative care depression treatment in ten VA primary care clinics across five states. Patients with depression or dysthymia were included in the study, and those who were acutely suicidal or had probable bipolar disorder were excluded. The sample of 606 patients was mainly male, white, and aged 55 or older. Health care utilization, costs, and medication data from VA administrative databases were analyzed over 12 months. Results: Patients with depression and PTSD (screen score >= 3) were more emotionally distressed, had more frequent mental health specialty visits (6.91 versus 1.68, p<.001), more total outpatient visits (26.16 versus 19.94, p<.001), and correspondingly higher outpatient mental health care costs over the previous 12 months compared with depressed patients without PTSD. Antidepressants were prescribed to a higher proportion of depressed patients with PTSD (61% versus 40%). Conclusions: Patients with PTSD and depression had greater utilization of specialty mental health treatments and antidepressant medications and higher mental health care costs in the previous 12 months than depressed patients without PTSD. As military personnel return from Iraq, both VA and non-VA health care providers need to plan for an increase in outpatient mental health services and costs, particularly among depressed veterans who also have PTSD. (Psychiatric Services 60: 1612-1617, 2009) C1 [Chan, Domin; Unutzer, Jurgen; Chaney, Edmund F.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Cheadle, Allen D.; Reiber, Gayle] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Reiber, Gayle; Chaney, Edmund F.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. RP Chan, D (reprint author), Univ Washington, Dept Psychiat & Behav Sci, Box 356560, Seattle, WA 98195 USA. EM dominc@u.washington.edu FU U. S. Department of Veterans Affairs; Veterans Health Administration; Health Services Research and Development Service [MHI 99375] FX The results reported here were from WAVES. The research reported was supported by the U. S. Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (MHI 99375). The authors recognize Chuan-Fen Liu, Ph. D., M. P. H., for contributing to the conceptual design, guidance in data preparation and review of this study; Lori Zoellner, Ph. D., for her PTSD content expertise; and Ming-Yu Fan, Ph. D., B. S., for her statistical consultation and guidance. The views expressed here are those of the authors and do not necessarily represent the views of the VA or the University of Washington. NR 33 TC 33 Z9 33 U1 7 U2 11 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD DEC PY 2009 VL 60 IS 12 BP 1612 EP 1617 PG 6 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 526FO UT WOS:000272273300008 PM 19952151 ER PT J AU Biederman, I Yue, XM Davidoff, J AF Biederman, Irving Yue, Xiaomin Davidoff, Jules TI Representation of Shape in Individuals From a Culture With Minimal Exposure to Regular, Simple Artifacts: Sensitivity to Nonaccidental Versus Metric Properties SO PSYCHOLOGICAL SCIENCE LA English DT Article ID OBJECT RECOGNITION; CORTEX AB Many of the phenomena underlying shape recognition can be derived from the greater sensitivity to nonaccidental properties of an image (e.g., whether a contour is straight or curved), which are invariant to orientation in depth, than to the metric properties of an image (e.g., a contour's degree of curvature), which can vary with orientation. What enables this sensitivity? One explanation is that it derives from people's immersion in a manufactured world in which simple, regular shapes distinguished by nonaccidental properties abound (e.g., a can, a brick), and toddlers are encouraged to play with toy shape sorters. This report provides evidence against this explanation. The Himba, a seminomadic people living in a remote region of northwestern Namibia where there is little exposure to regular, simple artifacts, were virtually identical to Western observers in their greater sensitivity to nonaccidental properties than to metric properties of simple shapes. C1 [Biederman, Irving] Univ So Calif, Dept Psychol Neurosci, Los Angeles, CA 90089 USA. [Yue, Xiaomin] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Cambridge, MA 02138 USA. [Davidoff, Jules] Univ London, Dept Psychol, Ctr Cognit Computat & Culture, London WC1E 7HU, England. RP Biederman, I (reprint author), Univ So Calif, Dept Psychol Neurosci, 3641 Watt Way,Hedco Neurosci Bldg,Room 316, Los Angeles, CA 90089 USA. EM bieder@usc.edu NR 17 TC 16 Z9 17 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0956-7976 J9 PSYCHOL SCI JI Psychol. Sci. PD DEC PY 2009 VL 20 IS 12 BP 1437 EP 1442 PG 6 WC Psychology, Multidisciplinary SC Psychology GA 524SQ UT WOS:000272163600001 PM 19883490 ER PT J AU Woodward, HE Taft, CT Gordon, RA Meis, LA AF Woodward, Halley E. Taft, Casey T. Gordon, Richard A. Meis, Laura A. TI Clinician Bias in the Diagnosis of Posttraumatic Stress Disorder and Borderline Personality Disorder SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY LA English DT Article DE posttraumatic stress disorder; borderline personality disorder; diagnostic bias; gender bias; anchoring effect AB A sample of volunteers from a group of randomly selected psychologists in New York State (N = 119) provided a primary diagnosis and rule-out diagnoses for a case vignette that included balanced criteria for borderline personality disorder (BPD) and posttraumatic stress disorder (PTSD) in a mail survey. Vignettes portrayed a male or a female client, and history of childhood sexual abuse was presented either first or last. Results indicated that cognitive-behavioral therapy (CBT) clinicians were more likely to diagnose PTSD than BPD or other disorders, and psychodynamic clinicians were more likely to diagnose BPD or other disorders than PTSD. An anchoring effect (i.e., evidence that one regards initial information as an anchor that may or may not be adjusted upon exposure to subsequent information) of abuse history presentation was found. Findings did not support a patient or clinician gender bias. C1 [Taft, Casey T.; Meis, Laura A.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA. [Taft, Casey T.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Woodward, Halley E.; Gordon, Richard A.] Bard Coll, Annandale On Hudson, NY USA. RP Taft, CT (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD, 150 S Huntington Ave, Boston, MA 02130 USA. EM casey.taft@va.gov NR 19 TC 4 Z9 4 U1 1 U2 9 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1942-9681 J9 PSYCHOL TRAUMA-US JI Psychol. Trauma PD DEC PY 2009 VL 1 IS 4 BP 282 EP 290 DI 10.1037/a0017944 PG 9 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA V16NK UT WOS:000207876100003 ER PT J AU Safren, SA Thomas, BE Mimiaga, MJ Chandrasekaran, V Menon, S Swaminathan, S Mayer, KH AF Safren, Steven A. Thomas, Beena E. Mimiaga, Matthew J. Chandrasekaran, V. Menon, Sunil Swaminathan, Soumya Mayer, Kenneth H. TI Depressive symptoms and human immunodeficiency virus risk behavior among men who have sex with men in Chennai, India SO PSYCHOLOGY HEALTH & MEDICINE LA English DT Article DE men who have sex with men; MSM; depression; India; HIV ID BASE-LINE DATA; BISEXUAL ADULTS; HIV PREVENTION; UNITED-STATES; DISORDERS; PERSPECTIVE; PREVALENCE; INFECTION; PARTNERS; EXPLORE AB Men who have sex with men (MSM) in India are a hidden population, facing unique environmental stressors and cultural pressures that place them at risk for depression. Depression may affect HIV risk behavior in MSM, and may affect the degree to which MSM may benefit from HIV prevention interventions. Depression in MSM in India, however, has largely been understudied. Two hundred ten MSM in Chennai completed an interviewer-administered behavioral assessment battery, which included the 20-item Center for Epidemiologic Studies Depression Scale (CES-D), demographics, sexual risk and identity, and other psychosocial variables. Over half (55%) of the sample exceeded the cutoff (CESD >= 16) to screen in for clinically significant depressive symptoms; this was associated with having had unprotected anal sex (OR = 1.97; 95% CI: 1.01-3.87) and higher number of male partners (OR = 1.04; 95% CI: 1.01-1.07). Statistically significant bivariate predictors of meeting the screen in for depressive symptoms included sexual identity (Kothi > Panthi; OR = 4.90; 95% CI: 2.30-10.54), not being married (OR = 3.40; 95% CI: 1.72-6.81), not having a child (OR = 4.40; 95% CI: 2.07-9.39), family not knowing about one's MSM identity (OR = 2.30; 95% CI: 1.18-4.90), having been paid for sex (OR = 5.10; p 95% CI: 2.87-9.47), and perceiving that one is at risk for acquiring HIV (OR 1.10; 95% CI: 1.02-1.17; continuous). In a multivariable logistic-regression model, unique predictors of screening in for depressive symptoms included not being married (AOR = 3.10; 95% CI: 1.23-7.65), having been paid for sex (AOR 3.80; 95% CI: 1.87-7.99) and the perception of increased risk for HIV (AOR = 1.10; 95% CI: 1.03-1.21; continuous); unprotected anal sex in the 3 months prior to study enrollment approached statistical significance (AOR 2.00; 95% CI: 0.91-4.48). Depression among MSM in Chennai is of concern and should be considered while developing HIV prevention interventions with this Population. MSM who are not married, sex workers, and those who perceive they are at risk for acquiring HIV may be of higher risk for symptoms of depression. C1 [Safren, Steven A.; Mimiaga, Matthew J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. [Safren, Steven A.; Mimiaga, Matthew J.; Mayer, Kenneth H.] Fenway Community Hlth, Fenway Inst, Boston, MA USA. [Thomas, Beena E.; Chandrasekaran, V.; Swaminathan, Soumya] Indian Council Med Res, TB Res Ctr, Div HIV AIDS, Madras, Tamil Nadu, India. [Menon, Sunil] Sahodaran, Madras, Tamil Nadu, India. [Mayer, Kenneth H.] Miriam Hosp, Brown Med Sch, Providence, RI 02906 USA. RP Safren, SA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. EM ssafren@partners.org FU supplement to parent [P30A1060354]; Lifespan/Tufts/Brown University Center for AIDS Research [P30 AI42853]; [1R21 MH085314] FX The authors thank Christine Cooper-Vince for her help with technical aspects of the manuscript. They also thank the staff of Sahodran for their assistance with recruitment and community outreach. Funding for this project was supported by a supplement to parent grant P30A1060354 on which Bruce Walker, MD is the PI, and Steven A. Safren, Ph.D. was the PI of the supplement. Support for some staff (KHM) was from the Lifespan/Tufts/Brown University Center for AIDS Research grant: NIH no. P30 AI42853. Support for analysis and write-up was from 1R21 MH085314 (Safren). NR 28 TC 28 Z9 29 U1 0 U2 4 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1354-8506 J9 PSYCHOL HEALTH MED JI Psychol. Health Med. PD DEC PY 2009 VL 14 IS 6 BP 705 EP 715 DI 10.1080/13548500903334754 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 550QS UT WOS:000274143700008 PM 20183543 ER PT J AU Chen, DC Wang, J Wang, B Yang, SC Zhang, CX Zheng, YL Li, YL Wang, N Yang, KB Xiu, MH Kosten, TR Zhang, XY AF Chen, Da Chun Wang, Jing Wang, Bo Yang, Sheng Chang Zhang, Chong Xi Zheng, You Lan Li, Yan Li Wang, Ning Yang, Ke Bing Xiu, Mei Hong Kosten, Thomas R. Zhang, Xiang Yang TI Decreased levels of serum brain-derived neurotrophic factor in drug-naive first-episode schizophrenia: relationship to clinical phenotypes SO PSYCHOPHARMACOLOGY LA English DT Article DE Schizophrenia; Brain-derived neurotrophic factor; First-episode psychosis; Psychopathology; Neurotrophin ID LONG-TERM TREATMENT; BDNF LEVELS; VAL66MET POLYMORPHISM; BIPOLAR DISORDER; RAT-BRAIN; ANTIPSYCHOTICS; EXPRESSION; PSYCHOSES; TRANSPORT; DOPAMINE AB There is accumulating evidence that brain-derived neurotrophic factor (BDNF) may be involved in the pathophysiology of patients with schizophrenia. Clinical studies show reductions in BDNF in schizophrenic patients treated with first generation antipsychotics or second generation antipsychotics. However, there have been few systematic studies to examine the relationship between BDNF levels and psychopathology in first-episode and drug-na < ve patients with schizophrenia. Serum BDNF levels were determined using enzyme-linked-immunosorbent assay (ELISA) in the serum of 88 never-medicated first-episode and 90 healthy controls subjects matched for age and gender. The schizophrenia symptomatology and the depressive symptoms were assessed by the positive and negative syndrome scale (PANSS) and the Hamilton rating (HAMD) scale for depression. The results showed that BDNF levels were significantly lower in first-episode patients with schizophrenia than in healthy control subjects (9.0 +/- 4.2 ng/ml vs 12.1 +/- 2.2 ng/ml; F = 37.6; df = 1, 176; p < 0.0001). A significant positive correlation between BDNF levels and PANSS positive subscore was observed (r = 0.29; df = 88; p = 0.008). Furthermore, higher BDNF levels were observed in patients with paranoid subtype of schizophrenia. However, no significant correlation between BDNF and HAMD total score was found. Low BDNF levels at the onset of psychosis suggest that it may contribute to the pathogenesis of schizophrenia and perhaps, could be a candidate biological marker for positive symptoms. C1 [Kosten, Thomas R.; Zhang, Xiang Yang] Baylor Coll Med, VA Med Ctr, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Chen, Da Chun; Li, Yan Li; Wang, Ning; Yang, Ke Bing; Xiu, Mei Hong] Beijing Huilongguan Hosp, Beijing, Peoples R China. [Wang, Jing; Yang, Sheng Chang] Guangxi Normal Univ, Coll Life Sci, Guilin 541004, Peoples R China. [Wang, Bo; Zheng, You Lan] Jilin Agr Univ, Coll Chinese Med Mat, Changchun 130118, Peoples R China. [Zhang, Chong Xi] Shandong Univ Weihai, Marine Coll, Shandong Weihai 264209, Peoples R China. RP Kosten, TR (reprint author), Baylor Coll Med, VA Med Ctr, Menninger Dept Psychiat & Behav Sci, Res Bldg 110,Room 229,2002 Holcombe Blvd, Houston, TX 77030 USA. EM kosten@bcm.edu; xyzhang@bcm.edu FU Beijing Municipal Natural Science Foundation [7072035]; Stanley Medical Research Institute [03T-459, 05T-726]; Department of Veterans Affairs, VISN 16, Mental Illness Research, Education, and Clinical Center, United States National Institute of Health [K05-DA0454, P50-DA18827, U01-MH79639] FX Supported by grants from the Beijing Municipal Natural Science Foundation (identification 7072035), the Stanley Medical Research Institute (03T-459 and 05T-726), and the Department of Veterans Affairs, VISN 16, Mental Illness Research, Education, and Clinical Center, United States National Institute of Health K05-DA0454, P50-DA18827, and U01-MH79639. NR 30 TC 47 Z9 50 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0033-3158 EI 1432-2072 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD DEC PY 2009 VL 207 IS 3 BP 375 EP 380 DI 10.1007/s00213-009-1665-6 PG 6 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 519FX UT WOS:000271751500003 PM 19787338 ER PT J AU Niewoehner, DE Lapidus, R Cote, C Sharafkhaneh, A Plautz, M Johnson, P Kesten, S AF Niewoehner, Dennis E. Lapidus, Robert Cote, Claudia Sharafkhaneh, Amir Plautz, Mark Johnson, Philip Kesten, Steven TI Therapeutic conversion of the combination of ipratropium and albuterol to tiotropium in patients with chronic obstructive pulmonary disease SO PULMONARY PHARMACOLOGY & THERAPEUTICS LA English DT Article DE COPD; Tiotropium; Ipratropium/albuterol; Clinical trial ID ONCE-DAILY TIOTROPIUM; HEALTH OUTCOMES; COPD; SALMETEROL; EFFICACY; TRIAL; MULTICENTER; BROMIDE AB Background: Ipratropium and albuterol, combined in a single formulation, is widely used as three to four times daily maintenance therapy in COPD. This trial compared tiotropium, once daily, as a potential alternative to patients already taking the ipratropium/albuterol combination. Methods: 676 patients with moderate to very severe stable COPD (mean FEV(1) = 39% of predicted) maintained on ipratropium/albuterol were randomized to receive over an 84 day period either tiotropium (18 mcg) each morning, or continue with ipratropium (26 mcg)/albuterol (206 mcg), 2 actuations 4 times daily, using a parallel group, double-blind, double-dummy design. Six-hour spirometry was assessed on study days 1, 22, and 84, along with safety assessments and other efficacy measures. Results: In terms of primary outcomes, mean trough FEV(1) at 84 days was larger in the tiotropium arm as, compared with the ipratropium/albuterol arm (difference = 86 ml: 95% CI. 49 to 123 ml, p < 0.0001). The mean FEV(1) AUC(0-6) at 84 days was also larger in the tiotropium arm (difference = 17 ml: 95% CI, -21 to 56 ml), this difference being statistically non-inferior to the ipratropium/albuterol arm (p < 0.001), but not statistically superior (p = 0.37). Other efficacy measures were similar in the two groups. Lower respiratory adverse events were reported in 40 tiotropium patients vs. 52 ipratropium/albuterol patients. Safety reporting was otherwise similar. Conclusion: Patients previously maintained on the ipratropium/albuterol combination taken four times daily can be switched to tiotropium once daily with the reasonable expectation of at least equivalent bronchodilation during daytime hours and superior bronchodilation during early morning hours. Published by Elsevier Ltd. C1 [Niewoehner, Dennis E.] Vet Affairs Med Ctr, Dept Med, Pulm Sect 111N, Minneapolis, MN 55417 USA. [Lapidus, Robert] Rocky Mt Ctr Clin Res, Wheat Ridge, CO 80033 USA. [Cote, Claudia] Vet Affairs Med Ctr, Bay Pines, FL 33744 USA. [Sharafkhaneh, Amir] Michael E DeBakey Vet Affairs Med Ctr, Pulm Sect 111 1, Houston, TX 77030 USA. [Plautz, Mark] Vet Affairs Med Ctr, Med Serv 111, Kansas City, MO 64128 USA. [Johnson, Philip] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA. [Kesten, Steven] Boehringer Ingelheim GmbH & Co KG, Corp Headquarters, D-52216 Ingelheim, Germany. RP Niewoehner, DE (reprint author), Vet Affairs Med Ctr, Dept Med, Pulm Sect 111N, 1 Vet Dr, Minneapolis, MN 55417 USA. EM niewo001@umn.edu; rlapidus@rockymtnpulmonary.com; Claudia.Cote@va.gov; amirs@bcm.tmc.edu; Mark.Plautz@va.gov; pjohnson@rdg.boehringer-ingelheim.com; skesten@rdg.boehringer-ingelheim.com NR 19 TC 9 Z9 11 U1 0 U2 1 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1094-5539 J9 PULM PHARMACOL THER JI Pulm. Pharmacol. Ther. PD DEC PY 2009 VL 22 IS 6 BP 587 EP 592 DI 10.1016/j.pupt.2009.08.006 PG 6 WC Pharmacology & Pharmacy; Respiratory System SC Pharmacology & Pharmacy; Respiratory System GA 523KR UT WOS:000272072600020 PM 19737620 ER PT J AU Bell, PD Komlosi, P Zhang, ZR AF Bell, P. Darwin Komlosi, Peter Zhang, Zhi-Ren TI ATP as a mediator of macula densa cell signalling SO PURINERGIC SIGNALLING LA English DT Review DE ATP; Macula densa; Cell signalling ID NITRIC-OXIDE SYNTHASE; TUBULO-GLOMERULAR FEEDBACK; RENAL VASCULAR-RESISTANCE; THICK ASCENDING LIMB; RAT MESANGIAL CELLS; TUBULOGLOMERULAR FEEDBACK; ANGIOTENSIN-II; JUXTAGLOMERULAR APPARATUS; FILTRATION-RATE; RENIN SECRETION AB Within each nephro-vascular unit, the tubule returns to the vicinity of its own glomerulus. At this site, there are specialised tubular cells, the macula densa cells, which sense changes in tubular fluid composition and transmit information to the glomerular arterioles resulting in alterations in glomerular filtration rate and blood flow. Work over the last few years has characterised the mechanisms that lead to the detection of changes in luminal sodium chloride and osmolality by the macula densa cells. These cells are true "sensor cells" since intracellular ion concentrations and membrane potential reflect the level of luminal sodium chloride concentration. An unresolved question has been the nature of the signalling molecule(s) released by the macula densa cells. Currently, there is evidence that macula densa cells produce nitric oxide via neuronal nitric oxide synthase (nNOS) and prostaglandin E(2) (PGE(2)) through cyclooxygenase 2 (COX 2)-microsomal prostaglandin E synthase (mPGES). However, both of these signalling molecules play a role in modulating or regulating the macula-tubuloglomerular feedback system. Direct macula densa signalling appears to involve the release of ATP across the basolateral membrane through a maxi-anion channel in response to an increase in luminal sodium chloride concentration. ATP that is released by macula densa cells may directly activate P2 receptors on adjacent mesangial cells and afferent arteriolar smooth muscle cells, or the ATP may be converted to adenosine. However, the critical step in signalling would appear to be the regulated release of ATP across the basolateral membrane of macula densa cells. C1 [Bell, P. Darwin] Med Univ S Carolina, Div Nephrol, Charleston, SC 29425 USA. [Bell, P. Darwin; Komlosi, Peter; Zhang, Zhi-Ren] Med Univ S Carolina, Dept Med, Div Nephrol, Childrens Res Inst, Charleston, SC 29425 USA. [Bell, P. Darwin; Komlosi, Peter; Zhang, Zhi-Ren] Ralph H Johnson VA Med Ctr, Dept Vet Affairs, Charleston, SC USA. RP Bell, PD (reprint author), Med Univ S Carolina, Div Nephrol, 173 Ashley Ave,210 CRI, Charleston, SC 29425 USA. EM BellPD@MUSC.EDU OI Komlosi, Peter/0000-0002-5284-8877 FU National Institute of Diabetes and Digestive and Kidney Disease [DK-32032]; American Heart Association; VA Merit Grant FX This work was supported by a grant from the National Institute of Diabetes and Digestive and Kidney Disease (DK-32032) and by a Scientist Development Award from the American Heart Association and a VA Merit Grant. We thank Ms. Barbara Harris for administrative assistance. NR 119 TC 21 Z9 21 U1 1 U2 6 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1573-9538 J9 PURINERG SIGNAL JI Purinergic Signal. PD DEC PY 2009 VL 5 IS 4 BP 461 EP 471 DI 10.1007/s11302-009-9148-0 PG 11 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 519AL UT WOS:000271737300004 PM 19330465 ER PT J AU Leape, L Berwick, D Clancy, C Conway, J Gluck, P Guest, J Lawrence, D Morath, J O'Leary, D O'Neill, P Pinakiewicz, D Isaac, T AF Leape, L. Berwick, D. Clancy, C. Conway, J. Gluck, P. Guest, J. Lawrence, D. Morath, J. O'Leary, D. O'Neill, P. Pinakiewicz, D. Isaac, T. CA Natl Patient Safety Fdn TI Transforming healthcare: a safety imperative SO QUALITY & SAFETY IN HEALTH CARE LA English DT Article ID WRONG-SITE SURGERY; ADVERSE EVENTS; PATIENT SAFETY; PREVENTION; PATTERNS; LESSONS AB Ten years ago, the Institute of Medicine reported alarming data on the scope and impact of medical errors in the US and called for national efforts to address this problem. While efforts to improve patient safety have proliferated during the past decade, progress toward improvement has been frustratingly slow. Some of this lack of progress may be attributable to the persistence of a medical ethos, institutionalized in the hierarchical structure of academic medicine and healthcare organizations, that discourages teamwork and transparency and undermines the establishment of clear systems of accountability for safe care. The Lucian Leape Institute, established by the US National Patient Safety Foundation to provide vision and strategic direction for the patient safety work, has identified five concepts as fundamental to the endeavor of achieving meaningful improvement in healthcare system safety. These five concepts are transparency, care integration, patient/consumer engagement, restoration of joy and meaning in work, and medical education reform. This paper introduces the five concepts and illustrates the meaning and implications of each as a component of a vision for healthcare safety improvement. In future roundtable sessions, the Institute will further elaborate on the meaning of each concept, identify the challenges to implementation, and issue recommendations for policy makers, organizations, and healthcare professionals. C1 [Leape, L.; Berwick, D.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Berwick, D.; Conway, J.] Inst Healthcare Improvement, Cambridge, MA USA. [Clancy, C.] Agcy Healthcare Res & Qual, Bethesda, MD USA. [Gluck, P.; Pinakiewicz, D.] Natl Patient Safety Fdn, Boston, MA USA. [Guest, J.] Consumers Union, Yonkers, NY USA. [Lawrence, D.] Kaiser Fdn Hlth Plan, Oakland, CA USA. [Morath, J.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [O'Neill, P.] ALCOA, Pittsburgh, PA 15219 USA. [Isaac, T.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Leape, L (reprint author), Harvard Univ, Sch Publ Hlth, 665 Huntington Ave, Boston, MA 02115 USA. EM leape@hsph.harvard.edu; dberwick@ihi.org; carolyn.clancy@ahrq.hhs.gov; jconway@ihi.org; astrogld2@aol.com; jguest@consumer.org; dmlawrencemd@gmail.com; julie.morath@childrensmn.org; do'leary@jointcommission.org; poneillpa@aol.com; dpinakiewicz@npsf.org; txi001@gmail.com NR 45 TC 179 Z9 181 U1 5 U2 43 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1475-3898 J9 QUAL SAF HEALTH CARE JI Qual. Saf. Health Care PD DEC PY 2009 VL 18 IS 6 BP 424 EP 428 DI 10.1136/qshc.2009.036954 PG 5 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 526VV UT WOS:000272324100005 PM 19955451 ER PT J AU Kopans, DB AF Kopans, Daniel B. TI Mammography: Yet Another Challenge SO RADIOLOGY LA English DT Editorial Material ID BREAST-CARCINOMA MORTALITY; CANCER C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Avon Comprehens Breast Evaluat Ctr,Dept Radiol, Boston, MA 02114 USA. RP Kopans, DB (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Avon Comprehens Breast Evaluat Ctr,Dept Radiol, 15 Parkman St,ACC240, Boston, MA 02114 USA. EM dkopans@partners.org NR 12 TC 2 Z9 2 U1 0 U2 1 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD DEC PY 2009 VL 253 IS 3 BP 587 EP 589 DI 10.1148/radiol.2533091517 PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 525WF UT WOS:000272247300002 PM 19952020 ER PT J AU Gunderman, RB Boland, GWL AF Gunderman, Richard B. Boland, Giles W. L. TI Value in Radiology SO RADIOLOGY LA English DT Editorial Material ID HEALTH-CARE C1 [Gunderman, Richard B.] Indiana Univ, Sch Med, Dept Radiol, Indianapolis, IN 46202 USA. [Boland, Giles W. L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA. RP Gunderman, RB (reprint author), Indiana Univ, Sch Med, Dept Radiol, 702 Barnhill Dr,Room 1053, Indianapolis, IN 46202 USA. EM rbgunder@iupui.edu NR 7 TC 7 Z9 7 U1 0 U2 0 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD DEC PY 2009 VL 253 IS 3 BP 597 EP 599 DI 10.1148/radiol.2533090741 PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 525WF UT WOS:000272247300005 PM 19952023 ER PT J AU Pandharipande, PV Gazelle, GS AF Pandharipande, Pari V. Gazelle, G. Scott TI Comparative Effectiveness Research: What It Means for Radiology SO RADIOLOGY LA English DT Editorial Material ID COST-EFFECTIVENESS ANALYSIS; SPIRAL COMPUTED-TOMOGRAPHY; INVASIVE CERVICAL-CANCER; LUNG-CANCER; BREAST-CANCER; DIAGNOSTIC PERFORMANCE; MUTATION CARRIERS; AMERICAN-COLLEGE; CT COLONOGRAPHY; IMAGING NETWORK C1 [Pandharipande, Pari V.; Gazelle, G. Scott] Massachusetts Gen Hosp, Dept Radiol, Inst Technol Assessment, Boston, MA 02114 USA. RP Pandharipande, PV (reprint author), Massachusetts Gen Hosp, Dept Radiol, Inst Technol Assessment, 101 Merrimac St,10th Floor, Boston, MA 02114 USA. EM pari@mgh-ita.org NR 42 TC 30 Z9 30 U1 0 U2 1 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD DEC PY 2009 VL 253 IS 3 BP 600 EP 605 DI 10.1148/radiol.2533091286 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 525WF UT WOS:000272247300006 PM 19952024 ER PT J AU Wilcox, SR Schmidt, UH AF Wilcox, Susan R. Schmidt, Ulrich H. TI Are Tracheostomized Patients Safe on Regular Hospital Wards? SO RESPIRATORY CARE LA English DT Editorial Material ID PROLONGED MECHANICAL VENTILATION; INTENSIVE-CARE UNITS; PROSPECTIVE COHORT; ICU; DECANNULATION; MORTALITY; OBESITY C1 [Wilcox, Susan R.; Schmidt, Ulrich H.] Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02111 USA. RP Wilcox, SR (reprint author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, 55 Fruit St, Boston, MA 02111 USA. EM swilcox1@partners.org NR 23 TC 0 Z9 0 U1 0 U2 1 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 J9 RESP CARE JI Respir. Care PD DEC PY 2009 VL 54 IS 12 BP 1632 EP 1634 PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 534NY UT WOS:000272905600001 PM 19961626 ER PT J AU Stelfox, HT Hess, DR Schmidt, UH AF Stelfox, Henry Thomas Hess, Dean R. Schmidt, Ulrich H. TI A North American Survey of Respiratory Therapist and Physician Tracheostomy Decannulation Practices SO RESPIRATORY CARE LA English DT Article DE tracheostomy; tracheotomy; critical care; intensive care; ventilators, mechanical; respiration, artificial; decannulation; survey ID MECHANICALLY VENTILATED PATIENTS; INTENSIVE-CARE-UNIT; OUTCOMES AB BACKGROUND: Tracheostomy is a common surgical procedure performed on critically ill patients. However, little is known about how clinicians make decisions to decannulate patients, and whether similar decisions are made by respiratory therapists (RTs) and physicians. METHODS: We performed a cross-sectional survey of RTs (n = 52) and physicians (n = 102) at 54 medical centers in North America, to characterize contemporary decannulation practices. RESULTS: RTs and physicians rated ability to tolerate capping, secretions, cough effectiveness, and level of consciousness as the most important factors in the decannulation decision, with RTs placing greater emphasis on ability to tolerate capping and physicians on level of consciousness. In the clinical scenarios, RTs and physicians recommended decannulation with similar frequency (52% vs 55%, P = .54). Patients were most likely to be recommended for decannulation if they had a strong cough, scant thin secretions, required minimal supplemental oxygen, and were alert and interactive. In addition, RTs were more likely to recommend decannulation for patients who demonstrated an ability to tolerate tracheostomy tube capping for 72 hours and whose etiology of respiratory failure was chronic obstructive pulmonary disease. RTs preferred shorter time frames for defining decannulation failure than did physicians (median response 48 h vs 96 h, P = .02 for test of proportions). Both groups identified 2-5% (median response) as an acceptable rate of decannulation failure (P = .48 for test of proportions). CONCLUSIONS: Important differences exist in the decannulation practices of North American RTs and physicians. Evidence-based tracheostomy guidelines are needed to facilitate the safe and effective management of patients with tracheostomies. C1 [Stelfox, Henry Thomas] Univ Calgary, Dept Crit Care Med, Foothills Med Ctr EG23A, Calgary, AB T2N 2T9, Canada. [Stelfox, Henry Thomas] Univ Calgary, Dept Med, Calgary, AB T2N 2T9, Canada. [Stelfox, Henry Thomas] Univ Calgary, Dept Community Hlth Sci, Calgary, AB T2N 2T9, Canada. [Hess, Dean R.] Massachusetts Gen Hosp, Dept Resp Care, Boston, MA 02114 USA. [Hess, Dean R.] Harvard Univ, Sch Med, Boston, MA USA. [Schmidt, Ulrich H.] Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. RP Stelfox, HT (reprint author), Univ Calgary, Dept Crit Care Med, Foothills Med Ctr EG23A, 1403 29 St NW, Calgary, AB T2N 2T9, Canada. EM tom.stelfox@albertahealthservices.ca NR 14 TC 12 Z9 14 U1 1 U2 1 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 J9 RESP CARE JI Respir. Care PD DEC PY 2009 VL 54 IS 12 BP 1658 EP 1664 PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 534NY UT WOS:000272905600006 PM 19961631 ER PT J AU Sanz, F Restrepo, MI Fernandez, E Briones, ML Blanquer, R Mortensen, EM Chiner, E Blanquer, J AF Sanz, Francisco Restrepo, Marcos I. Fernandez, Estrella Luisa Briones, Maria Blanquer, Rafael Mortensen, Eric M. Chiner, Eusebi Blanquer, Jose CA NAC-CV Study Grp TI Is it possible to predict which patients with mild pneumonias will develop hypoxemia? SO RESPIRATORY MEDICINE LA English DT Article DE Community-acquired pneumonia; Hypoxemia; Risk factors; Severity assessment ID COMMUNITY-ACQUIRED PNEUMONIA; LOW-RISK PATIENTS; RANDOMIZED-TRIAL; MANAGEMENT; OUTCOMES; HOSPITALIZATION; GUIDELINES; MORTALITY; DIAGNOSIS; ADULTS AB Usually, mortality due to mild community-acquired pneumonias (CAP) (Pneumonia severity index (PSI) classes I-III) is tow (<3%), but the appearance of hypoxemia significantly increases mortality. Our aim was to determine the clinical parameters associated with risk factors of developing hypoxemia in subjects with mild CAP (PSI I-III) and the clinical. outcomes of the hypoxemic group. We analyzed clinical characteristics and the outcomes of patients with mild CAP and hypoxemia (PaO(2)/FiO(2) < 300), in a prospective, multicenter cohort study of 1195 patients. Mild pneumonias (PSI I-III) were found in 645 cases (53.9%), of which 217 (33.6%) presented hypoxemia according to a PaO(2)/FiO(2) < 300. Patients with PaO(2)/FiO(2) < 300 required more ICU admissions, mechanical ventilation, and developed septic shock than other PSI I-III patients. The clinical parameters associated with hypoxemia were: COPD, bilateral chest X-ray involvement, and hypoalbuminemia. We conclude that patients with COPD, those with bilateral chest X-ray involvement, or hypoalbuminemia were significantly more Likely to have hypoxemia in mild CAP. Hypoxemic patients with low-risk pneumonia have worse clinical outcomes, including more ICU admission, need for mechanical ventilation and presence of septic shock than non-hypoxemic low-risk patients. (C) 2009 Elsevier Ltd. All rights reserved. C1 [Sanz, Francisco] Univ Valencia, Consorci Hosp Gen, Serv Neumol, Valencia 46014, Spain. [Restrepo, Marcos I.; Mortensen, Eric M.] VERDICT Res Program, San Antonio, TX 78229 USA. [Restrepo, Marcos I.; Mortensen, Eric M.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78284 USA. [Fernandez, Estrella; Blanquer, Rafael] Hosp Univ Dr Peset Valencia, Serv Neumol, Valencia 46017, Spain. [Luisa Briones, Maria] Univ Valencia, Hosp Clin, Serv Neumol, Valencia 46010, Spain. [Chiner, Eusebi] Hosp St Joan, Serv Neumol, Sant Joan dAlacant 03550, Spain. [Blanquer, Jose] Univ Valencia, Hosp Clin, Serv Med Intens, Valencia 46010, Spain. RP Sanz, F (reprint author), Univ Valencia, Consorci Hosp Gen, Serv Neumol, Av Tres Cruces 2, Valencia 46014, Spain. EM sanz_fraher@gva.es RI Restrepo, Marcos/H-4442-2014; OI Mortensen, Eric/0000-0002-3880-5563 NR 27 TC 9 Z9 9 U1 0 U2 1 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0954-6111 J9 RESP MED JI Respir. Med. PD DEC PY 2009 VL 103 IS 12 BP 1871 EP 1877 DI 10.1016/j.rmed.2009.06.013 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System SC Cardiovascular System & Cardiology; Respiratory System GA 526FK UT WOS:000272272900014 PM 19619999 ER PT J AU Weynnan, AE AF Weynnan, Arthur E. TI Future Directions in Echocardiography SO REVIEWS IN CARDIOVASCULAR MEDICINE LA English DT Review DE Real-time 3-dimensional imaging; Vascular imaging; Ultrasound; Atherosclerotic plaque AB Future developments in echocardiography will likely focus on the continued evolution of existing techniques, such as real-time 3-dimensional (RT3D) imaging and contrast-enhanced imaging; higher resolution imaging; and greater flexibility in imaging systems due to miniaturization, enhanced connectivity, and integration with other techniques. Improvements in RT3D image quality may include expanded parallel processing and use of transesophageal matrix arrays. Two areas of future clinical potential for contrast-enhanced echocardiography/ultrasound are the use of targeted microbubbles for diagnostic and therapeutic applications and expanded vascular imaging. Although molecular imaging holds great promise for the future, in the short-term, it is likely that contrast will be used more extensively for vascular imaging to assess both the effects of interventions on local perfusion and the activity of atherosclerotic plaque based on the size/density of the vasa vasorum. The widespread use of ultrasound will be facilitated by the development of a convenient portable or readily available ultrasonic equivalent of the stethoscope. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. RP Weynnan, AE (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. NR 32 TC 0 Z9 0 U1 0 U2 0 PU MEDREVIEWS PI NEW YORK PA 1333 BROADWAY, STE 400, NEW YORK, NY 10018 USA SN 1530-6550 J9 REV CARDIOVASC MED JI Rev. Cardiovasc. Med. PD WIN PY 2009 VL 10 IS 1 BP 4 EP 13 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 428FS UT WOS:000264834000003 ER PT J AU Ohning, GV Machicado, GA Jensen, DM AF Ohning, Gordon V. Machicado, Gustavo A. Jensen, Dennis M. TI Definitive Therapy for Internal Hemorrhoids-New Opportunities and Options SO REVIEWS IN GASTROENTEROLOGICAL DISORDERS LA English DT Review DE Symptomatic internal hemorrhoids; Anorectal symptoms; Sclerotherapy; Thermocoagulation; Electrocoagulation; Infrared coagulation; Rubber band ligation ID RUBBER BAND LIGATION; FISSURE AB Hemorrhoids are common in Western societies. Appropriate assessment and treatment of symptomatic hemorrhoids can substantially reduce morbidity and improve patient well-being. In this article, the clinical presentation, differential diagnoses, and current treatment options, including the CRH-O'Regan banding device, an emerging technology for the anoscopic treatment of symptomatic internal hemorrhoids, are reviewed. C1 [Ohning, Gordon V.; Machicado, Gustavo A.; Jensen, Dennis M.] Univ Calif Los Angeles, David Geffen Sch Med, Greater Los Angeles VA Healthcare Ctr, CURE,Digest Dis Res Ctr, Los Angeles, CA 90095 USA. RP Ohning, GV (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Greater Los Angeles VA Healthcare Ctr, CURE,Digest Dis Res Ctr, Los Angeles, CA 90095 USA. FU NIDDK NIH HHS [K24 DK02650, DK41301] NR 26 TC 4 Z9 4 U1 1 U2 4 PU MEDREVIEWS PI NEW YORK PA 1333 BROADWAY, STE 400, NEW YORK, NY 10018 USA SN 1533-001X J9 REV GASTROENTEROL DI JI Rev. Gastroenterol. Disord. PD WIN PY 2009 VL 9 IS 1 BP 16 EP 26 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 433IV UT WOS:000265198400003 PM 19367214 ER PT J AU Hoexter, MQ Shavitt, RG D'Alcante, CC Cecconi, JP Diniz, JB Belotto-Silva, C Hounie, AG Borcato, S Moraes, I Joaquim, MA Cappi, C Sampaio, AS de Mathis, MA Batistuzzo, MC Lopes, AC Rosa, ACF Muniz, RK Marques, AH Santos, LC Taub, A Duran, FLD Dougherty, DD Busatto, GF Bressan, RA Miguel, EC AF Hoexter, Marcelo Queiroz Shavitt, Roseli Gedanke D'Alcante, Carina Chaubet Cecconi, Janaina Philippi Diniz, Juliana Belo Belotto-Silva, Cristina Hounie, Ana Gabriela Borcato, Sonia Moraes, Ivanil Joaquim, Marines Alves Cappi, Carolina Sampaio, Aline Santos de Mathis, Maria Alice Batistuzzo, Marcelo Camargo Lopes, Antonio Carlos Ferreira Rosa, Ana Carolina Muniz, Renan Kawano Marques, Andrea Horvath Santos, Luciana Cristina Taub, Anita de Souza Duran, Fabio Luis Dougherty, Darin Dean Busatto, Geraldo Filho Bressan, Rodrigo Affonseca Miguel, Euripedes Constantino TI The drug-naive OCD patients imaging genetics, cognitive and treatment response study: methods and sample description SO REVISTA BRASILEIRA DE PSIQUIATRIA LA English DT Article DE Obsessive-compulsive disorder; Genetics; Cognition; Imaging; Treatment outcome ID OBSESSIVE-COMPULSIVE DISORDER; DOPAMINE TRANSPORTER; PARKINSONS-DISEASE; DECISION-MAKING; BRAIN; ABNORMALITIES; DYSFUNCTION; SEROTONIN; LESIONS; SPECT AB Objective: To describe a protocol that was based on an integrative neurobiological model of scientific investigation to better understand the pathophysiology of obsessive-compulsive disorder and to present the clinical and demographic characteristics of the sample. Method: A standardized research protocol that combines different methods of investigation (genetics, neuropsychology, morphometric magnetic resonance imaging and molecular neuroimaging of the dopamine transporter) obtained before and after treatment of drug-naive adult obsessive-compulsive disorder patients submitted to a sequentially allocated 12-week clinical trial with a selective serotonin reuptake inhibitor (fluoxetine) and group cognitive-behavioral therapy. Results: Fifty-two treatment-naive obsessive-compulsive disorder patients entered the clinical trial (27 received fluoxetine and 25 received group cognitive-behavioral therapy). At baseline, 47 blood samples for genetic studies, 50 neuropsychological evaluations, 50 morphometrical magnetic resonance images and 48 TRODAT-1 single-photon emission computed tomography (SPECT) exams were obtained. After 12 weeks, 38 patients completed the protocol (fluoxetine = 20 and GCBT = 18). Thirty-eight neuropsychological evaluations, 31 morphometrical magnetic resonance images and 34 TRODAT-1 SPECT exams were obtained post-treatment. Forty-one healthy controls matched for age, gender, socioeconomic status, level of education and laterality were submitted to the same research procedures at baseline. Conclusion: The comprehensive treatment response protocol applied in this project allowing integration on genetic, neuropsychological, morphometrical and molecular imaging of the dopamine transporter data in drug-naive patients has the potential to generate important original information on the neurobiology of obsessive-compulsive disorder, and at the same time be clinically meaningful. C1 [Hoexter, Marcelo Queiroz; Shavitt, Roseli Gedanke; D'Alcante, Carina Chaubet; Cecconi, Janaina Philippi; Diniz, Juliana Belo; Belotto-Silva, Cristina; Hounie, Ana Gabriela; Borcato, Sonia; Moraes, Ivanil; Joaquim, Marines Alves; Cappi, Carolina; Sampaio, Aline Santos; de Mathis, Maria Alice; Batistuzzo, Marcelo Camargo; Lopes, Antonio Carlos; Ferreira Rosa, Ana Carolina; Muniz, Renan Kawano; Marques, Andrea Horvath; Santos, Luciana Cristina; Taub, Anita; de Souza Duran, Fabio Luis; Busatto, Geraldo Filho; Miguel, Euripedes Constantino] Univ Sao Paulo, Dept Psychiat, Clin Hosp, Sch Med, Sao Paulo, Brazil. [Hoexter, Marcelo Queiroz; Shavitt, Roseli Gedanke; D'Alcante, Carina Chaubet; Cecconi, Janaina Philippi; Diniz, Juliana Belo; Belotto-Silva, Cristina; Hounie, Ana Gabriela; Borcato, Sonia; Moraes, Ivanil; Joaquim, Marines Alves; Cappi, Carolina; Sampaio, Aline Santos; de Mathis, Maria Alice; Batistuzzo, Marcelo Camargo; Lopes, Antonio Carlos; Ferreira Rosa, Ana Carolina; Muniz, Renan Kawano; Marques, Andrea Horvath; Santos, Luciana Cristina; Taub, Anita; de Souza Duran, Fabio Luis; Busatto, Geraldo Filho; Miguel, Euripedes Constantino] Univ Sao Paulo, Inst Psychiat, Clin Hosp, Sch Med, Sao Paulo, Brazil. [Hoexter, Marcelo Queiroz; Bressan, Rodrigo Affonseca] Univ Fed Sao Paulo, Interdisciplinary Lab Clin Neurosci, Dept Psychiat, Sao Paulo, Brazil. [Dougherty, Darin Dean] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Bressan, Rodrigo Affonseca] HIAE, IIEP, Sao Paulo, Brazil. RP Hoexter, MQ (reprint author), R Ovidio Pires de Campos 785-3O & Ala Norte Sala, BR-05403010 Sao Paulo, Brazil. EM mqhoexter@gmail.com RI Duran, Fabio/A-9744-2013; Bressan, Rodrigo/E-9178-2010; Busatto, Geraldo/D-4431-2009; Duran, Fabio/L-1371-2013; Duran, Fabio/I-5704-2012; Batistuzzo, Marcelo/H-7790-2015; Hoexter, Marcelo/D-7620-2013; Miguel, Euripedes/B-2871-2008; Diniz, Juliana/D-2503-2011; de mathis, maria alice/D-7269-2012 OI Duran, Fabio/0000-0002-7603-6152; Bressan, Rodrigo/0000-0002-0868-4449; Duran, Fabio/0000-0002-7603-6152; Duran, Fabio/0000-0003-2494-7250; Hoexter, Marcelo/0000-0002-9302-4380; Diniz, Juliana/0000-0001-9486-3779; FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, National Council for Scientific and Technological Development) [521369/96-7, 475919/2006-8, 481791/2004-3]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Foundation for the Support of Research in the State of Sao Paulo) [2005/55628-08, 06/61459-7, 06/50273-0]; Instituto Israelita de Ensino e Pesquisa do Hospital Israelita Albert Einstein (IIEP-HIAE) [150-06]; FAPESP [2005/04206-6]; Coordena ao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [BEX 4375/08-4] FX This study received financial support in the form of grants provided by the following Brazilian governmental agencies: the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, National Council for Scientific and Technological Development, Grant number: 521369/96-7, 475919/2006-8 and 481791/2004-3); and the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Foundation for the Support of Research in the State of Sao Paulo, Grant number: 2005/55628-08, 06/61459-7 and 06/50273-0). It also received support from the Instituto Israelita de Ensino e Pesquisa do Hospital Israelita Albert Einstein (IIEP-HIAE) (Process: 150-06). Dr. Hoexter is supported by a PhD scholarship from FAPESP (Process: 2005/04206-6) and by a doctorate "sandwich" from the Coordena ao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES, Agency for Support and Evaluation of Graduate Education) (Process: BEX 4375/08-4). NR 39 TC 5 Z9 5 U1 2 U2 3 PU ASSOC BRASILEIRA PSIQUIATRIA PI SAO PAULO PA SUBSCRIPTION DEPARTMENT, RUA PEDRO DE TOLEDO, 967 - CASA 01, SAO PAULO, SP 04039-032 A, BRAZIL SN 1516-4446 J9 REV BRAS PSIQUIATR JI Rev. Bras. Psiquiatr. PD DEC PY 2009 VL 31 IS 4 BP 345 EP 353 PG 9 WC Psychiatry SC Psychiatry GA 548PE UT WOS:000273977400010 ER PT J AU Scherer, A Choy, G Kropil, P Lanzman, RS Modder, U Abbara, S AF Scherer, A. Choy, G. Kroepil, P. Lanzman, R. S. Moedder, U. Abbara, S. TI Cardiac Pathologies Incidentally Detected with Non-Gated Chest CT SO ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN LA German DT Review DE cardiac; heart; CT; CT spiral; thorax; pericardium ID MULTIDETECTOR COMPUTED-TOMOGRAPHY; MULTISLICE SPIRAL CT; AORTIC-STENOSIS; CORONARY; DISEASE; ECHOCARDIOGRAPHY; ANGIOGRAPHY; MRI; CALCIFICATION; ABNORMALITIES AB Cardiac imaging using electrocardiogram-gated multi-detector computed tomography (MDCT) permits noninvasive diagnosis of congenital and acquired cardiac pathologies and has thus become increasingly important in the last years. Several studies investigated the incidence and relevance of incidental extracardiac structures within the lungs, mediastinum, chest wall, and abdomen with gated Coronary CT. This resulted in the general acceptance of the review of extracardiac structures as a routine component of coronary CT interpretation. On the other hand radiologists tend to neglect pericardial and cardiac pathologies in non-gated chest CT, which is primarily performed for the evaluation of the respiratory system or for tumor staging. Since the introduction of multi-detector spiral CT technology, the incidental detection of cardiac and pericardial findings has become possible using non-gated chest CT. This article reviews the imaging appearances and differential diagnostic considerations of incidental cardiac entities that may be encountered in non-gated chest CT. C1 [Scherer, A.; Kroepil, P.; Lanzman, R. S.; Moedder, U.] Univ Dusseldorf, Inst Radiol, Univ Klinikum Dusseldorf, D-40225 Dusseldorf, Germany. [Choy, G.; Abbara, S.] Harvard Univ, Cardiovasc Imaging Sect, Massachusetts Gen Hosp, Sch Med, Cambridge, MA 02138 USA. RP Scherer, A (reprint author), Univ Dusseldorf, Moorenstr 5, D-40225 Dusseldorf, Germany. EM axelscherer@gmx.de NR 45 TC 9 Z9 9 U1 0 U2 0 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 1438-9029 J9 ROFO-FORTSCHR RONTG JI Rofo-Fortschr. Gebiet Rontgenstrahlen Bildgeb. Verfahr. PD DEC PY 2009 VL 181 IS 12 BP 1127 EP 1134 DI 10.1055/s-0028-1109839 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 532OA UT WOS:000272757900002 PM 19862650 ER PT J AU Patsoukis, N Lafuente, EM Meraner, P Kim, JS Dombkowski, D Li, LQ Boussiotis, VA AF Patsoukis, Nikolaos Lafuente, Esther M. Meraner, Paul Kim, Jin Sub Dombkowski, David Li, Lequn Boussiotis, Vassiliki A. TI RIAM Regulates the Cytoskeletal Distribution and Activation of PLC-gamma 1 in T Cells SO SCIENCE SIGNALING LA English DT Article ID PHOSPHOLIPASE C-GAMMA-1 PLC-GAMMA-1; NUCLEOTIDE EXCHANGE FACTOR; ANTIGEN-RECEPTOR; ACTIN CYTOSKELETON; PLASMA-MEMBRANE; PLC-GAMMA; INTEGRIN ALPHA-IIB-BETA-3; RAS ACTIVATION; SH3 DOMAIN; C-GAMMA AB Rap1-guanosine triphosphate (GTP)-interacting adaptor molecule (RIAM) plays a critical role in actin reorganization and inside-out activation of integrins in lymphocytes and platelets. We investigated the role of RIAM in T cell receptor (TCR)-mediated signaling. Although phosphorylation of the kinase ZAP-70 and formation of a signalosome recruited to the adaptor protein LAT were unaffected, elimination of endogenous RIAM by short hairpin RNA impaired generation of inositol 1,4,5-trisphosphate, mobilization of intracellular calcium ions (Ca(2+)), and translocation of the transcription factor NFAT to the nucleus. The activation of Ras guanine nucleotide-releasing protein 1 was also impaired, which led to the diminished expression of the gene encoding interleukin-2. These events were associated with the impaired translocation of phosphorylated phospholipase C-gamma 1 (PLC-gamma 1) to the actin cytoskeleton, which was required to bring PLC-gamma 1 close to its substrate phosphatidylinositol 4,5-bisphosphate, and were reversed by reconstitution of cells with RIAM. Thus, by regulating the localization of PLC-gamma 1, RIAM plays a central role in TCR signaling and the transcription of target genes. C1 [Patsoukis, Nikolaos; Kim, Jin Sub; Li, Lequn; Boussiotis, Vassiliki A.] Harvard Univ, Sch Med, Dept Hematol Oncol & Canc Biol, Beth Israel Deaconess Med Ctr,Ctr Life Sci, Boston, MA 02215 USA. [Lafuente, Esther M.] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02129 USA. [Meraner, Paul] Harvard Univ, Sch Med, Ctr Blood Res, Infect Dis Inst, Boston, MA 02115 USA. [Dombkowski, David] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02129 USA. RP Boussiotis, VA (reprint author), Harvard Univ, Sch Med, Dept Hematol Oncol & Canc Biol, Beth Israel Deaconess Med Ctr,Ctr Life Sci, 330 Brookline Ave, Boston, MA 02215 USA. EM vboussio@bidmc.harvard.edu RI Lafuente, Esther M/K-5684-2014 OI Lafuente, Esther M/0000-0001-8466-1022 FU NCI NIH HHS [R01 CA104596-05, R21 CA123855, R21 CA123855-01A2, R01 CA104596]; NIAID NIH HHS [R01 AI043552, R01 AI043552-11] NR 49 TC 8 Z9 9 U1 0 U2 1 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 1937-9145 J9 SCI SIGNAL JI Sci. Signal. PD DEC 1 PY 2009 VL 2 IS 99 AR ra79 DI 10.1126/scisignal.2000409 PG 14 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 570BH UT WOS:000275646100005 PM 19952372 ER PT J AU Nelson, AA Wasserman, D Avram, MM AF Nelson, Andrew A. Wasserman, Daniel Avram, Mathew M. TI Cryolipolysis for Reduction of Excess Adipose Tissue SO SEMINARS IN CUTANEOUS MEDICINE AND SURGERY LA English DT Article DE cryolipolysis; Zeltiq; non-invasive; body contouring; fat removal; cold panniculitis ID COLD PANNICULITIS; CELLULITE; EFFICACY; FAT AB Controlled cold exposure has long been reported to be a cause of panniculitis in cases such as popsicle panniculitis. Cryolipolysis is a new technology that uses cold exposure, or energy extraction, to result in localized panniculitis and modulation of fat. Presently, the Zeltiq cryolipolysis device is FDA cleared for skin cooling, as well as various other indications, but not for lipolysis. There is, however, a pending premarket notification for noninvasive fat layer reduction. Initial animal and human studies have demonstrated significant reductions in the superficial fat layer thickness, ranging from 20% to 80%, following a single cryolipolysis treatment. The decrease in fat thickness occurs gradually over the first 3 months following treatment, and is most pronounced in patients with limited, discrete fat bulges. Erythema of the skin, bruising, and temporary numbness at the treatment site are commonly observed following treatment with the device, though these effects largely resolve in approximately 1 week. To date, there have been no reports of scarring, ulceration, or alterations in blood lipid or liver function profiles. Cryolipolysis is a new, noninvasive treatment option that may be of benefit in the treatment of excess adipose tissue. Semin Cutan Med Surg 28:244-249 (C) 2009 Elsevier Inc. All rights reserved. C1 [Avram, Mathew M.] Massachusetts Gen Hosp, Dermatol Laser & Cosmet Ctr, Wellman Ctr Photomed, Boston, MA 02114 USA. [Nelson, Andrew A.] Univ Calif Los Angeles, Div Dermatol, Med Ctr, Los Angeles, CA 90024 USA. [Wasserman, Daniel] Total Skin & Beauty Dermatol Ctr, Birmingham, AL USA. RP Avram, MM (reprint author), Massachusetts Gen Hosp, Dermatol Laser & Cosmet Ctr, Wellman Ctr Photomed, 50 Staniford St,Suite 250, Boston, MA 02114 USA. EM mavram@partners.org FU Candela Corporation FX Dr. Avram has received research grants from Candela Corporation and is a stock holder in Zeltiq Aesthetics, Inc. NR 19 TC 28 Z9 28 U1 2 U2 18 PU FRONTLINE MEDICAL COMMUNICATIONS PI THE WOODLANDS PA WRIGHTS MEDIA, 2407 TIMBERLOCH PLACE, SUITE B, THE WOODLANDS, TX 77386 USA SN 1085-5629 EI 1558-0768 J9 SEMIN CUTAN MED SURG JI Semin. Cutan. Med. Surg. PD DEC PY 2009 VL 28 IS 4 BP 244 EP 249 DI 10.1016/j.sder.2009.11.004 PG 6 WC Dermatology; Surgery SC Dermatology; Surgery GA 604SU UT WOS:000278299600007 PM 20123423 ER PT J AU Li, YJ Tsai, YC Chen, YC Christiani, DC AF Li, Yao-Jen Tsai, Yu-Chin Chen, Yen-Ching Christiani, David C. TI Human Papilloma Virus and Female Lung Adenocarcinoma SO SEMINARS IN ONCOLOGY LA English DT Review ID SQUAMOUS-CELL CARCINOMA; POLYMERASE-CHAIN-REACTION; CERVICAL-CANCER PATIENTS; ESTROGEN-RECEPTOR-BETA; HYBRID CAPTURE II; MESSENGER-RNA; ESOPHAGEAL CANCER; PERIPHERAL-BLOOD; INTRAEPITHELIAL NEOPLASIA; IN-SITU AB Lung cancer is the leading cause of cancer among women worldwide, and adenocarcinoma is the most common histological subtype among non-smoking women. Previous studies showed that human papillomavirus (HPV) infection may relate to the tumorigenesis of pulmonary adenocarcinoma. Women with anogenital malignancy have a higher risk of lung cancer, which raises the possibility of HPV transmission from the cervix to the lung. Two postulated pathways are discussed in this work. First, HPV may infect the female cervix and then move to the lung by blood circulation. The second transmission route is the HPV infection of oral cavity resulting from dangerous sexual contacts, and subsequently transmitted to the lung. This chapter also reviews the techniques for detecting the existence, subtypes, and viral load of HPV. Future studies are needed to demonstrate the causal inference between HPV infection and the risk of female lung adenocarcinoma. Semin Oncol 36:542-552 (C) 2009 Elsevier Inc. All rights reserved. C1 [Li, Yao-Jen; Tsai, Yu-Chin] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan. [Li, Yao-Jen] Natl Taiwan Univ, Grad Inst Epidemiol, Taipei 10764, Taiwan. [Chen, Yen-Ching] Natl Taiwan Univ, Inst Prevent Med, Taipei 10764, Taiwan. [Chen, Yen-Ching] Natl Taiwan Univ, Res Ctr Gene Environm & Human Hlth, Taipei 10764, Taiwan. [Christiani, David C.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Environm & Occupat Med & Epidemiol Program, Boston, MA 02115 USA. [Christiani, David C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pulm & Crit Care Unit,Dept Med, Boston, MA USA. RP Chen, YC (reprint author), 17 Xu Shou Rd, Taipei 10020, Taiwan. EM karenchen@ntu.edu.tw; dchris@hsph.harvard.edu RI Chen, Yen-Ching/D-1098-2010 OI Chen, Yen-Ching/0000-0002-8159-7202 NR 122 TC 17 Z9 18 U1 0 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0093-7754 J9 SEMIN ONCOL JI Semin. Oncol. PD DEC PY 2009 VL 36 IS 6 BP 542 EP 552 DI 10.1053/j.seminoncol.2009.10.002 PG 11 WC Oncology SC Oncology GA 601QV UT WOS:000278079100009 PM 19995646 ER PT J AU Hough, S AF Hough, Sigmund TI From the Editor SO SEXUALITY AND DISABILITY LA English DT Editorial Material C1 VA Boston Healthcare Syst, Spinal Cord Injury Serv SCI 128, W Roxbury, MA 02132 USA. RP Hough, S (reprint author), VA Boston Healthcare Syst, Spinal Cord Injury Serv SCI 128, 1400 VFW Pkwy, W Roxbury, MA 02132 USA. EM Sigmund_Hough@hms.harvard.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0146-1044 J9 SEX DISABIL JI Sex. Disabil. PD DEC PY 2009 VL 27 IS 4 BP 185 EP 185 DI 10.1007/s11195-009-9138-8 PG 1 WC Rehabilitation SC Rehabilitation GA 519ZZ UT WOS:000271810800001 ER PT J AU Fung, SJ Xi, MC Zhang, JH Yamuy, J Sampogna, S Tsai, KL Lim, V Morales, FR Chase, MH AF Fung, Simon J. Xi, Ming-Chu Zhang, Jian-Hua Yamuy, Jack Sampogna, Sharon Tsai, Kevin L. Lim, Vincent Morales, Francisco R. Chase, Michael H. TI Eszopiclone Prevents Excitotoxicity and Neurodegeneration in the Hippocampus Induced by Experimental Apnea SO SLEEP LA English DT Article DE Neuroprotection; GABA; OSA; CA1; apoptosis ID OBSTRUCTIVE SLEEP-APNEA; LONG-TERM POTENTIATION; GABA(A) RECEPTOR SUBUNITS; INTERMITTENT HYPOXIA; MONOCLONAL-ANTIBODY; GLUCOSE DEPRIVATION; ALPHA-CHLORALOSE; PYRAMIDAL CELLS; NEURONAL DEATH; A-RECEPTORS AB Study Objective: This study was designed to determine the effects of eszopiclone on apnea-induced excitotoxic synaptic processes and apoptosis in the hippocampus. Design: Recurrent periods of apnea, which consisted of a sequence of apnea (75% SpO(2)), followed by ventilation with recovery to normoxia (>95% SpO(2))' were induced for a period of three hours in anesthetized guinea pigs. The CA3 Schaffer collateral pathway in the hippocampus was stimulated and the field excitatory postsynaptic potential (fEPSP) response was recorded in CA1. Animals in the experimental group received an intravenous injection of eszopiclone (3 mg/kg) 10 min prior to the initiation of the periods of recurrent apnea, and once every 60 min thereafter; control animals received comparable injections of vehicle. At the end of the 3-h period of recurrent apnea, the animals were perfused, and hippocampal sections were immunostained in order to determine the presence of apoptosis, i.e., programmed cell death. Analyses and Results: Apnea resulted in a persistent increase in synaptic responsiveness of CA1 neurons as determined by analyses of the fEPSP. Eszopiclone antagonized the apnea-induced increase in the fEPSP Morphological analyses revealed significant apoptosis of CA1 neurons in control animals; however, there was no significant apoptosis in eszopiclone-treated animals. Conclusions: Eszopiclone was determined to suppress the apnea-induced hyperexcitability of hippocampal CA1 neurons, thereby reducing/eliminating neurotoxicity. These data lend credence to our hypothesis that eszopiclone, exclusive of its hypnotic actions, has the capacity to function as a potent neuroprotective agent. C1 [Fung, Simon J.; Xi, Ming-Chu; Zhang, Jian-Hua; Sampogna, Sharon; Tsai, Kevin L.; Lim, Vincent; Morales, Francisco R.; Chase, Michael H.] WebSci Int, Los Angeles, CA 90024 USA. [Yamuy, Jack] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Morales, Francisco R.; Chase, Michael H.] Univ Republica, Fac Med, Dept Fisiol, Montevideo, Uruguay. [Chase, Michael H.] Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90024 USA. RP Fung, SJ (reprint author), WebSci Int, 1251 Westwood Blvd, Los Angeles, CA 90024 USA. EM sfung@websciences.org FU Sepracor, Inc FX We are grateful to Oscar Ramos, Emi Koda, and Nichole Stevens for their excellent technical assistance. We would also like to thank Nichole Stevens and Daniel Bronson for their constructive input in revising this manuscript. Trent Wenzel provided expert computer support for AxoGraph X Scientific Software. Gerald Chao designed the software for automated control of the ventilator used in combination with the pulse oximeter for the apnea paradigms. This research was supported by Sepracor, Inc. NR 60 TC 8 Z9 8 U1 0 U2 1 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD DEC 1 PY 2009 VL 32 IS 12 BP 1593 EP 1601 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 527OL UT WOS:000272376300011 PM 20041595 ER PT J AU Clegg, LX Hankey, BF Tiwari, R Feuer, EJ Edwards, BK AF Clegg, Limin X. Hankey, Benjamin F. Tiwari, Ram Feuer, Eric J. Edwards, Brenda K. TI Estimating average annual per cent change in trend analysis SO STATISTICS IN MEDICINE LA English DT Article DE confidence interval for trends; geometric means; trend comparisons ID CANCER; NATION; RATES AB Trends in incidence or mortality rates over a specified time interval are usually described by the conventional annual per cent change (cAPC), under the assumption of a constant rate of change. When this assumption does not hold over the entire time interval, the trend may be characterized using the annual per cent changes from segmented analysis (sAPCs). This approach assumes that the change in rates is constant over each time partition defined by the transition points, but varies among different time partitions. Different groups (e.g. racial subgroups), however, may have different transition points and thus different time partitions over which they have constant rates of change, making comparison of sAPCs; problematic across groups over a common time interval of interest (e.g. the past 10 years). We propose a new measure, the average annual per cent change (AAPC), which uses sAPCs to summarize and compare trends for a specific time period. The advantage of the proposed AAPC is that it takes into account the trend transitions, whereas cAPC does not and can lead to erroneous conclusions. In addition, when the trend is constant over the entire time interval of interest, the AAPC has the advantage of reducing to both cAPC and sAPC. Moreover, because the estimated AAPC is based on the segmented analysis over the entire data series, any selected subinterval within a single time partition will yield the same AAPC estimate-that is it will be equal to the estimated sAPC for that time partition. The cAPC, however, is re-estimated using data only from that selected subinterval; thus, its estimate may be sensitive to the subinterval selected. The AAPC estimation has been incorporated into the segmented regression (free) software Joinpoint, which is used by many registries throughout the world for characterizing trends in cancer rates. Copyright (C) 2009 John Wiley & Sons, Ltd. C1 [Clegg, Limin X.] US Dept Vet Affairs, Off Inspector Gen, Washington, DC USA. [Hankey, Benjamin F.] Informat Management Serv Inc, Silver Spring, MD USA. [Tiwari, Ram] US FDA, Off Biostat, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA. [Feuer, Eric J.; Edwards, Brenda K.] NCI, Surveillance Res Program, Bethesda, MD 20892 USA. RP Clegg, LX (reprint author), US Dept Vet Affairs, Off Inspector Gen, 801 1 St NW,Room 1018, Washington, DC USA. EM lin_clegg@nih.gov NR 16 TC 118 Z9 123 U1 0 U2 4 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0277-6715 J9 STAT MED JI Stat. Med. PD DEC PY 2009 VL 28 IS 29 BP 3670 EP 3682 DI 10.1002/sim.3733 PG 13 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 533EU UT WOS:000272807300007 PM 19856324 ER PT J AU Cai, XX Lin, YF Friedrich, CC Neville, C Pomerantseva, I Sundback, CA Sharma, P Zhang, ZY Vacanti, JP Hauschka, PV Grottkau, BE AF Cai, Xiaoxiao Lin, Yunfeng Friedrich, Claudia C. Neville, Craig Pomerantseva, Irina Sundback, Cathryn A. Sharma, Parul Zhang, Zhiyuan Vacanti, Joseph P. Hauschka, Peter V. Grottkau, Brian E. TI Bone marrow Derived Pluripotent Cells are Pericytes which Contribute to Vascularization SO STEM CELL REVIEWS AND REPORTS LA English DT Article DE Bone marrow stromal cells; Pericytes; Multilineage differentiation; Endothelial cells; Vascularization ID PROGENITOR CELLS; STEM-CELLS; IN-VIVO; ENDOTHELIAL-CELLS; TISSUE; NETWORK; ALPHA; DIFFERENTIATION; IDENTIFICATION; VASCULATURE AB Pericytes are essential to vascularization, but the purification and characterization of pericytes remain unclear. Smooth muscle actin alpha (alpha-SMA) is one maker of pericytes. The aim of this study is to purify the alpha-SMA positive cells from bone marrow and study the characteristics of these cells and the interaction between alpha-SMA positive cells and endothelial cells. The bone marrow stromal cells were harvested from alpha-SMA-GFP transgenic mice, and the alpha-SMA-GFP positive cells were sorted by FACS. The proliferative characteristics and multilineage differentiation ability of the alpha-SMA-GFP positive cells were tested. A 3-D culture model was then applied to test their vascularization by loading alpha-SMA-GFP positive cells and endothelial cells on collagen-fibronectin gel. Results demonstrated that bone marrow stromal cells are mostly alpha-SMA-GFP positive cells which are pluripotent, and these cells expressed alpha-SMA during differentiation. The alpha-SMA-GFP positive cells could stimulate the endothelial cells to form tube-like structures and subsequently robust vascular networks in 3-D culture. In conclusion, the bone marrow derived pluripotent cells are pericytes and can contribute to vascularization. C1 [Cai, Xiaoxiao; Lin, Yunfeng] Sichuan Univ, W China Coll Stomatol, State Key Lab Oral Dis, Chengdu 610041, Peoples R China. [Cai, Xiaoxiao; Sharma, Parul; Zhang, Zhiyuan; Hauschka, Peter V.] Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Orthopaed Surg, Boston, MA USA. [Lin, Yunfeng; Friedrich, Claudia C.; Neville, Craig; Pomerantseva, Irina; Sundback, Cathryn A.; Vacanti, Joseph P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Regenerat Med, Boston, MA 02114 USA. [Lin, Yunfeng; Grottkau, Brian E.] Harvard Univ, Sch Med, Mass Gen Hosp Children, Dept Orthopaed Surg, Boston, MA USA. [Lin, Yunfeng; Grottkau, Brian E.] Harvard Univ, Sch Med, Pediat Orthopaed Lab Tissue Engn, Boston, MA USA. RP Lin, YF (reprint author), Sichuan Univ, W China Coll Stomatol, State Key Lab Oral Dis, Chengdu 610041, Peoples R China. EM yunfenglin@scu.edu.cn; bgrottkau@partners.org RI Lin, Yunfeng/M-5438-2013; Lin, Yunfeng/H-3393-2011; OI Lin, Yunfeng/0000-0003-1224-6561; Lin, Yunfeng/0000-0003-1224-6561; Cai, Xiaoxiao/0000-0002-5654-7414 FU Anthony and Constance Franchi Fund for Pediatric Orthopaedics at the MassGeneral Hospital for Children; Peabody Foundation Inc.; National Natural Science Foundation of China [30801304]; Foundation for the Author of National Excellent Doctoral Dissertation of PR China [FANEDD 200977]; Program for New Century Excellent Talents in University [NCET-08-0373] FX This work was funded by the Anthony and Constance Franchi Fund for Pediatric Orthopaedics at the MassGeneral Hospital for Children, The Peabody Foundation Inc., the National Natural Science Foundation of China (30801304), Foundation for the Author of National Excellent Doctoral Dissertation of PR China (FANEDD 200977) and Program for New Century Excellent Talents in University (NCET-08-0373). NR 27 TC 44 Z9 45 U1 1 U2 6 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1550-8943 J9 STEM CELL REV REP JI Stem Cell Rev. Rep. PD DEC PY 2009 VL 5 IS 4 BP 437 EP 445 DI 10.1007/s12015-009-9097-6 PG 9 WC Cell & Tissue Engineering; Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA 542DA UT WOS:000273470400016 PM 20058207 ER PT J AU Curley, MD Therrien, VA Cummings, CL Sergent, PA Koulouris, CR Friel, AM Roberts, DJ Seiden, MV Scadden, DT Rueda, BR Foster, R AF Curley, Michael D. Therrien, Vanessa A. Cummings, Christine L. Sergent, Petra A. Koulouris, Carolyn R. Friel, Anne M. Roberts, Drucilla J. Seiden, Michael V. Scadden, David T. Rueda, Bo R. Foster, Rosemary TI CD133 Expression Defines a Tumor Initiating Cell Population in Primary Human Ovarian Cancer SO STEM CELLS LA English DT Article DE CD133; Human; Ovarian cancer; Cancer stem cells; Tumor-initiating cells ID STEM-CELLS; PROSPECTIVE IDENTIFICATION; PANCREATIC-CANCER; POSITIVE CELLS; CONTRIBUTE; GROWTH AB Evidence is accumulating that solid tumors contain a rare phenotypically distinct population of cells, termed cancer stem cells (CSC), which give rise to and maintain the bulk of the tumor. These CSC are thought to be resistant to current chemotherapeutic strategies due to their intrinsic stem-like properties and thus may provide the principal driving force behind recurrent tumor growth. Given the high frequency of recurrent metastasis associated with human ovarian cancer, we sought to determine whether primary human ovarian tumors contain populations of cells with enhanced tumor-initiating capacity, a characteristic of CSC. Using an in vivo serial transplantation model, we show that primary uncultured human ovarian tumors can be reliably propagated in NOD/SCID mice, generating heterogeneous tumors that maintain the histological integrity of the parental tumor. The observed frequency of tumor engraftment suggests only certain subpopulations of ovarian tumor cells have the capacity to recapitulate tumor growth. Further profiling of human ovarian tumors for expression of candidate CSC surface markers indicated consistent expression of CD133. To determine whether CD133 expression could define a tumor-initiating cell population in primary human ovarian tumors, fluorescence-activated cell sorting (FACS) methods were employed. Injection of sorted CD133(+) and CD133(-) cell populations into NOD/SCID mice established that tumor-derived CD133(+) cells have an increased tumorigenic capacity and are capable of recapitulating the original heterogeneous tumor. Our data indicate that CD133 expression defines a NOD/SCID tumor initiating subpopulation of cells in human ovarian cancer that may be an important target for new chemotherapeutic strategies aimed at eliminating ovarian cancer. STEM CELLS 2009;27:2875-2883 C1 [Curley, Michael D.; Sergent, Petra A.; Friel, Anne M.; Rueda, Bo R.; Foster, Rosemary] Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Vincent Obstet & Gynecol Serv, Boston, MA 02114 USA. [Therrien, Vanessa A.; Cummings, Christine L.; Koulouris, Carolyn R.; Scadden, David T.; Rueda, Bo R.; Foster, Rosemary] Harvard Univ, Stem Cell Inst, Cambridge, MA 02138 USA. [Therrien, Vanessa A.; Cummings, Christine L.; Scadden, David T.; Foster, Rosemary] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. [Koulouris, Carolyn R.; Rueda, Bo R.] Massachusetts Gen Hosp, Div Gynecol Oncol, Vincent Obstet & Gynecol Serv, Boston, MA 02114 USA. [Roberts, Drucilla J.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Seiden, Michael V.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Scadden, David T.; Rueda, Bo R.; Foster, Rosemary] Massachusetts Gen Hosp, MGH Canc Ctr, Boston, MA 02114 USA. [Scadden, David T.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA. [Rueda, Bo R.; Foster, Rosemary] Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Cambridge, MA 02138 USA. RP Foster, R (reprint author), Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Vincent Obstet & Gynecol Serv, Thier 901,55 Fruit St, Boston, MA 02114 USA. EM Rfoster1@partners.org FU Dana Farber/Harvard Cancer Center Ovarian SPORE; Marsha Rivkin Center for Ovarian Cancer Research; Julie Fund; Advanced Medical Research Foundation; Ovarian Cancer Research Fund; Vincent Memorial Research Fund; Ovarian Cancer and Education Awareness Network FX This work was supported by an anonymous gift to the Harvard Stem Cell Institute and funding from the Dana Farber/Harvard Cancer Center Ovarian SPORE (RF/BRR), Marsha Rivkin Center for Ovarian Cancer Research (RF), The Julie Fund (RF), Advanced Medical Research Foundation (BRR), Ovarian Cancer Research Fund (BRR), Vincent Memorial Research Fund (BRR), Ovarian Cancer and Education Awareness Network (BRR), and a gift from Robert Lynn v. d. Luft and Christa v. d. Luft (BRR). NR 27 TC 210 Z9 222 U1 2 U2 14 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1066-5099 J9 STEM CELLS JI Stem Cells PD DEC PY 2009 VL 27 IS 12 BP 2875 EP 2883 DI 10.1002/stem.236 PG 9 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology GA 543IU UT WOS:000273569800001 PM 19816957 ER PT J AU Nogueira, RG Liebeskind, DS Sung, G Duckwiler, G Smith, WS AF Nogueira, Raul G. Liebeskind, David S. Sung, Gene Duckwiler, Gary Smith, Wade S. CA MERCI Multi MERCI Writing Comm TI Predictors of Good Clinical Outcomes, Mortality, and Successful Revascularization in Patients With Acute Ischemic Stroke Undergoing Thrombectomy Pooled Analysis of the Mechanical Embolus Removal in Cerebral Ischemia (MERCI) and Multi MERCI Trials SO STROKE LA English DT Article DE acute stroke; endovascular treatment; thrombectomy ID INDUCED ARTERIAL RECANALIZATION; INTRAARTERIAL THROMBOLYSIS; VESSEL RECANALIZATION; BLOOD-PRESSURE; OCCLUSION; HYPERGLYCEMIA; ASSOCIATION; EFFICACY AB Background and Purpose-The Mechanical Embolus Removal in Cerebral Ischemia (MERCI) and Multi MERCI trials evaluated the safety and efficacy of thrombectomy in the treatment of intracranial arterial occlusions within 8 hours of symptom onset. We sought to determine the predictors of clinical and angiographic outcomes in these patients. Methods-The trial cohorts were combined in a data set of 305 patients. Twenty-eight baseline variables were included in univariate and multivariate analyses to define the independent predictors of good outcomes (modified Rankin Scale score <= 2), mortality, and successful revascularization (Thrombolysis In Myocardial Ischemia 2 to 3 flow). Results-In the univariate analysis, final revascularization, baseline National Institutes of Health Stroke Scale, age, and systolic blood pressure were associated with both good outcomes and mortality at 90 days (P < 0.0018 for all). In the multivariate analysis, final revascularization (OR, 20.4; 95% CI, 7.7 to 53.9; P < 0.0001), baseline National Institutes of Health Stroke Scale (OR, 0.86; 95% CI, 0.81 to 0.92; P < 0.0001), and age (OR, 0.96; 95% CI, 0.95 to 0.98; P = 0.0004) were independent predictors of good outcome. Final revascularization (OR, 0.28; 95% CI, 0.16 to 0.50; P < 0.0001), baseline National Institutes of Health Stroke Scale score (odds ratio, 1.09; 95% CI, 1.04 to 1.14; P < 0.0001), age (OR, 1.05; 95% CI, 1.03 to 1.07; P < 0.0001), and internal carotid artery occlusion (OR, 2.17; 95% CI, 1.22 to 3.86; P = 0.0084) were the strongest predictors of mortality. Systolic blood pressure (<= 150 versus >= 150 mm Hg; OR, 0.42; 95% CI, 0.26 to 0.70; P = 0.0007) and M2 occlusion (OR, 3.86; 95% CI, 1.28 to 11.67; P = 0.0168) were independent predictors of revascularization. Conclusion-Final recanalization status represents the strongest predictor of clinical outcomes in patients undergoing thrombectomy. The ability to remove the clot is negatively influenced by systolic blood pressure on presentation perhaps because of the hydraulic forces imposed by higher blood pressures. Although internal carotid artery occlusions are associated with increased mortality, they do not appear to influence the chances of good outcomes. This finding supports the inclusion of internal carotid artery occlusions in future efficacy trials. (Stroke. 2009; 40: 3777-3783.) C1 [Nogueira, Raul G.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Nogueira, Raul G.] Massachusetts Gen Hosp, Dept Intervent Neuroradiol, Boston, MA 02114 USA. [Liebeskind, David S.; Smith, Wade S.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Sung, Gene] Univ So Calif, Dept Neurol, Los Angeles, CA USA. [Duckwiler, Gary] Univ Calif Los Angeles, Dept Intervent Neuroradiol, Los Angeles, CA USA. RP Nogueira, RG (reprint author), Massachusetts Gen Hosp, Dept Intervent Neuroradiol & Endovasc Neurosurg, 55 Fruit St,GRB-2-241, Boston, MA 02114 USA. EM rnogueira@partners.org NR 25 TC 141 Z9 150 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD DEC PY 2009 VL 40 IS 12 BP 3777 EP 3783 PG 7 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 531KD UT WOS:000272663900019 PM 19875740 ER PT J AU Smith, WS Lev, MH English, JD Camargo, EC Chou, M Johnston, SC Gonzalez, G Schaefer, PW Dillon, WP Koroshetz, WJ Furie, KL AF Smith, Wade S. Lev, Michael H. English, Joey D. Camargo, Erica C. Chou, Maggie Johnston, S. Claiborne Gonzalez, Gilberto Schaefer, Pamela W. Dillon, William P. Koroshetz, Walter J. Furie, Karen L. TI Significance of Large Vessel Intracranial Occlusion Causing Acute Ischemic Stroke and TIA SO STROKE LA English DT Article DE CT angiography; prognosis ID PROGNOSTIC MODELS; MINOR STROKE; VALIDATION; ATTACK; SCORE; RISK AB Background and Purpose-Acute ischemic stroke due to large vessel occlusion (LVO)-vertebral, basilar, carotid terminus, middle and anterior cerebral arteries-likely portends a worse prognosis than stroke unassociated with LVO. Because little prospective angiographic data have been reported on a cohort of unselected patients with stroke and with transient ischemic attack, the clinical impact of LVO has been difficult to quantify. Methods-The Screening Technology and Outcome Project in Stroke Study is a prospective imaging-based study of stroke outcomes performed at 2 academic medical centers. Patients with suspected acute stroke who presented within 24 hours of symptom onset and who underwent multimodality CT/CT angiography were approached for consent for collection of clinical data and 6-month assessment of outcome. Demographic and clinical variables and 6-month modified Rankin Scale scores were collected and combined with blinded interpretation of the CT angiography data. The OR of each variable, including occlusion of intracranial vascular segment in predicting good outcome and 6-month mortality, was calculated using univariate and multivariate logistic regression. Results-Over a 33-month period, 735 patients with suspected stroke were enrolled. Of these, 578 were adjudicated as stroke and 97 as transient ischemic attack. Among patients with stroke, 267 (46%) had LVO accounting for the stroke and 13 (13%) of patients with transient ischemic attack had LVO accounting for transient ischemic attack symptoms. LVO predicted 6-month mortality (OR, 4.5; 95% CI, 2.7 to 7.3; P<0.001). Six-month good outcome (modified Rankin Scale score <= 2) was negatively predicted by LVO (0.33; 0.24 to 0.45; P<0.001). Based on multivariate analysis, the presence of basilar and internal carotid terminus occlusions, in addition to National Institutes of Health Stroke Scale and age, independently predicted outcome. Conclusion-Large vessel intracranial occlusion accounted for nearly half of acute ischemic strokes in unselected patients presenting to academic medical centers. In addition to age and baseline stroke severity, occlusion of either the basilar or internal carotid terminus segment is an independent predictor of outcome at 6 months. (Stroke. 2009;40:3834-3840.) C1 [Smith, Wade S.; English, Joey D.; Johnston, S. Claiborne] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Dillon, William P.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA. [Lev, Michael H.; Gonzalez, Gilberto; Schaefer, Pamela W.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Camargo, Erica C.; Furie, Karen L.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Chou, Maggie] Columbia Univ, Dept Neurol, New York, NY USA. [Koroshetz, Walter J.] NINDS, Bethesda, MD 20892 USA. RP Smith, WS (reprint author), Univ Calif San Francisco, Dept Neurol, 505 Parnassus Ave, San Francisco, CA 94143 USA. EM smithw@neurology.ucsf.edu FU Department of Health and Human Services, Agency for Healthcare Research and Quality [RO1-HS011392-01A1]; Deane Institute FX W. S. S. has significant ownership interests and has served as a consultant to Concentric Medical, Inc (significant). K. L. F. is employed with Massachusetts General Hospital, has received financial support from Deane Institute (both significant), and has served as a consultant to Novartis, Biosante, and GE Healthcare (Modest). W.J.K. has an ownership interest in Neurologica (Modest). There are no other conflicts to report. NR 16 TC 97 Z9 101 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD DEC PY 2009 VL 40 IS 12 BP 3834 EP 3840 DI 10.1161/STROKEAHA.109.561787 PG 7 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 531KD UT WOS:000272663900028 PM 19834014 ER PT J AU Lin, CI Whang, EE Abramson, MA Jiang, XF Price, BD Donner, DB Moore, FD Ruan, DT AF Lin, Chi-Iou Whang, Edward E. Abramson, Michael A. Jiang, Xiaofeng Price, Brendan D. Donner, David B. Moore, Francis D., Jr. Ruan, Daniel T. TI Autophagy: A new target for advanced papillary thyroid cancer therapy SO SURGERY LA English DT Article; Proceedings Paper CT 30th Annual Meeting of the American-Association-of-Endocrine-Surgeons CY MAY 03-05, 2009 CL Madison, WI SP Amer Assoc Endocrine Surg ID MAMMALIAN TARGET; BREAST-CANCER; CELL-DEATH; APOPTOSIS; DOXORUBICIN; RAPAMYCIN; PATHWAY; MOUSE; MODEL; CHEMOTHERAPY AB Background. Autophagy is a conserved response to stress that facilitates cell survival in some contexts and promotes cell death in others. We sought to characterize autophagy in papillary thyroid cancer (PTC), and to determine the effects of autophagy inhibition on chemosensitivity and radiosensitivity. Methods. The human thyroid papillary carcinoma cell lines TPC-1 and 8505-C were treated with doxorubicin or radiation in the presence or absence of the autophagy-specific inhibitor 3-methyladenine (3-MA). Results. Although light chain 3 (LC3)-II protein levels were undetectable in normal thyroid and PTC specimens at baseline, doxorubicin exposure induced LC3-II expression and the formation of autophagosomes. Both PTC cell lines expressed low levels of LC3-II tinder standard conditions. Treatment of these cells with doxorubicin strongly induced LC3-II expression and the formation of autophagosomes; however, doxorubicin-mediated induction of LC3-II was abrogated by 3-MA. Moreover, 3-MA significantly increased the doxorubicin IC(50) in both PTC cell lines. Radiation exposure also induced LC3-II expression. Treatment with 3-MA abrogated the radiation-induced increase in LC3-II in both cell lines and reduced radiosensitivity by 49% and 31% in 8505-C and TPC-1 cells, respectively. Conclusion. Autophagy inhibition promotes PTC resistance to doxorubicin and radiation. Therefore, autophagy activation may be a useful adjunct treatment for patients with PTC that is refractory to conventional therapy. (Surgery 2009;746:1208-14.) C1 [Lin, Chi-Iou; Whang, Edward E.; Abramson, Michael A.; Moore, Francis D., Jr.; Ruan, Daniel T.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. [Jiang, Xiaofeng; Price, Brendan D.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Donner, David B.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. RP Ruan, DT (reprint author), Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA. EM druan@partners.org NR 33 TC 22 Z9 25 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0039-6060 J9 SURGERY JI Surgery PD DEC PY 2009 VL 146 IS 6 BP 1208 EP 1214 DI 10.1016/j.surg.2009.09.019 PG 7 WC Surgery SC Surgery GA 536YB UT WOS:000273078700032 PM 19958950 ER PT J AU Anaya, DA Bulger, EM Kwon, YS Kao, LS Evans, H Nathens, AB AF Anaya, Daniel A. Bulger, Eileen M. Kwon, Yong S. Kao, Lillian S. Evans, Heather Nathens, Avery B. TI Predicting Death in Necrotizing Soft Tissue Infections: A Clinical Score SO SURGICAL INFECTIONS LA English DT Article; Proceedings Paper CT 25th Annual Meeting of the Surgical-Infection-Society CY MAY 06, 2005 CL Miami, FL SP Surg Infect Soc ID EARLY-DIAGNOSIS; RISK-FACTORS; FASCIITIS; MANAGEMENT; MORTALITY; SURVIVAL; DISEASE; MODEL; CARE AB Background: Necrotizing soft tissue infections (NSTIs) are associated with a high mortality rate; however, there is no uniform way to categorize the severity of this disease early in its course. The goal of this study was to develop a clinical score based on data available at the time of initial assessment to aid in stratifying patients according to their risk of death. Methods: A cohort of all 350 patients admitted with NSTI to two institutions over a nine-year period was examined retrospectively. Using random split sampling, two datasets were created: Prediction (PD) and validation (VD). Multivariable stepwise regression analysis of the PD identified independent predictors of death using data available at the time of admission. Model performance was evaluated for accuracy, discrimination, and calibration. A clinical score to predict death was created, and using the Trauma and Injury Severity Score (TRISS) methodology, the score was validated on the VD (z-statistic). Results: Six admission parameters independently predicted death: Age >50 years, heart rate >110 beats/min, temperature <36 degrees C, white blood cell count >40,000/mcL, serum creatinine concentration >1.5 mg/dL, and hematocrit >50%. The accuracy of this model was 86.8%; the area under the receiver-operating characteristic curve was 0.81, and the Hosmer-Lemeshow statistic was 11.8. Additionally, the score had excellent performance in evaluation on the VD (z-score/statistic 0.23 to 0.83). Conclusion: A clinical score that categorizes patients with NSTI according to the risk of death was created. It uses simple variables, all available at the time of first assessment. It stratifies patients according to disease severity and can guide the use of aggressive or novel therapeutic strategies and selection of patients for clinical trials. C1 [Anaya, Daniel A.] Baylor Coll Med, Dept Surg, Michael E DeBakey Vet Affairs Med Ctr, Div Gen Surg, Houston, TX 77030 USA. [Bulger, Eileen M.; Kwon, Yong S.; Evans, Heather] Univ Washington, Harborview Med Ctr, Div Gen & Trauma Surg, Seattle, WA 98104 USA. [Bulger, Eileen M.; Kwon, Yong S.; Evans, Heather] Univ Washington, Dept Surg, Seattle, WA 98195 USA. [Kao, Lillian S.] Lyndon Baines Johnson Gen Hosp, Div Gen Surg, Houston, TX USA. [Kao, Lillian S.] Univ Texas Houston, Dept Surg, Houston, TX USA. [Nathens, Avery B.] Univ Toronto, St Michaels Hosp, Dept Surg, Div Gen Surg, Toronto, ON M5B 1W8, Canada. RP Anaya, DA (reprint author), Michael E DeBakey Houston VA Med Ctr, Dept Surg, 2002 Holcombe Blvd,Operat Care Line 112, Houston, TX 77030 USA. EM danaya@bcm.edu NR 28 TC 25 Z9 26 U1 0 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-2964 J9 SURG INFECT JI Surg. Infect. PD DEC PY 2009 VL 10 IS 6 BP 517 EP 522 DI 10.1089/sur.2008.112 PG 6 WC Infectious Diseases; Surgery SC Infectious Diseases; Surgery GA 613VY UT WOS:000279012800003 PM 20001332 ER PT J AU Virani, SS Nambi, V Lee, VV Elayda, MA Pan, W Petersen, LA Wilson, JM Willerson, JT Ballantyne, CM AF Virani, Salim S. Nambi, Vijay Lee, Vei-Vei Elayda, MacArthur A. Pan, Wei Petersen, Laura A. Wilson, James M. Willerson, James T. Ballantyne, Christie M. TI Obesity An Independent Predictor of In-Hospital Postoperative Renal Insufficiency among Patients Undergoing Cardiac Surgery? SO TEXAS HEART INSTITUTE JOURNAL LA English DT Article DE Body mass index; cardiac surgical procedures/adverse effects; cardiopulmonary bypass/adverse effects; inflammation/complications; kidney failure/etiology; obesity/complications; oxidative stress; postoperative complications; retrospective studies; risk factors; systemic inflammatory response syndrome; treatment outcome ID BODY-MASS INDEX; ARTERY-BYPASS-SURGERY; EXTREME OBESITY; KIDNEY-DISEASE; RISK-FACTOR; OUTCOMES; MORTALITY; CKD; HYPERTENSION; ASSOCIATION AB We sought to determine, retrospectively, whether obesity was associated with adverse renal outcomes in 17,630 patients who underwent cardiac surgery from January 7995 through December 2006. Obesity was defined as a body mass index >= 30 kg/m(2). The primary outcome was any episode of postoperative renal insufficiency (requiring or not requiring dialysis) before hospital discharge. Outcomes were evaluated in the entire cohort and in subgroups undergoing isolated coronary artery bypass grafting (CABG), isolated valve surgery, and combined CABG and valve surgery. The final analysis included 7 6,429 patients, 5,124 (31%) of whom were obese. In the entire cohort, obesity was associated both with increased risk of any postoperative renal insufficiency (odds ratio [OR], 1.37; 95% confidence interval [CI], 1.21-1.55) and with increased risk of renal insufficiency not requiring dialysis (OR, 1.41; 95% CI, 1.23-1.62). Obesity was associated with an increased risk of postoperative renal insufficiency in patients undergoing isolated CABG (OR, 1.38; 95% CI, 1.18-1.61), isolated valve surgeries (OR, 1.39; 95% CI, 1.05-1.85), and combined CABG and valve surgeries (OR, 7.35; 95% CI, 0.99-1.83; statistically nonsignificant). Development of postoperative renal insufficiency was associated with a significantly higher mortality rate (P<0.0001) and with a significantly longer hospital stay (23 vs 10.5 days; P <0.0001). We conclude that obesity is associated with a significant increase in postoperative renal insufficiency in cardiac surgery patients, an effect that we attribute to an increase in postoperative renal failure that does not require dialysis. (Tex Heart Inst J 2009,36(6):540-5) C1 [Virani, Salim S.; Nambi, Vijay; Ballantyne, Christie M.] Baylor Coll Med, Dept Med, Cardiol Sect, Houston, TX 77030 USA. [Virani, Salim S.; Nambi, Vijay; Ballantyne, Christie M.] Baylor Coll Med, Dept Med, Sect Atherosclerosis & Vasc Med, Houston, TX 77030 USA. [Petersen, Laura A.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Lee, Vei-Vei; Elayda, MacArthur A.] St Lukes Episcopal Hosp, Texas Heart Inst, Dept Biostat & Epidemiol, Houston, TX 77036 USA. [Virani, Salim S.; Wilson, James M.; Willerson, James T.] St Lukes Episcopal Hosp, Texas Heart Inst, Dept Cardiol, Houston, TX 77036 USA. [Pan, Wei] St Lukes Episcopal Hosp, Texas Heart Inst, Dept Anesthesiol, Houston, TX 77036 USA. [Virani, Salim S.; Nambi, Vijay; Ballantyne, Christie M.] Methodist DeBakey Heart & Vasc Ctr, Ctr Cardiovasc Dis Prevent, Houston, TX 77036 USA. [Petersen, Laura A.] Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77036 USA. RP Ballantyne, CM (reprint author), Baylor Coll Med, Dept Med, Cardiol Sect, 6565 Fannin,MS A-601,Suite A656, Houston, TX 77030 USA. EM cmb@bcm.tmc.edu OI Virani, Salim/0000-0001-9541-6954 FU Texas Heart Institute Muller Fund for Cardiovascular Research; Houston VA Health Services Research & Development Center of Excellence [HFP90-020] FX This is work was supported by the Texas Heart Institute Muller Fund for Cardiovascular Research and the Houston VA Health Services Research & Development Center of Excellence (grant number HFP90-020). NR 29 TC 12 Z9 12 U1 0 U2 2 PU TEXAS HEART INST PI HOUSTON PA PO BOX 20345, HOUSTON, TX 77225-0345 USA SN 0730-2347 J9 TEX HEART I J JI Tex. Heart Inst. J. PD DEC PY 2009 VL 36 IS 6 BP 540 EP 545 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 533EX UT WOS:000272807600006 PM 20069078 ER PT J AU Taylor, AM Zon, LI AF Taylor, Alison M. Zon, Leonard I. TI Zebrafish Tumor Assays: The State of Transplantation SO ZEBRAFISH LA English DT Article ID ACUTE MYELOID-LEUKEMIA; HUMAN-MELANOMA CELLS; TRANSGENIC ZEBRAFISH; ADULT ZEBRAFISH; IMMUNE-SYSTEM; SCID MICE; METASTASIS; MODEL; ANGIOGENESIS; ENGRAFTMENT AB Tumor transplant studies are important tools for studying cancer biology in a model organism. Transplantation is especially important for assaying tumor cell malignancy and migration capabilities, and is critical for identifying putative cancer stem cell populations. In this review, we discuss the current state of tumor transplantation studies performed in the zebrafish. We address several zebrafish-specific considerations for development of the transplant assay, including choosing recipient animals, transplant methods, and post-transplant observation. We also examine how the zebrafish is an advantageous model for transplantation, particularly with development of the translucent fish. Transplantation has already been critical for characterizing zebrafish models of leukemia, rhabdomyosarcoma, and melanoma. With further development of imaging techniques and other tools, zebrafish tumor transplantation will continue to contribute to our understanding of tumor cell biology. C1 [Zon, Leonard I.] Childrens Hosp, Stem Cell Program, Boston, MA 02115 USA. Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Howard Hughes Med Inst, Boston, MA 02115 USA. RP Zon, LI (reprint author), Childrens Hosp, Stem Cell Program, 7th Floor,Room 7211,1 Blackfan Circle, Boston, MA 02115 USA. EM zon@enders.tch.harvard.edu FU NCI NIH HHS [R01 CA103846, R01 CA103846-04] NR 43 TC 46 Z9 47 U1 0 U2 4 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1545-8547 J9 ZEBRAFISH JI Zebrafish PD DEC PY 2009 VL 6 IS 4 BP 339 EP 346 DI 10.1089/zeb.2009.0607 PG 8 WC Developmental Biology; Zoology SC Developmental Biology; Zoology GA 539KM UT WOS:000273253000004 PM 20047467 ER PT J AU Ignatius, MS Langenau, DM AF Ignatius, Myron S. Langenau, David M. TI Zebrafish as a Model for Cancer Self-Renewal SO ZEBRAFISH LA English DT Article ID ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; ZINC-FINGER NUCLEASES; PRIMITIVE HEMATOPOIETIC-CELL; TUMOR-INITIATING CELLS; HUMAN-MELANOMA CELLS; STEM-CELLS; TRANSGENIC ZEBRAFISH; PANCREATIC-CANCER; GLIOMA-CELLS AB Self-renewal is the process by which normal stem cells and cancer cells make more of themselves. In cancer, this process is ultimately responsible for the infinite replicative potential of malignant cells and is likely found in residual cell populations that evade conventional therapy. Two intrinsically opposing hypotheses have emerged to explain how self-renewal occurs in cancer. The cancer stem cell hypothesis states that self-renewal is confined to a discrete subpopulation of malignant cells, whereas the stochastic model suggests that all tumor cells have the potential to self-renew. Presently, the gold standard for measuring cancer self-renewal is limiting dilution cell transplantation into immune-matched or immune-deficient animals. From these experiments, tumor-initiating frequency can be calculated based on the number of animals that engraft disease following transplantation of various doses of tumor cells. Here, we describe how self-renewal assays are performed, summarize the current experimental models that support the cancer stem cell and stochastic models of cancer self-renewal, and enumerate how the zebrafish can be used to uncover important pathways in cancer self-renewal. C1 [Ignatius, Myron S.; Langenau, David M.] Massachusetts Gen Hosp, Dept Pathol, Mol Pathol Unit, Charlestown, MA 02129 USA. [Ignatius, Myron S.; Langenau, David M.] Massachusetts Gen Canc Ctr, Charlestown, MA USA. [Ignatius, Myron S.; Langenau, David M.] Harvard Stem Cell Inst, Boston, MA USA. RP Langenau, DM (reprint author), Massachusetts Gen Hosp, Dept Pathol, Mol Pathol Unit, 149 13th St,6th Floor 6012, Charlestown, MA 02129 USA. EM dlangenau@partners.org FU NIAMS NIH HHS [K01 AR055619-03S1, K01 AR055619-03, K01 AR055619]; NIH HHS [R24 OD016761] NR 70 TC 13 Z9 13 U1 2 U2 9 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1545-8547 J9 ZEBRAFISH JI Zebrafish PD DEC PY 2009 VL 6 IS 4 BP 377 EP 387 DI 10.1089/zeb.2009.0610 PG 11 WC Developmental Biology; Zoology SC Developmental Biology; Zoology GA 539KM UT WOS:000273253000008 PM 19954344 ER PT J AU Dovey, M White, RM Zon, LI AF Dovey, Michael White, Richard Mark Zon, Leonard I. TI Oncogenic NRAS Cooperates with p53 Loss to Generate Melanoma in Zebrafish SO ZEBRAFISH LA English DT Article ID MALIGNANT-MELANOMA; TUMOR PROGRESSION; BRAF MUTATIONS; RAS MUTATIONS; N-RAS; MELANOCYTIC LESIONS; SENESCENCE; EXPRESSION; NEVI; SUSCEPTIBILITY AB NRAS mutations are a common oncogenic event in skin cancer, occurring frequently in congenital nevi and malignant melanoma. To study the role of NRAS in zebrafish, a transgenic approach was applied to generate fish that express human oncogenic NRAS(Q61K) under the control of the melanocyte-restricted mitfa promoter. By screening the progeny of the injected animals, two strains stably expressing the NRAS transgene were identified: Tg(mitfa:EGFP:NRAS(Q61K))(1) and Tg(mitfa:EGFP:NRAS(Q61K))(2). Stable expression of this transgene results in hyperpigmented fish displaying a complete ablation of the normal pigment pattern. Although oncogenic NRAS expression alone was found to be insufficient to promote tumor formation, loss of functional p53 was found to collaborate with NRAS expression in the genesis of melanoma. The tumors derived from these animals are variably pigmented and closely resemble human melanoma. Underscoring the pathological similarities between these tumors and human disease and suggesting that common pathways are similar in these models and human disease, gene set enrichment analysis performed on microarray data found that the upregulated genes from zebrafish melanomas are highly enriched in human tumor samples. This work characterizes two zebrafish melanoma models that will be useful tools for the study of melanoma pathogenesis. C1 [Zon, Leonard I.] Childrens Hosp, Stem Cell Program & Hematol Oncol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Howard Hughes Med Inst, Dana Farber Canc Inst,Harvard Stem Cell Inst, Boston, MA 02115 USA. RP Zon, LI (reprint author), Childrens Hosp, Stem Cell Program & Hematol Oncol, Karp Family Res Bldg,Room 7211,1 Blackfan Circle, Boston, MA 02115 USA. EM zon@enders.tch.harvard.edu FU American Society for Clinical Oncology; Aid for Cancer Research Fellowship; National Institutes of Health [R01-DK53298-08] FX We would like to thank members of the Zon laboratory, especially Craig Ceol, for helpful discussions. R.M.W. is supported by an American Society for Clinical Oncology Young Investigator Award and an Aid for Cancer Research Fellowship. Melanoma research by L.I.Z. is funded by National Institutes of Health Grant R01-DK53298-08. NR 28 TC 48 Z9 50 U1 0 U2 10 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1545-8547 J9 ZEBRAFISH JI Zebrafish PD DEC PY 2009 VL 6 IS 4 BP 397 EP 404 DI 10.1089/zeb.2009.0606 PG 8 WC Developmental Biology; Zoology SC Developmental Biology; Zoology GA 539KM UT WOS:000273253000010 PM 19954345 ER PT J AU Lee, J Boo, JH Ryu, H AF Lee, Junghee Boo, Jung Hyun Ryu, Hoon TI The failure of mitochondria leads to neurodegeneration: Do mitochondria need a jump start? SO ADVANCED DRUG DELIVERY REVIEWS LA English DT Review DE Neuroprotection; Alzheimer's disease; Amyotrophic lateral sclerosis; Huntington's disease; Parkinson's disease; Therapeutics ID AMYOTROPHIC-LATERAL-SCLEROSIS; TRANSGENIC MOUSE MODELS; POSTMORTEM BRAIN-TISSUE; CYTOCHROME-C RELEASE; HUNTINGTONS-DISEASE; PARKINSONS-DISEASE; COENZYME Q(10); ALZHEIMERS-DISEASE; CELL-DEATH; ANIMAL-MODEL AB Mitochondria are the power engine generating biochemical energy in the cell. Mitochondrial dysfunction and bioenergy deficiency is closely linked to the pathogenesis of neurodegenerative disorders. Mitochondria play a variety of roles by integrating extracellular signals and executing important intracellular events in neuronal survival and death. in this context, the regulation of mitochondrial function via therapeutic approaches may exert some salutary and neuroprotective mechanisms. Understanding the relationship of mitochondria-dependent pathogenesis may provide important pharmacological utility in the treatment of neurodegenerative conditions such as Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Parkinson's disease. Indeed, the modulation of mitochondrial pathways is rapidly emerging as a novel therapeutic target. This review focuses on how mitochondria are involved in neurodegeneration and what therapeutics are available to target mitochondrial pathways. (C) 2009 Elsevier B.V. All rights reserved. C1 [Ryu, Hoon] VA Boston Healthcare Syst, Lab Neuronal Gene Regulat & Epigenet, Boston, MA 02130 USA. [Lee, Junghee; Ryu, Hoon] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. [Boo, Jung Hyun] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul, South Korea. RP Ryu, H (reprint author), VA Boston Healthcare Syst, Lab Neuronal Gene Regulat & Epigenet, Bldg 1A,Rm 109,150 S Huntington Ave, Boston, MA 02130 USA. EM hoonryu@bu.edu FU NIH [P30 AG13846, NS52724]; KOSEF [800-20080848] FX J.L. is an awardee of Les Turner ALS Foundation Grant. NIH P30 AG13846 O.L.), and NIH NS52724 (H.R.) supported this work. The WCU Neurocytomics Program Grant (800-20080848) through SNU from KOSEF (H.R.) supported this work, in part. NR 131 TC 29 Z9 29 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0169-409X J9 ADV DRUG DELIVER REV JI Adv. Drug Deliv. Rev. PD NOV 30 PY 2009 VL 61 IS 14 BP 1316 EP 1323 DI 10.1016/j.addr.2009.07.016 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 530NT UT WOS:000272600300007 PM 19716395 ER PT J AU Mito, JK Riedel, RF Dodd, L Lahat, G Lazar, AJ Dodd, RD Stangenberg, L Eward, WC Hornicek, FJ Yoon, SS Brigman, BE Jacks, T Lev, D Mukherjee, S Kirsch, DG AF Mito, Jeffrey K. Riedel, Richard F. Dodd, Leslie Lahat, Guy Lazar, Alexander J. Dodd, Rebecca D. Stangenberg, Lars Eward, William C. Hornicek, Francis J. Yoon, Sam S. Brigman, Brian E. Jacks, Tyler Lev, Dina Mukherjee, Sayan Kirsch, David G. TI Cross Species Genomic Analysis Identifies a Mouse Model as Undifferentiated Pleomorphic Sarcoma/Malignant Fibrous Histiocytoma SO PLOS ONE LA English DT Article ID SOFT-TISSUE SARCOMA; GENE-EXPRESSION; H-RAS; NORMALIZATION; MUTATIONS; INSIGHTS AB Undifferentiated pleomorphic sarcoma/Malignant Fibrous Histiocytoma (MFH) is one of the most common subtypes of human soft tissue sarcoma. Using cross species genomic analysis, we define a geneset from the LSL-Kras(G12D); Trp53(Flox/Flox) mouse model of soft tissue sarcoma that is highly enriched in human MFH. With this mouse geneset as a filter, we identify expression of the RAS target FOXM1 in human MFH. Expression of Foxm1 is elevated in mouse sarcomas that metastasize to the lung and tissue microarray analysis of human MFH correlates overexpression of FOXM1 with metastasis. These results suggest that genomic alterations present in human MFH are conserved in the LSL-Kras(G12D); p53(Flox/Flox) mouse model of soft tissue sarcoma and demonstrate the utility of this pre-clinical model. C1 [Mito, Jeffrey K.; Kirsch, David G.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA. [Riedel, Richard F.] Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Durham, NC 27710 USA. [Dodd, Leslie; Lev, Dina] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA. [Lahat, Guy] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA. [Lazar, Alexander J.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA. [Dodd, Rebecca D.; Kirsch, David G.] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC USA. [Stangenberg, Lars; Hornicek, Francis J.; Yoon, Sam S.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Stangenberg, Lars; Hornicek, Francis J.; Yoon, Sam S.] Harvard Univ, Sch Med, Boston, MA USA. [Eward, William C.; Brigman, Brian E.] Duke Univ, Med Ctr, Dept Surg, Div Orthopaed Surg, Durham, NC 27710 USA. [Jacks, Tyler] MIT, Ctr Canc Res, Cambridge, MA 02139 USA. [Jacks, Tyler] Howard Hughes Med Inst, Chevy Chase, MD USA. [Mukherjee, Sayan] Duke Univ, Dept Stat Sci, Durham, NC USA. [Mukherjee, Sayan] Duke Univ, Med Ctr, Inst Genome Sci & Policy, Durham, NC USA. RP Mito, JK (reprint author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA. EM david.kirsch@duke.edu RI Lazar, Alexander/A-3416-2008; OI Lazar, Alexander/0000-0002-6395-4499; Mukherjee, Sayan/0000-0002-6715-3920 FU Howard Hughes Medical Institute [KO8 CA 114176, RO1 CA 138265, T32 GM- 07171]; Maria Garcia-Estrada Foundation FX This study was supported by the Howard Hughes Medical Institute (TJ) and by KO8 CA 114176 and RO1 CA 138265 (DGK), T32 GM- 07171 (JM), and the Maria Garcia-Estrada Foundation (RR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 20 TC 27 Z9 29 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 30 PY 2009 VL 4 IS 11 AR e8075 DI 10.1371/journal.pone.0008075 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 533MQ UT WOS:000272828400022 PM 19956606 ER PT J AU Thurber, GM Figueiredo, JL Weissleder, R AF Thurber, Greg M. Figueiredo, Jose L. Weissleder, Ralph TI Multicolor Fluorescent Intravital Live Microscopy (FILM) for Surgical Tumor Resection in a Mouse Xenograft Model SO PLOS ONE LA English DT Article ID IN-VIVO; CANCER XENOGRAFTS; MICROVESSEL AREA; BREAST-CANCER; ANTIBODY; GROWTH; IDENTIFICATION; PROBES; MICE; INFLAMMATION AB Background: Complete surgical resection of neoplasia remains one of the most efficient tumor therapies. However, malignant cell clusters are often left behind during surgery due to the inability to visualize and differentiate them against host tissue. Here we establish the feasibility of multicolor fluorescent intravital live microscopy (FILM) where multiple cellular and/or unique tissue compartments are stained simultaneously and imaged in real time. Methodology/Principal Findings: Theoretical simulations of imaging probe localization were carried out for three agents with specificity for cancer cells, stromal host response, or vascular perfusion. This transport analysis gave insight into the probe pharmacokinetics and tissue distribution, facilitating the experimental design and allowing predictions to be made about the localization of the probes in other animal models and in the clinic. The imaging probes were administered systemically at optimal time points based on the simulations, and the multicolor FILM images obtained in vivo were then compared to conventional pathological sections. Our data show the feasibility of real time in vivo pathology at cellular resolution and molecular specificity with excellent agreement between intravital and traditional in vitro immunohistochemistry. Conclusions/Significance: Multicolor FILM is an accurate method for identifying malignant tissue and cells in vivo. The imaging probes distributed in a manner similar to predictions based on transport principles, and these models can be used to design future probes and experiments. FILM can provide critical real time feedback and should be a useful tool for more effective and complete cancer resection. C1 [Thurber, Greg M.; Figueiredo, Jose L.; Weissleder, Ralph] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Boston, MA 02115 USA. RP Thurber, GM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Boston, MA 02115 USA. EM rweissleder@mgh.harvard.edu OI Thurber, Greg/0000-0001-7570-2080 FU [P50 CA86355]; [U24 CA092782]; [T32 CA079443] FX This work was supported by grants P50 CA86355, U24 CA092782, and T32 CA079443. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 46 TC 17 Z9 17 U1 2 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 30 PY 2009 VL 4 IS 11 AR e8053 DI 10.1371/journal.pone.0008053 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 533MQ UT WOS:000272828400011 PM 19956597 ER PT J AU Noguchi, Y Young, JD Aleman, JO Hansen, ME Kelleher, JK Stephanopoulos, G AF Noguchi, Yasushi Young, Jamey D. Aleman, Jose O. Hansen, Michael E. Kelleher, Joanne K. Stephanopoulos, Gregory TI Effect of Anaplerotic Fluxes and Amino Acid Availability on Hepatic Lipoapoptosis SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID MASS ISOTOPOMER DISTRIBUTIONS; ENDOPLASMIC-RETICULUM STRESS; BIDIRECTIONAL REACTION STEPS; FATTY LIVER-DISEASE; HEPATOCYTE LIPOAPOPTOSIS; METABOLIC NETWORKS; INDUCED APOPTOSIS; BETA-CELLS; RAT-LIVER; EXPRESSION AB To identify metabolic pathways involved in hepatic lipoapoptosis, metabolic flux analysis using [U-(13)C(5)]glutamine as an isotopic tracer was applied to quantify phenotypic changes in H4IIEC3 hepatoma cells treated with either palmitate alone (PA-cells) or both palmitate and oleate in combination (PA/OA-cells). Our results indicate that palmitate inhibited glycolysis and lactate dehydrogenase fluxes while activating citric acid cycle (CAC) flux and glutamine uptake. This decoupling of glycolysis and CAC fluxes occurred during the period following palmitate exposure but preceding the onset of apoptosis. Oleate co-treatment restored most fluxes to their control levels, resulting in steatotic lipid accumulation while preventing apoptosis. In addition, palmitate strongly increased the cytosolic NAD(+)/NADH ratio, whereas oleate co-treatment had the opposite effect on cellular redox. We next examined the influence of amino acids on these free fatty acid-induced phenotypic changes. Increased medium amino acids enhanced reactive oxygen species (ROS) generation and apoptosis in PA-cells but not in PA/OA-cells. Overloading the medium with non-essential amino acids induced apoptosis, but essential amino acid overloading partially ameliorated apoptosis. Glutamate was the most effective single amino acid in promoting ROS. Amino acid overloading also increased cellular palmitoyl-ceramide; however, ceramide synthesis inhibitors had no effect on measurable indicators of apoptosis. Our results indicate that free fatty acid-induced ROS generation and apoptosis are accompanied by the decoupling of glycolysis and CAC fluxes leading to abnormal cytosolic redox states. Amino acids play a modulatory role in these processes via a mechanism that does not involve ceramide accumulation. C1 [Noguchi, Yasushi; Young, Jamey D.; Aleman, Jose O.; Hansen, Michael E.; Kelleher, Joanne K.; Stephanopoulos, Gregory] MIT, Dept Chem Engn, Cambridge, MA 02139 USA. [Kelleher, Joanne K.] Massachusetts Gen Hosp, Shriners Burn Hosp, Boston, MA 02115 USA. RP Stephanopoulos, G (reprint author), MIT, Dept Chem Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA. EM gregstep@mit.edu RI Young, Jamey/A-5857-2012; Hansen, Michael/C-9028-2011 OI Hansen, Michael/0000-0001-7879-2106 FU National Institutes of Health [DK075850, ES013925] FX This work was supported, in whole or in part, by National Institutes of Health Grants DK075850 and ES013925. NR 45 TC 36 Z9 37 U1 2 U2 6 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 27 PY 2009 VL 284 IS 48 BP 33425 EP 33436 DI 10.1074/jbc.M109.049478 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 522VS UT WOS:000272028500049 PM 19758988 ER PT J AU Doolittle, MH Neher, SB Ben-Zeev, O Jo, LL Gallagher, CM Hosseini, M Yin, F Wong, H Walter, P Peterfy, M AF Doolittle, Mark H. Neher, Saskia B. Ben-Zeev, Osnat Jo Ling-liao Gallagher, Ciara M. Hosseini, Maryam Yin, Fen Wong, Howard Walter, Peter Peterfy, Miklos TI Lipase Maturation Factor LMF1, Membrane Topology and Interaction with Lipase Proteins in the Endoplasmic Reticulum SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID FLUORESCENCE PROTEASE PROTECTION; N-TERMINAL DOMAIN; LIPOPROTEIN-LIPASE; HEPATIC LIPASE; SUBCELLULAR-LOCALIZATION; TRANSMEMBRANE ORGANIZATION; DEFICIENCY CLD/CLD; EPITOPE INSERTION; P-GLYCOPROTEIN; MOUSE AB Lipase maturation factor 1 (LMF1) is predicted to be a polytopic protein localized to the endoplasmic reticulum (ER) membrane. It functions in the post-translational attainment of enzyme activity for both lipoprotein lipase and hepatic lipase. By using transmembrane prediction methods in mouse and human orthologs, models of LMF1 topology were constructed and tested experimentally. Employing a tagging strategy that used insertion of ectopic glycan attachment sites and terminal fusions of green fluorescent protein, we established a five-transmembrane model, thus dividing LMF1 into six domains. Three domains were found to face the cytoplasm (the amino-terminal domain and loops B and D), and the other half was oriented to the ER lumen (loops A and C and the carboxyl-terminal domain). This representative model shows the arrangement of an evolutionarily conserved domain within LMF1 (DUF1222) that is essential to lipase maturation. DUF1222 comprises four of the six domains, with the two largest ones facing the ER lumen. We showed for the first time, using several naturally occurring variants featuring DUF1222 truncations, that Lmf1 interacts physically with lipoprotein lipase and hepatic lipase and localizes the lipase interaction site to loop C within DUF1222. We discuss the implication of our results with regard to lipase maturation and DUF1222 domain structure. C1 [Doolittle, Mark H.; Ben-Zeev, Osnat; Jo Ling-liao; Hosseini, Maryam; Yin, Fen; Wong, Howard; Peterfy, Miklos] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Doolittle, Mark H.; Ben-Zeev, Osnat; Hosseini, Maryam; Yin, Fen; Wong, Howard; Peterfy, Miklos] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Neher, Saskia B.; Gallagher, Ciara M.; Walter, Peter] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA. [Walter, Peter] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94158 USA. [Jo Ling-liao; Hosseini, Maryam; Yin, Fen; Peterfy, Miklos] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA. RP Doolittle, MH (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 113,Rm 312, Los Angeles, CA 90073 USA. EM markdool@ucla.edu; mpeterfy@ucla.edu FU National Institutes of Health [HL24841]; Cedars-Sinai Medical Center; United States Department of Veterans Affairs FX This work was supported, in whole or in part, by National Institutes of Health Grant HL24841. This work was also supported by the Cedars-Sinai Medical Center and the United States Department of Veterans Affairs. NR 41 TC 14 Z9 16 U1 0 U2 5 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 27 PY 2009 VL 284 IS 48 BP 33623 EP 33633 DI 10.1074/jbc.M109.049395 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 522VS UT WOS:000272028500066 PM 19783858 ER PT J AU Sonawane, SB Kim, JI Lee, MK Lee, SH Duff, PE Moore, DJ Lian, MM Deng, SP Choi, Y Yeh, HD Caton, AJ Markmann, JF AF Sonawane, Samsher B. Kim, James I. Lee, Major K. Lee, Seoung-Hoon Duff, Patrick E. Moore, Daniel J. Lian, Moh-Moh Deng, Shaoping Choi, Yongwon Yeh, Heidi Caton, Andrew J. Markmann, James F. TI GITR Blockade Facilitates Treg Mediated Allograft Survival SO TRANSPLANTATION LA English DT Article DE Rodent; Transplantation; Tolerance; Suppression; Anergy ID REGULATORY T-CELLS; INDUCED TNF RECEPTOR; TOLL-LIKE RECEPTORS; INFECTIOUS TRANSPLANTATION TOLERANCE; DENDRITIC CELLS; CUTTING EDGE; SELF-PEPTIDE; MAJOR HISTOCOMPATIBILITY; UP-REGULATION; CD4(+) AB Background. Many models of transplant tolerance have been found to depend on the induction of regulatory T cells (Tregs). Innate immune signals are known to suppress Tregs thereby augmenting immunity by abrogating Treg function. Such signals may also provide a barrier to transplantation tolerance mediated by Tregs. A number of cell surface molecules expressed by Tregs have been found to inhibit Treg activity, the best characterized of which is the glucocorticoid-induced tumor necrosis factor receptor-related (GITR) protein. Methods. By using an adoptive transfer model of allograft rejection, we can study the effects of inflammation and antigen-specific Tregs on graft survival. Inflammation resulting from the transplant procedure counter-regulates the suppressor activity of Tregs. To assess whether Treg activity could be enhanced by blocking GITR signaling, we compared the capacity of Tregs to prolong the survival of grafts in the presence or absence of activation-inducible TNF receptor (AITRL)-Fc, a novel construct that binds GITR. Results. We report that interruption of GITR-GITR ligand (GITRL) binding by AITRL-Fc resulted in long-term Treg-dependent acceptance of skin grafts in the setting of innate immune signals that otherwise interfere with Treg activity. Conclusions. Inflammation and other innate immune signals may activate antigen presenting cells to upregulate GITRL. GITR-GITRL interaction is one pathway by which antigen presenting cells may enhance the adaptive response to foreign antigen by counter-regulating Tregs and by costimulating effector T cells. By blocking this interaction with AITRL-Fc, one can sustain the benefit conferred by graft-protective Tregs. C1 [Markmann, James F.] Massachusetts Gen Hosp, Dept Surg, Div Transplantat, Boston, MA 02114 USA. [Sonawane, Samsher B.] Hosp Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Lee, Major K.] Hosp Univ Penn, Harrison Dept Surg Res, Philadelphia, PA 19104 USA. [Lee, Seoung-Hoon; Choi, Yongwon] Univ Penn, Abramson Family Canc Ctr, Philadelphia, PA 19104 USA. [Moore, Daniel J.] Vanderbilt Childrens Hosp, Dept Pediat, Div Endocrinol & Diabet, Nashville, TN USA. [Caton, Andrew J.] Wistar Inst Anat & Biol, Dept Immunol, Philadelphia, PA 19104 USA. [Lee, Seoung-Hoon] Wonkwang Univ, Sch Dent, Dept Oral Microbiol & Immunol, Iksan, Chonbuk, South Korea. RP Markmann, JF (reprint author), Massachusetts Gen Hosp, Dept Surg, Div Transplantat, 55 Fruit St, Boston, MA 02114 USA. EM jmarkmann@partners.org RI Moore, Daniel/A-4924-2008 OI Moore, Daniel/0000-0002-6889-9345 FU NIH [RO1AI048820-06, T32DK007006-33, K01 DK079207-02] FX This work was supported by NIH grants RO1AI048820-06 (J.F.M.), T32DK007006-33 (S.B.S.), and K01 DK079207-02 (J.I.K.). NR 52 TC 15 Z9 18 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0041-1337 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2009 VL 88 IS 10 BP 1169 EP 1177 DI 10.1097/TP.0b013e3181ba6f85 PG 9 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA 525NP UT WOS:000272223200005 PM 19935370 ER PT J AU Kimbrel, EA Lemieux, ME Xia, XB Davis, TN Rebel, VI Kung, AL AF Kimbrel, Erin A. Lemieux, Madeleine E. Xia, Xiaobo Davis, Tina N. Rebel, Vivienne I. Kung, Andrew L. TI Systematic in vivo structure-function analysis of p300 in hematopoiesis SO BLOOD LA English DT Article ID CREB-BINDING-PROTEIN; EMBRYONIC STEM-CELLS; MICE LACKING; BONE-MARROW; HISTONE H3; LYSINE 56; CBP; TRANSCRIPTION; GENE; ACETYLTRANSFERASE AB Cyclic adenosine monophosphate response element binding (CREB)-binding protein (CBP) and p300 are multidomain transcriptional coactivators that help assemble large regulatory complexes at sites of active transcription. Nullizygosity of CBP or p300 results in pervasive defects in hematopoiesis. To systematically assess the structural domains of p300 required for normal hematopoiesis, we used recombinase-mediated cassette exchange to create an allelic series of coisogenic embryonic stem cells, each expressing a different mutant of p300 from the endogenous locus. We found that deletion of either the KIX or CH1 domain caused profound and pervasive defects in hematopoiesis, whereas the loss of most other domains had only lineage-restricted effects. When expressed from the p300 locus, an extra copy of CBP largely compensated for a lack of p300. Surprisingly, mutation of the p300 histone acetyltransferase (HAT) domain had minimal effects on hematopoiesis, and actually increased progenitor and stem cell numbers and proliferative potential. Our results suggest that, in distinct contrast to other organ systems, HAT activity does not provide a critical function for hematopoietic development and emphasizes the importance of enzyme-independent functions of p300. (Blood. 2009; 114:4804-4812) C1 [Kimbrel, Erin A.; Lemieux, Madeleine E.; Xia, Xiaobo; Davis, Tina N.; Kung, Andrew L.] Childrens Hosp, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Kimbrel, Erin A.; Lemieux, Madeleine E.; Xia, Xiaobo; Davis, Tina N.; Kung, Andrew L.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Rebel, Vivienne I.] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA. RP Kung, AL (reprint author), Childrens Hosp, Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St,Mayer 649, Boston, MA 02115 USA. EM andrew_kung@dfci.harvard.edu OI Lemieux, Madeleine/0000-0001-6355-8691; Kung, Andrew/0000-0002-9091-488X NR 49 TC 19 Z9 19 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 26 PY 2009 VL 114 IS 23 BP 4804 EP 4812 DI 10.1182/blood-2009-04-217794 PG 9 WC Hematology SC Hematology GA 525CM UT WOS:000272190700009 PM 19822904 ER PT J AU Lue, N Choi, W Popescu, G Yaqoob, Z Badizadegan, K Dasari, RR Feld, MS AF Lue, Niyom Choi, Wonshik Popescu, Gabriel Yaqoob, Zahid Badizadegan, Kamran Dasari, Ramachandra R. Feld, Michael S. TI Live Cell Refractometry Using Hilbert Phase Microscopy and Confocal Reflectance Microscopy SO JOURNAL OF PHYSICAL CHEMISTRY A LA English DT Article ID DIGITAL HOLOGRAPHIC MICROSCOPY; REFRACTIVE-INDEX MEASUREMENT; LIGHT-MICROSCOPY; DYNAMICS; MORPHOMETRY; APERTURE; CONTRAST AB Quantitative chemical analysis has served as a useful tool for understanding cellular metabolisms in biology. Among many physical properties used in chemical analysis, refractive index in particular has provided molecular concentration that is an important indicator for biological activities. In this report, we present a method of extracting full-field refractive index maps of live cells in their native states. We first record full-field optical thickness maps of living cells by Hilbert phase microscopy and then acquire physical thickness maps of the same cells using a custom-built confocal reflectance microscope. Full-field and axially averaged refractive index maps are acquired from the ratio of optical thickness to physical thickness. The accuracy of the axially averaged index measurement is 0.002. This approach can provide novel biological assays of label-free living cells in situ. C1 [Lue, Niyom; Choi, Wonshik; Yaqoob, Zahid; Badizadegan, Kamran; Dasari, Ramachandra R.; Feld, Michael S.] MIT, GR Harrison Spect Lab, Cambridge, MA 02139 USA. [Choi, Wonshik] Korea Univ, Dept Phys, Seoul 136701, South Korea. [Popescu, Gabriel] Univ Illinois, Dept Elect & Comp Engn, Urbana, IL 61801 USA. [Badizadegan, Kamran] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02114 USA. [Badizadegan, Kamran] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Choi, W (reprint author), MIT, GR Harrison Spect Lab, 77 Massachusetts Ave, Cambridge, MA 02139 USA. EM wonshik@mit.edu FU National Center for Research Resources of the National Institutes of Health [P41-RR02594-18]; National Science Foundation [DBI-0754339, CAREER: 08-46660]; Hamamatsu Corporation FX This work was funded by the National Center for Research Resources of the National Institutes of Health (P41-RR02594-18), the National Science Foundation (DBI-0754339), and Hamamatsu Corporation. G.P. acknowledges support from NSF (CAREER: 08-46660). NR 23 TC 45 Z9 46 U1 3 U2 12 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1089-5639 J9 J PHYS CHEM A JI J. Phys. Chem. A PD NOV 26 PY 2009 VL 113 IS 47 BP 13327 EP 13330 DI 10.1021/jp904746r PG 4 WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical SC Chemistry; Physics GA 520FL UT WOS:000271825800030 PM 19803506 ER PT J AU Kroshinsky, D Kay, J Nazarian, RM AF Kroshinsky, Daniela Kay, Jonathan Nazarian, Rosalynn M. TI A 46-Year-Old Woman with Chronic Renal Failure, Leg Swelling, and Skin Changes Nephrogenic systemic fibrosis SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID OF-THE-LITERATURE; EXTRACORPOREAL PHOTOPHERESIS; EOSINOPHILIC FASCIITIS; GADOLINIUM EXPOSURE; DERMOPATHY; DISEASE; GROWTH; SCLEROMYXEDEMA; DERMATOLOGIST; EXPRESSION C1 [Kroshinsky, Daniela] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. [Nazarian, Rosalynn M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Kay, Jonathan] Massachusetts Gen Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA. [Kroshinsky, Daniela] Harvard Univ, Sch Med, Dept Dermatol, Cambridge, MA 02138 USA. [Kay, Jonathan] Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA. [Nazarian, Rosalynn M.] Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA. RP Kroshinsky, D (reprint author), Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. NR 40 TC 6 Z9 6 U1 0 U2 3 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 26 PY 2009 VL 361 IS 22 BP 2166 EP 2176 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 524BC UT WOS:000272117800012 PM 19940302 ER PT J AU Parsons, LM Petacchi, A Schmahmann, JD Bower, JM AF Parsons, Lawrence M. Petacchi, Augusto Schmahmann, Jeremy D. Bower, James M. TI Pitch discrimination in cerebellar patients: Evidence for a sensory deficit SO BRAIN RESEARCH LA English DT Review DE Discrimination; Impairment; Cerebellar atrophy; Sensory; Hearing ID VERBAL WORKING-MEMORY; GRANULE CELL LAYER; MAGNETIC-RESONANCE; SPEECH-PERCEPTION; INTERNAL-MODELS; FUNCTIONAL NEUROANATOMY; COGNITIVE DEFICITS; WILLIAMS-SYNDROME; COCHLEAR NUCLEUS; TIME PERCEPTION AB In the last two decades, a growing body of research showing cerebellar involvement in an increasing number of nonmotor tasks and systems has prompted an expansion of speculations concerning the function of the cerebellum. Here, we tested the predictions of a hypothesis positing cerebellar involvement in sensory data acquisition. Specifically, we examined the effect of global cerebellar degeneration on primary auditory sensory function by means of a pitch discrimination task. The just noticeable difference in pitch between two tones was measured in 15 healthy controls and in 15 high functioning patients afflicted with varying degrees of global cerebellar degeneration caused by hereditary, idiopathic, paraneoplastic, or postinfectious pancerebellitis. Participants also performed an auditory detection task assessing sustained attention, a test of verbal auditory working memory, and an audiometric test. Patient pitch discrimination thresholds were on average five and a half times those of controls and were proportional to the degree of cerebellar ataxia assessed independently. Patients and controls showed normal hearing thresholds and similar performance in control tasks in sustained attention and verbal auditory working memory. These results suggest there is an effect of cerebellar degeneration on primary auditory function. The findings are consistent with other recent demonstrations of cerebellar-related sensory impairments, and with robust cerebellar auditorily evoked activity, confirmed by quantitative meta-analysis, across a range of functional neuroimaging studies dissociated from attention, motor, affective, and cognitive variables. The data are interpreted in the context of a sensory hypothesis of cerebellar function. (C) 2009 Elsevier B.V. All rights reserved. C1 [Parsons, Lawrence M.] Univ Sheffield, Dept Psychol, Sheffield S10 2TP, S Yorkshire, England. [Petacchi, Augusto; Bower, James M.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, San Antonio, TX 78229 USA. [Schmahmann, Jeremy D.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Bower, James M.] Univ Texas San Antonio, Dept Biol, San Antonio, TX USA. RP Parsons, LM (reprint author), Univ Sheffield, Dept Psychol, Sheffield S10 2TP, S Yorkshire, England. EM L.Parsons@sheffield.ac.uk RI Bower, James/F-8343-2010 FU National Institutes of Mental Health [RO1-NS37109]; National Science Foundation [NSF 0217884] FX We are grateful to Richard Ivry, Mark Konishi, and Mark Tramo for helpful comments, to Stephen E. Grill for diagnostic assistance with patients, and to Michael Martinez for assistance with preparation of the experimental materials. This work was supported by grants from the National Institutes of Mental Health (RO1-NS37109 to L.M.P.) and the National Science Foundation (NSF 0217884 to J.M.B.). NR 225 TC 21 Z9 21 U1 0 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD NOV 25 PY 2009 VL 1303 BP 84 EP 96 DI 10.1016/j.brainres.2009.09.052 PG 13 WC Neurosciences SC Neurosciences & Neurology GA 525YO UT WOS:000272254200010 PM 19766609 ER PT J AU Barreto, K Bharathikumar, VM Ricardo, A DeCoteau, JF Luo, Y Geyer, CR AF Barreto, Kris Bharathikumar, V. M. Ricardo, Alonso DeCoteau, John F. Luo, Yu Geyer, C. Ronald TI A Genetic Screen for Isolating "Lariat" Peptide Inhibitors of Protein Function SO CHEMISTRY & BIOLOGY LA English DT Article ID ESCHERICHIA-COLI; CYCLIC-PEPTIDES; LEXA REPRESSOR; DNA-BINDING; LIBRARIES; SELECTION; CLEAVAGE; SCAFFOLD; RECA; IDENTIFICATION AB Functional genomic analyses provide information that allows hypotheses to be formulated on protein function. These hypotheses, however, need to be validated using reverse genetic approaches, which are difficult to perform on a large scale and in diploid organisms. We developed a genetic screen for isolating "lariat" peptides that function as trans dominant inhibitors of protein function. A lariat consists of a lactone-cyclized peptide with a covalently attached transcription activation domain, which allows combinatorial lariat libraries to be screened for protein interactions using the yeast two-hybrid assay. We isolated lariats against the bacterial repressor protein LexA. LexA regulates bacterial SOS response and LexA mutants that cannot undergo autoproteolysis make bacteria more sensitive to, and inhibit resistance against, cytotoxic reagents. We showed that an anti-LexA lariat blocked LexA autoproteolysis and potentiated the antimicrobial activity of mitomycin C. C1 [Barreto, Kris; Bharathikumar, V. M.; DeCoteau, John F.; Geyer, C. Ronald] Univ Saskatchewan, Canc Stem Cell Res Grp, Saskatoon, SK S7N 5E5, Canada. [Ricardo, Alonso] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA. RP Geyer, CR (reprint author), Univ Saskatchewan, Canc Stem Cell Res Grp, Saskatoon, SK S7N 5E5, Canada. EM ron.geyer@usask.ca FU Natural Sciences and Engineering Research Council of Canada FX We thank Cancer Stem Cell Research Group members for valuable discussions. We thank J. Wade for the sequences of the lexA primers used in the ChIP assay and G. Hagelin for his advice on the Na18OH hydrolysis. C.R.G. is a Canadian Institutes of Health Research New Investigator. Support for this work came from the Natural Sciences and Engineering Research Council of Canada. NR 44 TC 4 Z9 4 U1 2 U2 7 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1074-5521 J9 CHEM BIOL JI Chem. Biol. PD NOV 25 PY 2009 VL 16 IS 11 BP 1148 EP 1157 DI 10.1016/j.chembiol.2009.10.012 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 538TW UT WOS:000273207900008 PM 19942138 ER PT J AU Kumbhani, DJ Cannon, CP Fonarow, GC Liang, L Askari, AT Peacock, WF Peterson, ED Bhatt, DL AF Kumbhani, Dharam J. Cannon, Christopher P. Fonarow, Gregg C. Liang, Li Askari, Arman T. Peacock, W. Frank Peterson, Eric D. Bhatt, Deepak L. CA Get Guidelines Steering Comm Inves TI Association of Hospital Primary Angioplasty Volume in ST-Segment Elevation Myocardial Infarction With Quality and Outcomes SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID TO-BALLOON TIME; MORTALITY; CARE AB Context Earlier studies indicate an inverse relationship between hospital volume and mortality after primary angioplasty for patients presenting with ST-segment elevation myocardial infarction (STEMI). However, contemporary data are lacking. Objective To assess the relationship between hospital primary angioplasty volume and outcomes and quality of care measures in patients presenting with STEMI. Design, Setting, and Patients An observational analysis of data on 29 513 patients presenting with STEMI and undergoing primary angioplasty in the American Heart Association's Get With the Guidelines registry. Patients were treated between July 5, 2001, and December 31, 2007, at 166 angioplasty-capable hospitals across the United States. Hospitals were divided into tertiles (<36 procedures per year, 36-70 procedures per year, and >70 procedures per year) based on their annual primary angioplasty volume. Main Outcome Measures Door-to-balloon (DTB) times, length of hospital stay, adherence with evidence-based quality of care measures, and in-hospital mortality. Results Compared with low-and medium-volume centers, high-volume centers had better median DTB times (98 vs 90 vs 88 minutes, respectively; P for trend <.001). High-volume centers were more likely than low-volume centers to follow evidence-based guidelines at discharge. Length of stay was similar between the 3 groups (P for trend = .13). There was no significant difference in the crude mortality between the tertiles of volume (incidence rate, 3.9% vs 3.2% vs 3.0% for low-, medium-, and high-volume centers, respectively; P = .26 and P = .99 for low-and medium-vs high-volume hospitals, respectively). Sequential multivariable modeling using generalized estimating equations revealed no significant association between hospital primary angioplasty volume and in-hospital mortality (adjusted odds ratio [OR], 1.22; 95% confidence interval [CI], 0.78-1.91; P = .38 and adjusted OR, 1.14; 95% CI, 0.78-1.66; P = .49 for low-and medium-vs high-volume hospitals, respectively). Conclusion In a contemporary registry of patients with STEMI, higher-volume primary angioplasty centers vs lower-volume centers were associated with shorter DTB times and more use of evidence-based therapies, but not with adjusted in-hospital mortality or length of hospital stay. JAMA. 2009;302(20):2207-2213 C1 [Bhatt, Deepak L.] VA Boston Healthcare Syst, Boston, MA 02115 USA. [Kumbhani, Dharam J.; Askari, Arman T.; Peacock, W. Frank] Cleveland Clin, Cleveland, OH 44106 USA. [Cannon, Christopher P.] Brigham & Womens Hosp, TIMI Study Grp, Boston, MA 02115 USA. [Fonarow, Gregg C.] Ahmanson Univ Calif Los Angeles, Univ Calif Los Angeles, Cardiomyopathy Ctr, Div Cardiol, Los Angeles, CA USA. [Liang, Li; Peterson, Eric D.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. RP Bhatt, DL (reprint author), VA Boston Healthcare Syst, 75 Francis St,PBB 146, Boston, MA 02115 USA. EM dlbhattmd@post.harvard.edu FU Merck/Schering-Plough Pharmaceutical; AHA FX The Get With the Guidelines-Coronary Artery Disease is a program of the American Heart Association (AHA) and is supported by an unrestricted educational grant from Merck/Schering-Plough Pharmaceutical. Data collection and management were performed by Outcome Inc (Cambridge, Massachusetts). The analysis of registry data was performed at Duke Clinical Research Institute (Durham, North Carolina), which also receives funding from the AHA. NR 24 TC 48 Z9 48 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 25 PY 2009 VL 302 IS 20 BP 2207 EP 2213 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 523NI UT WOS:000272080500024 PM 19934421 ER PT J AU Yu, M Riva, L Xie, HF Schindler, Y Moran, TB Cheng, Y Yu, DN Hardison, R Weiss, MJ Orkin, SH Bernstein, BE Fraenkel, E Cantor, AB AF Yu, Ming Riva, Laura Xie, Huafeng Schindler, Yocheved Moran, Tyler B. Cheng, Yong Yu, Duonan Hardison, Ross Weiss, Mitchell J. Orkin, Stuart H. Bernstein, Bradley E. Fraenkel, Ernest Cantor, Alan B. TI Insights into GATA-1-Mediated Gene Activation versus Repression via Genome-wide Chromatin Occupancy Analysis SO MOLECULAR CELL LA English DT Article ID TRANSCRIPTION FACTOR GATA-1; DNA-BINDING FACTOR; ZINC-FINGER; MAMMALIAN-CELLS; ERYTHROID MATURATION; MOUSE DEVELOPMENT; STEM-CELLS; IN-VIVO; N-RAS; EXPRESSION AB The transcription factor GATA-1 is required for terminal erythroid maturation and functions as an activator or repressor depending on gene context. Yet its in vivo site selectivity and ability to distinguish between activated versus repressed genes remain incompletely understood. In this study, we performed GATA-1 ChIP-seq in erythroid cells and compared it to GATA-1-induced gene expression changes. Bound and differentially expressed genes contain a greater number of GATA-binding motifs, a higher frequency of palindromic GATA sites, and closer occupancy to the transcriptional start site versus nondifferentially expressed genes. Moreover, we show that the transcription factor Zbtb7a occupies GATA-1-bound regions of some direct GATA-1 target genes, that the presence of SCOL/TAL1 helps distinguish transcriptional activation versus repression, and that polycomb repressive complex 2 (PRC2) is involved in epigenetic silencing of a subset of GATA-1-repressed genes. These data provide insights into GATA-1-mediated gene regulation in vivo. C1 [Riva, Laura; Fraenkel, Ernest] MIT, Dept Biol Engn, Cambridge, MA 02139 USA. [Fraenkel, Ernest] MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA. [Orkin, Stuart H.] Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA. [Yu, Ming; Xie, Huafeng; Schindler, Yocheved; Moran, Tyler B.; Orkin, Stuart H.; Cantor, Alan B.] Childrens Hosp, Dept Pediat Hematol Oncol, Boston, MA 02115 USA. Harvard Univ, Dana Farber Canc Inst, Sch Med, Boston, MA 02115 USA. [Cheng, Yong; Hardison, Ross] Penn State Univ, Ctr Comparat Genom & Bioinformat, Dept Biochem & Mol Biol, University Pk, PA 16802 USA. [Yu, Duonan; Weiss, Mitchell J.] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA. [Bernstein, Bradley E.] Harvard Univ, Dept Pathol, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. [Bernstein, Bradley E.] Broad Inst, Boston, MA 02114 USA. [Bernstein, Bradley E.] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA. RP Fraenkel, E (reprint author), MIT, Dept Biol Engn, Cambridge, MA 02139 USA. EM fraenkel-admin@mit.edu; alan.cantor@childrens.harvard.edu RI Hardison, Ross/G-1142-2010; Yu, Ming/A-3354-2012; cheng, yong/I-4270-2012; Weiss, Mitchell/A-1245-2013; OI Hardison, Ross/0000-0003-4084-7516; Riva, Laura/0000-0001-5688-4915; Fraenkel, Ernest/0000-0001-9249-8181 FU National Institutes of Health (NIH) [P01 HL32262-25]; CSBi Merck-MIT FX A.B.C. is supported by a grant from the National Institutes of Health (NIH) (P01 HL32262-25). L.R. is supported by the CSBi Merck-MIT postdoctoral fellowship. E.F. is the recipient of the Eugene Bell Career Development Chair. The authors would like to thank Gerd Blobel, Xiaohua Shen, Jian Xu, and Jonathan Snow for critical review of the manuscript, and Pier Paolo Pandolfi for helpful discussions and for the Zbtb7a antibody. NR 58 TC 166 Z9 167 U1 0 U2 13 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1097-2765 J9 MOL CELL JI Mol. Cell PD NOV 25 PY 2009 VL 36 IS 4 BP 682 EP 695 DI 10.1016/j.molcel.2009.11.002 PG 14 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 529RL UT WOS:000272534800015 PM 19941827 ER PT J AU Ali, OA Emerich, D Dranoff, G Mooney, DJ AF Ali, Omar A. Emerich, Dwaine Dranoff, Glenn Mooney, David J. TI In Situ Regulation of DC Subsets and T Cells Mediates Tumor Regression in Mice SO SCIENCE TRANSLATIONAL MEDICINE LA English DT Article ID COLONY-STIMULATING FACTOR; DENDRITIC CELLS; GM-CSF; CANCER-IMMUNOTHERAPY; VIRAL-INFECTION; VIVO; VACCINES; RESPONSES; CD8(+); AUTOIMMUNITY AB Vaccines are largely ineffective for patients with established cancer, as advanced disease requires potent and sustained activation of CD8(+) cytotoxic T lymphocytes (CTLs) to kill tumor cells and clear the disease. Recent studies have found that subsets of dendritic cells (DCs) specialize in antigen cross-presentation and in the production of cytokines, which regulate both CTLs and T regulatory (Treg) cells that shut down effector T cell responses. Here, we addressed the hypothesis that coordinated regulation of a DC network, and plasmacytoid DCs (pDCs) and CD8(+) DCs in particular, could enhance host immunity in mice. We used functionalized biomaterials incorporating various combinations of an inflammatory cytokine, immune danger signal, and tumor lysates to control the activation and localization of host DC populations in situ. The numbers of pDCs and CD8(+) DCs, and the endogenous production of interleukin-12, all correlated strongly with the magnitude of protective antitumor immunity and the generation of potent CD8(+) CTLs. Vaccination by this method maintained local and systemic CTL responses for extended periods while inhibiting FoxP3 Treg activity during antigen clearance, resulting in complete regression of distant and established melanoma tumors. The efficacy of this vaccine as a monotherapy against large invasive tumors may be a result of the local activity of pDCs and CD8(+) DCs induced by persistent danger and antigen signaling at the vaccine site. These results indicate that a critical pattern of DC subsets correlates with the evolution of therapeutic antitumor responses and provide a template for future vaccine design. C1 [Ali, Omar A.; Mooney, David J.] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA. [Ali, Omar A.; Emerich, Dwaine] InCytu Inc, Lincoln, RI 02865 USA. [Ali, Omar A.; Mooney, David J.] Wyss Inst Biol Inspired Engn, Cambridge, MA 02138 USA. [Dranoff, Glenn] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Dranoff, Glenn] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA. [Dranoff, Glenn] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Dranoff, Glenn] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Mooney, DJ (reprint author), Harvard Univ, Sch Engn & Appl Sci, 29 Oxford St,319 Pierce Hall, Cambridge, MA 02138 USA. EM mooneyd@seas.harvard.edu FU NIH-National Institute of Dental and Craniofacial Research [R01-DE019917, 1 UL1 RR 025758-01]; Department of Defense [BC084682]; Harvard Clinical and Translational Science Center (NIH) [1 UL1 RR 025758-01]; InCytu Inc FX NIH-National Institute of Dental and Craniofacial Research grant R01-DE019917; Department of Defense (BC084682 Idea Award); Harvard Catalyst, the Harvard Clinical and Translational Science Center (NIH grant 1 UL1 RR 025758-01); financial contributions from participating institutions; and InCytu Inc. NR 42 TC 75 Z9 77 U1 4 U2 30 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 1946-6234 J9 SCI TRANSL MED JI Sci. Transl. Med. PD NOV 25 PY 2009 VL 1 IS 8 AR 8ra19 DI 10.1126/scitranslmed.3000359 PG 10 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA 590XS UT WOS:000277262400001 PM 20368186 ER PT J AU Newton-Cheh, C Cook, NR VanDenburgh, M Rimm, EB Ridker, PM Albert, CM AF Newton-Cheh, Christopher Cook, Nancy R. VanDenburgh, Martin Rimm, Eric B. Ridker, Paul M. Albert, Christine M. TI A Common Variant at 9p21 Is Associated With Sudden and Arrhythmic Cardiac Death SO CIRCULATION LA English DT Article DE arrhythmia; coronary disease; death, sudden; genetics; risk factors ID CORONARY-ARTERY-DISEASE; MYOCARDIAL-INFARCTION; VENTRICULAR-FIBRILLATION; CHROMOSOME 9P21.3; GENETIC-VARIATION; FAMILY-HISTORY; HEART-DISEASE; RISK-FACTOR; POPULATION; ARREST AB Background-Although a heritable basis for sudden cardiac death (SCD) is suggested by the impact of family history on SCD risk, common genetic determinants have been difficult to identify. We hypothesized that a common variant at chromosome 9p21 related to myocardial infarction would influence SCD risk. Methods and Results-This was a prospective, nested, case-control analysis among individuals of European ancestry enrolled in 6 prospective cohort studies. Study subjects were followed up for development of SCD, and genotypes for rs10757274 were determined for 492 sudden and/or arrhythmic deaths and 1460 controls matched for age, sex, cohort, history of cardiovascular disease, and follow-up time. Conditional logistic regression with fixed-effects meta-analysis assuming an additive model was used to test for associations. When individual study results were combined in the meta-analysis, each increasing copy of the G allele at rs10757274 conferred a significantly elevated age-adjusted odds ratio for SCD of 1.21 (95% confidence interval, 1.04 to 1.40; P=0.01). Controlling for cardiovascular and lifestyle risk factors strengthened these relationships (odds ratio, 1.29 per G-allele copy; 95% confidence interval, 1.09 to 1.53; P=0.003). These results were not materially altered in sensitivity analyses limited to definite SCD, in models that further controlled for the development of interim cardiovascular disease, or when the highly correlated variant rs2383207 was tested. Conclusions-The major allele of a single-nucleotide polymorphism previously associated with increased risk of coronary artery disease events is associated with increased risk of SCD in individuals of European ancestry. Study of the mechanism underlying this association may improve our understanding of lethal cardiovascular disease. (Circulation. 2009;120:2062-2068.) C1 Harvard Univ, Sch Med, Brigham & Womens Hosp,Div Cardiovasc, Div Prevent Med,Ctr Arrhythmia Prevent,Dept Med, Boston, MA 02115 USA. [Rimm, Eric B.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Channing Lab, Boston, MA 02115 USA. [Newton-Cheh, Christopher] Broad Inst Harvard & MIT, Cambridge, MA USA. [Newton-Cheh, Christopher] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. [Newton-Cheh, Christopher] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Cook, Nancy R.; Rimm, Eric B.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Rimm, Eric B.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. RP Albert, CM (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp,Div Cardiovasc, Div Prevent Med,Ctr Arrhythmia Prevent,Dept Med, 900 Commonwealth Ave E, Boston, MA 02115 USA. EM calbert@partners.org FU National Heart, Lung, and Blood Institute [HL-068070, HL-26490, HL-34595, HL-34594, HL-35464, HL-043851, HL-46959, HL-080467]; Donald W. Reynolds Foundation; American Heart Association; National Institutes of Health [K23-HL-080025]; Doris Duke Charitable Foundation; Burroughs Wellcome Fund; National Cancer Institute [CA-34944, CA-40360, CA-47988, CA-55075, CA-87969, CA-97193] FX This project was supported by a grant from the National Heart, Lung, and Blood Institute (HL-068070 to Dr Albert). Additional support for the DNA extraction in the Women's Health Study came from the Donald W. Reynolds Foundation. Dr Albert is also supported by an Established Investigator Award from the American Heart Association. Dr Newton-Cheh has been supported by an award from the National Institutes of Health (K23-HL-080025), a Doris Duke Charitable Foundation Clinical Scientist Development Award, and a Burroughs Wellcome Fund Career Award for Medical Scientists. The cohort studies were supported by grants HL-26490, HL-34595, HL-34594, HL-35464, HL-043851, HL-46959, and HL-080467 from the National Heart, Lung, and Blood Institute and CA-34944, CA-40360, CA-47988, CA-55075, CA-87969, and CA-97193 from the National Cancer Institute. NR 40 TC 44 Z9 45 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 24 PY 2009 VL 120 IS 21 BP 2062 EP U25 DI 10.1161/CIRCULATIONAHA.109.879049 PG 10 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 527FA UT WOS:000272351400007 PM 19901189 ER PT J AU Haywood, LJ Ford, CE Crow, RS Davis, BR Massie, BM Einhorn, PT Williard, A AF Haywood, L. Julian Ford, Charles E. Crow, Richard S. Davis, Barry R. Massie, Barry M. Einhorn, Paula T. Williard, Angela CA ALLHAT Collaborative Res Grp TI Atrial Fibrillation at Baseline and During Follow-Up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE hypertension; atrial fibrillation; clinical trial; chlorthalidone; amlodipine; lisinopril; doxazosin; pravastatin ID RANDOMIZED CONTROLLED-TRIALS; II RECEPTOR BLOCKADE; RISK-FACTORS; MAJOR OUTCOMES; BLOOD-PRESSURE; FAILURE; PREVALENCE; THERAPY; STROKE; CHLORTHALIDONE AB Objectives The ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) determined that treatment with amlodipine, lisinopril, or doxazosin was not superior to thiazide-like diuretic (chlorthalidone) in preventing coronary heart disease (CHD) or other cardiovascular events. This subanalysis examines baseline prevalence and in-trial incidence of new-onset atrial fibrillation (AF) or atrial flutter (AFL) and their influence on clinical outcomes. Background Limited information is available on whether atrial fibrillation incidence is affected differentially by different classes of antihypertensive medications or treatment with statins. Methods AF/AFL was identified from baseline and follow-up electrocardiograms performed biannually. Analyses were performed to identify characteristics associated with baseline AF/AFL and its subsequent incidence. Results AF/AFL was present at baseline in 423 participants (1.1%), more frequent in men (odds ratio: 1.72; 95% confidence interval [CI]: 1.37 to 2.17) and nonblacks (odds ratio: 2.09; 95% CI: 1.58 to 2.75). Its prevalence increased with age (p < 0.001) and was associated with CHD, cardiovascular disease, obesity, and high-density lipoprotein cholesterol <35 mg/dl. New-onset AF/AFL was associated with the same baseline risk factors plus electrocardiogram left ventricular hypertrophy. It occurred in 641 participants (2.0%) and, excluding doxazosin, did not differ by antihypertensive treatment group or, in a subset of participants, by pravastatin versus usual care. Baseline AF/AFL was associated with increased mortality (hazard ratio [HR]: 2.82; 95% CI: 2.36 to 3.37; p < 0.001), stroke (HR: 3.63; 95% CI: 2.72 to 4.86; p < 0.001), heart failure (HR: 3.17; 95% CI: 2.38 to 4.25; p < 0.001), and fatal CHD or nonfatal myocardial infarction (HR: 1.64; 95% CI: 1.22 to 2.21; p < 0.01). There was a nearly 2.5-fold increase in mortality risk when AF/AFL was present at baseline or developed during the trial (HR: 2.42; 95% CI: 2.11 to 2.77; p < 0.001). Conclusions In this high-risk hypertensive population, pre-existing and new-onset AF/AFL were associated with increased mortality. Excluding doxazosin, treatment assignment to either antihypertensive drugs or pravastatin versus usual care did not affect AF/AFL incidence. (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]; NCT00000542) (J Am Coll Cardiol 2009; 54:2023-31) (C) 2009 by the American College of Cardiology Foundation C1 [Haywood, L. Julian] Los Angeles Cty Univ So Calif Med Ctr, Los Angeles, CA USA. [Ford, Charles E.; Davis, Barry R.] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Houston, TX USA. [Crow, Richard S.] Univ Minnesota, Minneapolis, MN USA. [Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Einhorn, Paula T.] NHLBI, Div Prevent & Populat Sci, Bethesda, MD 20892 USA. [Williard, Angela] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA USA. RP Ford, CE (reprint author), Univ Texas Sch Publ Hlth, 1200 Herman Pressler Dr,E-827, Houston, TX 77030 USA. EM charles.e.ford@uth.tmc.edu FU Pfizer, Inc FX From the Los Angeles County/University of Southern California Medical Center, Los Angeles, California; dagger University of Texas Health Science Center at Houston, School of Public Health, Houston, Texas; University of Minnesota, Minneapolis, Minnesota; San Francisco Veterans Affairs Medical Center, San Francisco, California; parallel to Division of Prevention and Population Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland; and the Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana. This research was supported by Health and Human Services contract number N01-HC-35130 from the National Heart, Lung, and Blood Institute, National Institutes of Health, U. S. Department of Health and Human Services, Bethesda, Maryland. Additional financial support was provided by Pfizer, Inc. Study medications were supplied by Pfizer, Inc. (amlodipine and doxazosin), AstraZeneca (atenolol and lisinopril), and Bristol-Myers Squibb (pravastatin). Dr. Davis is on the Data Safety Monitoring Board of Takeda Pharmaceuticals. NR 35 TC 83 Z9 90 U1 2 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD NOV 24 PY 2009 VL 54 IS 22 BP 2023 EP 2031 DI 10.1016/j.jacc.2009.08.020 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 521EH UT WOS:000271902500006 PM 19926008 ER PT J AU Filley, CM AF Filley, Christopher M. TI Exploring white matter microstructure New insights from diffusion tensor imaging SO NEUROLOGY LA English DT Editorial Material ID DISCONNEXION SYNDROMES; ANIMALS; DISEASE C1 [Filley, Christopher M.] Univ Colorado, Denver Sch Med, Denver Vet Affairs Med Ctr, Behav Neurol Sect,Dept Neurol, Aurora, CO 80045 USA. [Filley, Christopher M.] Univ Colorado, Denver Sch Med, Denver Vet Affairs Med Ctr, Behav Neurol Sect,Dept Psychiat, Aurora, CO 80045 USA. RP Filley, CM (reprint author), Univ Colorado, Denver Sch Med, Denver Vet Affairs Med Ctr, Behav Neurol Sect,Dept Neurol, 12631 E 17th Ave,MS B185,POB 6511, Aurora, CO 80045 USA. EM christopher.filley@ucdenver.edu FU NIAMS NIH HHS [1 R01 AR04915-01A2, 3 RO1 AR049152-02S1] NR 12 TC 8 Z9 8 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD NOV 24 PY 2009 VL 73 IS 21 BP 1718 EP 1719 DI 10.1212/WNL.0b013e3181c2936b PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 523LY UT WOS:000272076200001 PM 19846831 ER PT J AU Hoops, S Nazem, S Siderowf, AD Duda, JE Xie, SX Stern, MB Weintraub, D AF Hoops, S. Nazem, S. Siderowf, A. D. Duda, J. E. Xie, S. X. Stern, M. B. Weintraub, D. TI Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease SO NEUROLOGY LA English DT Article ID MILD COGNITIVE IMPAIRMENT; MENTAL-STATE-EXAMINATION; COMMUNITY POPULATION; DIAGNOSTIC-CRITERIA; SCREENING TOOL; RATING-SCALE; INCIDENT; ACCURACY; COHORT AB Background: Due to the high prevalence of mild cognitive impairment (MCI) and dementia in Parkinson disease (PD), routine cognitive screening is important for the optimal management of patients with PD. The Montreal Cognitive Assessment (MoCA) is more sensitive than the commonly used Mini-Mental State Examination (MMSE) in detecting MCI and dementia in patients without PD, but its validity in PD has not been established. Methods: A representative sample of 132 patients with PD at 2 movement disorders centers was administered the MoCA, MMSE, and a neuropsychological battery with operationalized criteria for deficits. MCI and PD dementia (PDD) criteria were applied by an investigator blinded to the MoCA and MMSE results. The discriminant validity of the MoCA and MMSE as screening and diagnostic instruments was ascertained. Results: Approximately one third of the sample met diagnostic criteria for a cognitive disorder (12.9% PDD and 17.4% MCI). Mean (SD) MoCA and MMSE scores were 25.0 (3.8) and 28.1 (2.0). The overall discriminant validity for detection of any cognitive disorder was similar for the MoCA and the MMSE (receiver operating characteristic area under the curve [95% confidence interval]): MoCA (0.79 [0.72, 0.87]) and MMSE (0.76 [0.67, 0.85]), but as a screening instrument the MoCA (optimal cutoff point = 26/27, 64% correctly diagnosed, lack of ceiling effect) was superior to the MMSE (optimal cutoff point = 29/30, 54% correctly diagnosed, presence of ceiling effect). Conclusions: The Montreal Cognitive Assessment, but not the Mini-Mental State Examination, has adequate psychometric properties as a screening instrument for the detection of mild cognitive impairment or dementia in Parkinson disease. However, a positive screen using either instrument requires additional assessment due to suboptimal specificity at the recommended screening cutoff point. Neurology (R) 2009; 73: 1738-1745 C1 [Hoops, S.; Nazem, S.; Weintraub, D.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Siderowf, A. D.; Duda, J. E.; Stern, M. B.; Weintraub, D.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Xie, S. X.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Duda, J. E.; Stern, M. B.; Weintraub, D.] Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. [Weintraub, D.] Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. RP Weintraub, D (reprint author), 3615 Chestnut St,Room 330, Philadelphia, PA 19104 USA. EM daniel.weintraub@uphs.upenn.edu FU NIH [U10 NS044451, P50 NS053488, R43 NS0636071, RO1 NS41265-01, RO1 NS44266, K23 MH067894]; Department of Veterans Affairs; Michael J. Fox Foundation; Samueli Foundation; NIH/NINDS [NS053488]; Ceregene; Institute of Neurodegeneration, New Haven, CT; Department of Defense [USAMRAA810002]; Boehringer Ingelheim FX S. Hoops and S. Nazem report no disclosures. Dr. Siderowf serves on the editorial advisory board of Neura; serves on a speakers' bureau for Teva Pharmaceutical Industries Ltd.; serves as a consultant to Supernus Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Merck Serono, and Schering-Plough Corp.; and receives research support from the NIH [U10 NS044451 (Principal Investigator), P50 NS053488 (Project Leader), R43 NS0636071(Co-Investigator)]. Dr. Duda serves/has served on a scientific advisory boards for Boehringer Ingelheim, the Lewy Body Dementia Association, and the Lewy Body Society; has received honoraria for lectures or educational activities not funded by industry; and receives research support from the Department of Veterans Affairs [Biomedical Laboratory Research and Development Service Merit Award (PI), Cooperative Studies Program 468 (Site PI)], the NIH [RO1 NS41265-01 (Coinvestigator), RO1 NS44266 (Coinvestigator)], the Michael J. Fox Foundation, and the Samueli Foundation. Dr. Xie receives research support from the NIH/NINDS [NS053488 (Coinvestigator and Core Director)]. Dr. Stern receives royalties for publishing Deep Brain Stimulation for Parkinson's Disease (Taylor and Francis Group, 2007); has received honoraria from Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, and Novartis; serves as a consultant to Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Novartis, Vernalis plc, Ipsen, ScheringPlough Corp., and NuPathe Inc.; and receives research support from Ceregene, and a foundation grant from the Institute of Neurodegeneration, New Haven, CT, and the Department of Defense [USAMRAA810002 (Coinvestigator)]. Dr. Weintraub has served on a scientific advisory board for Boehringer Ingelheim; serves on the editorial board of Movement Disorders; has received honoraria from Boehringer Ingelheim, ACADIA Pharmaceuticals Inc., Novartis, Osmotica Pharmaceutical Corp., BrainCells Inc., Merck Serono, Sanofi-Aventis, and Pfizer Inc.; and receives research support from Boehringer Ingelheim and the NIH [K23 MH067894 (Principal Investigator)]. NR 40 TC 222 Z9 248 U1 8 U2 32 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD NOV 24 PY 2009 VL 73 IS 21 BP 1738 EP 1745 DI 10.1212/WNL.0b013e3181c34b47 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 523LY UT WOS:000272076200005 PM 19933974 ER PT J AU Shih, JJ LeslieMazwi, T Falcao, G Van Gerpen, J AF Shih, Jerry J. LeslieMazwi, Thabele Falcao, Germano Van Gerpen, Jay TI DIRECTED AGGRESSIVE BEHAVIOR IN FRONTAL LOBE EPILEPSY: A VIDEO-EEG AND ICTAL SPECT CASE STUDY SO NEUROLOGY LA English DT Editorial Material ID MECHANISMS; SEIZURES; ORIGIN C1 [Shih, Jerry J.; Falcao, Germano; Van Gerpen, Jay] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA. [LeslieMazwi, Thabele] Massachusetts Gen Hosp, Dept Neurol, Partners Healthcare WAC7, Boston, MA 02114 USA. RP Shih, JJ (reprint author), Mayo Clin, Dept Neurol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA. EM Shih.jerry@mayo.edu NR 7 TC 14 Z9 14 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD NOV 24 PY 2009 VL 73 IS 21 BP 1804 EP 1806 DI 10.1212/WNL.0b013e3181c2933f PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 523LY UT WOS:000272076200015 PM 19846832 ER PT J AU Kumar, S Sharafkhaneh, A Edmonds, J Schultz, R Hopkins, B AF Kumar, S. Sharafkhaneh, A. Edmonds, J. Schultz, R. Hopkins, B. TI TREATMENT OF VNS-INDUCED LARYNGOSPASM WITH BOTULINUM TOXIN SO NEUROLOGY LA English DT Editorial Material ID VAGUS NERVE-STIMULATION; REFRACTORY EPILEPSY; SLEEP; CHILDREN C1 [Kumar, S.; Sharafkhaneh, A.] Baylor Coll Med, Dept Pulm Crit Care & Sleep Med, Houston, TX 77030 USA. [Schultz, R.; Hopkins, B.] Baylor Coll Med, Dept Pediat, Sect Child Neurol & Dev Neurosci, Houston, TX 77030 USA. [Sharafkhaneh, A.] Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX USA. [Edmonds, J.] Otolaryngol Sect, Houston, TX USA. [Schultz, R.; Hopkins, B.] Texas Childrens Hosp, Houston, TX 77030 USA. RP Kumar, S (reprint author), 2128 Babcock Rd,Bldg 1,Suite C, San Antonio, TX 78229 USA. EM sumeetk55@gmail.com NR 7 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD NOV 24 PY 2009 VL 73 IS 21 BP 1808 EP 1810 DI 10.1212/WNL.0b013e3181c34ae3 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 523LY UT WOS:000272076200017 PM 19933985 ER PT J AU Barnett, JH Smoller, JW AF Barnett, J. H. Smoller, J. W. TI THE GENETICS OF BIPOLAR DISORDER SO NEUROSCIENCE LA English DT Review DE bipolar disorder; genetic; GWAS; genetic epidemiology; association; candidate gene ID GENOME-WIDE ASSOCIATION; COMORBIDITY SURVEY REPLICATION; SEROTONIN TRANSPORTER GENE; GLUTAMATE-RECEPTOR GENE; I-DISORDER; MOOD DISORDERS; PSYCHIATRIC-DISORDERS; 1ST-DEGREE RELATIVES; MORBID RISK; EARLY-ONSET AB Bipolar disorder is a mood disorder characterized by impairing episodes of mania and depression. Twin studies have established that bipolar disorder is among the most heritable of medical disorders and efforts to identify specific susceptibility genes have intensified over the past two decades. The search for genes influencing bipolar disorder has been complicated by a paucity of animal models, limited understanding of pathogenesis, and the genetic and phenotypic complexity of the syndrome. Linkage studies have implicated several chromosomal regions as harboring relevant genes, but results have been inconsistent. It is now widely accepted that the genetic liability to bipolar disorder reflects the action of many genes of individually small effect, a scenario for which linkage studies are poorly suited. Thus, association studies, which are more powerful for the detection of modest effect loci, have become the focus of gene-finding research. A large number of candidate genes, including biological candidates derived from hypotheses about the pathogenesis of the disorder and positional candidates derived from linkage and cytogenetic studies, have been evaluated. Several of these genes have been associated with the disorder in independent studies (including BDNF, DAOA, DISCI, GRIK4, SLC6A4, and TPH2), but none has been established. The clinical heterogeneity of bipolar disorder and its phenotypic and genetic overlap with other disorders (especially schizophrenia, schizoaffective disorder, and major depressive disorder) have raised questions about the optimal phenotype definition for genetic studies. Nevertheless, genome-wide association analysis, which has successfully identified susceptibility genes for a variety of complex disorders, has begun to implicate specific genes for bipolar disorder (DGKH, CACNA1C, ANK3). The polygenicity of the disorder means that very large samples will be needed to detect the modest effect loci that likely contribute to bipolar disorder. Detailed genetic dissection of the disorder may provide novel targets (both pharmacologic and psychosocial) for intervention. (C) 2009 IBRO. Published by Elsevier Ltd. All rights reserved. C1 [Barnett, J. H.; Smoller, J. W.] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Ctr Human Genet Res, Dept Psychiat, Boston, MA 02114 USA. [Barnett, J. H.; Smoller, J. W.] Massachusetts Gen Hosp, Psychiat Genet Program Mood & Anxiety Disorders, Boston, MA 02114 USA. [Barnett, J. H.] Univ Cambridge, Dept Psychiat, Cambridge, England. RP Smoller, JW (reprint author), Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Ctr Human Genet Res, Dept Psychiat, Simches Res Bldg,185 Cambridge St,2nd Floor, Boston, MA 02114 USA. EM jsmoller@hms.harvard.edu FU NIMH NIH HHS [R01 MH079799, R01 MH079799-02] NR 143 TC 118 Z9 125 U1 8 U2 39 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 EI 1873-7544 J9 NEUROSCIENCE JI Neuroscience PD NOV 24 PY 2009 VL 164 IS 1 SI SI BP 331 EP 343 DI 10.1016/j.neuroscience.2009.03.080 PG 13 WC Neurosciences SC Neurosciences & Neurology GA 517JI UT WOS:000271609000026 PM 19358880 ER PT J AU Becerra, L Harris, W Grant, M George, E Boas, D Borsook, D AF Becerra, Lino Harris, Will Grant, Margaret George, Edward Boas, David Borsook, David TI Diffuse Optical Tomography Activation in the Somatosensory Cortex: Specific Activation by Painful vs. Non-Painful Thermal Stimuli SO PLOS ONE LA English DT Article ID MEDIAN NERVE-STIMULATION; REPRESENTATION; FMRI AB Background: Pain is difficult to assess due to the subjective nature of self-reporting. The lack of objective measures of pain has hampered the development of new treatments as well as the evaluation of current ones. Functional MRI studies of pain have begun to delineate potential brain response signatures that could be used as objective read-outs of pain. Using Diffuse Optical Tomography (DOT), we have shown in the past a distinct DOT signal over the somatosensory cortex to a noxious heat stimulus that could be distinguished from the signal elicited by innocuous mechanical stimuli. Here we further our findings by studying the response to thermal innocuous and noxious stimuli. Methodology/Principal Findings: Innocuous and noxious thermal stimuli were applied to the skin of the face of the first division (ophthalmic) of the trigeminal nerve in healthy volunteers (N = 6). Stimuli temperatures were adjusted for each subject to evoke warm (equivalent to a 3/10) and painful hot (7/10) sensations in a verbal rating scale (0/10 = no/max pain). A set of 26 stimuli (5 sec each) was applied for each temperature with inter-stimulus intervals varied between 8 and 15 sec using a Peltier thermode. A DOT system was used to capture cortical responses on both sides of the head over the primary somatosensory cortical region (S1). For the innocuous stimuli, group results indicated mainly activation on the contralateral side with a weak ipsilateral response. For the noxious stimuli, bilateral activation was observed with comparable amplitudes on both sides. Furthermore, noxious stimuli produced a temporal biphasic response while innocuous stimuli produced a monophasic response. Conclusions/Significance: These results are in accordance with fMRI and our other DOT studies of innocuous mechanical and noxious heat stimuli. The data indicate the differentiation of DOT cortical responses for pain vs. innocuous stimuli that may be useful in assessing objectively acute pain. C1 [Becerra, Lino; Harris, Will; Grant, Margaret; George, Edward; Borsook, David] McLean Hosp, PAIN, Belmont, MA 02178 USA. [Boas, David] McLean Hosp, Photon Migrat Lab, Belmont, MA 02178 USA. [Becerra, Lino; Harris, Will; Grant, Margaret; George, Edward; Boas, David; Borsook, David] Massachusetts Gen Hosp, Charlestown, MA USA. [Becerra, Lino; Harris, Will; Grant, Margaret; Boas, David] Harvard Univ, Sch Med, Athinoula A Martinos Ctr Biomed Engn, Charlestown, MA USA. RP Becerra, L (reprint author), McLean Hosp, PAIN, 115 Mill St, Belmont, MA 02178 USA. EM lbecerra@partners.org FU Mayday Foundation; NINDS [K24 NS064050] FX Supported by a grant from the Mayday Foundation and a NINDS Mentor Training Grant to DB (K24 NS064050). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 13 TC 17 Z9 17 U1 1 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 24 PY 2009 VL 4 IS 11 AR e8016 DI 10.1371/journal.pone.0008016 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 533MH UT WOS:000272827500038 PM 19956637 ER PT J AU Liu, SM Okada, T Assmann, A Soto, J Liew, CW Bugger, H Shirihai, OS Abel, ED Kulkarni, RN AF Liu, Siming Okada, Terumasa Assmann, Anke Soto, Jamie Liew, Chong Wee Bugger, Heiko Shirihai, Orian S. Abel, E. Dale Kulkarni, Rohit N. TI Insulin Signaling Regulates Mitochondrial Function in Pancreatic beta-Cells SO PLOS ONE LA English DT Article ID ACTIVATED-RECEPTOR-GAMMA; N-TERMINAL KINASE; INDUCED C-JUN; IGF-I; GLUCOSE-HOMEOSTASIS; INTERACTING PROTEIN; OXIDATIVE STRESS; DOWN-REGULATION; SURVIVAL; GLUCOKINASE AB Insulin/IGF-I signaling regulates the metabolism of most mammalian tissues including pancreatic islets. To dissect the mechanisms linking insulin signaling with mitochondrial function, we first identified a mitochondria-tethering complex in beta-cells that included glucokinase (GK), and the pro-apoptotic protein, BAD(S). Mitochondria isolated from beta-cells derived from beta-cell specific insulin receptor knockout (beta IRKO) mice exhibited reduced BAD(S), GK and protein kinase A in the complex, and attenuated function. Similar alterations were evident in islets from patients with type 2 diabetes. Decreased mitochondrial GK activity in beta IRKOs could be explained, in part, by reduced expression and altered phosphorylation of BAD(S). The elevated phosphorylation of p70S6K and JNK1 was likely due to compensatory increase in IGF-1 receptor expression. Re-expression of insulin receptors in beta IRKO cells partially restored the stoichiometry of the complex and mitochondrial function. These data indicate that insulin signaling regulates mitochondrial function and have implications for beta-cell dysfunction in type 2 diabetes. C1 [Liu, Siming; Okada, Terumasa; Assmann, Anke; Liew, Chong Wee; Kulkarni, Rohit N.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Soto, Jamie; Bugger, Heiko; Abel, E. Dale] Univ Utah, Sch Med, Div Endocrinol Metab & Diabet, Salt Lake City, UT USA. [Soto, Jamie; Bugger, Heiko; Abel, E. Dale] Univ Utah, Sch Med, Program Mol Med, Salt Lake City, UT USA. [Shirihai, Orian S.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [Liu, Siming; Okada, Terumasa; Assmann, Anke; Liew, Chong Wee; Kulkarni, Rohit N.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02115 USA. RP Liu, SM (reprint author), Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. EM Rohit.Kulkarni@joslin.harvard.edu FU NIH [DK RO1 68721, DK RO1 67536, HL RO1 73167]; Joslin DERC [P30DK36836]; German Research Foundation DFG FX This study was supported by grants from the NIH DK RO1 68721 (R. N. K.), NIH DK RO1 67536 (R. N. K.), NIH HL RO1 73167 (E. D. A.), and the Joslin DERC P30DK36836 (Specialized Assay and Advanced Microscopy Cores). HB was supported by a grant from the German Research Foundation DFG. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 55 TC 30 Z9 31 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 24 PY 2009 VL 4 IS 11 AR e7983 DI 10.1371/journal.pone.0007983 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 533MH UT WOS:000272827500013 PM 19956695 ER PT J AU Margulies, DS Vincent, JL Kelly, C Lohmann, G Uddin, LQ Biswal, BB Villringer, A Castellanos, FX Milham, MP Petrides, M AF Margulies, Daniel S. Vincent, Justin L. Kelly, Clare Lohmann, Gabriele Uddin, Lucina Q. Biswal, Bharat B. Villringer, Arno Castellanos, F. Xavier Milham, Michael P. Petrides, Michael TI Precuneus shares intrinsic functional architecture in humans and monkeys SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE brain connectivity; functional MRI; posteromedial cortex; resting state ID POSTERIOR PARIETAL CORTEX; RESTING-STATE NETWORKS; RHESUS-MONKEY; CORTICAL AFFERENTS; MACAQUE MONKEY; POSTEROMEDIAL CORTEX; RETROSPLENIAL CORTEX; PREFRONTAL CORTEX; CINGULATE CORTEX; FRONTAL-CORTEX AB Evidence from macaque monkey tracing studies suggests connectivity-based subdivisions within the precuneus, offering predictions for similar subdivisions in the human. Here we present functional connectivity analyses of this region using resting-state functional MRI data collected from both humans and macaque monkeys. Three distinct patterns of functional connectivity were demonstrated within the precuneus of both species, with each subdivision suggesting a discrete functional role: (i) the anterior precuneus, functionally connected with the superior parietal cortex, paracentral lobule, and motor cortex, suggesting a sensorimotor region; (ii) the central precuneus, functionally connected to the dorsolateral prefrontal, dorsomedial prefrontal, and multimodal lateral inferior parietal cortex, suggesting a cognitive/associative region; and (iii) the posterior precuneus, displaying functional connectivity with adjacent visual cortical regions. These functional connectivity patterns were differentiated from the more ventral networks associated with the posterior cingulate, which connected with limbic structures such as the medial temporal cortex, dorsal and ventromedial prefrontal regions, posterior lateral inferior parietal regions, and the lateral temporal cortex. Our findings are consistent with predictions from anatomical tracer studies in the monkey, and provide support that resting-state functional connectivity (RSFC) may in part reflect underlying anatomy. These subdivisions within the precuneus suggest that neuroimaging studies will benefit from treating this region as anatomically (and thus functionally) heterogeneous. Furthermore, the consistency between functional connectivity networks in monkeys and humans provides support for RSFC as a viable tool for addressing cross-species comparisons of functional neuroanatomy. C1 [Kelly, Clare; Castellanos, F. Xavier; Milham, Michael P.] NYU, Ctr Child Study, Phyllis Green & Randolph Cowen Inst Pediat Neuros, New York, NY 10016 USA. [Margulies, Daniel S.; Villringer, Arno] Humboldt Univ, Berlin Sch Mind & Brain, D-10099 Berlin, Germany. [Margulies, Daniel S.; Lohmann, Gabriele; Villringer, Arno] Max Planck Inst Human Cognit & Brain Sci, D-04303 Leipzig, Germany. [Vincent, Justin L.] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA. [Vincent, Justin L.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Uddin, Lucina Q.] Stanford Univ, Sch Med, Dept Psychiat, Palo Alto, CA 94304 USA. [Biswal, Bharat B.] Univ Med & Dent New Jersey, Dept Radiol, Newark, NJ 07103 USA. [Biswal, Bharat B.; Castellanos, F. Xavier] Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA. [Petrides, Michael] McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada. RP Milham, MP (reprint author), NYU, Ctr Child Study, Phyllis Green & Randolph Cowen Inst Pediat Neuros, 550 1St Ave, New York, NY 10016 USA. EM michael.milham@nyumc.org; michael.petrides@mcgill.ca RI Vincent, Justin/B-5033-2012; Lohmann, Gabriele/C-3590-2008; Milham, Michael/K-9501-2014; Kelly, Clare/H-4629-2016; Margulies, Daniel/L-4719-2016; OI Lohmann, Gabriele/0000-0002-5922-9016; Kelly, Clare/0000-0001-8253-357X; Margulies, Daniel/0000-0002-8880-9204; Uddin, Lucina/0000-0003-2278-8962; Castellanos, Francisco/0000-0001-9192-9437 FU Stavros S. Niarchos Foundation; National Institute on Drug Abuse [DA016979]; Berlin School of Mind and Brain; Canadian Institutes of Health Research [MOP-14620]; National Institute of Neurological Disorders and Stroke [NS 06833]; Washington University FX We thank David Stark and Amelie Diester for assistance with manual seed selection and Will Brady for graphic design consultation. This work was supported by the Stavros S. Niarchos Foundation, the National Institute on Drug Abuse (Grant DA016979), the Berlin School of Mind and Brain, and the Canadian Institutes of Health Research (Grant MOP-14620). The monkey data were originally funded by the National Institute of Neurological Disorders and Stroke (Grant NS 06833) and discretionary research funds from the Mallinckrodt Institute of Radiology at Washington University, and have been made publicly available at www.brainscape.org. NR 56 TC 376 Z9 390 U1 0 U2 23 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD NOV 24 PY 2009 VL 106 IS 47 BP 20069 EP 20074 DI 10.1073/pnas.0905314106 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 524YS UT WOS:000272180900060 PM 19903877 ER PT J AU Bhattacharya, D Czechowicz, A Ooi, AGL Rossi, DJ Bryder, D Weissman, IL AF Bhattacharya, Deepta Czechowicz, Agnieszka Ooi, A. G. Lisa Rossi, Derrick J. Bryder, David Weissman, Irving L. TI Niche recycling through division-independent egress of hematopoietic stem cells SO JOURNAL OF EXPERIMENTAL MEDICINE LA English DT Article ID BONE-MARROW-TRANSPLANTATION; SEVERE COMBINED IMMUNODEFICIENCY; LONG-TERM ENGRAFTMENT; PROGENITOR CELLS; MURINE MARROW; SELF-RENEWAL; IN-VIVO; NONMYELOABLATED HOST; RAPID MOBILIZATION; YOLK-SAC AB Hematopoietic stem cells (HSCs) are thought to reside in discrete niches through stable adhesion, yet previous studies have suggested that host HSCs can be replaced by transplanted donor HSCs, even in the absence of cytoreductive conditioning. To explain this apparent paradox, we calculated, through cell surface phenotyping and transplantation of unfractionated blood, that similar to 1-5% of the total pool of HSCs enters into the circulation each day. Bromodeoxyuridine (BrdU) feeding experiments demonstrated that HSCs in the peripheral blood incorporate BrdU at the same rate as do HSCs in the bone marrow, suggesting that egress from the bone marrow to the blood can occur without cell division and can leave behind vacant HSC niches. Consistent with this, repetitive daily transplantations of small numbers of HSCs administered as new niches became available over the course of 7 d led to significantly higher levels of engraftment than did large, single-bolus transplantations of the same total number of HSCs. These data provide insight as to how HSC replacement can occur despite the residence of endogenous HSCs in niches, and suggest therapeutic interventions that capitalize upon physiological HSC egress. C1 [Bhattacharya, Deepta; Czechowicz, Agnieszka; Ooi, A. G. Lisa; Weissman, Irving L.] Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA. [Rossi, Derrick J.] Harvard Univ, Sch Med, Immune Dis Inst, Harvard Stem Cell Inst,Dept Pathol, Boston, MA 02115 USA. [Bryder, David] Lund Univ, Immunol Unit, Inst Expt Med Sci, S-22184 Lund, Sweden. RP Bhattacharya, D (reprint author), Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA. EM deeptab@wustl.edu FU National Institutes of Health [R01CA086065, R01HL058770, T32AI0729022, K01DK078318, R00AGO29760]; Cancer Research Institute; Medical Scholars Program at Stanford University School of Medicine; The Paul and Daisy Soros Fellowships for New Americans; Singapore National Agency for Science, Technology, and Research; Swedish Medical Research Council (STINT) FX This investigation was supported by National Institutes of Health grants R01CA086065 and R01HL058770 (to I. L. Weissman). D. Bhattacharya was supported by a fellowship from the Cancer Research Institute and National Institutes of Health grants T32AI0729022 and K01DK078318. A. Czechowicz is a Howard Hughes Medical Institute Medical Research Training Fellow, and was supported by a fellowship from the Medical Scholars Program at Stanford University School of Medicine. Research for this article was supported in part by a grant from The Paul and Daisy Soros Fellowships for New Americans. The program is not responsible for the views expressed. A. G. L. Ooi was supported by a scholarship from the Singapore National Agency for Science, Technology, and Research; D. J. Rossi was supported by National Institutes of Health grant R00AGO29760; and D. Bryder was supported by a scholarship from the Swedish Medical Research Council (STINT). NR 80 TC 60 Z9 62 U1 0 U2 0 PU ROCKEFELLER UNIV PRESS PI NEW YORK PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA SN 0022-1007 J9 J EXP MED JI J. Exp. Med. PD NOV 23 PY 2009 VL 206 IS 12 BP 2837 EP 2850 DI 10.1084/jem.20090778 PG 14 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 523MX UT WOS:000272079300020 PM 19887396 ER PT J AU Tsai, CC Vinegoni, C Weissleder, R AF Tsai, Chang-Ching Vinegoni, Claudio Weissleder, Ralph TI Diffractionless beam in free space with adiabatic changing refractive index in a single mode tapered slab waveguide SO OPTICS EXPRESS LA English DT Article ID EXTENDED FOCAL DEPTH; LINES; RESOLUTION; MICROSCOPY; AXICON AB We propose a novel design to produce a free space diffractionless beam by adiabatically reducing the difference of the refractive index between the core and the cladding regions of a single mode tapered slab waveguide. To ensure only one propagating eigenmode in the adiabatic transition, the correlation of the waveguide core width and the refractive index is investigated. Under the adiabatic condition, we demonstrate that our waveguide can emit a diffractionless beam in free space up to 500 micrometers maintaining 72% of its original peak intensity. The proposed waveguide could find excellent applications for imaging purposes where an extended depth of field is required. (C) 2009 Optical Society of America C1 [Tsai, Chang-Ching] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Tsai, CC (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. EM Tsai.Chang-Ching@mgh.harvard.edu FU NIH [1-RO1 EB006432, U24 CA 092782] FX This work was supported in part by NIH grants 1-RO1 EB006432 and U24 CA 092782. NR 25 TC 1 Z9 1 U1 0 U2 5 PU OPTICAL SOC AMER PI WASHINGTON PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA SN 1094-4087 J9 OPT EXPRESS JI Opt. Express PD NOV 23 PY 2009 VL 17 IS 24 BP 21723 EP 21731 DI 10.1364/OE.17.021723 PG 9 WC Optics SC Optics GA 525PU UT WOS:000272229400041 PM 19997414 ER PT J AU Xu, XK Yue, XM Lescroart, MD Biederman, I Kim, JG AF Xu, Xiaokun Yue, Xiaomin Lescroart, Mark D. Biederman, Irving Kim, Jiye G. TI Adaptation in the fusiform face area (FFA): Image or person? SO VISION RESEARCH LA English DT Article DE Face recognition; Fusiform face area; fMRI adaptation; Face representation; Gabor-jet scaling ID HUMAN VISUAL-CORTEX; FMRI-ADAPTATION; DIFFERENTIAL SENSITIVITY; DISTINCT REPRESENTATIONS; INDIVIDUAL FACES; UNFAMILIAR FACES; TEMPORAL CORTEX; FACIAL IDENTITY; PERCEPTION; RECOGNITION AB Viewing a sequence of faces of two different people results in a greater Blood Oxygenation Level Dependent (BOLD) response in FFA compared to a sequence of identical faces. Changes in identity, however, necessarily involve changes in the image. Is the release from adaptation a result of a change in face identity, per se, or could it be an effect that would arise from any change in the image of a face? Subjects viewed a sequence of two faces that could be of the same or different person, and in the same or different orientation in depth. Critically, the physical similarity of view changes of the same person was scaled, by Gabor-jet differences, to be equivalent to that produced by an identity change. Both person and orientation changes produced equivalent releases from adaptation in FFA (relative to identical faces) suggesting that FFA is sensitive to the physical similarity of faces rather than to the individuals depicted in the images. (C) 2009 Elsevier Ltd. All rights reserved. C1 [Xu, Xiaokun; Biederman, Irving; Kim, Jiye G.] Univ So Calif, Dept Psychol, Los Angeles, CA 90089 USA. [Yue, Xiaomin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Martinos Ctr Biomed Imaging, Boston, MA 02129 USA. [Lescroart, Mark D.; Biederman, Irving] Univ So Calif, Neurosci Program, Los Angeles, CA 90089 USA. RP Xu, XK (reprint author), Univ So Calif, Dept Psychol, Los Angeles, CA 90089 USA. EM xiaokunx@usc.edu FU NSF [0420794, 0531177, 0617699] FX We thank Kenneth Hayworth for helpful comments and Jiancheng Zhuang for his role in maintaining the MRI scanner. Supported by NSF 0420794, 0531177, and 0617699 to IB. The authors declare that they have no competing financial interests. NR 40 TC 33 Z9 33 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0042-6989 J9 VISION RES JI Vision Res. PD NOV 23 PY 2009 VL 49 IS 23 BP 2800 EP 2807 DI 10.1016/j.visres.2009.08.021 PG 8 WC Neurosciences; Ophthalmology SC Neurosciences & Neurology; Ophthalmology GA 524HI UT WOS:000272134000008 PM 19712692 ER PT J AU Henkner, K Sobolevsky, N Jakel, O Paganetti, H AF Henkner, K. Sobolevsky, N. Jaekel, O. Paganetti, H. TI Test of the nuclear interaction model in SHIELD-HIT and comparison to energy distributions from GEANT4 SO PHYSICS IN MEDICINE AND BIOLOGY LA English DT Article ID PROTON THERAPY; SIMULATION AB Monte Carlo codes are widely used to simulate dose distributions in ion radiotherapy. The benchmark of the implemented physical models against experimental data plays an important role in improving the accuracy of the simulations. To estimate the accuracy of the inelastic cross sections in SHIELD-HIT, the simulated charge is compared to measured data from a Multi Layer Faraday Cup. In addition, the results are compared to GEANT4, which are already published. Furthermore, energy distributions are simulated with SHIELD-HIT07 and GEANT4.8.1. From a comparison of depth distributions and beam profiles of 100 and 200 MeV protons, we estimate the level of agreement of the two codes. Nuclear interactions predicted by SHIELD-HIT underestimate the total amount of measured charge. The energy distributions from SHIELD-HIT and GEANT4 show differences exceeding the statistical uncertainties of 2%. Due to a difference of the Bragg curve of 0.5 +/- 0.3 mm on average, the mean difference in dose is 3.5% with a maximum deviation of 7% for the simulated cases. C1 [Henkner, K.; Jaekel, O.] German Canc Res Ctr, Dept Med Phys Radiat Oncol, D-69120 Heidelberg, Germany. [Sobolevsky, N.] Russian Acad Sci, Inst Nucl Res, Dept Neutron Res, Moscow 117312, Russia. [Henkner, K.; Jaekel, O.] Univ Heidelberg Hosp, Heidelberg Ion Beam Therapy Ctr, D-69120 Heidelberg, Germany. [Paganetti, H.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Paganetti, H.] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Henkner, K (reprint author), German Canc Res Ctr, Dept Med Phys Radiat Oncol, D-69120 Heidelberg, Germany. EM Katrin.Henkner@med.uni-heidelberg.de FU German Research Foundation (DFG) [JA 1687/1-1] FX Ms Henkner was supported by the German Research Foundation (DFG) under the contract number JA 1687/1-1. NR 22 TC 5 Z9 5 U1 0 U2 0 PU IOP PUBLISHING LTD PI BRISTOL PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND SN 0031-9155 J9 PHYS MED BIOL JI Phys. Med. Biol. PD NOV 21 PY 2009 VL 54 IS 22 BP N509 EP N517 DI 10.1088/0031-9155/54/22/N01 PG 9 WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Radiology, Nuclear Medicine & Medical Imaging GA 515EB UT WOS:000271448600019 PM 19864697 ER PT J AU Xu, J Sankaran, VG Fujiwara, Y Orkin, SH AF Xu, Jian Sankaran, Vijay G. Fujiwara, Yuko Orkin, Stuart H. TI Control of Hemoglobin Switching by BCL11A SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Xu, Jian; Sankaran, Vijay G.; Fujiwara, Yuko] Harvard Univ, Sch Med, Howard Hughes Med Inst, Div Hematol Oncol,Childrens Hosp Boston, Boston, MA 02115 USA. [Orkin, Stuart H.] Harvard Univ, Sch Med, Dept Pediat Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 4 EP 5 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800006 ER PT J AU Rego, EM Kim, HT Ruiz-Arguelles, GJ Uriarte, R Jacomo, RH Gutierrez-Aguirre, H Melo, RAM Bittencourt, R Pasquini, R Pagnano, KBB Fagundes, EM Chauffaille, MDLF Chiattone, C Martinez, L Meillon, LA Gomez-Almaguer, D Kwaan, HC Garces-Eisele, J Gallagher, RE Niemeyer, CM Lowenberg, B Ribeiro, RC Lo-Coco, F Sanz, MA AF Rego, Eduardo M. Kim, Haesook T. Ruiz-Arguelles, Guillermo J. Uriarte, Rosario Jacomo, Rafael H. Gutierrez-Aguirre, Homero Melo, Raul A. M. Bittencourt, Rosane Pasquini, Ricardo Pagnano, Katia B. B. Fagundes, Evandro M. Chauffaille, Maria de Lourdes L. F. Chiattone, Carlos Martinez, Lem Meillon, Luis A. Gomez-Almaguer, David Kwaan, Hau C. Garces-Eisele, Javier Gallagher, Robert E. Niemeyer, Charlotte M. Lowenberg, Bob Ribeiro, Raul C. Lo-Coco, Francesco Sanz, Miguel A. TI Improving the Treatment Outcome of Acute Promyelocytic Leukemia in Developing Countries through International Cooperative Network. Report On the International Consortium On Acute Promyelocytic Leukemia Study Group SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Rego, Eduardo M.] Univ Sao Paulo, Med Sch Ribeirao Preto, Hematol Serv, BR-14049 Ribeirao Preto, Brazil. [Kim, Haesook T.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Ruiz-Arguelles, Guillermo J.; Garces-Eisele, Javier] Clin Ruiz Puebla, Puebla, Mexico. [Uriarte, Rosario; Martinez, Lem] Asociac Espanola Primera Socorros Mutuos, Montevideo, Uruguay. [Gutierrez-Aguirre, Homero; Gomez-Almaguer, David] Hosp Univ Monterrey, Monterrey, Mexico. [Melo, Raul A. M.] HEMOPE, Recife, PE, Brazil. [Bittencourt, Rosane] Univ Fed Rio Grande do Sul, Porto Alegre, RS, Brazil. [Pasquini, Ricardo] Univ Fed Parana, BR-80060000 Curitiba, Parana, Brazil. [Pagnano, Katia B. B.] Univ Estadual Campinas, Campinas, SP, Brazil. [Fagundes, Evandro M.] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil. [Chauffaille, Maria de Lourdes L. F.] Univ Fed Sao Paulo, Sao Paulo, Brazil. [Chiattone, Carlos] Santa Casa Med Sch, Sao Paulo, Brazil. [Meillon, Luis A.] Ctr Med Nacl Siglo 21, Mexico City, DF, Mexico. [Kwaan, Hau C.] Northwestern Univ, Chicago, IL 60611 USA. [Gallagher, Robert E.] Albert Einstein Canc Ctr, Bronx, NY USA. [Niemeyer, Charlotte M.] Univ Med Ctr, Dept Pediat & Adolescent Med, Freiburg, Germany. [Lowenberg, Bob] Erasmus Univ, Med Ctr, Rotterdam, Netherlands. [Ribeiro, Raul C.] St Jude Childrens Hosp, Memphis, TN 38105 USA. [Lo-Coco, Francesco] Univ Roma Tor Vergata, Rome, Italy. [Sanz, Miguel A.] Hosp Univ La Fe, Valencia, Spain. RI Pagnano, Katia/K-6686-2012; Rego, Eduardo/A-1058-2012; Melo, Raul/D-4910-2013 OI Rego, Eduardo/0000-0003-1567-4086; Melo, Raul/0000-0001-7629-7144 NR 0 TC 2 Z9 2 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 5 EP 5 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800007 ER PT J AU Hertzberg, L Vendramini, E Ganmore, I Cazzaniga, G Schmitz, M Shiloh, R Chalker, J Iacobucci, I Shochat, C Zeligson, S Cario, G Stanulla, M Strehl, S Russel, LJ Harrison, C Bornhauser, B Yoda, A Rechavi, G Bercovich, D Borkardt, A Kempski, H Kronnie, GT Bourquin, JP Domany, E Izraeli, S AF Hertzberg, Libi Vendramini, Elena Ganmore, Ithamar Cazzaniga, Giovanni Schmitz, Maike Shiloh, Ruth Chalker, Jane Iacobucci, Ilaria Shochat, Chen Zeligson, Sharon Cario, Gunnar Stanulla, Martin Strehl, Sabine Russel, Lisa J. Harrison, Christine Bornhauser, Beat Yoda, Akinori Rechavi, Gideon Bercovich, Dani Borkardt, Arndt Kempski, Helena Kronnie, Geertruy te Bourquin, Jean-Pierre Domany, Eytan Izraeli, Shai TI DOWN'S Syndrome Acute Lymphoblastic LEUKEMIA: A HIGHLY Heterogeneous DISEASE DRIVEN by an Aberrant CRLF2/JAK2 Cooperation - A REPORT FROM the Ibfm-STUDY GROUP SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Hertzberg, Libi; Zeligson, Sharon] Chaim Sheba Med Ctr, Canc Res Ctr, Ramat Gan, Israel. [Vendramini, Elena; Kronnie, Geertruy te] Univ Padua, Padua, Italy. [Cazzaniga, Giovanni] Univ Milano Bicocca, Pediat Clin, M Tettamanti Res Ctr, Monza, Italy. [Schmitz, Maike; Bornhauser, Beat] Univ Zurich, Univ Childrens Hosp, Dept Pediat Oncol, CH-8006 Zurich, Switzerland. [Chalker, Jane] UCL, Inst Child Hlth, London, England. [Iacobucci, Ilaria] Univ Bologna, Dept Hematol Oncol L&A Seragnoli, Bologna, Italy. [Stanulla, Martin] Univ Hosp Schleswig Holstein, Dept Pediat, Kiel, Germany. [Strehl, Sabine] St Anna Childrens Hosp, Children Canc Res Inst, Vienna, Austria. [Harrison, Christine] Newcastle Univ, No Inst Canc Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Yoda, Akinori] Dana Farber Canc Inst, Boston, MA 02115 USA. [Rechavi, Gideon] Chaim Sheba Med Ctr, Canc Res Ctr, IL-52621 Tel Hashomer, Israel. [Borkardt, Arndt] Univ Dusseldorf, Dusseldorf, Germany. [Kempski, Helena] Great Ormond St Hosp Sick Children, Pediat Cytogenet Malignancy Unit, London WC1N 3JH, England. [Domany, Eytan] Weizmann Inst Sci, IL-76100 Rehovot, Israel. RI DOMANY, EYTAN/K-1560-2012; Bornhauser, Beat/M-4437-2014 NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 10 EP 10 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800012 ER PT J AU Rubnitz, J Inaba, H Dahl, G Bowman, WP Taub, J Pui, CH Pounds, S Lacayo, NJ Cao, XY Ribeiro, RC Meshinchi, S Degar, B Airewele, G Onciu, M Coustan-Smith, E Campana, D AF Rubnitz, Jeffrey Inaba, Hiroto Dahl, Gary Bowman, W. Paul Taub, Jeffrey Pui, Ching-Hon Pounds, Stanley Lacayo, Norman J. Cao, Xueyuan Ribeiro, Raul C. Meshinchi, Soheil Degar, Barbara Airewele, Gladstone Onciu, Mihaela Coustan-Smith, Elaine Campana, Dario TI Minimal Residual Disease-Directed Therapy for Childhood Acute Myeloid Leukemia: Results of the AML02 Multicenter Trial SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Rubnitz, Jeffrey; Inaba, Hiroto; Pui, Ching-Hon; Pounds, Stanley; Cao, Xueyuan; Ribeiro, Raul C.; Onciu, Mihaela; Coustan-Smith, Elaine; Campana, Dario] St Jude Childrens Hosp, Memphis, TN 38105 USA. [Dahl, Gary; Lacayo, Norman J.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. [Bowman, W. Paul] Cook Childrens Med Ctr, Ft Worth, TX USA. [Taub, Jeffrey] Childrens Hosp Michigan, Detroit, MI 48201 USA. [Meshinchi, Soheil] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Degar, Barbara] Dana Farber Canc Inst, Boston, MA 02115 USA. [Airewele, Gladstone] Texas Childrens Canc Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 12 EP 13 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800017 ER PT J AU Koreth, J Stevenson, KE Kim, HT McDonough, S Herrera, MI Reynolds, CG Murga, G Ho, VT Cutler, C Armand, P Soiffer, RJ Antin, JH Alyea, EP Ritz, J AF Koreth, John Stevenson, Kristen E. Kim, Haesook T. McDonough, Sean Herrera, Maria I. Reynolds, Carol G. Murga, Gorka Ho, Vincent T. Cutler, Corey Armand, Philippe Soiffer, Robert J. Antin, Joseph H. Alyea, Edwin P., III Ritz, Jerome TI Improved Immune Reconstitution After Bortezomib-Based Acute Graft-Versus-Host Disease Prophylaxis for HLA-Mismatched Unrelated Donor Reduced-Intensity Conditioning Allogeneic Transplantation SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Koreth, John; McDonough, Sean; Herrera, Maria I.; Reynolds, Carol G.; Murga, Gorka; Ho, Vincent T.; Cutler, Corey; Armand, Philippe; Soiffer, Robert J.; Antin, Joseph H.; Alyea, Edwin P., III; Ritz, Jerome] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Stevenson, Kristen E.; Kim, Haesook T.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 25 EP 25 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800049 ER PT J AU Murphy, EJ Emson, C Rassenti, LZ Hayes, G Holochwost, D Hellerstein, M Chiorazzi, N Neuberg, D Kipps, TJ Rai, KR AF Murphy, Elizabeth J. Emson, Claire Rassenti, Laura Z. Hayes, Gregory Holochwost, Daniel Hellerstein, Marc Chiorazzi, Nicholas Neuberg, Donna Kipps, Thomas J. Rai, Kanti R. TI Correlation of Leukemia-Cell Birth Rate Measured by Heavy Water Labeling with Other Prognostic Markers in Early Stage Chronic Lymphocytic Leukemia SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Murphy, Elizabeth J.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA USA. [Emson, Claire; Hayes, Gregory; Holochwost, Daniel; Hellerstein, Marc] KineMed Inc, Emeryville, CA USA. [Rassenti, Laura Z.; Kipps, Thomas J.] Moores UCSD Canc Ctr, CLL Res Consortium, La Jolla, CA USA. [Chiorazzi, Nicholas] NSLIJHS, Feinstein Inst Med Res, Manhasset, NY USA. [Neuberg, Donna] Dana Farber Canc Inst, Boston, MA 02115 USA. [Rai, Kanti R.] N Shore Long Isl Jewish Hlth Syst, Dept Med, New Hyde Pk, NY USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 30 EP 30 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800061 ER PT J AU Saito, T Fujisaki, J Carlson, A Lin, CP Sykes, M AF Saito, Toshiki Fujisaki, Joji Carlson, Alicia Lin, Charles P. Sykes, Megan TI Persistence of Donor-Derived Protein in Host Myeloid Cells After Induced Rejection of Engrafted Allogeneic Bone Marrow Cells SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Saito, Toshiki; Sykes, Megan] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02114 USA. [Fujisaki, Joji; Carlson, Alicia; Lin, Charles P.] Massachusetts Gen Hosp, Ctr Syst Biol, Adv Microscopy Program, Boston, MA 02114 USA. [Fujisaki, Joji; Carlson, Alicia; Lin, Charles P.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 31 EP 32 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800064 ER PT J AU Sanchez-Aguilera, A Lee, YJ Lo Celso, C Brumme, K Lin, CP Scadden, DT Williams, DA AF Sanchez-Aguilera, Abel Lee, Yun-Jung Lo Celso, Cristina Brumme, Kristina Lin, Charles P. Scadden, David T. Williams, David A. TI Regulation of Rho GTPases by the Hematopoietic-Specific Guanine Nucleotide Exchange Factor Vav1 Is Critical for Hematopoietic Stem Cell Retention in the Endosteal Niche and Engraftment. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Sanchez-Aguilera, Abel; Brumme, Kristina; Williams, David A.] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. [Lee, Yun-Jung] Univ Cincinnati, Cincinnati, OH USA. [Lo Celso, Cristina; Scadden, David T.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. [Lin, Charles P.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 37 EP 38 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800081 ER PT J AU Duy, C Yu, JJ Swaminathan, S Nahar, RR Kweon, SM Polo, JM Valls, E Klemm, L Cerchietti, L von Levetzow, G Herzog, S Jumaa, H de Alboran, IM Melnick, A Ye, BH Muschen, M AF Duy, Cihangir Yu, J. Jessica Swaminathan, Srividya Nahar, Rahul R. Kweon, Soo-mi Polo, Jose M. Valls, Ester Klemm, Lars Cerchietti, Leandro von Levetzow, Gregor Herzog, Sebastian Jumaa, Hassan Moreno de Alboran, Ignacio Melnick, Ari Ye, B. Hilda Muschen, Markus TI BCL6 Is Critical for the Development of a Diverse Primary B Cell Repertoire. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Duy, Cihangir; Swaminathan, Srividya; Nahar, Rahul R.; Kweon, Soo-mi; Klemm, Lars; von Levetzow, Gregor; Muschen, Markus] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Leukemia & Lymphoma Program, Los Angeles, CA 90033 USA. [Yu, J. Jessica; Ye, B. Hilda] Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10467 USA. [Polo, Jose M.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Polo, Jose M.] Harvard Univ, Stem Cell Inst, Boston, MA 02115 USA. [Valls, Ester] Weill Cornell Med Coll, Dept Pharmacol, New York, NY USA. [Cerchietti, Leandro; Melnick, Ari] Weill Cornell Med Coll, Div Hematol & Oncol, New York, NY USA. [Herzog, Sebastian; Jumaa, Hassan] Max Planck Inst Immunobiol, Dept Mol Immunol, Freiburg, Germany. [Moreno de Alboran, Ignacio] Ctr Nacl Biotecnol, Cines, Madrid, Spain. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 42 EP 42 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800092 ER PT J AU Ouyang, J Juszczynski, P O'Donnell, E Armant, M Rodig, SJ Takeyama, K Monti, S Rabinovich, G Kutok, JL Ritz, J Shipp, MA AF Ouyang, Jing Juszczynski, Przemyslaw O'Donnell, Evan Armant, Myriam Rodig, Scott J. Takeyama, Kunihiko Monti, Stefano Rabinovich, Gabriel Kutok, Jeffery Lorne Ritz, Jerome Shipp, Margaret A. TI Expression and Targeted Inhibition of the Immunoregulatory Carbohydrate-Binding Lectin, Galectin 1, in EBV-Driven Post-Transplant Lymphoproliferative Disorders. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Ouyang, Jing; Juszczynski, Przemyslaw; O'Donnell, Evan; Takeyama, Kunihiko; Ritz, Jerome; Shipp, Margaret A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Armant, Myriam] Harvard Univ, Sch Med, IDI, Ctr Human Cell Therapy, Boston, MA USA. [Rodig, Scott J.; Kutok, Jeffery Lorne] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Monti, Stefano] Broad Inst, Cambridge, MA USA. [Rabinovich, Gabriel] Consejo Nacl Invest Cient & Tecn, Inst Biol & Med Expt, Buenos Aires, DF, Argentina. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 44 EP 44 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800097 ER PT J AU Kumar, S Flinn, IW Hari, PN Callander, N Noga, SJ Stewart, AK Glass, J Raje, N Rifkin, RM Shi, HL Webb, IJ Richardson, PG Rajkumar, SV AF Kumar, Shaji Flinn, Ian W. Hari, Parameswaran N. Callander, Natalie Noga, Stephen J. Stewart, A. Keith Glass, Jonathan Raje, Noopur Rifkin, Robert M. Shi, Hongliang Webb, Iain J. Richardson, Paul G. Rajkumar, S. Vincent TI Novel Three- and Four-Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Kumar, Shaji; Rajkumar, S. Vincent] Mayo Clin, Rochester, MN USA. [Hari, Parameswaran N.] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Callander, Natalie] Univ Wisconsin, Ctr Comprehens Canc, Madison, WI USA. [Noga, Stephen J.] Sinai Hosp Baltimore, Baltimore, MD USA. [Stewart, A. Keith] Mayo Clin Arizona, Scottsdale, AZ USA. [Glass, Jonathan] LSUHSC, Shreveport, LA USA. [Raje, Noopur] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Rifkin, Robert M.] Rocky Mt Canc Ctr, Denver, CO USA. [Shi, Hongliang; Webb, Iain J.] Millennium Pharmaceut Inc, Cambridge, MA USA. [Richardson, Paul G.] Dana Farber Canc Inst, Boston, MA 02115 USA. RI Kumar, Shaji/A-9853-2008 OI Kumar, Shaji/0000-0001-5392-9284 NR 0 TC 2 Z9 2 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 57 EP 58 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800128 ER PT J AU Jakubowiak, AJ Reece, DE Hofmeister, CC Lonial, S Zimmerman, TM Campagnaro, EL Schlossman, RL Laubach, J Raje, N Anderson, T Griffith, K Hill, M Harvey, C Dollard, AM Wear, S Barrickman, J Tendler, C Esseltine, DL Kelley, SL Kaminski, MS Anderson, KC Richardson, PG AF Jakubowiak, Andrzej J. Reece, Donna E. Hofmeister, Craig C. Lonial, Sagar Zimmerman, Todd M. Campagnaro, Erica L. Schlossman, Robert L. Laubach, Jacob Raje, Noopur Anderson, Tara Griffith, Kent Hill, Melissa Harvey, Colleen Dollard, Akari M. Wear, Sandra Barrickman, Jennifer Tendler, Craig Esseltine, Dixie-Lee Kelley, Susan L. Kaminski, Mark S. Anderson, Kenneth C. Richardson, Paul G. TI Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Jakubowiak, Andrzej J.; Campagnaro, Erica L.; Anderson, Tara; Griffith, Kent; Hill, Melissa; Harvey, Colleen; Kaminski, Mark S.] Univ Michigan, Ann Arbor, MI 48109 USA. [Reece, Donna E.] Univ Hlth Network, Princess Margaret Hosp, Toronto, ON, Canada. [Hofmeister, Craig C.] Ohio State Univ, Columbus, OH 43210 USA. [Lonial, Sagar] Emory Univ, Sch Med, Atlanta, GA USA. [Zimmerman, Todd M.] Univ Chicago, Chicago, IL 60637 USA. [Schlossman, Robert L.; Laubach, Jacob; Anderson, Kenneth C.; Richardson, Paul G.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Raje, Noopur] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Dollard, Akari M.; Wear, Sandra; Kelley, Susan L.] Multiple Myeloma Res Consortium, Norwalk, CT USA. [Barrickman, Jennifer] Celgene Inc, Summit, NJ USA. [Tendler, Craig] Centocor Ortho Biotech, Bridgewater, NJ USA. [Esseltine, Dixie-Lee] Takeda Oncol Co, Millennium Pharmaceut, Cambridge, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 60 EP 60 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800133 ER PT J AU Zhu, JQ Zhu, JH Negri, A Provasi, D Filizola, M Coller, BS Springer, TA AF Zhu, Jieqing Zhu, Jianghai Negri, Ana Provasi, Davide Filizola, Marta Coller, Barry S. Springer, Timothy A. TI Structural, Functional, and Dynamic Characterization of the Binding Site of RUC-1, a Novel alpha IIb-Specific Inhibitor of Integrin alpha IIb beta 3. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Zhu, Jieqing; Zhu, Jianghai; Springer, Timothy A.] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA USA. [Zhu, Jieqing; Zhu, Jianghai; Springer, Timothy A.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Negri, Ana; Provasi, Davide; Filizola, Marta] Mt Sinai Sch Med, Dept Struct & Chem Biol, New York, NY USA. [Coller, Barry S.] Rockefeller Univ, Lab Blood & Vasc Biol, New York, NY 10021 USA. RI Zhu, Jianghai/B-7339-2014 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 68 EP 69 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800152 ER PT J AU Malek, S Ouillette, P Wang, Y Liu, Y Wright, W Roulston, D Dressel, AL Karp, J Bockenstedt, P Al-Zoubi, A Talpaz, M Kujawski, L Liu, Y Shedden, K Shakhan, S Li, C Erba, HP Parkin, B AF Malek, Sami Ouillette, Peter Wang, Yin Liu, Yan Wright, Whitney Roulston, Diane Dressel, Amanda L. Karp, Judith Bockenstedt, Paula Al-Zoubi, Ammar Talpaz, Moshe Kujawski, Lisa Liu, Yang Shedden, Kerby Shakhan, Sajid Li, Cheng Erba, Harry Paul Parkin, Brian TI Genome-Wide Analysis of Microdeletions and Identification of NF1 Inactivation in Acute Myelogenous Leukemia. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Malek, Sami; Ouillette, Peter; Wright, Whitney; Al-Zoubi, Ammar; Talpaz, Moshe; Shedden, Kerby; Shakhan, Sajid; Parkin, Brian] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Karp, Judith] Johns Hopkins Univ, Div Hematol, SOM, Baltimore, MD USA. [Bockenstedt, Paula] Univ Michigan, Ctr Hlth, Ann Arbor, MI 48109 USA. [Li, Cheng] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Li, Cheng] Harvard Univ, Sch Publ Hlth, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Li, Cheng] Dana Farber Canc Inst, Boston, MA 02115 USA. [Erba, Harry Paul] Univ Michigan Hlth Syst, Ann Arbor, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 73 EP 74 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800166 ER PT J AU Payne, E Sun, H Paw, BH Look, AT Khanna-Gupta, A AF Payne, Elspeth Sun, Hong Paw, Barry H. Look, A. Thomas Khanna-Gupta, Arati TI Both p53-Dependent and -Independent Pathways Contribute to Erythroid Dysplasia in a Zebrafish Model for Diamond Blackfan Anemia SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Payne, Elspeth] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Sun, Hong; Khanna-Gupta, Arati] Brigham & Womens Hosp, Boston, MA 02115 USA. [Paw, Barry H.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 78 EP 79 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800178 ER PT J AU Harb, J Neviani, P Huettner, C Marcucci, G Perrotti, D AF Harb, Jason Neviani, Paolo Huettner, Claudia Marcucci, Guido Perrotti, Danilo TI BCR/ABL Dosage Hierarchically and Temporally Influences hnRNP A1, hnRNP K and hnRNP E2 Expression in Hematopoietic Stem and Progenitor Cells SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Perrotti, Danilo] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol, Columbus, OH 43210 USA. [Huettner, Claudia] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 83 EP 84 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800192 ER PT J AU Zhang, B Strauss, AC Chu, S Hoi, YW Snyder, DS Huettner, C Shultz, L Holyoake, TL Bhatia, R AF Zhang, Bin Strauss, Adam Campbell Chu, So Hoi, Yin Wei Snyder, David S. Huettner, Claudia Shultz, Lenny Holyoake, Tessa L. Bhatia, Ravi TI Effective Targeting of Quiescent CML Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Zhang, Bin; Strauss, Adam Campbell; Chu, So; Hoi, Yin Wei; Snyder, David S.; Bhatia, Ravi] City Hope Natl Med Ctr, Duarte, CA 91010 USA. [Huettner, Claudia] Dana Farber Canc Inst, Boston, MA 02115 USA. [Shultz, Lenny] Jackson Lab, Bar Harbor, ME 04609 USA. [Holyoake, Tessa L.] Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 83 EP 83 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800191 ER PT J AU Bernt, K Faber, J Davis, TN Kung, A Armstrong, S AF Bernt, Kathrin Faber, Jorg Davis, Tina N. Kung, Andrew Armstrong, Scott TI DOT1L and Histone H3 Lysine79 Methylation as a Therapeutic Target in Mixed Lineage Leukemia SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Bernt, Kathrin; Faber, Jorg] Childrens Hosp, Dana Farber Canc Inst, Div Pediat Hematol Oncol, Boston, MA 02115 USA. [Davis, Tina N.; Kung, Andrew] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Armstrong, Scott] Harvard Univ, Stem Cell Inst, Dana Farber Canc Inst, Childrens Hosp Boston,Div Pediat Hematol Oncol, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 93 EP 93 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800213 ER PT J AU Raaijmakers, MHGP Mukherjee, S Guo, SQ Kobayashi, T Schoonmaker, J Aung, Z Ebert, BL Al-Shahrour, F Hasserjian, RP Vallet, S Scadden, E Lin, CP Scadden, DT AF Raaijmakers, Marc H. G. P. Mukherjee, Siddhartha Guo, Shangqin Kobayashi, Tatsuya Schoonmaker, Jesse Aung, Zinmar Ebert, Benjamin L. Al-Shahrour, Fatima Hasserjian, Robert P. Vallet, Sonia Scadden, Edward Lin, Charles P. Scadden, David T. TI Niche Induced Myelodysplasia and Secondary Hematopoietic Neoplasia Caused by Deletion of Dicer1 in Osteoprogenitor Cells SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Raaijmakers, Marc H. G. P.; Guo, Shangqin; Aung, Zinmar; Scadden, Edward; Scadden, David T.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. [Raaijmakers, Marc H. G. P.; Guo, Shangqin; Aung, Zinmar; Scadden, Edward] Harvard Univ, Sch Med, Boston, MA USA. [Kobayashi, Tatsuya] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. [Ebert, Benjamin L.; Al-Shahrour, Fatima] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA. [Vallet, Sonia] Dana Farber Canc Inst, Boston, MA 02115 USA. [Lin, Charles P.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Schoonmaker, Jesse] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Regenerat Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 105 EP 106 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800248 ER PT J AU Bai, XY Lee, J LeBlanc, J Sessa, A Yang, ZA Jiang, H Lin, S Zon, LI AF Bai, Xiaoying Lee, Joseph LeBlanc, Jocelyn Sessa, Anna Yang, Zhongan Jiang, Hong Lin, Shuo Zon, Leonard I. TI The Transcriptional Intermediary Factor TIF1 gamma Controls Erythroid Cell Fate by Specifically Regulating Transcriptional Elongation SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Bai, Xiaoying] Childrens Hosp Boston, HHMI, Bston, MA USA. [Yang, Zhongan; Jiang, Hong; Lin, Shuo] Univ Calif Los Angeles, Los Angeles, CA USA. [Zon, Leonard I.] Childrens Hosp, Stem Cell Program, Boston, MA 02115 USA. [Zon, Leonard I.] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. [Zon, Leonard I.] Harvard Stem Cell Inst, Howard Hughes Med Inst, Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 108 EP 108 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800255 ER PT J AU Bellucci, R Nguyen, HN Martin, A Schinzel, AC Heinrichs, S Hahn, WC Ritz, J AF Bellucci, Roberto Nguyen, Hong-Nam Martin, Allison Schinzel, Anna C. Heinrichs, Stefan Hahn, William C. Ritz, Jerome TI NOVEL Pathways Modulate TUMOR CELL Susceptibility to NK CELLS SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Ritz, Jerome] Harvard Univ, Sch Med, Dana Farber Canc Inst, Canc Vaccine Ctr,Div Hematol Malignancies, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 117 EP 118 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800278 ER PT J AU Hideshima, T Mitsiades, CS Ikeda, H Chauhan, D Raje, N Gorgun, G Fulciniti, M Cirstea, D Perron, G Santo, L Hideshima, A Podar, K Munshi, NC Richardson, P Carrasco, DR Anderson, KC AF Hideshima, Teru Mitsiades, Constantine S. Ikeda, Hiroshi Chauhan, Dharminder Raje, Noopur Gorgun, Gullu Fulciniti, Mariateresa Cirstea, Diana Perron, Giulia Santo, Loredana Hideshima, Ayaka Podar, Klaus Munshi, Nikhil C. Richardson, Paul Carrasco, Daniel R. Anderson, Kenneth C. TI Bcl6 as a Novel Therapeutic Target in Multiple Myeloma (MM) SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Hideshima, Teru; Mitsiades, Constantine S.; Ikeda, Hiroshi; Chauhan, Dharminder; Gorgun, Gullu; Fulciniti, Mariateresa; Cirstea, Diana; Perron, Giulia; Santo, Loredana; Hideshima, Ayaka; Podar, Klaus; Munshi, Nikhil C.; Richardson, Paul; Carrasco, Daniel R.; Anderson, Kenneth C.] Harvard Univ, Boston VA Canc Healthcare Syst, Jerome Lipper Multiple Myeloma Dis Ctr, Dana Farber Canc Inst,Dept Med Oncol,Sch Med, Boston, MA USA. [Raje, Noopur] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 124 EP 124 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800296 ER PT J AU Feng, R Huang, X Coulton, L De Raeve, H DiLiberto, M Ely, S Xiao, G Luo, M Menu, E Croucher, P Roodman, GD Vanderkerken, K Chen-Kiang, S Lentzsch, S AF Feng, Rentian Huang, Xiangao Coulton, Les De Raeve, Hendrik DiLiberto, Maurizio Ely, Scott Xiao, Guozhi Luo, Min Menu, Eline Croucher, Peter Roodman, G. David Vanderkerken, Karin Chen-Kiang, Selina Lentzsch, Suzanne TI Targeting CDK4/CDK6 Impairs Osteoclast Progenitor Pool Expansion and Blocks Osteolytic Lesion Development in Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Feng, Rentian; Xiao, Guozhi; Luo, Min; Roodman, G. David; Lentzsch, Suzanne] Univ Pittsburgh, Inst Canc, Dept Med, Div Hematol Oncol, Pittsburgh, PA USA. [Huang, Xiangao; DiLiberto, Maurizio; Ely, Scott] Weill Cornell Med Coll, Dept Pathol, New York, NY USA. [Coulton, Les] Univ Sheffield, Sch Med, Dept Musculoskeletal Sci, Sheffield, S Yorkshire, England. [De Raeve, Hendrik] UZ Brussel, Dept Pathol, Brussels, Belgium. [Menu, Eline; Vanderkerken, Karin] Vrije Univ Brussel, Myeloma Ctr Brussels, Dept Hematol & Immunol, Brussels, Belgium. [Croucher, Peter] Univ Sheffield, Sch Med, Dept Human Metab, Sheffield, S Yorkshire, England. [Roodman, G. David] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RI Vanderkerken, Karin/I-3513-2013; Menu, Eline/K-2856-2015 OI Menu, Eline/0000-0002-0805-6581 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 125 EP 126 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800299 ER PT J AU Raab, MS Breitkreutz, I Rebacz, B Larsen, TO Wagner, L Hayden, P Ho, AD Clausen, MH Goldschmidt, H Anderson, KC Kreamer, A AF Raab, Marc S. Breitkreutz, Iris Rebacz, Blanka Larsen, Thomas O. Wagner, Ludmila Hayden, Patrick Ho, Anthony D. Clausen, Mads H. Goldschmidt, Hartmut Anderson, Kenneth C. Kreamer, Alwin TI Centrosomal Clustering - a Novel Therapeutic Target for Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Raab, Marc S.; Rebacz, Blanka; Wagner, Ludmila; Kreamer, Alwin] Univ Heidelberg, German Canc Res Ctr, CCU Mol Hematol Oncol, Heidelberg, Germany. [Raab, Marc S.; Rebacz, Blanka; Wagner, Ludmila; Goldschmidt, Hartmut; Kreamer, Alwin] Univ Heidelberg, Dept Internal Med 5, Heidelberg, Germany. [Breitkreutz, Iris; Goldschmidt, Hartmut] Natl Ctr Tumor Dis NCT, Heidelberg, Germany. [Breitkreutz, Iris; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Larsen, Thomas O.] Tech Univ Denmark, Bioctr, Copenhagen, Denmark. [Hayden, Patrick] Galway Univ Hosp, Dept Haematol Blood & Tissue Estab, Galway, Ireland. [Clausen, Mads H.] Univ Denmark, Dept Chem, Lyngby, Denmark. RI Clausen, Mads/A-9656-2015 OI Clausen, Mads/0000-0001-9649-1729 NR 0 TC 1 Z9 1 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 126 EP 126 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800301 ER PT J AU Richardson, P Siegel, D Baz, R Kelley, SL Munshil, NC Sullivan, D McBride, L Doss, D Larkins, G Jacques, C Donaldson, A Anderson, KC AF Richardson, Paul Siegel, David Baz, Rachid Kelley, Susan L. Munshil, Nikhil C. Sullivan, Daniel McBride, Laura Doss, Deborah Larkins, Gail Jacques, Christian Donaldson, Arlene Anderson, Kenneth C. TI A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Richardson, Paul; Munshil, Nikhil C.; Doss, Deborah; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Siegel, David; McBride, Laura] Hackensack Univ, Med Ctr, Hackensack, NJ USA. [Baz, Rachid; Sullivan, Daniel] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [Kelley, Susan L.] Multiple Myeloma Res Consortium, Norwalk, CT USA. [Larkins, Gail; Jacques, Christian; Donaldson, Arlene] Celgene Corp, Summit, NJ USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 126 EP 127 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800302 ER PT J AU Siegel, D Weber, DM Mitsiades, CS Dimopoulos, MA Harousseau, JL Rizvi, S Howe, J Reiser, D Byrne, C Anderson, KC Richardson, P AF Siegel, David Weber, Donna M. Mitsiades, Constantine S. Dimopoulos, Meletios A. Harousseau, Jean-Luc Rizvi, Syed Howe, Jason Reiser, David Byrne, Catriona Anderson, Kenneth C. Richardson, Paul TI Combined Vorinostat, Lenalidomide and Dexamethasone Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase I Study SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Siegel, David] Hackensack Univ, Med Ctr, Hackensack, NJ USA. [Weber, Donna M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Mitsiades, Constantine S.; Anderson, Kenneth C.; Richardson, Paul] Dana Farber Canc Inst, Boston, MA 02115 USA. [Dimopoulos, Meletios A.] Univ Athens, Sch Med, Alexandra Hosp, Dept Clin Therapeut, Athens 11528, Greece. [Harousseau, Jean-Luc] Ctr Rene Gauducheau, St Herblain, France. [Rizvi, Syed; Howe, Jason; Reiser, David] Merck & Co Inc, Upper Gwynedd, PA USA. [Byrne, Catriona] Celgene Corp, Summit, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 129 EP 129 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800306 ER PT J AU Vrooman, LM Neuberg, DS Stevenson, KE Supko, JG Sallan, SE Silverman, LB AF Vrooman, Lynda M. Neuberg, Donna S. Stevenson, Kristen E. Supko, Jeffrey G. Sallan, Stephen E. Silverman, Lewis B. TI Dexamethasone and Individualized Asparaginase Dosing Are Each Associated with Superior Event-Free Survival in Childhood Acute Lymphoblastic Leukemia: Results From DFCI-ALL Consortium Protocol 00-01 SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Vrooman, Lynda M.; Neuberg, Donna S.; Stevenson, Kristen E.; Sallan, Stephen E.; Silverman, Lewis B.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Supko, Jeffrey G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 6 Z9 6 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 136 EP 136 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800322 ER PT J AU Sandmaier, BM Maris, M Storer, B Vindelov, L Langston, A Wade, JC Bethge, WA Pulsipher, M Lange, T Chauncey, T Petersen, F Hubel, K Woolfrey, A Flowers, MED Maloney, DG Storb, RF AF Sandmaier, Brenda M. Maris, Michael Storer, Barry Vindelov, Lars Langston, Amelia Wade, James C. Bethge, Wolfgang A. Pulsipher, Michael Lange, Thoralf Chauncey, Thomas Petersen, Finn Huebel, Kai Woolfrey, Ann Flowers, Mary E. D. Maloney, David G. Storb, Rainer F. TI A Randomized 3-Arm Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute Graft-Versus-Host Disease (GVHD) After Unrelated Donor Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Sandmaier, Brenda M.; Storer, Barry; Chauncey, Thomas; Woolfrey, Ann; Flowers, Mary E. D.; Maloney, David G.; Storb, Rainer F.] Univ Washington, Fred Hutchinson Canc Res Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Maris, Michael] Rocky Mt Canc Ctr, Denver, CO USA. [Vindelov, Lars] Univ Copenhagen, Rigshosp, DK-2100 Copenhagen, Denmark. [Langston, Amelia] Emory Univ, Atlanta, GA 30322 USA. [Wade, James C.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Bethge, Wolfgang A.] Univ Tubingen, Med Ctr, Tubingen, Germany. [Pulsipher, Michael] Univ Utah, Med Ctr, Salt Lake City, UT USA. [Lange, Thoralf] Univ Leipzig, Leipzig, Germany. [Petersen, Finn] LDS Hosp, Salt Lake City, UT USA. [Huebel, Kai] Univ Cologne, Cologne, Germany. NR 0 TC 4 Z9 4 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 147 EP 147 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800349 ER PT J AU Roti, G Ross, KN Ferrando, AA Blacklow, SC Aster, J Stegmaier, K AF Roti, Giovanni Ross, Kenneth N. Ferrando, Adolfo A. Blacklow, Stephen C. Aster, Jon Stegmaier, Kimberly TI Expression-Based Screen Identifies the Calcium Channel Antagonist Bepridil as a Notch1 Modulator in T-ALL SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Roti, Giovanni; Stegmaier, Kimberly] Dana Farber Canc Inst, Boston, MA 02115 USA. [Ross, Kenneth N.; Stegmaier, Kimberly] Harvard Univ, MIT, Broad Inst, Canc Program, Cambridge, MA 02139 USA. [Ferrando, Adolfo A.] Columbia Univ, Inst Canc Genet, New York, NY USA. [Blacklow, Stephen C.; Aster, Jon] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 154 EP 155 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800367 ER PT J AU Goessling, W Guan, X Dovey, M Stegner, J Armant, M Schlaeger, T Zon, LI North, T AF Goessling, Wolfram Guan, Xiao Dovey, Michael Stegner, Joseph Armant, Myriam Schlaeger, Thorsten Zon, Leonard I. North, Trista TI Human Umbilical Cord Blood Stem Cell Function Is Augmented by Exposure to Prostaglandin E2 SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Goessling, Wolfram] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA. [Goessling, Wolfram] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Gastroenterol, Boston, MA 02115 USA. [Guan, Xiao; Schlaeger, Thorsten; Zon, Leonard I.] Harvard Univ, Sch Med, Childrens Hosp, Stem Cell Program, Boston, MA 02115 USA. [Dovey, Michael; North, Trista] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathobiol, Boston, MA 02115 USA. [Stegner, Joseph; Armant, Myriam] Harvard Univ, Sch Med, Immune Dis Inst, Ctr Human Cell Therapy, Boston, MA 02115 USA. [Zon, Leonard I.] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. [Zon, Leonard I.] Harvard Stem Cell Inst, Howard Hughes Med Inst, Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 155 EP 156 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800370 ER PT J AU Kohno, K Lino, T Ito, K Mizuno, S Sicinski, P Akashi, K AF Kohno, Kentaro Lino, Tadafumi Ito, Kyoko Mizuno, Shin-ichi Sicinski, Piotr Akashi, Koichi TI Cyclin A2 Plays a Critical Role Not Only in Self-Renewal of Hematopoietic Stem Cells, but Also in Non-Self-Renewing Proliferation of Lymphoid progenitors SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Sicinski, Piotr] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 159 EP 160 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800382 ER PT J AU Rodriguez, S Mumaw, C LoCelso, C Sarmento, L Nakayama, K Carlesso, N AF Rodriguez, Sonia Mumaw, Christen LoCelso, Cristina Sarmento, Leonor Nakayama, Keiichi Carlesso, Nadia TI Differential Impact of the SKP2/P27 Pathway On HSC Pool Size and Myeloid Progenitor Differentiation SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [LoCelso, Cristina] Massachusetts Gen Hosp, Ctr Regenerat Med & Technol, Boston, MA 02114 USA. [Carlesso, Nadia] Indiana Univ, Sch Med, Canc Res Inst, Indianapolis, IN USA. [Sarmento, Leonor] Gulbenkian Inst Sci, Oeiras, Portugal. [Nakayama, Keiichi] Kyushu Univ, Fukuoka 812, Japan. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 159 EP 159 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800381 ER PT J AU Cornejo, MG Sykes, SM Lo Celso, C Tothova, Z Aster, J DePinho, RA Scadden, DT Gilliland, DG Mercher, T AF Cornejo, Melanie G. Sykes, Stephen M. Lo Celso, Cristina Tothova, Zuzana Aster, Jon DePinho, Ronald A. Scadden, David T. Gilliland, D. Gary Mercher, Thomas TI A Regulatory Network Between Notch and AKT Signaling Pathways Differentially Controls Megakaryocyte Development From Hematopoietic Stem or Committed Progenitor Cells SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Cornejo, Melanie G.; Sykes, Stephen M.; Tothova, Zuzana; Aster, Jon] Harvard Univ, Brigham & Womens Hosp, Div Hematol, Dept Med,Sch Med, Boston, MA 02115 USA. [Lo Celso, Cristina; Scadden, David T.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. [DePinho, Ronald A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Gilliland, D. Gary] Merck Res Labs, Boston, MA USA. [Mercher, Thomas] Univ Paris 05, INSERM, EMI0210, Paris, France. RI Mercher, Thomas/J-2446-2014 OI Mercher, Thomas/0000-0003-1552-087X NR 0 TC 1 Z9 1 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 160 EP 161 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800385 ER PT J AU Wang, YZ Krivtsov, AV Sinha, AU North, T Goessling, W Zon, LI Armstrong, S AF Wang, Yingzi Krivtsov, Andrei V. Sinha, Amit U. North, Trista Goessling, Wolfram Zon, Leonard I. Armstrong, Scott TI beta-Catenin Determines Developmental Stage Specific Transformation by Hox Genes SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Wang, Yingzi; Krivtsov, Andrei V.; Sinha, Amit U.] Harvard Univ, Sch Med, Childrens Hosp, Dept Hematol Oncol, Boston, MA USA. [North, Trista] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA. [Goessling, Wolfram] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA. [Zon, Leonard I.] Childrens Hosp, Stem Cell Program, Boston, MA 02115 USA. [Zon, Leonard I.] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. [Zon, Leonard I.; Armstrong, Scott] Harvard Stem Cell Inst, Howard Hughes Med Inst, Dana Farber Canc Inst, Boston, MA USA. [Armstrong, Scott] Harvard Univ, Sch Med, Childrens Hosp, Div Hematol Oncol,Dept Pediat Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 161 EP 161 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800386 ER PT J AU Trowbridge, JJ Snow, JW Kim, J Orkin, SH AF Trowbridge, Jennifer J. Snow, Jonathan W. Kim, Jonghwan Orkin, Stuart H. TI DNA Methyltransferase 1 Is Essential for and Uniquely Regulates Hematopoietic Stem and Progenitor Cells SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Trowbridge, Jennifer J.; Orkin, Stuart H.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Snow, Jonathan W.; Kim, Jonghwan] Childrens Hosp, Dept Hematol Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 163 EP 163 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800393 ER PT J AU LaCasce, A Vandergrift, JL Rodriguez, MA Crosby, AL Lepisto, EM Czuczman, MS Nademanee, AP Blayney, DW Gordon, LI Millenson, M Vanderplas, A Abel, GA Zelenetz, AD Friedberg, JW AF LaCasce, Ann Vandergrift, Jonathan L. Rodriguez, Maria A. Crosby, Allison L. Lepisto, Eva M. Czuczman, Myron S. Nademanee, Auayporn P. Blayney, Douglas W. Gordon, Leo I. Millenson, Michael Vanderplas, Ann Abel, Gregory A. Zelenetz, Andrew D. Friedberg, Jonathan W. TI R-CHOP, Followed by High Dose Therapy and Autologous Stem Cell Rescue (HDT/ASCR), and R-Hypercvad Have Equivalent Progression-Free Survival and Are Superior to R-CHOP Alone in Younger Patients with Mantle Cell Lymphoma: a Comparative Effectiveness Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma Outcomes Database Project SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [LaCasce, Ann; Crosby, Allison L.; Abel, Gregory A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Vandergrift, Jonathan L.; Lepisto, Eva M.] Natl Comprehens Canc Network, Ft Washington, PA USA. [Rodriguez, Maria A.] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA. [Czuczman, Myron S.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Nademanee, Auayporn P.; Vanderplas, Ann] City Hope Natl Med Ctr, Duarte, CA 91010 USA. [Blayney, Douglas W.] Univ Michigan, Ctr Canc, Ann Arbor, MI 48109 USA. [Gordon, Leo I.] Northwestern Univ, Dept Med, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA. [Millenson, Michael] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Zelenetz, Andrew D.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Friedberg, Jonathan W.] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 167 EP 168 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800404 ER PT J AU Azab, AK Quang, P Azab, F Roccaro, AM Sacco, A Runnels, JM Ngo, HT Melhem, MR Maiso, P Anderson, KC Lin, CP Ghobrial, IM AF Azab, Abdel Kareem Quang, Phong Azab, Feda Roccaro, Aldo M. Sacco, Antonio Runnels, Judith M. Ngo, Hai T. Melhem, Molly R. Maiso, Patricia Anderson, Kenneth C. Lin, Charles P. Ghobrial, Irene M. TI Role of Hypoxia in the Progression and Dissemination of Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Azab, Abdel Kareem; Quang, Phong; Azab, Feda; Roccaro, Aldo M.; Sacco, Antonio; Runnels, Judith M.; Ngo, Hai T.; Melhem, Molly R.; Maiso, Patricia; Anderson, Kenneth C.; Ghobrial, Irene M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Lin, Charles P.] Massachusetts Gen Hosp, Adv Microscopy Program, Ctr Syst Biol, Boston, MA 02114 USA. [Lin, Charles P.] Massachusetts Gen Hosp, Wellman Ctr Photonmed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 175 EP 175 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800422 ER PT J AU Richardson, P Hofmeister, C Jakubowiak, A Zimmerman, TM Spear, MA Palladino, MA Longenecker, AM Kelly, SL Neuteboom, S Cropp, GF Lloyd, GK Hannah, AL Anderson, KC AF Richardson, Paul Hofmeister, Craig Jakubowiak, Andrzej Zimmerman, Todd M. Spear, Matthew A. Palladino, Michael A. Longenecker, Angie M. Kelly, Susan L. Neuteboom, Saskia Cropp, Gillian F. Lloyd, G. Kenneth Hannah, Alison L. Anderson, Kenneth C. TI Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM) SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Richardson, Paul; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Hofmeister, Craig] Ohio State Univ, Med Ctr, Div Hematol, Columbus, OH 43210 USA. [Jakubowiak, Andrzej] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Spear, Matthew A.; Palladino, Michael A.; Longenecker, Angie M.; Cropp, Gillian F.; Lloyd, G. Kenneth; Hannah, Alison L.] Nereus Pharmaceut Inc, San Diego, CA USA. [Zimmerman, Todd M.] Univ Chicago, Chicago, IL 60637 USA. [Kelly, Susan L.] Multiple Myeloma Res Fdn, Norwalk, CT USA. [Neuteboom, Saskia] Nereus Pharmaceut Inc, San Diego, CA USA. NR 0 TC 4 Z9 4 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 179 EP 179 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800432 ER PT J AU Tanaka, M Butler, M Ansen, S Imataki, O Berezovskaya, A Nadler, L Hirano, N AF Tanaka, Makito Butler, Marcus Ansen, Sascha Imataki, Osamu Berezovskaya, Alla Nadler, Lee Hirano, Naoto TI Artificial APC-Based Generation of IL-21 Secreting CD4(+) T Cells That Can Provide Help to CD8(+) T Cells SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting and Exposition of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Tanaka, Makito; Butler, Marcus; Ansen, Sascha; Imataki, Osamu; Berezovskaya, Alla; Nadler, Lee; Hirano, Naoto] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 193 EP 193 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800467 ER PT J AU Brill, A Fuchs, T Yang, J Kollnberger, M Chauhan, AK Massberg, S Wagner, DD AF Brill, Alexander Fuchs, Tobias Yang, Janie Koellnberger, Maria Chauhan, Anil K. Massberg, Steffen Wagner, Denisa D. TI VWF-Mediated Platelet Adhesion is Required for Deep Vein Thrombosis in a Flow Restriction Model SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Brill, Alexander; Fuchs, Tobias; Chauhan, Anil K.; Wagner, Denisa D.] Childrens Hosp Boston, Immune Dis Inst, Program Cellular & Mol Med, Boston, MA USA. [Brill, Alexander; Fuchs, Tobias; Yang, Janie; Chauhan, Anil K.; Wagner, Denisa D.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Koellnberger, Maria; Massberg, Steffen] Tech Univ Munich, Deutsch Herzzentrum, Munich, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 195 EP 195 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800474 ER PT J AU Vinciguerra, P Godinho, S Parmar, K Pellman, D D'Andrea, A AF Vinciguerra, Patrizia Godinho, Susana Parmar, Kalindi Pellman, David D'Andrea, Alan TI Cytokinesis Failure in Fanconi Anemia Pathway Deficient Murine Hematopoietic Stem Cells. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Vinciguerra, Patrizia; Parmar, Kalindi; D'Andrea, Alan] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Godinho, Susana; Pellman, David] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 204 EP 205 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800496 ER PT J AU Mahindra, A Vesole, D Kalaycio, ME Vela-Ojeda, J Shrestha, S Zhang, MJ Dispenzieri, A Milone, GA Lonial, S Hari, PN AF Mahindra, Anuj Vesole, David Kalaycio, Matt E. Vela-Ojeda, Jorge Shrestha, Smriti Zhang, Mei-Jie Dispenzieri, Angela Milone, Gustavo A. Lonial, Sagar Hari, Parameswaran N. TI Autologous Hematopoietic Stem Cell Transplantation (HCT) is a Safe and Effective Treatment for Primary Plasma Cell Leukemia: The CIBMTR Experience SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Mahindra, Anuj] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kalaycio, Matt E.] Cleveland Clin Fdn, Cleveland, OH 44195 USA. [Lonial, Sagar] Emory Univ, Sch Med, Atlanta, GA USA. [Milone, Gustavo A.] Angelica Ocampo Fundaleu, Buenos Aires, DF, Argentina. [Vesole, David] John Theurer Canc Ctr, Hackensack, NJ USA. [Shrestha, Smriti; Zhang, Mei-Jie; Hari, Parameswaran N.] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Dispenzieri, Angela] Mayo Clin, Rochester, MN USA. [Vela-Ojeda, Jorge] Hosp Especialidades Ctr Med Nacl La Raza, IMSS, Mexico City, DF, Mexico. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 222 EP 222 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800533 ER PT J AU Ghobrial, IM Gertz, MA LaPlant, B Camoriano, J Hayman, SR Lacy, MQ Chuma, S Sheehy, P Harris, B Leduc, R Rourke, M Ansell, SM DeAngelo, DJ Dispenzieri, A Bergsagel, L Reeder, CB Anderson, KC Richardson, P Treon, S Witzig, TE AF Ghobrial, Irene M. Gertz, Morie A. LaPlant, Betsy Camoriano, John Hayman, Suzanne R. Lacy, Martha Q. Chuma, Stacey Sheehy, Patricia Harris, Brianna Leduc, Renee Rourke, Meghan Ansell, Stephen M. DeAngelo, Daniel J. Dispenzieri, Angela Bergsagel, Leif Reeder, Craig B. Anderson, Kenneth C. Richardson, Paul Treon, Steven Witzig, Thomas E. TI A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Sheehy, Patricia; DeAngelo, Daniel J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Ansell, Stephen M.; Witzig, Thomas E.] Mayo Clin, Coll Med, Rochester, MN USA. [Camoriano, John; Bergsagel, Leif; Reeder, Craig B.] Mayo Clin, Scottsdale, AZ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 244 EP 244 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800588 ER PT J AU Shammas, MA Loiseau, H Li, C Buon, L Amin, SB Shah, P Ben, K Fulciniti, M Thai, YT Richardson, P Minvielle, S Anderson, KC Munshi, NC AF Shammas, Masood A. Loiseau, Herve Li, Cheng Buon, Leutz Amin, Samir B. Shah, Parantu Ben, King Fulciniti, Mariateresa Thai, Yu-Tzu Richardson, Paul Minvielle, Stephane Anderson, Kenneth C. Munshi, Nikhil C. TI Evolution of Genomic Changes and Their Significance in Myeloma SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Shammas, Masood A.] Dana Farber Canc Inst, W Roxbury, MA USA. [Shammas, Masood A.] Boston VA Healthcare Syst, W Roxbury, MA USA. [Li, Cheng; Shah, Parantu] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Li, Cheng; Shah, Parantu] Harvard Univ, Sch Publ Hlth, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Amin, Samir B.; Munshi, Nikhil C.] Harvard Univ, Sch Med, Boston VA Healthcare Syst, Dana Farber Canc Inst, Boston, MA 02115 USA. [Ben, King; Thai, Yu-Tzu] Harvard Univ, Sch Med, Jerome Lipper Multiple Myeloma Ctr, Dana Farber Canc Inst, Boston, MA 02115 USA. [Fulciniti, Mariateresa] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Minvielle, Stephane] Hop Nantes, Dept Hematol, Nantes, France. RI Minvielle, Stephane/K-8251-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 250 EP 251 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800606 ER PT J AU Chauhan, D Tian, Z Nicholson, B Zhou, B Hideshima, T Munshi, N Richardson, P Anderson, KC AF Chauhan, Dharminder Tian, Ze Nicholson, Benjamin Zhou, Bin Hideshima, Teru Munshi, Nikhil Richardson, Paul Anderson, Kenneth C. TI Deubiquitylating Enzyme USP-7, a Novel Therapeutic Target in Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Chauhan, Dharminder; Tian, Ze; Hideshima, Teru; Munshi, Nikhil; Richardson, Paul; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Nicholson, Benjamin] Progenra Inc, Malvern, PA USA. [Zhou, Bin] Childrens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 2 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 252 EP 253 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800611 ER PT J AU Tai, YT de Weers, M Li, XF Song, WH Nahar, S Bakker, JM Vink, T Jacobs, D Oomen, L Bleeker, WK Munshi, NC van de Winkel, JGJ Parren, PWHI Richardson, P Anderson, KC AF Tai, Yu-Tzu de Weers, Michel Li, Xian-Feng Song, Weihua Nahar, Sabikun Bakker, Joost M. Vink, Tom Jacobs, Danielle Oomen, Lukas Bleeker, Wim K. Munshi, Nikhil C. van de Winkel, Jan G. J. Parren, Paul W. H. I. Richardson, Paul Anderson, Kenneth C. TI Daratumumab, a Novel Potent Human Anti-CD38 Monoclonal Antibody, Induces Significant Killing of Human Multiple Myeloma Cells: Therapeutic Implication SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston VA Canc Healthcare Syst, Boston, MA 02115 USA. [de Weers, Michel; Bakker, Joost M.; Vink, Tom; Jacobs, Danielle; Oomen, Lukas; Bleeker, Wim K.; van de Winkel, Jan G. J.] Genmab, Utrecht, Netherlands. [van de Winkel, Jan G. J.] UMCU, Utrecht, Netherlands. [Parren, Paul W. H. I.] Genmab BV, Utrecht, Netherlands. NR 0 TC 0 Z9 0 U1 1 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 252 EP 252 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800609 ER PT J AU Tai, YT Muchhal, U Li, XF Nahar, S Song, WH Horton, H Nguyen, H Karki, S Desjarlais, J Munshi, NC Richardson, P Anderson, KC AF Tai, Yu-Tzu Muchhal, Umesh Li, Xian-Feng Nahar, Sabikun Song, Weihua Horton, Holly Nguyen, Hanh Karki, Sher Desjarlais, John Munshi, Nikhil C. Richardson, Paul Anderson, Kenneth C. TI XmAb (R) 5592 Fc-Engineered Humanized Anti-HM1.24 Monoclonal Antibody Has Potent in Vitro and In Vivo Efficacy against Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston VA Canc Healthcare Syst, Boston, MA 02115 USA. [Muchhal, Umesh; Horton, Holly; Nguyen, Hanh; Karki, Sher; Desjarlais, John] Xencor Inc, Monrovia, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 252 EP 252 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800610 ER PT J AU Singh, AV Bandi, M Aujay, M Demo, S Hideshima, T Munshi, NC Richardson, PG Chauhan, D Anderson, KC AF Singh, Ajita V. Bandi, Madhavi Aujay, Monette Demo, Susan Hideshima, Teru Munshi, Nikhil C. Richardson, Paul G. Chauhan, Dharminder Anderson, Kenneth C. TI PR-924, a Selective Inhibitor of the Immunoproteasome Subunit LMP-7 Blocks Multiple Myeloma Cell Growth Both in Vitro and In Vivo SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston VA Healthcare Syst, Boston, MA 02115 USA. [Aujay, Monette; Demo, Susan] Proteolix Inc, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 253 EP 253 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800613 ER PT J AU Steensma, DP Dakhil, SR Dalton, R Kahanic, SP Kugler, JW Stella, PJ Rowland, KM Novotny, PJ Sloan, JA Loprinzi, CL AF Steensma, David P. Dakhil, Shaker R. Dalton, Robert Kahanic, Stephen P. Kugler, John W. Stella, Philip J. Rowland, Kendrith M., Jr. Novotny, Paul J. Sloan, Jeff A. Loprinzi, Charles L. TI A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation On the Erythropoietic Response to Darbepoetin Alfa for Patients with Chemotherapy-Associated Anemia: A Study of the Mayo Clinic Cancer Research Consortium (MCCRC) SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Steensma, David P.] Dana Farber Canc Inst, Dept Hematol Malignancies, Boston, MA 02115 USA. [Dakhil, Shaker R.] Canc Ctr Kansas PA, Wichita, KS USA. [Dalton, Robert] Immanuel St Josephs Mayo Hlth Syst, Mankato, MN USA. [Kahanic, Stephen P.] Siouxland Hematol Oncol Assoc, Sioux City, IA USA. [Kugler, John W.] Illinois Canc Care, Peoria, IL USA. [Stella, Philip J.] St Joseph Mercy, Ypsilanti, MI USA. [Rowland, Kendrith M., Jr.] Carle Clin Danville Vermil, Danville, PA USA. [Novotny, Paul J.; Sloan, Jeff A.] Mayo Clin, Canc Ctr Stat, Rochester, MN USA. [Loprinzi, Charles L.] Mayo Clin, Dept Oncol, Rochester, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 261 EP 261 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800631 ER PT J AU Stone, RM Fischer, T Paquette, R Schiller, G Schiffer, CA Ehninger, G Cortes, J Kantarjian, HM DeAngelo, DJ Huntsman-Labed, A Dutreix, C Rai, S Giles, F AF Stone, Richard M. Fischer, Thomas Paquette, Ronald Schiller, Gary Schiffer, Charles A. Ehninger, Gerhard Cortes, Jorge Kantarjian, Hagop M. DeAngelo, Daniel J. Huntsman-Labed, Alice Dutreix, Catherine Rai, Sumita Giles, Frank TI A Phase 1b Study of Midostaurin (PKC412) in Combination with Daunorubicin and Cytarabine Induction and High-Dose Cytarabine Consolidation in Patients Under Age 61 with Newly Diagnosed De Novo Acute Myeloid Leukemia: Overall Survival of Patients Whose Blasts Have FLT3 Mutations Is Similar to Those with Wild-Type FLT3 SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Stone, Richard M.; DeAngelo, Daniel J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Fischer, Thomas] Univ Hosp, Magdeburg, Germany. [Paquette, Ronald] Ronald Reagan UCLA, Med Ctr, Los Angeles, CA USA. [Schiller, Gary] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. [Schiffer, Charles A.] Wayne State Univ, Barbara Ann Karmanos Canc Ctr, Detroit, MI USA. [Ehninger, Gerhard] Univ Hosp, Med Clin 1, Dresden, Germany. [Cortes, Jorge] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA. [Huntsman-Labed, Alice] Novartis Oncol, Basel, Switzerland. [Rai, Sumita] Novartis Oncol, E Hanover, NJ USA. [Giles, Frank] Canc Therapy & Res Ctr S Texas, Inst Drug Dev, San Antonio, TX 78229 USA. NR 0 TC 4 Z9 4 U1 0 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 263 EP 263 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800635 ER PT J AU Horan, J Logan, BR Agovi, MA Lazarus, HM Bacigalupo, A Ballen, K Martino, R Juckett, MB Khoury, HJ Bredeson, C Gupta, V Smith, FO Hale, G Carabasi, M McCarthy, PL Rizzo, JD Pasquini, MC AF Horan, John Logan, Brent R. Agovi, Manza-A. Lazarus, Hillard M. Bacigalupo, Andrea Ballen, Karen Martino, Rodrigo Juckett, Mark B. Khoury, Hanna J. Bredeson, Christopher Gupta, Vikas Smith, Franklin O. Hale, Gregory Carabasi, Matthew McCarthy, Philip L. Rizzo, J. Douglas Pasquini, Marcelo C. TI Reducing the Risk for Transplant Related Mortality After Allogeneic Hematopoietic Cell Transplantation: How Much Progress Has Been Made? SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Horan, John] Childrens Healthcare Atlanta, Emory Sch Med, Atlanta, GA USA. [Logan, Brent R.] Med Coll Wisconsin, Div Biostat, Milwaukee, WI 53226 USA. [Agovi, Manza-A.; Rizzo, J. Douglas; Pasquini, Marcelo C.] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Lazarus, Hillard M.] Univ Hosp Cleveland, Ireland Canc Ctr, Cleveland, OH 44106 USA. [Bacigalupo, Andrea] Osped San Martino Genova, Genoa, Italy. [Ballen, Karen] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA. [Martino, Rodrigo] St Pau Hosp, Dept Hematol, Barcelona, Spain. [Juckett, Mark B.] Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA. [Khoury, Hanna J.] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA. [Gupta, Vikas] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. [Smith, Franklin O.] Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA. [Hale, Gregory] Univ S Florida, All Childrens Hosp, St Petersburg, FL 33701 USA. [Carabasi, Matthew] Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA. [McCarthy, Philip L.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 269 EP 270 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800650 ER PT J AU Barker, CC Agovi, MA Logan, B Gupta, V Lazarus, HM Ballen, KK Hale, GA Frangoul, H Rizzo, JD Pasquini, MC AF Barker, Collin C. Agovi, Manza- A. Logan, Brent Gupta, Vikas Lazarus, Hillard M. Ballen, Karen K. Hale, Gregory A. Frangoul, Haydar Rizzo, J. Douglas Pasquini, Marcelo C. TI Obesity Adversely Affects Survival of Pediatric Patients with Severe Aplastic Anemia After Hematopoietic Cell Transplantation SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Barker, Collin C.] BC Childrens Hosp, Vancouver, BC, Canada. [Agovi, Manza- A.; Logan, Brent; Rizzo, J. Douglas; Pasquini, Marcelo C.] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Gupta, Vikas] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. [Lazarus, Hillard M.] Univ Hosp Cleveland, Case Med Ctr, Ireland Canc Ctr, Cleveland, OH 44106 USA. [Ballen, Karen K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hale, Gregory A.] Univ S Florida, All Childrens Hosp, H Lee Moffitt Canc Ctr, St Petersburg, FL 33701 USA. [Frangoul, Haydar] Vanderbilt Univ, Pediat Blood & Marrow Transplant Program, Nashville, TN USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 271 EP 272 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800653 ER PT J AU Richardson, P Tomblyn, M Kernan, N Brochstein, JA Mineishi, S Termuhlen, A Arai, S Grupp, SA Guinan, E Martin, PL Corbacioglu, S Holler, E D'Agostino, R Massaro, J Hannah, AL Iacobelli, M Soiffer, RJ AF Richardson, Paul Tomblyn, Marcie Kernan, Nancy Brochstein, Joel A. Mineishi, Shin Termuhlen, Amanda Arai, Sally Grupp, Stephan A. Guinan, Eva Martin, Paul L. Corbacioglu, Selim Holler, Ernst D'Agostino, Ralph Massaro, Joseph Hannah, Alison L. Iacobelli, Massimo Soiffer, Robert J. TI Defibrotide (DF) in the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) Following Stem Cell Transplantation (SCT): Results of a Phase 3 Study Utilizing a Historical Control SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Richardson, Paul; Guinan, Eva; Soiffer, Robert J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Tomblyn, Marcie] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. [Kernan, Nancy] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Brochstein, Joel A.] Hackensack Univ, Med Ctr, Hackensack, NJ USA. [Mineishi, Shin] Univ Michigan, Ann Arbor, MI 48109 USA. [Termuhlen, Amanda] Nationwide Childrens Hosp, Dept Pediat Hem Oncol, Columbus, OH USA. [Arai, Sally] Stanford Univ, Med Ctr, Stanford, CA 94305 USA. [Grupp, Stephan A.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Grupp, Stephan A.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Martin, Paul L.] Duke Univ, Med Ctr, Durham, NC USA. [Corbacioglu, Selim] Univ Ulm, Dept Pediat, D-7900 Ulm, Germany. [Holler, Ernst] Klinikum Univ Regensburg, Abt Hamatol Intern Onkol, Regensburg, Germany. [D'Agostino, Ralph; Massaro, Joseph] Boston Univ, Boston, MA 02215 USA. [Hannah, Alison L.; Iacobelli, Massimo] Gentium Pharmaceut SPA, Villa Guardia, Italy. NR 0 TC 4 Z9 4 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 272 EP 273 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800655 ER PT J AU Devine, SM Soiffer, RJ Pasquini, MC Carter, S Hari, PN DeVore, S Stein, A Lazarus, HM Linker, C Stadtmauer, EA Keever-Taylor, CA O'Reilly, RJ AF Devine, Steven M. Soiffer, Robert J. Pasquini, Marcelo C. Carter, Shelly Hari, Parameswaran N. DeVore, Stephanie Stein, Anthony Lazarus, Hillard M. Linker, Charles Stadtmauer, Edward A. Keever-Taylor, Carolyn A. O'Reilly, Richard J. TI HLA-Identical Sibling-Matched, CD34(+) Selected, T Cell Depleted Peripheral Blood Stem Cells Following Myeloablative Conditioning for First or Second Remission Acute Myeloid Leukemia (AML): Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0303 SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting and Exposition of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Devine, Steven M.] Ohio State Univ, Columbus, OH 43210 USA. [Soiffer, Robert J.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Keever-Taylor, Carolyn A.] Med Coll Wisconsin, Froedtert Mem Lutheran Hosp E, Milwaukee, WI 53226 USA. [Carter, Shelly; DeVore, Stephanie] Emmes Corp, Bethesda, MD USA. [Stein, Anthony] City Hope Natl Med Ctr, Duarte, CA USA. [Lazarus, Hillard M.] Univ Hosp Cleveland, Ireland Canc Ctr, Case Med Ctr, Cleveland, OH 44106 USA. [Linker, Charles] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Stadtmauer, Edward A.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [O'Reilly, Richard J.] Mem Sloan Kettering Canc Ctr, Pediat BMT, New York, NY 10021 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 273 EP 273 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800656 ER PT J AU Kuter, DJ Rummel, MJ Boccia, RV Macik, BG Pabinger, I Selleslag, DLD Rodeghiero, F Chong, BH Muller-Beissenhirtz, H Gehl, L Wang, XN Berger, D AF Kuter, David J. Rummel, Mathias J. Boccia, Ralph Vincent Macik, B. Gail Pabinger, Ingrid Selleslag, Dominik L. D. Rodeghiero, Francesco Chong, Beng H. Mueller-Beissenhirtz, H. Gehl, Lara Wang, Xuena Berger, Dietmar TI Comparison of Splenectomy and Treatment Failure Incidence in Nonsplenectomized Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim or Medical Standard of Care: 1-Year Treatment and 6-Month Safety Follow-up SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Kuter, David J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Rummel, Mathias J.] Univ Hosp, Giessen, Germany. [Boccia, Ralph Vincent] Ctr Canc & Blood Disorders, Bethesda, MD USA. [Macik, B. Gail] Univ Virginia, Charlottesville, VA USA. [Pabinger, Ingrid] Med Univ Vienna, Dept Internal Med 1, Vienna, Austria. [Selleslag, Dominik L. D.] Algemeen Ziekenhuis St Jan, Brugge, Belgium. [Gehl, Lara; Wang, Xuena; Berger, Dietmar] Amgen Inc, Thousand Oaks, CA 91320 USA. [Mueller-Beissenhirtz, H.] Univ Klinikum Essen, Essen, Germany. [Chong, Beng H.] Univ NSW, St George Clin Sch, Kogarah, NSW, Australia. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 284 EP 284 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800680 ER PT J AU Bussel, JB Kuter, DJ Newland, A de Wolf, JTM Wasser, J Chang, P Nie, K Berger, D AF Bussel, James B. Kuter, David J. Newland, Adrian de Wolf, Joost T. M. Wasser, Jeffrey Chang, Paul Nie, Kun Berger, Dietmar TI Long-Term Efficacy and Safety of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia (ITP): 5-Year Update From An Open-Label Extension Study SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting and Exposition of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Bussel, James B.] New York Presbyterian Hosp, Div Hematol, Dept Pediat, New York, NY USA. [Bussel, James B.] New York Presbyterian Hosp, Div Hematol, Dept Med, New York, NY USA. [Kuter, David J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Newland, Adrian] Royal London Hosp, Dept Haematol, London E1 1BB, England. [de Wolf, Joost T. M.] Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands. [Wasser, Jeffrey] Manchester Mem Hosp, Manchester, CT USA. [Chang, Paul; Nie, Kun; Berger, Dietmar] Amgen Inc, Thousand Oaks, CA 91320 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 285 EP 285 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800682 ER PT J AU Ghosh, S Koralov, SB Stevanovic, I Sundrud, MS Sasaki, Y Rajewsky, K Rao, A Mueller, MR AF Ghosh, Srimoyee Koralov, Sergei B. Stevanovic, Irena Sundrud, Mark S. Sasaki, Yoshiteru Rajewsky, Klaus Rao, Aniana Mueller, Martin R. TI Hyperactivable NFAT1 Ameliorates Autoimmune Encephalitis In Vivo SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Ghosh, Srimoyee; Koralov, Sergei B.; Stevanovic, Irena; Sundrud, Mark S.; Rajewsky, Klaus; Rao, Aniana] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA USA. [Ghosh, Srimoyee; Koralov, Sergei B.; Stevanovic, Irena; Sundrud, Mark S.; Rajewsky, Klaus; Rao, Aniana] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Sasaki, Yoshiteru] RIKEN, Lab Stem Cell Biol, Ctr Dev Biol, Kobe, Hyogo, Japan. [Mueller, Martin R.] Univ Klinikum Tubingen, Med Klin & Poliklin, Tubingen, Germany. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 296 EP 297 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800712 ER PT J AU Boztug, K Kotlarz, D Glocker, E Gertz, ME Schaffer, AA Noyan, F Perro, M Diestelhorst, J Allroth, A Murugan, D Hatscher, N Pfeifer, D Sykora, KW Sauer, M Kreipe, H Lacher, M Nustede, R Woellner, C Baumann, U Salzer, U Koletzko, S Shah, N Segal, A Sauerbrey, A Buderus, S Snapper, S Grimbacher, B Klein, C AF Boztug, Kaan Kotlarz, Daniel Glocker, Erik Gertz, Mike E. Schaeffer, Alejandro A. Noyan, Fatih Perro, Mario Diestelhorst, Jana Allroth, Anna Murugan, Dhaarini Haetscher, Nadine Pfeifer, Dietmar Sykora, Karl-Walter Sauer, Martin Kreipe, Hans Lacher, Martin Nustede, Rainer Woellner, Cristina Baumann, Ulrich Salzer, Ulrich Koletzko, Sibylle Shah, Neil Segal, Anthony Sauerbrey, Axel Buderus, Stefan Snapper, Scott Grimbacher, Bodo Klein, Christoph TI Severe Early-Onset Inflammatory Bowel Disease Caused by IL10 Receptor Deficiency Can Be Cured by Allogeneic Hematopoietic Stem Cell Transplantation SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Boztug, Kaan; Kotlarz, Daniel; Diestelhorst, Jana; Haetscher, Nadine; Sauer, Martin] Hannover Med Sch, Dept Pediat Hematol Oncol, D-3000 Hannover, Germany. [Glocker, Erik; Perro, Mario; Woellner, Cristina; Grimbacher, Bodo] Royal Free Hosp, Dept Immunol, London, England. [Gertz, Mike E.; Schaeffer, Alejandro A.] NIH, Natl Ctr Biotechnol Informat, Bethesda, MD 20892 USA. [Noyan, Fatih; Allroth, Anna; Murugan, Dhaarini; Klein, Christoph] Hannover Med Sch, Dept Pediat Hematol Oncol, D-3000 Hannover, Germany. [Pfeifer, Dietmar] Univ Freiburg, Med Ctr, Dept Hematol Oncol, D-7800 Freiburg, Germany. [Kreipe, Hans] Hannover Med Sch, Dept Pathol, D-3000 Hannover, Germany. [Lacher, Martin; Koletzko, Sibylle] Univ Munich, Childrens Hosp, D-8000 Munich, Germany. [Nustede, Rainer] Hannover Med Sch, Dept Pediat Surg, D-3000 Hannover, Germany. [Baumann, Ulrich] Hannover Med Sch, Dept Pediat Rheumatol & Clin Immunol, D-3000 Hannover, Germany. [Salzer, Ulrich] Univ Med Ctr Freiburg, Dept Rheumatol & Clin Immunol, Freiburg, Germany. [Shah, Neil] Great Ormond St Hosp Sick Children, Dept Paediat Gastroenterol, London, England. [Segal, Anthony] UCL, Dept Med, London WC1E 6BT, England. [Sauerbrey, Axel] HELIOS Hosp, Dept Pediat, Erfurt, Germany. [Buderus, Stefan] St Marien Hosp Bonn, Dept Pediat, Bonn, Germany. [Snapper, Scott] Massachusetts Gen Hosp, Med MGH, Boston, MA 02114 USA. RI Schaffer, Alejandro/F-2902-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 297 EP 297 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800714 ER PT J AU Delmore, J Cervi, DN McMillin, D Kastritis, E Jakubikova, J Ooi, MG Klippel, S Negri, JM Buon, L Laubach, J Rastelli, L Clark, A Sarno, SM Richardson, PG Anderson, KC Mitsiades, CS AF Delmore, Jake Cervi, David N. McMillin, Douglas Kastritis, Efstathios Jakubikova, Jana Ooi, Melissa G. Klippel, Steffen Negri, Joseph M. Buon, Leutz Laubach, Jacob Rastelli, Luca Clark, Ann Sarno, Samantha M. Richardson, Paul G. Anderson, Kenneth C. Mitsiades, Constantine S. TI The Transcriptional Signature of Kinases Inhibited by the Multi-Targeted Kinase Inhibitor AS703569 Is Associated with Clinical Outcome in Multiple Myeloma (MM): Anti-MM Activity of AS703569 in Preclinical Studies SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Delmore, Jake; Cervi, David N.; McMillin, Douglas; Kastritis, Efstathios; Jakubikova, Jana; Ooi, Melissa G.; Klippel, Steffen; Negri, Joseph M.; Buon, Leutz; Laubach, Jacob; Richardson, Paul G.; Anderson, Kenneth C.; Mitsiades, Constantine S.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Rastelli, Luca; Clark, Ann; Sarno, Samantha M.] EMD Serono Res Inst, Rockland, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 304 EP 304 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800731 ER PT J AU Vallet, S Patel, K Vaghela, N Fulciniti, M Veiby, P Hideshima, T Pozzi, S Santo, L Mukherjee, S Cirstea, D Scadden, DT Anderson, KC Raje, N AF Vallet, Sonia Patel, Kishan Vaghela, Nileshwari Fulciniti, Mariateresa Veiby, Petter Hideshima, Teru Pozzi, Samantha Santo, Loredana Mukherjee, Siddhartha Cirstea, Diana Scadden, David T. Anderson, Kenneth C. Raje, Noopur TI Impairs Osteoblast Function Via Downregulation of Osteocalcin SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Vallet, Sonia; Patel, Kishan; Vaghela, Nileshwari; Mukherjee, Siddhartha; Raje, Noopur] Harvard Univ, Sch Med, Ctr Canc, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Fulciniti, Mariateresa; Hideshima, Teru; Pozzi, Samantha; Santo, Loredana; Cirstea, Diana; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Veiby, Petter] Millennium Pharmaceut Inc, Cambridge, MA USA. [Scadden, David T.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. RI Pozzi, Samantha/A-7617-2012 OI Pozzi, Samantha/0000-0001-7917-1774 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 307 EP 308 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800740 ER PT J AU Ghobrial, IM Vij, R Munshi, NC Schlossman, RL Laubach, J Campagnaro, EL Leduc, R Rourke, M Chuma, S Kunsman, J Dollard, AM Warren, D Harris, B Sam, A Anderson, KC Richardson, P AF Ghobrial, Irene M. Vij, Ravi Munshi, Nikhil C. Schlossman, Robert L. Laubach, Jacob Campagnaro, Erica L. Leduc, Renee Rourke, Meghan Chuma, Stacey Kunsman, Janet Dollard, Akari M. Warren, Diane Harris, Brianna Sam, Amy Anderson, Kenneth C. Richardson, Paul TI Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Ghobrial, Irene M.; Munshi, Nikhil C.; Schlossman, Robert L.; Laubach, Jacob; Leduc, Renee; Rourke, Meghan; Chuma, Stacey; Kunsman, Janet; Warren, Diane; Harris, Brianna; Sam, Amy; Anderson, Kenneth C.; Richardson, Paul] Harvard Univ, Sch Med, Boston VA Healthcare Syst, Dana Farber Canc Inst, Boston, MA 02115 USA. [Campagnaro, Erica L.] Univ Michigan, Ann Arbor, MI 48109 USA. [Dollard, Akari M.] Multiple Myeloma Res Consortium, Norwalk, CT USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 311 EP 312 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800749 ER PT J AU Padmanabhan, S Beck, JT Kelly, KR Munshi, NC Dzik-Jurasz, A Gangolli, E Ettenberg, S Miner, K Bilic, S Whyte, W Mehdi, F Chiang, LM Rae, PL Spencer, A Shah, J Anderson, KC Giles, FJ Stewart, AK AF Padmanabhan, Swaminathan Beck, Joseph Thaddeus Kelly, Kevin R. Munshi, Nikhil C. Dzik-Jurasz, Andy Gangolli, Esha Ettenberg, Seth Miner, Kelly Bilic, Sanela Whyte, Winston Mehdi, Fazal Chiang, Lu-May Rae, Patricia Liz Spencer, Andrew Shah, Jatin Anderson, Kenneth C. Giles, Francis J. Stewart, A. Keith TI A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx) SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Padmanabhan, Swaminathan; Kelly, Kevin R.; Giles, Francis J.] Univ Texas Hlth Sci Ctr San Antonio, Inst Drug Dev, CTRC, San Antonio, TX 78229 USA. [Beck, Joseph Thaddeus] Highlands Oncol Grp PA, Fayetteville, AR USA. [Munshi, Nikhil C.; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Dzik-Jurasz, Andy; Bilic, Sanela; Whyte, Winston; Mehdi, Fazal; Chiang, Lu-May; Rae, Patricia Liz] Novartis Pharmaceut, E Hanover, NJ USA. [Gangolli, Esha; Ettenberg, Seth; Miner, Kelly] Novartis Pharmaceut, Cambridge, MA USA. [Spencer, Andrew] Monash Univ, Alfred Hosp, Melbourne, Vic 3181, Australia. [Shah, Jatin] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Stewart, A. Keith] Mayo Clin Scottsdale, Coll Med, Div Hematol Oncol, Scottsdale, AZ USA. NR 0 TC 2 Z9 2 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 312 EP 313 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800751 ER PT J AU Pardanani, AD Gotlib, JR Jamieson, C Cortes, J Talpaz, M Stone, R Silverman, MH Shorr, J Gilliland, DG Tefferi, A AF Pardanani, Animesh D. Gotlib, Jason R. Jamieson, Catriona Cortes, Jorge Talpaz, Moshe Stone, Richard Silverman, Michael H. Shorr, Jolene Gilliland, D. Gary Tefferi, Ayalew TI A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2V617F Allele Burden SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Pardanani, Animesh D.; Tefferi, Ayalew] Mayo Clin, Rochester, MN USA. [Gotlib, Jason R.] Stanford Univ, Palo Alto, CA 94304 USA. [Jamieson, Catriona] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA. [Jamieson, Catriona] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA. [Cortes, Jorge] Univ Texas Houston, MD Anderson Canc Ctr, Leukemia Dept, Houston, TX 77030 USA. [Talpaz, Moshe] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Stone, Richard] Dana Farber Canc Inst, Boston, MA 02115 USA. [Silverman, Michael H.] Biostrategics Consulting Ltd, Marblehead, MA USA. [Shorr, Jolene] TargeGen Inc, San Diego, CA USA. [Gilliland, D. Gary] Merck Res Labs, Boston, MA USA. NR 0 TC 2 Z9 2 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 314 EP 315 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800756 ER PT J AU Hunter, Z Hanzis, C Ioakimidis, T Patterson, CJ Ciccarelli, B Lewicki, M Manning, R Xu, L Liu, X Tseng, H Gong, P Sun, J Zhou, YS Yang, G Sheehy, P Fox, EA Treon, S AF Hunter, Zachary Hanzis, Christina Ioakimidis, Thea Patterson, Christopher J. Ciccarelli, Bryan Lewicki, Megan Manning, Robert Xu, Lian Liu, Xia Tseng, Hsiuyi Gong, Ping Sun, Jenny Zhou, Yangsheng Yang, Guang Sheehy, Patricia Fox, Edward A. Treon, Steven TI Genome Wide Association Studies of Familial Waldenstrom's Macroglobulinemia (WM) Reveals a Loss of GSTM1 Is Common in Families with a History of B-Cell Disorders but Not in Those with a History Specific for WM SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Hunter, Zachary; Hanzis, Christina; Ioakimidis, Thea; Patterson, Christopher J.; Ciccarelli, Bryan; Lewicki, Megan; Manning, Robert; Xu, Lian; Liu, Xia; Tseng, Hsiuyi; Gong, Ping; Sun, Jenny; Zhou, Yangsheng; Yang, Guang; Sheehy, Patricia; Fox, Edward A.; Treon, Steven] Dana Farber Canc Inst, Waldenstroms Macroglubulinemia Ctr, Dept Med Oncol, Boston, MA 02115 USA. RI Hunter, Zachary/H-3018-2013 OI Hunter, Zachary/0000-0002-1689-1691 NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 317 EP 317 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800763 ER PT J AU Yang, G Gong, P Ioakimidis, T Xu, L Hunter, Z Sun, J Ciccarelli, B Zhou, Y Liu, X Tseng, H Cao, Y Manning, R Lewicki, M Hanzis, C Sheehy, P Patterson, CJ Treon, S AF Yang, Guang Gong, Ping Ioakimidis, Thea Xu, Lian Hunter, Zachary Sun, Jenny Ciccarelli, Bryan Zhou, Yangsheng Liu, Xia Tseng, Hsiuyi Cao, Yang Manning, Robert Lewicki, Megan Hanzis, Christina Sheehy, Patricia Patterson, Christopher J. Treon, Steven TI The IgM Flare Following Rituximab and IVIG Administration in Waldenstrom's Macroglobulinemia Is Related to IL-6 Production by Bystander Immune Cells, Possibly through Stimulation of the Fcgriia Receptor SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Yang, Guang; Gong, Ping; Ioakimidis, Thea; Xu, Lian; Hunter, Zachary; Sun, Jenny; Ciccarelli, Bryan; Zhou, Yangsheng; Liu, Xia; Tseng, Hsiuyi; Cao, Yang; Manning, Robert; Lewicki, Megan; Hanzis, Christina; Sheehy, Patricia; Patterson, Christopher J.; Treon, Steven] Dana Farber Canc Inst, Dept Med Oncol, Waldenstroms Macroglubulinemia Ctr, Boston, MA 02115 USA. RI Hunter, Zachary/H-3018-2013 OI Hunter, Zachary/0000-0002-1689-1691 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 317 EP 317 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800762 ER PT J AU Falet, H Pollitt, AY Weber, SE Duerschmied, D Wagner, DD Watson, SP Hartwig, JH AF Falet, Herve Pollitt, Alice Y. Weber, Sarah E. Duerschmied, Daniel Wagner, Denisa D. Watson, Steve P. Hartwig, John H. TI Filamin A Deficiency in Platelets Reveals Functional Impairment in ITAM-Based Signaling SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Falet, Herve; Weber, Sarah E.; Hartwig, John H.] Brigham & Womens Hosp, Div Translat Med, Boston, MA 02115 USA. [Falet, Herve; Weber, Sarah E.; Hartwig, John H.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Pollitt, Alice Y.; Watson, Steve P.] Univ Birmingham, Coll Med & Dent Sci, Inst Biomed Res, Ctr Cardiovasc Sci, Birmingham, W Midlands, England. [Duerschmied, Daniel; Wagner, Denisa D.] Childrens Hosp, Immune Dis Inst, Program Cellular & Mol Med, Boston, MA 02115 USA. [Duerschmied, Daniel; Wagner, Denisa D.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 319 EP 319 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800770 ER PT J AU Gavathiotis, E Davis, M Ruiz, DR Bird, GH Walensky, LD AF Gavathiotis, Evripidis Davis, Marguerite Ruiz, Denis Reyna Bird, Gregory H. Walensky, Loren D. TI Dissecting the Activation Pathway of Pro-Apoptotic BAX: Mechanistic Insights and Pharmacologic Opportunities SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Gavathiotis, Evripidis; Davis, Marguerite; Ruiz, Denis Reyna; Bird, Gregory H.; Walensky, Loren D.] Harvard Univ, Sch Med, Childrens Hosp Boston, Dana Farber Canc Inst,Dept Pediat Oncol, Boston, MA USA. [Gavathiotis, Evripidis; Davis, Marguerite; Ruiz, Denis Reyna; Bird, Gregory H.; Walensky, Loren D.] Harvard Univ, Sch Med, Childrens Hosp Boston, Dana Farber Canc Inst,Program Canc Chem Biol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 319 EP 319 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800769 ER PT J AU Huang, SC Yang, G Park, J Ou, A Benz, EJ AF Huang, Shu-Ching Yang, Guang Park, Jennie Ou, Alexander Benz, Edward J., Jr. TI Fox-2A Modulates Protein 4.1R Exon 16 5 ' Splice Site Activation SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Huang, Shu-Ching; Yang, Guang; Park, Jennie; Ou, Alexander; Benz, Edward J., Jr.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 322 EP 322 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800779 ER PT J AU Rosenblatt, J Glotzbecker, B Mills, H Keefe, W Wellenstein, K Vasir, B Wu, ZK Zarwan, C Schickler, M Rotem-Yehudar, R Kufe, D Avigan, D AF Rosenblatt, Jacalyn Glotzbecker, Brett Mills, Heidi Keefe, Whitney Wellenstein, Kerry Vasir, Baldev Wu, Zekui Zarwan, Corrine Schickler, Michael Rotem-Yehudar, Rinat Kufe, Donald Avigan, David TI CT-011, Anti-PD-1 Antibody, Enhances Ex-Vivo T Cell Responses to Autologous Dendritic/Myeloma Fusion Vaccine Developed for the Treatment of Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Rosenblatt, Jacalyn; Glotzbecker, Brett; Mills, Heidi; Keefe, Whitney; Wellenstein, Kerry; Zarwan, Corrine; Avigan, David] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Vasir, Baldev; Wu, Zekui; Kufe, Donald] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 1 U1 0 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 322 EP 323 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800782 ER PT J AU Butler, M Friedlander, P Mooney, M Drury, L Metzler, M Milstein, M Berezovskaya, A Flavin, M Imataki, O Tanaka, M Daley, H Hodi, FS Nadler, L Hirano, N AF Butler, Marcus Friedlander, Philip Mooney, Mary Drury, Linda Metzler, Martha Milstein, Matthew Berezovskaya, Alla Flavin, Marisa Imataki, Osamu Tanaka, Makito Daley, Heather Hodi, F. Stephen Nadler, Lee Hirano, Naoto TI Establishing CD8(+) T Cell Immunity by Adoptive Transfer of Autologous, IL-15 Expanded, Anti-Tumor CTL with a Central/Effector Memory Phenotype Can Induce Objective Clinical Responses SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting and Exposition of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Butler, Marcus; Friedlander, Philip; Mooney, Mary; Drury, Linda; Metzler, Martha; Milstein, Matthew; Berezovskaya, Alla; Flavin, Marisa; Imataki, Osamu; Tanaka, Makito; Daley, Heather; Hodi, F. Stephen; Nadler, Lee; Hirano, Naoto] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 323 EP 323 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800783 ER PT J AU Rosenblatt, J Avivi, I Vasir, B Katz, T Uhl, L Wu, ZK Somaiya, P Mills, H Joyce, R Levine, JD Tzachanis, D Boussiotis, V Glotzbecker, B Francoeur, K Dombagoda, D Tsumer, M Bisharat, L Giallombardo, N Conway, K Fitzgerald, D Barhad, R Richardson, P Anderson, KC Munshi, NC Rowe, JM Kufe, D Avigan, D AF Rosenblatt, Jacalyn Avivi, Irit Vasir, Baldev Katz, Tami Uhl, Lynne Wu, Zekui Somaiya, Poorvi Mills, Heidi Joyce, Robin Levine, James D. Tzachanis, Dimitrios Boussiotis, Vassiliki Glotzbecker, Brett Francoeur, Karen Dombagoda, Dilani Tsumer, Michal Bisharat, Lina Giallombardo, Nancy Conway, Katharine Fitzgerald, Donna Barhad, Rachal Richardson, Paul Anderson, Kenneth C. Munshi, Nikhil C. Rowe, Jacob M. Kufe, Donald Avigan, David TI Dendritic Cell Tumor Fusion Vaccination in Conjunction with Autologous Transplantation for Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Rosenblatt, Jacalyn; Uhl, Lynne; Somaiya, Poorvi; Mills, Heidi; Joyce, Robin; Levine, James D.; Tzachanis, Dimitrios; Boussiotis, Vassiliki; Glotzbecker, Brett; Francoeur, Karen; Dombagoda, Dilani; Giallombardo, Nancy; Conway, Katharine; Fitzgerald, Donna; Avigan, David] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Avivi, Irit; Katz, Tami; Tsumer, Michal; Bisharat, Lina; Barhad, Rachal; Rowe, Jacob M.] Rambam Med Ctr, IL-31096 Haifa, Israel. [Vasir, Baldev; Wu, Zekui; Richardson, Paul; Anderson, Kenneth C.; Munshi, Nikhil C.; Kufe, Donald] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 323 EP 324 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800784 ER PT J AU Levis, M Ravandi, F Wang, ES Baer, MR Perl, A Coutre, S Erba, H Stuart, RK Baccarani, M Cripe, LD Tallman, MS Meloni, G Godley, LA Langston, AA Amadori, S Lewis, ID Nagler, A Stone, R Yee, K Advani, A Douer, D Jedrzejczak, WW Juliusson, G Litzow, MR Petersdorf, S Sanz, M Kantarjian, HM Sato, T Tremmel, L Bensen-Kennedy, DM Small, D Smith, BD AF Levis, Mark Ravandi, Farhad Wang, Eunice S. Baer, Maria R. Perl, Alexander Coutre, Steven Erba, Harry Stuart, Robert K. Baccarani, Michele Cripe, Larry D. Tallman, Martin S. Meloni, Giovanna Godley, Lucy A. Langston, Amelia A. Amadori, Sergio Lewis, Ian D. Nagler, Arnon Stone, Richard Yee, Karen Advani, Anjali Douer, Dan Jedrzejczak, Wieslaw W. Juliusson, Gunnar Litzow, Mark R. Petersdorf, Stephen Sanz, Miguel Kantarjian, Hagop M. Sato, Takashi Tremmel, Lothar Bensen-Kennedy, Debra M. Small, Donald Smith, B. Douglas TI Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Levis, Mark; Sato, Takashi; Small, Donald] Johns Hopkins Univ, Baltimore, MD USA. [Ravandi, Farhad; Kantarjian, Hagop M.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Wang, Eunice S.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Baer, Maria R.] Univ Maryland, Baltimore, MD 21201 USA. [Perl, Alexander] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Coutre, Steven] Stanford Univ, Sch Med, Dept Med, Div Hematol, Stanford, CA 94305 USA. [Erba, Harry] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Stuart, Robert K.] Med Univ S Carolina, Charleston, SC 29425 USA. [Baccarani, Michele] Univ Bologna, Seragnoli Inst Hematol & Med Oncol, Bologna, Italy. [Cripe, Larry D.] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA. [Tallman, Martin S.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Meloni, Giovanna] Univ Roma La Sapienza, Rome, Italy. [Godley, Lucy A.] Univ Chicago, Med Ctr, Chicago, IL 60637 USA. [Langston, Amelia A.] Emory Univ, Sch Med, Atlanta, GA 30322 USA. [Amadori, Sergio] Univ Roma Tor Vergata, Dept Hematol, Rome, Italy. [Lewis, Ian D.] IMVS, Div Haematol, Adelaide, SA, Australia. [Nagler, Arnon] Chaim Sheba Med Ctr, Div Haematol & Bone Marrow Transplantat, IL-52621 Tel Hashomer, Israel. [Stone, Richard] Dana Farber Canc Inst, Boston, MA 02115 USA. [Yee, Karen] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. [Advani, Anjali] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44106 USA. [Douer, Dan] Univ So Calif, Keck Sch Med, Norris Cotton Canc Ctr, Los Angeles, CA 90033 USA. [Jedrzejczak, Wieslaw W.] Med Univ Warsaw, Warsaw, Poland. [Juliusson, Gunnar] Lund Stem Cell Ctr, Dept Hematol, Lund, Sweden. [Litzow, Mark R.] Mayo Clin, Rochester, MN USA. [Petersdorf, Stephen] Seattle Canc Care Alliance, Seattle, WA USA. [Sanz, Miguel] Hosp La Fe, E-46009 Valencia, Spain. [Tremmel, Lothar; Bensen-Kennedy, Debra M.] Cephalon Inc, Frazer, PA USA. [Small, Donald] Johns Hopkins Univ, Baltimore, MD USA. NR 0 TC 4 Z9 4 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 325 EP 326 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800789 ER PT J AU Ullrich, CK Dussel, V Hilden, JM Sheaffer, JW Lehmann, LE Wolfe, J AF Ullrich, Christina K. Dussel, Veronica Hilden, Joanne M. Sheaffer, Jan W. Lehmann, Leslie E. Wolfe, Joanne TI End-of-Life Experience of Children Undergoing Stem Cell Transplantation: Parent and Provider Perspectives and Patterns of Care SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Ullrich, Christina K.; Dussel, Veronica; Lehmann, Leslie E.; Wolfe, Joanne] Dana Farber Canc Inst, Boston, MA 02115 USA. [Hilden, Joanne M.] Peyton Manning Childrens Hosp St Vincent, Indianapolis, IN USA. [Sheaffer, Jan W.] Childrens Hosp & Clin Minnesota, St Paul, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 332 EP 333 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800806 ER PT J AU Adamia, S Fulciniti, M Avet-Loiseau, H Amin, SB Shah, P Carrasco, DR Minvielle, S Moreau, P Anderson, KC Munshi, NC AF Adamia, Sophia Fulciniti, Mariateresa Avet-Loiseau, Herve Amin, Samir B. Shah, Parantu Carrasco, Daniel Ruben Minvielle, Stephane Moreau, Philippe Anderson, Kenneth C. Munshi, Nikhil C. TI Biological and Therapeutic Potential of Mir-155, 585 and Let-7f in Myeloma in Vitro and In Vivo SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Amin, Samir B.; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston VA Healthcare Syst, Boston, MA 02115 USA. [Fulciniti, Mariateresa; Carrasco, Daniel Ruben; Anderson, Kenneth C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Minvielle, Stephane] CHU Nantes, Hematol Lab, F-44035 Nantes, France. [Shah, Parantu] Harvard Univ, Sch Publ Hlth, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Shah, Parantu] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Moreau, Philippe] Univ Hosp, Nantes, France. RI Minvielle, Stephane/K-8251-2015; richard, chrystelle/K-8595-2015 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 343 EP 343 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801013 ER PT J AU Chapman, MA Brunet, JP Keats, JJ Baker, A Adli, M Schinzel, AC Ahmann, G Christina, H Moore, A Shanmugam, V Perkins, LM Auclair, D Hahn, WC Bernstein, BE Bergsagel, L Fonseca, R Carpten, J Trent, J Golub, TR AF Chapman, Michael A. Brunet, Jean-Philippe Keats, Jonathan J. Baker, Angela Adli, Mazhar Schinzel, Anna C. Ahmann, Gregory Christina, Harview Moore, Anna Shanmugam, Vijayalakshmi Perkins, Louise M. Auclair, Daniel Hahn, William C. Bernstein, Bradley E. Bergsagel, Leif Fonseca, Rafael Carpten, John Trent, Jeffrey Golub, Todd R. TI HOXA9 Is a Novel Therapeutic Target in Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Chapman, Michael A.; Brunet, Jean-Philippe; Christina, Harview; Golub, Todd R.] Broad Inst, Cambridge, MA USA. [Keats, Jonathan J.; Ahmann, Gregory; Bergsagel, Leif; Fonseca, Rafael] Mayo Clin Scottsdale, Scottsdale, AZ USA. [Baker, Angela; Moore, Anna; Shanmugam, Vijayalakshmi; Carpten, John; Trent, Jeffrey] Translat Genom Res Inst, Phoenix, AZ USA. [Adli, Mazhar; Bernstein, Bradley E.] Massachusetts Gen Hosp, Charlestown, MA USA. [Adli, Mazhar; Bernstein, Bradley E.] Harvard Univ, Sch Med, Charlestown, MA USA. [Schinzel, Anna C.; Hahn, William C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Perkins, Louise M.; Auclair, Daniel] Multiple Myeloma Res Fdn, Norwalk, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 343 EP 343 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801012 ER PT J AU Lu, J Pipe, SW Miao, HZ Jacquemin, M Gilbert, GE AF Lu, Junhong Pipe, Steven W. Miao, Hongzhi Jacquemin, Marc Gilbert, Gary E. TI Membrane-Interactive Amino Acids in the Factor VIII C1 Domain Are Cooperative with C2 Domain Epitopes for Membrane Binding and Cofactor Function SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Lu, Junhong; Gilbert, Gary E.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, W Roxbury, MA USA. [Pipe, Steven W.; Miao, Hongzhi] L2110 Womens Hosp, Ann Arbor, MI USA. [Jacquemin, Marc] Katholieke Univ Leuven, Louvain, Belgium. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 349 EP 349 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801028 ER PT J AU Eiring, AM Harb, J Neviani, P Oaks, J Liu, SJ Spizzo, R Schwind, S Santhanam, R Hickey, C Becker, H Chandler, JC Andino, R Cortes, J Hokland, P Huettner, C Bhatia, R Roy, DC Liebhaber, S Caligiuri, MA Marcucci, G Garzon, R Croce, CM Calin, GA Perrotti, D AF Eiring, Anna M. Harb, Jason Neviani, Paolo Oaks, Joshua Liu, Shujun Spizzo, Riccardo Schwind, Sebastian Santhanam, Ramasamy Hickey, Christopher Becker, Heiko Chandler, Jason C. Andino, Raul Cortes, Jorge Hokland, Peter, Sr. Huettner, Claudia Bhatia, Ravi Roy, Denis-Claude Liebhaber, Stephen Caligiuri, Michael A. Marcucci, Guido Garzon, Ramiro Croce, Carlo M. Calin, George A. Perrotti, Danilo TI Suppression of RISC-Independent Decoy and RISC-Mediated mRNA Base-Pairing Activities of MicroRNA-328 Is Required for Differentiation-Arrest and Enhanced Survival of Blast Crisis CML Progenitors SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Eiring, Anna M.; Harb, Jason; Neviani, Paolo; Oaks, Joshua; Liu, Shujun; Schwind, Sebastian; Santhanam, Ramasamy; Hickey, Christopher; Becker, Heiko; Chandler, Jason C.; Caligiuri, Michael A.; Marcucci, Guido; Garzon, Ramiro; Croce, Carlo M.; Perrotti, Danilo] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. [Spizzo, Riccardo; Cortes, Jorge; Calin, George A.] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA. [Andino, Raul] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Hokland, Peter, Sr.] Aarhus Univ, Dept Hematol, Aarhus, Denmark. [Huettner, Claudia] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Bhatia, Ravi] City Hope Natl Med Ctr, Duarte, CA 91010 USA. [Roy, Denis-Claude] Univ Montreal, Blood & Marrow Transplant Program, Dept Hematol, Montreal, PQ, Canada. [Liebhaber, Stephen] Univ Penn, HHMI, Philadelphia, PA 19104 USA. RI Garzon, Ramiro/E-3104-2011 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 351 EP 352 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725801035 ER PT J AU Zhang, B Ho, YW Lee, SU Maeda, T Huettner, C Bhatia, R AF Zhang, Bin Ho, Yin Wei Lee, Sung-Uk Maeda, Takahiro Huettner, Claudia Bhatia, Ravi TI Characterization of Leukemia-Initiating Cells in a Transgenic Model of Chronic Phase Chronic Myelogenous Leukemia (CML) SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Zhang, Bin; Ho, Yin Wei; Lee, Sung-Uk; Maeda, Takahiro; Bhatia, Ravi] City Hope Natl Med Ctr, Duarte, CA 91010 USA. [Huettner, Claudia] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 353 EP 353 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801038 ER PT J AU Roberts, AW Seymour, JF Brown, JR Wierda, WG Kipps, TJ Carney, D Xiong, H Cui, Y Busman, T Enschede, S Krivoshik, A Humerickhouse, R AF Roberts, Andrew W. Seymour, John F. Brown, Jennifer R. Wierda, William G. Kipps, Thomas J. Carney, Dennis Xiong, Hao Cui, Yue Busman, Todd Enschede, Sari Krivoshik, Andrew Humerickhouse, Rod TI An Ongoing Phase 1/2a Study of ABT-263; Pharmacokinetics (PK), Safety and Anti-Tumor Activity in Patients (pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Roberts, Andrew W.] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Canc & Haem, Parkville, Vic 3050, Australia. [Carney, Dennis] Peter MacCallum Canc Inst, Dept Haematol, Melbourne, Vic 3000, Australia. [Brown, Jennifer R.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Wierda, William G.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Kipps, Thomas J.] Moores UCSD Canc Ctr, CLL Res Consortium, La Jolla, CA USA. [Xiong, Hao; Cui, Yue; Busman, Todd; Enschede, Sari; Krivoshik, Andrew; Humerickhouse, Rod] Abbott Labs, Abbott Pk, IL 60064 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 364 EP 364 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801063 ER PT J AU Gutierrez, A Grebliunaite, R Dahlberg, SE Neuberg, D Zhang, JH Sanda, T Protopopov, A Chin, L Winter, S Larson, RS Kutok, JL Silverman, LB Hunger, SP Sallan, SE Look, AT AF Gutierrez, Alejandro Grebliunaite, Ruta Dahlberg, Suzanne E. Neuberg, Donna Zhang, Jianhua Sanda, Takaomi Protopopov, Alexei Chin, Lynda Winter, Stuart Larson, Richard S. Kutok, Jeffery Lorne Silverman, Lewis B. Hunger, Stephen P. Sallan, Stephen E. Look, A. Thomas TI Absence of T-Cell Receptor Gene Rearrangements Predicts Induction Failure in Pediatric T-Cell Acute Lymphoblastic Leukemia SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Dahlberg, Suzanne E.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Gutierrez, Alejandro] Childrens Hosp, Boston, MA 02115 USA. [Zhang, Jianhua; Chin, Lynda] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA. [Winter, Stuart] Univ New Mexico, Dept Pediat, Albuquerque, NM 87131 USA. [Larson, Richard S.] Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA. [Kutok, Jeffery Lorne] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Hunger, Stephen P.] Univ Colorado, Coll Med, Pediat Heme Onc BMT, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 375 EP 375 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801090 ER PT J AU Quigley, M Pereyra, F Nilsson, B Eichbaum, Q Julg, B Jesneck, J Brosnahan, K Russell, K Toth, I Piechocka-Trocha, A Shin, HN Freeman, GJ Wherry, EJ Walker, BD Ebert, BL Haining, WN AF Quigley, Michael Pereyra, Florencia Nilsson, Bjorn Eichbaum, Quentin Julg, Boris Jesneck, Jonathan Brosnahan, Kathleen Russell, Kate Toth, Ildiko Piechocka-Trocha, Alicja Shin, Haina Freeman, Gordon J. Wherry, E. John Walker, Bruce D. Ebert, Benjamin L. Haining, W. Nicholas TI Integrative Genomic Analysis of HIV-Specific CD8(+) T Cells Reveals That PD-1 Inhibits T Cell Function by Upregulating the AP-1 Transcription Factor BATF SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting and Exposition of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Freeman, Gordon J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Pereyra, Florencia; Eichbaum, Quentin; Julg, Boris; Toth, Ildiko; Piechocka-Trocha, Alicja; Walker, Bruce D.] MIT, Ragon Inst MGH, Charlestown, MA USA. [Nilsson, Bjorn] Broad Inst, Cambridge, MA USA. [Shin, Haina; Wherry, E. John] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA. [Ebert, Benjamin L.] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 378 EP 378 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801096 ER PT J AU Flinn, IW Byrd, JC Furman, RR Brown, JR Benson, DM Coutre, SE Kahl, BS Smith, BD Wagner-Johnston, ND Spurgeon, SE Giese, NA Yu, AS AF Flinn, Ian W. Byrd, John C. Furman, Richard R. Brown, Jennifer R. Benson, Don M. Coutre, Steven E. Kahl, Brad S. Smith, B. Douglas Wagner-Johnston, Nina D. Spurgeon, Stephen E. Giese, Neill A. Yu, Albert S. TI Evidence of Clinical Activity in a Phase I Study of CAL-101, An Oral P110 Delta Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Flinn, Ian W.] Sarah Cannon Res Inst, Nashville, TN USA. [Byrd, John C.] Ohio State Univ, Coll Med, Columbus, OH 43210 USA. [Furman, Richard R.] Weill Cornell Med Coll, New York, NY USA. [Brown, Jennifer R.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Benson, Don M.] Ohio State Univ, Div Hematol Oncol, Columbus, OH 43210 USA. [Coutre, Steven E.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Kahl, Brad S.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Hematol Oncol Sect, Madison, WI USA. [Smith, B. Douglas] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. [Wagner-Johnston, Nina D.] Washington Univ, Sch Med, St Louis, MO USA. [Spurgeon, Stephen E.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Giese, Neill A.] Calistoga Pharmaceut Inc, Seattle, WA USA. [Yu, Albert S.] Calistoga Pharmaceut, Seattle, WA USA. NR 0 TC 6 Z9 6 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 380 EP 380 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801102 ER PT J AU Hagenbeek, A Fayad, L Delwail, V Rossi, JF Jacobsen, E Kuliczkowski, K Link, BK Pinter-Brown, L Radford, J Hellmann, A Gallop-Evans, E Gupta, I Arning, M Begtrup, K Schultz, M Bang, B Russell, CA Czuczman, MS AF Hagenbeek, Anton Fayad, Luis Delwail, Vincent Rossi, Jean Francois Jacobsen, Eric Kuliczkowski, Kazimierz Link, Brian K. Pinter-Brown, Lauren Radford, John Hellmann, Andrzej Gallop-Evans, Eve Gupta, Ira Arning, Michael Begtrup, Kamilla Schultz, Martin Bang, Bo Russell, Charlotte A. Czuczman, Myron S. TI Evaluation of Ofatumumab, a Novel Human CD20 Monoclonal Antibody, as Single Agent Therapy in Rituximab-Refractory Follicular Lymphoma SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Hagenbeek, Anton] Univ Amsterdam, Acad Med Ctr, Dept Haematol, NL-1105 AZ Amsterdam, Netherlands. [Fayad, Luis] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Delwail, Vincent] CHU Poitiers, INSERM, CIC 0802, Poitiers, France. [Rossi, Jean Francois] Univ Montpellier 1, Serv Hematol & Oncol Med, Montpellier, France. [Jacobsen, Eric] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kuliczkowski, Kazimierz] Klin Hematol Nowotworow Krwi & Transplantacji Szp, Wroclaw, Poland. [Link, Brian K.] Univ Iowa, Iowa City, IA USA. [Pinter-Brown, Lauren] Univ Calif Los Angeles, Los Angeles, CA USA. [Radford, John] Christie NHS Fdn Trust, Manchester, Lancs, England. [Radford, John] Univ Manchester, Manchester, Lancs, England. [Hellmann, Andrzej] Akad Ctr Klin AM Gdansk, Klin Hematol, Gdansk, Poland. [Gallop-Evans, Eve] Velindre Hosp, Cardiff, S Glam, Wales. [Gupta, Ira; Arning, Michael] GlaxoSmithKline Inc, Collegeville, PA USA. [Begtrup, Kamilla; Schultz, Martin; Bang, Bo; Russell, Charlotte A.] Genmab, Copenhagen, Denmark. [Czuczman, Myron S.] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA. [Czuczman, Myron S.] Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA. RI Radford, John/N-1331-2015 OI Radford, John/0000-0001-7898-2786 NR 0 TC 3 Z9 3 U1 0 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 385 EP 386 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725801115 ER PT J AU Kumar, M Narla, A Nonami, A Ball, B Chin, C Chen, C Kutok, JL Galili, N Raza, A Attar, EC Gllliland, DG Jacks, T Ebert, BL AF Kumar, Madhu Narla, Anupama Nonami, Atsushi Ball, Brian Chin, Christine Chen, Cindy Kutok, Jeffery Lorne Galili, Naomi Raza, Azra Attar, Eyal C. Gllliland, D. Gary Jacks, Tyler Ebert, Benjamin L. TI Coordinate Loss of a MicroRNA Mir 145 and a Protein-Coding Gene RPS14 Cooperate in the Pathogenesis of 5q-Syndrome SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Kumar, Madhu; Chin, Christine; Chen, Cindy] Koch Inst Integrat Canc Res, Dept Biol, Cambridge, MA USA. [Narla, Anupama] Childrens Hosp, Boston, MA 02115 USA. [Nonami, Atsushi; Ball, Brian; Gllliland, D. Gary; Ebert, Benjamin L.] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA. [Kutok, Jeffery Lorne] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Galili, Naomi; Raza, Azra] St Vincents Comprehens Canc Ctr, New York, NY USA. [Attar, Eyal C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA. [Ebert, Benjamin L.] MIT, Dept Biol, Cambridge, MA USA. [Ebert, Benjamin L.] MIT, Canc Res Ctr, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 391 EP 392 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725801127 ER PT J AU Gorgun, G Calabrese, E Hideshima, T Perrone, G Bianchi, G Ikeda, H Mani, M Hu, YG Cristea, D Santo, L Tai, YT Munshi, N Richardson, P Anderson, KC AF Gorgun, Gullu Calabrese, Elisabetta Hideshima, Teru Perrone, Giulia Bianchi, Giada Ikeda, Hiroshi Mani, Mala Hu, Yiguo Cristea, Diana Santo, Loredana Tai, Yu-Tzu Munshi, Nikhil Richardson, Paul Anderson, Kenneth C. TI Immunomodulatory EFFECTS of Lenalidomide and Pomalidomide ON INTERACTION of TUMOR and BONE MARROW Accessory CELLS IN MULTIPLE MYELOMA SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Gorgun, Gullu; Calabrese, Elisabetta; Hideshima, Teru; Perrone, Giulia; Bianchi, Giada; Ikeda, Hiroshi; Mani, Mala; Hu, Yiguo; Cristea, Diana; Santo, Loredana; Tai, Yu-Tzu; Munshi, Nikhil; Richardson, Paul; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 392 EP 393 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725801130 ER PT J AU Azab, AK Quang, P Azab, F Pitsillides, CM Patton, JT Smith, T Sarkar, A Runnels, JM Roccaro, AM Sacco, A Ngo, HT Melhem, MR Maiso, P Anderson, KC Lin, CP Magnani, JL Ghobrial, IM AF Azab, Abdel Kareem Quang, Phong Azab, Feda Pitsillides, Costas M. Patton, John T. Smith, Theodore Sarkar, Arun Runnels, Judith M. Roccaro, Aldo M. Sacco, Antonio Ngo, Hai T. Melhem, Molly R. Maiso, Patricia Anderson, Kenneth C. Lin, Charles P. Magnani, John L. Ghobrial, Irene M. TI Role of Selectins in the Pathogenesis of Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Azab, Abdel Kareem; Quang, Phong; Azab, Feda; Roccaro, Aldo M.; Sacco, Antonio; Ngo, Hai T.; Melhem, Molly R.; Maiso, Patricia; Anderson, Kenneth C.; Ghobrial, Irene M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Pitsillides, Costas M.; Lin, Charles P.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Smith, Theodore] GlycoMimetics Inc, Gaithersburg, MD USA. [Lin, Charles P.] Massachusetts Gen Hosp, Adv Microscopy Program, Ctr Syst Biol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 393 EP 393 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801131 ER PT J AU Jakubikova, J Cervi, DN Daley, JF Cholujova, D Ooi, MG Klippel, S Blotta, S Leiba, M Delmore, J McMillin, D Kastritis, E Laubach, J Richardson, P Sedlak, J Anderson, KC Mitsiades, CS AF Jakubikova, Jana Cervi, David N. Daley, John F. Cholujova, Danka Ooi, Melissa G. Klippel, Steffen Blotta, Simona Leiba, Merav Delmore, Jake McMillin, Douglas Kastritis, Efstathios Laubach, Jacob Richardson, Paul Sedlak, Jan Anderson, Kenneth C. Mitsiades, Constantine S. TI Targeting the Clonogenic Side Population of Multiple Myeloma by Immunomodulatory Drugs (IMiDs) in the Context of Stromal Cell Microenvironment: Pathophysiologic and Clinical Implications SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Jakubikova, Jana; Cervi, David N.; Daley, John F.; Ooi, Melissa G.; Klippel, Steffen; Blotta, Simona; Leiba, Merav; Delmore, Jake; McMillin, Douglas; Kastritis, Efstathios; Laubach, Jacob; Richardson, Paul; Anderson, Kenneth C.; Mitsiades, Constantine S.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Cholujova, Danka; Sedlak, Jan] Slovak Acad Sci, Canc Res Inst, Bratislava, Slovakia. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 394 EP 394 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801134 ER PT J AU Lane, SW Lo Celso, C Sykes, SM Shterental, S Paktinat, M Lin, CP Williams, DA Scadden, DT Gilliland, DG AF Lane, Steven W. Lo Celso, Cristina Sykes, Stephen M. Shterental, Sebastian Paktinat, Mahnaz Lin, Charles P. Williams, David A. Scadden, David T. Gilliland, D. Gary TI Leukemia Stem Cells Are Resistant to In Vivo, Cell Non-Autonomous Wnt Inhibition. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Lo Celso, Cristina] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. [Paktinat, Mahnaz] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Lin, Charles P.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Williams, David A.] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. [Scadden, David T.] MGH Ctr Regenerat Med, Boston, MA USA. [Gilliland, D. Gary] Merck Res Labs, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 424 EP 424 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801205 ER PT J AU Ravandi, F Kantarjian, HM Cripe, LD Maris, M Cooper, M Dakhil, SR Stone, RM Turturro, F Chen, TL Mahadocon, K Fox, J Berman, C Michelson, GC Stuart, RK AF Ravandi, Farhad Kantarjian, Hagop M. Cripe, Larry D. Maris, Michael Cooper, Maureen Dakhil, Shaker R. Stone, Richard M. Turturro, Francesco Chen, Tianling Mahadocon, Kristi Fox, Judith Berman, Craig Michelson, Glenn C. Stuart, Robert K. TI A Phase 2 Dose Regimen Optimization Study of Three Schedules of Voreloxin as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Ravandi, Farhad] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Cripe, Larry D.] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA. [Maris, Michael] Rocky Mt Blood & Marrow Transplant Program, Denver, CO USA. [Cooper, Maureen] St Francis Hosp & Hlth Ctr, Beech Grove, IN USA. [Dakhil, Shaker R.] Canc Ctr Kansas, Wichita, KS USA. [Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Turturro, Francesco] LSUHSC, Feist Weiller Canc Ctr, Shreveport, LA USA. [Mahadocon, Kristi] Sunesis Pharmaceut Inc, Clin Dev, San Francisco, CA USA. [Michelson, Glenn C.] Sunesis Pharmaceut Inc, Clin Sci, San Francisco, CA USA. [Stuart, Robert K.] Med Univ S Carolina, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 428 EP 429 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725801217 ER PT J AU Erba, HP O'Donnell, M Allen, SL Baer, MR Powell, BL Stone, RM Bennett, JM Lundberg, AS Capizzi, RL Rizzieri, DA AF Erba, Harry P. O'Donnell, Margaret Allen, Steven L. Baer, Maria R. Powell, Bayard L. Stone, Richard M. Bennett, John M. Lundberg, Ante S. Capizzi, Robert L. Rizzieri, David A. TI Amonafide L-Malate (AS1413) in Combination with Cytarabine Is Equally Effective in Older and Younger Patients with Secondary Acute Myeloid Leukemia (AML); Final Data From a Phase II Study. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Erba, Harry P.] Univ Michigan Hlth Syst, Ann Arbor, MI USA. [O'Donnell, Margaret] City Hope Natl Med Ctr, Duarte, CA USA. [Allen, Steven L.] N Shore Univ Hosp, Lake Success, NY USA. [Baer, Maria R.] Univ Maryland, Baltimore, MD 21201 USA. [Powell, Bayard L.] Wake Forest Univ, Med Ctr, Winston Salem, NC USA. [Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Bennett, John M.] Univ Rochester, Rochester, NY USA. [Lundberg, Ante S.; Capizzi, Robert L.] Antisoma Res Ltd, Cambridge, MA USA. [Rizzieri, David A.] Duke Univ, Med Ctr, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 433 EP 434 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725801227 ER PT J AU Pal, J Pelluru, D Fulciniti, M Amin, SB Buon, L Prabhala, R Anderson, KC Shammas, MA Munshi, NC AF Pal, Jagannath Pelluru, Dheeraj Fulciniti, Mariateresa Amin, Samir B. Buon, Leutz Prabhala, Rao Anderson, Kenneth C. Shammas, Masood A. Munshi, Nikhil C. TI Perturbation of Genomic Instability by Wortmannin in Myeloma. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Pal, Jagannath; Pelluru, Dheeraj; Fulciniti, Mariateresa; Amin, Samir B.; Prabhala, Rao; Shammas, Masood A.; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston VA Healthcare Syst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 454 EP 454 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801285 ER PT J AU Soriano, G Ho, VT Ballen, KK Armand, P Cutler, C Koreth, J Alyea, E Soiffer, RJ Baden, L Antin, JH Marty, FM AF Soriano, Gabriela Ho, Vincent T. Ballen, Karen K. Armand, Philippe Cutler, Corey Koreth, John Alyea, Edwin Soiffer, Robert J. Baden, Lindsey Antin, Joseph H. Marty, Francisco M. TI Adenovirus Infections in Patients Undergoing Umbilical Cord Blood Hematopoietic Stem Cell Transplantation. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Soriano, Gabriela; Baden, Lindsey; Marty, Francisco M.] Brigham & Womens Hosp, Dept Med, Div Infect Dis, Boston, MA 02115 USA. [Ho, Vincent T.; Armand, Philippe; Cutler, Corey; Koreth, John; Antin, Joseph H.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Ballen, Karen K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 465 EP 466 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725801312 ER PT J AU Glotzbecker, B Mills, H Rosenblatt, J Wu, ZK Wellenstein, K Vasir, B Joyce, R Levine, JD Tzachanis, D Zwicker, J Boussiotis, VA Stevenson, MA Spitzer, T Delaney, C Bonhoff, J Giallombardo, N Conway, K McDermott, DF Avigan, D AF Glotzbecker, Brett Mills, Heidi Rosenblatt, Jacalyn Wu, Zekui Wellenstein, Kerry Vasir, Baldev Joyce, Robin Levine, James D. Tzachanis, Dimitrios Zwicker, Jeffrey Boussiotis, Vassiliki A. Stevenson, Mary Ann Spitzer, Thomas Delaney, Carol Bonhoff, Jessica Giallombardo, Nancy Conway, Katharine McDermott, David F. Avigan, David TI A Comparative Analysis of Immune Reconstitution Following Reduced Intensity Conditioning with CAMPATH-1H and Total Lymphoid Irradiation/Anti-Thymocyte Globulin Prior to Allogeneic Stem Cell Transplantation. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Wellenstein, Kerry; Bonhoff, Jessica] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Hematol & Oncol, Boston, MA 02215 USA. [Wu, Zekui; Vasir, Baldev] Dana Farber Canc Inst, Boston, MA 02115 USA. [Zwicker, Jeffrey] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Hemostasis & Thrombosis, Boston, MA 02215 USA. [Boussiotis, Vassiliki A.] Beth Israel Deaconess Med Ctr, Harvard Inst Med, Boston, MA 02215 USA. [Spitzer, Thomas] Massachusetts Gen Hosp, Boston, MA 02114 USA. [McDermott, David F.] Beth Israel Deaconess Med Ctr, Dept Hem Onc, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 472 EP 472 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801328 ER PT J AU Sarantopoulos, S Cutler, C Makari-Judson, G Ropp, P Washel, W Brusic, V DeLuca, D Saldivar, JS Soiffer, RJ Antin, JH Ritz, J AF Sarantopoulos, Stefanie Cutler, Corey Makari-Judson, Grace Ropp, Patricia Washel, Whitney Brusic, Vladimir DeLuca, David Saldivar, Juan-Sebastian Soiffer, Robert J. Antin, Joseph H. Ritz, Jerome TI Factor VIII Is a Potential Autosomal B Cell Minor Histocompatibility Antigen in Chronic Gvhd. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Sarantopoulos, Stefanie] UNC Lineberger Comprehens Canc Ctr, Div Hematol Oncol, Chapel Hill, NC USA. [Cutler, Corey; DeLuca, David; Ritz, Jerome] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Makari-Judson, Grace] Baystate Med Ctr, Springfield, MA USA. [Ropp, Patricia] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Washel, Whitney] Dana Farber Canc Inst, Div Hematol Neoplasia, Boston, MA 02115 USA. [Brusic, Vladimir] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA. [Saldivar, Juan-Sebastian] City Hope Natl Med Ctr, Dept Pathol, Clin Mol Diagnost Lab, Duarte, CA 91010 USA. [Antin, Joseph H.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 479 EP 479 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801347 ER PT J AU Koreth, J Aldridge, J Kim, HT Alyea, EP Cutler, C Armand, P Ritz, J Antin, JH Soiffer, RJ Ho, VT AF Koreth, John Aldridge, Julie Kim, Haesook T. Alyea, Edwin P., III Cutler, Corey Armand, Philippe Ritz, Jerome Antin, Joseph H. Soiffer, Robert J. Ho, Vincent T. TI Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Hematologic Malignancies: Outcomes Are Not Impaired in Patients of Advanced Age. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Koreth, John; Alyea, Edwin P., III; Cutler, Corey; Armand, Philippe; Ritz, Jerome; Antin, Joseph H.; Soiffer, Robert J.; Ho, Vincent T.] Dana Farber Canc Inst, Div Hematol, Boston, MA 02115 USA. [Aldridge, Julie; Kim, Haesook T.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 496 EP 497 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725801388 ER PT J AU Ram, R Storb, RF Maloney, DG Sandmaier, BM Maris, M Shizuru, J Chauncey, T Langston, AA Georges, GE AF Ram, Ron Storb, Rainer F. Maloney, David G. Sandmaier, Brenda M. Maris, Michael Shizuru, Judith Chauncey, Thomas Langston, Amelia A. Georges, George E. TI Reduced Intensity Conditioning with Allogeneic Hematopoietic Cell Transplantation for the Treatment of High-Risk Acute Lymphoblastic Leukemia. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Ram, Ron; Storb, Rainer F.; Maloney, David G.; Sandmaier, Brenda M.; Georges, George E.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Ram, Ron; Storb, Rainer F.; Maloney, David G.; Sandmaier, Brenda M.; Georges, George E.] Univ Washington, Seattle, WA 98195 USA. [Maris, Michael] Rocky Mt Canc Ctr, Denver, CO USA. [Shizuru, Judith] Stanford Univ, Med Ctr, Stanford, CA 94305 USA. [Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Langston, Amelia A.] Emory Univ, Sch Med, Atlanta, GA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 497 EP 498 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725801390 ER PT J AU Rotem-Yehudar, R Armand, P Devine, S Fay, JW Hosing, C Mapara, MY Campagnero, E Uberti, JP Avigan, D Ballen, KK Winter, JN Nagler, A Gordon, LI AF Rotem-Yehudar, Rinat Armand, Philippe Devine, Steve Fay, Joseph W. Hosing, Chitra Mapara, Markus Y. Campagnero, Erica Uberti, Joseph P. Avigan, David Ballen, Karen K. Winter, Jane N. Nagler, Arnon Gordon, Leo I. TI The Humanized Anti PD-1 Antibody, CT-011, Increases Specific CD4+Effector/Memory and Memory T Lymphocytes in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Following Autologous Stem Cell Transplantation (AuSCT). SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Rotem-Yehudar, Rinat] CureTech Ltd, IL-81227 Yavne, Israel. [Armand, Philippe] Dana Farber Canc Inst, Boston, MA 02115 USA. [Devine, Steve] Ohio State Univ, Columbus, OH 43210 USA. [Fay, Joseph W.] Baylor Univ, Med Ctr, Dallas, TX USA. [Hosing, Chitra] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Mapara, Markus Y.] Univ Pittsburgh, Sch Med, Dept Med, Div Hematol Oncol, Pittsburgh, PA USA. [Mapara, Markus Y.] Inst Canc Res, Pittsburgh, PA USA. [Campagnero, Erica] Univ Michigan, Ctr Canc, Ann Arbor, MI 48109 USA. [Uberti, Joseph P.] Karmanos Canc Inst, Detroit, MI USA. [Avigan, David] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Ballen, Karen K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Gordon, Leo I.] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA. [Nagler, Arnon] Chaim Sheba Med Ctr, Div Hematol & Bone Marrow Transplantat, IL-52621 Tel Hashomer, Israel. RI mapara, markus/A-2134-2013 NR 0 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 500 EP 501 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725801396 ER PT J AU Richardson, PG Lonial, S Jakubowiak, AJ Jagannath, S Raje, NS Avigan, DE Ghobrial, I Schlossman, RL Mazumder, A Munshi, NC Laubach, J Vesole, D Joyce, R Rosenblatt, J Xie, WL Doss, D Warren, DL Ittleman, K Revta, C Francis, D Leister, C Kaster, S Delaney, C Lauria, M Mitsiades, CS Hideshima, T Knight, R Esseltine, DL Weller, E Anderson, KC AF Richardson, Paul G. Lonial, Sagar Jakubowiak, Andrzej J. Jagannath, Sundar Raje, Noopur S. Avigan, David E. Ghobrial, Irene Schlossman, Robert L. Mazumder, Amitabha Munshi, Nikhil C. Laubach, Jacob Vesole, David Joyce, Robin Rosenblatt, Jacalyn Xie, Wanling Doss, Deborah Warren, Diane L. Ittleman, Kate Revta, Carolyn Francis, Dixil Leister, Charles Kaster, Sarah Delaney, Carol Lauria, Marisa Mitsiades, Constantine S. Hideshima, Teru Knight, Robert Esseltine, Dixie-Lee Weller, Edie Anderson, Kenneth C. TI High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Richardson, Paul G.; Ghobrial, Irene; Schlossman, Robert L.; Munshi, Nikhil C.; Laubach, Jacob; Xie, Wanling; Doss, Deborah; Warren, Diane L.; Ittleman, Kate; Revta, Carolyn; Mitsiades, Constantine S.; Hideshima, Teru; Weller, Edie; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Lonial, Sagar; Francis, Dixil] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Jakubowiak, Andrzej J.; Leister, Charles] Univ Michigan, Ctr Comprehens Canc, Michigan, MI USA. [Jagannath, Sundar; Mazumder, Amitabha; Vesole, David] St Vincents Comprehens Can Ctr, New York, NY USA. [Raje, Noopur S.; Kaster, Sarah] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Avigan, David E.; Joyce, Robin; Rosenblatt, Jacalyn; Delaney, Carol; Lauria, Marisa] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Knight, Robert] Celgene Corp, Summit, NJ USA. [Esseltine, Dixie-Lee] Millennium Pharmaceut Inc, Cambridge, MA USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 501 EP 502 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725801398 ER PT J AU Danilov, AV Danilova, O Klein, A Brown, J Rabinowitz, AP Miller, KB Huber, BT AF Danilov, Alexey V. Danilova, Olga Klein, Andreas Brown, Jennifer Rabinowitz, Arthur P. Miller, Kenneth B. Huber, Brigitte T. TI ZAP-70 Disrupts Dipeptidyl Peptidase 2 (DPP2)-Regulated Quiescence in Chronic Lymphocytic Leukemia (CLL) SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Danilov, Alexey V.; Klein, Andreas; Miller, Kenneth B.] Tufts Med Ctr, Boston, MA USA. [Danilova, Olga; Huber, Brigitte T.] Tufts Univ, Boston, MA 02111 USA. [Brown, Jennifer] Dana Farber Canc Inst, Boston, MA 02115 USA. [Rabinowitz, Arthur P.] Lahey Clin Fdn, Burlington, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 515 EP 515 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801431 ER PT J AU Kai, X Chellappa, V Moya, J Taylor, KN Hochberg, EP Amrein, PC Pillai, S AF Kai, Xin Chellappa, Vasant Moya, Jesse Taylor, Kendra N. Hochberg, Ephraim P. Amrein, Philip C. Pillai, Shiv TI Defective Inhibitory Signaling in CLL B Cells and Increased Recruitment of PI3K by c-Cb1 in Zap-70+CLL SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Kai, Xin; Chellappa, Vasant; Moya, Jesse; Taylor, Kendra N.; Hochberg, Ephraim P.; Amrein, Philip C.; Pillai, Shiv] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 518 EP 518 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801438 ER PT J AU Nakase, K Cheng, JH Zhu, Q Marasco, WA AF Nakase, Koichi Cheng, Jihua Zhu, Quan Marasco, Wayne A. TI Unique Epigenetic Code of the SHP-1 P2 Promoter in HTLV-1 Transformed T-Cells, a Possible Mechanism of Resistance to Chemotherapy for Adult T-Cell Leukemia SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Nakase, Koichi; Cheng, Jihua; Zhu, Quan; Marasco, Wayne A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 522 EP 522 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801449 ER PT J AU Wieland, K Woo, A Akie, T Cantor, AB AF Wieland, Karen Woo, Andrew Akie, Thomas Cantor, Alan B. TI Increased Interferon-alpha a Signaling During Megakaryocyte Ontogeny: Implications for the Spontaneous Resolution of Down Syndrome Transient Myeloproliferative Disorder SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 Childrens Hosp Boston, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 523 EP 523 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801452 ER PT J AU Adamia, S Bar-Natan, M Stone, R Griffin, JD AF Adamia, Sophia Bar-Natan, Michal Stone, Richard Griffin, James D. TI Identification of Novel Splice Variants of Multiple Genes Using Genome-Wide Analysis of Alternative Splicing in Patients with Acute Myeloid Leukemia SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Adamia, Sophia] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 524 EP 525 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725801458 ER PT J AU Konig, H Kiefer, S Robbins, L Rauchman, M Salman, HS AF Konig, Heiko Kiefer, Susan Robbins, Lynn Rauchman, Michael Salman, Huda S. TI The Sal-Like 1 (SALL1) Protein is Highly Expressed in Primary Bone Marrow Cells Derived From Patients with Acute Myeloid Leukemia SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Konig, Heiko] St Louis Univ, Med Ctr, Dept Internal Med, St Louis, MO USA. [Kiefer, Susan; Robbins, Lynn; Rauchman, Michael] St Louis Vet Adm Med Ctr, Res & Educ Serv Line, Div Nephrol, US Dept Vet Affairs, St Louis, MO USA. [Salman, Huda S.] Case Western Reserve Univ, Div Hematol & Med Oncol, Cleveland, OH 44106 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 527 EP 527 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801465 ER PT J AU Howard, TE Cole, SA Kasper, CK Ameri, A Natarajan, K Watts, RG Manard, VA Nakaya, SM Kempton, CL Kennedy, M Kim, B Iyer, RV Almasy, L AF Howard, Tom E. Cole, Shelley A. Kasper, Carol K. Ameri, Afshin Natarajan, Kavita Watts, Raymond G. Manard, Valrie A. Nakaya, Shelley M. Kempton, Christine L. Kennedy, Martina Kim, Benjamin Iyer, Rathi V. Almasy, Laura TI The Role of Immune-Response Gene Variants in Inhibitor Development in Black Patients with Hemophilia SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Howard, Tom E.; Manard, Valrie A.; Kennedy, Martina] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Cole, Shelley A.; Almasy, Laura] SW Fdn Biomed Res, San Antonio, TX USA. [Kasper, Carol K.] Orthoped Hosp, Pasadena, CA USA. [Ameri, Afshin] Med Coll Georgia, Childrens Med Ctr, Augusta, GA 30912 USA. [Natarajan, Kavita] Med Coll Georgia, MCG Canc Ctr, Augusta, GA 30912 USA. [Watts, Raymond G.] Univ Alabama, Birmingham, AL USA. [Nakaya, Shelley M.] Puget Sound Blood Ctr, Seattle, WA 98104 USA. [Kempton, Christine L.] Emory Univ, Aflac Canc Ctr, Atlanta, GA 30322 USA. [Kempton, Christine L.] Emory Univ, Blood Disorders Serv, Atlanta, GA 30322 USA. [Kempton, Christine L.] Emory Univ, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA. [Kim, Benjamin] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Iyer, Rathi V.] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 533 EP 533 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801481 ER PT J AU Fuchs, T Brill, A Durschmied, D Schatzberg, D Hartwig, JH Myers, D Wakefield, TW Wagner, DD AF Fuchs, Tobias Brill, Alexander Duerschmied, Daniel Schatzberg, Daphne Hartwig, John H. Myers, Daniel Wakefield, Thomas W. Wagner, Denisa D. TI Neutrophil Extracellular Traps Induce Platelet Adhesion and Thrombus Formation. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Fuchs, Tobias; Brill, Alexander; Duerschmied, Daniel; Schatzberg, Daphne; Wagner, Denisa D.] Harvard Univ, Sch Med, Dept Pathol,Childrens Hosp, Immune Dis Inst,Program Cellular & Mol Med, Boston, MA 02115 USA. [Hartwig, John H.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Myers, Daniel; Wakefield, Thomas W.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 0 U2 5 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 549 EP 549 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801525 ER PT J AU Friese, CR Magazu, LS Neville, BA Richardson, LC Earle, CC Abel, GA AF Friese, Christopher R. Magazu, Lysa S. Neville, Bridget A. Richardson, Lisa C. Earle, Craig C. Abel, Gregory A. TI Diagnostic Delays and Survival for Medicare Patients with Chronic Myeloid Leukemia in the Pre-Imatinib Era SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Friese, Christopher R.] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA. [Magazu, Lysa S.; Neville, Bridget A.; Abel, Gregory A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Richardson, Lisa C.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Decatur, GA USA. [Earle, Craig C.] Canc Care Ontario, Inst Clin Evaluat Sci, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 557 EP 557 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801549 ER PT J AU Ciminello, L Toomey, CE Abramson, JS Sohani, AR Hochberg, EP AF Ciminello, Lauren Toomey, Christiana E. Abramson, Jeremy S. Sohani, Aliyah R. Hochberg, Ephraim P. TI Statins May Prolong Survival in Relapsed DLBCL by Upregulating p27: a Retrospective Case-Control Study SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Ciminello, Lauren] SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA. [Toomey, Christiana E.; Abramson, Jeremy S.; Hochberg, Ephraim P.] Massachusetts Gen Hosp, Ctr Canc, Ctr Lymphoma, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 562 EP 562 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801560 ER PT J AU Abel, GA Vanderplas, A Friedberg, JW Niland, J Rodriguez, MA Czuczman, MS Millenson, M Crosby, AL Gordon, LI Blayney, DW Zelenetz, AD LaCasce, AS AF Abel, Gregory A. Vanderplas, Ann Friedberg, Jonathan W. Niland, Joyce Rodriguez, Maria A. Czuczman, Myron S. Millenson, Michael Crosby, Allison L. Gordon, Leo I. Blayney, Douglas W. Zelenetz, Andrew D. LaCasce, Ann S. TI Variations in Surveillance Imaging for Patients with Treated Diffuse Large B-Cell Lymphoma in the National Comprehensive Cancer Network (NCCN) Lymphoma Database SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Abel, Gregory A.; Crosby, Allison L.; LaCasce, Ann S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Vanderplas, Ann; Niland, Joyce] City Hope Natl Med Ctr, Duarte, CA 91010 USA. [Friedberg, Jonathan W.] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA. [Rodriguez, Maria A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Czuczman, Myron S.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Millenson, Michael] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Gordon, Leo I.] Northwestern Univ, Dept Med, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA. [Blayney, Douglas W.] Univ Michigan, Ctr Canc, Ann Arbor, MI 48109 USA. [Zelenetz, Andrew D.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 565 EP 565 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801567 ER PT J AU Nombela-Arrieta, C Harley, B Pivarnik, G Mahoney, JE Levantini, E Protopopov, A Tenen, DG Silberstein, LE AF Nombela-Arrieta, Cesar Harley, Brendan Pivarnik, Gregory Mahoney, John E. Levantini, Elena Protopopov, Alexei Tenen, Daniel G. Silberstein, Leslie E. TI Quantitative Imaging of Femoral Bone Marrow Microenvironments Reveals a Heterogenous Distribution of Hematopoietic Stem and Progenitor Cells. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting and Exposition of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Nombela-Arrieta, Cesar] Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA. [Harley, Brendan] Univ Illinois, Dept Chem & Biomol Engn, Chicago, IL 60680 USA. [Mahoney, John E.; Protopopov, Alexei] Dana Farber Canc Inst, Boston, MA 02115 USA. [Levantini, Elena] Harvard Univ, Sch Med, Harvard Inst Med, Harvard Stem Cell Inst, Boston, MA USA. [Tenen, Daniel G.] Natl Univ Singapore, Canc Sci Inst, Singapore 117548, Singapore. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 589 EP 589 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801635 ER PT J AU Iino, T Jeong, Y Mizuno, S Kohno, K Ito, K Tenen, DG Reizis, B Akashi, K AF Iino, Tadafumi Jeong, Yong Mizuno, Shin-ichi Kohno, Kentaro Ito, Kyoko Tenen, Daniel G. Reizis, Boris Akashi, Koichi TI PU.1 Is Indispensable for Development of Mature Dendritic Cells and Their Function That Plays a Critical Role in Maintenance of Normal T Cell Pool. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Iino, Tadafumi; Jeong, Yong; Mizuno, Shin-ichi; Kohno, Kentaro; Ito, Kyoko; Akashi, Koichi] Dana Farber Canc Inst, Boston, MA 02115 USA. [Tenen, Daniel G.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Reizis, Boris] Columbia Univ, Coll Phys & Surg, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 593 EP 593 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801651 ER PT J AU Medicetty, S Ratajczak, MZ Kucia, MJ Zuba-Surma, EK Klich, I Marasco, WA Rodgerson, DO AF Medicetty, Satish Ratajczak, Mariusz Z. Kucia, Magdalena J. Zuba-Surma, Ewa K. Klich, Izabela Marasco, Wayne A. Rodgerson, Denis O. TI Evidence That Human Very Small Embryonic-Like Stem Cells (VSELs) Are Mobilized by G-CSF Into Peripheral Blood: A Novel Strategy to Obtain Human Pluripotent Stem Cells for Regenerative Medicine. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Medicetty, Satish; Rodgerson, Denis O.] NeoStem Inc, New York, NY USA. [Ratajczak, Mariusz Z.; Kucia, Magdalena J.; Zuba-Surma, Ewa K.; Klich, Izabela] Univ Louisville, James Graham Brown Canc Ctr, Stem Cell Inst, Louisville, KY 40292 USA. [Marasco, Wayne A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. RI Kucia, Magdalena/O-8058-2014; Ratajczak, Mariusz Zdzislaw/N-1599-2014 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 594 EP 594 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801654 ER PT J AU Rizzoli, V Masselli, E Prezioso, L Ferraro, F Lodi-Rizzini, E Mangoni, M Graiani, G Frati, C Spinetti, G Reni, C Emanueli, C Madeddu, P Quaini, F AF Rizzoli, Vittorio Masselli, Elena Prezioso, Lucia Ferraro, Francesca Lodi-Rizzini, Elisa Mangoni, Marcellina Graiani, Gallia Frati, Caterina Spinetti, Gaia Reni, Carlotta Emanueli, Costanza Madeddu, Paolo Quaini, Federico TI Diabetes Impairs Bone Marrow Microenvironment Affecting Progenitor Cell Number, Mobilization and Engraftment in Humans. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Rizzoli, Vittorio; Mangoni, Marcellina] Univ Parma, Hematol Unit, I-43100 Parma, Italy. [Rizzoli, Vittorio; Mangoni, Marcellina] Univ Parma, BMT, I-43100 Parma, Italy. [Ferraro, Francesca] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Regenerat Med, Boston, MA USA. [Spinetti, Gaia; Emanueli, Costanza; Madeddu, Paolo] Univ Bristol, Bristol Heart Inst, Bristol BS8 1TH, Avon, England. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 597 EP 597 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801662 ER PT J AU Harris, J Cutting, CC Dovey, M Goessling, W North, T AF Harris, James Cutting, Claire C. Dovey, Michael Goessling, Wolfram North, Trista TI Metabolic Endocrine Regulators of Hematopoietic Stem Cell Formation and Function SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Harris, James; Dovey, Michael; North, Trista] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA. [Cutting, Claire C.; Goessling, Wolfram] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Genet, Boston, MA 02115 USA. [Goessling, Wolfram] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Gastroenterol, Boston, MA 02115 USA. [Goessling, Wolfram] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 601 EP 601 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801676 ER PT J AU Bungartz, G Garrett, R Emerson, SG AF Bungartz, Gerd Garrett, Russell Emerson, Stephen G. TI NF-Ya Is Essential for Hematopoieic Stem Cell Proliferation. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Bungartz, Gerd] Massachusetts Gen Hosp, HMS, Ctr Regenerat Med, Boston, MA 02114 USA. [Garrett, Russell; Emerson, Stephen G.] Haverford Coll, Haverford, PA 19041 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 604 EP 604 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801687 ER PT J AU Whitman, SP Maharry, K Radmacher, MD Mrozek, K Margeson, D Holland, KB Becker, H Wu, YZ Schwind, S Baer, MR Powell, BL Stone, RM Carroll, AJ Larson, RA Caligiuri, MA Marcucci, G Bloomfield, CD AF Whitman, Susan P. Maharry, Kati Radmacher, Michael D. Mrozek, Krzysztof Margeson, Dean Holland, Kelsi B. Becker, Heiko Wu, Yue-Zong Schwind, Sebastian Baer, Maria R. Powell, Bayard L. Stone, Richard M. Carroll, Andrew J. Larson, Richard A. Caligiuri, Michael A. Marcucci, Guido Bloomfield, Clara D. TI Adverse Prognostic Impact of FLT3 Internal Tandem Duplication (ITD) Is Age-Associated in Older [>= 60 Years (Y)] De Novo cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Whitman, Susan P.; Maharry, Kati; Radmacher, Michael D.; Mrozek, Krzysztof; Margeson, Dean; Holland, Kelsi B.; Becker, Heiko; Wu, Yue-Zong; Schwind, Sebastian; Caligiuri, Michael A.; Marcucci, Guido; Bloomfield, Clara D.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. [Baer, Maria R.] Univ Maryland, Baltimore, MD 21201 USA. [Powell, Bayard L.] Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27109 USA. [Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Carroll, Andrew J.] Univ Alabama, Dept Genet, Birmingham, AL USA. [Larson, Richard A.] Univ Chicago, Hematol Oncol Sect, Chicago, IL 60637 USA. RI Mrozek, Krzysztof/A-3142-2008 NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 631 EP 632 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725801759 ER PT J AU Attar, EC Maharry, K Mrozek, K Radmacher, MD Whitman, SP Paschka, P Langer, C Holland, KB Powell, BL Kolitz, JE Carroll, AJ Larson, RA Marcucci, G Bloomfield, CD AF Attar, Eyal C. Maharry, Kati Mrozek, Krzysztof Radmacher, Michael D. Whitman, Susan P. Paschka, Peter Langer, Christian Holland, Kelsi B. Powell, Bayard L. Kolitz, Jonathan E. Carroll, Andrew J. Larson, Richard A. Marcucci, Guido Bloomfield, Clara D. TI Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Attar, Eyal C.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. [Maharry, Kati; Mrozek, Krzysztof; Radmacher, Michael D.; Whitman, Susan P.; Paschka, Peter; Langer, Christian; Holland, Kelsi B.; Marcucci, Guido; Bloomfield, Clara D.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. [Powell, Bayard L.] Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27109 USA. [Kolitz, Jonathan E.] N Shore Univ Hosp, Lake Success, NY USA. [Carroll, Andrew J.] Univ Alabama, Dept Genet, Birmingham, AL USA. [Larson, Richard A.] Univ Chicago, Chicago, IL 60637 USA. RI Mrozek, Krzysztof/A-3142-2008 NR 0 TC 3 Z9 3 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 645 EP 646 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725801796 ER PT J AU Heerema, NA Byrd, JC Dal Cin, P Dell'Aquila, ML Koduru, P Aviram, A Smoley, S Rassenti, LZ Greaves, A Brown, JR Rai, KR Kipps, TJ Kay, NE van Dyke, D AF Heerema, Nyla A. Byrd, John C. Dal Cin, Paola Dell'Aquila, Marie L. Koduru, Prasad Aviram, Ayala Smoley, Stephanie Rassenti, Laura Z. Greaves, Andrew Brown, Jennifer R. Rai, Kanti R. Kipps, Thomas J. Kay, Neil E. van Dyke, Daniel TI Karyotype Results From CpG Oligodeoxynucleotide Stimulated Chronic Lymphocytic Leukemia (CLL) Cultures Are Consistent Among Laboratories: a CLL Research Consortium (CRC) Study. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Byrd, John C.] Ohio State Univ, Coll Med, Columbus, OH 43210 USA. [Dal Cin, Paola] Brigham & Womens Hosp, Boston, MA 02115 USA. [Dell'Aquila, Marie L.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA. [Koduru, Prasad] N Shore Hosp, Manhasset, NY USA. [Aviram, Ayala] N Shore Long Isl Jewish Med Ctr, New Hyde Pk, NY USA. [Smoley, Stephanie; Kay, Neil E.; van Dyke, Daniel] Mayo Clin, Rochester, MN USA. [Rassenti, Laura Z.; Kipps, Thomas J.] CLL Res Consortium, Moores UCSD Canc Ctr, La Jolla, CA USA. [Greaves, Andrew] Moores Canc Ctr, UCSD, Dept Med, Div Hematol Oncol, La Jolla, CA USA. [Brown, Jennifer R.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Rai, Kanti R.] N Shore Long Isl Jewish Hlth Syst, Dept Med, New Hyde Pk, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 645 EP 645 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801794 ER PT J AU Song, WH Tai, YT Tian, Z Hideshima, T Chauhan, D Nanjappa, P Exley, MA Anderson, KC Munshi, NC AF Song, Weihua Tai, Yu-Tzu Tian, Ze Hideshima, Teru Chauhan, Dharminder Nanjappa, Puru Exley, Mark A. Anderson, Kenneth C. Munshi, Nikhil C. TI HDAC Inhibition by LBH589 Affects Phenotype and Function of Human Dendritic Cells. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, VA Boston Hlth Care Syst, Boston, MA 02115 USA. [Exley, Mark A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 657 EP 658 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725802014 ER PT J AU Kahl, BS Li, HL Smith, MR Gascoyne, RD Paietta, E Advani, R Horning, SJ AF Kahl, Brad S. Li, Hailun Smith, Mitchell R. Gascoyne, Randy D. Paietta, Elisabeth Advani, Ranjana Horning, Sandra J. TI The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405-A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Kahl, Brad S.] Univ Wisconsin, Dept Med, Hematol Oncol Sect, Sch Med & Publ Hlth, Madison, WI USA. [Li, Hailun] Dana Farber Canc Inst, Boston, MA 02115 USA. [Smith, Mitchell R.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Gascoyne, Randy D.] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada. [Paietta, Elisabeth] Montefiore Med Ctr N Div, Ctr Canc, Bronx, NY USA. [Advani, Ranjana; Horning, Sandra J.] Stanford Univ, Stanford, CA 94305 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 663 EP 663 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725802029 ER PT J AU Barnes, JA LaCasce, AS Feng, Y Toomey, C Neuberg, D Hochberg, EP Abramson, JS AF Barnes, Jeffrey A. LaCasce, Ann S. Feng, Yang Toomey, Christiana Neuberg, Donna Hochberg, Ephraim P. Abramson, Jeremy S. TI Rituximab Added to CODOX-M/IVAC has No Clear Benefit Compared to CODOX-M/IVAC alone in Adult Patients with Burkitt Lymphoma. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Barnes, Jeffrey A.; Toomey, Christiana; Hochberg, Ephraim P.; Abramson, Jeremy S.] Massachusetts Gen Hosp, Ctr Canc, Ctr Lymphoma, Boston, MA USA. [LaCasce, Ann S.; Feng, Yang; Neuberg, Donna] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 665 EP 666 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725802035 ER PT J AU Advani, RH Hong, FX Ganjoo, KN Manola, JB Swinnen, LJ Habermann, TM Horning, SJ AF Advani, Ranjana H. Hong, Fangxin Ganjoo, Kristen N. Manola, Judith B. Swinnen, Lode J. Habermann, Thomas M. Horning, Sandra J. TI Cardiac Toxicity Associated with the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin) in Combination with CROP (A-CHOP) Chemotherapy for Peripheral T Cell Lymphoma (PTCL): The ECOG 2404 Trial. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Advani, Ranjana H.; Horning, Sandra J.] Stanford Univ, Stanford, CA 94305 USA. [Hong, Fangxin; Manola, Judith B.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Ganjoo, Kristen N.] Stanford Univ, Palo Alto VAHCS, Palo Alto, CA 94304 USA. [Swinnen, Lode J.] Johns Hopkins Canc Ctr, Div Hem Malignancy, Baltimore, MD USA. [Habermann, Thomas M.] Mayo Clin, Coll Med, Rochester, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 667 EP 667 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725802039 ER PT J AU Gerstner, ER Hochberg, FH Plotkin, SR Eichler, AF Batchelor, TT AF Gerstner, Elizabeth R. Hochberg, Fred H. Plotkin, Scott R. Eichler, April F. Batchelor, Tracy T. TI High-Dose Methotrexate, Rituximab, and Temozolomide (MRT) for Patients with Primary CNS Lymphoma (PCNSL). SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Gerstner, Elizabeth R.; Plotkin, Scott R.; Eichler, April F.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Hochberg, Fred H.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 667 EP 667 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725802040 ER PT J AU Wilson, WH O'Connor, OA Czuczman, MS LaCasce, A Gerecitano, J Leonard, JP Tulpule, A Xiong, H Chiu, YL Busman, T Enschede, S Krivoshik, A Humerickhouse, R AF Wilson, Wyndham H. O'Connor, Owen A. Czuczman, Myron S. LaCasce, Ann Gerecitano, John Leonard, John P. Tulpule, Anil Xiong, Hao Chiu, Yi-Lin Busman, Todd Enschede, Sari Krivoshik, Andrew Humerickhouse, Rod TI Phase 1/2a Study of ABT-263 in Relapsed or Refractory Lymphoid Malignancies. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Wilson, Wyndham H.] NCI, CCR, NIH, Bethesda, MD 20892 USA. [O'Connor, Owen A.] NYU, Langone Med Ctr, Inst Canc, New York, NY USA. [Czuczman, Myron S.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [LaCasce, Ann] Dana Farber Canc Inst, Boston, MA 02115 USA. [Gerecitano, John] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, New York, NY 10021 USA. [Leonard, John P.] Weill Cornell Med Coll, New York, NY USA. [Tulpule, Anil] USC, Sch Med, Norris Canc Ctr, Los Angeles, CA USA. [Xiong, Hao; Chiu, Yi-Lin; Busman, Todd; Enschede, Sari; Krivoshik, Andrew; Humerickhouse, Rod] Abbott Labs, Abbott Pk, IL 60064 USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 682 EP 682 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725802079 ER PT J AU McMillin, D Delmore, J Weisberg, E Negri, JM Klippel, S Mitsiades, N Munshi, NC Griffin, JD Richardson, PG Anderson, KC Kung, AL Mitsiades, CS AF McMillin, Douglas Delmore, Jake Weisberg, Ellen Negri, Joseph M. Klippel, Steffen Mitsiades, Nicholas Munshi, Nikhil C. Griffin, James D. Richardson, Paul G. Anderson, Kenneth C. Kung, Andrew L. Mitsiades, Constantine S. TI Microenvironment-Dependent Synthetic Lethality: Implications for Tumor Pathophysiology and Anti-Cancer Drug Discovery. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [McMillin, Douglas; Delmore, Jake; Weisberg, Ellen; Negri, Joseph M.; Klippel, Steffen; Mitsiades, Nicholas; Munshi, Nikhil C.; Griffin, James D.; Richardson, Paul G.; Anderson, Kenneth C.; Kung, Andrew L.; Mitsiades, Constantine S.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 686 EP 686 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725802090 ER PT J AU Ooi, MG O'Connor, R Jakubikova, J Meiller, J Klippel, S Delmore, J Kastritis, E McMillin, D Clynes, M Richardson, P Mitsiades, CS O'Gorman, P Anderson, KC AF Ooi, Melissa G. O'Connor, Robert Jakubikova, Jana Meiller, Justine Klippel, Steffen Delmore, Jake Kastritis, Efstathios McMillin, Douglas Clynes, Martin Richardson, Paul Mitsiades, Constantine S. O'Gorman, Peter Anderson, Kenneth C. TI The Interaction of Bortezomib with P-Gp, MRP-1 and BCRP Drug Transporters: Implications for Therapeutic Applications of Bortezomib in Advanced Multiple Myeloma and Other Neoplasias. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Ooi, Melissa G.; Jakubikova, Jana; Klippel, Steffen; Delmore, Jake; Kastritis, Efstathios; McMillin, Douglas; Richardson, Paul; Mitsiades, Constantine S.; Anderson, Kenneth C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [O'Connor, Robert; Meiller, Justine; Clynes, Martin] Dublin City Univ, NICB, Dublin 9, Ireland. [O'Gorman, Peter] Mater Misericordiae Univ Hosp, Dublin 7, Ireland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 688 EP 689 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725802097 ER PT J AU Kampa, KM Mueller, S Rasp, KH Kanz, L Heinrich, MC Schittenhelm, MM AF Kampa, Kerstin M. Mueller, Sandra Rasp, Katharina-Henriette Kanz, Lothar Heinrich, Michael C. Schittenhelm, Marcus M. TI FLT3 and KIT Isoforms Activate PI3K/AKT Signaling Which Is Potently Blocked by the Novel Dual PI3K/Mtor Inhibitors NVP-BEZ235 and NVP-BGT226. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Kampa, Kerstin M.; Mueller, Sandra; Rasp, Katharina-Henriette] Univ Hosp Tuebingen, Tubingen, Germany. [Kanz, Lothar] Univ Tubingen, Dept Hematol Oncol Immunol Rheumatol & Pneumol, Med Ctr 2, Tubingen, Germany. [Heinrich, Michael C.] Oregon Hlth & Sci Univ, Inst Canc, Portland, OR 97201 USA. [Heinrich, Michael C.] Portland VA Med Ctr, Portland, OR USA. [Schittenhelm, Marcus M.] Univ Tubingen, Dept Hematol Oncol Rheumatol Immunol & Pulmol, Tubingen, Germany. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 692 EP 692 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725802108 ER PT J AU Klippel, S Jakubikova, J Delmore, J Ooi, MG McMillin, D Kastritis, E Laubach, J Richardson, PG Anderson, KC Mitsiades, CS AF Klippel, Steffen Jakubikova, Jana Delmore, Jake Ooi, Melissa G. McMillin, Douglas Kastritis, Efstathios Laubach, Jacob Richardson, Paul G. Anderson, Kenneth C. Mitsiades, Constantine S. TI Methyljasmonate, An Inhibitor of Glycolytic Energy Production, Displays Pre-Clinical Activity against Multiple Myeloma Cells. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Klippel, Steffen; Jakubikova, Jana; Delmore, Jake; Ooi, Melissa G.; McMillin, Douglas; Kastritis, Efstathios; Laubach, Jacob; Richardson, Paul G.; Anderson, Kenneth C.; Mitsiades, Constantine S.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 692 EP 692 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725802109 ER PT J AU Sekeres, MA Maciejewski, JP List, AF Steensma, DP Artz, A Swern, AS Scribner, P Huber, J Stone, R AF Sekeres, Mikkael A. Maciejewski, Jaroslaw P. List, Alan F. Steensma, David P. Artz, Andrew Swern, Arlene S. Scribner, Paul Huber, John Stone, Richard TI Perceptions of Disease State, Treatment Expectations, and Prognosis Among Patients with Myelodysplastic Syndromes SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Maciejewski, Jaroslaw P.] Cleveland Clin, Taussig Canc Ctr, Dept Translat Hematol & Oncol Res, Cleveland, OH 44106 USA. [List, Alan F.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL 33612 USA. [Steensma, David P.] Dana Farber Canc Inst, Dept Hematol Malignancies, Boston, MA 02115 USA. [Artz, Andrew] Univ Chicago Hosp, Chicago, IL 60637 USA. [Swern, Arlene S.] Celgene Corp, Summit, NJ USA. [Scribner, Paul; Huber, John] Aplast Anemia & MDS Int Fdn, Rockville, MD USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 704 EP 705 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725802139 ER PT J AU Gatt, ME Mani, M Lerner, M Hideshima, T Zhang, YY Dutta, J Carrasco, DE Protopopov, A Sangfelt, O Grander, D Barlogie, B Shaughnessy, JD Anderson, KC Carrasco, DR AF Gatt, Moshe E. Mani, Mala Lerner, Mikael Hideshima, Teru Zhang, Yunyu Dutta, Jui Carrasco, Daniel E. Protopopov, Alexei Sangfelt, Olle Grander, Dan Barlogie, Bart Shaughnessy, John D., Jr. Anderson, Kenneth C. Carrasco, Daniel Ruben TI RFP2 Modulates 20S Proteasome Activity, NF Kappa B Activation, and Tumor Cell Growth in Multiple Myeloma. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Gatt, Moshe E.; Zhang, Yunyu; Dutta, Jui] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Dis Ctr, Boston, MA 02115 USA. [Lerner, Mikael; Sangfelt, Olle] Karolinska Inst, Dept Pathol & Oncol, Stockholm, Sweden. [Lerner, Mikael; Sangfelt, Olle] Karolinska Univ Hosp, Stockholm, Sweden. [Grander, Dan] Karolinska Hosp & Inst, Stockholm, Sweden. [Barlogie, Bart; Shaughnessy, John D., Jr.] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 710 EP 710 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725802154 ER PT J AU Roccaro, AM Sacco, A Azab, AK Azab, F Ngo, H Melhem, MR Quong, P Runnels, JM Anderson, KC Ghobrial, I AF Roccaro, Aldo M. Sacco, Antonio Azab, Abdel Kareem Azab, Feda Ngo, Hai Melhem, Molly R. Quong, Phong Runnels, Judith M. Anderson, Kenneth C. Ghobrial, Irene TI MicroRNA Changes Occur in Multiple Myeloma Cells in the Context of Bone Marrow Milieu. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Roccaro, Aldo M.; Sacco, Antonio; Azab, Abdel Kareem; Azab, Feda; Ngo, Hai; Melhem, Molly R.; Quong, Phong; Runnels, Judith M.; Anderson, Kenneth C.; Ghobrial, Irene] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 710 EP 710 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725802153 ER PT J AU Vallet, S Mukherjee, S Vaghela, N Hideshima, T Fulciniti, M Pozzi, S Santo, L Cirstea, D Rahemtullah, A Attar, EC Guimaraes, AR Chauhan, D Xie, WL Patel, C Schoonmaker, J Churchill, M Patel, K Weller, E Munshi, NC Seehra, J Anderson, KC Scadden, DT Raje, N AF Vallet, Sonia Mukherjee, Siddhartha Vaghela, Nileshwari Hideshima, Teru Fulciniti, Mariateresa Pozzi, Samantha Santo, Loredana Cirstea, Diana Rahemtullah, Aliyah Attar, Eyal C. Guimaraes, Alexander R. Chauhan, Dharminder Xie, Wanling Patel, Chirayu Schoonmaker, Jesse Churchill, Michael Patel, Kishan Weller, Edie Munshi, Nikhil C. Seehra, Jasbir Anderson, Kenneth C. Scadden, David T. Raje, Noopur TI Molecular Sequaele of Activin A-Dependent Osteoblast Inhibition in Myeloma. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Vallet, Sonia; Vaghela, Nileshwari; Attar, Eyal C.; Churchill, Michael; Patel, Kishan] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. [Guimaraes, Alexander R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Mol Imaging Res, Boston, MA 02114 USA. [Guimaraes, Alexander R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Boston, MA 02114 USA. [Patel, Chirayu; Schoonmaker, Jesse] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Regenerat Med, Boston, MA USA. [Weller, Edie] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston VA Healthcare Syst, Boston, MA 02115 USA. [Scadden, David T.] MGH Ctr Regenerat Med, Boston, MA USA. [Seehra, Jasbir] Acceleron Pharma Inc, Cambridge, MA USA. RI Pozzi, Samantha/A-7617-2012 OI Pozzi, Samantha/0000-0001-7917-1774 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 711 EP 711 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725802157 ER PT J AU Bruns, I Bust, S Czibere, AG Cadeddu, RP Bruckmann, I Bhasin, M Fischer, JC Fenk, R Kobbe, G Trumpp, A Haas, R AF Bruns, Ingmar Buest, Sebastian Czibere, Akos G. Cadeddu, Ron-Patrick Brueckmann, Ines Bhasin, Manoj Fischer, Johannes C. Fenk, Roland Kobbe, Guido Trumpp, Andreas Haas, Rainer TI Malignant Myeloma Cells Impair Phenotype and Function of stem and Progenitor Cells. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Cadeddu, Ron-Patrick; Kobbe, Guido] Univ Dusseldorf, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany. [Czibere, Akos G.] Univ Hosp Duesseldorf, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany. [Brueckmann, Ines; Trumpp, Andreas] DKFZ, Div Stem Cells & Canc, Heidelberg, Germany. [Bhasin, Manoj] BIDMC, Genom Ctr, Boston, MA USA. [Fischer, Johannes C.] Univ Dusseldorf, Inst Transplantat Diagnost & Cell Therapeut, Dusseldorf, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 715 EP 715 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725802167 ER PT J AU Mahindra, A Amin, SB Motyckova, G Sohani, AR Patel, K Vallet, S Chetri, G Ackerman, A Pozzi, S Santo, L Cirstea, D Toomey, CE Hochberg, EP Dal Cin, P Hideshima, T Anderson, KC Munshi, N Raje, N AF Mahindra, Anuj Amin, Samir B. Motyckova, Gabriela Sohani, Aliyah R. Patel, Kishan Vallet, Sonia Chetri, Gaurav Ackerman, Adam Pozzi, Samantha Santo, Loredana Cirstea, Diana Toomey, Christiana E. Hochberg, Ephraim P. Dal Cin, Paola Hideshima, Teru Anderson, Kenneth C. Munshi, Nikhil Raje, Noopur TI Molecular Profiling of Extramedullary and Medullary Plasmacytomas SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Patel, Kishan; Vallet, Sonia] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA. [Amin, Samir B.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston VA Healthcare Syst, Boston, MA 02115 USA. [Toomey, Christiana E.; Hochberg, Ephraim P.] Massachusetts Gen Hosp, Ctr Canc, Ctr Lymphoma, Boston, MA USA. [Dal Cin, Paola] Brigham & Womens Hosp, Boston, MA 02115 USA. RI Pozzi, Samantha/A-7617-2012 OI Pozzi, Samantha/0000-0001-7917-1774 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 717 EP 718 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725802174 ER PT J AU Ooi, MG Dowling, P Richardson, P Mitsiades, CS Clynes, M Anderson, KC O'Gorman, P AF Ooi, Melissa G. Dowling, Paul Richardson, Paul Mitsiades, Constantine S. Clynes, Martin Anderson, Kenneth C. O'Gorman, Peter TI Proteomics as a Functional Tool in Evaluating Bortezomib Treatment and Drug Resistance Mechanism SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Ooi, Melissa G.; Richardson, Paul; Mitsiades, Constantine S.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Dowling, Paul; Clynes, Martin] Dublin City Univ, NICB, Dublin 9, Ireland. [O'Gorman, Peter] Mater Misericordiae Univ Hosp, Dublin 7, Ireland. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 717 EP 717 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725802173 ER PT J AU Fulciniti, M Sundararaman, S Nanjappa, P Amin, SB Chevireddy, P Gokden, N Hiatt, K High, W Shammas, MA Prabhala, R Hideshima, T Tassone, P Anderson, KC Shah, SV Munshi, NC AF Fulciniti, Mariateresa Sundararaman, Swaminathan Nanjappa, Puru Amin, Samir B. Chevireddy, Prajwal Gokden, Neriman Hiatt, Kim High, Whitney Shammas, Masood A. Prabhala, Rao Hideshima, Teru Tassone, Pierfrancesco Anderson, Kenneth C. Shah, Sudhir V. Munshi, Nikhil C. TI Gadolinium Containing Contrast Agent Promotes Multiple Myeloma Cell Growth: Implication for Clinical Use of MRI in Myeloma SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Sundararaman, Swaminathan; Hiatt, Kim; Shah, Sudhir V.] Univ Arkansas, Little Rock, AR 72204 USA. [Amin, Samir B.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston VA Healthcare Syst, Boston, MA 02115 USA. [Gokden, Neriman] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA. [Shammas, Masood A.] VA Boston Hlth Care Syst DFCI, W Roxbury, MA USA. [Prabhala, Rao] VA Boston Hlth Care Syst DFCI HMS, W Roxbury, MA USA. [Hideshima, Teru] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Dis Ctr, Boston, MA 02115 USA. [Tassone, Pierfrancesco] Magna Graecia Univ Catanzaro, Catanzaro, Italy. [Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston VA Canc Healthcare Syst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 719 EP 719 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725802177 ER PT J AU Ngo, HT Leontovich, AA Roccaro, AM Azab, AK Runnels, JM Azab, F Sacco, A Quang, P Anderson, KC Ghobrial, IM AF Ngo, Hai T. Leontovich, Alexey A. Roccaro, Aldo M. Azab, Abdel Kareem Runnels, Judith M. Azab, Feda Sacco, Antonio Quang, Phong Anderson, Kenneth C. Ghobrial, Irene M. TI Citron Rho Interacting Kinase (CRIK) Regulates Survival in IL-6 Dependent Multiple Myeloma Cells. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Ngo, Hai T.; Roccaro, Aldo M.; Azab, Abdel Kareem; Runnels, Judith M.; Azab, Feda; Sacco, Antonio; Quang, Phong; Anderson, Kenneth C.; Ghobrial, Irene M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Leontovich, Alexey A.] Mayo Clin, Coll Med, Rochester, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 725 EP 725 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725802193 ER PT J AU Runnels, JM Azab, AK Pitsillides, C Farag, J Wu, J Roccaro, AN Maiso, P Lin, CP Ghobrial, IM AF Runnels, Judith M. Azab, Abdel Kareem Pitsillides, Costas Farag, Jonathan Wu, Juwell Roccaro, Aldo N. Maiso, Patricia Lin, Charles P. Ghobrial, Irene M. TI The Effect of the CXCR4 Inhibitors, AMD3100 and AMD3465, in Multiple Myeloma Cell Homing and Its Interaction with the Bone Marrow Microenvironment. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Runnels, Judith M.; Azab, Abdel Kareem; Farag, Jonathan; Roccaro, Aldo N.; Maiso, Patricia; Ghobrial, Irene M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Pitsillides, Costas; Wu, Juwell; Lin, Charles P.] Massachusetts Gen Hosp, Ctr Syst Biol, Adv Microscopy Program, Boston, MA 02114 USA. [Pitsillides, Costas; Wu, Juwell; Lin, Charles P.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 725 EP 725 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725802194 ER PT J AU Fulcintti, M Hideshima, T Nanjappa, P Rodig, S Amin, SB Pelluru, D Pal, J Prabhala, R Shammas, MA Tassone, P Mohrland, S Anderson, KC Munshi, NC AF Fulcintti, Mariateresa Hideshima, Teru Nanjappa, Puru Rodig, Scott Amin, Samir B. Pelluru, Dheeraj Pal, Jagannath Prabhala, Rao Shammas, Masood A. Tassone, Pierfrancesco Mohrland, Scott Anderson, Kenneth C. Munshi, Nikhil C. TI Significant Biological Role of Sp1 Transactivation in Myeloma: Potential Therapeutic Application SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Fulcintti, Mariateresa; Nanjappa, Puru] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Rodig, Scott] Harvard Univ, Brigham & Womens Hosp, Dept Pathol, Sch Med, Boston, MA 02115 USA. [Amin, Samir B.; Pal, Jagannath; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston VA Healthcare Syst, Boston, MA 02115 USA. [Pelluru, Dheeraj] Boston VAMC, R&D, W Roxbury, MA USA. [Prabhala, Rao] HMS, DFCI, VA Boston Hlth Care Syst, W Roxbury, MA USA. [Tassone, Pierfrancesco] Magna Graecia Univ Catanzaro, Catanzaro, Italy. [Mohrland, Scott] Erimos Pharmaceut, Raleigh, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 731 EP 731 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725802209 ER PT J AU Podar, K Zimmerhackl, A Hainz, U Fulciniti, M Vallet, S Olsen, D Tai, YT Hideshima, T Chauhan, D Anderson, KC AF Podar, Klaus Zimmerhackl, Alexander Hainz, Ursula Fulciniti, Mariateresa Vallet, Sonia Olsen, Dian Tai, Yu-Tzu Hideshima, Teru Chauhan, Dharminder Anderson, Kenneth C. TI Potential Therapeutic Role of the Selective Adhesion Molecule (SAM) Inhibitor Natalizumab in Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Podar, Klaus; Zimmerhackl, Alexander; Hainz, Ursula; Fulciniti, Mariateresa; Tai, Yu-Tzu; Hideshima, Teru; Anderson, Kenneth C.] Harvard Univ, Dept Med Oncol, Dana Farber Canc Inst, Sch Med,Jerome Lipper Multiple Myeloma Ctr, Boston, MA USA. [Vallet, Sonia] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Olsen, Dian] Biogen Idec Inc, Oncol Mol Discovery, Cambridge, MA USA. NR 0 TC 1 Z9 2 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 734 EP 734 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725802218 ER PT J AU Prabhala, RH Efebera, YA Lee, S Han, AJ Pelluru, D Nanjappa, P Amin, S Pai, C Ghobrial, I Schlossman, RL Laubach, J Fulciniti, M Richardson, P Anderson, KC Munshi, NC AF Prabhala, Rao H. Efebera, Yvonne A. Lee, Saem Han, Andrew J. Pelluru, Dheeraj Nanjappa, Puru Amin, Samir Pai, Christine Ghobrial, Irene Schlossman, Robert L. Laubach, Jacob Fulciniti, Mariateresa Richardson, Paul Anderson, Kenneth C. Munshi, Nikhil C. TI Lack of Response to Vaccination in MGUS and Stable Myeloma SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Prabhala, Rao H.; Lee, Saem; Pai, Christine] VABHS HMS, W Roxbury, MA USA. [Efebera, Yvonne A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Han, Andrew J.; Pelluru, Dheeraj; Nanjappa, Puru; Amin, Samir; Ghobrial, Irene; Schlossman, Robert L.; Laubach, Jacob; Fulciniti, Mariateresa; Richardson, Paul; Anderson, Kenneth C.; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, VABHS HMS, Boston, MA USA. RI Efebera, Yvonne/E-3012-2011 NR 0 TC 1 Z9 1 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 734 EP 735 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725802220 ER PT J AU Chanan-Khan, AA Jagannath, S Heffner, LT Avigan, D Lee, KP Lutz, RJ Haeder, T Ruehle, M Uherek, C Wartenberg-Demand, AB Munshi, N Anderson, KC AF Chanan-Khan, Asher A. Jagannath, Sundar Heffner, Leonard T. Avigan, David Lee, Kelvin P. Lutz, Robert J. Haeder, Thomas Ruehle, Markus Uherek, Christoph Wartenberg-Demand, Andrea Barbara Munshi, Nikhil Anderson, Kenneth C. TI Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Chanan-Khan, Asher A.; Lee, Kelvin P.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Jagannath, Sundar] St Vincent Catholic Med Ctr, New York, NY USA. [Heffner, Leonard T.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Avigan, David] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Lutz, Robert J.] ImmunoGen Inc, Waltham, MA USA. [Haeder, Thomas; Wartenberg-Demand, Andrea Barbara] Biotest AG, Corp Clin Res, Dreieich, Germany. [Ruehle, Markus] Biotest AG, Corp Drug Safety, Dreieich, Germany. [Uherek, Christoph] Biotest AG, Preclin Dev Biotherapeut, Dreieich, Germany. [Munshi, Nikhil; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 738 EP 739 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725802230 ER PT J AU Richardson, P Wolf, JL Jakubowiak, A Zonder, JA Lonial, S Irwin, DH Krishnan, A Densmore, J Raje, N Bar, MH Schlossman, RL Ghobrial, I Munshi, NC Martin, T Laubach, J Allerton, JP Hideshima, T Gardner, L Sportelli, P Anderson, KC AF Richardson, Paul Wolf, Jeffrey Lee Jakubowiak, Andrzej Zonder, Jeffrey A. Lonial, Sagar Irwin, David H. Krishnan, Amrita Densmore, John Raje, Noopur Bar, Michael H. Schlossman, Robert L. Ghobrial, Irene Munshi, Nikhil C. Martin, Thomas Laubach, Jacob Allerton, Jeffrey P. Hideshima, Teru Gardner, Lesa Sportelli, Peter Anderson, Kenneth C. TI Perifosine in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezombib: Updated Phase I/II Trial Results SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Richardson, Paul; Schlossman, Robert L.; Ghobrial, Irene; Munshi, Nikhil C.; Laubach, Jacob; Hideshima, Teru; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Wolf, Jeffrey Lee; Martin, Thomas] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Jakubowiak, Andrzej] Univ Michigan, Ctr Canc, Ann Arbor, MI 48109 USA. [Zonder, Jeffrey A.] Karmanos Canc Inst, Detroit, MI USA. [Lonial, Sagar] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Irwin, David H.] Alta Bates Summit Canc Ctr, Berkeley, CA USA. [Krishnan, Amrita] City Hope Med Ctr, Duarte, CA USA. [Densmore, John] Univ Virginia, Charlottesville, VA USA. [Raje, Noopur] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Bar, Michael H.] Bennett Canc Ctr, Stamford, CT USA. [Allerton, Jeffrey P.] Guthrie Clin, Sayre, PA USA. [Gardner, Lesa; Sportelli, Peter] Keryx Biopharmaceut Inc, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 741 EP 742 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725802237 ER PT J AU Badros, AZ Richardson, PG Albitar, M Jagannath, S Tarantolo, S Wolf, JL Messina, M Berman, D Anderson, KC AF Badros, Ashraf Z. Richardson, Paul G. Albitar, Maher Jagannath, Sundar Tarantolo, Stefano Wolf, Jeffrey L. Messina, Marianne Berman, David Anderson, Kenneth C. TI Tanespimycin plus Bortezomib in Relapsed/Refractory Myeloma Patients: Results From the Time-2 Study SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Badros, Ashraf Z.] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA. [Richardson, Paul G.; Anderson, Kenneth C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Albitar, Maher] Quest Diagnost Nichols Inst, San Juan Capistrano, CA USA. [Jagannath, Sundar] St Vincents Comprehens Canc Ctr, New York, NY USA. [Tarantolo, Stefano] Oncol Hematol W, Omaha, NE USA. [Wolf, Jeffrey L.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Messina, Marianne; Berman, David] Bristol Myers Squibb Co, Princeton, NJ USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 742 EP 743 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725802239 ER PT J AU Ghobrial, IM Munshi, NC Harris, BN Yuan, Z Porter, NM Schlossman, RL Laubach, JP Anderson, KC Lin, CE Wooldridge, JE Richardson, PG Abonour, R AF Ghobrial, Irene M. Munshi, Nikhil C. Harris, Brianna N. Yuan, Zheng Porter, Nichole M. Schlossman, Robert L. Laubach, Jacob P. Anderson, Kenneth C. Lin, Courtney E. Wooldridge, James E. Richardson, Paul G. Abonour, Rafat TI A Phase I Safety Study of Enzastaurin Plus Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Ghobrial, Irene M.; Munshi, Nikhil C.; Harris, Brianna N.; Schlossman, Robert L.; Laubach, Jacob P.; Anderson, Kenneth C.; Richardson, Paul G.] Dana Farber Canc Inst, Multiple Myeloma Waldenstroms Macroglobulinemia P, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Yuan, Zheng; Lin, Courtney E.; Wooldridge, James E.] Eli Lilly & Co, Indianapolis, IN 46285 USA. [Porter, Nichole M.; Abonour, Rafat] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 742 EP 742 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725802238 ER PT J AU Dhawan, R Robinson, D Meunier, J Regnault, A Rosa, K Cakana, AZ van de Velde, H Richardson, PG San Miguel, JF AF Dhawan, Ravinder Robinson, Don, Jr. Meunier, Juliette Regnault, Antoine Rosa, Kathleen Cakana, Andrew Z. van de Velde, Helgi Richardson, Paul G. San Miguel, Jesus F. TI Sustained Health-Related Quality of Life (HRQoL) Improvement in Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib/Melphalan/Prednisone Versus Melphalan/Prednisone: Results From the VISTA Trial. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Dhawan, Ravinder; Robinson, Don, Jr.] Johnson & Johnson Pharmaceut Res & Dev, Raritan, NJ USA. [Meunier, Juliette; Regnault, Antoine] Mapi Values, Lyon, France. [Rosa, Kathleen] Mapi Values, Boston, MA USA. [Cakana, Andrew Z.] Johnson & Johnson Pharmaceut Res & Dev, High Wycombe, Bucks, England. [van de Velde, Helgi] Johnson & Johnson Pharmaceut Res & Dev, Bonaire, Neth Antilles. [Richardson, Paul G.] Dana Farber Canc Inst, Boston, MA 02115 USA. [San Miguel, Jesus F.] Hosp Univ Salamanca, Hematol Serv, Salamanca, Spain. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 747 EP 747 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725802249 ER PT J AU Bar-Natan, M Nelson, EA Walker, SR Barrett, R Frank, DA AF Bar-Natan, Michal Nelson, Erik A. Walker, Sarah R. Barrett, Rosemary Frank, David A. TI Inhibition of Both Jak2 and STAT5 Enhances Toxicity to Myeloproliferative Cells. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Bar-Natan, Michal; Nelson, Erik A.; Walker, Sarah R.; Barrett, Rosemary; Frank, David A.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 756 EP 756 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725802273 ER PT J AU Leleu, X Leduc, R Rourke, M Harris, B Roccaro, AM Yarar, D Farag, J Ghobrial, IM AF Leleu, Xavier Leduc, Renee Rourke, Meghan Harris, Brianna Roccaro, Aldo M. Yarar, Dilek Farag, Jonathan Ghobrial, Irene M. TI PET/CT a New Marker of Response in Waldenstrom Macroglobulinemia (WM) SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Leleu, Xavier] Ctr Hosp Reg & Univ Lille, Hop Huriez, Serv Malad Sang, F-59037 Lille, France. [Leduc, Renee; Rourke, Meghan; Harris, Brianna; Roccaro, Aldo M.; Yarar, Dilek; Farag, Jonathan; Ghobrial, Irene M.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 768 EP 768 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725802305 ER PT J AU Hunter, Z Manning, R Hanzis, C Ciccarelli, B Ioakimidis, T Patterson, CJ Lewicki, M Tseng, H Gong, P Liu, X Zhou, YS Yang, G Sun, J Xu, L Sheehy, P Morra, M Treon, S AF Hunter, Zachary Manning, Robert Hanzis, Christina Ciccarelli, Bryan Ioakimidis, Thea Patterson, Christopher J. Lewicki, Megan Tseng, Hsuiyi Gong, Ping Liu, Xia Zhou, Yangsheng Yang, Guang Sun, Jenny Xu, Lian Sheehy, Patricia Morra, Massimo Treon, Steven TI IgA and IgG Hypogammaglobulinemia Does Not Predict for Recurrent Infection Risk and Persists Despite Therapeutic Response in Patients with Waldentrom's Macroglobulinemia. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Manning, Robert; Tseng, Hsuiyi; Liu, Xia; Zhou, Yangsheng; Sun, Jenny; Sheehy, Patricia] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Patterson, Christopher J.] Dana Farber Canc Inst, Waldenstroms Macroglubulinemia Ctr, Boston, MA 02115 USA. [Morra, Massimo] Correlagen Diagnost Inc, Waltham, MA USA. RI Hunter, Zachary/H-3018-2013 OI Hunter, Zachary/0000-0002-1689-1691 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 771 EP 772 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725802315 ER PT J AU Gatt, ME Ebert, M Mani, M Zhang, YY Gazit, R Carrasco, DE Dutta, J Adamia, S Munshi, NC Minvielle, S Avet-Loiseau, H Tai, YT Anderson, KC Carrasco, DR AF Gatt, Moshe E. Ebert, Margaret Mani, Mala Zhang, Yunyu Gazit, Roi Carrasco, Daniel E. Dutta, Jui Adamia, Sophia Munshi, Nikhil C. Minvielle, Stephane Avet-Loiseau, Herve Tai, Yu-Tzu Anderson, Kenneth C. Carrasco, Daniel Ruben TI The Functional Role of Microrna 15a/16-1 as Tumor Suppressor Genes in Multiple Myeloma. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Gatt, Moshe E.; Zhang, Yunyu; Dutta, Jui] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Dis Ctr, Boston, MA 02115 USA. [Ebert, Margaret] MIT, Dept Biol, Cambridge, MA USA. [Gazit, Roi] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA USA. [Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston VA Healthcare Syst, Boston, MA 02115 USA. [Minvielle, Stephane] Univ Hosp Nance, Nantes, France. [Avet-Loiseau, Herve] Hop Nantes, Dept Hematol, Nantes, France. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 777 EP 778 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725802331 ER PT J AU Sakurai, N Maeda, M Lee, SU Saito, T Chiba, S Teruya-Feldstein, J Maeda, T AF Sakurai, Nagisa Maeda, Manami Lee, Sung-Uk Saito, Toshiki Chiba, Shigeru Teruya-Feldstein, Julie Maeda, Takahiro TI LRF Critically Regulates Mature B Cell Fate and Germinal Center Response Via Notch-Dependent and -Independent Mechanisms SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Sakurai, Nagisa; Maeda, Manami; Lee, Sung-Uk; Maeda, Takahiro] City Hope Natl Med Ctr, Beckman Res Inst, HSC & Leukemia Res, Duarte, CA USA. [Saito, Toshiki] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Chiba, Shigeru] Univ Tsukuba, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki, Japan. [Teruya-Feldstein, Julie] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 777 EP 777 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725802329 ER PT J AU Maes, K Huston, A Roodman, D Rivera, S Nemeth, E Lichtenstein, A Vanderkerken, K Ganz, T AF Maes, Ken Huston, Alissa Roodman, David Rivera, Seth Nemeth, Elizabeta Lichtenstein, Alan Vanderkerken, Karin Ganz, Tomas TI Characterization of Hepcidin-Inducing Cytokines in Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Maes, Ken; Vanderkerken, Karin] Vrije Univ Brussel, Brussels, Belgium. [Lichtenstein, Alan] Univ Calif Los Angeles, Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. [Huston, Alissa] Univ Rochester, Sch Med, Rochester, NY USA. [Roodman, David] Univ Pittsburgh, Sch Med, Dept Med, Div Hematol Oncol, Pittsburgh, PA USA. [Roodman, David] Inst Canc Res, Pittsburgh, PA USA. [Ganz, Tomas] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. RI Vanderkerken, Karin/I-3513-2013 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 790 EP 790 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725802369 ER PT J AU Downie, BJ Erba, HP Stone, RM Rizzieri, DA Foran, JM AF Downie, Ben J. Erba, Harry P. Stone, Richard M. Rizzieri, David A. Foran, James M. TI Monosomal Karyotype Is Predictive of Poor Response to Therapy and Worse Overall Survival in Secondary Acute Myeloid Leukemia (sAML); Analysis of a Multi-Center Phase II Study of Amonafide and Cytarabine Induction Therapy SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Downie, Ben J.; Foran, James M.] Univ Alabama, Birmingham, AL USA. [Erba, Harry P.] Univ Michigan Hlth Syst, Ann Arbor, MI USA. [Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Rizzieri, David A.] Duke Univ, Med Ctr, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 819 EP 820 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725802444 ER PT J AU Reddy, MM Fernandes, M Salgia, R Levine, RL Griffin, JD Sattler, M AF Reddy, Mamatha M. Fernandes, Margret Salgia, Ravi Levine, Ross L. Griffin, James D. Sattler, Martin TI NADPH Oxidases Are Important Regulators of Growth and Migration in Myeloid Neoplasms SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Reddy, Mamatha M.; Fernandes, Margret; Griffin, James D.; Sattler, Martin] Dana Farber Canc Inst, Boston, MA 02115 USA. [Salgia, Ravi] Univ Chicago, Med Ctr, Chicago, IL 60637 USA. [Levine, Ross L.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 861 EP 861 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725802558 ER PT J AU Prezioso, L Galaverna, F Tanzi, S Frati, C Savi, M Lagrasta, C Cavalli, S Galati, S Ferraro, F Deangelis, A Piegari, E Rossi, F Rizzoli, V Quaini, F AF Prezioso, Lucia Galaverna, Federica Tanzi, Silvia Frati, Caterina Savi, Monia Lagrasta, Costanza Cavalli, Stefano Galati, Serena Ferraro, Francesca Deangelis, Antonella Piegari, Elena Rossi, Francesco Rizzoli, Vittorio Quaini, Federico TI Imatinib Mesylate Induced Cardiotoxicity: a Cardiac Progenitor Cell Disease? SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Rizzoli, Vittorio] Univ Parma, Hematol Unit, I-43100 Parma, Italy. [Rizzoli, Vittorio] Univ Parma, BMT, I-43100 Parma, Italy. [Ferraro, Francesca] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Regenerat Med, Boston, MA USA. [Deangelis, Antonella; Piegari, Elena; Rossi, Francesco] Univ Naples Federico 2, Naples, Italy. RI SAvi, Monia/B-9562-2015 OI SAvi, Monia/0000-0002-7895-7756 NR 0 TC 2 Z9 2 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 866 EP 866 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725802568 ER PT J AU Yang, AS Jillella, A Miller, CB Akard, LP DeAngelo, DJ Goldberg, SL Williams, D Radich, JP AF Yang, Allen S. Jillella, Anand Miller, Carole B. Akard, Luke P. DeAngelo, Daniel J. Goldberg, Stuart L. Williams, Denise Radich, Jerald P. TI Nilotinib-Associated Molecular Responses Achieved in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients with a Suboptimal Molecular Response to Imatinib SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Yang, Allen S.] Univ So Calif, Jane Anne Nohl Div Hematol, Los Angeles, CA USA. [Jillella, Anand] Med Coll Georgia, Augusta, GA 30912 USA. [Miller, Carole B.] St Agnes Healthcare, Baltimore, MD USA. [Akard, Luke P.] Indiana Blood & Marrow Transplantat, Beech Grove, IN USA. [DeAngelo, Daniel J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Goldberg, Stuart L.] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA. [Williams, Denise] Novartis Pharmaceut, E Hanover, NJ USA. [Radich, Jerald P.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 868 EP 869 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725802574 ER PT J AU StCharles, M Bollu, VK Hornyak, E Coombs, J Blanchette, CM DeAngelo, DJ AF StCharles, Meaghan Bollu, Vamsi K. Hornyak, Elizabeth Coombs, John Blanchette, Christopher M. DeAngelo, Daniel J. TI Predictors of Treatment Non-Adherence in Patients Treated with Imatinib Mesylate for Chronic Myeloid Leukemia SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [StCharles, Meaghan; Blanchette, Christopher M.] Lovelace Resp Res Inst, Div Clin & Outcomes Res, Kannapolis, NC USA. [Bollu, Vamsi K.; Hornyak, Elizabeth] Novartis Pharmaceut, E Hanover, NJ USA. [Coombs, John] Novartis Pharmaceut, Global Oncol, Florham Pk, NJ USA. [DeAngelo, Daniel J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 870 EP 870 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725802577 ER PT J AU Jacobsohn, D Chai, XY Kurland, B Arai, S Arora, M Cutler, C Jagasia, M Pavletic, SZ Vogelsang, G Lee, SJ Flowers, MED AF Jacobsohn, David Chai, Xiaoyu Kurland, Brenda Arai, Sally Arora, Mukta Cutler, Corey Jagasia, Madan Pavletic, Steven Z. Vogelsang, Georgia Lee, Stephanie J. Flowers, Mary E. D. TI Correlation of the NIH and Vienna Skin Scores with Provider and Patient-Reported Skin Changes in Chronic Graft-Versus-Host Disease (GVHD) SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Jacobsohn, David] Childrens Mem Hosp, Chicago, IL 60614 USA. [Chai, Xiaoyu; Kurland, Brenda; Lee, Stephanie J.; Flowers, Mary E. D.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Arai, Sally] Stanford Univ, Med Ctr, Stanford, CA 94305 USA. [Arora, Mukta] Univ Minnesota, Minneapolis, MN USA. [Cutler, Corey] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Jagasia, Madan] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Pavletic, Steven Z.] NCI, Expt Transplantat & Immunol Branch, Canc Res Ctr, NIH, Bethesda, MD 20892 USA. [Vogelsang, Georgia] Johns Hopkins Univ, Baltimore, MD 21218 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 889 EP 889 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725802624 ER PT J AU Mahindra, A Bolwell, BJ Dean, R Kalaycio, M Avalos, B Rybicki, L Tench, S Elder, P Sobecks, R Sweetenham, J Pohlman, B Andresen, S Devine, S Copelan, E AF Mahindra, Anuj Bolwell, Brian J. Dean, Robert Kalaycio, Matt Avalos, Belinda Rybicki, Lisa Tench, Shawnda Elder, Patrick Sobecks, Ronald Sweetenham, John Pohlman, Brad Andresen, Steve Devine, Steve Copelan, Edward TI Etoposide Priming in Patients with Lymphoma Improves Mobilization without An Increased Risk of Secondary Hematologic Malignancies SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Mahindra, Anuj] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Bolwell, Brian J.; Dean, Robert; Kalaycio, Matt; Tench, Shawnda; Sobecks, Ronald; Sweetenham, John; Pohlman, Brad; Andresen, Steve; Copelan, Edward] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA. [Avalos, Belinda; Elder, Patrick; Devine, Steve] Ohio State Univ, Div Hematol Oncol, Columbus, OH 43210 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 892 EP 892 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725802632 ER PT J AU Biernacki, M Alonso, A Zhang, GL Zhang, L Zhang, WD Tai, YT Munshi, N Alyea, EP Soiffer, RJ Brusic, V Ritz, J Anderson, KC Wu, CJ AF Biernacki, Melinda Alonso, Anselmo Zhang, Guanglan Zhang, Li Zhang, Wandi Tai, Yu-Tzu Munshi, Nikhil Alyea, Edwin P., III Soiffer, Robert J. Brusic, Vladimir Ritz, Jerome Anderson, Kenneth C. Wu, Catherine J. TI DAPK2 and PIM1 Are Myeloma-Associated Antigens That Elicit Coordinated B and T Cell Immunity After Syngeneic HSCT SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Biernacki, Melinda] Brown Univ, Rhode Isl Hosp, Grad Med Educ, Providence, RI 02903 USA. [Alonso, Anselmo; Zhang, Guanglan; Zhang, Li; Zhang, Wandi; Brusic, Vladimir] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA. [Tai, Yu-Tzu] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Alyea, Edwin P., III; Ritz, Jerome] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Wu, Catherine J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 965 EP 965 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725803001 ER PT J AU Zhang, WD Choi, JW Zeng, WY Alyea, EP Canning, C Soiffer, RJ Sasada, T Reinherz, E Ritz, J Wu, CJ AF Zhang, Wandi Choi, Jaewon Zeng, Wanyong Alyea, Edwin P., III Canning, Christine Soiffer, Robert J. Sasada, Tetsuro Reinherz, Ellis Ritz, Jerome wu, Catherine J. TI Graft-Versus-Leukemia Antigen CML66 Elicits Coordinated B and T Cell Immunity After Donor Lymphocyte Infusion. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Zhang, Wandi; Choi, Jaewon; Zeng, Wanyong; Canning, Christine; Sasada, Tetsuro] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 966 EP 966 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725803005 ER PT J AU Ciminello, L Toomey, C Cobert, J Hochberg, FH Abramson, JS Hochberg, E AF Ciminello, Lauren Toomey, Christiana Cobert, Julien Hochberg, Fred H. Abramson, Jeremy S. Hochberg, Ephraim TI Statin Use Improves Overall Survival and Time to Treatment Failure in Patients with Primary CNS Lymphoma SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Ciminello, Lauren] SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA. [Abramson, Jeremy S.; Hochberg, Ephraim] Massachusetts Gen Hosp, Ctr Canc, Ctr Lymphoma, Boston, MA 02114 USA. [Cobert, Julien] Duke Univ, Durham, NC USA. [Hochberg, Fred H.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 985 EP 985 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725803052 ER PT J AU Garrett, R Bungartz, G Domashenko, A Emerson, SG AF Garrett, Russell Bungartz, Gerd Domashenko, Alevtina Emerson, Stephen G. TI Poly I:C Stimulates Sca-1 Expression in Murine Bone Marrow and Increases the Number of Phenotypic Hematopoietic Stem Cells SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Garrett, Russell; Emerson, Stephen G.] Haverford Coll, Haverford, PA 19041 USA. [Bungartz, Gerd] Massachusetts Gen Hosp, Ctr Regenerat Med, HMS, Boston, MA 02114 USA. [Domashenko, Alevtina] Univ Penn, Haverford Coll, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 988 EP 988 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725803060 ER PT J AU Allen, RS Jin, P North, T Goessling, W Tian, Y Metzger, ME Bonifacino, AC Stroncek, D Zon, LI Donahue, RE AF Allen, Robyn S. Jin, Ping North, Trista Goessling, Wolfram Tian, Yu Metzger, Mark E. Bonifacino, Aylin C. Stroncek, David Zon, Leonard I. Donahue, Robert E. TI Global Gene Expression Signatures in CD34+Hematopoietic Cells Following Exposure to 16,16-Dimethylprostaglandin E2 SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Allen, Robyn S.; Tian, Yu; Metzger, Mark E.; Bonifacino, Aylin C.; Donahue, Robert E.] NHLBI, Hematol Branch, Rockville, MD USA. [Jin, Ping; Stroncek, David] NIH, Bethesda, MD 20892 USA. [North, Trista] Harvard Univ, Sch Med, Dept Pathol, Beth Israel Deaconess Med Ctr, Boston, MA USA. [Goessling, Wolfram] Harvard Univ, Brigham & Womens Hosp, Div Genet, Sch Med, Boston, MA 02115 USA. [Goessling, Wolfram] Harvard Univ, Brigham & Womens Hosp, Div Gastroenterol, Sch Med, Boston, MA 02115 USA. [Goessling, Wolfram] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Zon, Leonard I.] Harvard Stem Cell Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 994 EP 994 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725803079 ER PT J AU Sun, BH Mallampati, S Gong, Y Wang, DH You, MJ Amin, HM Ma, YP Rajewsky, K Lefebvre, V Sun, XP AF Sun, Baohua Mallampati, Saradhi Gong, Yun Wang, Donghai You, M. James Amin, Hesham M. Ma, Yupo Rajewsky, Klaus Lefebvre, Veronique Sun, Xiaoping TI Conditional Knockout of Sox4 Markedly Affects B Lymphopoiesis in Adult Mice. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Sun, Baohua; Mallampati, Saradhi; Gong, Yun; You, M. James; Amin, Hesham M.; Sun, Xiaoping] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Wang, Donghai; Rajewsky, Klaus] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Wang, Donghai; Rajewsky, Klaus] Immune Dis Inst, Boston, MA USA. [Ma, Yupo] Nevada Canc Inst, Las Vegas, NV USA. [Lefebvre, Veronique] Cleveland Clin, Cleveland, OH 44106 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 994 EP 994 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725803080 ER PT J AU Ruan, J Martin, P Furman, RR Vose, JM LaCasce, A Cheung, YKK O'Loughlin, J Elstrom, R Niesvizky, R Chadburn, A Ely, S Cesarman, E Coleman, M Leonard, JP AF Ruan, Jia Martin, Peter Furman, Richard R. Vose, Julie M. LaCasce, Ann Cheung, Ying-Kuen K. O'Loughlin, Jennifer Elstrom, Rebecca Niesvizky, Ruben Chadburn, Amy Ely, Scott Cesarman, Ethel Coleman, Morton Leonard, John P. TI CHOP-R plus Bortezomib as Initial Therapy for Mantle Cell Lymphoma (MCL) SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Ruan, Jia; Martin, Peter; Furman, Richard R.; O'Loughlin, Jennifer; Elstrom, Rebecca; Niesvizky, Ruben; Ely, Scott; Cesarman, Ethel; Coleman, Morton; Leonard, John P.] Weill Cornell Med Coll, New York, NY USA. [Vose, Julie M.] Univ Nebraska Med Ctr, Internal Med Sect Hematol Oncol, Omaha, NE USA. [LaCasce, Ann] Dana Farber Canc Inst, Boston, MA 02115 USA. [Cheung, Ying-Kuen K.] Columbia Univ, New York, NY USA. [Chadburn, Amy] Northwestern Univ, Chicago, IL 60611 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1049 EP 1050 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725803237 ER PT J AU Ghobrial, IM Hong, FX Padmanabhan, S Badros, AZ Rourke, M Leduc, R Chuma, S Kunsman, J Warren, D Harris, B Sam, A Anderson, KC Richardson, P Treon, S Weller, E Matous, J AF Ghobrial, Irene M. Hong, Fangxin Padmanabhan, Swaminathan Badros, Ashraf Z. Rourke, Meghan Leduc, Renee Chuma, Stacey Kunsman, Janet Warren, Diane Harris, Brianna Sam, Amy Anderson, Kenneth C. Richardson, Paul Treon, Steven Weller, Edie Matous, Jeffrey TI Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Ghobrial, Irene M.; Hong, Fangxin; Rourke, Meghan; Leduc, Renee; Chuma, Stacey; Kunsman, Janet; Harris, Brianna; Sam, Amy; Weller, Edie] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Padmanabhan, Swaminathan] Roswell Pk Canc Ctr, Buffalo, NY USA. [Badros, Ashraf Z.] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA. [Matous, Jeffrey] Rocky Mt Canc Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1067 EP 1067 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725803282 ER PT J AU Kampa, KM Grandl, T Mueller, S Normant, E Walter, M Schuetz, W Kanz, L Heinrich, MC Schittenhelm, MM AF Kampa, Kerstin M. Grandl, Tanja Mueller, Sandra Normant, Emmanuel Walter, Michael Schuetz, Wolfgang Kanz, Lothar Heinrich, Michael C. Schittenhelm, Marcus M. TI KIT Inhibition Affects Heat Shock Protein (HSP) Activity: A Potential Rescue Mechanism towards KIT Tyrosine Kinase Inhibition and a Rationale for Dual KIT/HSP Inhibition. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Kampa, Kerstin M.; Grandl, Tanja; Mueller, Sandra; Schittenhelm, Marcus M.] Univ Hosp Tuebingen, Dept Hematol Oncol Rheumatol Immunol & Pulmol, Tubingen, Germany. [Normant, Emmanuel] Infin Pharmaceut Inc, Cambridge, MA USA. [Walter, Michael] Univ Tubingen, Microarray Facil, Tubingen, Germany. [Schuetz, Wolfgang] Univ Tubingen, Proteome Ctr Tuebingen, Tubingen, Germany. [Kanz, Lothar] Univ Tubingen, Med Ctr 2, Dept Hematol Oncol Immunol Rheumatol & Pneumol, Tubingen, Germany. [Heinrich, Michael C.] Oregon Hlth & Sci Univ, Inst Canc, Portland, OR 97201 USA. [Heinrich, Michael C.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1076 EP 1077 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725803308 ER PT J AU Broek, IV Leleu, X Duda, D Van Camp, B Vanderkerken, K van Riet, I AF Broek, Isabelle Vande Leleu, Xavier Duda, Dan Van Camp, Benjamin Vanderkerken, Karin van Riet, Ivan TI Changes in Blood Circulating Cell Populations May Reflect the Anti-Angiogenic and Chemosensitizing Effects of Bortezomib and Thalidomide Treatment in Patients with Multiple Myelomatreatment in Patients with Multiple Myeloma. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Broek, Isabelle Vande; Van Camp, Benjamin; van Riet, Ivan] Myeloma Ctr Brussels VUB, Brussels, Belgium. [Leleu, Xavier] CHRU Lille, Hop Huriez, Serv Malad Sang, Lille, France. [Duda, Dan] Massachusetts Gen Hosp, Dept Radiat Oncol, Steele Lab Tumor Biol, Boston, MA 02114 USA. [Vanderkerken, Karin] Vrije Univ Brussel, Brussels, Belgium. RI Vanderkerken, Karin/I-3513-2013 NR 0 TC 0 Z9 0 U1 1 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1097 EP 1098 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725803362 ER PT J AU Munshi, NC Avet-Loiseau, H Stephens, P Shammas, MA Li, C Buon, L Amin, SB Shah, P King, B Fulciniti, M Pal, J Tai, YT Richardson, P Minvielle, S Campbell, P Anderson, KC Futreal, A AF Munshi, Nikhil C. Avet-Loiseau, Herve Stephens, Phil Shammas, Masood A. Li, Cheng Buon, Leutz Amin, Samir B. Shah, Parantu King, Benjamin Fulciniti, Mariateresa Pal, Jagannath Tai, Yu-Tzu Richardson, Paul Minvielle, Stephane Campbell, Peter Anderson, Kenneth C. Futreal, Andrew TI Whole Genome Paired End Sequencing Identifies Genomic Evolution in Myeloma. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Munshi, Nikhil C.; Shammas, Masood A.; Amin, Samir B.; Pal, Jagannath] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston VA Healthcare Syst, Boston, MA 02115 USA. [Avet-Loiseau, Herve; Minvielle, Stephane] Hop Nantes, Dept Hematol, Nantes, France. [Stephens, Phil; Campbell, Peter; Futreal, Andrew] Wellcome Trust Sanger Inst, Canc Genome Project, Hinxton, France. [Li, Cheng; Shah, Parantu] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Li, Cheng; Shah, Parantu] Harvard Univ, Sch Publ Hlth, Dept Biostat & Computat Biol, Boston, MA 02115 USA. RI Minvielle, Stephane/K-8251-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1111 EP 1112 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725803401 ER PT J AU Perrone, G Calabrese, E Hideshima, T Gorgun, G Hiroshi, I Cristea, D Santo, L Hu, YG Anderson, KC AF Perrone, Giulia Calabrese, Elisabetta Hideshima, Teru Gorgun, Gullu Hiroshi, Ikeda Cristea, Diana Santo, Loredana Hu Yiguo Anderson, Kenneth C. TI Panobinostat Inhibits JAK2/STAT3 Pathway in Multiple Myeloma. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Perrone, Giulia; Calabrese, Elisabetta; Hideshima, Teru; Gorgun, Gullu; Hiroshi, Ikeda; Cristea, Diana; Santo, Loredana; Hu Yiguo; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1113 EP 1113 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725803404 ER PT J AU Feng, RT Kurihara, N Ma, HH Roodman, GD Lentzsch, S AF Feng, Rentian Kurihara, Noriyoshi Ma, Huihui Roodman, G. David Lentzsch, Suzanne TI Matrix Metalloproteinses-13 (Collagenase-3) Secreted by Multiple Myeloma Cells Enhances the Bone Resorptive Activity of Osteoclasts. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Feng, Rentian; Kurihara, Noriyoshi; Ma, Huihui; Roodman, G. David; Lentzsch, Suzanne] Univ Pittsburgh, Dept Med, Div Hematol Oncol, Inst Canc, Pittsburgh, PA USA. [Roodman, G. David] VA Pittsburgh Healthcare Syst, Dept Med, Div Hematol Oncol, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1114 EP 1114 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725803408 ER PT J AU Ishizuka, F Windle, J Roodman, D Kurihara, N AF Ishizuka, Fumito Windle, Jolene Roodman, David Kurihara, Noriyoshi TI p62 as a Therapeutic Target for Myeloma Cell Growth and Osteoclast Formation SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Ishizuka, Fumito; Roodman, David; Kurihara, Noriyoshi] Univ Pittsburgh, Ctr Bone Biol, UPMC, Pittsburgh, PA USA. [Roodman, David] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Windle, Jolene] Virginia Commonwealth Univ, Richmond, VA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1115 EP 1115 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725803412 ER PT J AU Agura, E Niesvizky, R Matous, J Munshi, N Hussein, M Parameswaran, RV Tarantolo, S Whiting, NC Drachman, JG Zonder, JA AF Agura, Edward Niesvizky, Ruben Matous, Jeffrey Munshi, Nikhil Hussein, Mohamad Parameswaran, Ramakrishnan V. Tarantolo, Stefano Whiting, Nancy C. Drachman, Jonathan G. Zonder, Jeffrey A. TI Dacetuzurmab (SGN-40), Lenalidomide, and Weekly Dexamethasone in Relapsed or Refractory Multiple Myeloma: Multiple Responses Observed in a Phase 1b Study SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Agura, Edward] Baylor Sammons Canc Ctr, Dallas, TX USA. [Niesvizky, Ruben] Weill Cornell Med Coll, New York, NY USA. [Matous, Jeffrey] Rocky Mt Canc Ctr, Denver, CO USA. [Munshi, Nikhil] Dana Farber Canc Inst, Boston, MA 02115 USA. [Hussein, Mohamad] Canc Inst New Jersey, New Brunswick, NJ USA. [Parameswaran, Ramakrishnan V.] Avera Canc Inst, Sioux Falls, SD USA. [Tarantolo, Stefano] Nebraska Methodist Hosp, Estabrook Canc Ctr, Omaha, NE USA. [Whiting, Nancy C.; Drachman, Jonathan G.] Seattle Genet Inc, Bothell, WA USA. [Zonder, Jeffrey A.] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1120 EP 1121 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725803425 ER PT J AU Kumar, S Blade, J Crowley, J Goldschmidt, H Hoering, A Jagannath, S Lahuerta, JJ Laubach, J Moreau, P Morgan, G Orlowski, RZ Palumbo, A Richardson, P San Miguel, JF Sezer, O Siegel, D Sonneveld, P Szymonifka, J Rajkumar, SV Durie, BGM AF Kumar, Shaji Blade, Joan Crowley, John Goldschmidt, Harmut Hoering, Antje Jagannath, Sundar Jose Lahuerta, Juan Laubach, Jacob Moreau, Philippe Morgan, Gareth Orlowski, Robert Z. Palumbo, Antonio Richardson, Paul San Miguel, Jesus F. Sezer, Orhan Siegel, David Sonneveld, Pieter Szymonifka, Jackie Vincent Rajkumar, S. Durie, Brian G. M. TI Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Kumar, Shaji; Vincent Rajkumar, S.] Mayo Clin, Rochester, MN USA. [Blade, Joan] Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain. [Crowley, John; Hoering, Antje; Szymonifka, Jackie] Canc Res & Biostat, Seattle, WA USA. [Goldschmidt, Harmut] Univ Heidelberg, Heidelberg, Germany. [Jagannath, Sundar] St Vincent Catholic Med Ctr, New York, NY USA. [Jose Lahuerta, Juan] Hosp 12 Octubre, E-28041 Madrid, Spain. [Laubach, Jacob; Richardson, Paul] Dana Farber Canc Inst, Boston, MA 02115 USA. [Moreau, Philippe] Univ Hosp, Nantes, France. [Morgan, Gareth] Royal Marsden Hosp, Surrey, England. [Orlowski, Robert Z.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Palumbo, Antonio] Univ Turin, Div Hematol, Turin, Italy. [San Miguel, Jesus F.] Hosp Univ Salamanca, Salamanca, Spain. [Sezer, Orhan] Univ Hosp Charite, Berlin, Germany. [Siegel, David] Hackensack Univ Med Ctr, Hackensack, NJ USA. [Sonneveld, Pieter] Erasmus MC, Dept Hematol, Rotterdam, Netherlands. [Durie, Brian G. M.] Samuel Oschin Comprehens Canc Inst, Cedars Sinai Outpatient Canc Ctr, Los Angeles, CA USA. RI Kumar, Shaji/A-9853-2008; richard, chrystelle/K-8595-2015 OI Kumar, Shaji/0000-0001-5392-9284; NR 0 TC 2 Z9 2 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1123 EP 1124 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725803433 ER PT J AU Chanan-Khan, A Wolf, J Gharibo, M Jagannath, S Munshi, NC Anderson, KC Manfredi, D Lee, KP Miller, KC Guild, R Zildjian, S Qin, A O'Leary, J Vescio, R AF Chanan-Khan, Asher Wolf, Jeffrey Gharibo, Mecide Jagannath, Sundar Munshi, Nikhil C. Anderson, Kenneth C. Manfredi, Debbie Lee, Kelvin P. Miller, Kena C. Guild, Robin Zildjian, Sybil Qin, Albert O'Leary, James Vescio, Robert TI Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Chanan-Khan, Asher; Manfredi, Debbie; Lee, Kelvin P.; Miller, Kena C.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Wolf, Jeffrey] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Gharibo, Mecide] Canc Inst NJ, Franklin Lakes, NJ USA. [Jagannath, Sundar] St Vincent Catholic Med Ctr, New York, NY USA. [Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston VA Canc Healthcare Syst, Boston, MA 02115 USA. [Guild, Robin; Zildjian, Sybil; Qin, Albert] Cedars Sinai Gen Inc, Waltham, MA USA. [O'Leary, James] ImmunoGen Inc, Waltham, MA USA. [Vescio, Robert] Samuel Oschin Comprehens Canc Inst, Cedars Sinai Outpatient Canc Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1126 EP 1126 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725803438 ER PT J AU Richardson, PG Chanan-Khan, AA Lonial, S Krishnan, AY Carroll, MP Albitar, M Kopit, J Berman, D Anderson, KC AF Richardson, Paul G. Chanan-Khan, Asher A. Lonial, Sagar Krishnan, Amrita Y. Carroll, Michael P. Albitar, Maher Kopit, Justin Berman, David Anderson, Kenneth C. TI Tanespimycin plus Bortezomib Demonstrates Safety, Activity, and Effective Target Inhibition in Relapsed/Refractory Myeloma Patients: Updated Results of a Phase 1/2 Study SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Richardson, Paul G.; Anderson, Kenneth C.] Dana Farber Canc Inst, Jerome Lipper Ctr Multiple Myeloma, Boston, MA 02115 USA. [Chanan-Khan, Asher A.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Lonial, Sagar] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Krishnan, Amrita Y.] City Hope Natl Med Ctr, Duarte, CA 91010 USA. [Carroll, Michael P.] Sutter Reg Canc Inst, Sacramento, CA USA. [Albitar, Maher] Quest Diagnost Nichols Inst, San Juan Capistrano, CA USA. [Kopit, Justin; Berman, David] Bristol Myers Squibb Co, Princeton, NJ USA. NR 0 TC 4 Z9 4 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1128 EP 1129 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725803445 ER PT J AU DeAngelo, DJ Spencer, A Fischer, T Kindler, T Ottmann, OG Prince, M Giles, FJ Cortes, J Liu, A Parker, K Yan, Y Scott, JW Bhalla, KN AF DeAngelo, Daniel J. Spencer, Andrew Fischer, Thomas Kindler, Thomas Ottmann, Oliver G. Prince, Miles Giles, Frank J. Cortes, Jorge Liu, Angela Parker, Kathryn Yan, Ying Scott, Jeffrey W. Bhalla, Kapil N. TI Activity of Oral Panobinostat (LBH589) in Patients with Myelofibrosis SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [DeAngelo, Daniel J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Spencer, Andrew] Monash Univ, Alfred Hosp, Melbourne, Vic 3181, Australia. [Fischer, Thomas; Kindler, Thomas] Johannes Gutenberg Univ Mainz, Dept Med 3, Mainz, Germany. [Ottmann, Oliver G.] Goethe Univ Frankfurt, Med Klin 2, Frankfurt, Germany. [Prince, Miles] Peter MacCallum Canc Ctr, Dept Haematol, Melbourne, Vic, Australia. [Giles, Frank J.] Univ Texas Hlth Sci Ctr San Antonio, Div Hematol & Med Oncol, San Antonio, TX 78229 USA. [Cortes, Jorge] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Liu, Angela; Parker, Kathryn; Yan, Ying; Scott, Jeffrey W.] Novartis Pharmaceut, E Hanover, NJ USA. [Bhalla, Kapil N.] Med Coll Georgia, Ctr Canc, Dept Med, Augusta, GA 30912 USA. RI Ottmann, Oliver/D-5007-2016 OI Ottmann, Oliver/0000-0001-9559-1330 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1132 EP 1132 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725803453 ER PT J AU Azab, AK Azab, F Roccaro, AM Sacco, A Quang, P Ngo, HT Melhem, MR Runnels, JM Maiso, P Ghobrial, IM AF Azab, Abdel Kareem Azab, Feda Roccaro, Aldo M. Sacco, Antonio Quang, Phong Ngo, Hai T. Melhem, Molly R. Runnels, Judith M. Maiso, Patricia Ghobrial, Irene M. TI Eph-B2 Receptor Tyrosine Kinase Is Overexpressed in Waldenstrom's Macroglubulinemia and Plays a Major Role in Its Interaction with the Bone Marrow Microenvironment. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Azab, Abdel Kareem; Azab, Feda; Roccaro, Aldo M.; Sacco, Antonio; Quang, Phong; Ngo, Hai T.; Melhem, Molly R.; Runnels, Judith M.; Maiso, Patricia; Ghobrial, Irene M.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1147 EP 1147 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725803490 ER PT J AU Zhou, YS Liu, X Xu, L Hunter, Z Sun, J Yang, G Ciccarelli, B Patterson, CJ Garrett-Sinha, LA Treon, S AF Zhou, Yangsheng Liu, Xia Xu, Lian Hunter, Zachary Sun, Jenny Yang, Guang Ciccarelli, Bryan Patterson, Christopher J. Garrett-Sinha, Lee A. Treon, Steven TI Involvement of Ets Factor Spi-B, E Protein E2-2, and Id2 in Waldenstrom's Macroglobulinemia SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Zhou, Yangsheng; Liu, Xia; Sun, Jenny] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Patterson, Christopher J.] Dana Farber Canc Inst, Waldenstroms Macroglubulinemia Ctr, Boston, MA 02115 USA. [Garrett-Sinha, Lee A.] SUNY Buffalo, Dept Biochem, Ctr Excellence Bioinformat & Life Sci, Buffalo, NY 14214 USA. RI Hunter, Zachary/H-3018-2013 OI Hunter, Zachary/0000-0002-1689-1691 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1151 EP 1151 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725803501 ER PT J AU Yang, G Hanzis, C Gong, P Verselis, S Fox, EA Xu, L Ciccarelli, B Zhou, YS Hunter, Z Sun, J Liu, X Tseng, H Cao, Y Manning, R Lewicki, M Ioakimidis, T Sheehy, P Patterson, CJ Treon, S AF Yang, Guang Hanzis, Christina Gong, Ping Verselis, Sigitas Fox, Edward A. Xu, Lian Ciccarelli, Bryan Zhou, Yangsheng Hunter, Zachary Sun, Jenny Liu, Xia Tseng, Hsiuyi Cao, Yang Manning, Robert Lewicki, Megan Ioakimidis, Thea Sheehy, Patricia Patterson, Christopher J. Treon, Steven TI Polymorphisms of Fc gamma RIIA, Fc gamma RIIB, and Fc gamma RIIIA and Therapeutic Response to Rituximab Combination Therapy in Patients with Waldenstrom's Macroglobulinemia SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Zhou, Yangsheng; Sun, Jenny; Liu, Xia; Tseng, Hsiuyi; Manning, Robert; Sheehy, Patricia] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Patterson, Christopher J.] Dana Farber Canc Inst, Waldenstroms Marcoglubulinemia Ctr, Boston, MA 02115 USA. RI Hunter, Zachary/H-3018-2013 OI Hunter, Zachary/0000-0002-1689-1691 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1152 EP 1153 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725803504 ER PT J AU Ciccarelli, B Patterson, CJ Hunter, Z Hanzis, C Ioakimidis, T Manning, R Yang, G Gong, P Xu, L Zhou, YS Sun, J Liu, X Tseng, H Cao, Y Sheehy, P Treon, S AF Ciccarelli, Bryan Patterson, Christopher J. Hunter, Zachary Hanzis, Christina Ioakimidis, Thea Manning, Robert Yang, Guang Gong, Ping Xu, Lian Zhou, Yangsheng Sun, Jenny Liu, Xia Tseng, Hsiuyi Cao, Yang Sheehy, Patricia Treon, Steven TI Patients with Waldenstrom's Macroglobulinemia Are Often Hypoferremic That Is Refractory to Oral Iron Repletion and Responsive to Parental Iron Infusions, and Demonstrate Elevated Levels of Hepcidin SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Patterson, Christopher J.] Dana Farber Canc Inst, Waldenstroms Macroglubulinemia Ctr, Boston, MA 02115 USA. [Manning, Robert; Zhou, Yangsheng; Sun, Jenny; Liu, Xia; Tseng, Hsiuyi; Sheehy, Patricia] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RI Hunter, Zachary/H-3018-2013 OI Hunter, Zachary/0000-0002-1689-1691 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1153 EP 1154 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725803507 ER PT J AU Hunter, Z Sun, J Adamia, S Cao, Y Tseng, H Lewicki, M Xu, L Yang, G Zhou, YS Liu, X Gong, P Hanzis, C Ioakimidis, T Ciccarelli, B Manning, R Sheehy, P Patterson, CJ Andry, C Treon, S AF Hunter, Zachary Sun, Jenny Adamia, Sophia Cao, Yang Tseng, Hsiuyi Lewicki, Megan Xu, Lian Yang, Guang Zhou, Yangsheng Liu, Xia Gong, Ping Hanzis, Christina Ioakimidis, Thea Ciccarelli, Bryan Manning, Robert Sheehy, Patricia Patterson, Christopher J. Andry, Christopher Treon, Steven TI Micro-RNA Expression Profiling Reveals Distinct Correlates to Disease Pathogenesis, and Identifies Novel Pathways Involved in Tumor Cell Senescence and IL-12A Signaling SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Sun, Jenny; Tseng, Hsiuyi; Zhou, Yangsheng; Liu, Xia; Manning, Robert; Sheehy, Patricia] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Adamia, Sophia] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Patterson, Christopher J.] Dana Farber Canc Inst, Waldenstroms Macroglubulinemia Ctr, Boston, MA 02115 USA. [Andry, Christopher] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA. RI Hunter, Zachary/H-3018-2013 OI Hunter, Zachary/0000-0002-1689-1691 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1153 EP 1153 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725803505 ER PT J AU Xu, L Ciccarelli, B Hatjiharissi, E Yang, G Zhou, Y Hunter, Z Sun, J Gong, P Liu, X Tseng, H Ioakimidis, T Manning, R Hanzis, C Cao, Y Lewicki, M Patterson, CJ Treon, S AF Xu, Lian Ciccarelli, Bryan Hatjiharissi, Evdoxia Yang, Guang Zhou, Yangsheng Hunter, Zachary Sun, Jenny Gong, Ping Liu, Xia Tseng, Hsiuyi Ioakimidis, Thea Manning, Robert Hanzis, Christina Cao, Yang Lewicki, Megan Patterson, Christopher J. Treon, Steven TI Aberrant DNA Methylation and Transcriptional Silencing of DLC-1 in Waldenstrom's Macroglobulinemia SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Zhou, Yangsheng; Sun, Jenny; Liu, Xia; Tseng, Hsiuyi; Manning, Robert] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Patterson, Christopher J.] Dana Farber Canc Inst, Waldenstroms Macroglubulinemia Ctr, Boston, MA 02115 USA. RI Hunter, Zachary/H-3018-2013 OI Hunter, Zachary/0000-0002-1689-1691 NR 0 TC 0 Z9 0 U1 0 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1154 EP 1154 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725803509 ER PT J AU Steensma, DP Dakhil, SR Novotny, PJ Sloan, JA Johnson, DB Anderson, DM Mattar, BI Moore, DF Nikcevich, D Loprinzi, CL AF Steensma, David P. Dakhil, Shaker R. Novotny, Paul J. Sloan, Jeff A. Johnson, David B. Anderson, Daniel. M. Mattar, Bassani I. Moore, Dennis F., Jr. Nikcevich, Daniel Loprinzi, Charles L. TI A Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week Epoetin Alfa and Every-3-Week Darbepoetin Alfa: A Study of the Mayo Clinic Cancer Research Consortium (MCCRC) SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Steensma, David P.] Dana Farber Canc Inst, Dept Hematol Malignancies, Boston, MA 02115 USA. [Dakhil, Shaker R.; Johnson, David B.; Mattar, Bassani I.; Moore, Dennis F., Jr.] Canc Ctr Kansas PA, Wichita, KS USA. [Novotny, Paul J.; Sloan, Jeff A.; Loprinzi, Charles L.] Mayo Clin, Canc Ctr Stat, Dept Oncol, Rochester, MN USA. [Anderson, Daniel. M.] Minnesota CGOP, St Paul, MN USA. [Nikcevich, Daniel] St Marys Duluth Clin, Duluth, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1172 EP 1172 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725803563 ER PT J AU Tanaka, M Sasada, T Nakamoto, T Ansen, S Imataki, O Berezovskaya, A Butler, M Nadler, L Hirano, N AF Tanaka, Makito Sasada, Tetsuro Nakamoto, Tetsuya Ansen, Sascha Imataki, Osamu Berezovskaya, Alla Butler, Marcus Nadler, Lee Hirano, Naoto TI Immunogenicity of Artificial Dendritic Cells Is Upregulated by ROCK Inhibition-Mediated Dendrite Formation SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Tanaka, Makito; Sasada, Tetsuro; Ansen, Sascha; Imataki, Osamu; Berezovskaya, Alla; Butler, Marcus; Nadler, Lee; Hirano, Naoto] Dana Farber Canc Inst, Boston, MA 02115 USA. [Nakamoto, Tetsuya] Tokyo Med & Dent Univ, Tokyo, Japan. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1177 EP 1178 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725803577 ER PT J AU Mizukami, Y Sasajima, J Nakamura, K Sato, K Sugiyama, Y Yamazaki, M Kawamoto, T Koizumi, K Sasaki, K Fujiya, M Tanno, S Okumura, T Shimizu, N Kawabe, J Kono, T Torimoto, Y Ii, M Bardeesy, N Chung, DC Kohgo, Y AF Mizukami, Yusuke Sasajima, Junpei Nakamura, Kazumasa Sato, Kazuya Sugiyama, Yoshiaki Yamazaki, Madoka Kawamoto, Toru Koizumi, Kazuya Sasaki, Katsunori Fujiya, Mikihiro Tanno, Satoshi Okumura, Toshikatsu Shimizu, Norihiko Kawabe, Jun-ichi Kono, Toru Torimoto, Yoshihiro Ii, Masaaki Bardeesy, Nabeei Chung, Daniel C. Kohgo, Yutaka TI Hedgehog Promotes Neovascularization through the Regulation of Bone-Marrow Derived Progenitors SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Mizukami, Yusuke; Sasajima, Junpei; Nakamura, Kazumasa; Sato, Kazuya; Sugiyama, Yoshiaki; Yamazaki, Madoka; Kawamoto, Toru; Koizumi, Kazuya; Sasaki, Katsunori; Fujiya, Mikihiro; Kohgo, Yutaka] Asahikawa Med Coll, Dept Med, Div Gastroenterol & Hematol Oncol, Asahikawa, Hokkaido 078, Japan. [Tanno, Satoshi; Okumura, Toshikatsu] Asahikawa Med Coll, Dept Gen Med, Asahikawa, Hokkaido 078, Japan. [Shimizu, Norihiko] Asahikawa Med Coll, Dept Anim Facil, Asahikawa, Hokkaido 078, Japan. [Kawabe, Jun-ichi] Asahikawa Med Coll, Dept Cardiovasc Regenerat & Innovat, Asahikawa, Hokkaido 078, Japan. [Kono, Toru] Asahikawa Med Coll, Dept Surg, Div Gastroenterol & Gen Surg, Asahikawa, Hokkaido 078, Japan. [Torimoto, Yoshihiro] Asahikawa Med Coll Hosp, Ctr Oncol, Asahikawa, Hokkaido, Japan. [Ii, Masaaki] Inst Biomed Res & Innovat, Grp Vasc Regenerat Res, Kobe, Hyogo, Japan. [Bardeesy, Nabeei; Chung, Daniel C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Bardeesy, Nabeei; Chung, Daniel C.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1187 EP 1187 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725803603 ER PT J AU Grabowski, EF Cheung, M Biliouris, EE Kushak, RI van Cott, EM AF Grabowski, Eric F. Cheung, Ming Biliouris, Emily E. Kushak, Rafail I. van Cott, Elizabeth M. TI Reduced Volume and Pattern of Platelet Aggregation imaged Using Epifluorescence Digital Videomicroscopy in a High Shear Rate Blood Flow Chamber Permit the Sensitive and Specific Diagnosis of Von Willebrand Disease SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Grabowski, Eric F.; Cheung, Ming; Biliouris, Emily E.; Kushak, Rafail I.; van Cott, Elizabeth M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1188 EP 1188 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725803606 ER PT J AU Grace, RF Dahlberg, SE Neuberg, D Sallan, SE Neufeld, EJ DeAngelo, DJ Silverman, LB AF Grace, Rachael F. Dahlberg, Suzanne E. Neuberg, Donna Sallan, Stephen E. Neufeld, Ellis J. DeAngelo, Daniel J. Silverman, Lewis B. TI The Frequency and Management of Asparaginase-Related Thrombosis in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia Treated On the Dana-Farber Cancer Institute (DFCI) Consortium Protocols SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Grace, Rachael F.; Sallan, Stephen E.; Neufeld, Ellis J.; Silverman, Lewis B.] Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. RI Neufeld, Ellis/F-9331-2011 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1194 EP 1195 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725803628 ER PT J AU Chauhan, AK Zhao, BQ Canault, M Patten, IS Yang, J Dockal, M Scheiflinger, F Wagner, DD AF Chauhan, Anil K. Zhao, Bing-Qiao Canault, Matthias Patten, Ian Sean Yang, Janie Dockal, Michael Scheiflinger, Friedrich Wagner, Denisa D. TI Recombinant ADAMTS13 Improves Neurological Outcome in Experimental Stroke in Mice SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Chauhan, Anil K.] Harvard Univ, Childrens Hosp, Sch Med, Immune Dis Inst, Boston, MA 02115 USA. [Chauhan, Anil K.] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA. [Zhao, Bing-Qiao; Canault, Matthias; Wagner, Denisa D.] Harvard Univ, Childrens Hosp, Sch Med, Immune Dis Inst,Program Cellular & Mol Med, Boston, MA 02115 USA. [Patten, Ian Sean; Yang, Janie] Childrens Hosp, Program Cellular & Mol Med, Immune Dis Inst, Boston, MA 02115 USA. [Dockal, Michael] Baxter BioSci, Prot Engn, Orth, Austria. [Scheiflinger, Friedrich] Baxter BioSci, R&D Discovery Res, Vienna, Austria. RI Canault, Matthias/H-5128-2013 OI Canault, Matthias/0000-0002-7880-5250 NR 0 TC 0 Z9 0 U1 3 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1218 EP 1218 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725803689 ER PT J AU Zhou, J Hou, JX Li, W Zhang, XQ Fu, YY Li, HB Xie, R Zhang, Z Gilbert, GE Shi, JL AF Zhou, Jin Hou, Jinxiao Li, Wen Zhang, Xiaoqian Fu, Yueyue Li, Huibo Xie, Rui Zhang, Zhuo Gilbert, Gary E. Shi, Jialan TI Lactadherin as a Probe for Phosphatidylserine Exposure and as An Anticoagulant for the Procoagulant Activity in the Study of Stored Platelets SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Zhou, Jin; Hou, Jinxiao; Li, Wen; Zhang, Xiaoqian; Fu, Yueyue; Li, Huibo; Xie, Rui; Zhang, Zhuo] Harbin Med Coll, Hosp 1, Harbin, Peoples R China. [Gilbert, Gary E.; Shi, Jialan] Harvard Univ, Sch Med, Brigham & Womens Hosp, VA Boston Healthcare Syst, W Roxbury, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1223 EP 1223 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725803705 ER PT J AU Pantazatos, D Gessner, C Woods, V Gilbert, GE AF Pantazatos, Dennis Gessner, Christopher Woods, Virgil Gilbert, Gary E. TI Effect of Membrane Binding Upon Intramolecular Dynamics of the Factor VIII C2 Domain SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Pantazatos, Dennis] Havard Med Sch, Div Hematol, W Roxbury, MA USA. [Woods, Virgil] Univ Calif San Diego, Dept 0656, La Jolla, CA 92093 USA. [Gilbert, Gary E.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, W Roxbury, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1229 EP 1229 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725803723 ER PT J AU Micallef, IN Jacobsen, E Shaughnessy, P Marulkar, S Mody, P van Rhee, F AF Micallef, Ivana N. Jacobsen, Eric Shaughnessy, Paul Marulkar, Sachin Mody, Purvi van Rhee, Frits TI Plerixafor (Mozobil (R)) Plus G-CSF Is Effective in Mobilizing Hematopoietic Stem Cells in Patients with Concurrent Thrombocytopenia Undergoing Autologous Hematopoietic Stem Cell Transplantation. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Jacobsen, Eric] Dana Farber Canc Inst, Boston, MA 02115 USA. [Shaughnessy, Paul] Texas Transplant Inst, San Antonio, TX USA. [Micallef, Ivana N.] Mayo Clin, Coll Med, Rochester, MN USA. [Marulkar, Sachin] Genzyme Corp, Biomed Data Sci & Informat, Cambridge, MA USA. [van Rhee, Frits] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1251 EP 1251 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725803784 ER PT J AU Miller, DM Yoda, A Yoda, Y Weinstock, DM AF Miller, David M. Yoda, Akinori Yoda, Yuka Weinstock, David M. TI Mechanisms of CRLF2 Rearrangement with IGH and P2RY8 in B-Cell Acute Lymphoblastic Leukemia SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Miller, David M.] Univ Massachusetts, Worcester, MA 01605 USA. [Yoda, Akinori; Yoda, Yuka] Dana Farber Canc Inst, Boston, MA 02115 USA. [Weinstock, David M.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1256 EP 1257 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725803798 ER PT J AU Oaks, J Neviani, P Mukhopadhyay, A Santhanam, R Ma, Y Mao, C Marcucci, G Chen, CS Cortes, J Caligiuri, MA Hokland, P Huettner, C Koschmieder, S Cancelas, J Briesewitz, R Bhatia, R Roy, DC Ogretmen, B Perrotti, D AF Oaks, Joshua Neviani, Paolo Mukhopadhyay, A. Santhanam, Ramasamy Ma, Y. Mao, Charlene Marcucci, Guido Chen, Ching-Shih Cortes, Jorge Caligiuri, Michael A. Hokland, Peter, Sr. Huettner, Claudia Koschmieder, Steffen Cancelas, Jose Briesewitz, Roger Bhatia, Ravi Roy, Denis-Claude Ogretmen, Besim Perrotti, Danilo TI FTY720 but Not Its Immunosuppressive Phosphorylated Form FTY720-P Exerts Anti-Leukemic Activity towards Ph(+) and Ph(-) Myeloproliferative Disorders through Reactivation of the PP2A Tumor Suppressor SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Santhanam, Ramasamy; Perrotti, Danilo] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol, Columbus, OH 43210 USA. [Mukhopadhyay, A.; Ogretmen, Besim] Med Univ S Carolina, Charleston, SC 29425 USA. [Chen, Ching-Shih] Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA. [Cortes, Jorge] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Hokland, Peter, Sr.] Aarhus Univ Hosp, Dept Hematol, DK-8000 Aarhus, Denmark. [Huettner, Claudia] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Koschmieder, Steffen] Univ Munster, Dept Med Hematol & Oncol, Munster, Germany. [Cancelas, Jose] Univ Cincinnati, Hoxworth Blood Ctr, Cincinnati, OH USA. [Bhatia, Ravi] City Hope Natl Med Ctr, Duarte, CA 91010 USA. [Roy, Denis-Claude] Univ Montreal, Blood & Marrow Transplant Program, Dept Hematol, Maisonneuve Rosemont Hosp, Montreal, PQ, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1261 EP 1262 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725803814 ER PT J AU Krause, DS Aldridge, J Kim, HT McDonough, S Gatzos, L Antin, JH Ho, V Cutler, C Armand, P Koreth, J Soiffer, RJ Ritz, J Kao, GS AF Krause, Daniela S. Aldridge, Julie Kim, Haesook T. McDonough, Sean Gatzos, Laura Antin, Joseph H. Ho, Vincent Cutler, Corey Armand, Philippe Koreth, John Soiffer, Robert J. Ritz, Jerome Kao, Grace S. TI Immune Reconstitution and Clinical Outcome After Donor Lymphocyte Infusion for Relapsed Disease After Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Diseases Other Than Chronic Myelogenous Leukemia SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Krause, Daniela S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Aldridge, Julie] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Cutler, Corey; Ritz, Jerome] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Antin, Joseph H.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1285 EP 1286 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725803871 ER PT J AU Budde, LE Guthrie, KA Till, BG Chauncey, T Press, OW Pagel, JM Petersdorf, S Bensinger, W Holmberg, L Shustov, AR Maloney, DG Gopal, AK AF Budde, Lihua E. Guthrie, Katherine A. Till, Brian G. Chauncey, Thomas Press, Oliver W. Pagel, John M. Petersdorf, Stephen Bensinger, William Holmberg, Leona Shustov, Andrei R. Maloney, David G. Gopal, Ajay K. TI Prognostic Factors On Outcome of Mantle Cell Lymphoma Patients Relapsing After Autologous Hematopoietic Stem Cell Transplantation SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Budde, Lihua E.; Guthrie, Katherine A.; Till, Brian G.; Press, Oliver W.; Pagel, John M.; Petersdorf, Stephen; Bensinger, William; Holmberg, Leona; Maloney, David G.; Gopal, Ajay K.] Univ Washington, Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98195 USA. [Chauncey, Thomas] Univ Washington, Fred Hutchinson Canc Res Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Shustov, Andrei R.] Univ Washington, Dept Hematol, Seattle, WA 98195 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1290 EP 1291 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725803882 ER PT J AU Armand, P Rhodes, J Kim, H Cutler, C Ho, VT Koreth, J Alyea, EP Soiffer, RJ Antin, JH AF Armand, Philippe Rhodes, Joanna Kim, Haesook Cutler, Corey Ho, Vincent T. Koreth, John Alyea, Edwin P., III Soiffer, Robert J. Antin, Joseph H. TI A Prospective Study of Iron Overload in Patients Undergoing Ablative Stem Cell Transplantation. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Armand, Philippe; Rhodes, Joanna; Kim, Haesook; Cutler, Corey; Ho, Vincent T.; Koreth, John; Alyea, Edwin P., III; Soiffer, Robert J.; Antin, Joseph H.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1293 EP 1293 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725803887 ER PT J AU Spitzer, TR Sykes, M Rubin, NT Kawai, T McAfee, SL Dey, B Ballen, K Delmonico, F Saidman, S Sachs, DH Cosimi, B AF Spitzer, Thomas R. Sykes, Megan Rubin, Nina Tolkoff Kawai, Tatsuo McAfee, Steven L. Dey, Bimalangshu Ballen, Karen Delmonico, Francis Saidman, Susan Sachs, David H. Cosimi, Benedict TI Long Term Follow-up of Recipients of Combined HLA-Matched Nonmyeloablative Bone Marrow and Kidney Transplantation for Multiple Myeloma with End-Stage Renal Disease SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1307 EP 1308 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725804033 ER PT J AU Rotta, M Storer, BE Lange, T Pulsipher, M Shizuru, J Bruno, B McSweeney, PA Agura, E Chauncey, T Appelbaum, FR Bensinger, W Sandmaier, BM Storb, RF Georges, GE Maloney, DG AF Rotta, Marcello Storer, Barry E. Lange, Thoralf Pulsipher, Michael Shizuru, Judith Bruno, Benedetto McSweeney, Peter A. Agura, Edward Chauncey, Thomas Appelbaum, Frederick R. Bensinger, William Sandmaier, Brenda M. Storb, Rainer F. Georges, George E. Maloney, David G. TI Nonmyeloablative Allogeneic HCT From Unrelated Donors for Multiple Myeloma (MM) SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Rotta, Marcello] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Storer, Barry E.; Appelbaum, Frederick R.; Bensinger, William; Sandmaier, Brenda M.; Storb, Rainer F.; Georges, George E.; Maloney, David G.] Univ Washington, Seattle, WA 98195 USA. [Lange, Thoralf] Univ Leipzig, Dept Hematol & Oncol, Leipzig, Germany. [Pulsipher, Michael] Univ Utah, Med Ctr, Salt Lake City, UT USA. [Shizuru, Judith] Stanford Univ, Stanford, CA 94305 USA. [Bruno, Benedetto] Univ Turin, Turin, Italy. [McSweeney, Peter A.] Rocky Mt Blood & Marrow Transplant Program, Denver, CO USA. [Agura, Edward] Baylor Sammons Canc Ctr, Dallas, TX USA. [Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1317 EP 1317 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804056 ER PT J AU Fernandez, HF Sun, ZX Litzow, MR Luger, SM Paietta, EM Dewald, GW Ketterling, RP Bennett, JM Rowe, JM Lazarus, HM Tallman, MS AF Fernandez, Hugo F. Sun, Zhuoxin Litzow, Mark R. Luger, Selina M. Paietta, Elisabeth M. Dewald, Gordon W. Ketterling, Rhett P. Bennett, John M. Rowe, Jacob M. Lazarus, Hillard M. Tallman, Martin S. TI Autologous Hematopoietic Cell Transplantation as Consolidation for Younger Patients with Acute Myeloid Leukemia in First Complete Remission: Follow-up of E1900. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Fernandez, Hugo F.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Bone Marrow Transplantat, Tampa, FL 33612 USA. [Sun, Zhuoxin] Dana Farber Canc Inst, Boston, MA 02115 USA. [Litzow, Mark R.; Dewald, Gordon W.; Ketterling, Rhett P.] Mayo Clin, Rochester, MN USA. [Luger, Selina M.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Paietta, Elisabeth M.] Montefiore Med Ctr, Ctr Canc, North Div, Bronx, NY 10467 USA. [Bennett, John M.] Univ Rochester, Rochester, NY USA. [Rowe, Jacob M.] Technion Israel Inst Technol, Rambam Med Ctr, Haifa, Israel. [Rowe, Jacob M.] Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel. [Lazarus, Hillard M.] Univ Hosp Cleveland, Case Med Ctr, Ireland Canc Ctr, Cleveland, OH 44106 USA. [Tallman, Martin S.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1322 EP 1322 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804070 ER PT J AU McCarthy, PL Owzar, K Stadtmauer, EA Giralt, S Hurd, DD Hassoun, H Hofmeister, C Richardson, P Weisdorf, DJ Pasquini, MC Hars, V Kelly, M Postiglione, J Sutherland, S Anderson, KC Linker, C AF McCarthy, Philip L. Owzar, Kouros Stadtmauer, Edward A. Giralt, Sergio Hurd, David D. Hassoun, Hani Hofmeister, Craig Richardson, Paul Weisdorf, Daniel J. Pasquini, Marcelo C. Hars, Vera Kelly, Michael Postiglione, John Sutherland, Susan Anderson, Kenneth C. Linker, Charles TI Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient Accrual and Adverse Events SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [McCarthy, Philip L.] Roswell Pk Canc Inst, BMT Program & Med, Buffalo, NY 14263 USA. [Owzar, Kouros; Hars, Vera; Postiglione, John; Sutherland, Susan] Duke Univ, Ctr Stat, Canc & Leukemia Grp B, Durham, NC USA. [Stadtmauer, Edward A.] Univ Penn, Myeloma Program, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Giralt, Sergio] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Hurd, David D.] Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA. [Hassoun, Hani] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Hofmeister, Craig] Ohio State Univ, Med Ctr, Div Hematol, Columbus, OH 43210 USA. [Richardson, Paul; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Weisdorf, Daniel J.] Univ Minnesota, Minneapolis, MN USA. [Pasquini, Marcelo C.] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Kelly, Michael] Canc & Leukemia Grp B, Chicago, IL USA. [Linker, Charles] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1327 EP 1327 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804081 ER PT J AU Popplewell, L Pro, B Jacobsen, E Horwitz, SM Boyd, A Patterson, M Fruchtman, S O'Connor, OA AF Popplewell, Leslie Pro, Barbara Jacobsen, Eric Horwitz, Steven M. Boyd, Adam Patterson, Molly Fruchtman, Steven O'Connor, Owen A. TI Stem Cell Transplant (SCT) and Pralatrexate Therapy: Outcome of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Who Received SCT Prior to or Following Pralatrexate Therapy SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Popplewell, Leslie] City Hope Natl Med Ctr, Duarte, CA USA. [Pro, Barbara] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Jacobsen, Eric] Dana Farber Canc Inst, Boston, MA 02115 USA. [Horwitz, Steven M.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Boyd, Adam; Fruchtman, Steven] Allos Therapeut Inc, Westminster, CO USA. [Patterson, Molly; O'Connor, Owen A.] NYU, Inst Canc, Langone Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1328 EP 1328 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804085 ER PT J AU Brown, JR Abramson, JS Hochberg, EP Mikler, E Dalton, V Reynolds, H Romano, J Werner, L Thompson, C McDonough, S Ritz, J Neuberg, D Freedman, AS AF Brown, Jennifer R. Abramson, Jeremy S. Hochberg, Ephraim P. Mikler, Evgeny Dalton, Virginia Reynolds, Hazel Romano, Jennifer Werner, Lillian Thompson, Christina McDonough, Sean Ritz, Jerome Neuberg, Donna Freedman, Arnold S. TI A Phase I Study of Lenalidomide in Combination with Fludarabine-Rituximab in Previously Untreated CLL/SLL. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Werner, Lillian] Dana Farber Canc Inst, Dept Biostat & Computat Biolog, Boston, MA 02115 USA. [Abramson, Jeremy S.] Massachusetts Gen Hosp, Ctr Canc, Ctr Lymphoma, Boston, MA USA. [Hochberg, Ephraim P.] Massachusetts Gen Hosp, Ctr Canc, Ctr Lymphoma, Newton, MA USA. [Ritz, Jerome] Harvard Univ, Sch Med, Dana Farber Canc Inst, Canc Vaccine Ctr,Div Hematol Malignancies, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1330 EP 1331 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725804091 ER PT J AU Camacho, LH Joyce, R Brown, JR Chanan-Khan, A Amrein, PC Assad, A Carrigan, M AF Camacho, Luis H. Joyce, Robin Brown, Jennifer R. Chanan-Khan, Asher Amrein, Philip C. Assad, Albert Carrigan, Marion TI A Phase 1, Open-Label, Multi-Center, Multiple-Dose, Dose-Escalation Study of MDX-1342 in Patients with CD19-Positive Refractory/Relapsed Chronic Lymphocytic Leukemia. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Camacho, Luis H.] Oncol Consultants PA, Houston, TX USA. [Joyce, Robin] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Brown, Jennifer R.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Chanan-Khan, Asher] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Amrein, Philip C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Massachusetts Gen Hosp Canc Ctr, Boston, MA USA. [Assad, Albert; Carrigan, Marion] Medarex Inc, Dept Clin Sci, Bloomsbury, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1330 EP 1330 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804090 ER PT J AU Krivtsov, AV Sinha, AU Stubbs, MC Kung, A Armstrong, S AF Krivtsov, Andrei V. Sinha, Amit U. Stubbs, Matthew C. Kung, Andrew Armstrong, Scott TI Cell of Origin Influences Leukemia Stem Cell Phenotype. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Krivtsov, Andrei V.] HMS, Childrens Hosp Boston, Dept Hematol Oncol, Boston, MA USA. [Kung, Andrew] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1344 EP 1344 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804124 ER PT J AU Mani, K Yoda, A Chiaretti, S Foa, R Weinstock, DM AF Mani, Kartik Yoda, Akinori Chiaretti, Sabina Foa, Robin Weinstock, David M. TI CRLF2/JAK Signaling in Adult and Pediatric Acute Lymphoblastic Leukemia Is Highly Similar to BCR/ABL. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Mani, Kartik; Yoda, Akinori] Dana Farber Canc Inst, Boston, MA USA. [Foa, Robin] Univ Roma La Sapienza, Div Hematol, Rome, Italy. [Weinstock, David M.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1344 EP 1344 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804126 ER PT J AU Lawler, EV Fonda, JR Horblyuk, RV Grotzinger, KM McLaughlin, C Morgan, T Pedrosa, M Gagnon, DR AF Lawler, Elizabeth V. Fonda, Jennifer R. Horblyuk, Ruslan V. Grotzinger, Kelly M. McLaughlin, Cara Morgan, Tim Pedrosa, Marcos Gagnon, David R. TI Risk Factors for Transition From Normal Platelet Count to Severe Thrombocytopenia Among Patients with Chronic Liver Disease SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Lawler, Elizabeth V.; Fonda, Jennifer R.; McLaughlin, Cara; Pedrosa, Marcos; Gagnon, David R.] VA Boston Healthcare Syst, Boston, MA USA. [Horblyuk, Ruslan V.] GlaxoSmithKline Inc, FP1280, Philadelphia, PA USA. [Grotzinger, Kelly M.] GlaxoSmithKline Inc, Collegeville, PA USA. [Morgan, Tim] Dept Vet Affairs, Long Beach, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1365 EP 1365 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804183 ER PT J AU de Jong, J Burns, CE Chen, A Pugach, E Mayhall, E Smith, A Feldman, HA Zhou, Y Zon, LI AF de Jong, Jill Burns, Caroline Erter Chen, Aye Pugach, Emily Mayhall, Elizabeth Smith, Alexandra Feldman, Henry A. Zhou, Yi Zon, Leonard I. TI Long-Term Hematopoietic Transplantation in Zebrafish Using Immume-Matched Marrow Cells SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [de Jong, Jill; Burns, Caroline Erter; Chen, Aye; Pugach, Emily; Mayhall, Elizabeth; Smith, Alexandra; Zhou, Yi; Zon, Leonard I.] Childrens Hosp, Stem Cell Program, Boston, MA 02115 USA. [de Jong, Jill; Burns, Caroline Erter; Chen, Aye; Pugach, Emily; Mayhall, Elizabeth; Smith, Alexandra; Zhou, Yi; Zon, Leonard I.] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. [de Jong, Jill; Burns, Caroline Erter; Chen, Aye; Pugach, Emily; Mayhall, Elizabeth; Smith, Alexandra; Zhou, Yi; Zon, Leonard I.] Harvard Stem Cell Inst, Howard Hughes Med Inst, Dana Farber Canc Inst, Boston, MA USA. [Feldman, Henry A.] Childrens Hosp, Clin Res Program, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1372 EP 1372 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804200 ER PT J AU Kwiatkowski, BA Richard, RE AF Kwiatkowski, Boguslaw A. Richard, Robert E. TI Angiotensin II Receptor-Associated Protein (AGTRAP) Synergizes with Mpl Signaling to Promote Survival and to Increase Proliferation Rate of Hematopoietic Cells. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Kwiatkowski, Boguslaw A.] VA Puget Sound Hlth Care Syst, Seattle Inst Biomed & Clin Res, Seattle, WA USA. [Richard, Robert E.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1395 EP 1395 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804270 ER PT J AU Gritsman, K Khandan, T Okabe, R Gozo, M Paktinat, M Gilliland, DG Roberts, TM Zhao, JJ AF Gritsman, Kira Khandan, Tulasi Okabe, Rachel Gozo, Maricel Paktinat, Mahnaz Gilliland, D. Gary Roberts, Thomas M. Zhao, Jean J. TI The p110 alpha Catalytic Isoform of PI3 Kinase Is Important for Erythropoiesis, but Has a Minimal Role in Hematopoietic Stem Cell Self-Renewal. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Gritsman, Kira] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol Malignancies,Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1399 EP 1399 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804284 ER PT J AU Lund, T Glass, T Tolar, J Zon, LI Blazar, BR AF Lund, Troy Glass, Tiffany Tolar, Jakob Zon, Leonard I. Blazar, Bruce R. TI A Model System for Visualization of Whole-Body Sdf-1 Expression During Hematopoietic Cell Transplant SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Blazar, Bruce R.] Univ Minnesota, Pediat Heme Onc BMT, Minneapolis, MN USA. [Zon, Leonard I.] Childrens Hosp, Stem Cell Program, Boston, MA 02115 USA. [Zon, Leonard I.] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. [Zon, Leonard I.] Harvard Stem Cell Inst, Howard Hughes Med Inst, Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1400 EP 1400 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804287 ER PT J AU Song, WH Tai, YT Hideshima, T Anderson, KC Munshi, NC AF Song, Weihua Tai, Yu-Tzu Hideshima, Teru Anderson, Kenneth C. Munshi, Nikhil C. TI Phenotypic and Functional Effects of Novel HDAC Inhibitor LBH589 On Human Lymphocyte Populations. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston VA Healthcare Syst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1418 EP 1418 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804345 ER PT J AU Vesole, S Jia, XY Roccaro, AM Sacco, A Ngo, HT Azab, F Azab, AK Melhem, MR Runnels, JM Quang, P Anderson, KC Ghobrial, IM AF Vesole, Steven Jia, Xiaoying Roccaro, Aldo M. Sacco, Antonio Ngo, Hai T. Azab, Feda Azab, Abdel Kareem Melhem, Molly R. Runnels, Judith M. Quang, Phong Anderson, Kenneth C. Ghobrial, Irene M. TI RAD001 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Vesole, Steven; Jia, Xiaoying; Roccaro, Aldo M.; Sacco, Antonio; Ngo, Hai T.; Azab, Feda; Azab, Abdel Kareem; Melhem, Molly R.; Runnels, Judith M.; Quang, Phong; Anderson, Kenneth C.; Ghobrial, Irene M.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1437 EP 1437 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804396 ER PT J AU Xu, L Patterson, CJ Sun, J Yang, G Zhou, YS Hunter, Z Hatjiharissi, E Ciccarelli, B Gong, P Liu, X Tseng, H Ioakimidis, T Manning, R Hanzis, C Cao, Y Lewicki, M Treon, S AF Xu, Lian Patterson, Christopher J. Sun, Jenny Yang, Guang Zhou, Yangsheng Hunter, Zachary Hatjiharissi, Evdoxia Ciccarelli, Bryan Gong, Ping Liu, Xia Tseng, Hsiuyi Ioakimidis, Thea Manning, Robert Hanzis, Christina Cao, Yang Lewicki, Megan Treon, Steven TI Involvement of Fatty Acid Synthase in Azacytidine-Induced Cytotoxicity in Waldenstrom's Macroglobulinemia. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Patterson, Christopher J.] Dana Farber Canc Inst, Waldenstroms Macroflublinemia Ctr, Boston, MA 02115 USA. [Sun, Jenny; Zhou, Yangsheng; Liu, Xia; Tseng, Hsiuyi] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RI Hunter, Zachary/H-3018-2013 OI Hunter, Zachary/0000-0002-1689-1691 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1437 EP 1437 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804395 ER PT J AU Yang, G Gong, P Xu, L Hunter, Z Sun, J Ciccarelli, B Zhou, YS Liu, X Tseng, H Cao, Y Manning, R Lewicki, M Hanzis, C Ioakimidis, T Sheehy, P Patterson, CJ Treon, S AF Yang, Guang Gong, Ping Xu, Lian Hunter, Zachary Sun, Jenny Ciccarelli, Bryan Zhou, Yangsheng Liu, Xia Tseng, Hsiuyi Cao, Yang Manning, Robert Lewicki, Megan Hanzis, Christina Ioakimidis, Thea Sheehy, Patricia Patterson, Christopher J. Treon, Steven TI The Inhibitory Receptor FcgRIIB Is Overexpressed, and Its Ligation by Anti- FcgRIIB Antibodies Suppresses IgM Production and Induces Apoptosis in Waldenstrom's Macroglobulinemia. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Xu, Lian; Hunter, Zachary; Ciccarelli, Bryan; Hanzis, Christina] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Patterson, Christopher J.] Dana Farber Canc Inst, Waldenstroms Macroglubulinemia Ctr, Boston, MA 02115 USA. RI Hunter, Zachary/H-3018-2013 OI Hunter, Zachary/0000-0002-1689-1691 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1438 EP 1439 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725804400 ER PT J AU Azab, F Azab, AK Roccaro, AM Sacco, A Quang, P Ngo, HT Melhem, MR Runnels, JM Maiso, P Ghobrial, IM AF Azab, Feda Azab, Abdel Kareem Roccaro, Aldo M. Sacco, Antonio Quang, Phong Ngo, Hai T. Melhem, Molly R. Runnels, Judith M. Maiso, Patricia Ghobrial, Irene M. TI The Role of FGFR in the Progression of Waldenstrom's Macroglubulinemia and the Effect of its Inhibition by TKI-258. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Azab, Feda; Azab, Abdel Kareem; Roccaro, Aldo M.; Sacco, Antonio; Quang, Phong; Ngo, Hai T.; Melhem, Molly R.; Runnels, Judith M.; Maiso, Patricia; Ghobrial, Irene M.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1439 EP 1439 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804401 ER PT J AU Sun, J Tseng, H Xu, L Hunter, Z Ciccarelli, B Fulciniti, M Yang, G Gong, P Zhou, YS Liu, X Munshi, NC Patterson, CJ Treon, S AF Sun, Jenny Tseng, Hsiuyi Xu, Lian Hunter, Zachary Ciccarelli, Bryan Fulciniti, Mariateresa Yang, Guang Gong, Ping Zhou, Yangsheng Liu, Xia Munshi, Nikhil C. Patterson, Christopher J. Treon, Steven TI Vorinostat Induced Cellular Stress Disrupts the Balance Between p38 MAPK and Erk Pathways Leading to Apoptosis in WM Cells SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Sun, Jenny; Tseng, Hsiuyi; Fulciniti, Mariateresa; Zhou, Yangsheng; Liu, Xia] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston VA Healthcare Syst, Boston, MA 02115 USA. [Patterson, Christopher J.] Dana Farber Canc Inst, Waldenstroms Macroglubulinemia Ctr, Boston, MA 02115 USA. RI Hunter, Zachary/H-3018-2013 OI Hunter, Zachary/0000-0002-1689-1691 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1440 EP 1440 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804404 ER PT J AU Fisher, DC Tawa, M Walsh, M Clark, RA Kupper, TS AF Fisher, David C. Tawa, Marianne Walsh, Michele Clark, Rachael A. Kupper, Thomas S. TI Low-Dose Alemtuzumab Is Uniquely Effective in Refractory Leukemic Cutaneous T Cell Lymphoma (L-CTCL) SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Fisher, David C.; Tawa, Marianne; Walsh, Michele] Dana Farber Canc Inst, Boston, MA 02115 USA. [Clark, Rachael A.; Kupper, Thomas S.] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1443 EP 1443 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804412 ER PT J AU Treon, SP Hanzis, C Manning, R Ioakimidis, T Patterson, CJ Hunter, Z Turnbull, B Sheehy, P AF Treon, Steven P. Hanzis, Christina Manning, Robert Ioakimidis, Thea Patterson, Christopher J. Hunter, Zachary Turnbull, Barry Sheehy, Patricia TI Maintenance Rituximab Is Associated with Improved Progression Free and Overall Survival in Waldenstrom's Macroglobulinemia SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Manning, Robert; Sheehy, Patricia] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Patterson, Christopher J.] Dana Farber Canc Inst, Waldenstroms Macroglubulinemia Ctr, Boston, MA 02115 USA. [Turnbull, Barry] BioBridges Inc, Boston, MA USA. RI Hunter, Zachary/H-3018-2013 OI Hunter, Zachary/0000-0002-1689-1691 NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1443 EP 1444 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725804414 ER PT J AU Ghobrial, IM Padmanabhan, S Badros, AZ Leduc, R Rourke, M Chuma, S Kunsman, J Warren, D Harris, B Sam, A Anderson, KC Richardson, P Treon, S Matous, J AF Ghobrial, Irene M. Padmanabhan, Swaminathan Badros, Ashraf Z. Leduc, Renee Rourke, Meghan Chuma, Stacey Kunsman, Janet Warren, Diane Harris, Brianna Sam, Amy Anderson, Kenneth C. Richardson, Paul Treon, Steven Matous, Jeffrey TI Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Untreated Patients with Waldenstrom's Macroglobulinemia SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Ghobrial, Irene M.; Leduc, Renee; Rourke, Meghan; Chuma, Stacey; Kunsman, Janet; Warren, Diane; Harris, Brianna; Sam, Amy; Anderson, Kenneth C.; Richardson, Paul; Treon, Steven] Dana Farber Canc Inst, Boston, MA 02115 USA. [Padmanabhan, Swaminathan] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Badros, Ashraf Z.] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA. [Matous, Jeffrey] Rocky Mt Canc Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1444 EP 1444 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804416 ER PT J AU Hochberg, EP Birrer, N Toomey, CE Barnes, JA Lee, AI LaCasce, A Abramson, JS AF Hochberg, Ephraim P. Birrer, Nicole Toomey, Christiana E. Barnes, Jeffrey A. Lee, Alfred Ian LaCasce, Ann Abramson, Jeremy S. TI Rituximab Does Not Improve Progression Free (PFS) or Overall Survival (OS) in Patients with Limited Stage Diffuse Large B Cell Lymphoma (DLBCL) SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Hochberg, Ephraim P.; Toomey, Christiana E.; Barnes, Jeffrey A.; Abramson, Jeremy S.] Massachusetts Gen Hosp, Ctr Canc, Ctr Lymphoma, Boston, MA USA. [Lee, Alfred Ian] Dana Farber Partners Canc Care, Boston, MA USA. [Birrer, Nicole] Cornell Univ, Ithaca, NY USA. [LaCasce, Ann] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1445 EP 1446 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725804419 ER PT J AU West, CN Yoda, A Chiaretti, S Mani, K Foa, R Bradner, J Weinstock, DM AF West, C. Nathan Yoda, Akinori Chiaretti, Sabina Mani, Kartik Foa, Robin Bradner, James Weinstock, David M. TI CRLF2/JAK Signaling Confers Susceptibility to JAK Inhibitors and Small Molecule Inhibitors of Protein Kinase C. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [West, C. Nathan] MIT, Broad Inst Harvard, Boston, MA USA. [Yoda, Akinori; Mani, Kartik; Bradner, James] Dana Farber Canc Inst, Boston, MA 02115 USA. [Foa, Robin] Univ Roma La Sapienza, Div Hematol, Dept Cellular Biotechnol & Hematol, Rome, Italy. [Weinstock, David M.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1450 EP 1450 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804431 ER PT J AU Hugo, SE Bundrick, SC Hanson, CA Steensma, DP AF Hugo, Sarah E. Bundrick, Sarah C. Hanson, Curtis A. Steensma, David P. TI Independent Validation of the MD Anderson Cancer Center Risk Model for Myelodysplastic Syndromes (MDS), and Comparison to the International Prognostic Scoring System (IPSS) and the World Health Organization-Based Prognostic Scoring System (WPSS) SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Hugo, Sarah E.; Bundrick, Sarah C.] Mayo Clin, Dept Med, Rochester, MN USA. [Steensma, David P.] Dana Farber Canc Inst, Dept Hematol Malignancies, Boston, MA 02115 USA. NR 0 TC 2 Z9 2 U1 0 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1467 EP 1468 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725804478 ER PT J AU Goldberg, SL Steensma, DP AF Goldberg, Stuart L. Steensma, David P. TI Myelodysplastic Syndrome Patients Obtaining a Cytogenetic Response to Outpatient Decitabine Experience Improved Hematological Responses and Longer Survival: Additional Analyses From the ADOPT Trial. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Goldberg, Stuart L.] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA. [Steensma, David P.] Dana Farber Canc Inst, Dept Hematol Malignancies, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1468 EP 1469 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725804481 ER PT J AU List, AF Baer, MR Steensma, DP Raza, A Esposito, J Martinez-Lopez, N Paley, C Feigert, J Besa, EC AF List, Alan F. Baer, Maria R. Steensma, David P. Raza, Azra Esposito, Jason Martinez-Lopez, Noelia Paley, Carole Feigert, John Besa, Emmanuel C. TI Two-Year Analysis of Efficacy and Safety of Deferasirox (Exjade (R)) Treatment in Myelodysplastic Syndrome Patients Enrolled in the US03 Study. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [List, Alan F.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL 33612 USA. [Baer, Maria R.] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA. [Steensma, David P.] Dana Farber Canc Inst, Dept Hematol Malignancies, Boston, MA 02115 USA. [Raza, Azra] St Vincents Comprehens Canc Ctr, New York, NY USA. [Esposito, Jason; Martinez-Lopez, Noelia; Paley, Carole] Novartis Pharmaceut, E Hanover, NJ USA. [Feigert, John] Arlington Fairfax Hematol Oncol, Arlington, VA USA. [Besa, Emmanuel C.] Thomas Jefferson Univ, Philadelphia, PA 19107 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1473 EP 1473 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804493 ER PT J AU Gorgun, G Calabrese, E Hideshima, T Ecsedy, J Bianchi, G Mani, M Bandi, M Ikeda, H Perrone, G Hu, YG Tai, YT Zheng, M Cristea, D Santo, L Carrasco, DR Munshi, N Richardson, P Anderson, KC AF Gorgun, Gullu Calabrese, Elisabetta Hideshima, Teru Ecsedy, Jeffrey Bianchi, Giada Mani, Mala Bandi, Madhavi Ikeda, Hiroshi Perrone, Giulia Hu, Yiguo Tai, Yu-Tzu Zheng, Mei Cristea, Diana Santo, Loredana Carrasco, Daniel R. Munshi, Nikhil Richardson, Paul Anderson, Kenneth C. TI A NOVEL Aurora A Kinase INHIBITOR MLN8237 Induces Cytotoxicity and CELL Cycle Arrest IN MULTIPLE MYELOMA. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Gorgun, Gullu; Calabrese, Elisabetta; Hideshima, Teru; Bianchi, Giada; Mani, Mala; Bandi, Madhavi; Ikeda, Hiroshi; Perrone, Giulia; Hu, Yiguo; Tai, Yu-Tzu; Zheng, Mei; Cristea, Diana; Santo, Loredana; Carrasco, Daniel R.; Munshi, Nikhil; Richardson, Paul; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Ecsedy, Jeffrey] Millennium Pharmaceut Inc, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1474 EP 1474 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804494 ER PT J AU Santo, L Hideshima, T Nelson, EA Cirstea, D Bandi, M Ikeda, H Gorgun, G Vallet, S Pozzi, S Perrone, G Patel, K Hu, YG Squires, MS Yule, M Calabrese, E Chauhan, D Munshi, NC Anderson, KC Raje, N AF Santo, Loredana Hideshima, Teru Nelson, Erik A. Cirstea, Diana Bandi, Madhavi Ikeda, Hiroshi Gorgun, Gullu Vallet, Sonia Pozzi, Samantha Perrone, Giulia Patel, Kishan Hu, Yiguo Squires, Matthew S. Yule, Murray Calabrese, Elisabetta Chauhan, Dharminder Munshi, Nikhil C. Anderson, Kenneth C. Raje, Noopur TI AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor Induces Antimyeloma Activity Via Potent Aurora Kinase and STAT3 Inhibition. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Santo, Loredana; Hideshima, Teru; Nelson, Erik A.; Cirstea, Diana; Bandi, Madhavi; Ikeda, Hiroshi; Gorgun, Gullu; Pozzi, Samantha; Perrone, Giulia; Hu, Yiguo; Calabrese, Elisabetta; Chauhan, Dharminder; Munshi, Nikhil C.; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, VA Healthcare Syst, Boston, MA 02115 USA. [Vallet, Sonia; Patel, Kishan] Harvard Univ, Sch Med, Ctr Canc, Massachusetts Gen Hosp, Boston, MA USA. [Squires, Matthew S.; Yule, Murray] Astex Therapeut Ltd, Cambridge, England. [Raje, Noopur] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dana Farber Canc Inst, Boston, MA USA. RI Pozzi, Samantha/A-7617-2012 OI Pozzi, Samantha/0000-0001-7917-1774 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1475 EP 1475 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804497 ER PT J AU Shi, YJ Gera, J Lichtenstein, A AF Shi, Yijiang Gera, Joseph Lichtenstein, Alan TI Interleukin-6 (IL-6) Enhances C-MYC Translation IN MULTIPLE MYELOMA (MM) CELLS: ROLE of IL-6-INDUCED EFFECTS On the C-MYC RNA-Binding PROTEIN, HNRNPA1 SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Shi, Yijiang; Gera, Joseph] Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1477 EP 1477 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804503 ER PT J AU Chauhan, D Singh, AV Bandi, M Raje, N Schlossman, RL Lloyd, GK Richardson, P Palladino, MA Anderson, KC AF Chauhan, Dharminder Singh, Ajita V. Bandi, Madhavi Raje, Noopur Schlossman, Robert L. Lloyd, G. Kenneth Richardson, Paul Palladino, Michael A. Anderson, Kenneth C. TI NPI-2358, a Novel Vascular Disrupting Agent Blocks Growth and Angiogenesis in Multiple Myeloma Cells SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Chauhan, Dharminder; Singh, Ajita V.; Bandi, Madhavi; Schlossman, Robert L.; Richardson, Paul; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Raje, Noopur] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Lloyd, G. Kenneth; Palladino, Michael A.] Nereus Pharmaceut Inc, San Diego, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1478 EP 1478 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804506 ER PT J AU Roccaro, AM Sacco, A Husu, EN Pitsillides, CM Vesole, S Azab, AK Azab, F Melhem, M Ngo, H Quang, P Maiso, P Runnels, JM Lin, CP Anderson, KC Ghobrial, I AF Roccaro, Aldo M. Sacco, Antonio Husu, Emanuel N. Pitsillides, Costas M. Vesole, Steven Azab, Abdel Kareem Azab, Feda Melhem, Molly Ngo, Hai Quang, Phong Maiso, Patricia Runnels, Judith M. Lin, Charles P. Anderson, Kenneth C. Ghobrial, Irene TI Primary Waldesntrom Macroglobulinemia Cells Harbor Constitutive Activation of Akt, mTOR, Rictor and Raptor: Rational for Testing a Dual Inhibitor of the PI3K/Akt and mTOR Pathways in This Disease SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Roccaro, Aldo M.; Sacco, Antonio; Husu, Emanuel N.; Vesole, Steven; Azab, Abdel Kareem; Azab, Feda; Melhem, Molly; Ngo, Hai; Quang, Phong; Maiso, Patricia; Runnels, Judith M.; Anderson, Kenneth C.; Ghobrial, Irene] Dana Farber Canc Inst, Boston, MA 02115 USA. [Pitsillides, Costas M.; Lin, Charles P.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1478 EP 1478 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804507 ER PT J AU Tai, YT Kim, K Li, XF Fulciniti, M Song, WH Nahar, S Burger, P Rumizen, MJ Podar, K Chauhan, D Hideshima, T Schlossman, RL Munshi, NC Richardson, P Clark, A Ogden, J Andreas, G Rastelli, L Anderson, KC AF Tai, Yu-Tzu Kim, Kihyun Li, Xian-Feng Fulciniti, Mariateresa Song, Weihua Nahar, Sabikun Burger, Peter Rumizen, Mathew J. Podar, Klaus Chauhan, Dharminder Hideshima, Teru Schlossman, Robert L. Munshi, Nikhil C. Richardson, Paul Clark, Ann Ogden, Janet Andreas, Goutopoulos Rastelli, Luca Anderson, Kenneth C. TI Targeting MEK1/2 Signaling Cascade by AS703026, a Novel Selective MEK1/2 Inhibitor, Induces Pleiotropic Anti-Myeloma Activity in Vitro and In Vivo. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Tai, Yu-Tzu; Li, Xian-Feng; Fulciniti, Mariateresa; Song, Weihua; Nahar, Sabikun; Burger, Peter; Rumizen, Mathew J.; Podar, Klaus; Hideshima, Teru; Schlossman, Robert L.; Munshi, Nikhil C.; Richardson, Paul; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Med Oncol Dept,Boston VA Healthcare Syst, Boston, MA USA. [Kim, Kihyun] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul, South Korea. [Clark, Ann; Ogden, Janet; Andreas, Goutopoulos; Rastelli, Luca] EMD Serono, Rockland, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1480 EP 1480 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804512 ER PT J AU San-Miguel, JF Sezer, O Siegel, D Guenther, A Mateos, MV Prosser, I Cavo, M Blade, J Boccadoro, M Bengoudifa, BR Klebsattel, M Bourquelot, PM Anderson, KC AF San-Miguel, Jesus F. Sezer, Orhan Siegel, David Guenther, Andreas Mateos, Maria-Victoria Prosser, Ian Cavo, Michele Blade, Joan Boccadoro, Mario Bengoudifa, Bourras R. Klebsattel, Martin Bourquelot, Priscille M. Anderson, Kenneth C. TI A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and IV Bortezomib in Patients with Relapsed Multiple Myeloma. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [San-Miguel, Jesus F.; Mateos, Maria-Victoria] Hosp Univ Salamanca, Salamanca, Spain. [Sezer, Orhan] Charite, D-13353 Berlin, Germany. [Siegel, David] Hackensack Univ Med Ctr, Hackensack, NJ USA. [Guenther, Andreas] Univ Kiel, Dept Med 2, Div Stem Cell Transplantat & Immunotherapy, Kiel, Germany. [Prosser, Ian] Canberra Hosp, Canberra, ACT, Australia. [Cavo, Michele] Univ Bologna, Seragnoli Inst Hematol & Med Oncol, Bologna, Italy. [Blade, Joan] Hosp Clin Barcelona, Barcelona, Spain. [Boccadoro, Mario] Univ Turin, Div Hematol, Turin, Italy. [Bengoudifa, Bourras R.; Klebsattel, Martin; Bourquelot, Priscille M.] Novartis Pharma AG, Basel, Switzerland. [Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 4 Z9 4 U1 2 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1481 EP 1482 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725804516 ER PT J AU Raje, N Richardson, P Hari, PN Mahindra, A Kaster, S Connolly, C Rivera, L Chetri, G Dean, S Jacobs, P Saad, A Laubach, J Ghobrial, IM Schlossman, RL Adams, J Makrides, W Weller, E Munshi, N Anderson, KC AF Raje, Noopur Richardson, Paul Hari, Parameswaran N. Mahindra, Anuj Kaster, Sarah Connolly, Christine Rivera, Linda Chetri, Gaurav Dean, Sarah Jacobs, Paulette Saad, Ayman Laubach, Jacob Ghobrial, Irene M. Schlossman, Robert L. Adams, Jennifer Makrides, Wendy Weller, Edie Munshi, Nikhil Anderson, Kenneth C. TI An Open-Label Phase I Study of the Safety and Efficacy of RAD001 in Combination with Lenalidomide in the Treatment of Patients with Relapsed and Relapsed/Refractory Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Raje, Noopur; Mahindra, Anuj; Kaster, Sarah; Connolly, Christine; Rivera, Linda; Chetri, Gaurav] Massachusetts Gen Hosp, Ctr Canc, Div Hematol & Oncol, Boston, MA 02114 USA. [Richardson, Paul; Dean, Sarah; Laubach, Jacob; Ghobrial, Irene M.; Schlossman, Robert L.; Weller, Edie; Munshi, Nikhil; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Hari, Parameswaran N.; Jacobs, Paulette; Saad, Ayman] Med Coll Wisconsin, Div Neoplast Dis, Milwaukee, WI 53226 USA. [Makrides, Wendy] Celgene Corp, Summit, NJ USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1483 EP 1483 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804520 ER PT J AU Mateos, MV Richardson, PG Schlag, R Khuageva, NK Dimopoulos, MA Shpilberg, O Kropff, M Spicka, I Petrucci, MT Palumbo, A Samoilova, OS Dmoszynska, A Abdulkadyrov, KM Schots, R Jiang, B Esseltine, DL Liu, K Cakana, AZ van de Velde, H San Miguel, JF AF Mateos, Maria-Victoria Richardson, Paul G. Schlag, Rudolf Khuageva, Nuriet K. Dimopoulos, Meletios A. Shpilberg, Ofer Kropff, Martin Spicka, Ivan Petrucci, Maria Teresa Palumbo, Antonio Samoilova, Olga S. Dmoszynska, Anna Abdulkadyrov, Kudrat M. Schots, Rik Jiang, Bin Esseltine, Dixie-Lee Liu, Kevin Cakana, Andrew Z. van de Velde, Heigi San Miguel, Jesus F. TI Bortezomib Plus Melphalan-Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan-Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and Extensive Subsequent Therapy Use SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Mateos, Maria-Victoria; San Miguel, Jesus F.] Hosp Univ Salamanca, Salamanca, Spain. [Richardson, Paul G.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Schlag, Rudolf] Praxis Hematol & Oncol, Wurzburg, Germany. [Khuageva, Nuriet K.] SP Botkin Moscow City Clin Hosp, Dept Hematol, Moscow, Russia. [Dimopoulos, Meletios A.] Univ Athens, Sch Med, Dept Clin Therapeut, Alexandra Hosp, Athens 11528, Greece. [Shpilberg, Ofer] Rabin Med Ctr, Petah Tiqwa, Israel. [Kropff, Martin] Univ Munster, Munster, Germany. [Spicka, Ivan] Charles Univ Prague, Fac Med 1, Dept Med 1, Dept Clin Haematol, Prague, Czech Republic. [Petrucci, Maria Teresa] Univ Roma La Sapienza, Div Hematol, Rome, Italy. [Palumbo, Antonio] Univ Turin, Div Hematol, Turin, Italy. [Samoilova, Olga S.] Nizhnii Novgorod Reg Clin Hosp, Nizhnii Novgorod, Russia. [Dmoszynska, Anna] Med Univ Lublin, Lublin, Poland. [Abdulkadyrov, Kudrat M.] St Petersburg Clin Res Inst Hematol & Transfusiol, St Petersburg, Russia. [Schots, Rik] Belgian Hematol Soc, Myeloma Study Grp, Brussels, Belgium. [Jiang, Bin] Peking Univ, Peoples Hosp, Beijing, Peoples R China. [Esseltine, Dixie-Lee] Millennium Pharmaceut Inc, Cambridge, MA USA. [Liu, Kevin] Johnson & Johnson Pharmaceut Res & Dev LLC, Raritan, NJ USA. [Cakana, Andrew Z.] Johnson & Johnson Pharmaceut Res & Dev, High Wycombe, Bucks, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1484 EP 1485 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725804523 ER PT J AU Richardson, PG Bruna, J Amato, AA Udina, E Mitsiades, CS Wen, PY Hedley-Whyte, ET Oaklander, AL Monbaliu, J Vynckier, A Silverman, L Anderson, KC Navarro, X AF Richardson, Paul G. Bruna, Jordi Amato, Anthony A. Udina, Esther Mitsiades, Constantine S. Wen, Patrick Y. Hedley-Whyte, E. Tessa Oaklander, Anne Louise Monbaliu, Johan Vynckier, An Silverman, Lee Anderson, Kenneth C. Navarro, Xavier TI Bortezomib-Associated Peripheral Neuropathy: Relationship Between Clinical Neurophysiologic Evidence in Previously Untreated Multiple Myeloma Patients and Preclinical Characterization in a Mouse Model SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Richardson, Paul G.; Mitsiades, Constantine S.; Wen, Patrick Y.; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Bruna, Jordi; Udina, Esther; Navarro, Xavier] Univ Autonoma Barcelona, Inst Neurosci, Bellaterra, Spain. [Amato, Anthony A.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. [Hedley-Whyte, E. Tessa] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Oaklander, Anne Louise] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Monbaliu, Johan; Vynckier, An] Johnson & Johnson, GPCD, Beerse, Belgium. [Silverman, Lee] Millennium Pharmaceut Inc, Cambridge, MA USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1485 EP 1485 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804524 ER PT J AU Ghobrial, IM Harousseau, JL Treon, SP Harris, B Lin, CE Yuan, Z Benhadji, K Wooldridge, JE Leblond, V AF Ghobrial, Irene M. Harousseau, Jean-Luc Treon, Steven P. Harris, Brianna Lin, Courtney E. Yuan, Zheng Benhadji, Karim Wooldridge, James E. Leblond, Veronique TI Enzastaurin in Previously Treated Waldenstrom's Macroglobulinemia: An Open-Label, Multicenter, Phase II Study SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Ghobrial, Irene M.; Treon, Steven P.; Harris, Brianna] Dana Farber Canc Inst, Boston, MA 02115 USA. [Harousseau, Jean-Luc] Univ Nantes, Nantes, France. [Lin, Courtney E.; Yuan, Zheng; Wooldridge, James E.] Eli Lilly & Co, Indianapolis, IN 46285 USA. [Benhadji, Karim] Eli Lilly Co, Paris, France. [Leblond, Veronique] Hop La Pitie Salpetriere, APHP, Serv Hematol Clin, Paris, France. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1488 EP 1488 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804531 ER PT J AU Jakubowiak, AJ Bensinger, W Siegel, D Zimmerman, TM Van Tornout, JM Zhao, C Singhal, A Anderson, K AF Jakubowiak, Andrzej J. Bensinger, William Siegel, David Zimmerman, Todd M. Van Tornout, Jan M. Zhao, Carol Singhal, Anil Anderson, Kenneth TI Phase 1/2 Study of Elotuzumab in Combination with Bortezomib in Patients with Multiple Myeloma with One to Three Prior Therapies: Interim Results SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Jakubowiak, Andrzej J.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Bensinger, William] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Bensinger, William] Univ Washington, Seattle, WA 98195 USA. [Siegel, David] Hackensack Univ Med Ctr, Hackensack, NJ USA. [Zimmerman, Todd M.] Univ Chicago, Chicago, IL 60637 USA. [Van Tornout, Jan M.] Bristol Myers Squibb Co, Res & Dev, Princeton, NJ USA. [Zhao, Carol; Singhal, Anil] Facet Biotech, Redwood City, CA USA. [Anderson, Kenneth] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1491 EP 1492 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725804540 ER PT J AU Ricci, DS Favis, R Sun, Y van de Velde, H Broderick, E Meyers, M Harousseau, JL Avet-Loiseau, H Richardson, PG San Miguel, JF AF Ricci, Deborah S. Favis, Reyna Sun, Yu van de Velde, Helgi Broderick, Erin Meyers, Michael Harousseau, Jean-Luc Avet-Loiseau, Herve Richardson, Paul G. San Miguel, Jesus F. TI Pharmacogenomic (PGx) Analysis of Bortezomib-Associated Peripheral Neuropathy in the Phase 3 VISTA Trial of Bortezomib Plus Melphalan-Prednisone Versus Melphalan-Prednisone in Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Ricci, Deborah S.; Favis, Reyna; Sun, Yu; Broderick, Erin; Meyers, Michael] Johnson & Johnson Pharmaceut Res & Dev, Raritan, NJ USA. [van de Velde, Helgi] Johnson & Johnson Pharmaceut Res & Dev, Beerse, Belgium. [Harousseau, Jean-Luc] Ctr Rene Gauducheau, F-44035 Nantes, France. [Avet-Loiseau, Herve] CHU Nantes, F-44035 Nantes 01, France. [Richardson, Paul G.] Dana Farber Canc Inst, Boston, MA 02115 USA. [San Miguel, Jesus F.] Hosp Univ Salamanca, CIC, IBMCC, USAL CSIC, Salamanca, Spain. NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1491 EP 1491 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804539 ER PT J AU Siegel, D Jagannath, S Lonial, S Dimopoulos, MA Graef, T Pietrangelo, D Lupinacci, L Reiser, D Rizvi, S Anderson, KC AF Siegel, David Jagannath, Sundar Lonial, Sagar Dimopoulos, Meletios A. Graef, Thorsten Pietrangelo, Dina Lupinacci, Lisa Reiser, David Rizvi, Syed Anderson, Kenneth C. TI Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Siegel, David] Hackensack Univ, Med Ctr, Hackensack, NJ USA. [Jagannath, Sundar] St Vincent Catholic Med Ctr, New York, NY USA. [Lonial, Sagar] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA. [Dimopoulos, Meletios A.] Univ Athens, Dept Therapeut, Athens, Greece. [Graef, Thorsten; Pietrangelo, Dina; Lupinacci, Lisa; Reiser, David; Rizvi, Syed] Merck & Co Inc, Upper Gwynedd, PA USA. [Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1497 EP 1497 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804554 ER PT J AU Hunter, Z Hatjiharissi, E Sun, J Cao, Y Tseng, H Lewicki, M Xu, L Yang, G Zhou, YS Liu, X Gong, P Hanzis, C Ioakimidis, T Patterson, CJ Sheehy, P Barlogie, B Shaughnessy, JD Treon, S AF Hunter, Zachary Hatjiharissi, Evdoxia Sun, Jenny Cao, Yang Tseng, Hsiuyi Lewicki, Megan Xu, Lian Yang, Guang Zhou, Yangsheng Liu, Xia Gong, Ping Hanzis, Christina Ioakimidis, Thea Patterson, Christopher J. Sheehy, Patricia Barlogie, Bart Shaughnessy, John D., Jr. Treon, Steven TI Gene Expression Profiling Distinguishes Waldenstrom's Macroglobulinemia Patients Presenting with Familial Disease, Advanced IPSS Prognostic Score, and Previous Treatment with Rituximab. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Sun, Jenny; Tseng, Hsiuyi; Zhou, Yangsheng; Liu, Xia; Sheehy, Patricia] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Patterson, Christopher J.] Dana Farber Canc Inst, Waldenstroms Macroglubulinemia Ctr, Boston, MA 02115 USA. [Barlogie, Bart; Shaughnessy, John D., Jr.] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA. RI Hunter, Zachary/H-3018-2013 OI Hunter, Zachary/0000-0002-1689-1691 NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1511 EP 1511 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804594 ER PT J AU Grass, S Preuss, KD Wikowicz, A Terpos, E Ziepert, M Ahlgrimm, M Fadle, N Regitz, E Murawski, N Dimopoulos, MA Treon, SP Hunter, Z Pfreundschuh, M AF Grass, Sandra Preuss, Klaus-Dieter Wikowicz, Alexandra Terpos, Evangelos Ziepert, Marita Ahlgrimm, Manfred Fadle, Natalie Regitz, Evi Murawski, Niels Dimopoulos, Meletios A. Treon, Steven P. Hunter, Zachary Pfreundschuh, Michael TI Hyperphosphorylated Paratarg-7 Is a Frequent Antigenic Target of IgM Paraproteins, Is Dominantly Inherited and Represents a Highly Significant Risk Factor for Monoclonal Gammopathy of Undetermined Significance of the IgM Type (IgM-MGUS) and Waldenstrom's Macroglobulinemia (WM), Allowing for the Identification of Family Members at Risk in Cases of Familial IgM-MGUS and WM. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Grass, Sandra; Preuss, Klaus-Dieter; Wikowicz, Alexandra; Ahlgrimm, Manfred; Fadle, Natalie; Regitz, Evi; Murawski, Niels; Pfreundschuh, Michael] Univ Saarland, Sch Med, Dept Internal Med 1, Jose Carreras Ctr Immuno & Gene Therapy, D-6650 Homburg, Germany. [Terpos, Evangelos] Univ Athens, Sch Med, Dept Clin Therapeut, GR-11527 Athens, Greece. [Ziepert, Marita] Univ Leipzig, Leipzig, Germany. [Dimopoulos, Meletios A.] Univ Athens, Sch Med, Alexandra Hosp, Dept Clin Therapeut, Athens 11528, Greece. [Treon, Steven P.; Hunter, Zachary] Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA. RI Hunter, Zachary/H-3018-2013 OI Hunter, Zachary/0000-0002-1689-1691 NR 0 TC 1 Z9 1 U1 0 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1513 EP 1513 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804599 ER PT J AU Zhou, YS Liu, X Gong, P Xu, L Ciccarelli, B Yang, G Patterson, CJ Treon, S AF Zhou, Yangsheng Liu, Xia Gong, Ping Xu, Lian Ciccarelli, Bryan Yang, Guang Patterson, Christopher J. Treon, Steven TI Metalloproteinase Inhibitors Inhibit the Release of Soluble CD27 by Waldenstrom's Macroglobulinemia Cells. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Zhou, Yangsheng; Liu, Xia] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Patterson, Christopher J.] Dana Farber Canc Inst, Waldenstroms Macroglubulinemia Ctr, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1516 EP 1516 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804606 ER PT J AU Leleu, X Leduc, R Rourke, M Chuma, S Sam, A Harris, B Kunsman, J Ghobrial, IM AF Leleu, Xavier Leduc, Renee Rourke, Meghan Chuma, Stacey Sam, Amy Harris, Brianna Kunsman, Janet Ghobrial, Irene M. TI Serum Immunoglobulin Free Light Chain (sFLC) Measurement as a New Marker of Response to Therapy and Survival in Waldenstrom Macroglobulinemia (WM). SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Leleu, Xavier] Ctr Hosp Reg & Univ Lille, Hop Huriez, Serv Malad Sang, F-59037 Lille, France. [Leduc, Renee; Rourke, Meghan; Chuma, Stacey; Sam, Amy; Harris, Brianna; Kunsman, Janet; Ghobrial, Irene M.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1519 EP 1520 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725804616 ER PT J AU Yan, QS Dutt, S Xu, R Graves, K Juszczynski, P Manis, J Shipp, MA AF Yan, Qingsheng Dutt, Shilpee Xu, Rong Graves, Katherine Juszczynski, Przemyslaw Manis, John Shipp, Margaret A. TI The BBAP E3 Ligase Monoubiquitylates Histone H4 at Lysine 91 and Selectively Modulates the DNA Damage Response in Chemotherapy-Resistant Lymphomas SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Yan, Qingsheng; Xu, Rong; Juszczynski, Przemyslaw; Shipp, Margaret A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Dutt, Shilpee] Brigham & Womens Hosp, Boston, MA 02115 USA. [Graves, Katherine] Childrens Hosp, Boston, MA 02115 USA. [Manis, John] Harvard Univ, Sch Med, Childrens Hosp, Dept Pathol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1522 EP 1522 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804622 ER PT J AU Forrester, AM Boyd, ER Grabher, C McBride, ER Da'as, S Kai, FB Look, AT Berman, JN AF Forrester, A. Michael Boyd, Ellen R. Grabher, Clemens McBride, Eileen R. Da'as, Sahar Kai, Fui Boon Look, A. Thomas Berman, Jason N. TI NUP98-HOXA9 Reprograms Embryonic Hematopoiesis, Suppresses Cellular Apoptosis, and Causes Malignant Tissue Infiltrates in Transgenic Zebrafish SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Forrester, A. Michael; Boyd, Ellen R.; McBride, Eileen R.; Da'as, Sahar; Kai, Fui Boon; Berman, Jason N.] Dalhousie Univ, IWK Hlth Ctr, Halifax, NS, Canada. [Grabher, Clemens] Karlsruhe Inst Technol, Inst Toxicol & Genet, Karlsruhe, Germany. [Look, A. Thomas] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1523 EP 1523 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804625 ER PT J AU Gutierrez, A Feng, H Faucherre, A Den Hertog, J Prochownik, EV Testa, JR Kanki, J Look, AT AF Gutierrez, Alejandro Feng, Hui Faucherre, Adele Den Hertog, Jeroen Prochownik, Edward V. Testa, Joseph R. Kanki, John Look, A. Thomas TI Pten Inactivating Mutations Promote Loss of MYC "Oncogene Addiction" in a Conditional Zebrafish Model of T-ALL SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Gutierrez, Alejandro; Feng, Hui; Kanki, John; Look, A. Thomas] Dana Farber Canc Inst, Boston, MA 02115 USA. [Gutierrez, Alejandro] Childrens Hosp, Boston, MA 02115 USA. [Faucherre, Adele] Ctr Regulacio Genomica, Barcelona, Spain. [Den Hertog, Jeroen] Hubrecht Inst, Utrecht, Netherlands. [Prochownik, Edward V.] Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA. [Testa, Joseph R.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1528 EP 1529 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725804641 ER PT J AU Luetkhoff, LK Albisetti, M Bernard, TJ Bonduel, M Brandao, LR Chabrier, S Chan, A Fiedler, B Fullerton, HJ Ganesan, V Goldenberg, NA Golomb, M Grabowski, EF Heller, C Holzhauer, S Iorio, A Journeycake, J Kenet, G Kirkham, FJ Kurnik, K Lynch, JK Male, C Manco-Johnson, MJ Mesters, R Monagle, P van Ommen, HC Raffini, L Simioni, P Straeter, R Young, G Nowak-Gottl, U AF Luetkhoff, Lisa K. Albisetti, Manuela Bernard, Timothy J. Bonduel, Mariana Brandao, Leonardo R. Chabrier, Stephanie Chan, Anthony Fiedler, Barbara Fullerton, Heather J. Ganesan, Vijeja Goldenberg, Neil A. Golomb, Meredith Grabowski, Eric F. Heller, Christine Holzhauer, Susanne Iorio, Alfonso Journeycake, Janna Kenet, Gili Kirkham, Fenella J. Kurnik, Karin Lynch, John K. Male, Christoph Manco-Johnson, Marilyn J. Mesters, Rolf Monagle, Paul van Ommen, Heleen C. Raffini, Leslie Simioni, Paolo Straeter, Ronald Young, Guy Nowak-Gottl, Ulrike TI Impact of Thrombophilia On Arterial Ischemic Stroke or Cerebral Venous Sinus Thromboses in Children: A Systematic Review & Meta-Analysis of Observational Studies SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Luetkhoff, Lisa K.; Fiedler, Barbara; Straeter, Ronald] Univ Childrens Hosp Munster, Munster, Germany. [Albisetti, Manuela] Univ Childrens Hosp Zurich, Zurich, Switzerland. [Bernard, Timothy J.] Univ Colorado, Dept Pediat, Sect Hem Onc BMT, Aurora, CO USA. [Bernard, Timothy J.] Univ Colorado, Mt States Reg Hemophilia & Thrombosis Ctr, Aurora, CO USA. [Bernard, Timothy J.; Goldenberg, Neil A.; Manco-Johnson, Marilyn J.] Childrens Hosp, Aurora, CO USA. [Bonduel, Mariana] Hosp Pediat Prof Dr JP Garrahan, Serv Hematol & Oncol, Buenos Aires, DF, Argentina. [Brandao, Leonardo R.] Hosp Sick Children, Toronto, ON M5G 1X8, Canada. [Chabrier, Stephanie] Ctr Hosp Univ, Unit Neonatol & Reanimat Pediat, St Etienne, France. [Chan, Anthony] McMaster Univ, Hamilton, ON, Canada. [Fullerton, Heather J.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Fullerton, Heather J.] UCSF Childrens Hosp, San Francisco, CA USA. [Ganesan, Vijeja; Kirkham, Fenella J.] UCL, Neurosci Unit 11, Inst Child Hlth, London, England. [Goldenberg, Neil A.] Univ Colorado Denver, Pediat & Mt States Reg Hemophilia & Thrombosis Ct, Aurora, CO USA. [Golomb, Meredith] Indiana Univ, Sch Med, Indianapolis, IN USA. [Grabowski, Eric F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Grabowski, Eric F.] Harvard Univ, Sch Med, Boston, MA USA. [Heller, Christine] Univ Hosp Frankfurt, Frankfurt, Germany. [Holzhauer, Susanne] Charite, Berlin, Germany. [Iorio, Alfonso] Univ Perugia, I-06100 Perugia, Italy. [Journeycake, Janna] Childrens Med Ctr Dallas, Dept Pediat 17, Dallas, TX USA. [Kenet, Gili] Chaim Sheba Med Ctr, Thrombosis Unit, IL-52621 Tel Hashomer, Israel. [Kurnik, Karin] Dr V Hauners Childrens Univ Hosp, Pediat Hemophilia Ctr, Munich, Germany. [Lynch, John K.] Natl Inst Neurol Disorders & Stroke, Div Stroke Diagnost & Therapeut 21, Bethesda, MD USA. [Male, Christoph] Med Univ Vienna, Dept Pediat, Vienna, Austria. [Mesters, Rolf] Univ Munster, Dept Internal Med, D-4400 Munster, Germany. [Monagle, Paul] Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia. [van Ommen, Heleen C.] Emma Childrens Hosp AMC, Dept Pediat Hematol 25, Amsterdam, Netherlands. [Raffini, Leslie] Childrens Hosp Philadelphia, Dept Pediat, Div Hematol 27, Philadelphia, PA 19104 USA. [Simioni, Paolo] Univ Padua, Sch Med, Padua, Italy. [Young, Guy] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. [Nowak-Gottl, Ulrike] Univ Childrens Hosp, Dept Pediat Hem Onc, Munster, Germany. RI Kirkham, Fenella/C-2442-2009; OI Kirkham, Fenella/0000-0002-2443-7958; Young, Guy/0000-0001-6013-1254 NR 0 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1534 EP 1535 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725804657 ER PT J AU Flaumenhaft, R VerPlank, L Dilks, JR Blair, PS Mairuhu, A Negri, J Burbank, J Walzer, G Aldredge, T Dockendorff, C Gould, R MacPherson, L Palmer, M AF Flaumenhaft, Robert VerPlank, Lynn Dilks, James R. Blair, Price S. Mairuhu, Albert Negri, Joseph Burbank, Jason Walzer, Gil Aldredge, Tyler Dockendorff, Chris Gould, Robert MacPherson, Lawrence Palmer, Michelle TI A Chemical Genetic Analysis of Platelet Activation SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Flaumenhaft, Robert; Dilks, James R.; Blair, Price S.; Mairuhu, Albert] Harvard Univ, Sch Med, Dept Med, Div Hemostasis & Thrombosis,BIDMC, Boston, MA USA. [VerPlank, Lynn; Negri, Joseph; Burbank, Jason; Walzer, Gil; Aldredge, Tyler; Dockendorff, Chris; Gould, Robert; MacPherson, Lawrence; Palmer, Michelle] Broad Inst, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1540 EP 1540 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804673 ER PT J AU Letai, A AF Letai, Anthony TI Testing the BCL-2 Family to Direct Therapy and Predict Response. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Letai, Anthony] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1578 EP 1578 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804774 ER PT J AU Babitt, JL AF Babitt, Jodie L. TI Hepcidin Regulation by the BMP Pathway SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Babitt, Jodie L.] Massachusetts Gen Hosp, Div Nephrol, Program Membrane Biol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1580 EP 1580 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804785 ER PT J AU Mempel, TR AF Mempel, Thorsten R. TI The Lymph Node Niche SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Mempel, Thorsten R.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1586 EP 1586 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804811 ER PT J AU Kulke, MH Tempero, MA Niedzwiecki, D Hollis, DR Kindler, HL Cusnir, M Enzinger, PC Gorsch, SM Goldberg, RM Mayer, RJ AF Kulke, Matthew H. Tempero, Margaret A. Niedzwiecki, Donna Hollis, Donna R. Kindler, Hedy L. Cusnir, Michael Enzinger, Peter C. Gorsch, Stefan M. Goldberg, Richard M. Mayer, Robert J. TI Randomized Phase II Study of Gemcitabine Administered at a Fixed Dose Rate or in Combination With Cisplatin, Docetaxel, or Irinotecan in Patients With Metastatic Pancreatic Cancer: CALGB 89904 SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID CLINICAL-TRIALS GROUP; PLUS GEMCITABINE; 30-MINUTE INFUSION; MULTICENTER; CHEMOTHERAPY; SURVIVAL; BENEFIT AB Purpose The relative value of gemcitabine-based combination chemotherapy therapy and prolonged infusions of gemcitabine in patients with advanced pancreatic cancer remains controversial. We explored the efficacy and toxicity of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in a multi-institutional, randomized, phase II study. Patients and Methods Patients with metastatic pancreatic cancer were randomly assigned to one of the following four regimens: gemcitabine 1,000 mg/m(2) on days 1, 8, and 15 with cisplatin 50 mg/m(2) on days 1 and 15 (arm A); gemcitabine 1,500 mg/m(2) at a rate of 10 mg/m(2)/min on days 1, 8, and 15 (arm B); gemcitabine 1,000 mg/m(2) with docetaxel 40 mg/m(2) on days 1 and 8 (arm C); or gemcitabine 1,000 mg/m(2) with irinotecan 100 mg/m(2) on days 1 and 8 (arm D). Patients were observed for response, toxicity, and survival. Results Two hundred fifty-nine patients were enrolled onto the study, of whom 245 were eligible and received treatment. Anticipated rates of myelosuppression, fatigue, and expected regimen-specific toxicities were observed. The overall tumor response rates were 12% to 14%, and the median overall survival times were 6.4 to 7.1 months among the four regimens. Conclusion Gemcitabine/cisplatin, fixed dose rate gemcitabine, gemcitabine/docetaxel, and gemcitabine/ irinotecan have similar antitumor activity in metastatic pancreatic cancer. In light of recent negative randomized studies directly comparing several of these regimens with standard gemcitabine, none of these approaches can be recommended for routine use in patients with this disease. C1 [Kulke, Matthew H.] Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA. Duke Univ, Canc & Leukemia Grp B, Ctr Stat, Durham, NC 27706 USA. Univ N Carolina, Ctr Comprehens Canc, Chapel Hill, NC USA. Univ Chicago, Med Ctr, Chicago, IL 60637 USA. Mt Sinai Comprehens Canc Ctr, Miami, FL USA. Martha Jefferson Hosp, Charlottesville, VA USA. RP Kulke, MH (reprint author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM matthew_kulke@dfci.harvard.edu RI Goldberg , Richard/M-1311-2013 FU National Cancer Institute [CA31946, CA33601] FX Supported, in part, by National Cancer Institute Grants No. CA31946 to the Cancer and Leukemia Group B (CALGB) and CA33601 to the CALGB Statistical Center. NR 22 TC 45 Z9 46 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 20 PY 2009 VL 27 IS 33 BP 5506 EP 5512 DI 10.1200/JCO.2009.22.1309 PG 7 WC Oncology SC Oncology GA 521VS UT WOS:000271954200006 PM 19858396 ER PT J AU Loggers, ET Maciejewski, PK Paulk, E DeSanto-Madeya, S Nilsson, M Viswanath, K Wright, AA Balboni, TA Temel, J Stieglitz, H Block, S Prigerson, HG AF Loggers, Elizabeth Trice Maciejewski, Paul K. Paulk, Elizabeth DeSanto-Madeya, Susan Nilsson, Matthew Viswanath, Kasisomayajula Wright, Alexi Anne Balboni, Tracy A. Temel, Jennifer Stieglitz, Heather Block, Susan Prigerson, Holly G. TI Racial Differences in Predictors of Intensive End-of-Life Care in Patients With Advanced Cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID BLACK-AND-WHITE; KARNOFSKY PERFORMANCE STATUS; NURSING-HOME RESIDENTS; SERIOUSLY ILL PATIENTS; TREATMENT PREFERENCES; CARDIOPULMONARY-RESUSCITATION; PROLONGING TREATMENTS; SUSTAINING TREATMENTS; ETHNIC-DIFFERENCES; AFRICAN-AMERICANS AB Purpose Black patients are more likely than white patients to receive life-prolonging care near death. This study examined predictors of intensive end-of-life (EOL) care for black and white advanced cancer patients. Patients and Methods Three hundred two self-reported black (n = 68) and white (n = 234) patients with stage IV cancer and caregivers participated in a US multisite, prospective, interview-based cohort study from September 2002 to August 2008. Participants were observed until death, a median of 116 days from baseline. Patient-reported baseline predictors included EOL care preference, physician trust, EOL discussion, completion of a Do Not Resuscitate (DNR) order, and religious coping. Caregiver postmortem interviews provided information regarding EOL care received. Intensive EOL care was defined as resuscitation and/or ventilation followed by death in an intensive care unit. Results Although black patients were three times more likely than white patients to receive intensive EOL care (adjusted odds ratio [aOR] = 3.04, P = .037), white patients with a preference for this care were approximately three times more likely to receive it (aOR = 13.20, P = .008) than black patients with the same preference (aOR = 4.46, P = .058). White patients who reported an EOL discussion or DNR order did not receive intensive EOL care; similar reports were not protective for black patients (aOR = 0.53, P = .460; and aOR = 0.65, P = .618, respectively). Conclusion White patients with advanced cancer are more likely than black patients with advanced cancer to receive the EOL care they initially prefer. EOL discussions and DNR orders are not associated with care for black patients, highlighting a need to improve communication between black patients and their clinicians. C1 [Prigerson, Holly G.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02114 USA. Dana Farber Canc Inst, Dept Psychooncol, Boston, MA 02114 USA. Dana Farber Canc Inst, Dept Palliat Care, Boston, MA 02114 USA. Dana Farber Canc Inst, Ctr Psychooncol & Palliat Care Res, Boston, MA 02114 USA. Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Cambridge, MA 02138 USA. Univ Massachusetts, Coll Nursing & Hlth Sci, Boston, MA 02125 USA. Massachusetts Gen Hosp, Ctr Canc, Ctr Thorac Canc, Boston, MA USA. Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA. RP Prigerson, HG (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St,Smith Bldg 268, Boston, MA 02114 USA. EM Holly_Prigerson@dfci.harvard.edu FU National Institute of Mental Health [MH63892]; National Cancer Institute [CA106370]; Dana-Farber/Harvard Cancer Center [U56CA118641, P30CA0651]; Center for Psycho-Oncology and Palliative Care Research, Dana-Farber Cancer Institute FX Supported in part by Grant No. MH63892 from the National Institute of Mental Health and Grant No. CA106370 from the National Cancer Institute (H.G.P.), Dana-Farber/Harvard Cancer Center pilot Grants No. U56CA118641 and P30CA0651 (H.G.P.), and the Center for Psycho-Oncology and Palliative Care Research, Dana-Farber Cancer Institute. NR 45 TC 65 Z9 65 U1 3 U2 9 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 20 PY 2009 VL 27 IS 33 BP 5559 EP 5564 DI 10.1200/JCO.2009.22.4733 PG 6 WC Oncology SC Oncology GA 521VS UT WOS:000271954200013 PM 19805675 ER PT J AU Matulonis, UA Berlin, S Ivy, P Tyburski, K Krasner, C Zarwan, C Berkenblit, A Campos, S Horowitz, N Cannistra, SA Lee, H Lee, J Roche, M Hill, M Whalen, C Sullivan, L Tran, C Humphreys, BD Penson, RT AF Matulonis, Ursula A. Berlin, Suzanne Ivy, Percy Tyburski, Karin Krasner, Carolyn Zarwan, Corrine Berkenblit, Anna Campos, Susana Horowitz, Neil Cannistra, Stephen A. Lee, Hang Lee, Julie Roche, Maria Hill, Margaret Whalen, Christin Sullivan, Laura Tran, Chau Humphreys, Benjamin D. Penson, Richard T. TI Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID GYNECOLOGIC-ONCOLOGY-GROUP; SOLID TUMORS; PHASE-I; COLORECTAL-CANCER; BEVACIZUMAB; PACLITAXEL; GUIDELINES; EVALUATE; AZD2171; LYMPHANGIOGENESIS AB Purpose Angiogenesis is important for epithelial ovarian cancer (EOC) growth, and blocking angiogenesis can lead to EOC regression. Cediranib is an oral tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, and c-kit. Patients and Methods We conducted a phase II study of cediranib for recurrent EOC or peritoneal or fallopian tube cancer; cediranib was administered as a daily oral dose, and the original dose was 45 mg daily. Because of toxicities observed in the first 11 patients, the dose was lowered to 30 mg. Eligibility included <= two lines of chemotherapy for recurrence. End points included response rate (via Response Evaluation Criteria in Solid Tumors [RECIST] or modified Gynecological Cancer Inter-group CA-125), toxicity, progression-free survival (PFS), and overall survival (OS). Results Forty-seven patients were enrolled; 46 were treated. Clinical benefit rate (defined as complete response [CR] or partial response [PR], stable disease [SD] > 16 weeks, or CA-125 nonprogression > 16 weeks), which was the primary end point, was 30%; eight patients (17%; 95% CI, 7.6% to 30.8%) had a PR, six patients (13%; 95% CI, 4.8% to 25.7%) had SD, and there were no CRs. Eleven patients (23%) were removed from study because of toxicities before two cycles. Grade 3 toxicities (> 20% of patients) included hypertension (46%), fatigue (24%), and diarrhea (13%). Grade 2 hypothyroidism occurred in 43% of patients. Grade 4 toxicities included CNS hemorrhage (n = 1), hypertriglyceridemia/hypercholesterolemia/elevated lipase (n = 1), and dehydration/elevated creatinine (n = 1). No bowel perforations or fistulas occurred. Median PFS was 5.2 months, and median OS has not been reached; median follow-up time is 10.7 months. Conclusion Cediranib has activity in recurrent EOC, tubal cancer, and peritoneal cancer with predictable toxicities observed with other TKIs. C1 [Matulonis, Ursula A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Massachusetts Gen Hosp, Dept Hematol & Oncol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. Brigham & Womens Hosp, Div Gynecol Oncol, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. Beth Israel Deaconess Med Ctr, Dept Hematol & Oncol, Boston, MA 02215 USA. Lahey Clin Fdn, Dept Hematol & Oncol, Burlington, MA USA. Wyeth Pharmaceut, Cambridge, MA USA. NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA. RP Matulonis, UA (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA. EM Ursula_matulonis@dfci.harvard.edu FU Madeline Franchi Ovarian Cancer Fund; Ovations for the Cure FX Supported in part by donations made by the Madeline Franchi Ovarian Cancer Fund and Ovations for the Cure. NR 26 TC 150 Z9 155 U1 0 U2 4 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 20 PY 2009 VL 27 IS 33 BP 5601 EP 5606 DI 10.1200/JCO.2009.23.2777 PG 6 WC Oncology SC Oncology GA 521VS UT WOS:000271954200019 PM 19826113 ER PT J AU McDermott, U Settleman, J AF McDermott, Ultan Settleman, Jeff TI Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Review ID CELL LUNG-CANCER; GASTROINTESTINAL STROMAL TUMORS; METASTATIC BREAST-CANCER; CHRONIC MYELOGENOUS LEUKEMIA; FACTOR RECEPTOR MUTATIONS; CHRONIC MYELOID-LEUKEMIA; EML4-ALK FUSION GENE; FACTOR-I RECEPTOR; TYROSINE KINASE; ACQUIRED-RESISTANCE AB Selective kinase inhibitors have emerged as an important class of anticancer agents, with demonstrated clinical efficacy and generally favorable toxicity profiles in several common disease settings where conventional treatments have previously provided only modest benefit. Consequently, a substantial effort is now underway to identify additional therapeutically relevant kinase targets and to develop and test inhibitors of those proteins in a variety of human malignancies. However, it has also become clear that the clinical benefit associated with these agents is typically limited to a subset of treated patients, who in many cases are defined by a specific genomic lesion within their tumor cells-frequently, an activating mutation within the gene encoding the target kinase. This discovery has prompted efforts to stratify patients before treatment with kinase inhibitors based on specific genomic biomarkers, with the goal of optimizing clinical outcomes through the effective personalization of treatment (ie, matching the right patients with the right therapies). With recent advances in our understanding of the relationship between tumor genotypes and cancer cell sensitivity to kinase inhibition, together with improved technologies for rapidly genotyping tumor biopsies for relevant lesions, the implementation of personalized cancer care with this exciting new class of inhibitors is now becoming a reality. In this review, we summarize recent developments in this area, and we highlight some of the logistical challenges posed by this emerging paradigm in medical oncology. C1 [McDermott, Ultan; Settleman, Jeff] Massachusetts Gen Hosp, Ctr Canc, Ctr Mol Therapeut, Charlestown, MA 02129 USA. RP Settleman, J (reprint author), Massachusetts Gen Hosp, Ctr Canc, Ctr Mol Therapeut, Bldg 149,7th Fl,13th St, Charlestown, MA 02129 USA. EM Settleman@helix.mgh.harvard.edu OI McDermott, Ultan/0000-0001-9032-4700 NR 111 TC 80 Z9 84 U1 0 U2 7 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 20 PY 2009 VL 27 IS 33 BP 5650 EP 5659 DI 10.1200/JCO.2009.22.9054 PG 10 WC Oncology SC Oncology GA 521VS UT WOS:000271954200026 PM 19858389 ER PT J AU Theman, TA Hartzell, TL Sinha, I Polson, K Morgan, J Demetri, GD Orgill, DP George, S AF Theman, Todd A. Hartzell, Tristan L. Sinha, Indranil Polson, Kathleen Morgan, Jeffrey Demetri, George D. Orgill, Dennis P. George, Suzanne TI Recognition of a New Chemotherapeutic Vesicant: Trabectedin (Ecteinascidin-743) Extravasation With Skin and Soft Tissue Damage SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID CONTINUOUS INTRAVENOUS-INFUSION; PHASE-II; ET-743; MANAGEMENT; SARCOMA; CANCER; AGENTS; INJURY C1 [Theman, Todd A.; Hartzell, Tristan L.; Sinha, Indranil; Orgill, Dennis P.] Brigham & Womens Hosp, Dept Surg, Div Plast Surg, Boston, MA 02115 USA. [Polson, Kathleen; Morgan, Jeffrey; Demetri, George D.; George, Suzanne] Dana Farber Canc Inst, Dept Med Oncol, Ctr Sarcoma & Bone Oncol, Boston, MA 02115 USA. RP Theman, TA (reprint author), Brigham & Womens Hosp, Dept Surg, Div Plast Surg, 75 Francis St, Boston, MA 02115 USA. OI Orgill, Dennis/0000-0002-8279-7310 NR 23 TC 14 Z9 14 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 20 PY 2009 VL 27 IS 33 BP E198 EP E200 DI 10.1200/JCO.2008.21.6473 PG 3 WC Oncology SC Oncology GA 521VS UT WOS:000271954200029 PM 19805684 ER PT J AU Wharton, W Dowling, M Khosropour, CM Carlsson, C Asthana, S Gleason, CE AF Wharton, Whitney Dowling, Maritza Khosropour, Christine M. Carlsson, Cynthia Asthana, Sanjay Gleason, Carey E. TI Cognitive benefits of hormone therapy: Cardiovascular factors and healthy-user bias SO MATURITAS LA English DT Article DE Hormone therapy; Estrogen; Healthy-user bias; Cardiovascular risk; Cognition; Alzheimer's disease ID CORONARY-HEART-DISEASE; ESTROGEN REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; BLOOD-PRESSURE; ALZHEIMERS-DISEASE; CLINICAL-TRIALS; PLUS PROGESTIN; SELF-REPORT; PREVENTION; HYPERTENSION AB Objective: The Women's Health Initiative (WHI) study and its ancillary Memory Study (WHIMS) revealed increased rates of cardiovascular risk, cognitive decline and dementia with opposed conjugated equine estrogens (CEE). As a result, previously accepted observational data suggesting cardiovascular and cognitive benefits and reduced risk for dementia with hormone therapy (HT) were largely attributed to 'healthy-user' bias. The present observational, community-based, case-controlled study examined the 'healthy-user' bias theory by comparing cognitive task performance in two groups of postmenopausal women, who were either HT users or non-users. Design: Participants were 213 non-demented, postmenopausal women residing in the community and in assisted-living facilities who completed a self-report health questionnaire and underwent a 1-h cognitive test battery. To study the independent contribution of variables in the prediction of cognitive performance, we employed a series of hierarchical regression models adding terms in three stages. The first stage included only HT, the second stage added demographics, and the last stage added alcohol, depression and a cardiovascular risk factor (CVRF) composite derived from a confirmatory factor analysis. The CVRF composite consisted of: stroke, diabetes, hypertension, and hypercholesterolemia. Results: Although independent samples t-tests revealed no statistically significant differences in the CVRF composite and its individual components between the two groups, HT users tended to possess fewer CVRF than non-users. Conversely, HT users were younger and more educated than non-users. HT users outperformed non-users on 7/9 cognitive variables. The full regression model controlling for CVRF, demographic variables, and mood showed HT users outperformed non-users on measures of verbal memory and abstract reasoning. Conclusions: While there is some evidence HT users possess fewer preexisting CVRF than non-users, the observed positive association between HT and cognition is not completely explained by this trend. (C) 2009 Elsevier Ireland Ltd. All rights reserved. C1 [Wharton, Whitney; Dowling, Maritza; Carlsson, Cynthia; Asthana, Sanjay; Gleason, Carey E.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53705 USA. [Khosropour, Christine M.] Emory Univ, Sch Publ Hlth, Atlanta, GA 30322 USA. [Wharton, Whitney; Dowling, Maritza; Carlsson, Cynthia; Asthana, Sanjay; Gleason, Carey E.] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI USA. RP Wharton, W (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, William S Middleton VA Hosp, 2500 Overlook Terrace,GRECC 11G, Madison, WI 53705 USA. EM wlwharto@medicine.wisc.edu FU NIH [AG029624, K07AG021582, K23AG024302, K23AG026752]; National Center for Research Resources, National Institutes of Health [1UL1RR025011] FX This research was conducted with the help of the Section of Geriatrics and Gerontology, Department of Medicine at the University of Wisconsin, Madison, and the Geriatric Research, Education and Clinical Center (GRECC), William S. Middleton Memorial Veterans Hospital. This research was supported by NIH grants AG029624, K07AG021582, K23AG024302 and K23AG026752, and by grant 1UL1RR025011 from the Clinical and Translational Science Award (CTSA) program of the National Center for Research Resources, National Institutes of Health. NR 37 TC 7 Z9 8 U1 0 U2 4 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0378-5122 J9 MATURITAS JI Maturitas PD NOV 20 PY 2009 VL 64 IS 3 BP 182 EP 187 DI 10.1016/j.maturitas.2009.09.014 PG 6 WC Geriatrics & Gerontology; Obstetrics & Gynecology SC Geriatrics & Gerontology; Obstetrics & Gynecology GA 526QQ UT WOS:000272308000007 PM 19879073 ER PT J AU Chen, L Kwon, YD Zhou, TQ Wu, XL O'Dell, S Cavacini, L Hessell, AJ Pancera, M Tang, M Xu, L Yang, ZY Zhang, MY Arthos, J Burton, DR Dimitrov, DS Nabel, GJ Posner, MR Sodroski, J Wyatt, R Mascola, JR Kwong, PD AF Chen, Lei Kwon, Young Do Zhou, Tongqing Wu, Xueling O'Dell, Sijy Cavacini, Lisa Hessell, Ann J. Pancera, Marie Tang, Min Xu, Ling Yang, Zhi-Yong Zhang, Mei-Yun Arthos, James Burton, Dennis R. Dimitrov, Dimiter S. Nabel, Gary J. Posner, Marshall R. Sodroski, Joseph Wyatt, Richard Mascola, John R. Kwong, Peter D. TI Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120 SO SCIENCE LA English DT Article ID IMMUNODEFICIENCY-VIRUS TYPE-1; HUMAN MONOCLONAL-ANTIBODY; NEUTRALIZING ANTIBODIES; BINDING-SITE; EFFICIENT NEUTRALIZATION; ENVELOPE GLYCOPROTEINS; INFECTED INDIVIDUALS; PROTEIN; PANEL; CRYSTALLIZATION AB The site on HIV-1 gp120 that binds to the CD4 receptor is vulnerable to antibodies. However, most antibodies that interact with this site cannot neutralize HIV-1. To understand the basis of this resistance, we determined co-crystal structures for two poorly neutralizing, CD4-binding site (CD4BS) antibodies, F105 and b13, in complexes with gp120. Both antibodies exhibited approach angles to gp120 similar to those of CD4 and a rare, broadly neutralizing CD4BS antibody, b12. Slight differences in recognition, however, resulted in substantial differences in F105- and b13-bound conformations relative to b12-bound gp120. Modeling and binding experiments revealed these conformations to be poorly compatible with the viral spike. This incompatibility, the consequence of slight differences in CD4BS recognition, renders HIV-1 resistant to all but the most accurately targeted antibodies. C1 [Chen, Lei; Kwon, Young Do; Zhou, Tongqing; Wu, Xueling; O'Dell, Sijy; Pancera, Marie; Tang, Min; Xu, Ling; Yang, Zhi-Yong; Nabel, Gary J.; Wyatt, Richard; Mascola, John R.; Kwong, Peter D.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA. [Cavacini, Lisa; Posner, Marshall R.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Head & Neck Oncol Program, Boston, MA 02115 USA. [Hessell, Ann J.; Burton, Dennis R.] Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA. [Hessell, Ann J.; Burton, Dennis R.] Scripps Res Inst, Dept Microbial Sci, La Jolla, CA 92037 USA. [Hessell, Ann J.; Burton, Dennis R.] Scripps Res Inst, Int AIDS Vaccine Initiat Neutralizing Antibody Ct, La Jolla, CA 92037 USA. [Zhang, Mei-Yun; Dimitrov, Dimiter S.] NCI, Ctr Canc Res, Frederick, MD 21702 USA. [Arthos, James] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA. [Burton, Dennis R.] Massachusetts Gen Hosp, MIT, Ragon Inst, Boston, MA 02114 USA. [Burton, Dennis R.] Harvard Univ, Boston, MA 02114 USA. [Sodroski, Joseph] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. RP Kwong, PD (reprint author), NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA. EM pdkwong@nih.gov; pdkwong@nih.gov RI Zhang, Mei-Yun/E-9908-2010; Kwon, Young Do/A-6957-2010; Zhou, Tongqing/A-6880-2010 OI Zhou, Tongqing/0000-0002-3935-4637 FU NIH; International AIDS Vaccine Initiative; Bill and Melinda Gates Foundation Grand Challenges in Global Heath Initiative FX L. Chen produced and assessed for crystallization CD4BS antibodies with unconstrained gp120, crystallized the F105-gp120 complex, assisted with F105-gp120 data collection and structure solution, and carried out mutagenesis and SPR binding experiments. Y. D. K. assisted with F105-gp120 crystallization, data collection, and structure solution and refined and analyzed the F105-gp120 structure. T. Z. purified, crystallized, solved, and analyzed the b13-gp120 complex. X. W., S. O.' D. and J. R. M. assessed neutralization potency and breadth of CD4, patient sera, and CD4BS antibodies. L. Chen and M. P. carried out cell-surface JR-FL binding experiments. M. T. and R. W. provided YU2 core gp120; L. X. and G. J. N. provided stabilized-core gp120; Z.-Y. Y. and G. J. N. converted b13 from Fab to IgG format and provided b13 IgG; L. Cavacini and M. R. P. provided F105; M.-Y. Z. and D. S. D. provided m6, m14, and m18; A. J. H. and D. R. B. provided b3, b6, b11, b12; and J. A. provided dodecameric CD4. J. A., D. R. B., D. S. D., G. J. N., M. R. P., J. S., R. W., and J. R. M. assisted with analysis and writing, and P. D. K. assisted with crystallography and experimental planning and wrote the first draft. Figures, tables, and supporting online material were produced by L. Chen, Y. D. K., M. P., T. Z. and X. W. We thank L. Shapiro and members of the Structural Biology Section, Vaccine Research Center (VRC), for discussions and comments on the manuscript, M. Connors for patient serum, M. Fung for antibodies G3-42 and G3-299, J. Robinson for antibodies 1.5e and F91, J. Stuckey for assistance with figures and tables, S. Subramaniam for EM tomograms, C. Winter and C. Huang for S2 production of core YU2 gp120, X. Yang for preparation of JR-FL gp120, and the Flow Cytometry Core, VRC, for assistance with antibody binding to cell-surface-expressed HIV-1 spikes. Support for this work was provided by the Intramural Research Program of NIH, the International AIDS Vaccine Initiative, a grant from the Bill and Melinda Gates Foundation Grand Challenges in Global Heath Initiative, and grants from NIH. The use of insertion device 22 (Southeast Region Collaborative Access Team) at the Advanced Photon Source was supported by the U. S. Department of Energy, Basic Energy Sciences, Office of Science, under contract number W-31-109-Eng-38. Coordinates and structure factors for the F105-gp120 complex (accession code 3HI1) and the b13-gp120 complexes (accession codes 3IDX and 3IDY for C222 and C2221 forms, respectively) have been deposited with the Protein Data Bank. NR 33 TC 187 Z9 192 U1 0 U2 21 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 0036-8075 J9 SCIENCE JI Science PD NOV 20 PY 2009 VL 326 IS 5956 BP 1123 EP 1127 DI 10.1126/science.1175868 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 521UW UT WOS:000271951000048 PM 19965434 ER PT J AU Amigo, JD Ackermann, GE Cope, JJ Yu, M Cooney, JD Ma, DD Langer, NB Shafizadeh, E Shaw, GC Horsely, W Trede, NS Davidson, AJ Barut, BA Zhou, Y Wojiski, SA Traver, D Moran, TB Kourkoulis, G Hsu, K Kanki, JP Shah, DI Lin, HF Handin, RI Cantor, AB Paw, BH AF Amigo, Julio D. Ackermann, Gabriele E. Cope, John J. Yu, Ming Cooney, Jeffrey D. Ma, Dongdong Langer, Nathaniel B. Shafizadeh, Ebrahim Shaw, George C. Horsely, Wyatt Trede, Nikolaus S. Davidson, Alan J. Barut, Bruce A. Zhou, Yi Wojiski, Sarah A. Traver, David Moran, Tyler B. Kourkoulis, George Hsu, Karl Kanki, John P. Shah, Dhvanit I. Lin, Hui Feng Handin, Robert I. Cantor, Alan B. Paw, Barry H. TI The role and regulation of friend of GATA-1 (FOG-1) during blood development in the zebrafish SO BLOOD LA English DT Article ID TRANSCRIPTION FACTOR GATA-1; MAST-CELL LINEAGE; TRANSGENIC ZEBRAFISH; T-CELL; GENE; EXPRESSION; FATE; PU.1; ERYTHROPOIESIS; ANTAGONISM AB The nuclear protein FOG-1 binds transcription factor GATA-1 to facilitate erythroid and megakaryocytic maturation. However, little is known about the function of FOG-1 during myeloid and lymphoid development or how FOG-1 expression is regulated in any tissue. We used in situ hybridization, gain- and loss-of-function studies in zebrafish to address these problems. Zebrafish FOG-1 is expressed in early hematopoietic cells, as well as heart, viscera, and paraspinal neurons, suggesting that it has multifaceted functions in organogenesis. We found that FOG-1 is dispensable for endoderm specification but is required for endoderm patterning affecting the expression of late-stage T-cell markers, independent of GATA-1. The suppression of FOG-1, in the presence of normal GATA-1 levels, induces severe anemia and thrombocytopenia and expands myeloid-progenitor cells, indicating that FOG-1 is required during erythroid/myeloid commitment. To functionally interrogate whether GATA-1 regulates FOG-1 in vivo, we used bioinformatics combined with transgenic assays. Thus, we identified 2 cis-regulatory elements that control the tissue-specific gene expression of FOG-1. One of these enhancers contains functional GATA-binding sites, indicating the potential for a regulatory loop in which GATA factors control the expression of their partner protein FOG-1. ( Blood. 2009; 114: 4654-4663) C1 [Amigo, Julio D.; Ackermann, Gabriele E.; Cope, John J.; Cooney, Jeffrey D.; Ma, Dongdong; Langer, Nathaniel B.; Shafizadeh, Ebrahim; Shaw, George C.; Wojiski, Sarah A.; Shah, Dhvanit I.; Lin, Hui Feng; Handin, Robert I.; Paw, Barry H.] Brigham & Womens Hosp, Div Hematol, Dept Med, Boston, MA 02115 USA. [Amigo, Julio D.; Trede, Nikolaus S.; Davidson, Alan J.; Zhou, Yi; Wojiski, Sarah A.; Kanki, John P.; Handin, Robert I.; Cantor, Alan B.; Paw, Barry H.] Harvard Univ, Sch Med, Boston, MA USA. [Yu, Ming; Horsely, Wyatt; Trede, Nikolaus S.; Davidson, Alan J.; Barut, Bruce A.; Zhou, Yi; Traver, David; Moran, Tyler B.; Cantor, Alan B.; Paw, Barry H.] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. [Trede, Nikolaus S.; Kourkoulis, George; Hsu, Karl; Kanki, John P.; Cantor, Alan B.; Paw, Barry H.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. RP Paw, BH (reprint author), Brigham & Womens Hosp, Div Hematol, Dept Med, 1 Blackfan Cir,Karp Bldg 06-213, Boston, MA 02115 USA. EM bpaw@rics.bwh.harvard.edu RI Yu, Ming/A-3354-2012 FU National Institutes of Health; William Randolph Hearst Foundation; March of Dimes Foundation; American Society of Hematology; American Heart Association; Swiss National Science Foundation FX This work was supported in part by grants from the National Institutes of Health ( B. H. P., A. B. C., N.S.T., D. T., J.P.K.), William Randolph Hearst Foundation ( B. H. P.), March of Dimes Foundation ( B. H. P.), American Society of Hematology ( A. B. C., G. C. S.), American Heart Association ( J.D.C.), and Swiss National Science Foundation ( G. E. A.). NR 49 TC 21 Z9 21 U1 1 U2 5 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2009 VL 114 IS 21 BP 4654 EP 4663 DI 10.1182/blood-2008-12-189910 PG 10 WC Hematology SC Hematology GA 521WQ UT WOS:000271957400009 PM 19729519 ER PT J AU Glocker, EO Kotlarz, D Boztug, K Gertz, EM Schaffer, AA Noyan, F Perro, M Diestelhorst, J Allroth, A Murugan, D Hatscher, N Pfeifer, D Sykora, KW Sauer, M Kreipe, H Lacher, M Nustede, R Woellner, C Baumann, U Salzer, U Koletzko, S Shah, N Segal, AW Sauerbrey, A Buderus, S Snapper, SB Grimbacher, B Klein, C AF Glocker, Erik-Oliver Kotlarz, Daniel Boztug, Kaan Gertz, E. Michael Schaeffer, Alejandro A. Noyan, Fatih Perro, Mario Diestelhorst, Jana Allroth, Anna Murugan, Dhaarini Haetscher, Nadine Pfeifer, Dietmar Sykora, Karl-Walter Sauer, Martin Kreipe, Hans Lacher, Martin Nustede, Rainer Woellner, Cristina Baumann, Ulrich Salzer, Ulrich Koletzko, Sibylle Shah, Neil Segal, Anthony W. Sauerbrey, Axel Buderus, Stephan Snapper, Scott B. Grimbacher, Bodo Klein, Christoph TI Inflammatory Bowel Disease and Mutations Affecting the Interleukin-10 Receptor SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID AUTOSOMAL RECESSIVE ENTEROCOLITIS; GENOME-WIDE ASSOCIATION; CROHNS-DISEASE; INTESTINAL INFLAMMATION; CYTOKINE PRODUCTION; ULCERATIVE-COLITIS; SEQUENCE VARIANTS; CRYSTAL-STRUCTURE; LOCI CONTRIBUTE; IL-10 AB BACKGROUND The molecular cause of inflammatory bowel disease is largely unknown. METHODS We performed genetic-linkage analysis and candidate-gene sequencing on samples from two unrelated consanguineous families with children who were affected by early-onset inflammatory bowel disease. We screened six additional patients with early-onset colitis for mutations in two candidate genes and carried out functional assays in patients' peripheral-blood mononuclear cells. We performed an allogeneic hematopoietic stem-cell transplantation in one patient. RESULTS In four of nine patients with early-onset colitis, we identified three distinct homozygous mutations in genes IL10RA and IL10RB, encoding the IL10R1 and IL10R2 proteins, respectively, which form a heterotetramer to make up the interleukin-10 receptor. The mutations abrogate interleukin-10-induced signaling, as shown by deficient STAT3 (signal transducer and activator of transcription 3) phosphorylation on stimulation with interleukin-10. Consistent with this observation was the increased secretion of tumor necrosis factor alpha and other proinflammatory cytokines from peripheral-blood mononuclear cells from patients who were deficient in IL10R subunit proteins, suggesting that interleukin-10-dependent "negative feedback" regulation is disrupted in these cells. The allogeneic stem-cell transplantation performed in one patient was successful. CONCLUSIONS Mutations in genes encoding the IL10R subunit proteins were found in patients with early-onset enterocolitis, involving hyperinflammatory immune responses in the intestine. Allogeneic stem-cell transplantation resulted in disease remission in one patient. C1 [Kotlarz, Daniel; Boztug, Kaan; Noyan, Fatih; Diestelhorst, Jana; Allroth, Anna; Murugan, Dhaarini; Haetscher, Nadine; Sykora, Karl-Walter; Sauer, Martin; Klein, Christoph] Hannover Med Sch, Dept Pediat Hematol Oncol, D-30625 Hannover, Germany. [Kreipe, Hans] Hannover Med Sch, Dept Pathol, D-30625 Hannover, Germany. [Nustede, Rainer] Hannover Med Sch, Dept Pediat Surg, D-30625 Hannover, Germany. [Baumann, Ulrich] Hannover Med Sch, Dept Pediat Pulmonol, D-30625 Hannover, Germany. [Glocker, Erik-Oliver; Perro, Mario; Woellner, Cristina; Grimbacher, Bodo] Royal Free Hosp, Dept Immunol, London NW3 2QG, England. [Segal, Anthony W.] UCL, Dept Med, London, England. [Shah, Neil] UCL, Great Ormond St Hosp, Dept Paediat Gastroenterol, London, England. [Gertz, E. Michael; Schaeffer, Alejandro A.] NIH, Natl Ctr Biotechnol Informat, Bethesda, MD 20892 USA. [Pfeifer, Dietmar] Univ Freiburg, Med Ctr, Dept Hematol Oncol, Core Facil Genom 2, D-7800 Freiburg, Germany. [Salzer, Ulrich] Univ Hosp Freiburg, Dept Rheumatol & Clin Immunol, Freiburg, Germany. [Lacher, Martin; Koletzko, Sibylle] Univ Munich, Dr von Haunersches Kinderspital, Munich, Germany. [Sauerbrey, Axel] HELIOS Hosp Erfurt, Dept Pediat, Erfurt, Germany. [Buderus, Stephan] St Marien Hosp Bonn, Dept Pediat, Bonn, Germany. [Snapper, Scott B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Snapper, Scott B.] Harvard Univ, Sch Med, Boston, MA USA. RP Klein, C (reprint author), Hannover Med Sch, Dept Pediat Hematol Oncol, Carl Neuberg Str 1, D-30625 Hannover, Germany. EM b.grimbacher@ucl.ac.uk; klein.christoph@mh-hannover.de RI Schaffer, Alejandro/F-2902-2012; OI Segal, Anthony/0000-0001-7602-9043; Gertz, E. Michael/0000-0001-8390-4387 FU European Commission Marie Curie Excellence program [MEXT-CT-2006-042316]; Deutsche Forschungsgemeinschaft [SFB621]; German Federal Ministry of Education and Research (PID-NET); Intramural Research Program of the National Institutes of Health; Deutsche Jose Carreras Leukmie-Stiftung; Else-Krner-Fresenius-Stiftung FX Supported by grants from the European Commission Marie Curie Excellence program (MEXT-CT-2006-042316,to Dr. Grim- bacher), Deutsche Forschungsgemeinschaft (SFB621, to Dr. Klein), and the German Federal Ministry of Education and Research (PID-NET), to Drs. Klein and Grimbacher; by the Intramural Research Program of the National Institutes of Health; and by fellowships from Deutsche Jose Carreras Leukmie-Stiftung (to Dr. Kotlarz) and Else-Krner-Fresenius-Stiftung ( to Dr. Boztug). NR 45 TC 504 Z9 523 U1 7 U2 23 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 19 PY 2009 VL 361 IS 21 BP 2033 EP 2045 DI 10.1056/NEJMoa0907206 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA 521DA UT WOS:000271898600008 PM 19890111 ER PT J AU Choy, E Digumarthy, SR Koplin, SA AF Choy, Edwin Digumarthy, Subba R. Koplin, Stephanie A. TI A Man with Cough, Hoarseness, and Abnormalities on Chest Imaging Ewing's sarcoma of the bone, with metastasis to the lung and mediastinal lymph nodes. SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID EWS CHIMERIC TRANSCRIPTS; PROGNOSTIC IMPACT; TUMOR; IFOSFAMIDE; ETOPOSIDE; INSULIN; FUSION C1 [Choy, Edwin] Massachusetts Gen Hosp, Div Med Oncol, Dept Med, Boston, MA 02114 USA. [Digumarthy, Subba R.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Koplin, Stephanie A.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Choy, Edwin] Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA. [Digumarthy, Subba R.] Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA. [Koplin, Stephanie A.] Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA. RP Choy, E (reprint author), Massachusetts Gen Hosp, Div Med Oncol, Dept Med, Boston, MA 02114 USA. NR 23 TC 1 Z9 1 U1 0 U2 1 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 19 PY 2009 VL 361 IS 21 BP 2080 EP 2087 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 521DA UT WOS:000271898600014 PM 19923580 ER PT J AU Ueno, S Tatetsu, H Hata, H Iino, T Niiro, H Akashi, K Tenen, DG Mitsuya, H Okuno, Y AF Ueno, S. Tatetsu, H. Hata, H. Iino, T. Niiro, H. Akashi, K. Tenen, D. G. Mitsuya, H. Okuno, Y. TI PU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL SO ONCOGENE LA English DT Article DE myeloma; PU.1; TRAIL; apoptosis; p21 ID OVERCOMES DRUG-RESISTANCE; TRANSCRIPTION FACTOR PU.1; HEMATOPOIETIC STEM-CELLS; MULTIPLE-MYELOMA; REGULATORY ELEMENTS; DISTAL ELEMENTS; LEUKEMIA-CELLS; GENE; EXPRESSION; GROWTH AB We earlier reported that PU.1 was downregulated in myeloma cell lines and myeloma cells in a subset of myeloma patients, and that conditional PU.1 expression in PU.1-negative myeloma cell lines, U266 and KMS12PE, induced growth arrest and apoptosis. To elucidate the molecular mechanisms of the growth arrest and apoptosis, we performed DNA microarray analyses to compare the difference in gene expression before and after PU.1 induction in U266 cells. Among cell cycle-related genes, cyclin A2, cyclin B1, CDK2 and CDK4 were downregulated and p21 was upregulated, although among apoptosis-related genes, tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) was found highly upregulated. When TRAIL was knocked down by small interference RNAs, apoptosis of PU-1-expressing cells was inhibited, suggesting that TRAIL has a critical role in PU.1-induced apoptosis in both U266 and KMS12PE myeloma cells. In both U266 and KMS12PE cells expressing PU.1, PU.1 directly bound to a region 30 bp downstream of the transcription start site of the TRAIL gene. Upregulation of PU.1-induced transactivation of the TRAIL promoter in reporter assays, and disruption of the PU.1-binding site in the TRAIL promoter eliminated this transactivation. Therefore, we conclude that PU.1 is capable of inducing apoptosis in certain myeloma cells by direct transactivation of TRAIL. Oncogene (2009) 28, 4116-4125; doi:10.1038/onc.2009.263; published online 14 September 2009 C1 [Ueno, S.; Tatetsu, H.; Hata, H.; Mitsuya, H.; Okuno, Y.] Kumamoto Univ Med, Dept Hematol, Kumamoto 8608556, Japan. [Iino, T.; Niiro, H.; Akashi, K.] Kyushu Univ, Grad Sch Med Sci, Fukuoka 812, Japan. [Iino, T.; Akashi, K.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. [Tenen, D. G.] Harvard Univ, Sch Med, Ctr Life Sci, Boston, MA USA. [Tenen, D. G.] Natl Univ Singapore, Canc Sci Inst, Singapore 117548, Singapore. RP Okuno, Y (reprint author), Kumamoto Univ Med, Dept Hematol, 1-1-1 Honjo, Kumamoto 8608556, Japan. EM yokuno@gpo.kumamoto-u.ac.jp OI Tenen, Daniel/0000-0002-6423-3888 FU International Myeloma Foundation Japan; Ministry of Education, Culture, Sports, Science and Technology of Japan FX This work was supported by The Award in Aki's Memory from The International Myeloma Foundation Japan (YO) and grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan. NR 33 TC 9 Z9 9 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0950-9232 J9 ONCOGENE JI Oncogene PD NOV 19 PY 2009 VL 28 IS 46 BP 4116 EP 4125 DI 10.1038/onc.2009.263 PG 10 WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity GA 530AE UT WOS:000272560500007 PM 19749795 ER PT J AU Gaziano, JM Gaziano, TA AF Gaziano, J. Michael Gaziano, Thomas A. TI Simplifying the Approach to the Management of Dyslipidemia SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID CARDIOVASCULAR-DISEASE; CHOLESTEROL; PREVENTION; RISK C1 [Gaziano, J. Michael] VA Boston Healthcare Syst, MAVERIC, Boston, MA 02130 USA. [Gaziano, J. Michael; Gaziano, Thomas A.] Brigham & Womens Hosp, Dept Med, Div Cardiol, Boston, MA USA. [Gaziano, J. Michael] Brigham & Womens Hosp, Dept Med, Div Aging, Boston, MA 02115 USA. [Gaziano, J. Michael] Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA. [Gaziano, Thomas A.] Harvard Univ, Sch Publ Hlth, Ctr Hlth Decis Sci, Dept Hlth Policy & Management, Boston, MA 02115 USA. RP Gaziano, JM (reprint author), VA Boston Healthcare Syst, MAVERIC 151MAV, 150 S Huntington Ave, Boston, MA 02130 USA. EM jmgaziano@partners.org FU FIC NIH HHS [2K01TW007141-05] NR 11 TC 6 Z9 7 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 18 PY 2009 VL 302 IS 19 BP 2148 EP 2149 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 520UG UT WOS:000271873900026 PM 19920241 ER PT J AU Costigan, M Moss, A Latremoliere, A Johnston, C Verma-Gandhu, M Herbert, TA Barrett, L Brenner, GJ Vardeh, D Woolf, CJ Fitzgerald, M AF Costigan, Michael Moss, Andrew Latremoliere, Alban Johnston, Caroline Verma-Gandhu, Monica Herbert, Teri A. Barrett, Lee Brenner, Gary J. Vardeh, Daniel Woolf, Clifford J. Fitzgerald, Maria TI T-Cell Infiltration and Signaling in the Adult Dorsal Spinal Cord Is a Major Contributor to Neuropathic Pain-Like Hypersensitivity SO JOURNAL OF NEUROSCIENCE LA English DT Article ID PERIPHERAL-NERVE INJURY; CHRONIC-CONSTRICTION-INJURY; INTERFERON-GAMMA RECEPTORS; MECHANICAL ALLODYNIA; SCIATIC-NERVE; HORN NEURONS; IN-VITRO; RAT; MICROGLIA; MICE AB Partial peripheral nerve injury in adult rats results in neuropathic pain-like hypersensitivity, while that in neonatal rats does not, a phenomenon also observed in humans. We therefore compared gene expression profiles in the dorsal horn of adult and neonatal rats in response to the spared nerve injury (SNI) model of peripheral neuropathic pain. The 148 differentially regulated genes in adult, but not young, rat spinal cords indicate a greater microglial and T-cell response in adult than in young animals. T-cells show a large infiltration in the adult dorsal horn but not in the neonate after SNI. T-cell-deficient Rag1-null adult mice develop less neuropathic mechanical allodynia than controls, and central expression of cytokines involved in T-cell signaling exhibits large relative differences between young and adult animals after SNI. One such cytokine, interferon-gamma (IFN gamma), is upregulated in the dorsal horn after nerve injury in the adult but not neonate, and we show that IFN gamma signaling is required for full expression of adult neuropathic hypersensitivity. These data reveal that T-cell infiltration and activation in the dorsal horn of the spinal cord following peripheral nerve injury contribute to the evolution of neuropathic pain-like hypersensitivity. The neuroimmune interaction following peripheral nerve injury has therefore a substantial adaptive immune component, which is absent or suppressed in the young CNS. C1 [Costigan, Michael; Latremoliere, Alban; Verma-Gandhu, Monica; Herbert, Teri A.; Barrett, Lee; Brenner, Gary J.; Vardeh, Daniel; Woolf, Clifford J.] Massachusetts Gen Hosp, Neural Plast Res Grp, Charlestown, MA 02129 USA. [Moss, Andrew; Fitzgerald, Maria] UCL, Dept Neurosci Physiol & Pharmacol, London WC1 EBT, England. [Johnston, Caroline] UCL, Dept Biochem, London WC1 EBT, England. RP Costigan, M (reprint author), Massachusetts Gen Hosp, Neural Plast Res Grp, Charlestown, MA 02129 USA. EM costigan@helix.mgh.harvard.edu; andrew.moss@pfizer.com RI Fitzgerald, Maria/C-5760-2008 FU National Institutes for Health [DE017821]; Medical Research Council, UK; Wellcome Trust Pain Consortium; Bogue research fellowship; Fondation pour la Recherche Medicale FX This work was supported by the National Institutes for Health (DE017821), the Medical Research Council, UK, and the Wellcome Trust Pain Consortium. A. M. was the recipient of a Bogue research fellowship. A. L. was the recipient of a Fondation pour la Recherche Medicale fellowship. NR 63 TC 151 Z9 157 U1 2 U2 8 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD NOV 18 PY 2009 VL 29 IS 46 BP 14415 EP 14422 DI 10.1523/JNEUROSCI.4569-09.2009 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 521SO UT WOS:000271944500005 PM 19923276 ER PT J AU Eichler, FS Hornemann, T McCampbell, A Kuljis, D Penno, A Vardeh, D Tamrazian, E Garofalo, K Lee, HJ Kini, L Selig, M Frosch, M Gable, K von Eckardstein, A Woolf, CJ Guan, GM Harmon, JM Dunn, TM Brown, RH AF Eichler, Florian S. Hornemann, Thorsten McCampbell, Alex Kuljis, Dika Penno, Anke Vardeh, Daniel Tamrazian, Eric Garofalo, Kevin Lee, Ho-Joon Kini, Lohit Selig, Martin Frosch, Matthew Gable, Ken von Eckardstein, Arnold Woolf, Clifford J. Guan, Guiman Harmon, Jeffrey M. Dunn, Teresa M. Brown, Robert H., Jr. TI Overexpression of the Wild-Type SPT1 Subunit Lowers Desoxysphingolipid Levels and Rescues the Phenotype of HSAN1 SO JOURNAL OF NEUROSCIENCE LA English DT Article ID HEREDITARY SENSORY NEUROPATHY; SERINE PALMITOYLTRANSFERASE; SPHINGOLIPID METABOLISM; CELLS; SPTLC1; EFFLUX; ENZYME; PAIN AB Mutations in the SPTLC1 subunit of serine palmitoyltransferase (SPT) cause an adult-onset, hereditary sensory, and autonomic neuropathy type I (HSAN1). We previously reported that mice bearing a transgene-expressing mutant SPTLC1 (tgSPTLC1(C133W)) show a reduction in SPT activity and hyperpathia at 10 months of age. Now analyzed at a later age, we find these mice develop sensory loss with a distal small fiber neuropathy and peripheral myelinopathy. This phenotype is largely reversed when these mice are crossed with transgenic mice overexpressing wild-type SPTLC1 showing that the mutant SPTLC1 protein is not inherently toxic. Simple loss of SPT activity also cannot account for the HSAN1 phenotype, since heterozygous SPTLC1 knock-out mice have reduced SPT activity but are otherwise normal. Rather, the presence of two newly identified, potentially deleterious deoxysphingoid bases in the tgSPTLC1(C133W), but not in the wild-type, double-transgenic tgSPTLC1(WT + C133W) or SPTLC1 (+/-) mice, suggests that the HSAN1 mutations alter amino acid selectivity of the SPT enzyme such that palmitate is condensed with alanine and glycine, in addition to serine. This observation is consistent with the hypothesis that HSAN1 is the result of a gain-of-function mutation in SPTLC1 that leads to accumulation of a toxic metabolite. C1 [Eichler, Florian S.; Kuljis, Dika; Garofalo, Kevin; Kini, Lohit] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Neurosci,Dept Neurol, Boston, MA 02114 USA. [Hornemann, Thorsten; Penno, Anke; von Eckardstein, Arnold] Univ Zurich Hosp, Inst Clin Chem, CH-8091 Zurich, Switzerland. [McCampbell, Alex; Tamrazian, Eric; Brown, Robert H., Jr.] Harvard Univ, Sch Med, Dept Neurol, Day Lab Neuromuscular Res, Boston, MA 02114 USA. [Vardeh, Daniel; Woolf, Clifford J.] Harvard Univ, Sch Med, Dept Anesthesia & Crit Care, Neural Plast Res Grp, Charlestown, MA 02129 USA. [Lee, Ho-Joon] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Vincent Ctr Reprod Biol, Boston, MA 02114 USA. [Selig, Martin; Frosch, Matthew] Harvard Univ, Massachusetts Gen Hosp, Sch Med, CS Kubik Lab Neuropathol,Dept Pathol, Boston, MA 02114 USA. [Gable, Ken; Guan, Guiman; Harmon, Jeffrey M.; Dunn, Teresa M.] Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Dept Biochem & Mol Biol, Bethesda, MD 20814 USA. [Brown, Robert H., Jr.] Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA 01655 USA. RP Eichler, FS (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Neurosci,Dept Neurol, 55 Fruit St,ACC708, Boston, MA 02114 USA. EM feichler@partners.org OI Harmon, Jeffrey/0000-0001-7833-931X FU National Institutes of Health [K08NS52550]; Peripheral Neuropathy Society; Deater Foundation and the Cecil B. Day Company FX The work was supported by National Institutes of Health Grant K08NS52550 (F.S.E.) and a grant from the Peripheral Neuropathy Society (D.K.). The Day Neuromuscular Research Laboratory receives generous support from the Deater Foundation and the Cecil B. Day Company. NR 18 TC 39 Z9 39 U1 0 U2 1 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD NOV 18 PY 2009 VL 29 IS 46 BP 14646 EP 14651 DI 10.1523/JNEUROSCI.2536-09.2009 PG 6 WC Neurosciences SC Neurosciences & Neurology GA 521SO UT WOS:000271944500026 PM 19923297 ER PT J AU MacConaill, LE Campbell, CD Kehoe, SM Bass, AJ Hatton, C Niu, LL Davis, M Yao, KL Hanna, M Mondal, C Luongo, L Emery, CM Baker, AC Philips, J Goff, DJ Fiorentino, M Rubin, MA Polyak, K Chan, J Wang, YX Fletcher, JA Santagata, S Corso, G Roviello, F Shivdasani, R Kieran, MW Ligon, KL Stiles, CD Hahn, WC Meyerson, ML Garraway, LA AF MacConaill, Laura E. Campbell, Catarina D. Kehoe, Sarah M. Bass, Adam J. Hatton, Charles Niu, Lili Davis, Matt Yao, Keluo Hanna, Megan Mondal, Chandrani Luongo, Lauren Emery, Caroline M. Baker, Alissa C. Philips, Juliet Goff, Deborah J. Fiorentino, Michelangelo Rubin, Mark A. Polyak, Kornelia Chan, Jennifer Wang, Yuexiang Fletcher, Jonathan A. Santagata, Sandro Corso, Gianni Roviello, Franco Shivdasani, Ramesh Kieran, Mark W. Ligon, Keith L. Stiles, Charles D. Hahn, William C. Meyerson, Matthew L. Garraway, Levi A. TI Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples SO PLOS ONE LA English DT Article ID METASTATIC COLORECTAL-CANCER; LOW-GRADE ASTROCYTOMAS; GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; PILOCYTIC ASTROCYTOMAS; HUMAN GENOME; GEFITINIB; CETUXIMAB; KRAS; CHEMOTHERAPY AB Background: Detection of critical cancer gene mutations in clinical tumor specimens may predict patient outcomes and inform treatment options; however, high-throughput mutation profiling remains underdeveloped as a diagnostic approach. We report the implementation of a genotyping and validation algorithm that enables robust tumor mutation profiling in the clinical setting. Methodology: We developed and implemented an optimized mutation profiling platform ("OncoMap'') to interrogate similar to 400 mutations in 33 known oncogenes and tumor suppressors, many of which are known to predict response or resistance to targeted therapies. The performance of OncoMap was analyzed using DNA derived from both frozen and FFPE clinical material in a diverse set of cancer types. A subsequent in-depth analysis was conducted on histologically and clinically annotated pediatric gliomas. The sensitivity and specificity of OncoMap were 93.8% and 100% in fresh frozen tissue; and 89.3% and 99.4% in FFPE-derived DNA. We detected known mutations at the expected frequencies in common cancers, as well as novel mutations in adult and pediatric cancers that are likely to predict heightened response or resistance to existing or developmental cancer therapies. OncoMap profiles also support a new molecular stratification of pediatric low-grade gliomas based on BRAF mutations that may have immediate clinical impact. Conclusions: Our results demonstrate the clinical feasibility of high-throughput mutation profiling to query a large panel of "actionable'' cancer gene mutations. In the future, this type of approach may be incorporated into both cancer epidemiologic studies and clinical decision making to specify the use of many targeted anticancer agents. RP MacConaill, LE (reprint author), Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA. EM Levi_Garraway@dfci.harvard.edu RI Meyerson, Matthew/E-7123-2012; Davis, Matt/F-9045-2012; OI Rubin, Mark/0000-0002-8321-9950; Kieran, Mark/0000-0003-2184-7692 FU NCI NIH HHS [K08 CA134931, K08CA134931, R21 CA126674, R21CA126674] NR 27 TC 248 Z9 250 U1 4 U2 14 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 18 PY 2009 VL 4 IS 11 AR e7887 DI 10.1371/journal.pone.0007887 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 521QH UT WOS:000271936700019 PM 19924296 ER PT J AU Uemura, K Lill, CM Li, XJ Peters, JA Ivanov, A Fan, ZY DeStrooper, B Bacskai, BJ Hyman, BT Berezovska, O AF Uemura, Kengo Lill, Christina M. Li, Xuejing Peters, Jessica A. Ivanov, Alexander Fan, Zhanyun DeStrooper, Bart Bacskai, Brian J. Hyman, Bradley T. Berezovska, Oksana TI Allosteric Modulation of PS1/gamma-Secretase Conformation Correlates with Amyloid beta(42/40) Ratio SO PLOS ONE LA English DT Article ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GAMMA-SECRETASE ACTIVITY; PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; IN-VIVO; CATALYTIC PORE; BETA-PROTEIN; PRESENILIN; NOTCH; APP AB Background: Presenilin 1(PS1) is the catalytic subunit of gamma-secretase, the enzyme responsible for the A beta C-terminal cleavage site, which results in the production of A beta peptides of various lengths. Production of longer forms of the A beta peptide occur in patients with autosomal dominant Alzheimer disease (AD) due to mutations in presenilin. Many modulators of gamma-secretase function have been described. We hypothesize that these modulators act by a common mechanism by allosterically modifying the structure of presenilin. Methodology/Principal Findings: To test this hypothesis we generated a genetically encoded GFP-PS1-RFP (G-PS1-R) FRET probe that allows monitoring of the conformation of the PS1 molecule in its native environment in live cells. We show that G-PS1-R can be incorporated into the gamma-secretase complex, reconstituting its activity in PS1/2 deficient cells. Using Forster resonance energy transfer (FRET)-based approaches we show that various pharmacological and genetic manipulations that target either gamma-secretase components (PS1, Pen2, Aph1) or gamma-secretase substrate (amyloid precursor protein, APP) and are known to change A beta(42) production are associated with a consistent conformational change in PS1. Conclusions/ Significance: These results strongly support the hypothesis that allosteric changes in PS1 conformation underlie changes in the A beta(42/40) ratio. Direct measurement of physiological and pathological changes in the conformation of PS1/gamma-secretase may provide insight into molecular mechanism of A beta(42) generation, which could be exploited therapeutically. RP Uemura, K (reprint author), Massachusetts Gen Hosp, MassGeneral Inst Neurodegenerat Dis, Alzheimer Res Unit, Charlestown, MA 02129 USA. EM oberezovska@partners.org RI De Strooper, Bart/F-6507-2012; Lill, Christina/J-9449-2015 OI De Strooper, Bart/0000-0001-5455-5819; Lill, Christina/0000-0002-2805-1307 FU NIA NIH HHS [AG026593, P01 AG015379, AG 15379, R01 AG026593]; NIBIB NIH HHS [EB000768, R01 EB000768] NR 38 TC 44 Z9 46 U1 1 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 18 PY 2009 VL 4 IS 11 AR e7893 DI 10.1371/journal.pone.0007893 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 521QH UT WOS:000271936700023 PM 19924286 ER PT J AU Mandelblatt, JS Cronin, KA Bailey, S Berry, DA de Koning, HJ Draisma, G Huang, H Lee, SJ Munsell, M Plevritis, SK Ravdin, P Schechter, CB Sigal, B Stoto, MA Stout, NK van Ravesteyn, NT Venier, J Zelen, M Feuer, EJ AF Mandelblatt, Jeanne S. Cronin, Kathleen A. Bailey, Stephanie Berry, Donald A. de Koning, Harry J. Draisma, Gerrit Huang, Hui Lee, Sandra J. Munsell, Mark Plevritis, Sylvia K. Ravdin, Peter Schechter, Clyde B. Sigal, Bronislava Stoto, Michael A. Stout, Natasha K. van Ravesteyn, Nicolien T. Venier, John Zelen, Marvin Feuer, Eric J. CA Canc Intervention Surveillance Mod TI Effects of Mammography Screening Under Different Screening Schedules: Model Estimates of Potential Benefits and Harms SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID CARCINOMA IN-SITU; COST-EFFECTIVENESS ANALYSIS; BREAST-CANCER MORTALITY; UPPER AGE LIMIT; RANDOMIZED-TRIALS; FOLLOW-UP; UNITED-STATES; OLDER WOMEN; OVERDIAGNOSIS; OVERTREATMENT AB Background: Despite trials of mammography and widespread use, optimal screening policy is controversial. Objective: To evaluate U. S. breast cancer screening strategies. Design: 6 models using common data elements. Data Sources: National data on age-specific incidence, competing mortality, mammography characteristics, and treatment effects. Target Population: A contemporary population cohort. Time Horizon: Lifetime. Perspective: Societal. Interventions: 20 screening strategies with varying initiation and cessation ages applied annually or biennially. Outcome Measures: Number of mammograms, reduction in deaths from breast cancer or life-years gained (vs. no screening), false-positive results, unnecessary biopsies, and overdiagnosis. Results of Base-Case Analysis: The 6 models produced consistent rankings of screening strategies. Screening biennially maintained an average of 81% (range across strategies and models, 67% to 99%) of the benefit of annual screening with almost half the number of false-positive results. Screening biennially from ages 50 to 69 years achieved a median 16.5% (range, 15% to 23%) reduction in breast cancer deaths versus no screening. Initiating biennial screening at age 40 years (vs. 50 years) reduced mortality by an additional 3% (range, 1% to 6%), consumed more resources, and yielded more false-positive results. Biennial screening after age 69 years yielded some additional mortality reduction in all models, but overdiagnosis increased most substantially at older ages. Results of Sensitivity Analysis: Varying test sensitivity or treatment patterns did not change conclusions. Limitation: Results do not include morbidity from false-positive results, patient knowledge of earlier diagnosis, or unnecessary treatment. Conclusion: Biennial screening achieves most of the benefit of annual screening with less harm. Decisions about the best strategy depend on program and individual objectives and the weight placed on benefits, harms, and resource considerations. C1 [Mandelblatt, Jeanne S.] Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA. Georgetown Univ, Med Ctr, Washington, DC 20007 USA. NIH, Bethesda, MD 20892 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Erasmus Univ, Med Ctr, Rotterdam, Netherlands. Harvard Univ, Sch Publ Hlth, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Pilgrim Hlth Care, Boston, MA USA. Stanford Univ, Palo Alto, CA 94304 USA. Albert Einstein Coll Med, New York, NY USA. RP Mandelblatt, JS (reprint author), Lombardi Comprehens Canc Ctr, 3300 Whitehaven St,NW,Suite 4100, Washington, DC 20007 USA. EM mandelbj@georgetown.edu FU NCI [2U01CA088270, 2U01CA088283, 2U01CA088248, F32 CA125984, HHSN261200800769P, HHSN261200800002C]; NCI-funded BCSC [U01CA63740, U01CA86076, U01CA86082, U01CA63736, U01CA70013, U01CA69976, U01CA63731, U01CA70040]; U.S. state public health departments and cancer registries FX By NCI cooperative agreements (2U01CA088270, 2U01CA088283, 2U01CA088248, and F32 CA125984). Portions of this work were performed under contract HHSN261200800769P. Data collection in the BCSC was supported by NCI-funded BCSC cooperative agreements (U01CA63740, U01CA86076, U01CA86082, U01CA63736, U01CA70013, U01CA69976, U01CA63731, and U01CA70040) and several U.S. state public health departments and cancer registries. CISNET data management and Web site support were provided by Cornerstone Systems Northwest (NCI contract HHSN261200800002C). NR 64 TC 320 Z9 327 U1 1 U2 25 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD NOV 17 PY 2009 VL 151 IS 10 BP 738 EP W247 PG 15 WC Medicine, General & Internal SC General & Internal Medicine GA 524LP UT WOS:000272145100007 PM 19920274 ER PT J AU Kerlikowske, K AF Kerlikowske, Karla TI Evidence-Based Breast Cancer Prevention: The Importance of Individual Risk SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material ID COST-EFFECTIVENESS ANALYSIS; SCREENING MAMMOGRAPHY; WOMEN 40; TAMOXIFEN; MODEL; TRIAL; AGE; CHEMOPREVENTION; VALIDATION; PHYSICIANS C1 San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA 94121 USA. RP Kerlikowske, K (reprint author), San Francisco VA Med Ctr, Gen Internal Med Sect, 111A1,4150 Clement St, San Francisco, CA 94121 USA. EM karla.kerlikowske@ucsf.edu FU NCI NIH HHS [P50 CA58207, U01CA63740] NR 30 TC 29 Z9 30 U1 1 U2 1 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD NOV 17 PY 2009 VL 151 IS 10 BP 750 EP 752 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 524LP UT WOS:000272145100009 PM 19920276 ER PT J AU Simon, JA AF Simon, Joel A. TI Review: Evidence for the effectiveness of vitamin D and calcium for reducing CV outcomes, cancer, and death is limited SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material ID D SUPPLEMENTATION C1 [Simon, Joel A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Simon, Joel A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Simon, JA (reprint author), San Francisco VA Med Ctr, San Francisco, CA USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD NOV 17 PY 2009 VL 151 IS 10 AR JC5-5 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 524LP UT WOS:000272145100016 PM 19920263 ER PT J AU Berger, JS Bhatt, DL Cannon, CP Chen, ZM Jiang, LX Jones, JB Mehta, SR Sabatine, MS Steinhubl, SR Topol, EJ Berger, PB AF Berger, Jeffrey S. Bhatt, Deepak L. Cannon, Christopher P. Chen, Zhengming Jiang, Lixin Jones, James B. Mehta, Shamir R. Sabatine, Marc S. Steinhubl, Steven R. Topol, Eric J. Berger, Peter B. TI The Relative Efficacy and Safety of Clopidogrel in Women and Men A Sex-Specific Collaborative Meta-Analysis SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE sex; antiplatelet agents; clopidogrel; randomized trial; cardiovascular disease ID ACUTE CORONARY SYNDROMES; GLYCOPROTEIN IIB/IIIA INHIBITORS; ACUTE MYOCARDIAL-INFARCTION; ST-SEGMENT ELEVATION; PLACEBO-CONTROLLED TRIAL; ASPIRIN RESISTANCE; RANDOMIZED-TRIALS; CARDIOVASCULAR-DISEASE; ATHEROTHROMBOTIC EVENTS; ANTIPLATELET THERAPY AB Objectives This study sought to investigate the efficacy and safety of clopidogrel in women and men. Background Previous analyses have shown sex-based differences in response to several antiplatelet medications. Little is known about the efficacy and safety of clopidogrel in women and men. Methods This study performed a meta-analysis of all blinded randomized clinical trials comparing clopidogrel and placebo (CURE [Clopidogrel in Unstable Angina to Prevent Recurrent Events], CREDO [Clopidogrel for the Reduction of Events During Observation], CLARITY-TIMI 28 [Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis In Myocardial Infarction 28], COMMIT [Clopidogrel and Metoprolol in Myocardial Infarction Trial], and CHARISMA [Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance] trials), involving a total of 79,613 patients, of whom 30% were women. The relative efficacy and safety of clopidogrel at reducing cardiovascular events (cardiovascular death, myocardial infarction [MI], or stroke) in women and men was estimated using random-effects modeling. Results Overall, clopidogrel was associated with a highly significant 14% proportional reduction in the risk of cardiovascular events (odds ratio [OR]: 0.86; 95% confidence interval [CI]: 0.80 to 0.93), with no significant differences in treatment effect between women and men. Among the 23,533 women enrolled, there were fewer cardiovascular events in the clopidogrel group compared with the placebo group (11.0% vs. 11.8%; OR: 0.93; 95% CI: 0.86 to 1.01). In women the risk reduction with clopidogrel seemed to be greatest for MI (OR: 0.81; 95% CI: 0.70 to 0.93), with the effects on stroke (OR: 0.91; 95% CI: 0.69 to 1.21) or total death (OR: 0.99; 95% CI: 0.90 to 1.08) not statistically significant. Among the 56,091 men enrolled, there were fewer cardiovascular events in those receiving clopidogrel compared with placebo (7.8% vs. 9.0%; OR: 0.84; 95% CI: 0.78 to 0.91), and the risk reduction was significant for MI (OR: 0.83; 95% CI: 0.76 to 0.92), stroke (OR: 0.83; 95% CI: 0.71 to 0.96), and total death (OR: 0.91; 95% CI: 0.84 to 0.97). Clopidogrel increased the risk of major bleeding in both women (OR: 1.43; 95% CI: 1.15 to 1.79) and men (OR: 1.22; 95% CI: 1.05 to 1.42). Conclusions Clopidogrel reduces the risk of cardiovascular events in both women and men. (J Am Coll Cardiol 2009; 54: 1935-45) (C) 2009 by the American College of Cardiology Foundation C1 [Berger, Jeffrey S.] NYU, Sch Med, New York, NY 10016 USA. [Bhatt, Deepak L.] VA Boston Healthcare Syst, Boston, MA USA. [Bhatt, Deepak L.; Cannon, Christopher P.; Sabatine, Marc S.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Chen, Zhengming] Univ Oxford, Oxford, England. [Jiang, Lixin] Chinese Acad Med Sci, Fuwai Hosp, Beijing 100037, Peoples R China. [Mehta, Shamir R.] McMaster Univ, Hamilton, ON, Canada. [Sabatine, Marc S.] Harvard Univ, Sch Med, Boston, MA USA. [Topol, Eric J.] Scripps Translat Res Inst, La Jolla, CA USA. [Jones, James B.; Steinhubl, Steven R.; Berger, Peter B.] Weis Ctr Res, Geisinger Clin, Danville, PA 17822 USA. RP Berger, JS (reprint author), NYU, Sch Med, 530 1st Ave,Skirball 9R, New York, NY 10016 USA. EM jeffrey.berger@nyumc.org OI Topol, Eric/0000-0002-1478-4729 FU American Heart Association [0775074]; AstraZeneca; Bristol-Myers Squibb; Eisai; Ethicon; Heartscape; Sanofi-Aventis; Medicines Company; Accumetrics; GlaxoSmithKline; Intekrin Therapeutics; Merck; Merck/Schering-Plough Partnership; Novartis; Takeda; Roche; DSI; Eli Lilly; Schering-Plough; Thrombovision; Helena; Haemoscope; Corgenix/Aspirin Works; Eli Lilly/Daiichi Sankyo FX From the *New York University School of Medicine, New York, New York; dagger VA Boston Healthcare System, Boston, Massachusetts; double dagger Brigham and Women's Hospital, Boston, Massachusetts; University of Oxford, Oxford, England; parallel to Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China; McMaster University, Hamilton, Ontario, Canada; #Harvard Medical School, Boston, Massachusetts; **Scripps Translational Research Institute, La Jolla, California; and the dagger dagger Geisinger Clinic, Danville, Pennsylvania. This was an investigator-initiated study, and was supported by American Heart Association Fellow to Faculty Award 0775074. Dr. Berger has received research support (<$ 10,000) from AstraZeneca. Dr. Bhatt is a consultant for Arena, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Cardax, Centocor, Daiichi-Sankyo, Eisai, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, McNeil, Medtronic, Millennium, Molecular Insights, Otsuka, ParinGenix, PDL Biopharma, Philips, Portola, Sanofi, Schering, Takeda, The Medicines Company, and Vertex, and has received research grants from Bristol-Myers Squibb, Eisai, Ethicon, Heartscape, Sanofi-Aventis, and The Medicines Company. Dr. Cannon has received research grants/support from Accumetrics, AstraZeneca, Bristol-Myers Squibb/Sanofi Partnership, GlaxoSmithKline, Intekrin Therapeutics, Merck, Merck/Schering-Plough Partnership, Novartis, and Takeda, and serves as Clinical Advisor and has equity in Automedics Medical Systems. Dr. Chen has received research grants from AstraZeneca and Merck. Dr. Jones has received unrestricted research grants from Merck, GlaxoSmithKline, Roche, DSI, Takeda, and AstraZeneca. Dr. Mehta has received institutional research grant support from Sanofi-Aventis, Bristol-Myers Squibb, and GlaxoSmithKline, and has received honoraria from AstraZeneca, Eli Lilly, Astellas, Pfizer, Sanofi, Bristol-Myers Squibb, and GlaxoSmithKline. Dr. Sabatine has served on scientific advisory boards for AstraZeneca; has received honoraria for education presentations and served on the Speakers' Bureau for Bristol-Myers Squibb; has received honoraria for education presentations from Eli Lilly; has received research grant support, served on the scientific advisory board, and received honoraria for education presentations from Sanofi-Aventis; and has received research grant support from Schering-Plough. Dr. Steinhubl is currently a full-time employee of The Medicines Company. Dr. Topol is a consultant to Sanofi-Aventis and Daiichi Sankyo. Dr. Berger is a consultant to Accumetrics, The Medicines Company, Eli Lilly/Daiichi Sankyo, and Novartis/Portola (<$ 10,000/year), and has received research funding from Thrombovision, Helena, Accumetrics, AstraZeneca, Haemoscope, The Medicines Company, Corgenix/Aspirin Works, and Eli Lilly/Daiichi Sankyo. NR 50 TC 56 Z9 60 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD NOV 17 PY 2009 VL 54 IS 21 BP 1935 EP 1945 DI 10.1016/j.jacc.2009.05.074 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 517NE UT WOS:000271620600006 PM 19909874 ER PT J AU Kidwell, CS Greenberg, SM AF Kidwell, Chelsea S. Greenberg, Steven M. TI Red meets white Do microbleeds link hemorrhagic and ischemic cerebrovascular disease? SO NEUROLOGY LA English DT Editorial Material C1 [Kidwell, Chelsea S.] Georgetown Univ, Dept Neurol, Washington, DC 20007 USA. [Kidwell, Chelsea S.] Georgetown Univ, Stroke Ctr, Washington, DC 20007 USA. [Greenberg, Steven M.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. RP Kidwell, CS (reprint author), Georgetown Univ, Dept Neurol, Bldg D,Suite 150,4000 Reservoir Rd, Washington, DC 20007 USA. EM ck256@georgetown.edu FU NIA NIH HHS [5R01AG026484-05]; NINDS NIH HHS [P50 NS044378, U54 NS057405] NR 6 TC 15 Z9 15 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD NOV 17 PY 2009 VL 73 IS 20 BP 1614 EP 1615 DI 10.1212/WNL.0b013e3181c17fa1 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 520FD UT WOS:000271824800002 PM 19846833 ER PT J AU Faber, AC Li, DA Song, Y Liang, MC Yeap, BY Bronson, RT Lifshits, E Chen, Z Maira, SM Garcia-Echeverria, C Wong, KK Engelman, JA AF Faber, Anthony C. Li, Danan Song, YoungChul Liang, Mei-Chih Yeap, Beow Y. Bronson, Roderick T. Lifshits, Eugene Chen, Zhao Maira, Sauveur-Michel Garcia-Echeverria, Carlos Wong, Kwok-Kin Engelman, Jeffrey A. TI Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE Mcl-1; MEK; BIM; acquired resistance; AKT ID GROWTH-FACTOR-RECEPTOR; CELL LUNG-CANCER; PHOSPHATIDYLINOSITOL 3-KINASE/MAMMALIAN TARGET; TYROSINE KINASE INHIBITORS; ACQUIRED-RESISTANCE; ANTITUMOR-ACTIVITY; RAPAMYCIN INHIBITOR; T790M MUTATIONS; GEFITINIB; PATHWAY AB Non-small cell lung cancers with activating mutations in the epidermal growth factor receptor (EGFR) are highly responsive to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. Such cancers are "addicted'' to EGFR, and treatment with a TKI invariably leads to down-regulation of the PI3K-AKT-mTOR and MEK-ERK signaling pathways, resulting in apoptosis. Using a dual PI3K-mTOR inhibitor, NVP-BEZ235, we evaluated whether PI3K-mTOR inhibition alone induced apoptosis in these cancers. In contrast to HER2-amplified breast cancers, we found that PI3K-mTOR inhibition did not promote substantial apoptosis in the EGFR mutant lung cancers. However, blocking both PI3K-mTOR and MEK simultaneously led to apoptosis to similar levels as the EGFR TKIs, suggesting that down-regulation of these pathways may account for much of the apoptosis promoted by EGFR inhibition. In EGFR mutant lung cancers, down-regulation of both intracellular pathways converged on the BH3 family of proteins regulating apoptosis. PI3K inhibition led to down-regulation of Mcl-1, and MEK inhibition led to up-regulation of BIM. In fact, down-regulation of Mcl-1 by siRNA was sufficient to sensitize these cancers to single-agent MEK inhibitors. Surprisingly, an AKT inhibitor did not decrease Mcl-1 levels, and when combined with MEK inhibitors, failed to induce apoptosis. Importantly, we observed that the combination of PI3K-mTOR and MEK inhibitors effectively shrunk tumors in a transgenic and xenograft model of EGFR T790M-L858R cancers. These data indicate simultaneous inhibition of PI3K-mTOR and MEK signaling is an effective strategy for treating EGFR mutant lung cancers, including those with acquired resistance to EGFR TKIs. C1 [Li, Danan; Liang, Mei-Chih; Chen, Zhao; Wong, Kwok-Kin] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Faber, Anthony C.; Song, YoungChul; Yeap, Beow Y.; Lifshits, Eugene; Engelman, Jeffrey A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Charlestown, MA 02129 USA. [Li, Danan; Liang, Mei-Chih; Chen, Zhao; Wong, Kwok-Kin] Dana Farber Harvard Canc Ctr, Ludwig Ctr, Boston, MA 02115 USA. [Yeap, Beow Y.; Wong, Kwok-Kin; Engelman, Jeffrey A.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Bronson, Roderick T.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Maira, Sauveur-Michel; Garcia-Echeverria, Carlos] Novartis Inst BioMed Res, CH-4002 Basel, Switzerland. RP Wong, KK (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. EM kwong1@partners.org; jengelman@partners.org OI wong, kwok kin/0000-0001-6323-235X FU National Institutes of Health [K08 CA120060-01, R01CA137008-01, 1R01CA140594, K08 AG024004, R01CA122794, R01AG2400401]; Lung SPORE [P50CA090578]; DanaFarber/Harvard Cancer Center GI Cancer SPORE [P50 CA127003]; VFoundation; Ellison Foundation Scholar; American Cancer Society [RSG-06-102-1]; Joan Scarangello Foundation to Conquer Lung Cancer; Cecily and Robert Harris Foundation; Flight Attendant Medical Research Institute FX We thank Michael Waring (Ragon Institute, Massachusetts General Hospital) for help with flow cytometry experiments, Alan Eastman (Dartmouth Medical School) for helpful discussions regarding SUM102 cells, and Thomas Gilmore (Department of Biology, Boston University) for the CHAPS. This work was supported by National Institutes of Health Grants K08 CA120060-01 (to J.A.E.), R01CA137008-01 (to J.A.E.), 1R01CA140594 (to J.A.E. and K.-K. W.), K08 AG024004(to K.-K. W.), R01CA122794 (to K.-K.W.), and R01AG2400401(to K.-K.W.); Lung SPORE Grant P50CA090578 (to J.A.E. and K.-K.W.); DanaFarber/Harvard Cancer Center GI Cancer SPORE Grant P50 CA127003 (to J.A.E.); the VFoundation (to J.A.E.); the Ellison Foundation Scholar (to J.A.E.); American Cancer Society RSG-06-102-1 (to J.A.E.); the Joan Scarangello Foundation to Conquer Lung Cancer (to K.-K.W.); the Cecily and Robert Harris Foundation (to K.-K.W.); and the Flight Attendant Medical Research Institute (to K.-K.W.). NR 45 TC 200 Z9 206 U1 1 U2 20 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD NOV 17 PY 2009 VL 106 IS 46 BP 19503 EP 19508 DI 10.1073/pnas.0905056106 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 521GC UT WOS:000271907400051 PM 19850869 ER EF